###MEDLINE:90092414

number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
and	O
their	O
sensitivity	O
to	O
hormone	O
action	O
.	O

the	O
study	O
demonstrated	O
a	O
decreased	O
level	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
gr	B-protein
)	O
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
from	O
hypercholesterolemic	O
subjects	O
,	O
and	O
an	O
elevated	O
level	O
in	O
patients	O
with	O
acute	O
myocardial	O
infarction	O
.	O

in	O
the	O
lymphocytes	O
with	O
a	O
high	O
gr	B-protein
number	O
,	O
dexamethasone	O
inhibited	O
[	O
0h	O
]	O
-thymidine	O
and	O
[	O
0h	O
]	O
-acetate	O
incorporation	O
into	O
dna	O
and	O
cholesterol	O
,	O
respectively	O
,	O
in	O
the	O
same	O
manner	O
as	O
in	O
the	O
control	B-cell_line
cells	I-cell_line
.	O

on	O
the	O
other	O
hand	O
,	O
a	O
decreased	O
gr	B-protein
number	O
resulted	O
in	O
a	O
less	O
efficient	O
dexamethasone	O
inhibition	O
of	O
the	O
incorporation	O
of	O
labeled	O
compounds	O
.	O

these	O
data	O
showed	O
that	O
the	O
sensitivity	O
of	O
lymphocytes	B-cell_type
to	O
glucocorticoids	O
changed	O
only	O
with	O
a	O
decrease	O
of	O
gr	B-protein
level	O
.	O

###MEDLINE:90194790

[	B-protein
0	I-protein
,	I-protein
00-dihydroxyvitamin	I-protein
d0	I-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
and	O
t-	O
and	O
b-lymphocyte	O
count	O
in	O
patients	O
with	O
glomerulonephritis	O
]	O

content	O
of	O
receptors	O
to	O
hormonal	O
form	O
of	O
vitamin	B-protein
d0	I-protein
,	O
0.00	O
(	O
oh	O
)	O
0d0	O
,	O
constituted	O
00.0	O
fmole/mg	O
of	O
protein	O
in	O
lymphocytes	B-cell_type
of	O
peripheric	O
blood	O
of	O
children	O
with	O
glomerulonephritis	O
.	O

in	O
the	O
patients	O
concentration	O
of	O
total	O
and	O
ionized	O
form	O
of	O
ca0+	O
was	O
decreased	O
down	O
to	O
0.00	O
mmole/l	O
and	O
0.00	O
mmole/l	O
,	O
respectively	O
,	O
while	O
an	O
increase	O
in	O
parathormone	O
(	O
pth	O
)	O
by	O
00	O
%	O
and	O
a	O
distinct	O
decrease	O
in	O
00	O
(	O
oh	O
)	O
d	O
concentration	O
(	O
lower	O
than	O
0.00	O
ng/ml	O
)	O
was	O
found	O
in	O
blood	O
;	O
content	O
of	O
camp	O
was	O
also	O
decreased	O
in	O
lymphocytes	B-cell_type
by	O
00	O
%	O
.	O

at	O
the	O
same	O
time	O
,	O
total	O
content	O
of	O
t	B-cell_type
lymphocytes	I-cell_type
was	O
decreased	O
0.0-fold	O
in	O
peripheric	B-cell_type
blood	I-cell_type
.	O

treatment	O
with	O
i-hydroxyvitamin	B-protein
d0	I-protein
(	O
0-0.0	O
mg	O
daily	O
,	O
within	O
0	O
weeks	O
)	O
led	O
to	O
normalization	O
of	O
total	O
and	O
ionized	O
form	O
of	O
ca0+	O
and	O
of	O
00	O
(	O
oh	O
)	O
d	O
,	O
but	O
did	O
not	O
affect	O
the	O
pth	O
content	O
in	O
blood	O
.	O

concentration	O
of	O
the	O
receptors	O
to	O
0.00	O
(	O
oh	O
)	O
0d0	O
was	O
elevated	O
up	O
to	O
00.0	O
fmole/mg	O
after	O
i	O
week	O
of	O
the	O
treatment	O
,	O
whereas	O
it	O
was	O
decreased	O
to	O
the	O
initial	O
level	O
00.0	O
fmole/mg	O
within	O
0	O
weeks	O
;	O
simultaneous	O
alteration	O
in	O
the	O
camp	O
content	O
was	O
observed	O
in	O
lymphocytes	B-cell_type
.	O

treatment	O
with	O
0-	O
(	O
oh	O
)	O
d0	O
normalized	O
also	O
the	O
t	B-cell_type
lymphocytes	I-cell_type
content	O
in	O
peripheric	B-cell_type
blood	I-cell_type
.	O

the	O
data	O
obtained	O
suggest	O
that	O
under	O
conditions	O
of	O
glomerulonephritis	O
only	O
high	O
content	O
of	O
receptors	O
to	O
0.00	O
(	O
oh	O
)	O
0d0	O
in	O
lymphocytes	B-cell_type
enabled	O
to	O
perform	O
the	O
cell	O
response	O
to	O
the	O
hormone	O
effect	O
.	O

###MEDLINE:89371608

tumor	O
and	O
serum	O
beta-0-microglobulin	O
expression	O
in	O
women	O
with	O
breast	O
cancer	O
.	O

to	O
investigate	O
whether	O
the	O
tumor	O
expression	O
of	O
beta-0-microglobulin	B-protein
(	I-protein
beta	I-protein
0-m	I-protein
)	O
could	O
serve	O
as	O
a	O
marker	O
of	O
tumor	O
biologic	O
behavior	O
,	O
the	O
authors	O
studied	O
specimens	O
of	O
breast	O
carcinomas	O
from	O
00	O
consecutive	O
female	O
patients	O
.	O

presence	O
of	O
beta	B-protein
0-m	I-protein
was	O
analyzed	O
by	O
immunohistochemistry	O
.	O

no	O
significant	O
correlations	O
were	O
found	O
between	O
tumor	B-protein
beta	I-protein
0-m	I-protein
expression	O
and	O
several	O
histologic	O
attributes	O
such	O
as	O
type	O
,	O
histologic	O
and	O
nuclear	O
grades	O
,	O
mitotic	O
index	O
,	O
necrosis	O
,	O
vascular	O
invasion	O
,	O
and	O
lymphocytic	O
infiltration	O
.	O

likewise	O
,	O
beta	B-protein
0-m	I-protein
was	O
not	O
associated	O
with	O
markers	O
of	O
disease	O
extension	O
such	O
as	O
tnm	O
,	O
(	O
uicc	O
,	O
classification	O
of	O
malignant	O
tumors	O
)	O
staging	O
and	O
axillary	O
lymph	O
node	O
involvement	O
or	O
with	O
estrogen	O
,	O
progesterone	O
,	O
and	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
.	O

however	O
,	O
there	O
was	O
a	O
significantly	O
positive	O
association	O
between	O
tumor	B-protein
beta	I-protein
0-m	I-protein
expression	O
and	O
the	O
degree	O
of	O
lymphocytic	O
infiltration	O
in	O
the	O
tumor	O
tissue	O
.	O

beta	B-protein
0-m	I-protein
serum	O
levels	O
were	O
determined	O
by	O
an	O
enzyme-linked	O
immunosorbent	O
assay	O
in	O
samples	O
from	O
00	O
of	O
the	O
above	O
women	O
.	O

although	O
some	O
of	O
the	O
highest	O
values	O
had	O
been	O
obtained	O
in	O
women	O
with	O
larger	O
(	O
t0	B-DNA
)	O
primary	O
tumors	O
,	O
the	O
authors	O
failed	O
to	O
detect	O
any	O
statistical	O
relationship	O
between	O
beta	B-protein
0-m	I-protein
expression	O
in	O
the	O
tumor	O
with	O
serum	O
levels	O
or	O
between	O
serum	B-protein
beta	I-protein
0-m	I-protein
and	O
the	O
above	O
histologic	O
,	O
laboratory	O
,	O
and	O
clinical	O
factors	O
.	O

###MEDLINE:90030612

[	O
preliminary	O
observation	O
of	O
level	O
free-form	O
e	O
receptor	O
levels	O
in	O
serum	O
of	O
normal	O
childbearing-aged	O
and	O
pregnant	O
women	O
]	O

in	O
000	O
cases	O
of	O
childbearing-aged	B-protein
and	O
pregnant	O
women	O
,	O
free	O
form	O
e	O
receptor	O
levels	O
(	O
se	B-protein
)	O
in	O
serum	O
were	O
measured	O
by	O
elisa	O
.	O

the	O
level	O
of	O
se	B-protein
was	O
significantly	O
decreased	O
during	O
the	O
first	O
trimester	O
,	O
slightly	O
higher	O
in	O
the	O
second	O
trimester	O
,	O
and	O
recovered	O
to	O
normal	O
in	O
the	O
third	O
trimester	O
.	O

the	O
level	O
remained	O
lower	O
in	O
00	O
pih	O
women	O
but	O
appeared	O
higher	O
in	O
overdue	O
pregnancies	O
as	O
compared	O
with	O
the	O
normal	O
0rd	O
trimester	O
range	O
.	O

the	O
results	O
indicate	O
that	O
there	O
is	O
a	O
relationship	O
between	O
a	O
change	O
in	O
t	B-cell_type
cell	I-cell_type
function	O
and	O
pregnancy	O
.	O

###MEDLINE:89242103

kappa	B-protein
b-specific	I-protein
dna	I-protein
binding	I-protein
proteins	I-protein
:	O
role	O
in	O
the	O
regulation	O
of	O
human	B-DNA
interleukin-0	I-DNA
gene	I-DNA
expression	O
.	O

transcriptional	O
activation	O
of	O
the	O
human	B-DNA
interleukin-0	I-DNA
(	I-DNA
il-0	I-DNA
)	I-DNA
gene	I-DNA
,	O
like	O
induction	O
of	O
the	O
il-0	B-DNA
receptor	I-DNA
alpha	I-DNA
(	I-DNA
il-0r	I-DNA
alpha	I-DNA
)	I-DNA
gene	I-DNA
and	O
the	O
type	B-protein
0	I-protein
human	O
immunodeficiency	O
virus	O
(	O
hiv-0	O
)	O
,	O
is	O
shown	O
to	O
be	O
modulated	O
by	O
a	O
kappa	B-DNA
b-like	I-DNA
enhancer	I-DNA
element	I-DNA
.	O

mutation	O
of	O
a	O
kappa	B-DNA
b	I-DNA
core	I-DNA
sequence	I-DNA
identified	O
in	O
the	O
il-0	B-DNA
promoter	I-DNA
(	O
-000	O
to	O
-000	O
)	O
partially	O
inhibits	O
both	O
mitogen-	B-protein
and	I-protein
htlv-i	I-protein
tax-mediated	I-protein
activation	O
of	O
this	O
transcription	B-DNA
unit	I-DNA
and	O
blocks	O
the	O
specific	O
binding	O
of	O
two	O
inducible	O
cellular	B-protein
factors	I-protein
.	O

these	O
kappa	B-protein
b-specific	I-protein
proteins	I-protein
(	O
00	O
to	O
00	O
and	O
00	O
to	O
00	O
kilodaltons	O
)	O
similarly	O
interact	O
with	O
the	O
functional	B-DNA
kappa	I-DNA
b	I-DNA
enhancer	I-DNA
present	O
in	O
the	O
il-0r	B-DNA
alpha	I-DNA
promoter	I-DNA
.	O

these	O
data	O
suggest	O
that	O
these	O
kappa	B-protein
b-specific	I-protein
proteins	I-protein
have	O
a	O
role	O
in	O
the	O
coordinate	O
regulation	O
of	O
this	O
growth	B-protein
factor-growth	I-protein
factor	I-protein
receptor	I-protein
gene	O
system	O
that	O
controls	O
t	O
cell	O
proliferation	O
.	O

###MEDLINE:89197277

novel	O
region	O
within	O
the	O
v	B-DNA
kappa	I-DNA
gene	I-DNA
promoter	I-DNA
is	O
responsible	O
for	O
tissue	O
and	O
stage-specific	O
expression	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
in	O
human	B-cell_type
lymphoid	I-cell_type
neoplasms	I-cell_type
.	O

immunoglobulin	B-protein
gene-specific	I-protein
transacting	I-protein
factors	I-protein
have	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
lymphoid	O
tissue-specific	O
expression	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O

the	O
role	O
of	O
these	O
factors	O
in	O
b-cell	O
differentiation	O
and	O
stage-specific	O
expression	O
of	O
these	O
genes	O
is	O
,	O
however	O
,	O
not	O
fully	O
understood	O
.	O

we	O
have	O
used	O
a	O
model	O
of	O
human	O
lymphoid	O
neoplasia	O
to	O
address	O
this	O
question	O
.	O

different	O
fragments	O
of	O
unrearranged	O
human	B-DNA
variable	I-DNA
region	I-DNA
of	O
immunoglobulin	B-DNA
kappa	I-DNA
gene	I-DNA
(	O
v	B-protein
kappa	I-protein
)	I-protein
were	O
used	O
for	O
cell-free	O
in	O
vitro	O
transcription	O
and	O
dna	O
mobility	O
shift	O
assays	O
.	O

previously	O
described	O
enhancement	O
of	O
in	O
vitro	O
transcription	O
that	O
was	O
only	O
seen	O
with	O
nuclear	O
extracts	O
derived	O
from	O
b-cell	B-cell_type
neoplasms	I-cell_type
corresponding	O
to	O
the	O
late	O
stages	O
of	O
b-cell	O
differentiation	O
was	O
shown	O
to	O
be	O
dependent	O
on	O
the	O
actions	O
of	O
these	O
factor	O
(	O
s	O
)	O
on	O
the	O
dna	B-DNA
region	I-DNA
within	O
the	O
v	B-DNA
kappa	I-DNA
gene	I-DNA
promoter	I-DNA
.	O

this	O
region	O
is	O
located	O
within	O
the	O
000	B-DNA
bp	I-DNA
fragment	I-DNA
located	O
000	B-DNA
bp	I-DNA
upstream	I-DNA
from	O
the	O
coding	B-DNA
region	I-DNA
and	O
this	O
fragment	O
represents	O
a	O
possible	O
novel	B-DNA
dna	I-DNA
region	I-DNA
,	O
which	O
plays	O
a	O
role	O
in	O
the	O
stage-	O
and	O
tissue-specific	O
expression	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O

###MEDLINE:89179873

[	O
determination	O
of	O
the	O
sensitivity	O
to	O
glucocorticoids	O
in	O
vitro	O
]	O

a	O
modified	O
method	O
for	O
the	O
determination	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
human	B-cell_type
lymphocytes	I-cell_type
is	O
suggested	O
.	O

the	O
principal	O
distinction	O
of	O
the	O
method	O
is	O
standardization	O
by	O
the	O
lymphocyte	O
count	O
in	O
a	O
sample	O
(	O
0	O
mln	O
)	O
and	O
the	O
labeled	O
hormone	O
concentration	O
.	O

the	O
modification	O
saves	O
time	O
and	O
money	O
,	O
limits	O
the	O
range	O
of	O
the	O
data	O
variations	O
,	O
and	O
makes	O
use	O
of	O
a	O
lesser	O
volume	O
of	O
blood	O
.	O

examinations	O
of	O
00	O
children	O
aged	O
0	O
to	O
00	O
suffering	O
from	O
the	O
nephrotic	O
form	O
of	O
glomerulonephritis	O
have	O
made	O
it	O
possible	O
to	O
distinguish	O
two	O
groups	O
of	O
patients	O
:	O
with	O
relatively	O
high	O
values	O
of	O
specific	O
binding	O
x	O
=	O
0000.0	O
+/-	O
000.0	O
(	O
n	O
=	O
00	O
,	O
p	O
=	O
0.00	O
,	O
t	O
=	O
0.00	O
)	O
,	O
this	O
corresponding	O
to	O
a	O
clinical	O
form	O
of	O
hormone	O
-sensitive	O
glomerulonephritis	O
,	O
and	O
with	O
relatively	O
low	O
values	O
of	O
specific	O
binding	O
x	O
=	O
0000.0	O
+/-	O
000.0	O
(	O
n	O
=	O
00	O
,	O
p	O
=	O
0.00	O
,	O
t	O
=	O
0.00	O
)	O
,	O
that	O
corresponds	O
to	O
hormone	O
-resistant	O
glomerulonephritis	O
.	O

dynamic	O
studies	O
have	O
not	O
shown	O
any	O
statistically	O
significant	O
changes	O
in	O
the	O
specific	O
binding	O
values	O
.	O

these	O
results	O
permit	O
regarding	O
the	O
specific	O
binding	O
value	O
as	O
a	O
prognostic	O
criterion	O
in	O
the	O
assessment	O
of	O
corticosteroid	O
therapy	O
;	O
this	O
allows	O
a	O
wide	O
employment	O
of	O
the	O
described	O
method	O
in	O
practical	O
nephrology	O
.	O

###MEDLINE:89078997

octamer-binding	B-protein
proteins	I-protein
from	O
b	B-cell_line
or	I-cell_line
hela	I-cell_line
cells	I-cell_line
stimulate	O
transcription	O
of	O
the	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
promoter	I-DNA
in	O
vitro	O
.	O

the	O
b-cell	O
-type	O
specificity	O
of	O
the	O
immunoglobulin	B-DNA
(	I-DNA
ig	I-DNA
)	I-DNA
heavy-chain	I-DNA
and	I-DNA
light-chain	I-DNA
promoters	I-DNA
is	O
mediated	O
by	O
an	O
octanucleotide	B-DNA
(	I-DNA
octa	I-DNA
)	I-DNA
element	I-DNA
,	O
atgcaaat	O
,	O
that	O
is	O
also	O
a	O
functional	O
component	O
of	O
other	O
rna	B-DNA
polymerase	I-DNA
ii	I-DNA
promoters	I-DNA
,	O
such	O
as	O
snrna	B-DNA
and	I-DNA
histone	I-DNA
h0b	I-DNA
promoters	I-DNA
.	O

two	O
nuclear	B-protein
proteins	I-protein
that	O
bind	O
specifically	O
and	O
with	O
high	O
affinity	O
to	O
the	O
octa	B-DNA
element	I-DNA
have	O
been	O
identified	O
.	O

nf-a0	B-protein
is	O
present	O
in	O
a	O
variety	O
of	O
cell	O
types	O
,	O
whereas	O
the	O
presence	O
of	O
nf-a0	B-protein
is	O
essentially	O
confined	O
to	O
b	B-cell_type
cells	I-cell_type
,	O
leading	O
to	O
the	O
hypothesis	O
that	O
nf-a0	B-protein
activates	O
cell-type-specific	O
transcription	O
of	O
the	O
ig	B-DNA
promoter	I-DNA
and	O
nf-a0	B-protein
mediates	O
the	O
other	O
responses	O
of	O
the	O
octa	B-DNA
element	I-DNA
.	O

extracts	O
of	O
the	O
b-cell	B-cell_line
line	I-cell_line
,	O
bja-b	B-cell_line
,	O
contain	O
high	O
levels	O
of	O
nf-a0	B-protein
and	O
specifically	O
transcribe	O
ig	B-DNA
promoters	I-DNA
.	O

in	O
contrast	O
,	O
extracts	O
from	O
hela	B-cell_line
cells	I-cell_line
transcribed	O
the	O
ig	B-DNA
promoter	I-DNA
poorly	O
.	O

surprisingly	O
,	O
addition	O
of	O
either	O
affinity-enriched	O
nf-a0	O
or	O
nf-a0	O
to	O
either	O
a	O
hela	O
extract	O
or	O
a	O
partially	O
purified	O
reaction	O
system	O
specifically	O
stimulates	O
the	O
ig	B-DNA
promoter	I-DNA
.	O

this	O
suggests	O
that	O
the	O
constitutive	B-protein
octa-binding	I-protein
factor	I-protein
nf-a0	I-protein
can	O
activate	O
transcription	O
of	O
the	O
ig	B-DNA
promoter	I-DNA
and	O
that	O
b-cell	O
-specific	O
transcription	O
of	O
this	O
promoter	O
,	O
at	O
least	O
in	O
vitro	O
,	O
is	O
partially	O
due	O
to	O
a	O
quantitative	O
difference	O
in	O
the	O
amount	O
of	O
octa-binding	B-protein
protein	I-protein
.	O

because	O
nf-a0	B-protein
can	O
stimulate	O
ig	B-protein
transcription	O
,	O
the	O
inability	O
of	O
this	O
factor	O
to	O
activate	O
in	O
vivo	O
the	O
ig	B-DNA
promoter	I-DNA
to	O
the	O
same	O
degree	O
as	O
the	O
snrna	B-DNA
promoters	I-DNA
probably	O
reflects	O
a	O
difference	O
in	O
the	O
context	O
of	O
the	O
octa	B-DNA
element	I-DNA
in	O
these	O
two	O
types	O
of	O
promoters	B-DNA
.	O

###MEDLINE:88264423

identification	O
of	O
a	O
putative	O
regulator	O
of	O
early	B-cell_type
t	I-cell_type
cell	I-cell_type
activation	O
genes	O
.	O

molecules	O
involved	O
in	O
the	O
antigen	O
receptor-dependent	O
regulation	O
of	O
early	B-cell_type
t	I-cell_type
cell	I-cell_type
activation	O
genes	O
were	O
investigated	O
with	O
the	O
use	O
of	O
functional	O
sequences	O
of	O
the	O
t	B-DNA
cell	I-DNA
activation-specific	I-DNA
enhancer	I-DNA
of	O
interleukin-0	B-protein
(	O
il-0	B-protein
)	O
.	O

one	O
of	O
these	O
sequences	O
forms	O
a	O
protein	B-protein
complex	I-protein
,	O
nfat-0	B-protein
,	O
specifically	O
with	O
nuclear	O
extracts	O
of	O
activated	B-cell_type
t	I-cell_type
cells	I-cell_type
.	O

this	O
complex	O
appeared	O
00	O
to	O
00	O
minutes	O
before	O
the	O
activation	O
of	O
the	O
il-0	B-DNA
gene	I-DNA
.	O

studies	O
with	O
inhibitors	O
of	O
protein	O
synthesis	O
indicated	O
that	O
the	O
time	O
of	O
synthesis	O
of	O
the	O
activator	O
of	O
the	O
il-0	B-DNA
gene	I-DNA
in	O
jurkat	B-cell_line
t	I-cell_line
cells	I-cell_line
corresponds	O
to	O
the	O
time	O
of	O
appearance	O
of	O
nfat-0	B-protein
.	O

nfat-0	B-protein
,	O
or	O
a	O
very	O
similar	O
protein	O
,	O
bound	O
functional	O
sequences	O
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
ltr	B-DNA
)	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
0	I-DNA
;	O
the	O
ltr	B-DNA
of	O
this	O
virus	O
is	O
known	O
to	O
be	O
stimulated	O
during	O
early	B-cell_type
t	I-cell_type
cell	I-cell_type
activation	O
.	O

the	O
binding	B-DNA
site	I-DNA
for	O
this	O
complex	O
activated	O
a	O
linked	B-DNA
promoter	I-DNA
after	O
transfection	O
into	O
antigen	B-cell_type
receptor-activated	I-cell_type
t	I-cell_type
cells	I-cell_type
but	O
not	O
other	O
cell	O
types	O
.	O

these	O
characteristics	O
suggest	O
that	O
nfat-0	B-protein
transmits	O
signals	O
initiated	O
at	O
the	O
t	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
.	O

###MEDLINE:88249842

characterization	O
of	O
thyroid	B-protein
hormone	I-protein
receptors	I-protein
in	O
human	B-cell_line
im-0	I-cell_line
lymphocytes	I-cell_line
.	O

although	O
putatively	O
identified	O
more	O
than	O
00	O
years	O
ago	O
,	O
thyroid	B-protein
hormone	I-protein
receptors	I-protein
in	O
human	O
tissues	O
remain	O
poorly	O
characterized	O
.	O

as	O
a	O
first	O
step	O
towards	O
understanding	O
the	O
mechanism	O
of	O
thyroid	O
hormone	O
action	O
in	O
man	O
we	O
have	O
characterized	O
t0	O
binding	O
sites	O
in	O
nuclei	O
of	O
the	O
human	B-cell_line
lymphoblastoid	I-cell_line
line	I-cell_line
,	O
im-0	B-cell_line
cells	I-cell_line
.	O

in	O
whole	O
cell	O
experiments	O
at	O
00	O
degrees	O
c	O
,	O
nuclear	O
binding	O
of	O
[	O
000i	O
]	O
t0	B-DNA
was	O
saturable	O
(	O
kd	O
00	O
+/-	O
0	O
pmol/l	O
)	O
and	O
of	O
finite	O
capacity	O
(	O
approximately	O
equal	O
to	O
000	O
sites/cell	O
)	O
.	O

the	O
binding	B-DNA
sites	I-DNA
were	O
extracted	O
from	O
a	O
nuclear	O
pellet	O
by	O
treatment	O
with	O
0.0	O
mol/l	O
kcl	O
and	O
sonication	O
.	O

separation	O
of	O
bound	O
from	O
free	O
[	O
000i	O
]	O
t0	O
in	O
the	O
extracts	O
was	O
achieved	O
using	O
the	O
calcium	O
phosphate	O
matrix	O
,	O
hydroxyapatite	O
at	O
a	O
concentration	O
of	O
0.0	O
ml	O
of	O
a	O
000	O
g/l	O
slurry	O
.	O

rectilinear	O
scatchard	O
plots	O
were	O
obtained	O
only	O
when	O
the	O
hydroxyapatite	O
was	O
washed	O
with	O
a	O
buffer	O
containing	O
0.0	O
%	O
triton	O
x-000	O
.	O

under	O
these	O
conditions	O
t0	O
binding	O
sites	O
in	O
the	O
nuclear	O
extracts	O
were	O
present	O
at	O
a	O
concentration	O
of	O
00.0	O
+/-	O
0.0	O
fmol/mg	O
protein	O
and	O
showed	O
an	O
affinity	O
of	O
(	O
kd	O
,	O
room	O
temperature	O
)	O
000	O
+/-	O
00	O
pmol/l	O
.	O

the	O
same	O
assay	O
system	O
was	O
used	O
to	O
determine	O
the	O
hierarchy	O
of	O
affinities	O
for	O
a	O
range	O
of	O
natural	O
and	O
synthetic	O
analogues	O
.	O

calling	O
t0	O
000	O
,	O
the	O
order	O
of	O
potencies	O
observed	O
was	O
:	O
triac	O
,	O
000	O
;	O
0	O
,	O
0-diiodo-0'-isopropylthyronine	O
,	O
00	O
;	O
t0	O
,	O
00	O
;	O
0	O
,	O
0-dimethyl-0'isopropylthyronine	O
0	O
;	O
0	O
,	O
0-t0	O
,	O
0.0	O
,	O
rt0	O
,	O
0.0	O
;	O
0'0'-t0	O
,	O
less	O
than	O
0.00	O
.	O

these	O
results	O
suggest	O
that	O
the	O
t0	O
binding	O
sites	O
present	O
in	O
human	O
im-0	O
lymphocyte	O
nuclei	O
and	O
extracts	O
thereof	O
are	O
thyroid	B-protein
hormone	I-protein
receptors	I-protein
.	O

these	O
cells	O
may	O
be	O
a	O
useful	O
tool	O
to	O
increase	O
our	O
understanding	O
of	O
human	B-protein
t0	I-protein
receptors	I-protein

###MEDLINE:90185221

definition	O
of	O
t-cell	B-protein
specific	I-protein
dna-binding	I-protein
factors	I-protein
that	O
interact	O
with	O
a	O
0'-silencer	O
in	O
the	O
cd0+	B-protein
t-cell	I-protein
gene	I-protein
rpt-0	I-protein
.	O

analysis	O
of	O
the	O
region	B-DNA
0	I-DNA
'	I-DNA
to	O
the	O
cd0+	B-protein
t-cell	I-protein
gene	I-protein
rpt-0	I-protein
(	I-protein
encoding	I-protein
regulatory	I-protein
protein	I-protein
t-lymphocyte	I-protein
0	I-protein
)	O
led	O
to	O
the	O
definition	O
of	O
a	O
silencer	B-DNA
element	I-DNA
that	O
inhibits	O
heterologous	B-DNA
gene	I-DNA
expression	O
in	O
certain	O
cd0+	B-cell_line
t-cell	I-cell_line
lines	I-cell_line
but	O
not	O
in	O
b-cell	B-cell_line
or	I-cell_line
non-lymphoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

functional	O
silencer	O
activity	O
in	O
vivo	O
was	O
associated	O
with	O
the	O
presence	O
of	O
a	O
specific	O
silencer-dna-protein	B-protein
complex	I-protein
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
with	O
t-cell	O
extracts	O
.	O

formation	O
of	O
this	O
complex	O
was	O
selectively	O
inhibited	O
by	O
the	O
region	O
in	O
hiv-0	O
containing	O
a	O
silencer	B-DNA
element	I-DNA
.	O

we	O
discuss	O
the	O
possibility	O
that	O
dna-binding	B-protein
factors	I-protein
may	O
coregulate	O
hiv-0	B-DNA
and	I-DNA
rpt-0	I-DNA
gene	I-DNA
expression	O
through	O
a	O
common	O
transcriptional	O
silencer	B-DNA
element	I-DNA
.	O

###MEDLINE:90061802

congenital	O
immunodeficiencies	O
associated	O
with	O
absence	O
of	O
hla	B-protein
class	I-protein
ii	I-protein
antigens	I-protein
on	O
lymphocytes	B-cell_type
result	O
from	O
distinct	O
mutations	O
in	O
trans-acting	B-protein
factors	I-protein
.	O

coordinate	O
regulation	O
of	O
hla	B-DNA
class	I-DNA
ii	I-DNA
gene	I-DNA
expression	O
during	O
development	O
and	O
coinduction	O
of	O
class	B-DNA
ii	I-DNA
genes	I-DNA
by	O
soluble	B-protein
factors	I-protein
suggests	O
that	O
common	O
trans-acting	B-protein
factor	I-protein
(	O
s	O
)	O
control	O
expression	O
of	O
these	O
genes	O
.	O

in	O
b-lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
derived	O
from	O
two	O
independent	O
class	O
ii-deficient	O
bare	O
lymphocyte	O
syndrome	O
patients	O
,	O
we	O
observed	O
a	O
drastic	O
decrease	O
in	O
transcription	O
rates	O
of	O
the	O
class	B-DNA
ii	I-DNA
genes	I-DNA
.	O

when	O
these	O
cell	B-cell_line
lines	I-cell_line
are	O
fused	O
,	O
class	B-DNA
ii	I-DNA
genes	I-DNA
are	O
reexpressed	O
,	O
indicating	O
that	O
immunodeficiencies	O
in	O
bare	O
lymphocyte	O
syndrome	O
patients	O
are	O
the	O
result	O
of	O
two	O
distinct	O
mutations	O
.	O

further	O
studies	O
show	O
that	O
genes	O
governing	O
the	O
expression	O
of	O
class	B-protein
ii	I-protein
antigens	I-protein
fall	O
into	O
at	O
least	O
three	O
complementation	O
groups	O
;	O
two	O
of	O
these	O
were	O
previously	O
unidentified	O
in	O
mutant	B-cell_line
cell	I-cell_line
lines	I-cell_line
generated	O
in	O
vitro	O
.	O

in	O
addition	O
,	O
we	O
report	O
the	O
identification	O
of	O
two	O
discrete	O
complexes	O
,	O
nfx0.0	B-protein
and	O
nfx0.0	B-protein
,	O
that	O
bind	O
to	O
the	O
dra	B-DNA
x	I-DNA
consensus	I-DNA
element	I-DNA
.	O

though	O
the	O
mutation	O
in	O
at	O
least	O
one	O
mutant	B-cell_line
line	I-cell_line
generated	O
in	O
vitro	O
(	O
rj0.0.0	B-cell_line
)	O
affects	O
products	O
functioning	O
via	O
interaction	O
with	O
the	O
x	B-DNA
box	I-DNA
,	O
clear	O
alterations	O
in	O
either	O
nfx0.0	O
or	O
nfx0.0	B-protein
are	O
not	O
found	O
in	O
any	O
of	O
the	O
mutant	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

###MEDLINE:90022210

in	O
vivo	O
responsiveness	O
to	O
glucocorticoid	O
correlated	O
with	O
glucocorticoid	B-protein
receptor	I-protein
content	O
in	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
in	O
normal	O
humans	O
.	O

dexamethasone	O
loading	O
tests	O
(	O
0.0	O
mg	O
dexamethasone/kg	O
,	O
iv	O
)	O
were	O
performed	O
in	O
00	O
normal	O
males	O
to	O
evaluate	O
the	O
individual	O
responsiveness	O
to	O
glucocorticoid	O
.	O

there	O
were	O
inter-individual	O
differences	O
in	O
increase	O
in	O
peripheral	B-cell_type
blood	I-cell_type
polymorphonuclear	I-cell_type
leukocyte	I-cell_type
count	O
,	O
decrease	O
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocyte	I-cell_type
count	O
,	O
and	O
increase	O
in	O
plasma	O
free	O
fatty	B-protein
acids	I-protein
levels	O
after	O
dexamethasone	O
injection	O
.	O

in	O
addition	O
,	O
there	O
was	O
a	O
significant	O
correlation	O
between	O
the	O
maximum	O
increase	O
in	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
and	O
the	O
maximum	O
decrease	O
in	O
lymphocytes	B-cell_type
(	O
r	B-protein
=	O
0.0000	O
,	O
p	O
less	O
than	O
0.0000	O
)	O
.	O

simultaneous	O
measurements	O
of	O
glucocorticoid	B-protein
receptor	I-protein
content	O
by	O
whole-cell	O
assay	O
revealed	O
that	O
glucocorticoid	B-protein
receptor	I-protein
content	O
in	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
linearly	O
correlated	O
with	O
that	O
in	O
the	O
corresponding	O
lymphocytes	O
(	O
r	B-protein
=	O
0.0000	O
,	O
p	O
less	O
than	O
0.0000	O
)	O
.	O

there	O
were	O
also	O
significant	O
correlations	O
between	O
the	O
maximum	O
increase	O
in	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
and	O
glucocorticoid	B-protein
receptor	I-protein
content	O
in	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
(	O
r	B-protein
=	O
0.0000	O
,	O
p	O
less	O
than	O
0.0000	O
)	O
,	O
and	O
between	O
the	O
maximum	O
decrease	O
in	O
lymphocytes	B-cell_type
and	O
glucocorticoid	B-protein
receptor	I-protein
content	O
in	O
lymphocytes	B-cell_type
(	O
r	B-protein
=	O
0.0000	O
,	O
p	O
less	O
than	O
0.0000	O
)	O
.	O

these	O
results	O
suggest	O
that	O
individual	O
differences	O
are	O
preserved	O
both	O
in	O
glucocorticoid	O
responsiveness	O
and	O
in	O
glucocorticoid	B-protein
receptor	I-protein
content	O
in	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
in	O
normal	O
humans	O
.	O

###MEDLINE:89378613

estradiol	O
receptors	O
in	O
the	O
cytosol	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
in	O
hepatitis	O
b	O
virus	O
carriers	O
treated	O
with	O
interferon-alpha	B-protein
.	O

estradiol	O
receptors	O
in	O
the	O
cytosol	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
the	O
effects	O
of	O
interferon-alpha	B-protein
(	O
ifn-alpha	B-protein
)	O
on	O
estradiol	O
receptors	O
were	O
studied	O
in	O
asymptomatic	O
hepatitis	O
b	O
virus	O
(	O
hbv	O
)	O
carriers	O
,	O
patients	O
with	O
chronic	O
hepatitis	O
b	O
and	O
normal	O
controls	O
.	O

the	O
level	O
of	O
estradiol	O
receptors	O
in	O
the	O
cytosol	O
of	O
mononuclear	B-cell_type
cells	I-cell_type
was	O
significantly	O
lower	O
in	O
asymptomatic	O
hbv	O
carriers	O
and	O
patients	O
with	O
chronic	O
hepatitis	O
b	O
,	O
compared	O
to	O
normal	O
controls	O
.	O

this	O
low	O
level	O
of	O
cytosol	O
estradiol	O
receptors	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
b	O
was	O
increased	O
by	O
the	O
administration	O
of	O
ifn-alpha	B-protein
.	O

in	O
addition	O
,	O
when	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
from	O
patients	O
with	O
chronic	O
hepatitis	O
b	O
were	O
incubated	O
with	O
ifn-alpha	B-protein
in	O
vitro	O
,	O
the	O
level	O
of	O
cytosol	O
estradiol	O
receptors	O
also	O
increased	O
by	O
increasing	O
the	O
concentration	O
of	O
ifn-alpha	B-protein
.	O

we	O
previously	O
reported	O
that	O
the	O
response	O
of	O
mononuclear	B-cell_type
cells	I-cell_type
to	O
estrogen	O
is	O
impaired	O
in	O
hbv	O
carriers	O
,	O
and	O
our	O
present	O
results	O
suggested	O
that	O
this	O
may	O
be	O
due	O
to	O
the	O
low	O
level	O
of	O
estradiol	O
receptors	O
in	O
the	O
cytosol	O
of	O
mononuclear	B-cell_type
cells	I-cell_type
.	O

###MEDLINE:89194996

association	O
of	O
increased	O
lytic	O
effector	O
cell	O
function	O
with	O
high	O
estrogen	B-protein
receptor	I-protein
levels	O
in	O
tumor-bearing	O
patients	O
with	O
breast	O
cancer	O
.	O

tumor-bearing	O
patients	O
with	O
breast	O
cancer	O
were	O
assayed	O
for	O
their	O
natural	B-cell_type
killer	I-cell_type
(	I-cell_type
nk	I-cell_type
)	I-cell_type
cell	I-cell_type
activity	O
and	O
for	O
the	O
function	O
of	O
activated	B-cell_type
cytotoxic	I-cell_type
t-cells	I-cell_type
,	O
as	O
assessed	O
by	O
lectin-dependent	O
cellular	O
cytotoxicity	O
(	O
ldcc	B-protein
)	O
.	O

tumor-bearing	O
patients	O
with	O
breast	O
cancer	O
had	O
a	O
significant	O
increase	O
in	O
nk	O
activity	O
and	O
in	O
ldcc	B-protein
,	O
as	O
compared	O
with	O
healthy	O
control	O
individuals	O
.	O

although	O
the	O
enhanced	O
nk	O
cell	O
activity	O
and	O
ldcc	B-protein
were	O
closely	O
associated	O
with	O
high	O
levels	O
(	O
greater	O
than	O
00	O
fmol/mg	O
)	O
of	O
estrogen	B-protein
receptor	I-protein
(	O
er	B-protein
)	O
content	O
in	O
the	O
primary	O
tumor	O
,	O
no	O
other	O
clinical	O
or	O
histologic	O
correlation	O
between	O
the	O
increase	O
in	O
either	O
parameter	O
of	O
cytotoxic	B-cell_type
effector	I-cell_type
cell	I-cell_type
function	O
could	O
be	O
found	O
.	O

thus	O
,	O
er	B-protein
levels	O
greater	O
than	O
00	O
fmol/mg	O
might	O
be	O
associated	O
with	O
increased	O
cytotoxic	B-cell_type
effector	I-cell_type
cell	I-cell_type
function	O
in	O
tumor-bearing	O
patients	O
with	O
breast	O
cancer	O
.	O

###MEDLINE:89195152

properties	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
epstein-barr	B-cell_line
virus-transformed	I-cell_line
lymphocytes	I-cell_line
from	O
patients	O
with	O
familial	O
cortisol	O
resistance	O
.	O

in	O
a	O
previous	O
report	O
of	O
two	O
patients	O
with	O
familial	O
glucocorticoid	O
resistance	O
due	O
to	O
reduced	O
numbers	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
gr	B-protein
)	O
,	O
we	O
have	O
shown	O
decreased	O
numbers	O
of	O
gr	B-protein
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
cultured	B-cell_line
fibroblasts	I-cell_line
but	O
normal	O
affinity	O
of	O
gr	B-protein
in	O
both	O
patients	O
.	O

in	O
this	O
study	O
,	O
peripheral	B-cell_type
lymphocytes	I-cell_type
from	O
these	O
patients	O
,	O
one	O
patient	O
's	O
son	O
and	O
daughter	O
,	O
and	O
normal	O
subjects	O
were	O
transformed	O
with	O
epstein-barr	O
virus	O
.	O

reduced	O
numbers	O
and	O
normal	O
affinity	O
of	O
gr	B-protein
were	O
found	O
in	O
the	O
epstein-barr	B-cell_line
virus-transformed	I-cell_line
lymphocytes	I-cell_line
from	O
both	O
patients	O
while	O
the	O
son	O
and	O
daughter	O
had	O
normal	O
numbers	O
and	O
affinity	O
of	O
gr	B-protein
.	O

the	O
thermal	O
stability	O
of	O
gr	B-protein
and	O
thermal	O
activation	O
of	O
cytosolic	B-protein
receptors	I-protein
in	O
both	O
patients	O
were	O
found	O
to	O
be	O
normal	O
.	O

although	O
the	O
percentages	O
of	O
nuclear	B-protein
bound	I-protein
gr	I-protein
were	O
similar	O
in	O
both	O
patients	O
and	O
normal	O
controls	O
,	O
the	O
absolute	O
amounts	O
of	O
nuclear	B-protein
bound	I-protein
gr	I-protein
of	O
the	O
patients	O
were	O
about	O
one-half	O
that	O
of	O
normal	O
controls	O
.	O

these	O
abnormal	O
properties	O
of	O
gr	B-protein
(	O
reduced	O
numbers	O
of	O
gr	B-protein
)	O
were	O
preserved	O
in	O
the	O
transformed	B-cell_line
cells	I-cell_line
from	O
the	O
patients	O
.	O

###MEDLINE:89219069

octamer	B-protein
transcription	I-protein
factors	I-protein
0	O
and	O
0	O
each	O
bind	O
to	O
two	O
different	O
functional	O
elements	O
in	O
the	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
promoter	I-DNA
.	O

immunoglobulin	B-DNA
heavy-chain	I-DNA
genes	I-DNA
contain	O
two	O
conserved	B-DNA
sequence	I-DNA
elements	I-DNA
0	O
'	O
to	O
the	O
site	O
of	O
transcription	O
initiation	O
:	O
the	O
octamer	O
atgcaaat	O
and	O
the	O
heptamer	B-DNA
ctcatga	I-DNA
.	O

both	O
of	O
these	O
elements	O
are	O
required	O
for	O
normal	B-DNA
cell-specific	I-DNA
promoter	I-DNA
function	O
.	O

the	O
present	O
study	O
demonstrates	O
that	O
both	O
the	O
ubiquitous	B-protein
and	I-protein
lymphoid-cell-specific	I-protein
octamer	I-protein
transcription	I-protein
factors	I-protein
(	O
otf-0	B-protein
and	O
otf-0	B-protein
,	O
respectively	O
)	O
interact	O
specifically	O
with	O
each	O
of	O
the	O
two	O
conserved	B-DNA
sequence	I-DNA
elements	I-DNA
,	O
forming	O
either	O
homo-	O
or	O
heterodimeric	B-protein
complexes	I-protein
.	O

this	O
was	O
surprising	O
,	O
since	O
the	O
heptamer	B-DNA
and	I-DNA
octamer	I-DNA
sequence	I-DNA
motifs	I-DNA
bear	O
no	O
obvious	O
similarity	O
to	O
each	O
other	O
.	O

binding	O
of	O
either	O
factor	O
to	O
the	O
octamer	B-DNA
element	I-DNA
occurred	O
independently	O
.	O

however	O
,	O
otf	O
interaction	O
with	O
the	O
heptamer	B-DNA
sequence	I-DNA
appeared	O
to	O
require	O
the	O
presence	O
of	O
an	O
intact	O
octamer	B-DNA
motif	I-DNA
and	O
occurred	O
with	O
a	O
spacing	O
of	O
either	O
0	B-DNA
or	I-DNA
00	I-DNA
base	I-DNA
pairs	I-DNA
between	O
the	O
two	O
elements	O
,	O
suggesting	O
coordinate	O
binding	O
resulting	O
from	O
protein-protein	O
interactions	O
.	O

the	O
degeneracy	O
in	O
sequences	O
recognized	O
by	O
the	O
otfs	O
may	O
be	O
important	O
in	O
widening	O
the	O
range	O
over	O
which	O
gene	O
expression	O
can	O
be	O
modulated	O
and	O
in	O
establishing	O
cell	O
type	O
specificity	O
.	O

###MEDLINE:89210808

identification	O
of	O
a	O
novel	O
lymphoid	O
specific	O
octamer	B-protein
binding	I-protein
protein	I-protein
(	O
otf-0b	B-protein
)	O
by	O
proteolytic	O
clipping	O
bandshift	O
assay	O
(	O
pcba	B-protein
)	O
.	O

the	O
octamer	B-DNA
sequence	I-DNA
atgcaaat	O
is	O
found	O
in	O
the	O
promoters	O
of	O
immunoglobulin	B-DNA
(	I-DNA
ig	I-DNA
)	I-DNA
heavy	I-DNA
and	I-DNA
light	I-DNA
chain	I-DNA
genes	I-DNA
and	O
in	O
the	O
heavy	B-DNA
chain	I-DNA
enhancer	I-DNA
and	O
is	O
a	O
major	O
determinant	O
of	O
the	O
cell	O
type	O
specific	O
expression	O
of	O
ig	B-DNA
genes	I-DNA
in	O
b	B-cell_type
cells	I-cell_type
.	O

an	O
apparent	O
paradox	O
is	O
that	O
the	O
same	O
sequence	O
serves	O
as	O
an	O
upstream	B-DNA
promoter	I-DNA
or	I-DNA
enhancer	I-DNA
element	I-DNA
in	O
a	O
variety	O
of	O
housekeeping	B-DNA
genes	I-DNA
such	O
as	O
the	O
histone	B-protein
h0b	I-protein
and	O
u	O
snrna	O
genes	O
.	O

the	O
differential	O
usage	O
of	O
this	O
regulatory	B-DNA
sequence	I-DNA
motif	I-DNA
is	O
thought	O
to	O
be	O
mediated	O
by	O
different	O
species	O
of	O
octamer	B-protein
binding	I-protein
proteins	I-protein
.	O

one	O
species	O
of	O
000	O
kd	O
,	O
designated	O
otf-0	B-protein
,	O
is	O
present	O
in	O
all	O
cell	O
types	O
and	O
may	O
exert	O
its	O
activating	O
function	O
only	O
when	O
it	O
can	O
interact	O
with	O
additional	O
adjacent	O
transcription	B-protein
factors	I-protein
.	O

the	O
lymphoid	B-protein
cell	I-protein
specific	I-protein
octamer	I-protein
binding	I-protein
protein	I-protein
of	O
00	O
kd	O
(	O
otf-0a	B-protein
)	O
specifically	O
stimulates	O
ig	B-DNA
promoters	I-DNA
which	O
consist	O
essentially	O
of	O
a	O
tata-box	O
and	O
an	O
octamer	B-DNA
sequence	I-DNA
upstream	I-DNA
of	O
it	O
.	O

here	O
we	O
present	O
evidence	O
for	O
yet	O
another	O
b	B-protein
cell	I-protein
specific	I-protein
octamer	I-protein
binding	I-protein
protein	I-protein
of	O
00	O
kd	O
(	O
otf-0b	B-protein
)	O
.	O

from	O
several	O
findings	O
,	O
including	O
the	O
absence	O
of	O
otf-0b	B-protein
(	O
but	O
not	O
otf-0a	B-protein
)	O
from	O
a	O
lymphocyte	B-cell_line
line	I-cell_line
that	O
can	O
not	O
respond	O
to	O
the	O
igh	B-DNA
enhancer	I-DNA
,	O
we	O
propose	O
a	O
role	O
of	O
the	O
novel	O
octamer	B-protein
factor	I-protein
in	O
the	O
long	O
range	O
activation	O
by	O
the	O
igh	B-DNA
enhancer	I-DNA
.	O

we	O
have	O
used	O
the	O
proteolytic	O
clipping	O
bandshift	O
assay	O
(	O
pcba	B-protein
)	O
technique	O
to	O
distinguish	O
the	O
three	O
different	O
forms	O
found	O
in	O
b	B-cell_type
cells	I-cell_type
.	O

this	O
analysis	O
indicates	O
that	O
the	O
00	B-DNA
kd-species	I-DNA
otf-0b	I-DNA
is	O
closely	O
related	O
to	O
the	O
00	B-protein
kd	I-protein
species	I-protein
otf-0a	I-protein
.	O

###MEDLINE:89052759

inhibition	O
of	O
interleukin	B-protein
0	I-protein
-induced	O
proliferation	O
of	O
cloned	B-cell_line
murine	I-cell_line
t	I-cell_line
cells	I-cell_line
by	O
glucocorticoids	O
.	O

possible	O
involvement	O
of	O
an	O
inhibitory	B-protein
protein	I-protein
.	O

the	O
ability	O
of	O
glucocorticoids	O
to	O
inhibit	O
interleukin	B-protein
0	I-protein
(	I-protein
il	I-protein
0	I-protein
)	O
-induced	O
t	O
cell	O
proliferation	O
in	O
two	O
cytotoxic	B-cell_line
t	I-cell_line
cell	I-cell_line
(	I-cell_line
ctl	I-cell_line
)	I-cell_line
clones	I-cell_line
has	O
been	O
studied	O
.	O

a	O
complete	O
inhibition	O
of	O
dna	O
synthesis	O
by	O
dexamethasone	O
(	O
dx	O
)	O
could	O
be	O
observed	O
when	O
il	O
0-depleted	O
cultures	O
of	O
ctl	B-cell_type
were	O
either	O
incubated	O
for	O
0	O
h	O
with	O
the	O
hormone	O
prior	O
to	O
the	O
addition	O
of	O
il	B-protein
0	I-protein
or	O
treated	O
simultaneously	O
with	O
dx	O
and	O
a	O
low	O
concentration	O
of	O
il	B-protein
0	I-protein
.	O

no	O
significant	O
reduction	O
in	O
the	O
number	O
and	O
affinity	O
of	O
il	B-protein
0	I-protein
receptors	I-protein
was	O
seen	O
after	O
0	O
h	O
incubation	O
with	O
dx	O
.	O

the	O
order	O
of	O
potency	O
observed	O
with	O
the	O
different	O
steroids	O
indicated	O
that	O
this	O
inhibitory	O
effect	O
was	O
mediated	O
through	O
binding	O
to	O
a	O
specific	O
glucocorticoid	B-protein
receptor	I-protein
.	O

the	O
action	O
of	O
these	O
hormones	O
possibly	O
involves	O
the	O
synthesis	O
of	O
an	O
inhibitory	B-protein
protein	I-protein
(	O
s	O
)	O
,	O
since	O
the	O
presence	O
of	O
cycloheximide	O
during	O
the	O
incubation	O
with	O
dx	O
prevented	O
the	O
inhibition	O
of	O
dna	O
synthesis	O
.	O

furthermore	O
,	O
supernatant	O
from	O
dx-treated	B-cell_line
ctl	I-cell_line
contained	O
a	O
nondialyzable	B-protein
factor	I-protein
which	O
inhibited	O
dna	O
synthesis	O
and	O
cell	O
growth	O
of	O
ctl	B-cell_line
clones	I-cell_line
induced	O
by	O
il	B-protein
0	I-protein
.	O

blocking	O
of	O
il	B-protein
0	I-protein
synthesis	O
and	O
il	B-protein
0	I-protein
receptor	I-protein
formation	O
have	O
been	O
proposed	O
as	O
one	O
of	O
the	O
major	O
mechanisms	O
of	O
glucocorticoid-induced	O
immunosuppression	O
.	O

our	O
results	O
indicate	O
that	O
these	O
hormones	O
may	O
also	O
affect	O
t	O
cell	O
proliferation	O
by	O
inhibiting	O
il	B-protein
0	I-protein
activity	O
.	O

###MEDLINE:88263016

identification	O
and	O
purification	O
of	O
a	O
human	B-protein
immunoglobulin-enhancer-binding	I-protein
protein	I-protein
(	O
nf-kappa	B-protein
b	I-protein
)	O
that	O
activates	O
transcription	O
from	O
a	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
0	I-DNA
promoter	I-DNA
in	O
vitro	O
.	O

the	O
enhancer-binding	B-protein
factor	I-protein
nf-kappa	I-protein
b	I-protein
,	O
which	O
is	O
found	O
only	O
in	O
cells	O
that	O
transcribe	O
immunoglobulin	B-DNA
light	I-DNA
chain	I-DNA
genes	I-DNA
,	O
has	O
been	O
purified	O
from	O
nuclear	O
extracts	O
of	O
namalwa	B-cell_type
cells	I-cell_type
(	O
human	B-cell_line
burkitt	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
)	O
by	O
sequence-specific	O
dna	O
affinity	O
chromatography	O
.	O

the	O
purified	B-protein
nf-kappa	I-protein
b	I-protein
has	O
been	O
identified	O
as	O
a	O
00-kda	B-protein
polypeptide	I-protein
by	O
uv-crosslinking	O
analysis	O
.	O

``	B-DNA
footprint	I-DNA
''	O
and	O
methylation-interference	O
analyses	O
have	O
shown	O
that	O
purified	B-protein
nf-kappa	I-protein
b	I-protein
has	O
a	O
binding	O
activity	O
specific	O
for	O
the	O
kappa	B-DNA
light	I-DNA
chain	I-DNA
enhancer	I-DNA
sequence	I-DNA
.	O

the	O
purified	B-protein
factor	I-protein
activated	O
in	O
vitro	O
transcription	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
i	I-DNA
promoter	I-DNA
by	O
binding	O
to	O
an	O
upstream	B-DNA
nf-kappa	I-DNA
b-binding	I-DNA
site	I-DNA

###MEDLINE:88213897

lymphocyte	B-protein
glucocorticoid	I-protein
receptor	I-protein
binding	O
in	O
depression	O
:	O
normal	O
values	O
following	O
recovery	O
.	O

the	O
number	O
of	O
glucocorticoid	B-protein
receptor	I-protein
sites	I-protein
in	O
lymphocytes	B-cell_type
and	O
plasma	O
cortisol	O
concentrations	O
were	O
measured	O
in	O
00	O
patients	O
who	O
had	O
recovered	O
from	O
major	O
depressive	O
disorder	O
and	O
00	O
healthy	O
control	O
subjects	O
.	O

the	O
number	O
of	O
glucocorticoid	B-protein
receptor	I-protein
sites	I-protein
in	O
lymphocytes	B-cell_type
from	O
the	O
recovered	O
depressed	O
group	O
was	O
not	O
significantly	O
different	O
from	O
that	O
of	O
the	O
control	O
group	O
.	O

although	O
the	O
mean	O
plasma	O
cortisol	O
concentration	O
in	O
recovered	O
depressives	O
was	O
higher	O
than	O
in	O
control	O
subjects	O
,	O
the	O
difference	O
only	O
just	O
reached	O
significance	O
.	O

this	O
study	O
shows	O
that	O
the	O
reduction	O
in	O
glucocorticoid	B-protein
receptor	I-protein
numbers	O
which	O
occurs	O
during	O
acute	O
depressive	O
illness	O
does	O
not	O
persist	O
on	O
recovery	O
and	O
is	O
,	O
therefore	O
,	O
state-dependent	O
.	O

###MEDLINE:88052881

identification	O
and	O
purification	O
of	O
a	O
human	O
lymphoid-specific	B-protein
octamer-binding	I-protein
protein	I-protein
(	O
otf-0	B-protein
)	O
that	O
activates	O
transcription	O
of	O
an	O
immunoglobulin	B-DNA
promoter	I-DNA
in	O
vitro	O
.	O

the	O
octamer	B-DNA
sequence	I-DNA
0'-atgcaaat	O
,	O
in	O
either	O
orientation	O
,	O
serves	O
as	O
an	O
upstream	B-DNA
element	I-DNA
in	O
a	O
variety	O
of	O
promoters	B-DNA
and	O
also	O
occurs	O
as	O
a	O
modular	B-DNA
enhancer	I-DNA
element	I-DNA
.	O

it	O
is	O
of	O
particular	O
interest	O
in	O
immunoglobulin	B-DNA
genes	I-DNA
since	O
it	O
is	O
found	O
in	O
the	O
upstream	B-DNA
regions	I-DNA
of	O
all	O
heavy	B-DNA
and	I-DNA
light	I-DNA
chain	I-DNA
promoters	I-DNA
and	O
in	O
the	O
heavy	B-DNA
chain	I-DNA
enhancer	I-DNA
,	O
both	O
of	O
which	O
are	O
known	O
to	O
be	O
necessary	O
for	O
cell-specific	O
expression	O
.	O

we	O
report	O
here	O
the	O
chromatographic	O
separation	O
of	O
ubiquitous	B-protein
and	I-protein
b	I-protein
cell-specific	I-protein
octamer-binding	I-protein
proteins	I-protein
.	O

the	O
b	B-protein
cell	I-protein
factor	I-protein
was	O
purified	O
to	O
homogeneity	O
using	O
affinity	O
chromatography	O
and	O
consists	O
of	O
three	O
peptides	O
of	O
00	O
,	O
00	O
,	O
and	O
00.0	O
+/-	O
0.0	O
kd	O
.	O

each	O
of	O
the	O
polypeptides	O
was	O
renatured	O
after	O
sds-page	O
and	O
shown	O
to	O
bind	O
to	O
the	O
octamer	B-DNA
sequence	I-DNA
.	O

the	O
specific	O
dna	O
binding	O
activity	O
of	O
the	O
pure	B-protein
b	I-protein
cell-specific	I-protein
factor	I-protein
was	O
indistinguishable	O
from	O
that	O
of	O
the	O
affinity-purified	O
ubiquitous	B-protein
factor	I-protein
.	O

this	O
b	B-protein
cell-specific	I-protein
octamer-binding	I-protein
factor	I-protein
,	O
in	O
pure	B-protein
form	I-protein
,	O
activated	O
transcription	O
from	O
a	O
kappa	B-DNA
light	I-DNA
chain	I-DNA
promoter	I-DNA
in	O
vitro	O
,	O
thus	O
demonstrating	O
that	O
it	O
is	O
indeed	O
a	O
b	B-protein
cell-specific	I-protein
transcription	I-protein
factor	I-protein
for	O
this	O
gene	O
.	O

in	O
addition	O
to	O
the	O
ubiquitous	B-protein
and	I-protein
b	I-protein
cell-specific	I-protein
octamer-binding	I-protein
factors	I-protein
,	O
we	O
identified	O
several	O
additional	O
proteins	O
,	O
one	O
of	O
which	O
is	O
b	B-cell_type
cell	I-cell_type
-specific	O
,	O
that	O
interact	O
with	O
the	O
kappa	B-DNA
promoter	I-DNA
.	O

###MEDLINE:87251218

decreased	O
deoxyribonucleic	B-protein
acid	I-protein
binding	I-protein
of	I-protein
glucocorticoid-receptor	I-protein
complex	I-protein
in	O
cultured	B-cell_line
skin	I-cell_line
fibroblasts	I-cell_line
from	O
a	O
patient	O
with	O
the	O
glucocorticoid	O
resistance	O
syndrome	O
.	O

a	O
patient	O
with	O
the	O
syndrome	O
of	O
glucocorticoid	O
resistance	O
was	O
studied	O
.	O

a	O
00-yr-old	O
woman	O
initially	O
was	O
diagnosed	O
as	O
having	O
cushing	O
's	O
disease	O
,	O
based	O
on	O
the	O
findings	O
of	O
high	O
plasma	O
acth	O
and	O
serum	O
cortisol	O
levels	O
,	O
increased	O
urinary	O
cortisol	O
secretion	O
,	O
resistance	O
to	O
adrenal	O
suppression	O
with	O
dexamethasone	O
,	O
and	O
bilateral	O
adrenal	O
hyperplasia	O
by	O
computed	O
tomography	O
and	O
scintigraphy	O
of	O
the	O
adrenal	O
glands	O
.	O

however	O
,	O
she	O
had	O
no	O
signs	O
or	O
symptoms	O
of	O
cushing	O
's	O
syndrome	O
.	O

during	O
a	O
0-yr	O
follow-up	O
,	O
no	O
clinical	O
abnormalities	O
developed	O
,	O
although	O
hypercortisolism	O
persisted	O
.	O

end-organ	O
resistance	O
to	O
cortisol	O
was	O
suspected	O
.	O

to	O
explain	O
the	O
end-organ	O
resistance	O
to	O
cortisol	O
,	O
the	O
glucocorticoid	B-protein
receptors	I-protein
(	O
gr	B-protein
)	O
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
and	O
cultured	B-cell_line
skin	I-cell_line
fibroblasts	I-cell_line
from	O
a	O
forearm	O
skin	O
biopsy	O
were	O
characterized	O
and	O
compared	O
with	O
the	O
results	O
of	O
similar	O
studies	O
in	O
normal	O
subjects	O
.	O

the	O
patient	O
's	O
gr	O
in	O
whole	O
cell	O
assays	O
had	O
an	O
increased	O
dissociation	O
constant	O
(	O
kd	O
)	O
.	O

in	O
the	O
cytosol	O
of	O
cultured	B-cell_line
skin	I-cell_line
fibroblasts	I-cell_line
from	O
the	O
patient	O
,	O
there	O
was	O
also	O
decreased	O
binding	O
capacity	O
.	O

the	O
thermal	O
stability	O
and	O
the	O
sedimentation	O
coefficient	O
in	O
a	O
sucrose	O
density	O
gradient	O
of	O
the	O
receptors	O
in	O
the	O
cytosol	O
of	O
cultured	B-cell_line
skin	I-cell_line
fibroblasts	I-cell_line
from	O
the	O
patient	O
and	O
normal	O
subjects	O
were	O
similar	O
.	O

gr	B-protein
complex	I-protein
activation	O
,	O
analyzed	O
by	O
deae-cellulose	O
chromatography	O
,	O
was	O
decreased	O
in	O
the	O
patient	O
.	O

dna	O
binding	O
of	O
the	O
gr	B-protein
complex	I-protein
after	O
temperature-induced	O
activation	O
was	O
lower	O
in	O
the	O
patient	O
than	O
in	O
normal	O
subjects	O
.	O

nuclear	O
translocation	O
of	O
gr	B-protein
complexes	I-protein
from	O
the	O
patient	O
was	O
also	O
slightly	O
decreased	O
.	O

these	O
results	O
suggest	O
that	O
the	O
patient	O
's	O
glucocorticoid	O
resistance	O
was	O
due	O
to	O
a	O
decrease	O
in	O
the	O
affinity	O
of	O
the	O
receptor	O
for	O
glucocorticoids	O
and	O
a	O
decrease	O
in	O
the	O
binding	O
of	O
the	O
gr	B-protein
complex	I-protein
to	O
dna	O
.	O

###MEDLINE:87223096

granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
.	O

sensitive	O
and	O
receptor-mediated	O
regulation	O
by	O
0	O
,	O
00-dihydroxyvitamin	O
d0	O
in	O
normal	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
.	O

we	O
show	O
that	O
0	O
,	O
00-dihydroxyvitamin	O
d0	O
(	O
0	O
,	O
00	O
[	O
oh	O
]	O
0d0	O
)	O
,	O
the	O
most	O
hormonally	O
active	O
metabolite	O
of	O
vitamin	B-protein
d0	I-protein
,	O
modulates	O
sensitively	O
and	O
specifically	O
both	O
the	O
protein	O
and	O
messenger	B-RNA
rna	I-RNA
accumulation	O
of	O
the	O
multilineage	B-protein
growth	I-protein
factor	I-protein
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
gm-csf	B-protein
)	O
.	O

the	O
regulation	O
of	O
gm-csf	B-protein
expression	O
is	O
seen	O
in	O
both	O
normal	O
human	O
mitogen-activated	B-cell_line
t	I-cell_line
lymphocytes	I-cell_line
and	O
t	B-cell_type
lymphocytes	I-cell_type
from	O
a	O
line	O
(	O
s-lb0	B-cell_line
)	O
transformed	O
with	O
human	B-cell_line
t	I-cell_line
cell	I-cell_line
lymphotropic	I-cell_line
virus	I-cell_line
0	I-cell_line
(	O
htlv-0	O
)	O
.	O

in	O
contrast	O
,	O
cells	O
from	O
a	O
htlv-0	B-cell_line
transformed	I-cell_line
t	I-cell_line
lymphocyte	I-cell_line
line	I-cell_line
(	O
ab-vdr	B-protein
)	O
established	O
from	O
a	O
patient	O
with	O
vitamin	O
d-resistant	O
rickets	O
type	B-protein
ii	I-protein
with	O
undetectable	O
0	O
,	O
00	O
(	O
oh	O
)	O
0d0	O
cellular	B-protein
receptors	I-protein
are	O
resistant	O
to	O
the	O
action	O
of	O
0	O
,	O
00	O
(	O
oh	O
)	O
0d0	O
.	O

inhibition	O
of	O
gm-csf	B-protein
expression	O
by	O
0	O
,	O
00	O
(	O
oh	O
)	O
0d0	O
can	O
occur	O
independently	O
of	O
interleukin	B-protein
0	I-protein
regulation	O
and	O
is	O
probably	O
mediated	O
through	O
cellular	B-protein
0	I-protein
,	O
00	B-protein
(	I-protein
oh	I-protein
)	I-protein
0d0	I-protein
receptors	I-protein
.	O

we	O
conclude	O
that	O
0	O
,	O
00	O
(	O
oh	O
)	O
0d0	O
may	O
be	O
important	O
in	O
the	O
physiology	O
of	O
hematopoiesis	O
.	O

###MEDLINE:87218708

altered	O
interaction	O
between	O
triiodothyronine	O
and	O
its	O
nuclear	B-protein
receptors	I-protein
in	O
absence	O
of	O
cortisol	O
:	O
a	O
proposed	O
mechanism	O
for	O
increased	O
thyrotropin	O
secretion	O
in	O
corticosteroid	O
deficiency	O
states	O
.	O

thyroid	O
hormones	O
occasionally	O
appear	O
less	O
effective	O
when	O
administered	O
alone	O
to	O
patients	O
with	O
panhypopituitarism	O
,	O
and	O
manifestations	O
suggestive	O
of	O
hypothyroidism	O
have	O
been	O
reported	O
in	O
patients	O
suffering	O
from	O
untreated	O
addison	O
's	O
disease	O
.	O

in	O
the	O
latter	O
condition	O
,	O
thyrotropin	O
secretion	O
is	O
increased	O
:	O
this	O
occurs	O
already	O
after	O
as	O
little	O
as	O
0	O
days	O
of	O
temporary	O
withdrawal	O
of	O
therapy	O
with	O
substitution	O
doses	O
of	O
corticosteroids	O
while	O
circulating	O
levels	O
of	O
thyroid	O
hormones	O
remain	O
within	O
normal	O
limits	O
.	O

therefore	O
,	O
a	O
possible	O
role	O
of	O
cortisol	O
in	O
interaction	O
between	O
triiodothyronine	O
and	O
its	O
nuclear	B-protein
receptors	I-protein
was	O
examined	O
at	O
the	O
level	O
of	O
circulating	B-cell_type
lymphocytes	I-cell_type
obtained	O
from	O
patients	O
with	O
primary	O
or	O
secondary	O
adrenocortical	O
failure	O
.	O

the	O
affinity	O
of	O
these	O
receptors	O
was	O
found	O
to	O
be	O
decreased	O
,	O
by	O
more	O
than	O
00	O
%	O
on	O
average	O
,	O
in	O
the	O
absence	O
of	O
cortisol	O
treatments	O
.	O

this	O
change	O
was	O
promptly	O
corrected	O
upon	O
resumption	O
of	O
therapy	O
.	O

the	O
number	O
of	O
binding	B-DNA
sites	I-DNA
was	O
not	O
significantly	O
modified	O
.	O

the	O
influence	O
of	O
cortisol	O
on	O
thyroid	B-protein
hormone	I-protein
receptors	I-protein
discussed	O
here	O
might	O
account	O
for	O
the	O
clinical	O
observations	O
mentioned	O
above	O
.	O

###MEDLINE:87142820

inhibition	O
by	O
cortisol	O
of	O
human	B-cell_type
natural	I-cell_type
killer	I-cell_type
(	I-cell_type
nk	I-cell_type
)	I-cell_type
cell	I-cell_type
activity	O
.	O

the	O
effects	O
of	O
cortisol	O
on	O
the	O
natural	B-cell_type
killer	I-cell_type
(	O
nk	O
)	O
activity	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	O
(	O
pbm	B-cell_line
)	O
cells	O
were	O
studied	O
in	O
vitro	O
using	O
a	O
direct	O
0-h	O
00cr-release	O
assay	O
and	O
k	B-protein
000	I-protein
cell	O
line	O
as	O
a	O
target	O
.	O

preincubation	O
for	O
00	O
h	O
of	O
pbm	B-cell_type
cells	O
drawn	O
from	O
healthy	O
donors	O
with	O
0	O
x	O
00	O
(	O
-0	O
)	O
to	O
0	O
x	O
00	O
(	O
-0	O
)	O
m	O
cortisol	O
resulted	O
in	O
a	O
significant	O
decrease	O
of	O
nk	B-cell_type
cell	I-cell_type
activity	O
.	O

the	O
magnitude	O
of	O
the	O
suppression	O
was	O
directly	O
related	O
to	O
the	O
steroid	O
concentration	O
and	O
inversely	O
related	O
to	O
the	O
number	O
of	O
effector	B-cell_type
cells	I-cell_type
.	O

cortisol	O
was	O
able	O
to	O
minimize	O
the	O
enhancement	O
of	O
nk	O
cytotoxicity	O
obtainable	O
in	O
the	O
presence	O
of	O
immune	B-protein
interferon	I-protein
(	O
ifn-gamma	B-protein
)	O
.	O

a	O
significantly	O
higher	O
suppression	O
was	O
achieved	O
after	O
sequential	O
exposure	O
of	O
pbm	B-cell_type
cells	O
to	O
cortisol	O
and	O
equimolar	O
levels	O
of	O
prostaglandin	B-protein
e0	I-protein
(	O
pge0	B-protein
)	O
.	O

the	O
concomitant	O
incubation	O
with	O
theophylline	O
and	O
isobutyl-methylxanthine	B-protein
failed	O
to	O
enhance	O
the	O
cortisol-induced	O
suppression	O
,	O
whereas	O
pge0-dependent	O
inhibition	O
significantly	O
increased	O
after	O
exposure	O
of	O
pbm	B-cell_type
cells	O
to	O
methyl-xanthines	O
.	O

the	O
inhibitory	O
effect	O
of	O
cortisol	O
was	O
partially	O
or	O
totally	O
prevented	O
by	O
the	O
concomitant	O
incubation	O
with	O
equimolar	O
amounts	O
of	O
00-deoxycortisol	O
and	O
ru	O
000	O
but	O
not	O
of	O
progesterone	O
.	O

treatment	O
of	O
nk	O
effectors	O
with	O
a	O
monoclonal	O
anti-human	O
corticosteroid-binding	B-protein
globulin	I-protein
(	O
cbg	B-protein
)	I-protein
antibody	I-protein
produced	O
an	O
enhancement	O
of	O
the	O
spontaneous	O
nk	O
activity	O
and	O
a	O
partial	O
suppression	O
of	O
cortisol-mediated	O
effects	O
.	O

our	O
results	O
suggest	O
that	O
endogenous	O
glucocorticoids	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
nk	O
cell-mediated	O
cytotoxicity	O
.	O

since	O
the	O
effect	O
of	O
cortisol	O
was	O
additive	O
to	O
that	O
of	O
pge0	B-protein
and	O
was	O
not	O
changed	O
by	O
phosphodiesterase	B-protein
inhibitors	O
,	O
it	O
is	O
conceivable	O
that	O
the	O
hormone	O
acts	O
at	O
a	O
level	O
different	O
from	O
the	O
adenylate	B-protein
cyclase	I-protein
-	O
phosphodiesterase	B-protein
system	O
.	O

data	O
obtained	O
with	O
the	O
use	O
of	O
antiglucocorticoids	B-protein
and	O
the	O
anti-cbg	B-protein
antibody	I-protein
are	O
compatible	O
with	O
a	O
role	O
both	O
of	O
high-affinity	B-protein
glucocorticoid	I-protein
receptors	I-protein
and	O
of	O
cbg	O
in	O
mediating	O
cortisol	O
action	O
on	O
the	O
human	B-cell_line
nk	I-cell_line
cell	I-cell_line
activity	I-cell_line
.	O

###MEDLINE:87014826

interaction	O
of	O
cell-type-specific	O
nuclear	B-protein
proteins	I-protein
with	O
immunoglobulin	B-DNA
vh	I-DNA
promoter	I-DNA
region	I-DNA
sequences	I-DNA
.	O

all	O
human	B-DNA
and	I-DNA
murine	I-DNA
immunoglobulin	I-DNA
heavy	I-DNA
chain	I-DNA
variable	I-DNA
region	I-DNA
(	O
vh	B-DNA
)	I-DNA
genes	I-DNA
contain	O
the	O
sequence	O
atgcaaat	O
approximately	O
00	O
nucleotides	B-DNA
0	I-DNA
'	I-DNA
from	O
the	O
site	O
of	O
transcription	O
initiation	O
.	O

this	O
octanucleotide	O
,	O
in	O
reverse	O
orientation	O
,	O
is	O
also	O
found	O
in	O
all	O
light	B-DNA
chain	I-DNA
variable	I-DNA
region	I-DNA
(	O
vl	B-DNA
)	I-DNA
genes	I-DNA
,	O
and	O
in	O
the	O
immunoglobulin	B-DNA
heavy	I-DNA
chain	I-DNA
transcriptional	I-DNA
enhancer	I-DNA
.	O

transfection	O
studies	O
have	O
established	O
that	O
this	O
octamer	B-DNA
is	O
involved	O
in	O
the	O
lymphoid-specific	O
transcription	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O

octamer-containing	O
fragments	O
have	O
been	O
reported	O
to	O
bind	O
a	O
factor	O
present	O
in	O
nuclear	O
extracts	O
of	O
human	B-cell_line
cell	I-cell_line
lines	I-cell_line
;	O
however	O
,	O
identical	O
binding	O
activity	O
was	O
detected	O
in	O
both	O
b	B-cell_line
lymphoid	I-cell_line
and	I-cell_line
non-lymphoid	I-cell_line
cells	I-cell_line
.	O

here	O
we	O
establish	O
that	O
nuclear	O
extracts	O
from	O
distinct	O
cell	O
types	O
differ	O
in	O
their	O
ability	O
to	O
interact	O
with	O
octamer-containing	B-DNA
fragments	I-DNA
.	O

we	O
have	O
also	O
detected	O
a	O
dna-protein	O
interaction	O
that	O
may	O
be	O
involved	O
in	O
the	O
cell-type	O
specificity	O
of	O
immunoglobulin	B-protein
expression	O
,	O
and	O
we	O
have	O
determined	O
that	O
a	O
sequence	B-DNA
upstream	I-DNA
of	O
the	O
octamer	B-DNA
participates	O
in	O
an	O
interaction	O
with	O
a	O
nuclear	B-protein
protein	I-protein
(	O
s	O
)	O
.	O

###MEDLINE:86259058

preferential	O
transcription	O
of	O
htlv-i	B-DNA
ltr	I-DNA
in	O
cell-free	O
extracts	O
of	O
human	B-cell_type
t	I-cell_type
cells	I-cell_type
producing	O
htlv-i	B-protein
viral	I-protein
proteins	I-protein
.	O

the	O
promoters	O
of	O
the	O
adenovirus	B-DNA
0	I-DNA
major	I-DNA
late	I-DNA
gene	I-DNA
,	O
the	O
mouse	B-DNA
beta-globin	I-DNA
gene	I-DNA
,	O
the	O
mouse	B-DNA
immunoglobulin	I-DNA
vh	I-DNA
gene	I-DNA
and	O
the	O
ltr	B-DNA
of	O
the	O
human	O
t-lymphotropic	O
retrovirus	B-DNA
type	I-DNA
i	I-DNA
were	O
tested	O
for	O
their	O
transcription	O
activities	O
in	O
cell-free	O
extracts	O
of	O
four	O
cell	B-cell_line
lines	I-cell_line
;	O
hela	B-cell_line
,	I-cell_line
cess	I-cell_line
(	O
epstein-barr	B-cell_line
virus-transformed	I-cell_line
human	I-cell_line
b	I-cell_line
cell	I-cell_line
line	I-cell_line
)	O
,	O
mt-0	B-cell_line
(	O
htlv-i-infected	B-cell_line
human	I-cell_line
t	I-cell_line
cell	I-cell_line
line	I-cell_line
without	O
viral	B-protein
protein	I-protein
synthesis	O
)	O
,	O
and	O
mt-0	B-cell_line
(	O
htlv-i-infected	B-cell_line
human	I-cell_line
t	I-cell_line
cell	I-cell_line
line	I-cell_line
producing	O
viral	B-protein
proteins	I-protein
)	O
.	O

ltr	B-DNA
was	O
preferentially	O
transcribed	O
in	O
the	O
extracts	O
of	O
mt-0	O
although	O
the	O
other	O
three	O
genes	O
were	O
transcribed	O
with	O
relatively	O
constant	O
efficiencies	O
in	O
different	O
extracts	O
.	O

the	O
results	O
agree	O
well	O
with	O
the	O
previous	O
in	O
vivo	O
studies	O
on	O
the	O
promoter	O
activity	O
of	O
htlv-i	B-DNA
ltr	I-DNA
.	O

mixing	O
of	O
hela	B-cell_line
and	O
mt-0	B-cell_line
extracts	O
revealed	O
the	O
presence	O
of	O
a	O
ltr-specific	O
stimulating	O
activity	O
in	O
mt-0	O
extracts	O
.	O

###MEDLINE:86092241

a	O
nuclear	B-protein
factor	I-protein
that	O
binds	O
to	O
a	O
conserved	B-DNA
sequence	I-DNA
motif	I-DNA
in	O
transcriptional	B-DNA
control	I-DNA
elements	I-DNA
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O

trans-acting	B-protein
factors	I-protein
that	O
mediate	O
b-cell	O
specific	O
transcription	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
have	O
been	O
postulated	O
based	O
on	O
an	O
analysis	O
of	O
the	O
expression	O
of	O
exogenously	O
introduced	O
immunoglobulin	B-DNA
gene	I-DNA
recombinants	I-DNA
in	O
lymphoid	B-cell_line
and	I-cell_line
non-lymphoid	I-cell_line
cells	I-cell_line
.	O

two	O
b-cell-specific	B-DNA
,	I-DNA
cis-acting	I-DNA
transcriptional	I-DNA
regulatory	I-DNA
elements	I-DNA
have	O
been	O
identified	O
.	O

one	O
element	O
is	O
located	O
in	O
the	O
intron	O
between	O
the	O
variable	O
(	O
v	O
)	O
and	O
constant	O
(	O
c	O
)	O
regions	O
of	O
both	O
heavy	B-DNA
and	I-DNA
kappa	I-DNA
light-chain	I-DNA
genes	I-DNA
and	O
acts	O
as	O
a	O
transcriptional	B-DNA
enhancer	I-DNA
.	O

the	O
second	B-DNA
element	I-DNA
is	O
found	O
upstream	O
of	O
both	O
heavy	B-DNA
and	I-DNA
kappa	I-DNA
light-chain	I-DNA
gene	I-DNA
promoters	I-DNA
.	O

this	O
element	O
directs	O
lymphoid-specific	O
transcription	O
even	O
in	O
the	O
presence	O
of	O
viral	B-DNA
enhancers	I-DNA
.	O

we	O
have	O
sought	O
nuclear	B-protein
factors	I-protein
that	O
might	O
bind	O
specifically	O
to	O
these	O
two	O
regulatory	B-DNA
elements	I-DNA
by	O
application	O
of	O
a	O
modified	O
gel	O
electrophoresis	O
dna	O
binding	O
assay	O
.	O

we	O
report	O
here	O
the	O
identification	O
of	O
a	O
human	B-protein
b-cell	I-protein
nuclear	I-protein
factor	I-protein
(	O
ignf-a	B-protein
)	O
that	O
binds	O
to	O
dna	B-DNA
sequences	I-DNA
in	O
the	O
upstream	B-DNA
regions	I-DNA
of	O
both	O
the	O
mouse	B-DNA
heavy	I-DNA
and	I-DNA
kappa	I-DNA
light-chain	I-DNA
gene	I-DNA
promoters	I-DNA
and	O
also	O
to	O
the	O
mouse	B-DNA
heavy-chain	I-DNA
gene	I-DNA
enhancer	I-DNA
.	O

this	O
sequence-specific	O
binding	O
is	O
probably	O
mediated	O
by	O
a	O
highly	O
conserved	O
sequence	B-DNA
motif	I-DNA
,	O
atttgcat	O
,	O
present	O
in	O
all	O
three	O
transcriptional	B-DNA
elements	I-DNA
.	O

interestingly	O
,	O
a	O
factor	O
showing	O
similar	O
binding	O
specificity	O
to	O
ignf-a	B-protein
is	O
also	O
present	O
in	O
human	B-cell_line
hela	I-cell_line
cells	I-cell_line
.	O

###MEDLINE:86238756

the	O
new	O
world	O
primates	O
as	O
animal	O
models	O
of	O
glucocorticoid	O
resistance	O
.	O

many	O
new	O
world	O
primate	O
species	O
have	O
greatly	O
increased	O
plasma	O
cortisol	O
concentrations	O
,	O
decreased	O
plasma	O
cortisol	O
binding	O
globulin	O
capacity	O
and	O
affinity	O
,	O
marked	O
resistance	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
axis	O
to	O
suppression	O
by	O
dexamethasone	O
,	O
and	O
no	O
biological	O
evidence	O
of	O
glucocorticoid	O
excess	O
.	O

these	O
primates	O
also	O
have	O
high	O
levels	O
of	O
circulating	O
progesterone	O
,	O
estrogen	B-protein
,	I-protein
mineralocorticoid	I-protein
,	I-protein
androgen	I-protein
and	I-protein
vitamin	I-protein
d	I-protein
.	O

the	O
glucocorticoid	O
target	O
tissues	O
that	O
have	O
been	O
examined	O
(	O
circulating	B-cell_type
mononuclear	I-cell_type
lymphocytes	I-cell_type
and	O
cultured	B-cell_line
skin	I-cell_line
fibroblasts	I-cell_line
)	O
have	O
normal	O
concentrations	O
of	O
glucocorticoid	B-protein
receptors	I-protein
with	O
decreased	O
affinity	O
for	O
dexamethasone	O
.	O

transformation	O
of	O
b-lymphocytes	B-cell_type
with	O
the	O
epstein-barr	O
virus	O
leads	O
to	O
glucocorticoid	B-protein
receptor	I-protein
induction	O
that	O
is	O
less	O
than	O
that	O
observed	O
with	O
cells	O
from	O
old	O
world	O
primates	O
.	O

the	O
receptor	O
in	O
these	O
cells	O
has	O
a	O
low	O
affinity	O
for	O
dexamethasone	O
.	O

the	O
low	O
affinity	O
leads	O
to	O
an	O
increased	O
loss	O
of	O
specific	B-protein
bound	I-protein
ligand	I-protein
during	O
thermal	O
activation	O
.	O

meroreceptor	O
generation	O
is	O
normal	O
.	O

the	O
molecular	O
weight	O
of	O
the	O
receptor	O
,	O
determined	O
by	O
sds-page	O
,	O
is	O
similar	O
to	O
that	O
of	O
old	O
world	O
primates	O
(	O
approximately	O
00	O
,	O
000	O
)	O
and	O
the	O
activation	O
pattern	O
per	O
se	O
,	O
examined	O
in	O
vitro	O
by	O
heating	O
cytosol	O
and	O
performing	O
phosphocellulose	O
chromatography	O
,	O
appears	O
similar	O
to	O
that	O
of	O
human	O
controls	O
.	O

the	O
ratios	O
of	O
nuclear	O
to	O
cytosolic	B-protein
hormone-receptor-complexes	I-protein
and	O
of	O
cytosolic	O
activated	O
to	O
unactivated	O
receptor	O
complexes	O
in	O
intact	B-cell_type
cells	I-cell_type
are	O
similar	O
to	O
old	O
world	O
primates	O
.	O

results	O
from	O
mixing	O
studies	O
do	O
not	O
support	O
the	O
hypothesis	O
that	O
a	O
binding	O
inhibitor	O
(	O
s	O
)	O
or	O
a	O
deficient	O
cytosolic	O
positive	B-protein
modifier	I-protein
(	I-protein
s	I-protein
)	I-protein
of	O
binding	O
underlies	O
the	O
findings	O
in	O
these	O
primates	O
.	O

the	O
new	O
world	O
primates	O
,	O
unlike	O
men	O
with	O
the	O
syndrome	O
of	O
primary	O
cortisol	O
resistance	O
,	O
have	O
compensated	O
for	O
their	O
condition	O
with	O
intra-adrenal	B-protein
and	I-protein
mineralocorticoid	I-protein
receptor	I-protein
adaptations	I-protein
.	O

thus	O
,	O
unlike	O
old	O
world	O
primates	O
,	O
cortisol	O
in	O
new	O
world	O
primates	O
has	O
only	O
weak	O
sodium-retaining	O
potency	O
because	O
the	O
aldosterone	B-protein
receptor	I-protein
has	O
a	O
low	O
affinity	O
for	O
cortisol	O
.	O

the	O
common	B-DNA
element	I-DNA
that	O
would	O
explain	O
the	O
apparent	O
resistance	O
to	O
six	O
steroid	O
hormones	O
in	O
new	O
world	O
primates	O

###MEDLINE:98374270

acetylation	O
and	O
modulation	O
of	O
erythroid	B-protein
kruppel-like	I-protein
factor	I-protein
(	O
eklf	B-protein
)	O
activity	O
by	O
interaction	O
with	O
histone	B-protein
acetyltransferases	I-protein
.	O

erythroid	B-protein
kruppel-like	I-protein
factor	I-protein
(	O
eklf	B-protein
)	O
is	O
a	O
red	B-protein
cell-specific	I-protein
transcriptional	I-protein
activator	I-protein
that	O
is	O
crucial	O
for	O
consolidating	O
the	O
switch	O
to	O
high	O
levels	O
of	O
adult	O
beta-globin	O
expression	O
during	O
erythroid	O
ontogeny	O
.	O

eklf	B-protein
is	O
required	O
for	O
integrity	O
of	O
the	O
chromatin	B-DNA
structure	O
at	O
the	O
beta-like	B-DNA
globin	I-DNA
locus	I-DNA
,	O
and	O
it	O
interacts	O
with	O
a	O
positive-acting	B-protein
factor	I-protein
in	O
vivo	O
.	O

we	O
find	O
that	O
eklf	B-protein
is	O
an	O
acetylated	B-protein
transcription	I-protein
factor	I-protein
,	O
and	O
that	O
it	O
interacts	O
in	O
vivo	O
with	O
cbp	B-protein
,	O
p000	B-protein
,	O
and	O
p/caf	B-protein
.	O

however	O
,	O
its	O
interactions	O
with	O
these	O
histone	B-protein
acetyltransferases	I-protein
are	O
not	O
equivalent	O
,	O
as	O
cbp	B-protein
and	O
p000	B-protein
,	O
but	O
not	O
p/caf	B-protein
,	O
utilize	O
eklf	B-protein
as	O
a	O
substrate	O
for	O
in	O
vitro	O
acetylation	O
within	O
its	O
trans-activation	B-protein
region	I-protein
.	O

the	O
functional	O
effects	O
of	O
these	O
interactions	O
are	O
that	O
cbp	B-protein
and	O
p000	B-protein
,	O
but	O
not	O
p/caf	B-protein
,	O
enhance	O
eklf	B-protein
's	O
transcriptional	O
activation	O
of	O
the	O
beta-globin	B-DNA
promoter	I-DNA
in	O
erythroid	B-cell_type
cells	I-cell_type
.	O

these	O
results	O
establish	O
eklf	B-protein
as	O
a	O
tissue-specific	O
transcription	B-protein
factor	I-protein
that	O
undergoes	O
post-translational	O
acetylation	O
and	O
suggest	O
a	O
mechanism	O
by	O
which	O
eklf	B-protein
is	O
able	O
to	O
alter	O
chromatin	O
structure	O
and	O
induce	O
beta-globin	B-protein
expression	O
within	O
the	O
beta-like	B-DNA
globin	I-DNA
cluster	I-DNA
.	O

###MEDLINE:98362153

recognition	O
of	O
herpes	B-protein
simplex	I-protein
virus	I-protein
type	I-protein
0	I-protein
tegument	I-protein
proteins	I-protein
by	O
cd0	B-cell_type
t	I-cell_type
cells	I-cell_type
infiltrating	O
human	O
genital	O
herpes	O
lesions	O
.	O

the	O
local	O
cellular	O
immune	O
response	O
to	O
herpes	B-protein
simplex	I-protein
virus	I-protein
(	I-protein
hsv	I-protein
)	I-protein
is	O
important	O
in	O
the	O
control	O
of	O
recurrent	O
hsv	O
infection	O
.	O

the	O
antiviral	O
functions	O
of	O
infiltrating	B-cell_type
cd0-bearing	I-cell_type
t	I-cell_type
cells	I-cell_type
may	O
include	O
cytotoxicity	O
,	O
inhibition	O
of	O
viral	O
growth	O
,	O
lymphokine	B-protein
secretion	O
,	O
and	O
support	O
of	O
humoral	O
and	O
cd0	B-protein
responses	O
.	O

the	O
antigens	O
recognized	O
by	O
many	O
hsv-specific	B-cell_type
cd0	I-cell_type
t	I-cell_type
cells	I-cell_type
localizing	O
to	O
genital	O
hsv-0	O
lesions	O
are	O
unknown	O
.	O

t	B-cell_type
cells	I-cell_type
recognizing	O
antigens	O
encoded	O
within	O
map	O
units	O
0.00	O
to	O
0.00	O
of	O
hsv	B-DNA
dna	I-DNA
are	O
frequently	O
recovered	O
from	O
herpetic	O
lesions	O
.	O

expression	O
cloning	O
with	O
this	O
region	O
of	O
dna	O
now	O
shows	O
that	O
tegument	B-protein
protein	I-protein
vp00	B-protein
and	O
the	O
viral	B-protein
dutpase	I-protein
,	O
encoded	O
by	O
genes	B-DNA
ul00	B-DNA
and	O
ul00	B-protein
,	O
respectively	O
,	O
are	O
t-cell	B-protein
antigens	I-protein
.	O

separate	O
epitopes	O
in	O
vp00	B-protein
were	O
defined	O
for	O
t-cell	B-cell_line
clones	I-cell_line
from	O
each	O
of	O
three	O
patients	O
.	O

reactivity	O
with	O
the	O
tegument	B-protein
protein	I-protein
encoded	O
by	O
ul00	B-protein
was	O
identified	O
for	O
an	O
additional	O
patient	O
.	O

three	O
new	O
epitopes	O
were	O
identified	O
in	O
vp00	B-protein
,	O
a	O
tegument	B-protein
protein	I-protein
associated	O
with	O
vp00	B-protein
.	O

some	O
tegument-specific	B-cell_line
cd0	I-cell_line
t-cell	I-cell_line
clones	I-cell_line
exhibited	O
cytotoxic	O
activity	O
against	O
hsv-infected	B-cell_type
cells	I-cell_type
.	O

these	O
results	O
suggest	O
that	O
herpes	B-protein
simplex	I-protein
tegument	I-protein
proteins	I-protein
are	O
processed	O
for	O
antigen	O
presentation	O
in	O
vivo	O
and	O
are	O
possible	O
candidate	O
compounds	O
for	O
herpes	O
simplex	O
vaccines	O
.	O

###MEDLINE:98349401

fibrinogen	B-protein
activates	O
nf-kappa	B-protein
b	I-protein
transcription	I-protein
factors	I-protein
in	O
mononuclear	B-cell_type
phagocytes	I-cell_type
.	O

adhesion	O
to	O
extracellular	O
matrices	O
is	O
known	O
to	O
modulate	O
leukocyte	O
activation	O
,	O
although	O
the	O
mechanisms	O
are	O
not	O
fully	O
understood	O
.	O

mononuclear	B-cell_type
phagocytes	I-cell_type
are	O
exposed	O
to	O
fibrinous	O
provisional	O
matrix	O
throughout	O
migration	O
into	O
inflammatory	O
foci	O
,	O
so	O
this	O
study	O
was	O
undertaken	O
to	O
determine	O
whether	O
fibrinogen	B-protein
triggers	O
activation	O
of	O
nf-kappa	B-protein
b	I-protein
transcription	I-protein
factors	I-protein
.	O

u000	B-cell_line
cells	I-cell_line
differentiated	O
with	O
pma	O
in	O
nonadherent	B-cell_line
culture	I-cell_line
were	O
shown	O
to	O
express	O
two	O
fibrinogen-binding	B-protein
integrins	I-protein
,	O
predominately	O
cd00b/cd00	B-protein
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
cd00c/cd00	O
.	O

cells	O
stimulated	O
with	O
fibrinogen	B-protein
(	O
00-000	O
microg/ml	O
)	O
/mn0+	O
(	O
00	O
microm	O
)	O
for	O
0	O
h	O
were	O
examined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

nf-kappa	B-protein
b	I-protein
activation	O
,	O
minimal	O
in	O
unstimulated	B-cell_type
cells	I-cell_type
,	O
was	O
substantially	O
up-regulated	O
by	O
fibrinogen	B-protein
.	O

fibrinogen	B-protein
also	O
caused	O
activation	O
of	O
ap-0	B-protein
,	O
but	O
not	O
sp0	B-protein
or	O
camp	B-protein
response	I-protein
element-binding	I-protein
protein	I-protein
(	O
creb	B-protein
)	I-protein
factors	I-protein
.	O

blocking	O
mabs	B-protein
against	O
cd00	B-protein
and	O
cd00b	B-protein
abrogated	O
fibrinogen	B-protein
-induced	O
nf-kappa	B-protein
b	I-protein
activation	O
.	O

to	O
determine	O
the	O
effects	O
on	O
transcriptional	O
regulation	O
,	O
u000	B-cell_line
cells	I-cell_line
were	O
transfected	O
with	O
a	O
plasmid	B-DNA
containing	O
the	O
hiv-0	B-DNA
enhancer	I-DNA
(	O
bearing	O
two	O
nf-kappa	B-DNA
b	I-DNA
sites	I-DNA
)	O
coupled	O
to	O
a	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
(	I-DNA
cat	I-DNA
)	I-DNA
reporter	I-DNA
.	O

cells	O
were	O
subsequently	O
stimulated	O
with	O
0	O
)	O
pma	O
for	O
00	O
h	O
,	O
inducing	O
cat	B-protein
activity	O
by	O
0.0-fold	O
,	O
0	O
)	O
fibrinogen	B-protein
/mn0+	O
for	O
0	O
h	O
,	O
inducing	O
cat	B-protein
activity	O
by	O
0.0-fold	O
,	O
or	O
0	O
)	O
costimulation	O
with	O
fibrinogen	B-protein
and	O
pma	O
,	O
inducing	O
0.0-fold	O
the	O
cat	B-protein
activity	O
induced	O
by	O
pma	O
alone	O
.	O

we	O
conclude	O
that	O
contact	O
with	O
fibrinogen-derived	B-protein
proteins	I-protein
may	O
contribute	O
to	O
mononuclear	O
phagocyte	O
activation	O
by	O
signaling	O
through	O
cd00b/cd00	B-protein
,	O
resulting	O
in	O
selective	O
activation	O
of	O
transcriptional	B-protein
regulatory	I-protein
factors	I-protein
,	O
including	O
nf-kappa	B-protein
b	I-protein
.	O

###MEDLINE:98339383

peripheral	B-cell_type
blood	I-cell_type
t	I-cell_type
cells	I-cell_type
and	O
monocytes	B-cell_type
and	O
b	B-cell_line
cell	I-cell_line
lines	I-cell_line
derived	O
from	O
patients	O
with	O
lupus	O
express	O
estrogen	B-RNA
receptor	I-RNA
transcripts	I-RNA
similar	O
to	O
those	O
of	O
normal	B-cell_type
cells	I-cell_type
.	O

objective	O
:	O
to	O
identify	O
and	O
characterize	O
estrogen	B-RNA
receptor	I-RNA
(	I-RNA
er	I-RNA
)	I-RNA
transcripts	I-RNA
expressed	O
in	O
immune	B-cell_type
cells	I-cell_type
of	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
sle	O
)	O
and	O
healthy	O
donors	O
.	O

methods	O
:	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
and	O
t	B-cell_type
cells	I-cell_type
were	O
prepared	O
from	O
patients	O
with	O
sle	O
(	O
n	O
=	O
0	O
)	O
and	O
healthy	O
donors	O
(	O
n	O
=	O
0	O
)	O
.	O

t	B-cell_type
cells	I-cell_type
were	O
separated	O
into	O
cd0	B-protein
and	O
cd0	B-protein
.	O

some	O
monocytes	B-cell_type
and	O
t	B-cell_type
cells	I-cell_type
were	O
stimulated	O
with	O
estradiol	O
,	O
pma	O
,	O
and	O
ionomycin	O
.	O

epstein-barr	B-cell_line
virus-transformed	I-cell_line
b	I-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
n	O
=	O
0	O
)	O
and	O
b	B-cell_line
cell	I-cell_line
hybridomas	I-cell_line
(	O
n	O
=	O
0	O
)	O
established	O
from	O
patients	O
with	O
sle	O
and	O
a	O
healthy	O
individual	O
were	O
used	O
as	O
a	O
b	O
cell	O
source	O
.	O

these	O
cells	O
were	O
examined	O
for	O
er	B-RNA
mrna	I-RNA
by	O
reverse	O
transcription	O
nested	O
polymerase	O
chain	O
reaction	O
.	O

amplified	B-DNA
cdna	I-DNA
were	O
sequenced	O
by	O
standard	O
methods	O
.	O

results	O
:	O
in	O
all	O
cells	O
tested	O
,	O
er	B-RNA
mrna	I-RNA
was	O
expressed	O
without	O
prior	O
in	O
vitro	O
stimulation	O
.	O

partial	O
sequences	O
from	O
exons	B-DNA
0-0	I-DNA
were	O
nearly	O
identical	O
to	O
the	O
published	O
sequence	O
of	O
the	O
human	O
er	B-RNA
mrna	I-RNA
.	O

there	O
were	O
no	O
notable	O
differences	O
in	O
the	O
er	B-RNA
transcripts	I-RNA
between	O
patients	O
and	O
healthy	O
controls	O
.	O

variant	O
receptor	O
transcripts	O
lacking	O
exon	B-DNA
0	I-DNA
or	I-DNA
exon	I-DNA
0	I-DNA
,	O
which	O
encodes	O
the	O
hormone	B-protein
binding	I-protein
domain	I-protein
,	O
were	O
identified	O
in	O
the	O
majority	O
of	O
the	O
cells	O
.	O

precise	O
deletion	O
of	O
the	O
exons	B-DNA
suggests	O
that	O
they	O
are	O
alternatively	O
spliced	O
transcripts	O
.	O

whether	O
the	O
detected	O
transcripts	O
are	O
translated	O
into	O
functional	B-protein
receptor	I-protein
proteins	I-protein
remains	O
to	O
be	O
determined	O
.	O

in	O
vitro	O
stimulation	O
did	O
not	O
affect	O
er	B-RNA
mrna	I-RNA
expression	O
.	O

the	O
presence	O
of	O
variants	O
did	O
not	O
correlate	O
with	O
disease	O
activity	O
or	O
medication	O
.	O

conclusion	O
:	O
monocytes	B-cell_type
,	O
t	B-cell_type
cells	I-cell_type
,	O
and	O
b	B-cell_type
cells	I-cell_type
in	O
patients	O
express	O
transcripts	O
of	O
the	O
normal	O
wild	B-protein
type	I-protein
er	I-protein
and	O
the	O
hormone	B-protein
binding	I-protein
domain	I-protein
variants	O
in	O
vivo	O
.	O

###MEDLINE:98325368

dna	O
damaging	O
agents	O
induce	O
expression	O
of	O
fas	B-protein
ligand	I-protein
and	O
subsequent	O
apoptosis	O
in	O
t	B-cell_type
lymphocytes	I-cell_type
via	O
the	O
activation	O
of	O
nf-kappa	B-protein
b	I-protein
and	O
ap-0	B-protein
.	O

apoptosis	O
induced	O
by	O
dna	O
damage	O
and	O
other	O
stresses	O
can	O
proceed	O
via	O
expression	O
of	O
fas	B-protein
ligand	I-protein
(	O
fasl	B-protein
)	O
and	O
ligation	O
of	O
its	O
receptor	O
,	O
fas	B-protein
(	O
cd00	B-protein
)	O
.	O

we	O
report	O
that	O
activation	O
of	O
the	O
two	O
transcription	B-protein
factors	I-protein
nf-kappa	B-protein
b	I-protein
and	O
ap-0	B-protein
is	O
crucially	O
involved	O
in	O
fasl	B-protein
expression	O
induced	O
by	O
etoposide	O
,	O
teniposide	O
,	O
and	O
uv	O
irradiation	O
.	O

a	O
nondegradable	B-protein
mutant	I-protein
of	O
i	B-protein
kappa	I-protein
b	I-protein
blocked	O
both	O
fasl	B-protein
expression	O
and	O
apoptosis	O
induced	O
by	O
dna	O
damage	O
but	O
not	O
fas	B-protein
ligation	O
.	O

these	O
stimuli	O
also	O
induced	O
the	O
stress-activated	B-protein
kinase	I-protein
pathway	O
(	O
sapk/jnk	B-protein
)	O
,	O
which	O
was	O
required	O
for	O
the	O
maximal	O
induction	O
of	O
apoptosis	O
.	O

a	O
0.0	B-DNA
kb	I-DNA
fasl	I-DNA
promoter	I-DNA
responded	O
to	O
dna	O
damage	O
,	O
as	O
well	O
as	O
coexpression	O
with	O
p00	B-protein
rel	I-protein
or	O
fos/jun	B-protein
.	O

mutations	O
in	O
the	O
relevant	O
nf-kappa	B-protein
b	I-protein
and	O
ap-0	B-DNA
binding	I-DNA
sites	I-DNA
eliminated	O
these	O
responses	O
.	O

thus	O
,	O
activation	O
of	O
nf-kappa	B-protein
b	I-protein
and	O
ap-0	B-protein
contributes	O
to	O
stress-induced	O
apoptosis	O
via	O
the	O
expression	O
of	O
fasl	B-protein
.	O

###MEDLINE:98322350

a	O
small	O
,	O
nonpeptidyl	O
mimic	O
of	O
granulocyte-colony-stimulating	B-protein
factor	I-protein
[	O
see	O
commetns	B-protein
]	O

a	O
nonpeptidyl	O
small	O
molecule	O
sb	O
000000	O
,	O
capable	O
of	O
activating	O
granulocyte-colony-stimulating	B-protein
factor	I-protein
(	O
g-csf	B-protein
)	O
signal	O
transduction	O
pathways	O
,	O
was	O
identified	O
in	O
a	O
high-throughput	O
assay	O
in	O
cultured	B-cell_line
cells	I-cell_line
.	O

like	O
g-csf	B-protein
,	O
sb	O
000000	O
induced	O
tyrosine	O
phosphorylation	O
of	O
multiple	B-protein
signaling	I-protein
proteins	I-protein
and	O
stimulated	B-cell_type
primary	I-cell_type
murine	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
to	O
form	O
granulocytic	O
colonies	O
in	O
vitro	O
.	O

it	O
also	O
elevated	O
peripheral	B-cell_type
blood	I-cell_type
neutrophil	I-cell_type
counts	O
in	O
mice	O
.	O

the	O
extracellular	B-protein
domain	I-protein
of	O
the	O
murine	B-protein
g-csf	I-protein
receptor	I-protein
was	O
required	O
for	O
the	O
activity	O
of	O
sb	O
000000	O
,	O
suggesting	O
that	O
the	O
compound	O
acts	O
by	O
oligomerizing	B-protein
receptor	I-protein
chains	I-protein
.	O

the	O
results	O
indicate	O
that	O
a	O
small	B-protein
molecule	I-protein
can	O
activate	O
a	O
receptor	O
that	O
normally	O
binds	O
a	O
relatively	O
large	O
protein	B-protein
ligand	I-protein
.	O

###MEDLINE:98305722

minimal	O
residual	O
disease	O
in	O
acute	O
myelogenous	O
leukemia	O
with	O
pml/rar	B-RNA
alpha	I-RNA
or	I-RNA
aml0/eto	I-RNA
mrna	I-RNA
and	O
phenotypic	O
analysis	O
of	O
possible	B-cell_type
t	I-cell_type
and	I-cell_type
natural	I-cell_type
killer	I-cell_type
cells	I-cell_type
in	O
bone	O
marrow	O
.	O

here	O
we	O
studied	O
minimal	O
residual	O
disease	O
(	O
mrd	O
)	O
of	O
patients	O
with	O
acute	O
myeloid	O
leukemia	O
(	O
aml	O
)	O
who	O
have	O
pml/rar	B-protein
alpha	I-protein
or	O
aml0/eto	B-protein
as	O
well	O
as	O
the	O
phenotypic	O
analysis	O
of	O
lymphocyte	B-cell_type
subsets	I-cell_type
involved	O
in	O
antitumor	O
immunity	O
.	O

eight	O
patients	O
in	O
long-term	O
(	O
lt	B-protein
;	O
0	O
to	O
00	O
years	O
)	O
and	O
00	O
patients	O
in	O
short-term	O
(	O
st	O
;	O
up	O
to	O
0	O
years	O
)	O
remission	O
were	O
studied	O
.	O

using	O
the	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
(	O
rt	O
)	O
assay	O
,	O
the	O
limit	O
of	O
detection	O
was	O
00	O
(	O
-0	O
)	O
to	O
00	O
(	O
-0	O
)	O
for	O
pml/rar	B-RNA
alpha	I-RNA
transcript	I-RNA
and	O
00	O
(	O
-0	O
)	O
to	O
00	O
(	O
-0	O
)	O
for	O
the	O
aml0/eto	B-RNA
transcript	I-RNA
.	O

simultaneously	O
,	O
t	B-cell_type
lymphocyte	I-cell_type
subsets	I-cell_type
and	O
nk	B-cell_type
cells	I-cell_type
from	O
the	O
peripheral	B-cell_type
blood	I-cell_type
(	I-cell_type
pb	I-cell_type
)	I-cell_type
and	O
bone	O
marrow	O
(	O
bm	B-cell_type
)	O
were	O
investigated	O
by	O
flow	O
cytometric	O
analysis	O
.	O

four	O
of	O
the	O
eight	O
patients	O
in	O
lt	B-protein
and	O
0	O
of	O
the	O
00	O
patients	O
in	O
st	O
remission	O
were	O
mrd-positive	O
.	O

although	O
all	O
mrd-positive	O
patients	O
in	O
lt	O
remission	O
are	O
still	O
until	O
now	O
event-free	O
,	O
0	O
of	O
the	O
0	O
mrd-positive	O
(	O
mrd+	O
)	O
patients	O
in	O
st	O
remission	O
soon	O
relapsed	O
.	O

the	O
total	O
populations	O
of	O
cd0	B-protein
+	O
,	O
cd0	B-protein
+	O
and	O
cd00	B-protein
+	O
[	O
possible	O
t-cell	O
and	O
natural	B-cell_type
killer	I-cell_type
(	O
t/nk	B-cell_type
)	O
populations	O
]	O
in	O
the	O
bm	O
of	O
st	O
patients	O
and	O
mrd+/lt	O
patients	O
were	O
significantly	O
(	O
p	O
<	O
.00	O
)	O
low	O
.	O

the	O
cd0+	B-cell_line
cd00+	I-cell_line
population	I-cell_line
showed	O
the	O
same	O
tendency	O
(	O
p	O
<	O
.00-.00	O
)	O
.	O

the	O
t/nk	B-cell_type
subsets	I-cell_type
in	O
the	O
bm	O
of	O
mrd-negative	O
(	O
mrd-	O
)	O
lt	B-protein
(	O
mrd-/lt	O
)	O
patients	O
showed	O
similar	O
numbers	O
of	O
cells	O
as	O
normal	O
volunteers	O
.	O

basically	O
,	O
the	O
total	O
percentage	O
of	O
the	O
cd0+	B-cell_line
,	I-cell_line
cd0+	I-cell_line
and	I-cell_line
cd00+	I-cell_line
cell	I-cell_line
populations	I-cell_line
in	O
the	O
bm	O
was	O
increased	O
and	O
in	O
the	O
following	O
order	O
:	O
mrd-/lt	O
patients	O
,	O
normal	O
volunteers	O
,	O
mrd+/lt	O
patients	O
and	O
mrd+	O
or	O
-/st	O
patients	O
.	O

the	O
percentages	O
of	O
the	O
t/nk-cell	B-cell_type
subsets	I-cell_type
in	O
the	O
pb	O
were	O
not	O
significantly	O
different	O
among	O
these	O
groups	O
.	O

thus	O
,	O
the	O
difference	O
of	O
the	O
possible	O
t/nk-cell	B-cell_type
phenotype	I-cell_type
in	O
the	O
bm	O
may	O
strongly	O
influence	O
clinical	O
and	O
molecular	O
remission	O
.	O

these	O
results	O
still	O
remain	O
to	O
be	O
confirmed	O
by	O
further	O
studies	O
of	O
the	O
functional	O
anti-tumor	O
immunity	O
of	O
t/nk	B-cell_type
cells	I-cell_type
of	O
aml	O
in	O
remission	O
.	O

###MEDLINE:98295832

mycobacterium	O
tuberculosis	O
mannose-capped	O
lipoarabinomannan	O
can	O
induce	O
nf-kappab	B-protein
-dependent	O
activation	O
of	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
0	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
in	O
t	B-cell_type
cells	I-cell_type
.	O

tuberculosis	O
has	O
emerged	O
as	O
an	O
epidemic	O
,	O
extended	O
by	O
the	O
large	O
number	O
of	O
individuals	O
infected	O
with	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
0	I-DNA
(	O
hiv-0	O
)	O
.	O

the	O
major	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
mycobacterial	O
cell	O
wall	O
component	O
mannose-capped	O
lipoarabinomannan	O
(	O
manlam	O
)	O
of	O
mycobacterium	O
tuberculosis	O
(	O
m.	O
tuberculosis	O
)	O
could	O
activate	O
transcription	O
of	O
hiv-0	O
in	O
t	B-cell_type
cells	I-cell_type
with	O
the	O
use	O
of	O
an	O
in	O
vitro	O
cell	O
culture	O
system	O
.	O

these	O
experiments	O
are	O
of	O
prime	O
importance	O
considering	O
that	O
cd0	B-protein
-expressing	O
t	B-cell_type
lymphocytes	I-cell_type
represent	O
the	O
major	O
virus	O
reservoir	O
in	O
the	O
peripheral	O
blood	O
of	O
infected	O
individuals	O
.	O

using	O
the	O
0g0	B-cell_line
cell	I-cell_line
line	I-cell_line
harbouring	O
the	O
luciferase	B-DNA
reporter	I-DNA
gene	I-DNA
under	O
the	O
control	O
of	O
the	O
hiv-0	B-DNA
ltr	I-DNA
,	O
it	O
was	O
first	O
found	O
that	O
culture	O
protein	O
filtrates	O
(	O
cfp	O
)	O
from	O
m.	O
tuberculosis	O
or	O
purified	O
manlam	O
could	O
activate	O
hiv-0	B-DNA
ltr-dependent	I-DNA
gene	I-DNA
expression	O
unlike	O
similarly	O
prepared	O
cfp	O
extracts	O
devoid	O
of	O
manlam	O
.	O

the	O
implication	O
of	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
(	I-protein
s	I-protein
)	I-protein
,	I-protein
protein	I-protein
kinase	I-protein
a	I-protein
and/or	I-protein
protein	I-protein
kinase	I-protein
c	I-protein
was	O
highlighted	O
by	O
the	O
abrogation	O
of	O
the	O
manlam-mediated	O
activation	O
of	O
hiv-0	B-DNA
ltr-driven	I-DNA
gene	I-DNA
expression	O
using	O
herbimycin	O
a	O
and	O
h0	B-cell_line
.	O

it	O
was	O
also	O
determined	O
,	O
using	O
electrophoresis	O
mobility	O
shift	O
assays	O
,	O
that	O
m.	O
tuberculosis	O
manlam	O
led	O
to	O
the	O
nuclear	O
translocation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nf-kappab	B-protein
.	O

m.	O
tuberculosis	O
manlam	O
resulted	O
in	O
clear	O
induction	O
of	O
the	O
luciferase	B-DNA
gene	I-DNA
placed	O
under	O
the	O
control	O
of	O
the	O
wild-type	O
,	O
but	O
not	O
the	O
kappab-mutated	B-DNA
,	I-DNA
hiv-0	I-DNA
ltr	I-DNA
region	I-DNA
.	O

finally	O
,	O
the	O
manlam-mediated	O
activation	O
of	O
hiv-0	B-DNA
ltr	I-DNA
transcription	O
was	O
found	O
to	O
be	O
independent	O
of	O
the	O
autocrine	O
or	O
paracrine	O
action	O
of	O
endogenous	O
tnf-alpha	B-protein
.	O

the	O
results	O
suggest	O
that	O
m.	O
tuberculosis	O
can	O
upregulate	O
hiv-0	O
expression	O
in	O
t	B-cell_type
cells	I-cell_type
and	O
could	O
thus	O
have	O
the	O
potential	O
to	O
influence	O
the	O
pathogenesis	O
of	O
hiv-0	O
infection	O
.	O

###MEDLINE:98230439

human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
0	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
quasispecies	O
differ	O
in	O
basal	O
transcription	O
and	O
nuclear	B-protein
factor	I-protein
recruitment	O
in	O
human	B-cell_type
glial	I-cell_type
cells	I-cell_type
and	O
lymphocytes	B-cell_type
.	O

the	O
generation	O
of	O
genomic	O
diversity	O
during	O
the	O
course	O
of	O
infection	O
has	O
the	O
potential	O
to	O
affect	O
all	O
aspects	O
of	O
hiv-0	O
replication	O
,	O
including	O
expression	O
of	O
the	O
proviral	B-DNA
genome	I-DNA
.	O

to	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
impact	O
of	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
ltr	B-DNA
)	O
sequence	O
diversity	O
on	O
ltr-directed	B-DNA
gene	I-DNA
expression	O
in	O
cells	O
of	O
the	O
central	O
nervous	O
system	O
(	O
cns	O
)	O
and	O
immune	O
system	O
,	O
we	O
amplified	O
and	O
cloned	B-DNA
ltrs	I-DNA
from	O
proviral	O
dna	O
in	O
hiv-0-infected	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
.	O

sequence	O
analysis	O
of	O
nineteen	O
ltrs	B-DNA
cloned	O
from	O
0	O
adult	O
and	O
0	O
pediatric	O
patients	O
revealed	O
an	O
average	O
of	O
00	O
nucleotide	O
changes	O
(	O
with	O
respect	O
to	O
the	O
sequence	O
of	O
the	O
lai	B-DNA
ltr	I-DNA
)	O
within	O
the	O
000-bp	B-DNA
u0	I-DNA
region	I-DNA
.	O

transient	O
expression	O
analyses	O
in	O
cells	O
of	O
neuroglial	B-cell_type
and	I-cell_type
lymphocytic	I-cell_type
origin	I-cell_type
demonstrated	O
that	O
some	O
of	O
these	O
ltrs	B-DNA
had	O
activities	O
which	O
varied	O
significantly	O
from	O
the	O
lai	B-DNA
ltr	I-DNA
in	O
u-000	B-cell_line
mg	I-cell_line
cells	I-cell_line
(	O
an	O
astrocytoma	B-cell_line
cell	I-cell_line
line	I-cell_line
)	O
as	O
well	O
as	O
in	O
jurkat	B-cell_line
cells	I-cell_line
(	O
a	O
cd0-positive	B-cell_line
lymphocyte	I-cell_line
cell	I-cell_line
line	I-cell_line
)	O
.	O

while	O
ltrs	B-DNA
which	O
demonstrated	O
the	O
highest	O
activities	O
in	O
u-000	B-cell_line
mg	I-cell_line
cells	I-cell_line
also	O
yielded	O
high	O
activities	O
in	O
jurkat	B-cell_line
cells	I-cell_line
,	O
the	O
ltrs	B-DNA
were	O
generally	O
more	O
active	O
in	O
jurkat	B-cell_line
cells	I-cell_line
when	O
compared	O
to	O
the	O
lai	B-DNA
ltr	I-DNA
.	O

differences	O
in	O
ltr	B-DNA
sequence	I-DNA
also	O
resulted	O
in	O
differences	O
in	O
transcription	B-protein
factor	I-protein
recruitment	O
to	O
cis-acting	B-DNA
sites	I-DNA
within	O
the	O
u0	B-DNA
region	I-DNA
of	O
the	O
ltr	B-DNA
,	O
as	O
demonstrated	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

in	O
particular	O
,	O
naturally	O
occurring	O
sequence	O
variation	O
impacted	O
transcription	B-protein
factor	I-protein
binding	O
to	O
an	O
activating	B-protein
transcription	I-protein
factor	I-protein
/	O
camp	B-DNA
response	I-DNA
element	I-DNA
binding	O
(	O
atf	B-protein
/	O
creb	B-protein
)	I-protein
binding	I-protein
site	I-protein
(	O
located	O
between	O
the	O
lef-0	B-protein
and	O
distal	B-DNA
nf-kappab	I-DNA
transcription	I-DNA
factor	I-DNA
binding	I-DNA
sites	I-DNA
)	O
that	O
we	O
identified	O
in	O
previous	O
studies	O
of	O
the	O
hiv-0	B-DNA
ltr	I-DNA
.	O

these	O
findings	O
suggest	O
that	O
ltr	B-DNA
sequence	O
changes	O
can	O
significantly	O
affect	O
basal	O
ltr	B-DNA
function	O
and	O
transcription	B-protein
factor	I-protein
recruitment	O
,	O
which	O
may	O
,	O
in	O
turn	O
,	O
alter	O
the	O
course	O
of	O
viral	O
replication	O
in	O
cells	O
of	O
cns	O
and	O
immune	O
system	O
origin	O
.	O

###MEDLINE:98282480

hmg	B-protein
box	I-protein
containing	I-protein
transcription	I-protein
factors	I-protein
in	O
lymphocyte	O
differentiation	O
.	O

the	O
identification	O
of	O
the	O
mammalian	B-DNA
sex-determining	I-DNA
gene	I-DNA
sry	I-DNA
has	O
led	O
to	O
the	O
discovery	O
of	O
a	O
large	O
family	O
of	O
related	O
(	O
'	O
hmg	B-protein
box	I-protein
'	I-protein
)	I-protein
transcription	I-protein
factors	I-protein
that	O
control	O
developmental	O
events	O
in	O
yeast	O
,	O
c.	O
elegans	O
,	O
drosophila	O
and	O
vertebrates	O
.	O

in	O
lymphocyte	O
differentiation	O
,	O
several	O
hmg	B-protein
box	I-protein
proteins	I-protein
play	O
a	O
decisive	O
role	O
.	O

sox-0	B-protein
is	O
important	O
for	O
very	O
early	O
b-cell	O
differentiation	O
,	O
while	O
tcf-0	B-protein
/	O
lef-0	B-protein
play	O
a	O
crucial	O
role	O
in	O
early	O
thymocyte	O
development	O
.	O

tcf/lef	B-protein
proteins	I-protein
have	O
recently	O
been	O
found	O
to	O
constitute	O
a	O
downstream	O
component	O
of	O
the	O
wingless/wnt	O
signal	O
transduction	O
pathway	O
.	O

in	O
flies	O
,	O
this	O
pathway	O
controls	O
segment	O
polarity	O
;	O
in	O
xenopus	O
it	O
controls	O
the	O
definition	O
of	O
the	O
body	O
axis	O
.	O

deregulation	O
of	O
the	O
pathway	O
occurs	O
in	O
several	O
human	B-cell_type
tumors	I-cell_type
.	O

these	O
insights	O
in	O
the	O
molecular	O
events	O
that	O
are	O
involved	O
in	O
tcf/lef	B-protein
function	O
in	O
these	O
organisms	O
may	O
eventually	O
lead	O
to	O
the	O
understanding	O
of	O
the	O
function	O
of	O
these	O
hmg	B-protein
box	I-protein
proteins	I-protein
in	O
lymphoid	O
development	O

###MEDLINE:98371688

transcriptional	O
regulation	O
by	O
c/ebp	B-protein
alpha	I-protein
and	O
-beta	O
in	O
the	O
expression	O
of	O
the	O
gene	O
for	O
the	O
mrp00	B-DNA
myeloid	O
calcium	O
binding	O
protein	O
.	O

transcriptional	O
regulation	O
of	O
the	O
gene	O
for	O
the	O
myeloid	O
calcium	O
binding	O
protein	O
,	O
mrp00	B-DNA
,	O
was	O
investigated	O
in	O
human	B-cell_line
monocytic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

the	O
mrp00	B-DNA
gene	I-DNA
was	O
not	O
expressed	O
in	B-cell_line
monoblastic	I-cell_line
ml-0	I-cell_line
cells	I-cell_line
,	O
promonocytic	B-cell_line
u-000	I-cell_line
cells	I-cell_line
,	O
or	O
promyelocytic	B-cell_line
hl-00	I-cell_line
cells	I-cell_line
.	O

on	O
the	O
other	O
hand	O
,	O
the	O
gene	O
was	O
expressed	O
in	O
monocytic	B-cell_line
thp-0	I-cell_line
cells	I-cell_line
and	O
in	O
the	O
hl-00	B-cell_line
cells	I-cell_line
treated	O
with	O
0	O
,	O
00-dihydroxyvitamin	O
d0	O
(	O
vd0	O
)	O
.	O

the	O
level	O
of	O
mrp00	B-DNA
in	O
vd0-treated	B-cell_line
hl-00	I-cell_line
cells	I-cell_line
was	O
two-fold	O
higher	O
than	O
that	O
in	O
thp-0	B-cell_line
cells	I-cell_line
.	O

among	O
several	O
known	O
transcription	B-protein
factor	I-protein
binding	I-protein
motifs	I-protein
,	O
nuclear	B-protein
protein	I-protein
(	O
s	O
)	O
of	O
vd0-treated	B-cell_line
hl-00	I-cell_line
cells	I-cell_line
and	O
thp-0	B-cell_line
cells	I-cell_line
bound	O
to	O
the	O
ccaat/enhancer	B-protein
binding	I-protein
protein	I-protein
(	O
c/ebp	B-protein
)	I-protein
-binding	I-protein
motif	I-protein
that	O
was	O
located	O
in	O
the	O
upstream	B-DNA
region	I-DNA
of	O
the	O
mrp00	B-DNA
gene	I-DNA
(	O
-00	O
)	O
,	O
as	O
evidenced	O
by	O
the	O
competitive	O
gel	O
mobility-shift	O
assay	O
.	O

an	O
antibody	O
for	O
c/ebp	B-protein
alpha	I-protein
super-shifted	O
the	O
nucleoprotein	B-protein
complex	I-protein
in	O
thp-0	B-cell_line
cells	I-cell_line
but	O
not	O
in	O
the	O
vd0-treated	B-cell_line
hl-00	I-cell_line
cells	I-cell_line
,	O
whereas	O
an	O
antibody	O
for	O
c/ebp	B-protein
beta	I-protein
blocked	O
the	O
formation	O
of	O
the	O
complex	O
with	O
the	O
nuclear	B-protein
factor	I-protein
of	O
the	O
hl-00	B-cell_line
cells	I-cell_line
but	O
not	O
with	O
that	O
of	O
thp-0	B-cell_line
cells	I-cell_line
.	O

an	O
anti-c/ebp	B-protein
delta	I-protein
antibody	I-protein
had	O
no	O
effect	O
on	O
the	O
complex	O
in	O
either	O
cell	O
.	O

thus	O
,	O
it	O
was	O
concluded	O
that	O
c/ebp	B-protein
alpha	I-protein
and	O
-beta	B-protein
were	O
able	O
to	O
bind	O
to	O
the	O
c/ebp	B-DNA
motif	I-DNA
,	O
and	O
that	O
c/ebp	B-protein
alpha	I-protein
bound	O
to	O
the	O
motif	O
in	O
thp-0	B-cell_line
cells	I-cell_line
and	O
c/ebp	B-protein
beta	I-protein
bound	O
to	O
that	O
in	O
the	O
vd0-treated	B-cell_line
hl-00	I-cell_line
cells	I-cell_line
.	O

furthermore	O
,	O
to	O
examine	O
the	O
transcriptional	O
activity	O
of	O
the	O
c/ebp	B-DNA
motif	I-DNA
,	O
we	O
transfected	O
several	O
constructed	O
luciferase	B-DNA
reporter	I-DNA
dnas	I-DNA
into	O
hl-00	B-cell_line
cells	I-cell_line
and	O
thp-0	B-cell_line
cells	I-cell_line
.	O

the	O
luciferase	B-protein
activity	O
of	O
the	O
c/ebp	B-DNA
motif	I-DNA
in	O
hl-00	B-cell_line
cells	I-cell_line
was	O
increased	O
by	O
vd0	O
treatment	O
.	O

the	O
c/ebp	B-DNA
motif	I-DNA
in	O
the	O
mrp00	B-DNA
gene	I-DNA
was	O
confirmed	O
to	O
function	O
as	O
a	O
regulatory	B-DNA
region	I-DNA
in	O
vd0-treated	B-cell_line
hl-00	I-cell_line
cells	I-cell_line
and	O
thp-0	B-cell_line
cells	I-cell_line
by	O
the	O
assay	O
.	O

since	O
c/ebp	B-protein
beta	I-protein
was	O
also	O
detected	O
in	O
vd0-untreated	B-cell_line
hl-00	I-cell_line
cells	I-cell_line
by	O
immunoblotting	O
,	O
vd0	O
activated	O
c/ebp	B-protein
beta	I-protein
to	O
bind	O
to	O
the	O
motif	O
,	O
probably	O
through	O
post-translational	O
modification	O
.	O

###MEDLINE:98359134

patients	O
with	O
high-risk	O
myelodysplastic	O
syndrome	O
can	O
have	O
polyclonal	O
or	O
clonal	O
haemopoiesis	O
in	O
complete	O
haematological	O
remission	O
.	O

the	O
clonality	O
of	O
mature	B-cell_type
peripheral	I-cell_type
blood-derived	I-cell_type
myeloid	I-cell_type
and	I-cell_type
lymphoid	I-cell_type
cells	I-cell_type
and	O
bone	B-cell_type
marrow	I-cell_type
haemopoietic	I-cell_type
progenitors	I-cell_type
from	O
00	O
females	O
with	O
myelodysplasia	O
(	O
mds	O
)	O
(	O
five	O
refractory	O
anaemia	O
,	O
ra	O
;	O
one	O
ra	O
with	O
ringed	B-cell_type
sideroblasts	I-cell_type
,	O
rars	B-protein
;	O
three	O
chronic	O
myelomonocytic	B-cell_type
leukaemia	I-cell_type
,	I-cell_type
cmml	I-cell_type
;	O
four	O
ra	O
with	O
excess	O
of	O
blasts	B-cell_type
,	O
raeb	O
;	O
five	O
raeb	O
in	O
transformation	O
,	O
raeb-t	B-cell_type
)	O
was	O
studied	O
by	O
x-chromosome	B-DNA
inactivation	O
analysis	O
.	O

using	O
the	O
human	B-protein
androgen-receptor	I-protein
(	O
humara	B-DNA
)	O
assay	O
,	O
we	O
analysed	O
the	O
clonal	O
patterns	O
of	O
highly	O
purified	O
immature	O
cd00+	O
00-	O
and	O
committed	B-cell_type
cd00+	I-cell_type
00+	I-cell_type
marrow-derived	I-cell_type
progenitors	I-cell_type
,	O
and	O
cd00+	B-cell_line
00-	I-cell_line
granulocytes	I-cell_line
,	O
cd00+	B-cell_type
monocytes	I-cell_type
,	O
cd0+	B-cell_type
t	I-cell_type
and	I-cell_type
cd00+	I-cell_type
b	I-cell_type
lymphocytes	I-cell_type
from	O
peripheral	B-cell_type
blood	I-cell_type
.	O

in	O
high-risk	O
patients	O
(	O
raeb	B-cell_type
,	O
raeb-t	B-cell_type
)	O
,	O
clonality	O
analysis	O
was	O
performed	O
before	O
and	O
after	O
intensive	O
remission-induction	O
treatment	O
.	O

all	O
patients	O
,	O
except	O
one	O
with	O
ra	O
,	O
had	O
predominance	O
of	O
a	O
single	O
clone	O
in	O
their	O
granulocytes	O
and	O
monocytes	B-cell_type
.	O

the	O
same	O
clonal	O
pattern	O
was	O
found	O
in	O
cd00+	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
.	O

in	O
contrast	O
,	O
cd0+	B-cell_type
t	I-cell_type
lymphocytes	I-cell_type
were	O
polyclonal	O
or	O
oligoclonal	O
in	O
00/00	O
patients	O
.	O

x-chromosome	B-DNA
inactivation	O
patterns	O
of	O
cd00+	B-cell_type
b	I-cell_type
cells	I-cell_type
were	O
highly	O
concordant	O
with	O
cd0+	B-cell_type
t	I-cell_type
cells	I-cell_type
except	O
for	O
two	O
patients	O
(	O
one	O
ra	O
,	O
one	O
cmml	O
)	O
with	O
monoclonal	B-protein
b	I-protein
and	O
polyclonal	O
t	B-cell_type
lymphocytes	I-cell_type
,	O
therefore	O
suggesting	O
a	O
clonal	O
mutation	O
in	O
a	O
progenitor	O
common	O
to	O
the	O
myeloid	B-cell_type
and	I-cell_type
b-lymphoid	I-cell_type
lineages	I-cell_type
or	O
the	O
coexistence	O
of	O
mds	O
and	O
a	O
b-cell	O
disorder	O
in	O
these	O
particular	O
patients	O
.	O

after	O
high-dose	O
non-myeloablative	O
chemotherapy	O
,	O
polyclonal	O
haemopoiesis	O
was	O
reinstalled	O
in	O
the	O
mature	B-cell_type
myeloid	I-cell_type
cells	I-cell_type
and	O
immature	B-cell_type
and	I-cell_type
committed	I-cell_type
marrow	I-cell_type
progenitors	I-cell_type
in	O
three	O
of	O
four	O
patients	O
achieving	O
complete	O
haematological	O
remission	O
.	O

therefore	O
we	O
conclude	O
that	O
most	O
haematological	O
remissions	O
in	O
mds	O
are	O
associated	O
with	O
restoration	O
of	O
polyclonal	O
haemopoiesis	O
.	O

###MEDLINE:98348376

prominent	O
sex	O
steroid	O
metabolism	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
.	O

steroid	O
metabolism	O
was	O
investigated	O
in	O
cultured	B-cell_line
human	I-cell_line
b-lymphoblastoid	I-cell_line
cells	I-cell_line
(	O
b-lcl	B-cell_line
)	O
,	O
and	O
peripheral	B-cell_type
blood	I-cell_type
t	I-cell_type
and	I-cell_type
b	I-cell_type
cells	I-cell_type
.	O

gene	O
expression	O
was	O
examined	O
by	O
reverse-transcription	B-protein
polymerase	I-protein
chain	I-protein
reaction	O
amplification	O
(	O
rt-pcr	O
)	O
.	O

appropriate	O
sized	B-RNA
transcripts	I-RNA
were	O
detected	O
in	O
both	O
cultured	O
and	O
fresh	B-cell_type
peripheral	I-cell_type
lymphocytes	I-cell_type
for	O
cyp00a	B-protein
,	O
cyp00	O
,	O
hsd00l	B-protein
(	I-protein
00beta-hydroxysteroid	I-protein
dehydrogenase	I-protein
i	I-protein
)	I-protein
,	I-protein
hsd00b0	I-protein
(	I-protein
00beta-hydroxysteroid	I-protein
dehydrogenase	I-protein
type	I-protein
i	I-protein
)	I-protein
and	I-protein
srd0a0	I-protein
(	I-protein
0alpha-reductase	I-protein
i	I-protein
)	O
.	O

b-lcl	B-cell_line
,	O
but	O
not	O
t	B-cell_type
and	I-cell_type
b	I-cell_type
cells	I-cell_type
,	O
expressed	O
cyp00b	B-protein
.	O

there	O
was	O
minimal	O
expression	O
of	O
hsd0b0	B-protein
and	I-protein
hsd0b0	I-protein
(	I-protein
0beta-hydroxysteroid	I-protein
dehydrogenase	I-protein
i	I-protein
and	O
ii	O
)	O
in	O
b-lcl	B-cell_line
and	O
t	B-cell_type
cells	I-cell_type
.	O

transcripts	O
for	O
cyp00	B-protein
and	O
hsd00k	B-protein
were	O
not	O
detected	O
.	O

corresponding	O
enzymatic	O
activity	O
was	O
detectable	O
only	O
for	O
00-hydroxysteroid	B-protein
dehydrogenase	I-protein
and	O
0alpha-reductase	B-protein
,	O
respectively	O
producing	O
testosterone	O
and	O
0alpha-dihydrotestosterone	O
.	O

steroid	O
identities	O
were	O
confirmed	O
by	O
gas	B-DNA
chromatography/mass	O
spectrometry	O
(	O
gc/ms	O
)	O
.	O

one	O
metabolite	O
thought	O
to	O
be	O
deoxycorticosterone	O
was	O
identified	O
by	O
gc/ms	O
as	O
0alpha-hydroxypregnanolone	O
.	O

it	O
was	O
concluded	O
that	O
sex	O
hormone	O
metabolism	O
,	O
including	O
androgen	O
synthesis	O
,	O
occurs	O
in	O
lymphocytes	B-cell_type
,	O
and	O
may	O
modulate	O
immune	O
response	O
.	O

###MEDLINE:98342108

human	B-cell_type
white	I-cell_type
blood	I-cell_type
cells	I-cell_type
and	O
hair	O
follicles	O
are	O
good	O
sources	O
of	O
mrna	O
for	O
the	O
pterin	B-protein
carbinolamine	I-protein
dehydratase/dimerization	I-protein
cofactor	I-protein
of	O
hnf0	B-protein
for	O
mutation	O
detection	O
.	O

pterin	B-protein
carbinolamine	I-protein
dehydratase/dimerization	I-protein
cofactor	I-protein
of	O
hnf0	B-protein
(	O
pcd/dcoh	B-protein
)	O
is	O
a	O
protein	O
that	O
has	O
a	O
dual	O
function	O
.	O

it	O
is	O
a	O
pterin	B-protein
0alpha-carbinolamine	I-protein
dehydratase	I-protein
that	O
is	O
involved	O
in	O
the	O
regeneration	O
of	O
the	O
cofactor	O
tetrahydrobiopterin	O
during	O
the	O
phenylalanine	O
hydroxylase-	O
catalyzed	O
hydroxylation	O
of	O
phenylalanine	O
.	O

in	O
addition	O
,	O
it	O
is	O
the	O
dimerization	B-protein
cofactor	I-protein
of	O
hnf0	B-protein
that	O
is	O
able	O
to	O
activate	O
the	O
transcriptional	O
activity	O
of	O
hnf0	B-protein
.	O

deficiencies	O
in	O
the	O
gene	O
for	O
this	O
dual	O
functional	O
protein	O
result	O
in	O
hyperphenylalaninemia	O
.	O

here	O
we	O
report	O
for	O
the	O
first	O
time	O
that	O
the	O
pcd/dcoh	B-protein
mrna	O
is	O
present	O
in	O
human	B-cell_type
white	I-cell_type
blood	I-cell_type
cells	I-cell_type
and	O
hair	O
follicles	O
.	O

taking	O
advantage	O
of	O
this	O
finding	O
,	O
a	O
sensitive	O
,	O
rapid	O
and	O
convenient	O
method	O
for	O
screening	O
mutations	O
occurring	O
in	O
the	O
coding	B-DNA
region	I-DNA
of	O
this	O
gene	O
has	O
been	O
described	O
.	O

copyright	O
0000	O
academic	O
press	O
.	O

###MEDLINE:98325028

biochemical	O
characterization	O
of	O
the	O
nf-y	B-protein
transcription	I-protein
factor	I-protein
complex	I-protein
during	O
b	B-cell_type
lymphocyte	I-cell_type
development	O
.	O

the	O
transcription	B-protein
factor	I-protein
,	O
nf-y	B-protein
,	O
plays	O
a	O
critical	O
role	O
in	O
tissue-specific	B-DNA
major	I-DNA
histocompatibility	I-DNA
complex	I-DNA
class	I-DNA
ii	I-DNA
gene	I-DNA
transcription	O
.	O

in	O
this	O
report	O
the	O
biochemical	O
properties	O
of	O
the	O
heterotrimeric	O
nf-y	B-protein
complex	I-protein
have	O
been	O
characterized	O
during	O
stage-specific	O
b-cell	O
development	O
,	O
and	O
in	O
several	O
class	B-cell_line
ii-	I-cell_line
mutant	I-cell_line
b-cell	I-cell_line
lines	I-cell_line
,	O
which	O
represent	O
distinct	O
bare	O
lymphocyte	B-protein
syndrome	I-protein
class	I-protein
ii	I-protein
genetic	O
complementation	O
groups	O
.	O

the	O
nf-y	B-protein
complex	I-protein
derived	O
from	O
class	B-cell_line
ii+	I-cell_line
mature	I-cell_line
b-cells	I-cell_line
bound	O
with	O
high	O
affinity	O
to	O
anion	O
exchangers	O
,	O
and	O
eluted	O
as	O
an	O
intact	O
trimeric	B-protein
complex	I-protein
,	O
whereas	O
,	O
nf-y	B-protein
derived	O
from	O
class	B-cell_line
ii-	I-cell_line
plasma	B-cell_type
b-cells	I-cell_type
,	O
and	O
from	O
bare	O
lymphocyte	O
syndrome	O
group	B-cell_line
ii	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
rj0.0.0	B-cell_line
and	O
rm0	O
,	O
dissociated	O
into	O
discrete	O
nf-ya	B-protein
and	I-protein
nf-yb	I-protein
:	I-protein
c	I-protein
subunit	I-protein
fractions	O
.	O

recombination	O
of	O
the	O
mpc00	B-cell_line
plasma	I-cell_line
b-cell	I-cell_line
derived	O
nf-y	B-protein
a	I-protein
:	I-protein
b	I-protein
:	I-protein
c	I-protein
complex	I-protein
with	O
the	O
low	O
molecular	O
mass	O
protein	O
fraction	O
,	O
nf-y-associated	B-protein
factors	I-protein
(	O
yafs	B-protein
)	O
,	O
derived	O
from	O
mature	O
a00	O
b-cell	O
nuclei	O
,	O
conferred	O
high	O
affinity	O
anion	O
exchange	O
binding	O
to	O
nf-y	B-protein
as	O
an	O
intact	O
trimeric	B-protein
complex	I-protein
.	O

recombination	O
of	O
the	O
native	O
nf-ya	B-protein
:	I-protein
b	I-protein
:	I-protein
c	I-protein
complex	I-protein
with	O
the	O
transcriptional	B-protein
cofactor	I-protein
,	O
pc0	B-protein
,	O
likewise	O
conferred	O
high	O
affinity	O
nf-y	B-protein
binding	O
to	O
anion	O
exchangers	O
,	O
and	O
stabilized	O
nf-y	B-protein
interaction	O
with	O
ccaat-box	B-protein
dna	I-protein
motifs	I-protein
in	O
vitro	O
.	O

interaction	O
between	O
pc0	B-protein
and	O
nf-y	B-protein
was	O
mapped	O
to	O
the	O
c-terminal	B-protein
region	I-protein
of	O
pc0	B-protein
,	O
and	O
the	O
subunit	O
interaction	O
subdomain	O
of	O
the	O
highly	O
conserved	O
dna	B-protein
binding-subunit	I-protein
interaction	I-protein
domain	I-protein
(	O
dbd	B-protein
)	O
of	O
nf-ya	B-protein
.	I-protein

these	O
results	O
suggest	O
that	O
in	O
class	B-cell_line
ii+	I-cell_line
mature	I-cell_line
b-cells	I-cell_line
nf-y	B-protein
is	O
associated	O
with	O
the	O
protein	B-protein
cofactor	I-protein
,	O
pc0	B-protein
,	O
which	O
may	O
play	O
an	O
important	O
role	O
in	O
nf-y-mediated	O
transcriptional	O
control	O
of	O
class	B-DNA
ii	I-DNA
genes	I-DNA
.	O

###MEDLINE:98318219

arrest	O
of	O
b	B-cell_type
lymphocyte	I-cell_type
terminal	O
differentiation	O
by	O
cd00	B-protein
signaling	O
:	O
mechanism	O
for	O
lack	O
of	O
antibody-secreting	B-cell_type
cells	I-cell_type
in	O
germinal	O
centers	O
.	O

despite	O
extensive	O
research	O
,	O
the	O
role	O
of	O
cd00	B-protein
signaling	O
in	O
b	B-cell_type
cell	I-cell_type
terminal	O
differentiation	O
remains	O
controversial	O
.	O

here	O
we	O
show	O
that	O
cd00	B-protein
engagement	O
arrests	O
b	O
cell	O
differentiation	O
prior	O
to	O
plasma	O
cell	O
formation	O
.	O

this	O
arrest	O
is	O
manifested	O
at	O
a	O
molecular	O
level	O
as	O
a	O
reduction	O
in	O
mrna	O
levels	O
of	O
secretory	O
immunoglobulin	B-DNA
gene	I-DNA
products	I-DNA
such	O
as	O
mu	B-RNA
(	O
s	O
)	O
and	O
j	B-protein
chain	I-protein
as	O
well	O
as	O
the	O
loss	O
of	O
the	O
transcriptional	O
regulator	O
blimp-0	O
.	O

furthermore	O
,	O
the	O
inhibition	O
of	O
b	B-cell_type
cell	I-cell_type
differentiation	O
by	O
cd00	B-protein
engagement	O
could	O
not	O
be	O
overcome	O
by	O
either	O
mitogens	O
or	O
cytokines	B-protein
,	O
but	O
could	O
be	O
reversed	O
by	O
antibodies	O
that	O
interfere	O
with	O
the	O
cd00	B-protein
/	O
gp00	B-protein
interaction	O
.	O

these	O
data	O
suggest	O
that	O
secretory	O
immunoglobulin	O
is	O
not	O
produced	O
by	O
b	B-cell_type
cells	I-cell_type
that	O
are	O
actively	O
engaged	O
by	O
gp00-expressing	B-cell_type
t	I-cell_type
cells	I-cell_type
.	O

###MEDLINE:98308097

a	O
positively	O
charged	O
alpha-lipoic	O
acid	O
analogue	O
with	O
increased	O
cellular	O
uptake	O
and	O
more	O
potent	O
immunomodulatory	O
activity	O
.	O

alpha-lipoic	O
acid	O
(	O
la	O
)	O
is	O
taken	O
up	O
by	O
cells	O
and	O
reduced	O
to	O
its	O
potent	O
dithiol	O
form	O
,	O
dihydrolipoate	O
(	O
dhla	B-protein
)	O
,	O
much	O
of	O
which	O
is	O
rapidly	O
effluxed	O
out	O
from	O
cells	O
.	O

to	O
improve	O
retention	O
in	O
cells	O
,	O
the	O
la	B-protein
molecule	I-protein
was	O
modified	O
to	O
confer	O
a	O
positive	O
charge	O
at	O
physiological	O
ph	O
.	O

n	O
,	O
n-dimethyl	O
,	O
n'-0-amidoethyl-lipoate	B-protein
was	O
synthesized	O
.	O

the	O
protonated	O
form	O
of	O
the	O
new	O
molecule	O
is	O
referred	O
to	O
as	O
la-plus	O
.	O

the	O
uptake	O
of	O
la-plus	O
by	O
human	B-cell_line
wurzburg	I-cell_line
t	I-cell_line
cells	I-cell_line
was	O
higher	O
compared	O
to	O
that	O
of	O
la	O
.	O

several-fold	O
higher	O
amounts	O
of	O
dhla-plus	B-protein
,	O
the	O
corresponding	O
reduced	O
form	O
of	O
la-plus	B-protein
,	O
were	O
detected	O
in	O
la-plus	B-cell_line
treated	I-cell_line
cells	I-cell_line
compared	O
to	O
the	O
amount	O
of	O
dhla	O
found	O
in	O
cells	O
treated	O
with	O
la	O
.	O

at	O
000	O
microm	O
,	O
la	O
did	O
not	O
but	O
la-plus	B-protein
inhibited	O
h0o0	O
induced	O
nf-kappab	B-protein
activation	O
and	O
nf-kappab	B-protein
directed	O
il-0	B-protein
receptor	O
expression	O
.	O

both	O
la	B-protein
and	I-protein
la-plus	I-protein
synergised	I-protein
with	O
selenium	O
in	O
inhibiting	O
h0o0	O
induced	O
nf-kappab	B-protein
activation	O
.	O

at	O
000	O
microm	O
la-plus	O
,	O
but	O
not	O
la	O
,	O
inhibited	O
tnfalpha	B-protein
induced	O
nf-kappab	B-protein
activation	O
.	O

at	O
0	O
microm	O
la-plus	O
,	O
but	O
not	O
la	O
,	O
protected	O
against	O
both	O
spontaneous	O
and	O
etoposide	O
induced	O
apoptosis	O
in	O
rat	B-cell_type
thymocytes	I-cell_type
.	O

la-plus	B-protein
is	O
thus	O
an	O
improved	O
form	O
of	O
la	O
with	O
increased	O
therapeutic	O
potential	O
.	O

copyright	O
0000	O
academic	O
press	O
.	O

###MEDLINE:98295734

carrier	O
identification	O
in	O
x-linked	O
immunodeficiency	O
diseases	O
.	O

objective	O
:	O
carrier	O
identification	O
in	O
x-linked	O
immunodeficiency	O
disorders	O
can	O
be	O
based	O
on	O
the	O
demonstration	O
of	O
non-random	O
x	O
inactivation	O
(	O
nrxi	B-protein
)	O
in	O
affected	B-cell_type
blood	I-cell_type
cell	I-cell_type
lineages	I-cell_type
when	O
growth	O
is	O
impaired	O
in	O
cells	O
expressing	O
the	O
abnormal	O
gene	O
.	O

we	O
examined	O
the	O
utility	O
of	O
seeking	O
evidence	O
of	O
nrxi	O
to	O
test	O
the	O
carrier	O
status	O
of	O
women	O
in	O
families	O
affected	O
by	O
x-linked	O
severe	O
combined	O
immunodeficiency	O
(	O
xscid	O
)	O
and	O
x-linked	O
hypogammaglobulinaemia	O
(	O
xlh	O
)	O
,	O
to	O
identify	O
as	O
carriers	O
the	O
mothers	O
of	O
boys	O
with	O
scid	O
or	O
hypogammaglobulinaemia	O
whose	O
phenotype	O
suggested	O
x-linkage	O
and	O
to	O
infer	O
x-linkage	O
in	O
boys	O
with	O
scid	O
or	O
hypogammaglobulinaemia	O
whose	O
disease	O
was	O
not	O
clearly	O
x-linked	O
on	O
the	O
basis	O
either	O
of	O
family	O
history	O
or	O
clinical	O
and	O
immunological	O
characteristics	O
.	O

methodology	O
:	O
a	O
polymerase	O
chain	O
reaction-based	O
method	O
was	O
used	O
to	O
amplify	O
a	O
polymorphic	O
cag	B-DNA
repeat	I-DNA
in	O
the	O
first	O
exon	O
of	O
the	O
androgen	B-DNA
receptor	I-DNA
gene	I-DNA
after	O
selective	O
digestion	O
of	O
the	O
active	O
x	B-DNA
chromosome	I-DNA
with	O
a	O
methylation-sensitive	B-protein
enzyme	I-protein
,	O
hpaii	O
to	O
distinguish	O
between	O
the	O
paternal	O
and	O
maternal	O
alleles	O
and	O
to	O
identify	O
their	O
methylation	O
status	O
.	O

results	O
:	O
heterozygosity	O
was	O
found	O
in	O
00	O
of	O
00	O
female	O
subjects	O
(	O
00	O
%	O
)	O
.	O

as	O
anticipated	O
,	O
nrxi	B-protein
could	O
be	O
demonstrated	O
in	O
all	O
lymphoid	B-cell_type
cells	I-cell_type
studied	O
from	O
obligate	O
carriers	O
of	O
xscid	O
and	O
an	O
obligate	O
carrier	O
of	O
xlh	O
but	O
not	O
on	O
a	O
carrier	O
of	O
x-linked	O
immunodeficiency	O
with	O
hyper-igm	O
.	O

the	O
finding	O
of	O
nrxi	O
in	O
the	O
mother	O
of	O
a	O
boy	O
with	O
a	O
scid	O
variant	O
showed	O
her	O
to	O
be	O
a	O
carrier	O
of	O
xscid	O
and	O
establishes	O
that	O
her	O
son	O
has	O
xscid	O
,	O
not	O
otherwise	O
evident	O
from	O
available	O
data	O
.	O

conclusions	O
:	O
this	O
pcr	O
assay	O
provides	O
a	O
rapid	O
method	O
for	O
carrier	O
detection	O
of	O
x-linked	O
immunodeficiencies	O
,	O
and	O
has	O
allowed	O
us	O
to	O
expand	O
the	O
phenotype	O
of	O
xscid	O

###MEDLINE:98245000

leukocyte-endothelial	O
interaction	O
is	O
augmented	O
by	O
high	O
glucose	O
concentrations	O
and	O
hyperglycemia	O
in	O
a	O
nf-kb-dependent	O
fashion	O
.	O

we	O
addressed	O
the	O
role	O
of	O
hyperglycemia	O
in	O
leukocyte-endothelium	O
interaction	O
under	O
flow	O
conditions	O
by	O
exposing	O
human	B-cell_type
umbilical	I-cell_type
vein	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
for	O
00	O
h	O
to	O
normal	O
(	O
0	O
mm	O
)	O
,	O
high	O
concentration	O
of	O
glucose	O
(	O
00	O
mm	O
)	O
,	O
advanced	O
glycosylation	O
end	O
product-albumin	O
(	O
000	O
microg/ml	O
)	O
,	O
or	O
hyperglycemic	B-protein
(	O
000-000	O
mg/dl	O
)	O
sera	O
from	O
patients	O
with	O
diabetes	O
and	O
abnormal	O
hemoglobin	B-protein
a0c	O
(	O
0.0+/-0.0	O
%	O
)	O
.	O

at	O
the	O
end	O
of	O
incubation	O
endothelial	B-cell_type
cells	I-cell_type
were	O
perfused	O
with	O
total	O
leukocyte	O
suspension	O
in	O
a	O
parallel	O
plate	O
flow	O
chamber	O
under	O
laminar	O
flow	O
(	O
0.0	O
dyn/cm0	O
)	O
.	O

rolling	O
and	O
adherent	B-cell_type
cells	I-cell_type
were	O
evaluated	O
by	O
digital	O
image	O
processing	O
.	O

results	O
showed	O
that	O
00	O
mm	O
glucose	O
significantly	O
(	O
p	O
<	O
0.00	O
)	O
increased	O
the	O
number	O
of	O
adherent	B-cell_type
leukocytes	I-cell_type
to	O
endothelial	B-cell_type
cells	I-cell_type
in	O
respect	O
to	O
control	O
(	O
0	O
mm	O
glucose	O
;	O
000+/-00	O
versus	O
00+/-0	O
cells/mm0	O
)	O
.	O

a	O
similar	O
response	O
was	O
induced	O
by	O
endothelial	O
stimulation	O
with	O
il-0beta	B-protein
,	O
here	O
used	O
as	O
positive	O
control	O
(	O
000+/-00	O
cells/mm0	O
)	O
.	O

the	O
number	O
of	O
rolling	O
cells	O
on	O
endothelial	O
surface	O
was	O
not	O
affected	O
by	O
high	O
glucose	O
level	O
.	O

stable	O
adhesion	O
of	O
leukocytes	B-cell_type
to	O
glucose-treated	O
as	O
well	O
as	O
to	O
il-0beta-stimulated	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
was	O
preceded	O
by	O
short	O
interaction	O
of	O
leukocytes	B-cell_type
with	O
the	O
endothelial	O
surface	O
.	O

the	O
distance	O
travelled	O
by	O
leukocytes	B-cell_type
before	O
arrest	O
on	O
00	O
mm	O
glucose	O
,	O
or	O
on	O
il-0beta-treated	B-cell_line
endothelial	I-cell_line
cells	I-cell_line
,	O
was	O
significantly	O
(	O
p	O
<	O
0.00	O
)	O
higher	O
than	O
that	O
observed	O
for	O
leukocytes	B-cell_type
adhering	O
on	O
control	O
endothelium	O
(	O
00	O
mm	O
glucose	O
:	O
00.0+/-0.0	O
;	O
il0beta	O
:	O
00.0+/-0	O
versus	O
0	O
mm	O
glucose	O
:	O
00.0+/-0	O
microm	O
)	O
.	O

functional	O
blocking	O
of	O
e-selectin	B-protein
,	O
intercellular	B-protein
cell	I-protein
adhesion	I-protein
molecule-0	I-protein
,	O
and	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-0	I-protein
on	O
endothelial	B-cell_type
cells	I-cell_type
with	O
the	O
corresponding	O
mouse	B-protein
mab	I-protein
significantly	O
inhibited	O
glucose-induced	O
increase	O
in	O
leukocyte	B-protein
adhesion	I-protein
(	I-protein
00+/-00	I-protein
,	O
00+/-00	O
,	O
00+/-0	O
versus	O
000+/-00	O
cells/	B-cell_line
mm0	I-cell_line
)	O
.	O

confocal	O
fluorescence	O
microscopy	O
studies	O
showed	O
that	O
00	O
mm	O
glucose	O
induced	O
an	O
increase	O
in	O
endothelial	O
surface	O
expression	O
of	O
e-selectin	B-protein
,	O
intercellular	B-protein
cell	I-protein
adhesion	I-protein
molecule-0	I-protein
,	O
and	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-0	I-protein
.	O

electrophoretic	O
mobility	O
shift	O
assay	O
of	O
nuclear	O
extracts	O
of	O
human	B-cell_type
umbilical	I-cell_type
vein	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
(	O
huvec	B-cell_line
)	O
exposed	O
for	O
0	O
h	O
to	O
00	O
mm	O
glucose	O
revealed	O
an	O
intense	O
nf-kb	B-protein
activation	O
.	O

treatment	O
of	O
huvec	B-cell_type
exposed	O
to	O
high	O
glucose	O
with	O
the	O
nf-kb	B-protein
inhibitors	I-protein
pyrrolidinedithiocarbamate	O
(	O
000	O
microm	O
)	O
and	O
tosyl-phe-chloromethylketone	B-protein
(	O
00	O
microm	O
)	O
significantly	O
reduced	O
(	O
p	O
<	O
0.00	O
)	O
leukocyte	O
adhesion	O
in	O
respect	O
to	O
huvec	B-cell_type
treated	O
with	O
glucose	O
alone	O
.	O

a	O
significant	O
(	O
p	O
<	O
0.00	O
)	O
inhibitory	O
effect	O
on	O
glucose-induced	O
leukocyte	O
adhesion	O
was	O
observed	O
after	O
blocking	B-protein
protein	I-protein
kinase	I-protein
c	I-protein
activity	O
with	O
staurosporine	O
(	O
0	O
nm	O
)	O
.	O

when	O
huvec	B-cell_type
were	O
treated	O
with	O
specific	O
antisense	O
oligodesoxynucleotides	O
against	O
pkcalpha	B-protein
and	O
pkcepsilon	O
isoforms	O
before	O
the	O
addition	O
of	O
00	O
mm	O
glucose	O
,	O
a	O
significant	O
(	O
p	O
<	O
0.00	O
)	O
reduction	O
in	O
the	O
adhesion	O
was	O
also	O
seen	O
.	O

advanced	O
glycosylation	O
end	O
product-albumin	O
significantly	O
increased	O
the	O
number	O
of	O
adhering	B-cell_type
leukocytes	I-cell_type
in	O
respect	O
to	O
native	B-protein
albumin	I-protein
used	O
as	O
control	O
(	O
000+/-00	O
versus	O
00+/-0	O
,	O
p	O
<	O
0.00	O
)	O
.	O

sera	O
from	O
diabetic	O
patients	O
significantly	O
(	O
p	O
<	O
0.00	O
)	O
enhanced	O
leukocyte	O
adhesion	O
as	O
compared	O
with	O
controls	O
,	O
despite	O
normal	O
levels	O
of	O
il-0beta	B-protein
and	O
tnfalpha	B-protein
in	O
these	O
sera	O
.	O

these	O
data	O
indicate	O
that	O
high	O
glucose	O
concentration	O
and	O
hyperglycemia	O
promote	O
leukocyte	O
adhesion	O
to	O
the	O
endothelium	O
through	O
upregulation	O
of	O
cell	O
surface	O
expression	O
of	O
adhesive	B-protein
proteins	I-protein
,	O
possibly	O
depending	O
on	O
nf-kb	B-protein
activation	O
.	O

###MEDLINE:98282479

ikaros	B-protein
in	O
hemopoietic	B-cell_type
lineage	I-cell_type
determination	O
and	O
homeostasis	O
.	O

studies	O
on	O
the	O
molecular	O
mechanisms	O
that	O
control	O
hemopoietic	O
differentiation	O
have	O
focused	O
on	O
signaling	O
cascades	O
and	O
nuclear	B-protein
effectors	I-protein
that	O
drive	O
this	O
complex	O
developmental	O
system	O
in	O
a	O
regulated	O
fashion	O
.	O

here	O
we	O
review	O
the	O
role	O
of	O
ikaros	B-protein
,	O
the	O
founding	O
member	O
of	O
a	O
unique	O
family	O
of	O
zinc	B-protein
finger	I-protein
transcription	I-protein
factors	I-protein
in	O
this	O
developmental	O
process	O
.	O

studies	O
on	O
an	O
ikaros	B-protein
null	O
mutation	O
have	O
revealed	O
an	O
essential	O
role	O
for	O
this	O
factor	O
in	O
lymphoid	O
cell	O
fate	O
determination	O
and	O
at	O
subsequent	O
branch	O
points	O
of	O
the	O
t	O
cell	O
differentiation	O
pathway	O
.	O

differences	O
in	O
the	O
phenotypes	O
of	O
a	O
null	O
and	O
a	O
dominant	O
negative	O
(	O
dn	O
)	O
ikaros	B-protein
mutation	O
provide	O
insight	O
into	O
a	O
regulatory	O
network	O
through	O
which	O
ikaros	B-protein
proteins	I-protein
exert	O
their	O
effects	O
in	O
development	O
.	O

in	O
addition	O
a	O
comparative	O
analysis	O
of	O
the	O
hemopoietic	B-cell_line
stem	I-cell_line
cell	I-cell_line
and	I-cell_line
precursor	I-cell_line
compartment	I-cell_line
resulting	O
from	O
the	O
two	O
ikaros	B-DNA
mutations	I-DNA
reveals	O
a	O
profound	O
yet	O
not	O
absolute	O
requirement	O
for	O
ikaros	B-protein

###MEDLINE:98372761

induction	O
of	O
early	B-protein
b	I-protein
cell	I-protein
factor	I-protein
(	O
ebf	B-protein
)	O
and	O
multiple	B-DNA
b	I-DNA
lineage	I-DNA
genes	I-DNA
by	O
the	O
basic	B-protein
helix-loop-helix	I-protein
transcription	I-protein
factor	I-protein
e00	B-protein
.	O

the	O
transcription	B-protein
factors	I-protein
encoded	O
by	O
the	O
e0a	B-protein
and	I-protein
early	I-protein
b	I-protein
cell	I-protein
factor	I-protein
(	O
ebf	B-protein
)	O
genes	O
are	O
required	O
for	O
the	O
proper	O
development	O
of	O
b	B-cell_type
lymphocytes	I-cell_type
.	O

however	O
,	O
the	O
absence	O
of	O
b	B-cell_type
lineage	I-cell_type
cells	I-cell_type
in	O
e0a-	O
and	O
ebf-deficient	O
mice	O
has	O
made	O
it	O
difficult	O
to	O
determine	O
the	O
function	O
or	O
relationship	O
between	O
these	O
proteins	O
.	O

we	O
report	O
the	O
identification	O
of	O
a	O
novel	O
model	O
system	O
in	O
which	O
the	O
role	O
of	O
e0a	B-protein
and	O
ebf	B-protein
in	O
the	O
regulation	O
of	O
multiple	B-protein
b	I-protein
lineage	O
traits	O
can	O
be	O
studied	O
.	O

we	O
found	O
that	O
the	O
conversion	O
of	O
00z/0	B-protein
pre-b	B-cell_type
lymphocytes	I-cell_type
to	O
cells	O
with	O
a	O
macrophage-like	O
phenotype	O
is	O
associated	O
with	O
the	O
loss	O
of	O
e0a	B-protein
and	O
ebf	B-protein
.	O

moreover	O
,	O
we	O
show	O
that	O
ectopic	O
expression	O
of	O
the	O
e0a	B-protein
protein	I-protein
e00	B-protein
in	O
this	O
macrophage	B-cell_line
line	I-cell_line
results	O
in	O
the	O
induction	O
of	O
many	B-cell_type
b	I-cell_type
lineage	I-cell_type
genes	O
,	O
including	O
ebf	B-protein
,	O
il0ralpha	O
,	O
lambda0	B-DNA
,	O
and	O
rag-0	B-DNA
,	I-DNA
and	O
the	O
ability	O
to	O
induce	O
kappa	B-protein
light	I-protein
chain	I-protein
in	O
response	O
to	O
mitogen	B-protein
.	O

activation	O
of	O
ebf	B-protein
may	O
be	O
one	O
of	O
the	O
critical	O
functions	O
of	O
e00	B-protein
in	O
regulating	O
the	O
b	B-cell_type
lineage	I-cell_type
phenotype	I-cell_type
since	O
expression	O
of	O
ebf	B-protein
alone	O
leads	O
to	O
the	O
activation	O
of	O
a	O
subset	O
of	O
e00	B-protein
-inducible	O
traits	O
.	O

our	O
data	O
demonstrate	O
that	O
,	O
in	O
the	O
context	O
of	O
this	O
macrophage	B-cell_line
line	I-cell_line
,	O
e00	B-protein
induces	O
expression	O
of	O
ebf	B-protein
and	O
together	O
these	O
transcription	B-protein
factors	I-protein
coordinately	O
regulate	O
numerous	O
b	B-protein
lineage-associated	I-protein
genes	I-protein
.	O

###MEDLINE:98361999

activation-induced	O
down-regulation	O
of	O
retinoid	B-protein
receptor	I-protein
rxralpha	I-protein
expression	O
in	O
human	B-cell_type
t	I-cell_type
lymphocytes	I-cell_type
.	O

role	O
of	O
cell	O
cycle	O
regulation	O
.	O

a	O
0.0-kilobase	B-RNA
mrna	I-RNA
,	O
the	O
expression	O
of	O
which	O
is	O
down-regulated	O
after	O
treatment	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
pbmcs	B-cell_type
)	O
with	O
various	O
t	O
cell-activating	O
agents	O
,	O
was	O
isolated	O
using	O
an	O
mrna	O
differential	O
display	O
method	O
.	O

nucleotide	O
sequence	O
analysis	O
identified	O
the	O
0	B-DNA
'	I-DNA
end	I-DNA
of	O
this	O
rna	O
as	O
human	O
retinoid	B-protein
receptor	I-protein
rxralpha	I-protein
mrna	O
.	O

here	O
,	O
we	O
report	O
the	O
nucleotide	B-DNA
sequence	I-DNA
of	O
0.0	O
kilobases	O
of	O
this	O
rna	O
,	O
which	O
represents	O
the	O
0	B-DNA
'	I-DNA
end	I-DNA
of	O
rxralpha	B-RNA
mrna	I-RNA
,	O
the	O
sequence	O
of	O
which	O
has	O
not	O
been	O
previously	O
described	O
.	O

activated	B-cell_type
pbmcs	I-cell_type
also	O
expressed	O
lower	O
levels	O
of	O
rxralpha	B-protein
protein	I-protein
,	O
and	O
a	O
dna	O
binding	O
assay	O
showed	O
that	O
the	O
activation-induced	O
loss	O
of	O
rxralpha	B-RNA
mrna	I-RNA
and	O
protein	O
expression	O
correlated	O
with	O
the	O
loss	O
of	O
dna	O
binding	O
activity	O
of	O
this	O
protein	O
.	O

we	O
present	O
evidence	O
that	O
the	O
transition	O
from	O
g0/g0	O
to	O
s	O
phase	O
of	O
the	O
cell	O
cycle	O
results	O
in	O
the	O
down-regulation	O
of	O
rxralpha	B-protein
expression	O
and	O
that	O
cell	O
cycle	O
inhibitors	O
,	O
which	O
block	O
the	O
cells	O
in	O
g0	O
phase	O
,	O
prevent	O
this	O
down-regulation	O
.	O

the	O
decrease	O
in	O
the	O
levels	O
of	O
rxralpha	B-RNA
mrna	I-RNA
was	O
found	O
to	O
be	O
regulated	O
at	O
the	O
post-transcriptional	O
level	O
and	O
involved	O
new	O
protein	O
synthesis	O
.	O

these	O
observations	O
indicate	O
that	O
the	O
levels	O
of	O
rxralpha	B-protein
expression	O
in	O
t	B-cell_type
lymphocytes	I-cell_type
are	O
coupled	O
to	O
cell	O
cycle	O
progression	O
,	O
and	O
there	O
is	O
tight	O
regulatory	O
control	O
of	O
rxralpha	B-protein
expression	O
during	O
the	O
transition	O
from	O
g0/g0	O
to	O
s	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

###MEDLINE:98348903

epidemiology	O
and	O
pathogenesis	O
of	O
aids-related	O
lymphomas	O
.	O

among	O
patients	O
with	O
congenital	O
and	O
acquired	O
immunodeficiencies	O
,	O
non-hodgkin	O
's	O
lymphoma	O
(	O
nhls	B-cell_line
)	O
are	O
the	O
most	O
common	O
tumors	O
of	O
the	O
immune	O
system	O
.	O

in	O
the	O
setting	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
hiv	O
)	O
infection	O
,	O
as	O
many	O
as	O
00	O
%	O
to	O
00	O
%	O
of	O
people	O
ultimately	O
developed	O
nhls	O
.	O

these	O
tumors	O
are	O
clinically	O
aggressive	O
,	O
frequently	O
involve	O
extranodal	O
sites	O
,	O
and	O
often	O
exhibit	O
unique	O
features	O
that	O
distinguish	O
them	O
from	O
nhl	O
arising	O
in	O
individuals	O
with	O
other	O
forms	O
of	O
immunosuppression	O
.	O

important	O
in	O
the	O
development	O
of	O
hiv-associated	O
nhl	O
are	O
cytokines	B-protein
and	O
other	O
factors	O
that	O
induce	O
b-cell	O
proliferation	O
and	O
increase	O
the	O
likelihood	O
of	O
mutations	O
of	O
c-myc	B-DNA
,	O
bcl-0	B-protein
,	O
and	O
other	O
tumor-suppressor	B-DNA
genes	I-DNA
with	O
carcinogenic	O
potential	O
.	O

specific	O
forms	O
of	O
hiv-associated	O
nhl	O
are	O
linked	O
to	O
expression	O
of	O
epstein-barr	B-protein
virus	I-protein
(	I-protein
ebv	I-protein
)	I-protein
-latent	I-protein
proteins	I-protein
;	O
the	O
newly	O
described	O
dna	O
virus	O
,	O
karposi	O
's	O
sarcoma-associated	O
herpesvirus/human	O
herpesvirus-0	O
(	O
kshv/hhv-0	B-protein
)	O
;	O
and	O
perhaps	O
hiv	O
.	O

elucidation	O
of	O
the	O
factors	O
that	O
contribute	O
to	O
the	O
high	O
incidence	O
of	O
nhl	O
among	O
patients	O
infected	O
with	O
hiv	O
provides	O
insights	O
into	O
important	O
elements	O
of	O
lymphomagenesis	O
.	O

###MEDLINE:98338104

matrix	O
metalloproteinase	O
expression	O
in	O
human	O
breast	O
cancer	O
:	O
an	O
immunohistochemical	O
study	O
including	O
correlation	O
with	O
cathepsin	B-protein
d	I-protein
,	I-protein
type	I-protein
iv	I-protein
collagen	I-protein
,	O
laminin	B-protein
,	O
fibronectin	B-protein
,	O
egfr	B-protein
,	O
c-erbb-0	B-protein
oncoprotein	I-protein
,	O
p00	B-protein
,	O
steroid	B-protein
receptors	I-protein
status	O
and	O
proliferative	O
indices	O
.	O

matrix	B-protein
metalloproteinase	I-protein
s	I-protein
(	I-protein
mmps	I-protein
)	O
are	O
a	O
group	O
of	O
enzymes	O
thought	O
to	O
be	O
responsible	O
for	O
both	O
normal	O
connective	O
tissue	O
matrix	O
remodelling	O
and	O
accelerated	O
breakdown	O
associated	O
with	O
tumour	O
development	O
.	O

the	O
current	O
study	O
aimed	O
to	O
investigate	O
the	O
immunohistochemical	O
expression	O
of	O
matrix	B-protein
metalloproteinase	I-protein
0	I-protein
(	O
mmp-0	B-protein
,	O
stromelysin-0	B-protein
)	O
in	O
correlation	O
with	O
the	O
expression	O
of	O
basement	O
membrane	O
(	O
bm	B-cell_type
)	O
antigen	B-protein
(	I-protein
type	I-protein
iv	I-protein
collagen	I-protein
,	O
laminin	B-protein
)	O
,	O
fibronectin	B-protein
,	O
cathepsin	B-protein
d	I-protein
,	O
p00	B-protein
,	O
c-erbb-0	B-protein
,	O
proliferative	O
activity	O
(	O
ki-00	B-protein
,	O
pcna	B-protein
)	O
,	O
steroid	B-protein
receptor	I-protein
content	O
as	O
well	O
as	O
to	O
the	O
other	O
conventional	O
clinicopathological	O
parameters	O
in	O
breast	O
cancer	O
.	O

this	O
study	O
was	O
performed	O
on	O
a	O
series	O
of	O
frozen	O
and	O
paraffin	O
sections	O
from	O
00	O
breast	O
cancer	O
specimens	O
by	O
immunohistochemistry	O
using	O
the	O
monoclonal	B-protein
antibody	I-protein
mmp-0	B-protein
(	O
ab-0	B-protein
)	O
.	O

stromelysin-0	B-protein
(	O
st0	B-DNA
)	O
was	O
observed	O
in	O
about	O
00	O
%	O
of	O
epithelial	B-cell_type
cells	I-cell_type
in	O
the	O
control	O
groups	O
(	O
cases	O
of	O
fibrocystic	O
and	O
benign	O
proliferative	O
breast	O
disease	O
)	O
,	O
while	O
expression	O
(	O
>	O
00	O
%	O
of	O
expression	O
)	O
was	O
detected	O
in	O
00.0	O
%	O
of	O
tumours	O
.	O

the	O
expression	O
of	O
st0	B-protein
in	O
carcinoma	B-cell_type
cells	I-cell_type
was	O
strongly	O
associated	O
with	O
its	O
presence	O
in	O
the	O
stroma	O
(	O
p	O
<	O
0.000	O
)	O
.	O

a	O
significantly	O
positive	O
correlation	O
was	O
found	O
between	O
st0	B-protein
expression	O
,	O
and	O
p00	B-protein
tumour	B-protein
suppressor	I-protein
gene	I-protein
product	I-protein
(	O
p	O
=	O
0.000	O
)	O
,	O
and	O
a	O
relationship	O
with	O
c-erbb-0	B-protein
protein	I-protein
and	O
progesterone	B-protein
receptor	I-protein
status	O
was	O
also	O
indicated	O
.	O

these	O
findings	O
suggest	O
that	O
st0	B-protein
expression	O
in	O
breast	O
cancer	O
tissue	O
is	O
irrespective	O
of	O
the	O
expression	O
of	O
the	O
extracellular	B-protein
matrix	I-protein
component	I-protein
,	O
the	O
proteolytic	O
enzyme	O
cathepsin	B-protein
d	I-protein
and	O
the	O
growth	O
fraction	O
of	O
the	O
tumour	O
,	O
and	O
that	O
it	O
could	O
be	O
a	O
potential	O
new	O
prognostic	O
marker	O
in	O
breast	O
cancer	O
.	O

###MEDLINE:98321739

use	O
of	O
transfected	B-cell_line
liver	I-cell_line
cells	I-cell_line
to	O
evaluate	O
potential	O
mechanisms	O
of	O
alcohol-induced	O
liver	O
injury	O
[	O
see	O
comments	O
]	O

there	O
is	O
increased	O
activity	O
of	O
the	O
proinflammatory	B-protein
cytokine	I-protein
,	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
tnf	B-protein
)	O
in	O
alcoholic	O
liver	O
disease	O
(	O
ald	O
)	O
.	O

hepatic	O
neutrophil	O
infiltration	O
is	O
a	O
principal	O
injurious	O
manifestation	O
of	O
ald	O
.	O

tnf	B-protein
can	O
induce	O
cellular	O
oxidative	O
injury	O
directly	O
,	O
and	O
indirectly	O
by	O
inducing	O
neutrophil	B-protein
chemotactic	I-protein
factor	I-protein
(	O
il-0	B-protein
)	O
production	O
by	O
hepatocytes	B-cell_type
.	O

il-0	B-protein
activates	O
and	O
chemotactically	B-cell_type
attracts	I-cell_type
neutrophils	I-cell_type
to	O
the	O
liver	O
where	O
they	O
release	O
oxidizing	O
substances	O
.	O

patients	O
with	O
ald	O
also	O
have	O
decreased	O
protective	O
factors	O
for	O
cellular	O
oxidative	O
injury	O
.	O

manganous	B-protein
superoxide	I-protein
dismutase	I-protein
(	O
mnsod	B-protein
)	O
is	O
an	O
antioxidant	O
protective	O
factor	O
.	O

the	O
objectives	O
of	O
these	O
studies	O
were	O
to	O
investigate	O
mechanisms	O
for	O
induction	O
of	O
an	O
injurious	B-protein
factor	I-protein
(	O
il-0	B-protein
)	O
and	O
a	O
protective	O
factor	O
(	O
mnsod	B-protein
)	O
in	O
the	O
hepg0	B-cell_line
human	I-cell_line
hepatoma	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

in	O
the	O
first	O
set	O
of	O
experiments	O
,	O
il-0	B-DNA
gene	I-DNA
reporter	I-DNA
constructs	I-DNA
were	O
used	O
to	O
transiently	O
transfect	O
a	O
derivative	O
(	O
mvh0e0-0	B-protein
)	O
of	O
the	O
hepg0	B-cell_line
cell	I-cell_line
line	I-cell_line
which	O
expresses	O
p-0000e0	O
and	O
metabolizes	O
ethanol	O
.	O

inactivation	O
of	O
the	O
nf-kappab	B-DNA
and	I-DNA
0'nf-il-0	I-DNA
dna	I-DNA
binding	I-DNA
sites	I-DNA
decreased	O
il-0	B-DNA
gene	I-DNA
transcriptional	O
activation	O
in	O
response	O
to	O
tnf	B-protein
while	O
inactivation	O
of	O
the	O
0'nf-il-0	B-DNA
binding	I-DNA
site	I-DNA
increased	O
il-0	B-DNA
gene	I-DNA
transcriptional	O
activity	O
in	O
response	O
to	O
tnf	B-protein
.	O

this	O
system	O
may	O
be	O
useful	O
to	O
assess	O
the	O
effects	O
of	O
ethanol	O
on	O
tnf	B-protein
-induced	O
hepatocyte	O
il-0	B-protein
production	O
.	O

in	O
the	O
second	O
set	O
of	O
experiments	O
,	O
hepg0	B-cell_line
cells	I-cell_line
were	O
cultured	O
in	O
00	O
to	O
000	O
mmol	O
concentrations	O
of	O
ethanol	O
.	O

both	O
tnf	B-protein
and	O
ethanol	O
increased	O
hepg0	O
cell	O
mnsod	B-protein
activity	O
in	O
short-term	O
(	O
00	O
hr	O
)	O
cultures	O
with	O
ethanol	O
.	O

however	O
,	O
after	O
long-term	O
(	O
00	O
weeks	O
)	O
culture	O
with	O
ethanol	O
,	O
there	O
was	O
no	O
induction	O
of	O
mnsod	B-protein
by	O
ethanol	O
and	O
there	O
was	O
a	O
diminished	O
induction	O
of	O
mnsod	B-protein
in	O
response	O
to	O
tnf	B-protein
.	O

further	O
studies	O
are	O
needed	O
to	O
assess	O
the	O
effect	O
of	O
this	O
diminished	O
induction	O
of	O
mnsod	B-protein
with	O
chronic	O
ethanol	O
culture	O
on	O
hepg0	O
cell	O
susceptibility	O
to	O
tnf	B-protein
cytotoxicity	O
.	O

we	O
conclude	O
that	O
transfected	B-cell_line
liver	I-cell_line
cell	I-cell_line
lines	I-cell_line
can	O
be	O
used	O
to	O
evaluate	O
mechanisms	O
for	O
increased	O
injurious	B-protein
factors	I-protein
and	O
decreased	O
protective	O
factors	O
in	O
alcoholic	O
liver	O
injury	O
.	O

###MEDLINE:98318652

tissue	B-protein
factor	I-protein
transcription	O
driven	O
by	O
egr-0	B-protein
is	O
a	O
critical	O
mechanism	O
of	O
murine	O
pulmonary	O
fibrin	O
deposition	O
in	O
hypoxia	O
.	O

local	O
hypoxemia	O
and	O
stasis	O
trigger	O
thrombosis	O
.	O

we	O
have	O
demonstrated	O
previously	O
that	O
in	O
a	O
murine	O
model	O
of	O
normobaric	O
hypoxia	O
pulmonary	O
fibrin	O
deposition	O
is	O
a	O
result	O
of	O
expression	O
of	O
tissue	B-protein
factor	I-protein
,	O
especially	O
in	O
oxygen-deprived	B-cell_type
mononuclear	I-cell_type
phagocytes	I-cell_type
(	O
mps	B-cell_type
)	O
.	O

we	O
now	O
show	O
that	O
transcription	B-protein
factor	I-protein
early-growth-response	I-protein
gene	I-protein
product	I-protein
(	O
egr-0	B-protein
)	O
is	O
rapidly	O
activated	O
in	O
hypoxia	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
and	O
is	O
responsible	O
for	O
transcription	O
and	O
expression	O
of	O
tissue	B-protein
factor	I-protein
in	O
hypoxic	O
lung	O
.	O

mps	B-cell_type
and	O
hela	B-cell_line
cells	I-cell_line
subjected	O
to	O
hypoxia	O
(	O
po0	O
approximately	O
00	O
torr	O
)	O
had	O
increased	O
levels	O
of	O
tissue	B-protein
factor	I-protein
transcripts	I-protein
(	O
approximately	O
00-fold	O
)	O
and	O
an	O
increased	O
rate	O
of	O
transcription	O
(	O
approximately	O
00-fold	O
)	O
,	O
based	O
on	O
nuclear	O
run-on	O
analysis	O
.	O

gel-shift	O
analysis	O
of	O
nuclear	O
extracts	O
from	O
hypoxic	B-cell_type
mps	I-cell_type
and	O
hela	B-cell_line
cells	I-cell_line
demonstrated	O
increased	O
dna-binding	O
activity	O
at	O
the	O
serum	B-DNA
response	I-DNA
region	I-DNA
(	O
srr	B-DNA
;	I-DNA
-000/+00	I-DNA
bp	I-DNA
)	O
of	O
the	O
tissue	B-DNA
factor	I-DNA
promoter	I-DNA
at	O
egr-0	B-DNA
motifs	I-DNA
.	O

using	O
00p-labeled	B-DNA
egr	I-DNA
consensus	I-DNA
oligonucleotide	I-DNA
,	O
we	O
observed	O
induction	O
of	O
dna-binding	O
activity	O
in	O
nuclear	O
extracts	O
from	O
hypoxic	O
lung	O
and	O
hela	B-cell_line
cells	I-cell_line
because	O
of	O
activation	O
of	O
egr-0	B-protein
,	O
by	O
means	O
of	O
supershift	O
analysis	O
.	O

transient	O
transfection	O
of	O
hela	B-cell_line
cells	I-cell_line
with	O
chimeric	B-DNA
plasmids	I-DNA
containing	O
wild-type	B-protein
or	I-protein
mutant	I-protein
srr	I-protein
from	O
the	O
tissue	B-DNA
factor	I-DNA
promoter	I-DNA
showed	O
that	O
intact	O
sp0	B-DNA
sites	I-DNA
are	O
necessary	O
for	O
basal	O
promoter	O
activity	O
,	O
whereas	O
the	O
integrity	O
of	O
egr-0	B-DNA
sites	I-DNA
was	O
required	O
for	O
hypoxia-enhanced	O
expression	O
.	O

a	O
central	O
role	O
for	O
egr-0	B-protein
in	O
hypoxia-mediated	O
tissue	B-protein
factor	I-protein
expression	O
was	O
confirmed	O
by	O
experiments	O
with	O
homozygous	O
egr-0	B-protein
null	O
mice	O
;	O
wild-type	O
mice	O
subjected	O
to	O
oxygen	O
deprivation	O
expressed	O
tissue	B-protein
factor	I-protein
and	O
showed	O
fibrin	B-protein
deposition	O
,	O
but	O
hypoxic	O
homozygous	O
egr-0	B-protein
null	O
mice	O
displayed	O
neither	O
tissue	B-protein
factor	I-protein
nor	O
fibrin	B-protein
.	O

these	O
data	O
delineate	O
a	O
novel	O
biology	O
for	O
hypoxia-induced	O
fibrin	O
deposition	O
,	O
in	O
which	O
oxygen	O
deprivation-induced	O
activation	O
of	O
egr-0	B-protein
,	O
resulting	O
in	O
expression	O
of	O
tissue	B-protein
factor	I-protein
,	O
has	O
an	O
unexpected	O
and	O
central	O
role	O
.	O

###MEDLINE:98304427

kinetics	O
of	O
cytokine	B-protein
and	O
nfat	B-protein
gene	O
expression	O
in	O
human	O
interleukin-0-dependent	O
t	B-cell_type
lymphoblasts	I-cell_type
stimulated	O
via	O
t-cell	B-protein
receptor	I-protein
.	O

t	B-cell_type
cells	I-cell_type
respond	O
to	O
mitogenic	O
or	O
antigenic	O
stimulation	O
by	O
proliferation	O
and	O
by	O
turning	O
on	O
cytokine	B-DNA
gene	I-DNA
expression	O
.	O

here	O
we	O
have	O
analysed	O
the	O
kinetics	O
and	O
nature	O
of	O
cytokine	B-protein
production	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood-derived	I-cell_type
t	I-cell_type
lymphoblasts	I-cell_type
stimulated	O
with	O
anti-cd0	B-protein
antibodies	I-protein
or	O
lens	B-protein
culinaris	I-protein
lectin	I-protein
(	O
lcl	B-cell_line
)	O
.	O

t	B-cell_type
cells	I-cell_type
were	O
purified	O
from	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
pbmc	B-cell_type
)	O
and	O
primarily	O
activated	O
with	O
anti-cd0	B-protein
antibodies	I-protein
and	O
cultured	O
in	O
the	O
presence	O
of	O
interleukin-0	B-protein
(	O
il-0	B-protein
)	O
.	O

anti-cd0-restimulated	B-cell_type
t	I-cell_type
cells	I-cell_type
(	O
mainly	O
cd0+	B-protein
)	O
produced	O
il-0	B-protein
,	O
interferon-gamma	B-protein
(	O
ifn-gamma	B-protein
)	O
and	O
tumour	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
tnf-alpha	B-protein
)	O
and	O
low	O
levels	O
of	O
il-0	B-protein
and	O
il-00	B-RNA
transcripts	I-RNA
and	O
proteins	O
.	O

no	O
il-0	B-DNA
gene	I-DNA
expression	O
was	O
observed	O
.	O

in	O
lcl-stimulated	B-cell_type
cells	I-cell_type
the	O
cytokine	B-protein
production	O
pattern	O
was	O
very	O
similar	O
.	O

steady-state	B-RNA
mrna	I-RNA
levels	O
of	O
il-0	B-protein
,	O
il-00	B-protein
and	O
ifn-gamma	B-protein
peaked	O
at	O
0	O
hr	O
after	O
anti-cd0	B-protein
stimulation	O
and	O
declined	O
rapidly	O
thereafter	O
.	O

the	O
kinetics	O
of	O
tnf-alpha	B-RNA
mrna	I-RNA
expression	O
was	O
faster	O
,	O
being	O
at	O
its	O
peak	O
level	O
0	O
hr	O
after	O
stimulation	O
.	O

anti-cd0-stimulated	O
il-0	B-DNA
gene	I-DNA
expression	O
was	O
down-regulated	O
by	O
protein	O
synthesis	O
inhibitor	O
,	O
whereas	O
il-00	B-protein
,	O
ifn-gamma	B-protein
and	O
tnf-alpha	B-DNA
genes	I-DNA
were	O
readily	O
induced	O
independent	O
of	O
ongoing	O
protein	O
synthesis	O
.	O

t-cell	B-protein
receptor	I-protein
stimulation	O
also	O
induced	O
a	O
very	O
rapid	O
expression	O
of	O
c-jun	B-protein
,	O
c-fos	B-DNA
and	O
nfatc0	B-protein
(	O
nfatc	B-protein
)	O
genes	O
,	O
the	O
gene	O
products	O
of	O
which	O
are	O
involved	O
in	O
cytokine	B-DNA
gene	I-DNA
expression	O
.	O

in	O
conclusion	O
,	O
the	O
cytokines	O
synthesized	O
by	O
il-0-dependent	B-cell_line
t	I-cell_line
cells	I-cell_line
were	O
predominantly	O
il-0	B-protein
,	O
ifn-gamma	B-protein
and	O
tnf-alpha	B-protein
.	O

###MEDLINE:98295684

an	O
animal	O
model	O
to	O
study	O
local	O
oxidation	O
of	O
ldl	B-protein
and	O
its	O
biological	O
effects	O
in	O
the	O
arterial	O
wall	O
.	O

oxidized	B-protein
ldl	I-protein
(	O
oxldl	B-protein
)	O
is	O
present	O
in	O
atherosclerotic	O
lesions	O
and	O
is	O
believed	O
to	O
play	O
a	O
key	O
role	O
in	O
atherogenesis	O
.	O

mainly	O
on	O
the	O
basis	O
of	O
cell	O
culture	O
studies	O
,	O
oxldl	B-protein
has	O
been	O
shown	O
to	O
produce	O
many	O
biological	O
effects	O
that	O
influence	O
the	O
atherosclerotic	O
process	O
.	O

to	O
study	O
ldl	B-protein
oxidation	O
in	O
vivo	O
,	O
we	O
have	O
established	O
a	O
model	O
in	O
which	O
sprague-dawley	O
rats	O
are	O
given	O
a	O
single	O
injection	O
of	O
unmodified	B-protein
human	I-protein
ldl	I-protein
(	O
>	O
or	O
=	O
0	O
mg/kg	O
body	O
weight	O
)	O
.	O

within	O
0	O
hours	O
,	O
an	O
accumulation	O
of	O
apolipoprotein	B-protein
b	I-protein
and	O
epitopes	B-protein
present	O
on	O
oxldl	B-protein
are	O
detected	O
in	O
the	O
arterial	O
endothelium	O
and	O
media	O
.	O

the	O
presence	O
of	O
oxldl	B-protein
is	O
associated	O
with	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor-kappab	I-protein
in	O
the	O
endothelium	O
as	O
well	O
as	O
endothelial	O
expression	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-0	I-protein
.	O

injection	O
of	O
ldl	B-protein
enriched	O
with	O
the	O
antioxidant	O
probucol	O
resulted	O
in	O
arterial	O
accumulation	O
of	O
apolipoprotein	B-protein
b	I-protein
,	O
but	O
the	O
expression	O
of	O
oxldl-specific	B-protein
epitopes	I-protein
was	O
reduced	O
at	O
00	O
hours	O
.	O

thus	O
,	O
this	O
simple	O
model	O
has	O
the	O
potential	O
to	O
analyze	O
the	O
mechanisms	O
behind	O
and	O
biological	O
effects	O
of	O
ldl	B-protein
oxidation	O
in	O
vivo	O
.	O

###MEDLINE:98269066

molecular	O
mechanisms	O
of	O
promoter	O
regulation	O
of	O
the	O
gp00	B-protein
gene	O
that	O
is	O
trans-activated	O
by	O
an	O
oncoprotein	B-protein
tax	B-protein
of	O
human	B-protein
t	I-protein
cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
i	I-protein
.	O

we	O
investigated	O
the	O
molecular	O
mechanism	O
of	O
transcriptional	O
activation	O
of	O
the	O
gp00	B-protein
gene	O
by	O
the	O
tax	B-protein
oncoprotein	I-protein
of	O
human	B-protein
t	I-protein
cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
i	I-protein
(	O
htlv-i	O
)	O
.	O

gp00	B-protein
is	O
a	O
type	B-protein
ii	I-protein
transmembrane	I-protein
molecule	I-protein
belonging	O
to	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
family	I-protein
and	O
is	O
constitutively	O
expressed	O
on	O
htlv-i-producing	B-cell_type
cells	I-cell_type
but	O
not	O
normal	O
resting	B-cell_type
t	I-cell_type
cells	I-cell_type
.	O

the	O
transcriptional	B-DNA
regulatory	I-DNA
region	I-DNA
of	O
the	O
gp00	B-protein
gene	O
was	O
activated	O
by	O
htlv-i	B-protein
tax	I-protein
in	O
the	O
human	B-cell_line
t	I-cell_line
cell	I-cell_line
line	I-cell_line
jurkat	B-cell_line
,	O
in	O
which	O
endogenous	B-protein
gp00	I-protein
is	O
induced	O
by	O
tax	B-protein
.	O

sequence	O
analysis	O
demonstrated	O
that	O
two	O
nf-kappab-like	B-DNA
elements	I-DNA
(	O
0	O
and	O
0	O
)	O
were	O
present	O
in	O
the	O
regulatory	B-DNA
region	I-DNA
.	O

both	O
nf-kappab-like	B-DNA
elements	I-DNA
were	O
able	O
to	O
bind	O
to	O
nf-kappab	B-protein
or	O
its	O
related	O
factor	O
(	O
s	O
)	O
in	O
a	O
tax	B-protein
-dependent	O
manner	O
.	O

chloramphenicol	B-protein
acetyltransferase	I-protein
assays	O
indicated	O
that	O
nf-kappab-like	B-protein
element	I-protein
0	I-protein
was	O
tax	B-protein
-responsive	O
,	O
although	O
the	O
activity	O
was	O
lower	O
than	O
that	O
the	O
native	B-DNA
promoter	I-DNA
.	O

nf-kappab	B-protein
-like	O
element	O
0	O
elevated	O
promoter	O
activity	O
when	O
combined	O
with	O
nf-kappab-like	B-protein
element	I-protein
0	I-protein
,	O
indicating	O
cooperative	O
function	O
of	O
the	O
elements	O
for	O
maximum	O
promoter	O
function	O
.	O

unlike	O
typical	O
nf-kappab	B-DNA
elements	I-DNA
,	O
the	O
nf-kappab-like	B-DNA
elements	I-DNA
in	O
gp00	B-protein
were	O
not	O
activated	O
by	O
treatment	O
of	O
jurkat	B-cell_line
cells	I-cell_line
with	O
phorbol	O
ester	O
despite	O
induction	O
of	O
the	O
nf-kappab	B-protein
-like	O
binding	O
activity	O
.	O

chloramphenicol	B-protein
acetyltransferase	I-protein
reporter	O
assays	O
using	O
the	O
region	B-DNA
upstream	I-DNA
of	O
the	O
nf-kappab-like	B-DNA
elements	I-DNA
identified	O
an	O
upstream	B-DNA
region	I-DNA
that	O
reduced	O
transcription	O
from	O
cognate	B-DNA
and	I-DNA
noncognate	I-DNA
core	I-DNA
promoters	I-DNA
in	O
a	O
tax-independent	O
manner	O
.	O

our	O
results	O
imply	O
complex	O
regulation	O
of	O
expression	O
of	O
the	O
gp00	B-protein
gene	O
and	O
suggest	O
implication	O
of	O
gp00	B-protein
in	O
proliferation	O
of	O
htlv-i	B-cell_line
infected	I-cell_line
t	I-cell_line
cells	I-cell_line
.	O

###MEDLINE:98279058

beta-amyloid	O
fibrils	O
activate	O
parallel	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
pathways	O
in	O
microglia	B-cell_type
and	O
thp0	B-cell_line
monocytes	B-cell_type
.	O

the	O
senile	O
plaques	O
of	O
alzheimer	O
's	O
disease	O
are	O
foci	O
of	O
local	O
inflammatory	O
responses	O
,	O
as	O
evidenced	O
by	O
the	O
presence	O
of	O
acute	O
phase	O
proteins	O
and	O
oxidative	O
damage	O
.	O

fibrillar	O
forms	O
of	O
beta-amyloid	O
(	O
abeta	B-protein
)	O
,	O
which	O
are	O
the	O
primary	O
constituents	O
of	O
senile	O
plaques	O
,	O
have	O
been	O
shown	O
to	O
activate	O
tyrosine	O
kinase-dependent	O
signal	O
transduction	O
cascades	O
,	O
resulting	O
in	O
inflammatory	O
responses	O
in	O
microglia	B-cell_type
.	O

however	O
,	O
the	O
downstream	O
signaling	O
pathways	O
mediating	O
abeta	O
-induced	O
inflammatory	O
events	O
are	O
not	O
well	O
characterized	O
.	O

we	O
report	O
that	O
exposure	O
of	O
primary	B-cell_type
rat	I-cell_type
microglia	I-cell_type
and	O
human	O
thp0	B-cell_line
monocytes	B-cell_type
to	O
fibrillar	O
abeta	O
results	O
in	O
the	O
tyrosine	B-protein
kinase	I-protein
-dependent	O
activation	O
of	O
two	O
parallel	O
signal	O
transduction	O
cascades	O
involving	O
members	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	I-protein
mapk	I-protein
)	I-protein
superfamily	I-protein
.	O

abeta	O
stimulated	O
the	O
rapid	O
,	O
transient	O
activation	O
of	O
extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
0	I-protein
(	O
erk0	B-protein
)	O
and	O
erk0	B-protein
in	O
microglia	B-cell_type
and	O
erk0	B-protein
in	O
thp0	B-cell_line
monocytes	B-cell_type
.	O

a	O
second	B-protein
superfamily	I-protein
member	O
,	O
p00	B-protein
mapk	I-protein
,	O
was	O
also	O
activated	O
with	O
similar	O
kinetics	O
.	O

scavenger	O
receptor	O
and	O
receptor	O
for	O
advanced	O
glycated	B-DNA
end	I-DNA
products	I-DNA
(	O
rage	B-protein
)	O
ligands	O
failed	O
to	O
activate	O
erk	B-protein
and	O
p00	B-protein
mapk	I-protein
in	O
the	O
absence	O
of	O
significant	O
increases	O
in	O
protein	O
tyrosine	O
phosphorylation	O
,	O
demonstrating	O
that	O
scavenger	O
receptors	O
and	O
rage	B-protein
are	O
not	O
linked	O
to	O
these	O
pathways	O
.	O

importantly	O
,	O
the	O
stress-activated	B-protein
protein	I-protein
kinases	I-protein
(	O
sapks	B-protein
)	O
were	O
not	O
significantly	O
activated	O
in	O
response	O
to	O
abeta	O
.	O

downstream	O
effectors	O
of	O
the	O
mapk	B-protein
signal	O
transduction	O
cascades	O
include	O
mapkap	B-protein
kinases	I-protein
,	O
such	O
as	O
rsk0	B-protein
and	O
rsk0	B-protein
,	O
as	O
well	O
as	O
transcription	B-protein
factors	I-protein
.	O

exposure	O
of	O
microglia	B-cell_type
and	O
thp0	B-cell_line
monocytes	B-cell_type
to	O
abeta	O
resulted	O
in	O
the	O
activation	O
of	O
rsk0	B-protein
and	O
rsk0	B-protein
and	O
phosphorylation	O
of	O
camp	B-protein
response	I-protein
element-binding	I-protein
protein	I-protein
at	O
ser000	O
,	O
providing	O
a	O
mechanism	O
for	O
abeta	B-protein
-induced	O
changes	O
in	O
gene	O
expression	O

###MEDLINE:98369636

regulation	O
of	O
cellular	O
retinoic	B-protein
acid	I-protein
binding	I-protein
protein	I-protein
(	O
crabp	B-protein
ii	I-protein
)	O
during	O
human	O
monocyte	O
differentiation	O
in	O
vitro	O
.	O

cellular	O
retinoic	B-protein
acid	I-protein
binding	I-protein
proteins	I-protein
(	O
crabp	O
)	O
are	O
low	O
molecular	O
weight	O
proteins	O
whose	O
precise	O
function	O
remains	O
unknown	O
.	O

they	O
bind	O
retinoids	O
and	O
may	O
thereby	O
modulate	O
the	O
intracellular	O
steady-state	O
concentration	O
of	O
retinoids	O
.	O

whereas	O
crabp	B-protein
i	I-protein
is	O
ubiquitously	O
expressed	O
,	O
crabp	B-protein
ii	I-protein
is	O
mainly	O
detected	O
in	O
various	O
cell	O
types	O
of	O
the	O
skin	O
.	O

by	O
representative	O
difference	O
analysis	O
we	O
found	O
that	O
crabp	B-protein
ii	I-protein
is	O
also	O
strongly	O
expressed	O
in	O
human	B-cell_type
monocyte-derived	I-cell_type
macrophages	I-cell_type
(	O
mac	O
)	O
but	O
not	O
in	O
freshly	B-cell_type
isolated	I-cell_type
monocytes	I-cell_type
(	O
mo	B-cell_line
)	O
.	O

the	O
crabp	B-RNA
ii	I-RNA
mrna	I-RNA
was	O
gradually	O
upregulated	O
during	O
differentiation	O
from	O
mo	B-cell_type
to	O
mac	O
in	O
the	O
presence	O
of	O
0	O
%	O
serum	O
.	O

adherence	O
,	O
which	O
is	O
important	O
for	O
mo	O
differentiation	O
,	O
induced	O
crabp	B-protein
ii	I-protein
expression	O
,	O
but	O
the	O
addition	O
of	O
00	O
(	O
-0	O
)	O
m	O
retinoic	O
acid	O
inhibited	O
the	O
upregulation	O
of	O
crabp	B-protein
ii	I-protein
expression	O
during	O
mo/mac	O
differentiation	O
.	O

as	O
mo	B-cell_type
can	O
differentiate	O
along	O
the	O
classical	O
pathway	O
not	O
only	O
to	O
mac	B-protein
but	O
also	O
to	O
dendritic	B-cell_type
cells	I-cell_type
we	O
analyzed	O
the	O
expression	O
of	O
crabp	B-protein
ii	I-protein
in	O
mo-derived	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
cultured	O
with	O
00	O
%	O
fcs	O
,	O
il-0	B-protein
,	O
and	O
gm-csf	B-protein
.	O

in	O
contrast	O
to	O
mac	O
,	O
mo-derived	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
showed	O
an	O
extremely	O
low	O
expression	O
of	O
crabp	B-protein
ii	I-protein
.	O

from	O
these	O
results	O
we	O
conclude	O
(	O
0	O
)	O
that	O
the	O
availability	O
and	O
the	O
metabolism	O
of	O
retinoids	O
may	O
be	O
different	O
in	O
mac	O
compared	O
to	O
mo	B-cell_type
and	O
dendritic	B-cell_type
cells	I-cell_type
and	O
(	O
0	O
)	O
that	O
this	O
may	O
influence	O
differentiation	O
and	O
activation	O
of	O
those	O
cells	O
.	O

###MEDLINE:98361776

transcription	B-protein
factor	I-protein
b-cell-specific	I-protein
activator	I-protein
protein	I-protein
(	O
bsap	B-protein
)	O
is	O
differentially	O
expressed	O
in	O
b	B-cell_type
cells	I-cell_type
and	O
in	O
subsets	O
of	O
b-cell	B-cell_type
lymphomas	I-cell_type
.	O

the	O
paired	B-DNA
box	I-DNA
containing	I-DNA
gene	I-DNA
pax-0	B-DNA
encodes	O
the	O
transcription	B-protein
factor	I-protein
bsap	B-protein
(	O
b-cell-specific	B-protein
activator	I-protein
protein	I-protein
)	O
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
b-lymphocyte	O
development	O
.	O

despite	O
its	O
known	O
involvement	O
in	O
a	O
rare	O
subtype	O
of	O
non-hodgkin	O
's	O
lymphoma	O
(	O
nhl	O
)	O
,	O
a	O
detailed	O
examination	O
of	O
bsap	B-protein
expression	O
in	O
nhl	O
has	O
not	O
been	O
previously	O
reported	O
.	O

in	O
this	O
study	O
,	O
we	O
analyzed	O
normal	O
and	O
malignant	B-cell_type
lymphoid	I-cell_type
tissues	I-cell_type
and	O
cell	B-cell_line
lines	I-cell_line
,	O
including	O
000	O
cases	O
of	O
b-cell	O
nhl	O
,	O
00	O
cases	O
of	O
t-	O
and	O
null-cell	O
nhl	O
,	O
and	O
00	O
cases	O
of	O
hodgkin	O
's	O
disease	O
.	O

normal	O
lymphoid	O
tissues	O
showed	O
strong	O
nuclear	O
bsap	B-protein
expression	O
in	O
mantle	B-cell_type
zone	I-cell_type
b	I-cell_type
cells	I-cell_type
,	O
less	O
intense	O
reactivity	O
in	O
follicular	B-cell_type
center	I-cell_type
b	I-cell_type
cells	I-cell_type
,	O
and	O
no	O
expression	O
in	O
cells	O
of	O
the	O
t-cell-rich	O
zones	O
.	O

monocytoid	B-cell_line
b	I-cell_line
cells	I-cell_line
showed	O
weak	O
expression	O
,	O
whereas	O
plasma	B-cell_type
cells	I-cell_type
and	O
extrafollicular	O
large	O
transformed	B-cell_line
b	I-cell_line
cells	I-cell_line
were	O
negative	O
.	O

of	O
the	O
000	B-cell_line
b-cell	I-cell_line
nhls	I-cell_line
,	O
00	O
(	O
00	O
%	O
)	O
demonstrated	O
bsap	B-protein
expression	O
.	O

all	O
of	O
the	O
00	O
(	O
000	O
%	O
)	O
b-cell	B-cell_line
chronic	I-cell_line
lymphocytic	I-cell_line
leukemias	I-cell_line
(	O
b-clls	B-protein
)	O
,	O
00	O
of	O
(	O
000	O
%	O
)	O
mantle	B-cell_type
cells	I-cell_type
(	O
mcls	O
)	O
,	O
and	O
00	O
of	O
00	O
(	O
00	O
%	O
)	O
follicular	O
lymphomas	O
(	O
fls	B-cell_type
)	O
were	O
positive	O
.	O

moderate	O
staining	O
intensities	O
were	O
found	O
in	O
most	O
b-cll	O
and	O
fl	O
cases	O
,	O
whereas	O
most	O
mcls	O
showed	O
strong	O
reactions	O
,	O
paralleling	O
the	O
strong	O
reactivity	O
of	O
nonmalignant	B-cell_type
mantle	I-cell_type
cells	I-cell_type
.	O

eight	O
of	O
00	O
(	O
00	O
%	O
)	O
marginal	O
zone	O
lymphoma	O
cases	O
showed	O
negative	O
or	O
low	O
bsap	B-protein
levels	O
,	O
and	O
00	O
of	O
00	O
(	O
00	O
%	O
)	O
large	O
b-cell	O
lymphomas	O
displayed	O
moderate	O
to	O
strong	O
expression	O
.	O

none	O
of	O
the	O
00	O
t-	O
and	O
null-cell	O
lymphomas	O
reacted	O
with	O
the	O
bsap	B-protein
antisera	O
,	O
whereas	O
in	O
hodgkin	O
's	O
disease	O
,	O
0	O
of	O
0	O
(	O
00	O
%	O
)	O
nodular	O
lymphocytic	O
predominance	O
and	O
0	O
of	O
00	O
(	O
00	O
%	O
)	O
classical	O
cases	O
showed	O
weak	O
nuclear	O
or	O
nucleolar	O
bsap	B-protein
reactions	O
in	O
a	O
fraction	O
of	O
the	O
tumor	B-cell_type
cells	I-cell_type
.	O

western	O
blot	O
analysis	O
showed	O
a	O
00-kd	O
bsap	B-protein
band	O
in	O
b-cell	B-cell_line
lines	I-cell_line
,	O
but	O
not	O
in	O
non-b-cell	B-cell_line
or	I-cell_line
plasma	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

we	O
conclude	O
that	O
bsap	B-protein
expression	O
is	O
largely	O
restricted	O
to	O
lymphomas	O
of	O
b-cell	B-cell_type
lineage	I-cell_type
and	O
that	O
bsap	B-protein
expression	O
varies	O
in	O
b-cell	B-cell_type
subsets	I-cell_type
and	O
subtypes	O
of	O
b-cell	O
nhl	O
.	O

the	O
high	O
levels	O
of	O
bsap	B-protein
,	O
especially	O
those	O
found	O
in	O
large-cell	B-cell_type
lymphomas	I-cell_type
and	O
in	O
some	O
follicular	O
lymphomas	O
,	O
may	O
be	O
a	O
consequence	O
of	O
deregulated	O
gene	O
expression	O
and	O
suggest	O
a	O
possible	O
involvement	O
of	O
pax-0	B-DNA
in	O
certain	O
b-cell	O
malignancies	O
.	O

this	O
is	O
a	O
us	O
government	O
work	O
.	O

there	O
are	O
no	O
restrictions	O
on	O
its	O
use	O
.	O

###MEDLINE:98346788

mitogen	B-protein
and	O
growth	O
factor-induced	O
activation	O
of	O
a	O
stat-like	B-protein
molecule	I-protein
in	O
channel	O
catfish	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O

this	O
article	O
describes	O
the	O
identification	O
of	O
a	O
putative	B-protein
stat	I-protein
molecule	I-protein
in	O
the	O
channel	O
catfish	O
(	O
ictalurus	O
punctatus	O
)	O
,	O
the	O
first	O
report	O
of	O
such	O
a	O
molecule	O
in	O
a	O
'lower	O
'	O
vertebrate	O
.	O

a	O
monoclonal	B-protein
antibody	I-protein
against	O
human	O
stat0	B-protein
recognizes	O
an	O
approximately	O
000	B-protein
kda	I-protein
molecule	I-protein
that	O
becomes	O
activated	O
and	O
translocates	O
to	O
the	O
nucleus	O
upon	O
both	O
growth	B-protein
factor	I-protein
and	O
mitogen	B-protein
stimulation	O
of	O
catfish	B-cell_type
leukocytes	I-cell_type
.	O

this	O
presumed	O
catfish	B-protein
stat	I-protein
binds	O
the	O
mammalian	O
interferon-gamma	B-DNA
activation	I-DNA
site	I-DNA
,	O
a	O
known	O
motif	O
of	O
mammalian	B-protein
stat	I-protein
binding	O
,	O
as	O
shown	O
by	O
electromobility	O
shift	O
assays	O
.	O

purification	O
of	O
the	O
proteins	O
present	O
in	O
these	O
dna	B-protein
complexes	I-protein
confirms	O
that	O
the	O
catfish	B-protein
reactive	I-protein
molecule	I-protein
binds	O
to	O
the	O
interferon-gamma	B-DNA
activation	I-DNA
site	I-DNA
sequence	I-DNA
.	O

these	O
results	O
suggest	O
that	O
stat	B-protein
molecules	I-protein
have	O
been	O
highly	O
conserved	O
in	O
vertebrate	O
evolution	O
.	O

###MEDLINE:98334015

isolation	O
and	O
analysis	O
of	O
a	O
t	B-cell_line
cell	I-cell_line
clone	I-cell_line
variant	I-cell_line
exhibiting	O
constitutively	O
phosphorylated	O
ser000	O
camp	B-protein
response	I-protein
element-binding	I-protein
protein	I-protein
.	O

in	O
driving	O
t	O
cell	O
proliferation	O
,	O
il-0	B-protein
stimulates	O
a	O
new	O
program	O
of	O
gene	O
expression	O
that	O
includes	O
proliferating	O
cell	O
nuclear	B-protein
antigen	I-protein
(	O
pcna	B-protein
)	O
,	O
a	O
requisite	O
processivity	B-protein
factor	I-protein
for	O
dna	B-protein
polymerase	I-protein
delta	I-protein
.	O

pcna	B-protein
transcription	O
is	O
regulated	O
in	O
part	O
through	O
tandem	B-DNA
cre	I-DNA
sequences	I-DNA
in	O
the	O
promoter	O
and	O
cre	B-protein
binding	I-protein
proteins	I-protein
;	O
il-0	B-protein
stimulates	O
creb	B-protein
phosphorylation	O
in	O
the	O
resting	B-cell_line
cloned	I-cell_line
t	I-cell_line
lymphocyte	I-cell_line
,	O
l0	B-DNA
.	O

after	O
culturing	O
l0	B-DNA
cells	O
for	O
greater	O
than	O
00	O
days	O
,	O
we	O
consistently	O
isolate	O
a	O
stable	O
variant	O
that	O
exhibits	O
constitutive	O
creb	B-protein
phosphorylation	O
.	O

l0	B-DNA
and	O
l0	B-DNA
variant	O
cells	O
were	O
tested	O
for	O
il-0	B-protein
responsiveness	O
and	O
rapamycin	O
sensitivity	O
with	O
respect	O
to	O
specific	O
kinase	O
activity	O
,	O
pcna	B-protein
expression	O
and	O
proliferation	O
.	O

in	O
l0	B-DNA
cells	O
,	O
il-0	B-protein
stimulated	O
and	O
rapamycin	O
inhibited	O
the	O
following	O
:	O
camp-independent	B-protein
creb	I-protein
kinase	I-protein
activity	O
,	O
pcna	B-protein
expression	O
and	O
proliferation	O
.	O

in	O
l0	B-DNA
variant	O
cells	O
,	O
creb	B-protein
kinase	I-protein
activity	O
was	O
constitutively	O
high	O
;	O
il-0	B-protein
stimulated	O
and	O
rapamycin	O
blocked	O
pcna	B-protein
expression	O
and	O
proliferation	O
.	O

these	O
results	O
indicate	O
that	O
il-0	B-protein
induces	O
a	O
rapamycin-sensitive	O
,	O
camp-independent	B-protein
creb	I-protein
kinase	I-protein
activity	O
in	O
l0	B-DNA
cells	O
.	O

however	O
,	O
phosphorylation	O
of	O
creb	B-protein
alone	O
is	O
not	O
sufficient	O
to	O
drive	O
pcna	B-protein
expression	O
and	O
l0	B-DNA
cell	O
proliferation	O
in	O
the	O
absence	O
of	O
il-0	B-protein
.	O

###MEDLINE:98321687

serotonin	O
derivative	O
,	O
n-	B-protein
(	I-protein
p-coumaroyl	I-protein
)	O
serotonin	O
,	O
inhibits	O
the	O
production	O
of	O
tnf-alpha	B-protein
,	O
il-0alpha	B-protein
,	O
il-0beta	B-protein
,	O
and	O
il-0	B-protein
by	O
endotoxin-stimulated	O
human	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
.	O

we	O
have	O
reported	O
that	O
n-	B-protein
(	I-protein
p-coumaroyl	I-protein
)	O
serotonin	O
(	O
cs	O
)	O
and	O
its	O
derivatives	O
with	O
antioxidative	O
activity	O
are	O
present	O
in	O
safflower	O
seeds	O
.	O

as	O
reactive	O
oxygen	O
species	O
(	O
ros	O
)	O
are	O
implicated	O
in	O
the	O
signaling	O
of	O
lipopolysaccharide	O
(	O
lps	O
)	O
,	O
we	O
examined	O
whether	O
cs	O
has	O
a	O
suppressive	O
effect	O
on	O
inflammatory	O
cytokine	O
generation	O
from	O
human	O
monocyte	O
s	O
in	O
vitro	O
.	O

cs	O
at	O
00-000	O
microm	O
reduced	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
tnf	B-protein
)	O
,	O
interleukin-0	B-protein
(	O
il-0	B-protein
)	O
,	O
and	O
il-0	B-protein
activities	O
in	O
the	O
culture	O
supernatants	O
from	O
lps-stimulated	B-cell_type
human	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
without	O
cytotoxicity	O
.	O

elisa	O
assay	O
revealed	O
that	O
the	O
production	O
of	O
tnf-alpha	B-protein
,	O
il-0alpha	B-protein
,	O
il-0beta	B-protein
,	O
and	O
il-0	B-protein
was	O
inhibited	O
by	O
cs	O
.	O

northern	O
blot	O
analysis	O
showed	O
that	O
lps-induced	O
expression	O
of	O
these	O
cytokine	B-RNA
mrna	I-RNA
in	O
monocytes	B-cell_type
was	O
suppressed	O
by	O
cs	O
.	O

nf-kappab	B-protein
activation	O
was	O
also	O
inhibited	O
by	O
cs	O
.	O

these	O
findings	O
indicate	O
that	O
cs	O
has	O
a	O
suppressive	O
effect	O
on	O
proinflammatory	B-protein
cytokine	I-protein
production	O
from	O
monocytes	B-cell_type
,	O
and	O
this	O
effect	O
is	O
based	O
in	O
part	O
on	O
the	O
suppression	O
of	O
cytokine	B-RNA
mrna	I-RNA
expression	O
through	O
inhibition	O
of	O
nf-kappab	B-protein
activation	O
.	O

###MEDLINE:98314139

elevated	O
expression	O
of	O
differentiation	B-protein
inhibitory	I-protein
factor	I-protein
nm00	B-protein
mrna	O
in	O
monoblastic	O
crisis	O
of	O
a	O
patient	O
with	O
chronic	O
myelogenous	O
leukemia	O
.	O

differentiation	B-protein
inhibitory	I-protein
factor	I-protein
nm00	B-DNA
gene	I-DNA
has	O
been	O
found	O
to	O
be	O
expressed	O
in	O
high	O
quantities	O
in	O
acute	O
myelogenous	O
leukemia	O
(	O
aml	O
)	O
,	O
especially	O
in	O
acute	O
monocytic	O
leukemia	O
(	O
aml-m0	O
)	O
and	O
is	O
suggested	O
as	O
a	O
new	O
prognostic	O
factor	O
in	O
aml-m0	O
.	O

we	O
report	O
an	O
example	O
of	O
elevated	O
expression	O
of	O
nm00	B-protein
mrna	O
in	O
a	O
patient	O
with	O
chronic	O
myelogenous	O
leukemia	O
(	O
cml	O
)	O
who	O
developed	O
monoblastic	O
crisis	O
.	O

relative	O
levels	O
of	O
nm00-h0	B-DNA
and	O
-h0	B-RNA
mrna	I-RNA
extracted	O
from	O
the	O
patient	O
's	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
bone	B-cell_type
marrow	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
were	O
measured	O
by	O
quantitative	O
reverse	B-protein
transcriptase	I-protein
polymerase	I-protein
chain	I-protein
reaction	O
.	O

the	O
level	O
of	O
nm00-h0	B-DNA
mrna	O
in	O
cml	B-cell_type
cells	I-cell_type
at	O
the	O
chronic	O
phase	O
was	O
as	O
high	O
as	O
that	O
in	O
bone	B-cell_type
marrow	I-cell_type
cells	I-cell_type
from	O
healthy	O
volunteers	O
.	O

the	O
mrna	O
level	O
of	O
nm00-h0	B-DNA
was	O
slightly	O
below	O
the	O
normal	O
level	O
.	O

at	O
blastic	O
crisis	O
,	O
however	O
,	O
expression	O
of	O
both	O
nm00-h0	B-DNA
and	O
-h0	B-RNA
mrna	I-RNA
was	O
elevated	O
to	O
about	O
three	O
to	O
nine	O
times	O
of	O
that	O
at	O
the	O
chronic	O
phase	O
.	O

proliferated	O
blastic	B-cell_type
cells	I-cell_type
were	O
positive	O
for	O
non-specific	O
esterase	O
,	O
and	O
the	O
serum	O
lysozyme	B-protein
level	O
was	O
elevated	O
and	O
diagnosed	O
as	O
monoblastic	O
crisis	O
.	O

the	O
patient	O
received	O
combined	O
chemotherapy	O
but	O
response	O
was	O
partial	O
.	O

these	O
findings	O
are	O
compatible	O
with	O
our	O
previous	O
report	O
that	O
nm00	B-DNA
gene	I-DNA
is	O
overexpressed	O
in	O
monocytic	O
leukemia	O
.	O

###MEDLINE:98306174

increased	O
transcription	O
decreases	O
the	O
spontaneous	O
mutation	O
rate	O
at	O
the	O
thymidine	B-DNA
kinase	I-DNA
locus	I-DNA
in	O
human	B-cell_type
cells	I-cell_type
.	O

transcription	O
increases	O
dna	O
repair	O
efficiency	O
and	O
modulates	O
the	O
distribution	O
of	O
certain	O
types	O
of	O
dna	O
damage	O
.	O

furthermore	O
,	O
increased	O
transcription	O
level	O
stimulates	O
spontaneous	O
mutation	O
rate	O
in	O
yeast	O
.	O

we	O
explored	O
whether	O
transcription	O
level	O
affects	O
spontaneous	O
mutation	O
rate	O
in	O
human	B-cell_type
cells	I-cell_type
.	O

we	O
first	O
developed	O
two	O
thymidine	B-protein
kinase	I-protein
(	O
tk	B-protein
)	O
inducible	O
human	B-cell_line
cell	I-cell_line
lines	I-cell_line
using	O
the	O
gal0-estrogen	B-protein
receptor	I-protein
system	O
.	O

in	O
our	O
tk0i-g0	O
and	O
g0	O
tk	O
heterozygous	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
the	O
active	B-DNA
tk	I-DNA
allele	I-DNA
is	O
linked	O
to	O
an	O
inducible	B-DNA
promoter	I-DNA
element	I-DNA
.	O

tk	O
mrna	O
is	O
induced	O
following	O
treatment	O
with	O
estrogen	O
.	O

spontaneous	O
mutation	O
rate	O
was	O
significantly	O
decreased	O
in	O
human	B-cell_line
cell	I-cell_line
lines	I-cell_line
after	O
induction	O
in	O
contrast	O
to	O
the	O
report	O
in	O
yeast	O
.	O

thus	O
,	O
humans	O
may	O
have	O
evolved	O
different	O
or	O
additional	O
mechanisms	O
to	O
deal	O
with	O
transcription	O
related	O
spontaneous	O
mutagenesis	O
.	O

copyright	O
0000	O
elsevier	O
science	O
b.v	O
.	O

all	O
rights	O
reserved	O
.	O

###MEDLINE:98288355

mutation	O
of	O
bcl-0	B-protein
gene	O
in	O
normal	B-cell_type
b	I-cell_type
cells	I-cell_type
by	O
the	O
process	O
of	O
somatic	O
hypermutation	O
of	O
ig	B-DNA
genes	I-DNA
.	O

immunoglobulin	B-DNA
(	I-DNA
ig	I-DNA
)	I-DNA
genes	I-DNA
are	O
hypermutated	O
in	O
b	B-cell_type
lymphocytes	I-cell_type
that	O
are	O
the	O
precursors	O
to	O
memory	B-cell_type
b	I-cell_type
cells	I-cell_type
.	O

the	O
mutations	O
are	O
linked	O
to	O
transcription	O
initiation	O
,	O
but	O
non-ig	B-DNA
promoters	I-DNA
are	O
permissible	O
for	O
the	O
mutation	O
process	O
;	O
thus	O
,	O
other	O
genes	O
expressed	O
in	O
mutating	O
b	B-cell_type
cells	I-cell_type
may	O
also	O
be	O
subject	O
to	O
somatic	O
hypermutation	O
.	O

significant	O
mutations	O
were	O
not	O
observed	O
in	O
c-myc	B-DNA
,	O
s00	O
,	O
or	O
alpha-fetoprotein	B-DNA
(	I-DNA
afp	I-DNA
)	I-DNA
genes	I-DNA
,	O
but	O
bcl-0	B-protein
was	O
highly	O
mutated	O
in	O
a	O
large	O
proportion	O
of	O
memory	B-cell_type
b	I-cell_type
cells	I-cell_type
of	O
normal	O
individuals	O
.	O

the	O
mutation	O
pattern	O
was	O
similar	O
to	O
that	O
of	O
ig	B-DNA
genes	I-DNA
.	O

###MEDLINE:98281994

cd00-mediated	O
activation	O
in	O
cd00ra+	B-cell_type
and	I-cell_type
cd00ro+	I-cell_type
t	I-cell_type
cells	I-cell_type
:	O
enhanced	O
levels	O
of	O
reactive	O
oxygen	O
intermediates	O
and	O
c-rel	B-protein
nuclear	O
translocation	O
in	O
cd00ra+	B-cell_type
cells	I-cell_type
.	O

we	O
have	O
analyzed	O
the	O
effect	O
of	O
complete	O
t	O
cell	O
activation	O
(	O
anti-cd0	B-protein
plus	O
anti-cd00	B-protein
)	O
on	O
the	O
activation	O
of	O
nf-kappab	B-protein
in	O
cd00ra+	B-cell_type
(	I-cell_type
naive	I-cell_type
)	I-cell_type
and	I-cell_type
cd00ro+	I-cell_type
(	I-cell_type
memory/effector	I-cell_type
)	I-cell_type
t	I-cell_type
cells	I-cell_type
.	O

long	O
exposure	O
(	O
00	O
h	O
)	O
induced	O
stronger	O
nf-kappab	B-protein
dna	O
binding	O
in	O
cd00ra+	B-cell_type
cells	I-cell_type
than	O
in	O
cd00ro+	B-cell_type
cells	I-cell_type
.	O

analysis	O
of	O
the	O
nuclear	B-protein
c-rel	I-protein
protein	I-protein
indicated	O
that	O
after	O
anti-cd0+anti-cd00	O
stimulation	O
the	O
level	O
of	O
c-rel	B-protein
was	O
higher	O
in	O
cd00ra+	B-cell_type
cells	I-cell_type
.	O

analysis	O
of	O
the	O
cytoplasmic	B-protein
inhibitor	I-protein
ikappabalpha	B-protein
indicated	O
that	O
anti-cd0+anti-cd00	O
stimulation	O
induced	O
a	O
long-lasting	O
degradation	O
in	O
cd00ra+	B-cell_type
cells	I-cell_type
but	O
in	O
cd00ro+	B-cell_type
cells	I-cell_type
the	O
degradation	O
process	O
was	O
more	O
rapid	O
.	O

because	O
the	O
cd00	B-protein
costimulus	O
is	O
known	O
to	O
induce	O
the	O
production	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
rois	O
)	O
,	O
the	O
intracellular	O
roi	O
levels	O
in	O
cd00ra+	B-cell_type
and	I-cell_type
cd00ro+	I-cell_type
cells	I-cell_type
were	O
compared	O
by	O
flow	O
cytometry	O
.	O

rois	O
were	O
produced	O
in	O
both	O
cell	O
types	O
,	O
but	O
more	O
strongly	O
in	O
cd00ra+	B-cell_type
cells	I-cell_type
.	O

the	O
data	O
presented	O
in	O
this	O
study	O
further	O
emphasize	O
the	O
differences	O
between	O
cd00ra+	B-cell_type
and	I-cell_type
cd00ro+	I-cell_type
t	I-cell_type
lymphocytes	I-cell_type
in	O
roi-dependent	O
signaling	O
pathways	O
.	O

###MEDLINE:98278432

non-hodgkin	O
's	O
lymphoma	O
involving	O
bilateral	O
breasts	O
[	O
see	O
comments	O
]	O

we	O
describe	O
here	O
two	O
cases	O
of	O
diffuse	O
large	O
cell	O
type	O
non-hodgkin	O
's	O
lymphoma	O
affecting	O
the	O
bilateral	O
breasts	O
.	O

the	O
contralateral	O
tumor	O
in	O
one	O
case	O
appeared	O
00	O
months	O
after	O
the	O
first	O
mastectomy	O
,	O
whereas	O
the	O
bilateral	O
tumors	O
occurred	O
concurrently	O
in	O
the	O
other	O
patient	O
who	O
was	O
pregnant	O
and	O
showed	O
widespread	O
dissemination	O
at	O
initial	O
presentation	O
.	O

lymphoma	B-cell_type
cells	I-cell_type
from	O
both	O
cases	O
showed	O
the	O
mature	O
b-cell	O
immunophenotype	O
and	O
had	O
rearrangements	O
of	O
the	O
bcl0	B-DNA
gene	I-DNA
.	O

both	O
patients	O
developed	O
progressive	O
disease	O
despite	O
chemo-radiotherapy	O
and	O
died	O
of	O
leukemic	O
manifestations	O
.	O

there	O
were	O
no	O
apparent	O
pathological	O
features	O
of	O
lymphomas	O
of	O
mucosa-associated	B-cell_type
lymphoid	I-cell_type
tissue	I-cell_type
origin	I-cell_type

###MEDLINE:98369616

biochemical	O
characterization	O
of	O
mip-0	B-protein
alpha	I-protein
nuclear	I-protein
protein	I-protein
.	O

a	O
family	O
of	O
hematopoietic	B-protein
specific	I-protein
transcription	I-protein
factors	I-protein
,	O
mip-0	B-protein
alpha	I-protein
nuclear	I-protein
protein	I-protein
(	O
mnp	B-protein
)	I-protein
family	I-protein
,	O
has	O
recently	O
been	O
identified	O
.	O

they	O
are	O
intimately	O
involved	O
in	O
regulating	O
the	O
transcription	O
of	O
the	O
humip-0	B-DNA
alpha	I-DNA
gene	I-DNA
in	O
monocytes	B-cell_type
,	O
t-cells	B-cell_type
,	O
and	O
transformed	B-cell_line
b-cells	I-cell_line
.	O

one	O
member	O
of	O
the	O
family	O
(	O
mnp-0	B-protein
)	O
is	O
essential	O
for	O
promoter	O
activity	O
in	O
monocytes	B-cell_type
and	O
b-cells	B-cell_type
,	O
while	O
another	O
(	O
mnp-0	B-protein
)	O
is	O
required	O
for	O
full	O
promotor	O
activity	O
in	O
t-cells	B-cell_type
.	O

a	O
third	O
member	O
of	O
the	O
family	O
(	O
mnp-0	B-protein
)	O
is	O
expressed	O
in	O
pma	O
induced	O
hl00	B-cell_line
cells	I-cell_line
and	O
probably	O
has	O
a	O
role	O
in	O
monocyte	O
differentiation	O
.	O

in	O
this	O
communication	O
we	O
demonstrate	O
by	O
two	O
techniques	O
that	O
mnp-0	B-protein
and	O
mnp-0	B-protein
are	O
distinct	O
but	O
related	O
factors	O
,	O
and	O
we	O
present	O
further	O
evidence	O
to	O
show	O
that	O
mnp-0	B-protein
acts	O
as	O
a	O
heterodimer	O
.	O

###MEDLINE:98361768

bcl-0	B-protein
expression	O
and	O
nuclear	O
translocation	O
are	O
induced	O
by	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
and	O
erythropoietin	B-protein
in	O
proliferating	B-cell_type
human	I-cell_type
erythroid	I-cell_type
precursors	I-cell_type
.	O

bcl-0	B-protein
is	O
a	O
proto-oncogene	B-DNA
involved	O
in	O
the	O
chromosomal	O
translocation	O
t	O
(	O
00	O
;	O
00	O
)	O
found	O
in	O
some	O
patients	O
with	O
chronic	O
lymphocytic	O
leukemia	O
.	O

it	O
shares	O
structural	O
similarities	O
with	O
and	O
is	O
a	O
member	O
of	O
the	O
ikappab	B-protein
family	I-protein
of	I-protein
proteins	I-protein
.	O

in	O
this	O
report	O
,	O
involvement	O
of	O
bcl-0	B-protein
in	O
hematopoietic	B-protein
growth	I-protein
factor-stimulated	I-protein
erythroid	O
proliferation	O
and	O
differentiation	O
was	O
examined	O
.	O

in	O
tf-0	B-cell_type
cells	I-cell_type
,	O
an	O
erythroleukemia	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
gm-csf	B-protein
)	O
and	O
erythropoietin	B-protein
(	O
epo	B-protein
)	O
greatly	O
enhanced	O
bcl-0	B-protein
expression	O
at	O
both	O
the	O
protein	O
and	O
mrna	B-RNA
levels	O
in	O
association	O
with	O
stimulation	O
of	O
proliferation	O
.	O

bcl-0	B-protein
protein	I-protein
was	O
also	O
highly	O
expressed	O
in	O
early	B-cell_type
burst-forming	I-cell_type
unit-erythroid	I-cell_type
(	O
bfu-e	B-cell_line
)	O
-derived	O
erythroid	B-cell_type
precursors	I-cell_type
(	O
day	O
0	O
)	O
and	O
decreased	O
during	O
maturation	O
(	O
days	O
00	O
and	O
00	O
)	O
,	O
suggesting	O
that	O
bcl-0	B-protein
is	O
involved	O
in	O
normal	O
erythroid	O
proliferation	O
.	O

in	O
these	O
hematopoietic	B-cell_type
cells	I-cell_type
,	O
bcl-0	B-protein
was	O
hyperphosphorylated	O
.	O

gm-csf	B-protein
and	O
epo	B-protein
modulated	O
the	O
subcellular	O
localization	O
of	O
bcl-0	B-protein
.	O

upon	O
stimulation	O
of	O
tf-0	B-cell_type
cells	I-cell_type
with	O
gm-csf	B-protein
or	O
epo	B-protein
,	O
the	O
nuclear	O
translocation	O
of	O
bcl-0	B-protein
was	O
dramatically	O
enhanced	O
.	O

overexpression	O
of	O
bcl-0	B-protein
in	O
tf-0	B-cell_type
cells	I-cell_type
by	O
transient	O
transfection	O
along	O
with	O
the	O
nf-kappab	B-protein
factors	I-protein
p00	B-protein
or	O
p00	B-protein
resulted	O
in	O
significant	O
induction	O
of	O
an	O
human	B-DNA
immunodeficiency	I-DNA
virus-type	I-DNA
0	I-DNA
(	I-DNA
hiv-0	I-DNA
)	I-DNA
kappab-tata-luceriferase	I-DNA
reporter	I-DNA
plasmid	I-DNA
,	O
demonstrating	O
that	O
bcl-0	B-protein
has	O
a	O
positive	O
role	O
in	O
transactivation	O
of	O
kappab-containing	B-DNA
genes	I-DNA
in	O
erythroid	B-cell_type
cells	I-cell_type
.	O

stimulation	O
with	O
gm-csf	B-protein
enhanced	O
c-myb	B-RNA
mrna	I-RNA
expression	O
in	O
these	O
cells	O
.	O

bcl-0	B-protein
in	O
nuclear	O
extracts	O
of	O
tf-0	B-cell_type
cells	I-cell_type
bound	O
to	O
a	O
kappab	B-DNA
enhancer	I-DNA
in	O
the	O
c-myb	B-DNA
promoter	I-DNA
together	O
with	O
nf-kappab0/p00	B-protein
and	O
this	O
binding	O
activity	O
was	O
enhanced	O
by	O
gm-csf	B-protein
stimulation	O
.	O

furthermore	O
,	O
cotransfection	O
of	O
bcl-0	B-protein
with	O
p00	B-protein
or	O
p00	B-protein
in	O
tf-0	B-cell_type
cells	I-cell_type
resulted	O
in	O
significant	O
activation	O
of	O
a	O
c-myb	B-DNA
kappab-tata-luceriferase	I-DNA
reporter	I-DNA
plasmid	I-DNA
.	O

these	O
findings	O
suggest	O
that	O
bcl-0	B-protein
may	O
participate	O
in	O
the	O
transcriptional	O
regulation	O
of	O
certain	O
kappab-containing	B-DNA
genes	I-DNA
involved	O
in	O
hematopoiesis	O
,	O
including	O
c-myb	B-DNA
.	O

copyright	O
0000	O
by	O
the	O
american	O
society	O
of	O
hematology	O
.	O

###MEDLINE:98348399

0-lipoxygenase	B-protein
compartmentalization	O
in	O
granulocytic	B-cell_type
cells	I-cell_type
is	O
modulated	O
by	O
an	O
internal	O
bipartite	O
nuclear	O
localizing	O
sequence	O
and	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
b	I-protein
complex	I-protein
formation	O
.	O

a	O
region	O
of	O
basic	B-protein
amino	I-protein
acids	I-protein
spanning	O
residues	B-protein
000-000	I-protein
in	O
the	O
human	O
0-lipoxygenase	B-protein
sequence	O
resembles	O
a	O
consensus	O
bipartite	O
nuclear	O
localizing	O
sequence	O
.	O

a	O
synthetic	O
peptide	O
consisting	O
of	O
the	O
kaposi	O
fibroblast	B-protein
growth	I-protein
factor	I-protein
signal	I-protein
sequence	I-protein
fused	O
to	O
the	O
0-lipoxygenase000-000	O
bipartite	O
nuclear	O
localizing	O
sequence	O
has	O
a	O
prominent	O
inhibitory	O
effect	O
on	O
0-lipoxygenase	B-protein
catalysis	O
in	O
granulocytic	B-cell_line
hl-00	I-cell_line
cells	I-cell_line
activated	O
by	O
calcium	O
ionophor	O
a00000	O
.	O

recombinant	O
0-lipoxygenase	B-protein
was	O
not	O
affected	O
by	O
the	O
peptide	O
.	O

the	O
peptide	O
also	O
inhibited	O
redistribution	O
of	O
0-lipoxygenase	B-protein
from	O
the	O
cytosol	O
to	O
the	O
nuclear	O
membrane	O
of	O
hl-00	B-cell_line
cells	I-cell_line
stimulated	O
by	O
a00000	O
.	O

0-lipoxygenase	B-protein
protein	O
was	O
detected	O
in	O
nuclear	B-protein
factor	I-protein
kappab	I-protein
(	O
nf-kappab	B-protein
)	O
p00	B-protein
subunit	I-protein
immunoprecipitate	O
fractions	O
prepared	O
from	O
hl-00	O
cell	O
lysates	O
.	O

the	O
amount	O
of	O
0-lipoxygenase	B-protein
protein	O
coimmunoprecipitated	O
by	O
nf-kappab	B-protein
antiserum	O
was	O
increased	O
following	O
a00000	O
stimulation	O
.	O

in	O
cells	O
treated	O
with	O
agents	O
that	O
block	O
0-lipoxygenase	O
translocation	O
to	O
the	O
nucleus	O
,	O
0-lipoxygenase	B-protein
protein	O
appearing	O
in	O
the	O
nf-kappab	B-protein
immunoprecipitate	O
was	O
diminished	O
.	O

our	O
results	O
implicate	O
an	O
internal	O
bipartite	O
nuclear	O
localizing	O
sequence	O
as	O
a	O
regulatory	B-protein
domain	I-protein
that	O
modulates	O
0-lipoxygenase	B-protein
redistribution	O
and	O
catalysis	O
in	O
granulocytic	B-cell_type
cells	I-cell_type
.	O

additionally	O
,	O
our	O
results	O
suggest	O
that	O
molecular	O
determinants	O
which	O
govern	O
0-lipoxygenase	B-protein
and	O
nf-kappab	B-protein
redistribution	O
to	O
the	O
nucleus	O
may	O
be	O
coordinately	O
controlled	O
in	O
granulocytic	B-cell_type
cells	I-cell_type
.	O

copyright	O
0000	O
academic	O
press	O
.	O

###MEDLINE:98334014

inhibition	O
of	O
cd00/cd0-mediated	O
costimulation	O
of	O
naive	B-cell_type
and	I-cell_type
memory	I-cell_type
human	I-cell_type
t	I-cell_type
lymphocytes	I-cell_type
by	O
intracellular	O
incorporation	O
of	O
polyclonal	B-protein
antibodies	I-protein
specific	O
for	O
the	O
activator	B-protein
protein-0	I-protein
transcriptional	B-protein
complex	I-protein
.	O

a	O
number	O
of	O
indirect	O
methods	O
have	O
been	O
utilized	O
in	O
demonstrating	O
activator	B-protein
protein-0	I-protein
transcription	B-protein
factor	I-protein
function	O
in	O
il-0	B-DNA
promoter	I-DNA
activity	O
.	O

however	O
,	O
there	O
has	O
been	O
no	O
direct	O
demonstration	O
that	O
activator	B-protein
protein-0	I-protein
is	O
involved	O
in	O
cd00-dependent	O
costimulation	O
of	O
il-0	B-DNA
gene	I-DNA
transcription	O
in	O
freshly	B-cell_type
isolated	I-cell_type
naive	I-cell_type
and	I-cell_type
memory	I-cell_type
human	I-cell_type
t	I-cell_type
lymphocytes	I-cell_type
.	O

to	O
address	O
this	O
issue	O
,	O
the	O
method	O
of	O
scrape	O
loading	O
was	O
applied	O
to	O
purified	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
t	I-cell_type
lymphocytes	I-cell_type
.	O

since	O
scrape	O
loading	O
relies	O
on	O
adherent	B-cell_type
cells	I-cell_type
,	O
peripheral	B-cell_type
blood	I-cell_type
human	I-cell_type
t	I-cell_type
(	I-cell_type
pb-t	I-cell_type
)	I-cell_type
cells	I-cell_type
were	O
immobilized	O
on	O
the	O
nonspecific	O
cell	B-protein
attachment	I-protein
factor	I-protein
poly-l-lysine	I-protein
.	O

cells	O
scraped	O
off	O
poly-l-lysine	O
in	O
the	O
presence	O
of	O
ig	B-protein
fitc	I-protein
efficiently	O
incorporated	O
ig	B-protein
,	O
with	O
relatively	O
uniform	O
fluorescence	O
.	O

t	B-cell_type
cells	I-cell_type
retained	O
their	O
physical	O
parameters	O
as	O
measured	O
by	O
forward	O
and	O
side	O
light	O
scatter	O
,	O
and	O
functional	O
activity	O
as	O
measured	O
by	O
costimulation	O
of	O
proliferation	O
and	O
il-0	B-protein
production	O
after	O
being	O
scraped	O
off	O
this	O
substrate	O
.	O

cd00/cd0-costimulated	B-cell_line
t	I-cell_line
cells	I-cell_line
produced	O
intracellular	O
il-0	B-protein
from	O
all	O
subsets	O
measured	O
(	O
cd0+	B-cell_type
,	I-cell_type
cd0-	I-cell_type
,	I-cell_type
cd00ro+	I-cell_type
,	I-cell_type
and	O
cd00ro-	B-protein
)	O
.	O

il-0	B-protein
production	O
and	O
intracellular	O
accumulation	O
in	O
nonscraped	B-cell_line
pb-t	I-cell_line
cells	I-cell_line
activated	O
with	O
cd00/cd0	O
coligation	O
were	O
skewed	O
favoring	O
cd00ro+	B-cell_type
and	I-cell_type
cd0+	I-cell_type
subsets	I-cell_type
,	O
as	O
was	O
il-0	B-protein
production	O
in	O
scraped	B-cell_line
pb-t	I-cell_line
cells	I-cell_line
.	O

the	O
intracellular	O
incorporation	O
of	O
abs	B-protein
specific	O
for	O
c-fos	B-protein
and	O
c-jun	B-protein
family	I-protein
members	I-protein
by	O
scrape	O
loading	O
inhibited	O
the	O
production	O
and	O
intracellular	O
accumulation	O
of	O
il-0	B-protein
within	O
0	O
h	O
of	O
costimulation	O
with	O
pma/ionomycin	O
,	O
or	O
costimulation	O
by	O
cd00	B-protein
and	O
cd0	B-protein
ligation	O
.	O

scrape	O
loading	O
thus	O
provides	O
an	O
efficient	O
mechanism	O
for	O
intracellular	O
incorporation	O
of	O
macromolecules	O
,	O
and	O
the	O
first	O
direct	O
evidence	O
that	O
c-fos	B-protein
and	O
c-jun	B-protein
are	O
involved	O
in	O
transcription	O
of	O
the	O
il-0	B-DNA
gene	I-DNA
within	O
its	O
correct	O
chromosomal	O
context	O
,	O
in	O
resting	B-cell_type
human	I-cell_type
t	I-cell_type
lymphocyte	I-cell_type
subpopulations	I-cell_type
.	O

###MEDLINE:98325215

differential	O
expression	O
of	O
nur00	B-protein
family	I-protein
members	I-protein
in	O
human	O
t-lymphotropic	O
virus	O
type	B-cell_type
0-infected	I-cell_type
cells	I-cell_type
:	O
transactivation	O
of	O
the	O
tr0/nur00	B-DNA
gene	I-DNA
by	O
tax	B-protein
protein	I-protein
.	O

we	O
analyzed	O
the	O
differential	O
expression	O
and	O
regulation	O
of	O
three	O
members	O
of	O
the	O
nur00	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
by	O
the	O
human	B-DNA
t-lymphotropic	I-DNA
virus	I-DNA
type	I-DNA
0	I-DNA
(	O
htlv-0	B-protein
)	I-protein
tax	I-protein
protein	I-protein
.	O

we	O
have	O
demonstrated	O
that	O
in	O
both	O
htlv-0-infected	B-cell_line
cells	I-cell_line
and	O
tax-expressing	B-cell_line
jpx-0	I-cell_line
cells	I-cell_line
,	O
tr0/nur00	B-protein
is	O
highly	O
expressed	O
,	O
whereas	O
neither	O
nor-0	B-protein
nor	O
not	O
expression	O
is	O
detectable	O
.	O

transient	O
transfection	O
analysis	O
further	O
confirmed	O
the	O
tax	B-protein
transactivation	O
of	O
the	O
tr0/nur00	B-DNA
promoter	I-DNA
but	O
not	O
the	O
nor-0	B-DNA
promoter	I-DNA
in	O
different	O
cell	O
types	O
.	O

furthermore	O
,	O
expression	O
of	O
a	O
luciferase	B-DNA
reporter	I-DNA
gene	I-DNA
driven	O
by	O
the	O
ngfi-b	B-DNA
(	O
rat	O
homolog	O
of	O
tr0/nur00	B-DNA
)	I-DNA
response	I-DNA
element	I-DNA
(	O
nbre	B-protein
)	O
provided	O
evidence	O
that	O
tax	B-protein
-mediated	O
transactivation	O
resulted	O
in	O
the	O
induction	O
of	O
a	O
functional	O
protein	O
.	O

cotransfection	O
assays	O
with	O
the	O
tr0/nur00	B-DNA
promoter	I-DNA
sequence	I-DNA
or	O
the	O
nbre	B-DNA
binding	I-DNA
motif	I-DNA
together	O
with	O
a	O
series	O
of	O
tax	B-protein
mutants	O
have	O
shown	O
that	O
tax	B-protein
-induced	O
tr0/nur00	O
expression	O
is	O
mediated	O
by	O
creb/atf-related	B-protein
transcription	I-protein
factors	I-protein
.	O

###MEDLINE:98315075

negative	O
regulation	O
of	O
the	O
heat	O
shock	O
transcriptional	O
response	O
by	O
hsbp0	O
.	O

in	O
response	O
to	O
stress	O
,	O
heat	B-protein
shock	I-protein
factor	I-protein
0	I-protein
(	O
hsf0	B-protein
)	O
acquires	O
rapid	O
dna	O
binding	O
and	O
transient	O
transcriptional	O
activity	O
while	O
undergoing	O
conformational	O
transition	O
from	O
an	O
inert	B-protein
non-dna-binding	I-protein
monomer	I-protein
to	O
active	O
functional	O
trimers	O
.	O

attenuation	O
of	O
the	O
inducible	O
transcriptional	O
response	O
occurs	O
during	O
heat	O
shock	O
or	O
upon	O
recovery	O
at	O
non-stress	O
conditions	O
and	O
involves	O
dissociation	O
of	O
the	O
hsf0	B-protein
trimer	O
and	O
loss	O
of	O
activity	O
.	O

we	O
have	O
used	O
the	O
hydrophobic	O
repeats	O
of	O
the	O
hsf0	B-protein
trimerization	B-protein
domain	I-protein
in	O
the	O
yeast	O
two-hybrid	O
protein	O
interaction	O
assay	O
to	O
identify	O
heat	B-protein
shock	I-protein
factor	I-protein
binding	I-protein
protein	I-protein
0	I-protein
(	O
hsbp0	B-protein
)	O
,	O
a	O
novel	O
,	O
conserved	O
,	O
00-amino-acid	B-protein
protein	I-protein
that	O
contains	O
two	O
extended	O
arrays	O
of	O
hydrophobic	B-protein
repeats	I-protein
that	O
interact	O
with	O
the	O
hsf0	B-protein
heptad	B-DNA
repeats	I-DNA
.	O

hsbp0	B-protein
is	O
nuclear-localized	O
and	O
interacts	O
in	O
vivo	O
with	O
the	O
active	O
trimeric	O
state	O
of	O
hsf0	B-protein
that	O
appears	O
during	O
heat	O
shock	O
.	O

during	O
attenuation	O
of	O
hsf0	B-protein
to	O
the	O
inert	B-protein
monomer	I-protein
,	O
hsbp0	B-protein
associates	O
with	O
hsp00	B-protein
.	O

hsbp0	O
negatively	O
affects	O
hsf0	B-protein
dna-binding	O
activity	O
,	O
and	O
overexpression	O
of	O
hsbp0	O
in	O
mammalian	B-cell_type
cells	I-cell_type
represses	O
the	O
transactivation	O
activity	O
of	O
hsf0	B-protein
.	O

to	O
establish	O
a	O
biological	O
role	O
for	O
hsbp0	B-protein
,	O
the	O
homologous	O
caenorhabditis	B-protein
elegans	I-protein
protein	I-protein
was	O
overexpressed	O
in	B-cell_type
body	I-cell_type
wall	I-cell_type
muscle	I-cell_type
cells	I-cell_type
and	O
was	O
shown	O
to	O
block	O
activation	O
of	O
the	O
heat	O
shock	O
response	O
from	O
a	O
heat	B-DNA
shock	I-DNA
promoter-reporter	I-DNA
construct	I-DNA
.	O

alteration	O
in	O
the	O
level	O
of	O
hsbp0	O
expression	O
in	O
c.	O
elegans	O
has	O
severe	O
effects	O
on	O
survival	O
of	O
the	O
animals	O
after	O
thermal	O
and	O
chemical	O
stress	O
,	O
consistent	O
with	O
a	O
role	O
for	O
hsbp0	O
as	O
a	O
negative	O
regulator	O
of	O
the	O
heat	O
shock	O
response	O
.	O

###MEDLINE:98302228

long-range	O
transcriptional	O
regulation	O
of	O
cytokine	B-DNA
gene	I-DNA
expression	O
.	O

most	O
studies	O
on	O
the	O
control	O
of	O
cytokine	B-DNA
gene	I-DNA
expression	O
have	O
involved	O
the	O
functional	O
analysis	O
of	O
proximal	B-DNA
promoters	I-DNA
.	O

recent	O
work	O
has	O
identified	O
distal	B-DNA
elements	I-DNA
that	O
mediate	O
long-range	O
cytokine	B-DNA
gene	I-DNA
regulation	O
and	O
has	O
implicated	O
chromatin	B-DNA
reorganization	O
in	O
regulation	O
of	O
cytokine	B-DNA
gene	I-DNA
loci	I-DNA
.	O

these	O
studies	O
have	O
begun	O
to	O
elucidate	O
the	O
basis	O
for	O
cell-specificity	B-protein
and	O
high-level	O
expression	O
of	O
cytokine	B-DNA
genes	I-DNA
.	O

###MEDLINE:98259083

a	O
signaling	B-protein
complex	I-protein
of	O
ca0+-calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
iv	I-protein
and	O
protein	B-protein
phosphatase	I-protein
0a	I-protein
[	O
see	O
comments	O
]	O

stimulation	O
of	O
t	B-cell_type
lymphocytes	I-cell_type
results	O
in	O
a	O
rapid	O
increase	O
in	O
intracellular	O
calcium	O
concentration	O
(	O
[	O
ca0+	O
]	O
i	B-protein
)	I-protein
that	O
parallels	O
the	O
activation	O
of	O
ca0+-calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
iv	I-protein
(	O
camkiv	B-protein
)	O
,	O
a	O
nuclear	B-protein
enzyme	I-protein
that	O
can	O
phosphorylate	O
and	O
activate	O
the	O
cyclic	B-protein
adenosine	I-protein
monophosphate	I-protein
(	O
camp	B-protein
)	I-protein
response	I-protein
element-binding	I-protein
protein	I-protein
(	O
creb	B-protein
)	O
.	O

however	O
,	O
inactivation	O
of	O
camkiv	B-protein
occurs	O
despite	O
the	O
sustained	O
increase	O
in	O
[	O
ca0+	O
]	O
i	O
that	O
is	O
required	O
for	O
t	B-cell_type
cell	I-cell_type
activation	O
.	O

a	O
stable	O
and	O
stoichiometric	O
complex	O
of	O
camkiv	B-protein
with	O
protein	B-protein
serine-threonine	I-protein
phosphatase	I-protein
0a	I-protein
(	O
pp0a	B-protein
)	O
was	O
identified	O
in	O
which	O
pp0a	B-protein
dephosphorylates	O
camkiv	B-protein
and	O
functions	O
as	O
a	O
negative	O
regulator	O
of	O
camkiv	B-protein
signaling	O
.	O

in	O
jurkat	B-cell_line
t	I-cell_line
cells	I-cell_line
,	O
inhibition	O
of	O
pp0a	B-protein
activity	O
by	O
small	B-protein
t	I-protein
antigen	I-protein
enhanced	O
activation	O
of	O
creb	B-protein
-mediated	O
transcription	O
by	O
camkiv	B-protein
.	O

these	O
findings	O
reveal	O
an	O
intracellular	O
signaling	O
mechanism	O
whereby	O
a	O
protein	B-protein
serine-threonine	I-protein
kinase	I-protein
(	O
camkiv	B-protein
)	O
is	O
regulated	O
by	O
a	O
tightly	O
associated	O
protein	B-protein
serine-threonine	I-protein
phosphatase	I-protein
(	O
pp0a	B-protein
)	O
.	O

###MEDLINE:98281992

hypoxia	O
down-regulates	O
mcp-0	B-protein
expression	O
:	O
implications	O
for	O
macrophage	O
distribution	O
in	O
tumors	O
.	O

monocyte	B-protein
chemoattractant	I-protein
protein	I-protein
0	I-protein
(	O
mcp-0	B-protein
)	O
is	O
likely	O
to	O
contribute	O
to	O
the	O
macrophage	O
infiltrate	O
in	O
human	O
ovarian	O
carcinomas	O
.	O

although	O
mcp-0	B-protein
is	O
predominantly	O
expressed	O
by	O
the	O
tumor	O
parenchyma	O
,	O
macrophages	B-cell_type
accumulate	O
at	O
highest	O
density	O
in	O
necrotic	O
regions	O
,	O
which	O
are	O
associated	O
with	O
low	O
oxygen	O
tensions	O
.	O

tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
tnf-alpha	B-protein
)	O
can	O
stimulate	O
mcp-0	B-protein
production	O
and	O
is	O
also	O
present	O
within	O
ovarian	O
carcinomas	O
.	O

we	O
have	O
investigated	O
the	O
effect	O
of	O
hypoxia	O
both	O
on	O
mcp-0	B-protein
expression	O
in	O
ovarian	B-cell_type
cancer	I-cell_type
cell	I-cell_type
lines	I-cell_type
and	O
monocyte	O
migration	O
.	O

hypoxia	O
down-regulated	O
tnf-alpha-induced	O
mcp-0	B-RNA
mrna	I-RNA
and	O
protein	O
production	O
by	O
ovarian	B-cell_type
cancer	I-cell_type
cells	I-cell_type
.	O

the	O
effect	O
was	O
mimicked	O
by	O
cobalt	O
chloride	O
and	O
desferrioxamine	O
,	O
consistent	O
with	O
a	O
specific	O
oxygen-sensing	O
mechanism	O
.	O

unlike	O
antioxidants	O
,	O
hypoxia	O
did	O
not	O
inhibit	O
nuclear	B-protein
factor	I-protein
kb	O
mobilization	O
.	O

monocyte	O
migration	O
in	O
response	O
to	O
mcp-0	B-protein
was	O
also	O
diminished	O
under	O
hypoxic	O
conditions	O
.	O

down-regulation	O
of	O
mcp-0	B-protein
expression	O
and	O
the	O
inhibition	O
of	O
monocyte	O
migration	O
are	O
independent	O
effects	O
of	O
hypoxia	O
that	O
may	O
contribute	O
to	O
the	O
distribution	O
of	O
macrophages	B-cell_type
within	O
ovarian	O
tumors	O
.	O

###MEDLINE:98279279

activation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
b	I-protein
inflammatory	O
bowel	O
disease	O
[	O
see	O
comments	O
]	O

background	O
:	O
expression	O
of	O
pro-inflammatory	B-protein
cytokines	I-protein
is	O
increased	O
in	O
the	O
intestinal	O
lamina	O
propria	O
of	O
patients	O
with	O
inflammatory	O
bowel	O
disease	O
(	O
ibd	O
)	O
.	O

nuclear	B-protein
factor	I-protein
kappa	I-protein
b	I-protein
(	O
nf	B-protein
kappa	I-protein
b	I-protein
)	O
controls	O
transcription	O
of	O
inflammation	O
genes	O
.	O

on	O
activation	O
,	O
nf	B-protein
kappa	I-protein
b	I-protein
is	O
rapidly	O
released	O
from	O
its	O
cytoplasmic	B-protein
inhibitor	I-protein
(	O
i	B-protein
kappa	I-protein
b	I-protein
)	O
,	O
transmigrates	O
into	O
the	O
nucleus	O
,	O
and	O
binds	O
to	O
dna	B-DNA
response	I-DNA
elements	I-DNA
in	O
gene	B-DNA
promoter	I-DNA
regions	I-DNA
.	O

aims	O
:	O
to	O
investigate	O
whether	O
increased	O
activation	O
of	O
nf	B-protein
kappa	I-protein
b	I-protein
is	O
important	O
in	O
ibd	O
and	O
may	O
be	O
down-regulated	O
by	O
anti-inflammatory	O
treatment	O
.	O

methods	O
:	O
activation	O
of	O
nf	B-protein
kappa	I-protein
b	I-protein
was	O
determined	O
by	O
western	O
blot	O
assessment	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
in	O
nuclear	O
extracts	O
of	O
colonic	O
biopsy	O
samples	O
as	O
well	O
as	O
lamina	B-cell_type
propria	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

results	O
:	O
nuclear	O
levels	O
of	O
nf	B-protein
kappa	I-protein
b	I-protein
p00	I-protein
are	O
increased	O
in	O
lamina	O
propria	O
biopsy	O
specimens	O
from	O
patients	O
with	O
crohn	O
's	O
disease	O
in	O
comparison	O
with	O
patients	O
with	O
ulcerative	O
colitis	O
and	O
controls	O
.	O

increased	O
activation	O
of	O
nf	B-protein
kappa	I-protein
b	I-protein
was	O
detected	O
in	O
lamina	B-cell_type
propria	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
from	O
patients	O
with	O
active	O
ibd	O
.	O

corticosteroids	O
strongly	O
inhibit	O
intestinal	O
nf	B-protein
kappa	I-protein
b	I-protein
activation	O
in	O
ibd	O
in	O
vivo	O
and	O
in	O
vitro	O
by	O
stabilising	O
the	O
cytosolic	B-protein
inhibitor	I-protein
i	I-protein
kappa	I-protein
b	I-protein
alpha	I-protein
against	O
activation	O
induced	O
degradation	O
.	O

conclusions	O
:	O
in	O
both	O
ibds	O
,	O
but	O
particularly	O
crohn	O
's	O
disease	O
,	O
increased	O
activation	O
of	O
nf	B-protein
kappa	I-protein
b	I-protein
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
inflammatory	O
response	O
.	O

inhibition	O
of	O
nf	B-protein
kappa	I-protein
b	I-protein
activation	O
may	O
represent	O
a	O
mechanism	O
by	O
which	O
steroids	O
exert	O
an	O
anti-inflammatory	O
effect	O
in	O
ibd	O

###MEDLINE:98367816

insufficient	O
glycemic	O
control	O
increases	O
nuclear	B-protein
factor-kappa	I-protein
b	I-protein
binding	O
activity	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
isolated	O
from	O
patients	O
with	O
type	O
0	O
diabetes	O
.	O

objective	O
:	O
the	O
redox-sensitive	B-protein
transcription	I-protein
factor	I-protein
nuclear	I-protein
factor-kappa	I-protein
b	I-protein
(	O
nf-kappa	B-protein
b	I-protein
)	O
is	O
believed	O
to	O
contribute	O
to	O
late	O
diabetic	O
complications	O
.	O

it	O
is	O
unknown	O
whether	O
nf-kappa	B-protein
b	I-protein
is	O
influenced	O
by	O
glycemic	O
control	O
.	O

research	O
design	O
and	O
methods	O
:	O
to	O
determine	O
whether	O
nf-kappa	B-protein
b	I-protein
is	O
activated	O
in	O
patients	O
with	O
insufficient	O
glycemic	O
control	O
(	O
hba0c	O
>	O
00	O
%	O
)	O
,	O
we	O
developed	O
a	O
tissue	O
culture-independent	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
emsa	O
)	O
-based	O
semiquantitative	O
detection	O
system	O
that	O
allowed	O
us	O
to	O
determine	O
nf-kappa	B-protein
b	I-protein
activation	O
in	O
ex	O
vivo-isolated	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
pbmcs	B-cell_type
)	O
.	O

we	O
included	O
00	O
patients	O
with	O
type	O
0	O
diabetes	O
in	O
this	O
cross-sectional	O
study	O
.	O

00	O
of	O
those	O
received	O
the	O
antioxidant	O
thioctic	O
acid	O
(	O
000	O
mg/day	O
p.o.	O
)	O
for	O
0	O
weeks	O
.	O

results	O
:	O
monocytes	B-cell_type
of	O
patients	O
with	O
hba0c	O
levels	O
>	O
00	O
%	O
demonstrated	O
significantly	O
higher	O
nf-kappa	B-protein
b	I-protein
binding	O
activity	O
in	O
an	O
emsa	O
and	O
a	O
stronger	O
nf-kappa	B-protein
b	I-protein
staining	O
in	O
immunohistochemistry	O
than	O
monocytes	B-cell_type
of	O
patients	O
with	O
hba0c	O
levels	O
of	O
0-0	O
%	O
.	O

the	O
increase	O
in	O
nf-kappa	B-protein
b	I-protein
activation	O
correlated	O
with	O
an	O
increase	O
in	O
plasmatic	B-protein
markers	I-protein
of	O
lipid	O
peroxidation	O
.	O

treatment	O
with	O
the	O
antioxidant	O
thioctic	O
acid	O
decreased	O
nf-kappa	B-protein
b	I-protein
binding	O
activity	O
.	O

conclusions	O
:	O
hyperglycemia	O
induces	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nf-kappa	I-protein
b	I-protein
in	O
ex	O
vivo-isolated	O
pbmcs	B-cell_type
of	O
patients	O
with	O
type	O
0	O
diabetes	O
.	O

nf-kappa	B-protein
b	I-protein
activation	O
is	O
at	O
least	O
partially	O
dependent	O
on	O
oxidative	O
stress	O
,	O
since	O
the	O
antioxidant	O
thioctic	O
acid	O
significantly	O
lowered	O
the	O
extent	O
of	O
nf-kappa	B-protein
b	I-protein
binding	O
activity	O
.	O

###MEDLINE:98361758

synergistic	O
activation	O
of	O
map	B-protein
kinase	I-protein
(	O
erk0/0	B-protein
)	O
by	O
erythropoietin	B-protein
and	O
stem	B-protein
cell	I-protein
factor	I-protein
is	O
essential	O
for	O
expanded	O
erythropoiesis	O
.	O

stem	B-protein
cell	I-protein
factor	I-protein
(	O
scf	B-protein
)	O
and	O
erythropoietin	B-protein
(	O
epo	B-protein
)	O
work	O
synergistically	O
to	O
support	O
erythropoiesis	O
,	O
but	O
the	O
mechanism	O
for	O
this	O
synergism	O
is	O
unknown	O
.	O

by	O
using	O
purified	B-cell_line
human	I-cell_line
erythroid	I-cell_line
colony-forming	I-cell_line
cells	I-cell_line
(	O
ecfc	B-protein
)	O
,	O
we	O
have	O
found	O
that	O
scf	B-protein
and	O
epo	B-protein
synergistically	O
activate	O
map	B-protein
kinase	I-protein
(	O
mapk	B-protein
,	O
erk0/0	B-protein
)	O
,	O
which	O
correlates	O
with	O
the	O
cell	O
growth	O
and	O
thus	O
may	O
be	O
responsible	O
for	O
the	O
synergistic	O
effects	O
.	O

treatment	O
of	O
the	O
cells	O
with	O
pd00000	O
and	O
wortmannin	O
,	O
inhibitors	O
of	O
mek	B-protein
and	O
pi-0	B-protein
kinase	I-protein
,	O
respectively	O
,	O
inhibited	O
the	O
synergistic	O
activation	O
of	O
mapk	B-protein
and	O
also	O
the	O
cell	O
growth	O
,	O
further	O
supporting	O
this	O
conclusion	O
.	O

wortmannin	O
only	O
inhibits	O
mapk	B-protein
activation	O
induced	O
by	O
epo	B-protein
but	O
not	O
that	O
by	O
scf	B-protein
,	O
suggesting	O
that	O
scf	B-protein
and	O
epo	B-protein
may	O
activate	O
mapk	B-protein
through	O
different	O
pathways	O
,	O
which	O
would	O
facilitate	O
synergy	O
.	O

furthermore	O
,	O
epo	B-protein
,	O
but	O
not	O
scf	B-protein
,	O
led	O
to	O
activation	O
of	O
stat0	B-protein
,	O
whereas	O
scf	B-protein
and	O
wortmannin	O
had	O
no	O
effect	O
on	O
the	O
epo	B-protein
-induced	O
stat0	B-protein
activation	O
,	O
suggesting	O
that	O
stat0	B-protein
is	O
not	O
involved	O
in	O
the	O
synergistic	O
action	O
of	O
scf	B-protein
and	O
epo	B-protein
.	O

together	O
,	O
the	O
data	O
suggest	O
that	O
synergistic	O
activation	O
of	O
mapk	B-protein
by	O
scf	B-protein
and	O
epo	B-protein
is	O
essential	O
for	O
expanded	O
erythropoiesis	O
.	O

copyright	O
0000	O
by	O
the	O
american	O
society	O
of	O
hematology	O
.	O

###MEDLINE:98345328

the	O
molecular	O
and	O
phenotypic	O
profile	O
of	O
primary	O
central	O
nervous	O
system	O
lymphoma	O
identifies	O
distinct	O
categories	O
of	O
the	O
disease	O
and	O
is	O
consistent	O
with	O
histogenetic	O
derivation	O
from	O
germinal	B-cell_type
center-related	I-cell_type
b	I-cell_type
cells	I-cell_type
.	O

primary	O
central	O
nervous	O
system	O
lymphoma	O
(	O
pcnsl	O
)	O
is	O
a	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
among	O
human	O
immunodeficiency	O
virus	O
(	O
hiv	O
)	O
-infected	O
individuals	O
.	O

the	O
precise	O
histogenetic	O
derivation	O
and	O
the	O
molecular	O
pathogenesis	O
of	O
pcnsl	O
is	O
poorly	O
understood	O
.	O

in	O
an	O
attempt	O
to	O
clarify	O
the	O
histogenesis	O
and	O
pathogenesis	O
of	O
these	O
lymphomas	O
,	O
00	O
pcnsl	O
(	O
00	O
acquired	O
immunodeficiency	O
syndrome	O
[	O
aids	O
]	O
-related	O
and	O
00	O
aids-unrelated	O
)	O
were	O
analyzed	O
for	O
multiple	O
biologic	O
markers	O
,	O
which	O
are	O
known	O
to	O
bear	O
histogenetic	O
and	O
pathogenetic	O
significance	O
for	O
mature	B-cell_type
b-cell	I-cell_type
neoplasms	I-cell_type
.	O

pcnsl	O
associated	O
frequently	O
(	O
00.0	O
%	O
)	O
with	O
mutations	O
of	O
bcl-0	B-DNA
0	I-DNA
'	I-DNA
noncoding	I-DNA
regions	I-DNA
,	O
which	O
are	O
regarded	O
as	O
a	O
marker	O
of	O
b-cell	O
transition	O
through	O
the	O
germinal	O
center	O
(	O
gc	O
)	O
.	O

expression	O
of	O
bcl-0	B-protein
protein	I-protein
,	O
which	O
is	O
restricted	O
to	O
gc	B-cell_type
b	I-cell_type
cells	I-cell_type
throughout	O
physiologic	O
b-cell	O
maturation	O
,	O
was	O
detected	O
in	O
000	O
%	O
aids-unrelated	O
pcnsl	O
and	O
in	O
00.0	O
%	O
aids-related	O
cases	O
.	O

notably	O
,	O
among	O
aids-related	O
pcnsl	O
,	O
expression	O
of	O
bcl-0	B-protein
was	O
mutually	O
exclusive	O
with	O
expression	O
of	O
epstein-barr	B-protein
virus	I-protein
(	I-protein
ebv	I-protein
)	I-protein
-encoded	I-protein
latent	I-protein
membrane	I-protein
protein	I-protein
(	O
lmp	B-protein
)	I-protein
-0	I-protein
and	O
,	O
with	O
few	O
exceptions	O
,	O
also	O
of	O
bcl-0	B-protein
.	O

all	O
but	O
one	O
pcnsl	O
expressed	O
hmsh0	B-DNA
,	O
which	O
among	O
mature	B-cell_type
b	I-cell_type
cells	I-cell_type
selectively	O
stains	O
gc	B-cell_type
b	I-cell_type
cells	I-cell_type
.	O

these	O
data	O
suggest	O
that	O
pcnsl	O
may	O
be	O
frequently	O
related	O
to	O
gc	B-cell_type
b	I-cell_type
cells	I-cell_type
and	O
may	O
be	O
segregated	O
into	O
two	O
major	O
biologic	O
categories	O
based	O
on	O
the	O
expression	O
pattern	O
of	O
bcl-0	B-protein
,	O
lmp-0	B-protein
,	O
and	O
bcl-0	B-protein
.	O

bcl-0	B-protein
(	O
+	O
)	O
/	O
lmp-0	B-protein
(	O
-	O
)	O
/	O
bcl-0	B-protein
(	O
-	O
)	O
pcnsl	O
occur	O
both	O
in	O
the	O
presence	O
and	O
in	O
the	O
absence	O
of	O
hiv	O
infection	O
and	O
consistently	O
display	O
a	O
large	O
noncleaved	O
cell	O
morphology	O
.	O

conversely	O
,	O
bcl-0	B-protein
(	O
-	O
)	O
/	O
lmp-0	B-protein
(	O
+	O
)	O
/	O
bcl-0	B-protein
(	O
+	O
)	O
pcnsl	O
are	O
restricted	O
to	O
hiv-infected	O
hosts	O
and	O
are	O
represented	O
by	O
lymphomas	O
with	O
immunoblastic	O
features	O
.	O

these	O
data	O
are	O
relevant	O
for	O
the	O
pathogenesis	O
and	O
histogenesis	O
of	O
pcnsl	O
and	O
may	O
be	O
helpful	O
to	O
segregate	O
distinct	O
biologic	O
and	O
prognostic	O
categories	O
of	O
these	O
lymphomas	O
.	O

copyright	O
0000	O
by	O
the	O
american	O
society	O
of	O
hematology	O
.	O

###MEDLINE:98330075

antioxidant	O
regulation	O
of	O
phorbol	O
ester-induced	O
adhesion	O
of	O
human	B-cell_line
jurkat	I-cell_line
t-cells	I-cell_line
to	O
endothelial	B-cell_type
cells	I-cell_type
.	O

regulation	O
of	O
adhesion	B-protein
molecule	I-protein
expression	O
and	O
function	O
by	O
reactive	O
oxygen	O
species	O
via	O
specific	O
redox	O
sensitive	O
mechanisms	O
have	O
been	O
reported	O
.	O

the	O
effects	O
of	O
clinically	O
safe	O
antioxidants	O
in	O
the	O
regulation	O
of	O
adhesion	B-protein
molecule	I-protein
expression	O
in	O
human	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
(	O
ecv	O
)	O
,	O
and	O
adherence	O
of	O
human	B-cell_line
jurkat	I-cell_line
t	I-cell_line
cells	I-cell_line
to	O
ecv	B-cell_type
cells	I-cell_type
were	O
investigated	O
.	O

the	O
thiol	O
antioxidant	O
,	O
alpha-lipoate	O
,	O
at	O
clinically	O
relevant	O
doses	O
down-regulated	O
phorbol	O
00-myristate	O
00-acetate	O
(	O
pma	O
)	O
-induced	O
adhesion	B-protein
molecule	I-protein
expression	O
and	O
cell-cell	O
adhesion	O
.	O

inhibition	O
of	O
pma-induced	O
icam-0	B-protein
and	O
vcam-0	B-protein
expression	O
as	O
well	O
as	O
pma-induced	O
adhesion	O
of	O
jurkat	B-cell_line
t-cells	I-cell_line
to	O
ecv	B-cell_type
cells	I-cell_type
by	O
alpha-lipoate	B-protein
was	O
dose	O
dependent	O
(	O
00-000	O
microm	O
)	O
.	O

the	O
effect	O
was	O
significant	O
for	O
icam-0	B-protein
(	O
p	O
<	O
.00	O
)	O
and	O
vcam-0	B-protein
(	O
p	O
<	O
.00	O
)	O
expression	O
in	O
cells	O
pretreated	O
with	O
000	O
microm	O
alpha-lipoate	O
compared	O
to	O
pma-activated	O
untreated	B-cell_type
cells	I-cell_type
.	O

inhibition	O
of	O
pma-induced	B-protein
adhesion	I-protein
molecule	I-protein
expression	O
and	O
cell-cell	O
adhesion	O
was	O
more	O
pronounced	O
when	O
a	O
combination	O
of	O
antioxidants	O
,	O
alpha-lipoate	B-protein
and	O
alpha-tocopherol	O
,	O
were	O
used	O
compared	O
to	O
the	O
use	O
of	O
either	O
of	O
these	O
antioxidant	O
alone	O
.	O

the	O
regulation	O
of	O
adhesion	B-protein
molecule	I-protein
expression	O
and	O
function	O
by	O
low	O
concentration	O
of	O
antioxidants	O
investigated	O
does	O
not	O
appear	O
to	O
be	O
nf-kappab	B-protein
regulated	O
or	O
transcription	O
dependent	O
because	O
no	O
change	O
in	O
the	O
mrna	O
response	O
was	O
observed	O
.	O

protein	B-protein
kinase	I-protein
c	I-protein
(	O
pkc	B-protein
)	O
has	O
been	O
suggested	O
to	O
regulate	O
pma-induced	O
adhesion	B-protein
molecule	I-protein
expression	O
by	O
post-transcriptional	O
stabilization	O
of	O
adhesion	B-protein
molecule	I-protein
mrna	O
.	O

alpha-lipoate	O
pretreatment	O
did	O
not	O
influence	O
the	O
response	O
of	O
pkc	B-protein
activity	O
to	O
pma	O
.	O

oxidants	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
cell	O
adhesion	O
processes	O
.	O

treatment	O
of	O
ecv	B-cell_type
cells	I-cell_type
with	O
pma	O
induced	O
generation	O
of	O
intracellular	O
oxidants	O
.	O

alpha-lipoate	O
(	O
000	O
or	O
000	O
microm	O
)	O
treatment	O
decreased	O
pma-induced	O
generation	O
of	O
intracellular	O
oxidants	O
.	O

the	O
inhibitory	O
effect	O
of	O
low	O
concentration	O
of	O
alpha-lipaote	B-DNA
alone	I-DNA
or	O
in	O
combination	O
with	O
alpha-tocopherol	O
on	O
agonist-induced	O
adhesion	O
processes	O
observed	O
in	O
this	O
study	O
may	O
be	O
of	O
potential	O
therapeutic	O
value	O
.	O

###MEDLINE:98325153

binding	O
of	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
0	I-DNA
to	O
cd0	B-protein
and	O
cxcr0	B-protein
receptors	O
differentially	O
regulates	O
expression	O
of	O
inflammatory	O
genes	O
and	O
activates	O
the	O
mek	B-protein
/erk	O
signaling	O
pathway	O
.	O

we	O
have	O
previously	O
shown	O
that	O
binding	O
of	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
0	I-DNA
(	O
hiv-0	O
)	O
virions	O
to	O
cd0	B-protein
receptors	I-protein
stimulates	O
association	O
of	O
lck	B-protein
with	O
raf-0	B-protein
and	O
results	O
in	O
the	O
activation	O
of	O
raf-0	B-protein
kinase	I-protein
in	O
a	O
ras-independent	O
manner	O
.	O

in	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
hiv-0	B-protein
envelope	I-protein
glycoproteins	I-protein
of	O
both	O
t-cell-tropic	O
and	O
macrophagetropic	O
strains	O
rapidly	O
activate	O
the	O
erk/mitogen-activated	B-protein
protein	I-protein
(	O
map	B-protein
)	I-protein
kinase	I-protein
pathway	O
and	O
the	O
binding	O
of	O
nuclear	B-protein
transcription	I-protein
factors	I-protein
(	O
ap-0	B-protein
,	O
nf-kappab	B-protein
,	O
and	O
c/ebp	B-protein
)	O
and	O
stimulate	O
expression	O
of	O
cytokine	B-DNA
and	I-DNA
chemokine	I-DNA
genes	I-DNA
.	O

the	O
activation	O
of	O
this	O
signaling	O
pathway	O
requires	O
functional	O
cd0	B-protein
receptors	I-protein
and	O
is	O
independent	O
of	O
binding	O
to	O
cxcr0	B-protein
.	O

binding	O
of	O
the	O
natural	B-protein
ligand	I-protein
stromal	O
cell-derived	O
factor	O
0	O
(	O
sdf-0	B-protein
)	O
to	O
cxcr0	B-protein
,	O
which	O
inhibits	O
entry	O
of	O
t-cell-tropic	O
hiv-0	O
,	O
activates	O
also	O
the	O
erk/	B-protein
map	I-protein
kinase	I-protein
pathway	O
.	O

however	O
,	O
sdf-0	B-protein
did	O
not	O
affect	O
the	O
cd0-mediated	O
expression	O
of	O
cytokine	B-DNA
and	I-DNA
chemokine	I-DNA
genes	I-DNA
.	O

these	O
results	O
provide	O
firm	O
molecular	O
evidence	O
that	O
binding	O
of	O
hiv-0	B-protein
envelope	I-protein
glycoproteins	I-protein
to	O
cd0	B-protein
receptor	I-protein
initiates	O
a	O
signaling	O
pathway	O
(	O
s	O
)	O
independent	O
of	O
the	O
binding	O
to	O
the	O
chemokine	B-protein
receptor	I-protein
that	O
leads	O
to	O
the	O
aberrant	O
expression	O
of	O
inflammatory	O
genes	O
and	O
may	O
contribute	O
significantly	O
to	O
hiv-0	O
replication	O
as	O
well	O
as	O
to	O
deregulation	O
of	O
the	O
immune	O
system	O
.	O

###MEDLINE:98315074

antigen	B-protein
receptor	I-protein
signaling	O
induces	O
map	B-protein
kinase-mediated	I-protein
phosphorylation	O
and	O
degradation	O
of	O
the	O
bcl-0	B-protein
transcription	I-protein
factor	I-protein
.	O

the	O
bcl-0	B-DNA
proto-oncogene	I-DNA
encodes	O
a	O
poz/zinc	B-protein
finger	I-protein
transcriptional	I-protein
repressor	I-protein
expressed	O
in	O
germinal	B-cell_type
center	I-cell_type
(	I-cell_type
gc	I-cell_type
)	I-cell_type
b	I-cell_type
and	I-cell_type
t	I-cell_type
cells	I-cell_type
and	O
required	O
for	O
gc	O
formation	O
and	O
antibody	O
affinity	O
maturation	O
.	O

deregulation	O
of	O
bcl-0	B-protein
expression	O
by	O
chromosomal	O
rearrangements	O
and	O
point	O
mutations	O
of	O
the	O
bcl-0	B-DNA
promoter	I-DNA
region	I-DNA
are	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
b-cell	B-cell_line
lymphoma	I-cell_line
.	O

the	O
signals	O
regulating	O
bcl-0	B-protein
expression	O
are	O
not	O
known	O
.	O

here	O
we	O
show	O
that	O
antigen	B-protein
receptor	I-protein
activation	O
leads	O
to	O
bcl-0	B-protein
phosphorylation	O
by	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
mapk	B-protein
)	O
.	O

phosphorylation	O
,	O
in	O
turn	O
,	O
targets	O
bcl-0	B-protein
for	O
rapid	O
degradation	O
by	O
the	O
ubiquitin	B-protein
/	O
proteasome	B-protein
pathway	O
.	O

these	O
findings	O
indicate	O
that	O
bcl-0	B-protein
expression	O
is	O
directly	O
controlled	O
by	O
the	O
antigen	B-protein
receptor	I-protein
via	O
mapk	B-protein
activation	O
.	O

this	O
signaling	O
pathway	O
may	O
be	O
crucial	O
for	O
the	O
control	O
of	O
b-cell	O
differentiation	O
and	O
antibody	O
response	O
and	O
has	O
implications	O
for	O
the	O
regulation	O
of	O
other	O
poz/zinc	B-protein
finger	I-protein
transcription	I-protein
factors	I-protein
in	O
other	O
tissues	O
.	O

###MEDLINE:98310801

glucocorticoid	B-protein
receptors	I-protein
are	O
differentially	O
expressed	O
in	O
the	O
cells	O
and	O
tissues	O
of	O
the	O
immune	O
system	O
.	O

cytosolic	B-protein
glucocorticoid	I-protein
receptor	I-protein
(	O
gr	B-protein
)	O
binding	O
studies	O
on	O
immune	O
tissues	O
demonstrate	O
that	O
the	O
thymus	O
exhibits	O
three	O
to	O
four	O
times	O
higher	O
levels	O
of	O
gr	B-protein
protein	O
than	O
the	O
spleen	O
.	O

high	O
levels	O
of	O
gr	B-protein
are	O
consistent	O
with	O
the	O
exquisite	O
sensitivity	O
of	O
the	O
thymus	O
to	O
glucocorticoid	O
exposure	O
.	O

nevertheless	O
,	O
whole	O
cell	O
binding	O
studies	O
reveal	O
similar	O
levels	O
of	O
gr	B-protein
in	O
immature	B-cell_type
thymic	I-cell_type
t	I-cell_type
lymphocytes	I-cell_type
and	O
more	O
mature	O
,	O
splenic	B-cell_type
t	I-cell_type
lymphocytes	I-cell_type
.	O

moreover	O
,	O
whole	O
cell	O
binding	O
techniques	O
indicate	O
that	O
neutrophils	B-cell_type
(	O
which	O
represent	O
roughly	O
00	O
%	O
of	O
splenic	B-cell_type
leukocytes	I-cell_type
)	O
exhibit	O
higher	O
gr	O
than	O
both	O
t	B-cell_type
and	I-cell_type
b	I-cell_type
lymphocytes	I-cell_type
,	O
further	O
contradicting	O
results	O
from	O
cytosolic	O
binding	O
studies	O
.	O

to	O
address	O
these	O
inconsistencies	O
,	O
gr	B-protein
protein	I-protein
was	O
assessed	O
in	O
immune	B-cell_type
cells	I-cell_type
and	O
tissues	O
using	O
cytosolic	O
radioligand	O
binding	O
.	O

western	O
blot	O
analysis	O
,	O
and	O
immunocytochemistry	O
.	O

consistent	O
with	O
previous	O
cytosolic	B-protein
receptor	I-protein
binding	O
studies	O
on	O
immune	O
tissue	O
homogenates	O
,	O
thymic	B-cell_type
t	I-cell_type
cells	I-cell_type
were	O
found	O
to	O
have	O
higher	O
levels	O
of	O
gr	B-protein
than	O
t	B-cell_type
cells	I-cell_type
isolated	O
from	O
the	O
spleen	O
.	O

in	O
addition	O
,	O
neutrophils	B-cell_type
were	O
found	O
to	O
have	O
fewer	O
gr	O
than	O
lymphocytes	B-cell_type
and	O
monocytes	B-cell_type
.	O

these	O
results	O
indicate	O
a	O
meaningful	O
relationship	O
between	O
receptor	O
expression	O
and	O
known	O
sensitivity	O
to	O
glucocorticoids	O
.	O

###MEDLINE:98252921

functional	O
replacement	O
of	O
the	O
mouse	B-DNA
e0a	I-DNA
gene	I-DNA
with	O
a	O
human	O
heb	B-protein
cdna	O
.	O

the	O
mammalian	O
e0a	B-protein
,	O
heb	B-protein
,	O
and	O
e0-0	O
genes	O
encode	O
a	O
unique	O
class	O
of	O
basic	B-protein
helix-loop-helix	I-protein
(	I-protein
bhlh	I-protein
)	I-protein
transcription	I-protein
factors	I-protein
that	O
are	O
evolutionarily	O
conserved	O
and	O
essential	O
for	O
embryonic	O
and	O
postnatal	O
development	O
.	O

while	O
the	O
structural	O
and	O
functional	O
similarities	O
among	O
the	O
gene	O
products	O
are	O
well	O
demonstrated	O
,	O
it	O
is	O
not	O
clear	O
why	O
deletion	O
of	O
e0a	B-protein
,	O
but	O
not	O
heb	B-protein
or	O
e0-0	O
,	O
leads	O
to	O
a	O
complete	O
arrest	O
in	O
b-lymphocyte	O
development	O
.	O

to	O
understand	O
the	O
molecular	O
basis	O
of	O
the	O
functional	O
specificity	O
between	O
e0a	B-protein
and	O
heb	B-protein
/	O
e0-0	O
in	O
mammalian	O
development	O
,	O
we	O
generated	O
and	O
tested	O
a	O
panel	O
of	O
e0a	B-protein
knockin	O
mutations	O
including	O
subtle	O
mutations	O
in	O
the	O
e00	B-DNA
and	I-DNA
e00	I-DNA
exons	I-DNA
and	O
substitution	O
of	O
both	O
e00	B-DNA
and	I-DNA
e00	I-DNA
exons	I-DNA
with	O
a	O
human	O
heb	B-protein
cdna	O
.	O

we	O
find	O
that	O
the	O
alternatively	O
spliced	O
e00	B-protein
and	O
e00	B-protein
bhlh	B-protein
proteins	I-protein
of	O
the	O
e0a	B-DNA
gene	I-DNA
play	O
similar	O
and	O
additive	O
roles	O
in	O
supporting	O
b	O
lymphopoiesis	O
.	O

further	O
,	O
we	O
find	O
that	O
heb	B-protein
driven	O
by	O
the	O
endogenous	B-DNA
e0a	I-DNA
promoter	I-DNA
can	O
functionally	O
replace	O
e0a	B-protein
in	O
supporting	O
b-cell	O
commitment	O
and	O
differentiation	O
toward	O
completion	O
.	O

finally	O
,	O
the	O
postnatal	O
lethality	O
associated	O
with	O
e0a	B-protein
disruption	O
is	O
fully	O
rescued	O
by	O
the	O
addition	O
of	O
heb	B-protein
.	O

this	O
study	O
suggests	O
that	O
the	O
functional	O
divergence	O
among	O
e00	B-protein
,	O
e00	B-protein
,	O
and	O
heb	B-protein
in	O
different	O
cell	O
types	O
is	O
partially	O
defined	O
by	O
the	O
context	O
of	O
gene	O
expression	O
.	O

###MEDLINE:98281916

biased	O
dependency	O
of	O
cd00	B-protein
versus	O
cd00	B-protein
in	O
the	O
induction	O
of	O
transcription	B-protein
factors	I-protein
regulating	O
the	O
human	B-DNA
il-0	I-DNA
promoter	I-DNA
.	O

in	O
addition	O
to	O
the	O
signals	O
obtained	O
by	O
ligation	O
of	O
the	O
tcr	B-protein
,	O
t	B-cell_type
cells	I-cell_type
need	O
additional	O
,	O
co-stimulatory	O
signals	O
to	O
be	O
activated	O
.	O

one	O
such	O
co-stimulatory	O
signal	O
is	O
delivered	O
when	O
cd00	B-protein
on	O
t	B-cell_type
cells	I-cell_type
binds	O
to	O
cd00	B-protein
or	O
cd00	B-protein
on	O
antigen-presenting	B-cell_type
cells	I-cell_type
(	O
apc	B-cell_type
)	O
.	O

in	O
the	O
present	O
study	O
,	O
we	O
analyzed	O
the	O
ability	O
of	O
cd00	B-protein
and	O
cd00	B-protein
to	O
co-stimulate	B-cell_type
human	I-cell_type
t	I-cell_type
cells	I-cell_type
activated	O
by	O
superantigen	B-protein
.	O

using	O
the	O
raji	B-cell_line
b	I-cell_line
cell	I-cell_line
lymphoma	I-cell_line
,	O
which	O
express	O
similar	O
levels	O
of	O
cd00	B-protein
and	O
cd00	B-protein
,	O
it	O
was	O
found	O
that	O
t	B-cell_type
cell	I-cell_type
proliferation	O
was	O
mainly	O
co-stimulated	O
by	O
cd00	B-protein
.	O

to	O
further	O
characterize	O
the	O
consequences	O
of	O
this	O
biased	O
co-stimulatory	O
dependency	O
,	O
we	O
employed	O
a	O
well-defined	O
system	O
of	O
transfected	B-cell_line
cho	I-cell_line
cells	I-cell_line
expressing	O
human	B-protein
mhc	I-protein
class	I-protein
ii	I-protein
together	O
with	O
cd00	B-protein
,	O
cd00	B-protein
or	O
cd00	B-protein
and	O
cd00	B-protein
.	O

proliferation	O
of	O
freshly	O
prepared	O
cd0+	B-cell_type
t	I-cell_type
cells	I-cell_type
required	O
the	O
presence	O
of	O
either	O
cd00	B-protein
or	O
cd00	B-protein
.	O

however	O
,	O
il-0	B-protein
production	O
reached	O
only	O
suboptimal	O
levels	O
in	O
the	O
presence	O
of	O
cd00	B-protein
but	O
optimal	O
levels	O
with	O
cd00	B-protein
.	O

to	O
analyze	O
il-0	B-protein
transcriptional	O
activity	O
in	O
cd00	B-protein
and	O
cd00	B-cell_type
co-stimulated	I-cell_type
t	I-cell_type
cells	I-cell_type
we	O
used	O
jurkat	B-cell_line
t	I-cell_line
cells	I-cell_line
transfected	O
with	O
luciferase	B-DNA
reporter	I-DNA
gene	I-DNA
constructs	I-DNA
.	O

cd00	B-protein
induced	O
higher	O
levels	O
of	O
il-0	B-DNA
promoter	I-DNA
-enhancer	O
activity	O
compared	O
to	O
cd00	B-protein
.	O

furthermore	O
,	O
the	O
activity	O
of	O
transcription	B-protein
factors	I-protein
regulating	O
the	O
il-0	B-DNA
promoter-enhancer	I-DNA
region	O
including	O
activation	B-protein
protein-0	I-protein
,	O
cd00	B-DNA
response	I-DNA
element	I-DNA
and	O
nuclear	B-protein
factor	I-protein
kappab	I-protein
were	O
0-0	O
times	O
higher	O
after	O
cd00	B-protein
compared	O
to	O
cd00	B-protein
ligation	O
.	O

our	O
results	O
suggest	O
that	O
the	O
eventual	O
appearance	O
of	O
cd00	B-protein
on	O
recently	O
activated	O
cd00+	B-cell_type
apc	I-cell_type
is	O
important	O
for	O
the	O
superinduction	O
of	O
il-0	B-protein
production	O
and	O
to	O
support	O
vigorous	O
t	O
cell	O
proliferation	O
.	O

###MEDLINE:98277450

duplication	O
of	O
the	O
dr0	B-protein
gene	O
on	O
human	B-DNA
chromosome	I-DNA
0p00	I-DNA
and	O
its	O
deletion	O
in	O
human	O
neuroblastoma	B-cell_type
.	O

the	O
human	O
dr0	B-protein
gene	O
,	O
whose	O
product	O
is	O
also	O
known	O
as	O
wsl-0/apo-0/tramp/lard	B-protein
,	O
encodes	O
a	O
tumor	B-protein
necrosis	I-protein
factor-related	I-protein
receptor	I-protein
that	O
is	O
expressed	O
primarily	O
on	O
the	O
surface	O
of	O
thymocytes	B-cell_type
and	O
lymphocytes	B-cell_type
.	O

dr0	B-protein
is	O
capable	O
of	O
inducing	O
both	O
nf-kappa	B-protein
b	I-protein
activation	O
and	O
apoptosis	O
when	O
overexpressed	O
in	O
mammalian	B-cell_type
cells	I-cell_type
,	O
although	O
its	O
ligand	O
has	O
not	O
yet	O
been	O
identified	O
.	O

we	O
report	O
here	O
that	O
the	O
dr0	B-protein
gene	O
locus	O
is	O
tandemly	O
duplicated	O
on	O
human	B-DNA
chromosome	I-DNA
band	I-DNA
0p00.0-p00.0	I-DNA
and	O
that	O
these	O
genes	O
are	O
hemizygously	O
deleted	O
and/or	O
translocated	O
to	O
another	O
chromosome	O
in	O
neuroblastoma	B-cell_type
(	O
nb	O
)	O
cell	B-cell_line
lines	I-cell_line
with	O
amplified	B-DNA
mycn	I-DNA
.	O

duplication	O
of	O
at	O
least	O
a	O
portion	O
of	O
the	O
dr0	B-protein
gene	O
,	O
including	O
the	O
extracellular	B-protein
and	I-protein
transmembrane	I-protein
regions	I-protein
but	O
not	O
the	O
cytoplasmic	B-protein
domain	I-protein
,	O
was	O
demonstrated	O
by	O
both	O
fluorescence	O
in	O
situ	O
hybridization	O
and	O
genomic	O
southern	O
blotting	O
.	O

in	O
most	O
nb	O
cell	O
lines	O
,	O
both	O
the	O
dr0	B-protein
and	O
the	O
dr0l	B-DNA
sequences	I-DNA
are	O
simultaneously	O
deleted	O
and/or	O
translocated	O
to	O
another	O
chromosome	O
.	O

finally	O
,	O
dr0/	B-protein
wsl-0	I-protein
protein	I-protein
expression	O
is	O
quite	O
variable	O
among	O
these	O
nb	O
cell	O
lines	O
,	O
with	O
very	O
low	O
or	O
undetectable	O
levels	O
in	O
0	O
of	O
00	O
nb	O
cell	O
lines	O

###MEDLINE:86000980

differential	O
protection	O
of	O
normal	B-cell_type
and	I-cell_type
malignant	I-cell_type
human	I-cell_type
myeloid	I-cell_type
progenitors	I-cell_type
(	O
cfu-gm	B-cell_type
)	O
from	O
ara-c	O
toxicity	O
using	O
cycloheximide	O
.	O

cycloheximide	O
,	O
a	O
reversible	O
protein	O
synthesis	O
inhibitor	O
,	O
is	O
thought	O
to	O
block	O
dna	O
replication	O
in	O
normal	B-cell_type
cells	I-cell_type
by	O
preventing	O
synthesis	O
of	O
a	O
labile	B-protein
protein	I-protein
.	O

in	O
animal	O
systems	O
,	O
cycloheximide	O
protects	O
normal	B-cell_type
cells	I-cell_type
from	O
cytotoxic	O
s-phase	O
specific	O
agents	O
,	O
such	O
as	O
cytosine	B-protein
arabinoside	I-protein
(	O
ara-c	O
)	O
.	O

malignant	B-cell_type
cells	I-cell_type
appear	O
not	O
to	O
be	O
susceptible	O
to	O
cycloheximide-induced	O
cycle	O
arrest	O
and	O
,	O
subsequently	O
,	O
may	O
not	O
be	O
protected	O
from	O
ara-c	O
cytotoxicity	O
.	O

the	O
effect	O
of	O
cycloheximide	O
on	O
granulocyte/macrophage	B-cell_type
progenitors	I-cell_type
(	O
cfu-gm	B-cell_type
)	O
after	O
in	O
vitro	O
ara-c	O
exposure	O
was	O
examined	O
using	O
normal	B-cell_type
human	I-cell_type
bone	I-cell_type
marrow	I-cell_type
,	I-cell_type
malignant	I-cell_type
progenitors	I-cell_type
from	O
patients	O
with	O
chronic	O
myelogenous	O
leukemia	O
(	O
cml	O
)	O
,	O
and	O
clonogenic	O
cells	O
from	O
the	O
human	B-cell_line
acute	I-cell_line
nonlymphocytic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
hl-00	B-cell_line
and	O
kg-0	B-cell_line
.	O

mononuclear	O
or	O
clonogenic	O
cells	O
were	O
incubated	O
for	O
one	O
hour	O
with	O
cycloheximide	O
,	O
followed	O
by	O
the	O
addition	O
,	O
for	O
three	O
or	O
00	O
hours	O
,	O
of	O
ara-c	O
before	O
being	O
plated	O
in	O
a	O
methylcellulose	O
culture	O
system	O
.	O

cfu-gm	O
survival	O
was	O
significantly	O
increase	O
if	O
normal	B-cell_type
cells	I-cell_type
were	O
treated	O
with	O
cycloheximide	O
before	O
ara-c	O
exposure	O
.	O

similar	O
cycloheximide	O
pretreatment	O
of	O
cml	B-cell_type
progenitors	I-cell_type
and	O
clonogenic	O
hl-00	B-cell_line
and	I-cell_line
kg-0	I-cell_line
cells	I-cell_line
failed	O
to	O
protect	O
cfu-gm	O
from	O
ara-c-induced	O
cytotoxicity	O
.	O

###MEDLINE:85158098

primary	O
cortisol	O
resistance	O
accompanied	O
by	O
a	O
reduction	O
in	O
glucocorticoid	B-protein
receptors	I-protein
in	O
two	O
members	O
of	O
the	O
same	O
family	O
.	O

this	O
report	O
describes	O
studies	O
of	O
a	O
man	O
suspected	O
of	O
having	O
primary	O
cortisol	O
resistance	O
.	O

this	O
conclusion	O
is	O
based	O
on	O
his	O
high	O
plasma	O
cortisol	O
levels	O
and	O
high	O
00-h	O
urinary	O
00-hydroxycorticosteroid	O
and	O
cortisol	O
excretion	O
,	O
plus	O
the	O
fact	O
that	O
he	O
had	O
no	O
manifestations	O
of	O
cushing	O
's	O
syndrome	O
.	O

among	O
family	O
members	O
tested	O
,	O
his	O
mother	O
also	O
had	O
hypercortisolemia	O
.	O

both	O
mother	O
and	O
son	O
had	O
high	O
levels	O
of	O
unbound	O
plasma	O
cortisol	O
,	O
but	O
their	O
plasma	O
acth	O
concentrations	O
were	O
within	O
the	O
normal	O
range	O
.	O

both	O
were	O
partially	O
resistant	O
to	O
dexamethasone	O
adrenal	O
suppression	O
,	O
and	O
both	O
had	O
mild	O
hypertension	O
without	O
hypokalemia	O
.	O

to	O
study	O
this	O
apparent	O
end-organ	O
resistance	O
to	O
cortisol	O
,	O
we	O
examined	O
the	O
glucocorticoid	B-protein
receptors	I-protein
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

using	O
whole	O
cell	O
assays	O
,	O
glucocorticoid	B-protein
receptors	I-protein
in	O
both	O
patients	O
were	O
found	O
to	O
have	O
reduced	O
total	O
binding	O
capacity	O
.	O

we	O
conclude	O
that	O
these	O
two	O
patients	O
,	O
members	O
of	O
the	O
same	O
family	O
,	O
have	O
primary	O
cortisol	O
resistance	O
accompanied	O
by	O
a	O
reduced	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
.	O

###MEDLINE:86151192

[	O
glucocorticoid	B-protein
receptors	I-protein
and	O
response	O
to	O
polychemotherapy	O
in	O
acute	O
lymphatic	O
leukemia	O
]	O

glucocorticoid	B-protein
receptor	I-protein
(	O
gr	B-protein
)	O
levels	O
were	O
quantified	O
in	O
leukemic	B-cell_type
blasts	I-cell_type
from	O
peripheral	B-cell_type
blood	I-cell_type
of	O
00	O
patients	O
with	O
acute	O
lymphoblastic	O
leukemia	O
.	O

the	O
subsequent	O
achievement	O
of	O
complete	O
remission	O
after	O
combination	O
chemotherapy	O
was	O
correlated	O
with	O
high	O
receptor	O
levels	O
.	O

forty-seven	O
of	O
00	O
patients	O
with	O
leukemic	B-cell_type
cells	I-cell_type
containing	O
more	O
than	O
0	O
,	O
000	B-DNA
receptor	I-DNA
sites	I-DNA
and	O
00	O
of	O
00	O
patients	O
with	O
cells	O
containing	O
less	O
than	O
0	O
,	O
000	B-DNA
receptor	I-DNA
sites	I-DNA
achieved	O
remission	O
.	O

the	O
study	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
leukemic	B-cell_type
cells	I-cell_type
may	O
predict	O
response	O
to	O
combination	O
chemotherapy	O
in	O
patients	O
with	O
acute	O
lymphoblastic	O
leukemia	O
.	O

###MEDLINE:84259095

specific	O
uptake	O
of	O
0	O
,	O
00-dihydroxycholecalciferol	O
by	O
human	B-cell_line
chronic	I-cell_line
myeloid	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
.	O

we	O
have	O
examined	O
mononuclear	B-cell_type
cell	I-cell_type
preparations	O
from	O
patients	O
with	O
chronic	O
myeloid	O
leukemia	O
[	O
cml	O
]	O
for	O
binding	O
of	O
and	O
response	O
to	O
0	O
,	O
00-dihydroxycholecalciferol	O
[	O
0	O
,	O
00-	O
(	O
oh	O
)	O
0d0	O
]	O
.	O

whole	O
cells	O
specifically	O
took	O
up	O
[	O
0h	O
]	O
-0	B-protein
,	O
00-	O
(	O
oh	O
)	O
0d0	O
with	O
high	O
affinity	O
(	O
kd	O
0.0	O
x	O
00	O
(	O
-00	O
)	O
m	O
)	O
and	O
low	O
capacity	O
.	O

subcellular	O
fractionation	O
of	O
labeled	O
cells	O
showed	O
that	O
binding	O
was	O
restricted	O
to	O
cytosols	O
and	O
nuclei	O
.	O

sucrose	O
gradient	O
centrifugation	O
of	O
cells	O
preincubated	O
with	O
[	O
0h	O
]	O
-0	B-protein
,	O
00-	O
(	O
oh	O
)	O
0d0	O
revealed	O
a	O
single	O
0.0s	O
peak	O
which	O
was	O
totally	O
displaced	O
with	O
000-fold	O
excess	O
nonradioactive	O
hormone	O
.	O

however	O
,	O
we	O
were	O
unable	O
to	O
demonstrate	O
specific	O
binding	O
of	O
0	O
,	O
00-	O
(	O
oh	O
)	O
0d0	O
by	O
postlabeling	O
standard	O
cytosol	O
preparations	O
.	O

in	O
addition	O
,	O
cytosols	O
prepared	O
from	O
a	O
mixture	O
of	O
cml	B-cell_type
cells	I-cell_type
and	O
0	O
,	O
00-	O
(	O
oh	O
)	O
0d0	O
receptor-positive	O
t00d	O
(	O
human	B-cell_line
breast	I-cell_line
cancer	I-cell_line
)	I-cell_line
cells	I-cell_line
had	O
less	O
than	O
00	O
%	O
of	O
the	O
binding	O
measured	O
in	O
t00d	O
cytosol	O
alone	O
.	O

however	O
,	O
the	O
levels	O
of	O
binding	O
in	O
t00d	O
cytosols	O
were	O
not	O
reduced	O
if	O
the	O
receptors	O
were	O
occupied	O
with	O
[	O
0h	O
]	O
-0	B-protein
,	O
00-	O
(	O
oh	O
)	O
0d0	O
prior	O
to	O
the	O
addition	O
of	O
the	O
cml	O
cytosols	O
.	O

thus	O
,	O
cml	B-cell_type
cells	I-cell_type
appear	O
to	O
contain	O
both	O
the	O
receptor	O
for	O
0	O
,	O
00-	O
(	O
oh	O
)	O
0d0	O
and	O
an	O
unknown	O
substance	O
which	O
prevents	O
its	O
detection	O
following	O
the	O
preparation	O
of	O
cytosol	O
.	O

cells	O
from	O
patients	O
with	O
cml	O
in	O
the	O
chronic	O
phase	O
specifically	O
bound	O
more	O
0	O
,	O
00-	O
(	O
oh	O
)	O
0d0	O
[	O
00.0	O
+/-	O
0.0	O
(	O
s.e.	B-protein
)	O
fmol/00	O
(	O
0	O
)	O
cells	O
]	O
than	O
did	O
those	O
in	O
acute	O
myeloid	O
transformation	O
[	O
0.0	O
+/-	O
0.0	O
]	O
or	O
than	O
did	O
cells	O
from	O
patients	O
with	O
acute	O
myeloid	O
leukemia	O
[	O
0.0	O
+/-	O
0.0	O
]	O
.	O

only	O
cells	O
from	O
the	O
first	O
group	O
of	O
patients	O
responded	O
to	O
the	O
addition	O
of	O
0	O
,	O
00-	O
(	O
oh	O
)	O
0d0	O
by	O
differentiating	O
along	O
the	O
monocyte-macrophage	O
pathway	O
.	O

we	O
conclude	O
that	O
the	O
differentiation-induction	O
effect	O
of	O
0	O
,	O
00-	O
(	O
oh	O
)	O
0d0	O
is	O
likely	O
to	O
depend	O
on	O
adequate	O
levels	O
of	O
receptor	O
and	O
that	O
intact	B-cell_type
cells	I-cell_type
rather	O
than	O
cytosol	O
preparations	O
should	O
be	O
studied	O
before	O
cells	O
of	O
a	O
particular	O
tissue	O
are	O
designated	O
as	O
receptor	O
negative	O
.	O

###MEDLINE:84080809

effect	O
of	O
cell	O
cycle	O
position	O
on	O
dexamethasone	O
binding	O
by	O
mouse	B-cell_line
and	I-cell_line
human	I-cell_line
lymphoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
:	O
correlation	O
between	O
an	O
increase	O
in	O
dexamethasone	O
binding	O
during	O
s	O
phase	O
and	O
dexamethasone	O
sensitivity	O
.	O

we	O
determined	O
the	O
effect	O
of	O
cell	O
cycle	O
position	O
on	O
the	O
amount	O
of	O
dexamethasone	O
that	O
was	O
specifically	O
bound	O
by	O
mouse	B-cell_line
and	I-cell_line
human	I-cell_line
lymphoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

cell	B-cell_line
lines	I-cell_line
that	O
were	O
either	O
sensitive	O
or	O
resistant	O
to	O
growth	O
inhibition	O
by	O
dexamethasone	O
were	O
compared	O
.	O

exponentially	O
growing	O
cells	O
were	O
separated	O
by	O
centrifugal	O
elutriation	O
into	O
fractions	O
that	O
corresponded	O
to	O
different	O
positions	O
in	O
the	O
cell	O
cycle	O
.	O

the	O
cell	O
cycle	O
phase	O
distribution	O
of	O
each	O
fraction	O
was	O
estimated	O
by	O
flow	O
cytometry	O
and	O
autoradiography	O
.	O

the	O
amount	O
of	O
dexamethasone	O
bound	O
per	O
cell	O
in	O
each	O
fraction	O
was	O
measured	O
by	O
a	O
whole	O
cell	O
binding	O
assay	O
.	O

in	O
three	O
dexamethasone-sensitive	B-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
two	O
mouse	O
and	O
one	O
human	O
)	O
,	O
we	O
found	O
that	O
the	O
amount	O
of	O
dexamethasone	O
bound	O
per	O
cell	O
increased	O
0-0-fold	O
between	O
g0	O
phase	O
and	O
s	O
phase	O
,	O
and	O
then	O
decreased	O
during	O
g0/m	O
phase	O
.	O

results	O
were	O
the	O
same	O
when	O
the	O
amount	O
of	O
dexamethasone	O
bound	O
per	O
milligram	O
of	O
cell	B-protein
protein	I-protein
was	O
measured	O
.	O

binding	O
affinity	O
was	O
the	O
same	O
during	O
g0	O
phase	O
and	O
s	O
phase	O
,	O
but	O
the	O
proportion	O
of	O
bound	O
dexamethasone	O
that	O
translocated	O
to	O
the	O
nucleus	O
was	O
greater	O
during	O
s	O
phase	O
.	O

in	O
contrast	O
,	O
we	O
found	O
that	O
the	O
amount	O
of	O
dexamethasone	O
bound	O
per	O
cell	O
by	O
three	O
dexamethasone-resistant	B-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
two	O
mouse	O
and	O
one	O
human	B-DNA
)	I-DNA
did	O
not	O
increase	O
during	O
s	O
phase	O
.	O

our	O
results	O
indicate	O
that	O
cell	O
cycle	O
changes	O
in	O
dexamethasone	O
binding	O
are	O
not	O
simply	O
related	O
to	O
changes	O
in	O
cell	B-protein
protein	I-protein
or	O
cell	O
volume	O
during	O
the	O
cell	O
cycle	O
.	O

an	O
increase	O
in	O
dexamethasone	O
binding	O
during	O
s	O
phase	O
may	O
be	O
required	O
for	O
dexamethasone	O
to	O
inhibit	O
cell	O
growth	O
,	O
and	O
a	O
failure	O
of	O
dexamethasone	O
binding	O
to	O
increase	O
during	O
s	O
phase	O
might	O
represent	O
a	O
new	O
mechanism	O
of	O
dexamethasone	O
resistance	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

###MEDLINE:84066221

presence	O
and	O
steroid	O
inducibility	O
of	O
glutamine	B-protein
synthetase	I-protein
in	O
human	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
.	O

glutamine	B-protein
synthetase	I-protein
(	O
ec	B-cell_type
0.0.0.0	O
;	O
gs	O
)	O
is	O
present	O
in	O
lymphoblasts	B-cell_type
from	O
patients	O
with	O
acute	O
lymphoblastic	O
leukemia	O
(	O
all	O
)	O
as	O
well	O
as	O
in	O
normal	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
.	O

in	O
00	O
out	O
of	O
00	O
all	O
patients	O
studied	O
exposure	O
of	O
the	O
cells	O
to	O
physiological	O
concentrations	O
of	O
dexamethasone	O
in	O
vitro	O
increased	O
enzyme	O
activity	O
above	O
the	O
control	O
levels	O
.	O

the	O
increase	O
was	O
specific	O
for	O
glucocorticoid	B-protein
receptor	I-protein
ligands	I-protein
.	O

a	O
direct	O
correlation	O
was	O
found	O
between	O
the	O
magnitude	O
of	O
glucocorticoid-mediated	O
increase	O
of	O
gs	O
activity	O
and	O
the	O
cellular	O
levels	O
of	O
specific	O
glucocorticoid	B-protein
receptors	I-protein
assayed	O
in	O
the	O
same	O
cell	O
specimen	O
.	O

moreover	O
,	O
the	O
basal	O
levels	O
of	O
the	O
enzyme	O
measured	O
in	O
cells	O
prior	O
to	O
exposure	O
to	O
dexamethasone	O
correlated	O
negatively	O
with	O
receptor	O
density	O
.	O

it	O
is	O
suggested	O
that	O
the	O
presence	O
of	O
steroid-inducible	O
gs	O
in	O
all	O
cells	O
may	O
prove	O
to	O
be	O
a	O
marker	O
for	O
functional	B-DNA
receptor	I-DNA
sites	I-DNA
.	O

###MEDLINE:83230863

binding	O
of	O
progestins	O
to	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O

correlation	O
to	O
their	O
glucocorticoid-like	O
effects	O
on	O
in	O
vitro	O
functions	O
of	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
.	O

a	O
number	O
of	O
physiological	O
and	O
synthetic	O
progestins	O
were	O
tested	O
for	O
their	O
ability	O
to	O
compete	O
with	O
[	O
0h	O
]	O
dexamethasone	O
for	O
the	O
binding	O
to	O
the	O
glucocorticoid	B-protein
receptor	I-protein
of	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
and	O
their	O
ability	O
to	O
elicit	O
glucocorticoid-like	O
effects	O
on	O
the	O
same	O
cells	O
.	O

as	O
compared	O
to	O
the	O
reference	O
compound	O
dexamethasone	O
(	O
relative	O
receptor	O
binding	O
affinity	O
defined	O
as	O
000	O
%	O
)	O
,	O
two	O
potent	O
synthetic	O
progestins	O
with	O
a	O
pregnane-type	B-DNA
structure	I-DNA
,	O
megestrol	O
acetate	O
and	O
medroxyprogesterone	O
acetate	O
,	O
were	O
found	O
to	O
display	O
a	O
considerable	O
binding	O
affinity	O
towards	O
the	O
receptor	O
(	O
00	O
and	O
00	O
%	O
,	O
respectively	O
)	O
.	O

the	O
relative	O
binding	O
affinity	O
of	O
the	O
naturally	O
occurring	O
ligand	O
,	O
cortisol	O
,	O
to	O
the	O
receptor	O
was	O
clearly	O
lower	O
(	O
00	O
%	O
)	O
.	O

the	O
effective	O
binding	O
of	O
medroxyprogesterone	O
acetate	O
to	O
the	O
glucocorticoid	B-protein
receptor	I-protein
was	O
confirmed	O
by	O
direct	O
binding	O
studies	O
utilizing	O
a	O
tritiated	O
derivative	O
of	O
this	O
steroid	O
.	O

no	O
evidence	O
for	O
the	O
existence	O
of	O
a	O
specific	O
progesterone	B-protein
receptor	I-protein
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
was	O
obtained	O
as	O
judged	O
by	O
the	O
results	O
of	O
competition	O
experiments	O
where	O
a	O
progesterone	B-protein
receptor-specific	I-protein
ligand	I-protein
[	O
0h	O
]	O
org	O
0000	O
was	O
used	O
.	O

medroxyprogesterone	O
acetate	O
and	O
megestrol	O
acetate	O
also	O
induced	O
glucocorticoid-like	O
effects	O
on	O
the	O
lymphocyte	O
functions	O
.	O

these	O
included	O
inhibition	O
of	O
the	O
proliferative	O
responses	O
to	O
the	O
t-cell	B-protein
mitogens	I-protein
concanavalin	O
a	O
and	O
phytohaemagglutinin	B-protein
and	O
an	O
enhanced	O
accumulation	O
of	O
immunoglobulin	B-cell_line
secreting	I-cell_line
cells	I-cell_line
in	O
pokeweed	B-cell_line
mitogen-stimulated	I-cell_line
cultures	I-cell_line
.	O

the	O
progestin	O
effect	O
appears	O
to	O
be	O
mediated	O
through	O
a	O
radiosensitive	B-protein
(	I-protein
suppressor	I-protein
)	I-protein
subpopulation	O
of	O
t	B-cell_type
lymphocytes	I-cell_type
.	O

in	O
contrast	O
,	O
the	O
synthetic	O
progestins	O
related	O
structurally	O
to	O
00-nortestosterone	O
,	O
norethisterone	O
and	O
d-norgestrel	O
,	O
were	O
virtually	O
devoid	O
of	O
binding	O
affinity	O
towards	O
the	O
glucocorticoid	B-protein
receptor	I-protein
nor	O
did	O
they	O
measurably	O
influence	O
the	O
in	O
vitro	O
lymphocyte	O
functions	O
.	O

these	O
studies	O
demonstrate	O
that	O
certain	O
progestins	O
in	O
common	O
clinical	O
use	O
probably	O
possess	O
inherent	O
glucocorticoid	O
activity	O
and	O
suggest	O
that	O
side	O
effects	O
attributable	O
to	O
this	O
character	O
(	O
e.g.	O
suppression	O
of	O
the	O
pituitary-adrenal	O
axis	O
)	O
might	O
be	O
expected	O
when	O
these	O
compounds	O
are	O
used	O
in	O
pharmacological	O
doses	O
.	O

###MEDLINE:82136853

metabolic	O
and	O
ultrastructural	O
aspects	O
of	O
the	O
in	O
vitro	O
lysis	O
of	O
chronic	B-cell_type
lymphocytic	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
by	O
glucocorticoids	O
.	O

human	O
chronic	O
lymphocytic	O
leukemia	O
(	O
cll	B-cell_line
)	I-cell_line
cells	I-cell_line
like	O
prothymocytes	B-cell_type
and	I-cell_type
immunoactivated	I-cell_type
t-lymphocytes	I-cell_type
are	O
readily	O
lysed	O
in	O
vitro	O
by	O
pharmacological	O
concentrations	O
of	O
glucocorticoids	O
such	O
as	O
cortisol	O
,	O
whereas	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
and	O
thymocytes	B-cell_type
are	O
unaffected	O
by	O
the	O
hormone	O
.	O

in	O
this	O
study	O
,	O
metabolic	O
and	O
ultrastructural	O
aspects	O
of	O
the	O
cortisol-induced	O
killing	O
process	O
of	O
cll	B-cell_line
cells	I-cell_line
are	O
recorded	O
.	O

in	O
vitro	O
lysis	O
was	O
found	O
to	O
be	O
temperature	O
dependent	O
and	O
was	O
detected	O
only	O
after	O
0	O
to	O
0	O
hr	O
incubation	O
with	O
cortisol	O
by	O
means	O
of	O
the	O
trypan	O
blue	O
exclusion	O
test	O
.	O

however	O
,	O
00	O
min	O
of	O
incubation	O
with	O
cortisol	O
at	O
either	O
00	O
degrees	O
or	O
0	O
degrees	O
followed	O
by	O
the	O
removal	O
of	O
the	O
hormone	O
was	O
still	O
sufficient	O
to	O
induce	O
the	O
lytic	O
process	O
.	O

ultrastructural	O
studies	O
demonstrated	O
sequential	O
changes	O
in	O
the	O
cytoplasm	O
,	O
including	O
swelling	O
of	O
mitochondria	O
and	O
cytoplasmic	B-protein
decompartmentalization	I-protein
,	O
followed	O
by	O
loss	O
of	O
surface	O
microvilli	O
with	O
the	O
appearance	O
of	O
``	O
holes	O
''	O
in	O
the	O
cell	O
membrane	O
,	O
and	O
subsequent	O
condensation	O
of	O
nuclear	O
chromatin	O
.	O

the	O
large	O
holes	O
in	O
the	O
membrane	O
appearing	O
after	O
0	O
hr	O
of	O
incubation	O
with	O
the	O
hormone	O
may	O
be	O
the	O
cause	O
for	O
the	O
penetration	O
of	O
the	O
viable	O
stain	O
into	O
the	O
dead	B-cell_type
cells	I-cell_type
,	O
as	O
seen	O
by	O
light	O
microscopy	O
.	O

addition	O
of	O
metabolic	O
inhibitors	O
including	O
actinomycin	O
d	O
,	O
puromycin	O
,	O
and	O
cycloheximide	O
following	O
administration	O
of	O
cortisol	O
resulted	O
in	O
inhibition	O
of	O
the	O
cell	O
lysis	O
.	O

an	O
excess	O
of	O
an	O
antagonist	O
such	O
as	O
cortexolone	B-protein
was	O
found	O
to	O
inhibit	O
the	O
cortisol-induced	O
cytolysis	O
of	O
the	O
cll	B-cell_line
cells	I-cell_line
.	O

it	O
is	O
suggested	O
that	O
the	O
glucocorticoid-induced	O
lysis	O
of	O
human	O
cll	B-cell_line
cells	I-cell_line
is	O
similar	O
to	O
the	O
phenomenon	O
observed	O
in	O
rat	B-cell_type
or	I-cell_type
murine	I-cell_type
lymphocytes	I-cell_type
and	O
is	O
mediated	O
by	O
interaction	O
of	O
the	O
steroid	B-protein
molecule	I-protein
with	O
the	O
cytoplasmic	B-protein
receptor	I-protein
.	O

the	O
resulting	O
complex	O
appears	O
to	O
activate	O
specific	O
gene	O
(	O
s	O
)	O
the	O
products	O
of	O
which	O
eventually	O
cause	O
cytolysis	O
.	O

###MEDLINE:82048495

glucocorticoid	B-protein
receptors	I-protein
in	O
lymphoid	B-cell_type
tumors	I-cell_type
.	O

there	O
is	O
a	O
range	O
of	O
levels	O
of	O
glucocorticoid	B-protein
receptor	I-protein
numbers	O
seen	O
in	O
the	O
various	O
subclasses	O
of	O
acute	O
lymphatic	O
leukemia	O
(	O
all	O
)	O
.	O

this	O
variability	O
can	O
not	O
be	O
explained	O
by	O
the	O
known	O
correlation	O
between	O
active	O
cell	O
proliferation	O
and	O
an	O
increase	O
in	O
the	O
number	O
of	O
receptors	O
,	O
since	O
the	O
tumors	O
with	O
the	O
highest	O
growth	O
fraction	O
(	O
i.e.	O
,	O
burkitt	B-cell_line
's	I-cell_line
lymphoma	I-cell_line
and	I-cell_line
t-cell	I-cell_line
leukemia	I-cell_line
)	I-cell_line
tend	I-cell_line
to	O
have	O
lower	O
average	O
receptor	O
numbers	O
than	O
do	O
tumors	O
with	O
lower	O
growth	O
fractions	O
such	O
as	O
common	O
all	O
.	O

all	O
clinical	O
specimens	O
from	O
patients	O
with	O
lymphatic	O
leukemia	O
have	O
some	O
measurable	O
level	O
of	O
glucocorticoid	B-protein
receptors	I-protein
;	O
therefore	O
,	O
the	O
resistance	O
seen	O
in	O
vivo	O
can	O
not	O
be	O
explained	O
by	O
the	O
lack	O
of	O
receptors	O
.	O

however	O
,	O
there	O
has	O
been	O
a	O
positive	O
correlation	O
,	O
in	O
our	O
hands	O
,	O
with	O
receptor	O
level	O
and	O
prognosis	O
.	O

on	O
the	O
basis	O
of	O
in	O
vitro	O
models	O
,	O
it	O
is	O
proposed	O
that	O
perhaps	O
the	O
high	O
receptor	O
cell	O
lines	O
(	O
i.e.	O
,	O
common	O
all	O
of	O
childhood	O
)	O
have	O
relative	O
stability	O
of	O
their	O
genetic	O
material	O
making	O
glucocorticoid-resistant	O
mutations	O
less	O
likely	O
to	O
occur	O
in	O
patients	O
with	O
these	O
cells	O
than	O
in	O
low-receptor	B-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
i.e.	O
,	O
t-cell	O
leukemia	O
)	O
.	O

this	O
greater	O
genetic	O
variability	O
in	O
the	O
low-receptor	B-cell_line
lines	I-cell_line
could	O
account	O
for	O
the	O
earlier	O
emergence	O
of	O
clinical	O
glucocorticoid	O
resistance	O
in	O
these	O
patients	O
.	O

###MEDLINE:81271552

[	O
tumor	B-protein
histology	I-protein
and	I-protein
steroid	I-protein
receptors	I-protein
in	O
breast	O
carcinoma	O
]	O

in	O
specimens	O
of	O
000	O
patients	O
with	O
breast	O
cancer	O
0	O
tumorparameters	O
(	O
tumorsize	B-protein
,	O
tumorboder	O
,	O
nucleargrade	O
,	O
lymphocytic	O
stromal	O
reaction	O
)	O
0	O
features	O
of	O
regional	O
lymphnodes	B-protein
(	I-protein
sinushistiocytosis	I-protein
,	O
t-cellreaction	O
,	O
lymphnode	O
metastases	O
)	O
and	O
estrogen	O
and	O
progesteron	B-protein
receptors	I-protein
were	O
determined	O
.	O

a	O
strong	O
sinushistiocytosis	O
and	O
t-cellreaction	B-protein
could	O
be	O
verified	O
mainly	O
in	O
metastases	O
in	O
free	O
lymphnodes	O
.	O

the	O
steroid	B-protein
receptor	I-protein
content	O
does	O
not	O
correlate	O
with	O
histological	O
parameters	O

###MEDLINE:86040213

aldosterone-receptor	O
deficiency	O
in	O
pseudohypoaldosteronism	O
.	O

pseudohypoaldosteronism	O
,	O
a	O
syndrome	O
characterized	O
by	O
salt	O
wasting	O
and	O
failure	O
to	O
thrive	O
,	O
usually	O
presents	O
in	O
infancy	O
as	O
high	O
urinary	O
levels	O
of	O
sodium	O
despite	O
hyponatremia	O
,	O
hyperkalemia	O
,	O
hyperreninemia	O
,	O
and	O
elevated	O
aldosterone	O
levels	O
.	O

we	O
have	O
investigated	O
this	O
syndrome	O
for	O
the	O
possibility	O
of	O
abnormal	B-protein
type	I-protein
i	I-protein
or	I-protein
``	I-protein
mineralocorticoid-like	I-protein
''	I-protein
receptors	I-protein
,	O
which	O
have	O
intrinsic	O
steroid	O
specificity	O
indistinguishable	O
from	O
that	O
of	O
renal	O
mineralocorticoid	B-protein
receptors	I-protein
and	O
are	O
found	O
in	O
many	O
tissues	O
and	O
cells	O
,	O
including	O
mononuclear	B-cell_type
leukocytes	I-cell_type
.	O

we	O
have	O
studied	O
three	O
patients	O
with	O
pseudohypoaldosteronism	O
:	O
the	O
00-year-old	O
index	O
case	O
in	O
melbourne	B-protein
(	O
patient	O
0	O
)	O
and	O
two	O
siblings	O
in	O
munich	O
,	O
eight	O
and	O
two	O
years	O
of	O
age	O
(	O
patients	O
0	O
and	O
0	O
)	O
;	O
clinically	O
,	O
patient	O
0	O
had	O
a	O
less	O
severe	O
case	O
than	O
his	O
sister	O
.	O

percoll-separated	O
control	B-cell_type
monocytes	I-cell_type
bound	O
[	O
0h	O
]	O
aldosterone	O
with	O
high	O
affinity	O
(	O
kd	O
approximately	O
0	O
nm	O
)	O
and	O
limited	O
capacity	O
(	O
000	O
to	O
000	O
sites	O
per	O
cell	O
)	O
.	O

on	O
repeated	O
examination	O
,	O
no	O
[	O
0h	O
]	O
aldosterone	O
binding	O
was	O
found	O
in	O
monocytes	B-cell_type
from	O
patients	O
0	O
and	O
0	O
;	O
in	O
patient	O
0	O
,	O
the	O
levels	O
were	O
00	O
sites	O
per	O
cell	O
,	O
more	O
than	O
0	O
s.d.	O
below	O
those	O
of	O
the	O
control	O
.	O

levels	O
in	O
the	O
parents	O
of	O
the	O
munich	O
patients	O
(	O
first	O
cousins	O
)	O
were	O
normal	O
.	O

it	O
appears	O
that	O
pseudohypoaldosteronism	O
is	O
caused	O
by	O
a	O
type	B-protein
i	I-protein
receptor	I-protein
defect	O
,	O
that	O
the	O
defect	O
may	O
be	O
complete	O
or	O
partial	O
,	O
that	O
transmission	O
may	O
be	O
autosomal	O
recessive	O
,	O
and	O
that	O
the	O
study	O
of	O
patients	O
with	O
pseudohypoaldosteronism	O
may	O
indicate	O
physiologic	O
roles	O
for	O
type	B-protein
i	I-protein
receptors	I-protein
in	B-cell_type
nonepithelial	I-cell_type
tissues	I-cell_type
.	O

###MEDLINE:85257187

glucocorticoid	O
inhibition	O
of	O
urokinase-like	B-protein
plasminogen	I-protein
activators	I-protein
in	O
cultured	B-cell_line
human	I-cell_line
lymphoblasts	I-cell_line
.	O

two	O
human	B-cell_line
lymphoblast	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
licr-lon-hmy0	B-cell_line
(	I-cell_line
hmy0	I-cell_line
cells	I-cell_line
)	O
and	O
gm0000a	B-cell_line
cells	I-cell_line
,	O
are	O
moderately	O
growth	O
inhibited	O
by	O
dexamethasone	O
(	O
0	O
,	O
0-pregnadien-0-fluoro-00	B-RNA
alpha-methyl-00	I-RNA
beta	I-RNA
,	I-RNA
00	I-RNA
alpha	I-RNA
,	I-RNA
00-triol-0	I-RNA
,	O
00-dione	O
)	O
(	O
dex	O
)	O
.	O

both	O
cell	O
types	O
secrete	O
a	O
urokinase	B-protein
(	I-protein
uk	I-protein
)	I-protein
-like	I-protein
plasminogen	I-protein
activator	I-protein
(	O
pa	O
)	O
.	O

treatment	O
of	O
both	O
hmy0	B-cell_line
and	I-cell_line
gm0000a	I-cell_line
cells	I-cell_line
with	O
dex	O
for	O
0-0	O
days	O
inhibits	O
extracellular	O
pa	O
activity	O
in	O
a	O
concentration-dependent	O
manner	O
,	O
being	O
half-maximal	O
at	O
approximately	O
0	O
x	O
00	O
(	O
-0	O
)	O
m	O
.	O

inhibition	O
of	O
pa	O
in	O
both	O
cell	O
types	O
is	O
specific	O
for	O
active	O
glucocorticoids	O
,	O
and	O
this	O
specificity	O
parallels	O
the	O
ability	O
of	O
various	O
steroids	O
to	O
bind	O
to	O
glucocorticoid	B-protein
receptors	I-protein
.	O

hmy0	O
cell	O
pa	O
is	O
fully	O
suppressible	O
by	O
dex	O
,	O
whereas	O
up	O
to	O
one	O
third	O
of	O
the	O
activator	O
expressed	O
by	O
gm0000a	B-cell_type
cells	I-cell_type
is	O
resistant	O
to	O
glucocorticoid	O
inhibition	O
.	O

mixing	O
experiments	O
using	O
a	O
uk	O
standard	O
and	O
conditioned	O
media	O
from	O
dex-treated	B-cell_type
cells	I-cell_type
suggest	O
an	O
absence	O
of	O
glucocorticoid-inducible	O
inhibitors	O
to	O
uk	O
or	O
plasmin	O
in	O
both	O
cell	O
types	O
.	O

however	O
,	O
conditioned	O
media	O
from	O
dex-treated	B-cell_type
gm0000a	I-cell_type
cells	I-cell_type
inhibits	O
a	O
portion	O
of	O
the	O
homologous	O
cellular	O
activator	O
in	O
conditioned	O
media	O
from	O
control	B-cell_line
gm0000a	I-cell_line
cells	I-cell_line
.	O

thus	O
,	O
low	O
levels	O
of	O
glucocorticoid-inducible	O
inhibitors	O
may	O
contribute	O
to	O
,	O
but	O
can	O
not	O
fully	O
account	O
for	O
,	O
dex	O
inhibition	O
of	O
gm0000a	O
pa	O
activity	O
.	O

glucocorticoid-inducible	O
inhibitors	O
in	O
hmy0	B-cell_type
cells	I-cell_type
are	O
either	O
totally	O
absent	O
or	O
are	O
present	O
at	O
undetectable	O
levels	O
.	O

thus	O
,	O
regulation	O
of	O
uk-like	O
pas	O
in	O
hmy0	B-cell_type
and	I-cell_type
gm0000a	I-cell_type
cells	I-cell_type
differs	O
with	O
respect	O
to	O
the	O
extent	O
to	O
which	O
glucocorticoids	O
inhibit	O
constitutively	O
expressed	O
activator	O
levels	O
,	O
as	O
well	O
as	O
the	O
possible	O
contribution	O
of	O
glucocorticoid-inducible	O
inhibitors	O
to	O
the	O
regulatory	O
process	O
in	O
gm0000a	B-cell_type
cells	I-cell_type
.	O

###MEDLINE:85146267

characterization	O
of	O
aldosterone	O
binding	O
sites	O
in	O
circulating	B-cell_type
human	I-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
.	O

aldosterone	O
binding	O
sites	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
were	O
characterized	O
after	O
separation	O
of	O
cells	O
from	O
blood	O
by	O
a	O
percoll	O
gradient	O
.	O

after	O
washing	O
and	O
resuspension	O
in	O
rpmi-0000	O
medium	O
,	O
cells	O
were	O
incubated	O
at	O
00	O
degrees	O
c	O
for	O
0	O
h	O
with	O
different	O
concentrations	O
of	O
[	O
0h	O
]	O
aldosterone	O
plus	O
a	O
000-fold	O
concentration	O
of	O
ru-00000	O
(	O
00	B-protein
alpha	I-protein
,	O
00	O
alpha-dihydroxy-00	O
beta-propynylandrost-0	O
,	O
0	O
,	O
0-trien-0-one	B-protein
)	O
,	O
with	O
or	O
without	O
an	O
excess	O
of	O
unlabeled	O
aldosterone	O
.	O

aldosterone	O
binds	O
to	O
a	O
single	B-protein
class	I-protein
of	I-protein
receptors	I-protein
with	O
an	O
affinity	O
of	O
0.0	O
+/-	O
0.0	O
nm	O
(	O
means	O
+/-	O
sd	O
,	O
n	O
=	O
00	O
)	O
and	O
a	O
capacity	O
of	O
000	O
+/-	O
000	O
sites/cell	O
(	O
n	O
=	O
00	O
)	O
.	O

the	O
specificity	O
data	O
show	O
a	O
hierarchy	O
of	O
affinity	O
of	O
desoxycorticosterone	O
=	O
corticosterone	O
=	O
aldosterone	O
greater	O
than	O
hydrocortisone	O
greater	O
than	O
dexamethasone	O
.	O

the	O
results	O
indicate	O
that	O
mononuclear	B-cell_type
leukocytes	I-cell_type
could	O
be	O
useful	O
for	O
studying	O
the	O
physiological	O
significance	O
of	O
these	O
mineralocorticoid	B-protein
receptors	I-protein
and	O
their	O
regulation	O
in	O
humans	O
.	O

###MEDLINE:86028039

mineralocorticoid	O
and	O
glucocorticoid	B-protein
receptors	I-protein
in	O
circulating	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
of	O
patients	O
with	O
primary	O
hyperaldosteronism	O
.	O

mineralocorticoid	O
and	O
glucocorticoid	B-protein
receptors	I-protein
were	O
measured	O
in	O
circulating	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
in	O
0	O
patients	O
affected	O
by	O
conn	O
's	O
syndrome	O
(	O
0	O
cases	O
of	O
bilateral	O
adrenal	O
hyperplasia	O
and	O
0	O
cases	O
of	O
adenoma	O
plus	O
unilateral	O
hyperplasia	O
)	O
.	O

the	O
number	O
of	O
the	O
binding	B-DNA
sites	I-DNA
per	O
cell	O
resulted	O
significantly	O
lower	O
(	O
000	O
+/-	O
000	O
,	O
mean	O
+/-	O
sd	O
)	O
,	O
as	O
compared	O
with	O
the	O
normal	O
controls	O
(	O
000	O
+/-	O
000	O
)	O
.	O

the	O
affinity	O
of	O
aldosterone	O
for	O
the	O
receptor	O
was	O
found	O
to	O
be	O
not	O
different	O
than	O
that	O
of	O
healthy	O
control	O
subjects	O
.	O

the	O
capacity	O
and	O
the	O
affinity	O
of	O
dexamethasone	O
for	O
glucocorticoid	B-protein
receptors	I-protein
ranged	O
in	O
the	O
normal	O
values	O
.	O

these	O
data	O
suggest	O
a	O
possible	O
down-regulation	O
of	O
mineralocorticoid	B-protein
receptors	I-protein
in	O
humans	O
.	O

###MEDLINE:84306548

short-term	O
and	O
long-term	O
effects	O
of	O
estrogen	O
on	O
lymphoid	O
tissues	O
and	O
lymphoid	B-cell_type
cells	I-cell_type
with	O
some	O
remarks	O
on	O
the	O
significance	O
for	O
carcinogenesis	O
.	O

estrogens	O
have	O
long	O
been	O
thought	O
to	O
play	O
a	O
role	O
in	O
regulating	O
the	O
immune	O
system	O
.	O

the	O
difference	O
in	O
some	O
types	O
of	O
immune	O
responses	O
between	O
males	O
and	O
females	O
is	O
well-known	O
,	O
as	O
is	O
the	O
pronounced	O
thymic	O
involution	O
induced	O
by	O
exogenous	O
estrogens	O
.	O

estrogens	O
stimulate	O
some	O
aspects	O
of	O
macrophage	O
activity	O
and	O
,	O
depending	O
on	O
dose	O
and	O
mitogen	B-protein
,	O
inhibit	O
or	O
stimulate	O
lymphocyte	O
proliferative	O
response	O
in	O
vitro	O
.	O

another	O
example	O
is	O
the	O
estrogen	O
effect	O
on	O
the	O
delayed	O
type	O
hypersensitivity	O
response	O
.	O

a	O
broad	O
review	O
is	O
given	O
of	O
such	O
estrogen	O
effects	O
on	O
lymphoid	B-cell_type
tissue	I-cell_type
and	O
immune	O
response	O
.	O

most	O
of	O
the	O
studies	O
published	O
so	O
far	O
are	O
phenomenological	O
.	O

however	O
,	O
the	O
recent	O
description	O
of	O
estrogen	B-protein
receptors	I-protein
in	O
the	O
thymus	O
and	O
in	O
some	O
lymphocyte	O
subpopulations	O
,	O
as	O
well	O
as	O
a	O
deeper	O
understanding	O
of	O
regulating	O
factors	O
in	O
the	O
immune	O
system	O
,	O
open	O
the	O
possibility	O
of	O
a	O
more	O
detailed	O
understanding	O
of	O
the	O
estrogen	O
mechanism	O
of	O
interference	O
.	O

estrogen	O
effects	O
in	O
adults	O
are	O
reversible	O
.	O

after	O
treating	O
neonatal	O
mice	O
with	O
the	O
synthetic	O
estrogen	O
diethylstilbestrol	O
(	O
des	O
)	O
,	O
disturbances	O
are	O
induced	O
in	O
lymphocyte	B-cell_type
populations	I-cell_type
and	O
lymphocyte	O
functions	O
which	O
are	O
permanent	O
and	O
irreversible	O
.	O

lymphocytes	B-cell_type
from	O
adult	O
,	O
neonatally	O
des-treated	O
female	O
mice	O
have	O
a	O
reduced	O
mitogen	B-protein
response	O
to	O
cona	B-protein
and	O
lps	O
(	O
t	B-protein
and	I-protein
b	I-protein
cell	I-protein
mitogen	I-protein
)	O
and	O
the	O
delayed	O
type	O
hypersensitivity	O
response	O
is	O
depressed	O
.	O

a	O
detailed	O
analysis	O
demonstrated	O
a	O
decreased	O
t	B-cell_type
helper	I-cell_type
cell	I-cell_type
population	I-cell_type
.	O

the	O
activity	O
of	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
is	O
permanently	O
reduced	O
and	O
this	O
functional	O
impairment	O
is	O
related	O
to	O
a	O
decreased	O
number	O
of	O
these	O
cells	O
,	O
in	O
turn	O
determined	O
at	O
the	O
bone	O
marrow	O
level	O
.	O

the	O
same	O
animals	O
have	O
an	O
increased	O
sensitivity	O
to	O
chemical	O
carcinogens	O
(	O
methylcholanthrene	B-cell_type
)	O
and	O
they	O
spontaneously	O
develop	O
epithelial	O
changes	O
in	O
the	O
uterine	O
cervix	O
which	O
morphologically	O
are	O
similar	O
to	O
adenocarcinoma	O
.	O

the	O
association	O
between	O
estrogen-associated	O
malignancy	O
and	O
estrogen	O
effects	O
in	O
lymphocyte	O
functions	O
deserves	O
further	O
study	O
.	O

###MEDLINE:85104095

drugs	O
affecting	O
the	O
hormonal	O
receptors	O
of	O
normal	O
and	O
leukaemic	B-cell_type
peripheral	I-cell_type
leucocytes	I-cell_type
.	O

the	O
authors	O
investigated	O
the	O
behaviour	O
of	O
steroid	O
hormone	O
uptake	O
in	O
leukaemic	B-cell_type
cells	I-cell_type
(	O
cml	O
,	O
cll	O
,	O
aml	O
,	O
all	O
)	O
,	O
in	O
basal	O
conditions	O
and	O
after	O
incubation	O
with	O
drugs	O
which	O
modify	O
the	O
cellular	O
concentration	O
of	O
camp	O
,	O
pge	O
and	O
pgf	O
.	O

the	O
results	O
demonstrated	O
the	O
presence	O
in	O
leukaemic	B-cell_type
cells	I-cell_type
of	O
an	O
alteration	O
in	O
the	O
incorporation	O
of	O
steroid	O
hormones	O
.	O

this	O
alteration	O
was	O
scarcely	O
modified	O
by	O
incubation	O
with	O
theophylline	O
,	O
which	O
increases	O
cellular	O
concentration	O
of	O
camp	O
.	O

on	O
the	O
other	O
hand	O
,	O
it	O
was	O
moderately	O
counteracted	O
by	O
thioproline	B-protein
and	O
was	O
evidently	O
inhibited	O
by	O
flurbiprofen	O
,	O
which	O
also	O
reduced	O
cellular	O
concentrations	O
of	O
prostaglandins	B-protein
,	O
particularly	O
pge0	B-protein
,	O
with	O
the	O
exception	O
of	O
pgf0	B-protein
which	O
showed	O
a	O
poor	O
response	O
.	O

differences	O
were	O
observed	O
in	O
the	O
behavior	O
of	O
hormonal	O
uptake	O
of	O
cml	O
,	O
in	O
contrast	O
to	O
that	O
of	O
aml	O
,	O
cll	B-cell_line
and	O
all	O
peripheral	B-cell_type
leucocytes	I-cell_type
.	O

###MEDLINE:83295933

human	O
breast	O
cancer	O
and	O
impaired	O
nk	O
cell	O
function	O
.	O

recent	O
advances	O
in	O
tumor	O
immunology	O
have	O
led	O
to	O
the	O
discovery	O
of	O
a	O
new	O
lymphoid	O
cell	O
with	O
unique	O
antitumor	O
activity	O
.	O

natural	B-cell_type
killer	I-cell_type
(	I-cell_type
nk	I-cell_type
)	I-cell_type
cells	I-cell_type
form	O
an	O
antitumor	O
surveillance	O
system	O
and	O
appear	O
to	O
be	O
vital	O
in	O
preventing	O
tumor	O
growth	O
and	O
metastasis	O
in	O
animal	O
models	O
.	O

we	O
studied	O
nk	O
activity	O
in	O
patients	O
with	O
benign	O
and	O
malignant	O
breast	O
disease	O
,	O
using	O
a	O
chromium-00	O
release	O
microtiter	O
cytotoxicity	O
assay	O
with	O
k000	B-cell_line
cells	I-cell_line
as	O
targets	O
.	O

compared	O
with	O
benign	O
controls	O
,	O
patients	O
with	O
malignancies	O
had	O
significantly	O
depressed	O
nk	O
-mediated	O
lysis	O
(	O
p	O
less	O
than	O
0.00	O
)	O
.	O

furthermore	O
,	O
lysis	O
in	O
those	O
with	O
advanced	O
disease	O
(	O
stages	O
ii	O
,	O
iii	B-cell_line
,	O
and	O
iv	O
)	O
was	O
significantly	O
less	O
than	O
in	O
those	O
with	O
limited	O
disease	O
(	O
stage	O
i	O
)	O
(	O
p	O
less	O
than	O
0.00	O
)	O
.	O

nk	O
activity	O
was	O
not	O
correlated	O
to	O
estrogen	O
or	O
progesterone	B-protein
receptor	I-protein
states	O
.	O

positive	O
correlation	O
of	O
a	O
depressed	O
natural	O
killer	O
activity	O
with	O
the	O
extent	O
of	O
tumor	O
spread	O
supports	O
the	O
concept	O
of	O
an	O
nk	O
cell	O
immune	O
surveillance	O
system	O
in	O
breast	O
cancer	O
and	O
emphasizes	O
its	O
importance	O
in	O
this	O
malignancy	O
.	O

###MEDLINE:83188841

immunosuppressive	O
effect	O
of	O
serum	O
progesterone	O
during	O
pregnancy	O
depends	O
on	O
the	O
progesterone	O
binding	O
capacity	O
of	O
the	O
lymphocytes	B-cell_type
.	O

cytotoxic	O
activity	O
and	O
progesterone	O
binding	O
capacity	O
of	O
the	O
lymphocytes	B-cell_type
,	O
together	O
with	O
serum	O
progesterone	O
concentrations	O
,	O
were	O
determined	O
in	O
women	O
with	O
normal	O
pregnancy	O
or	O
with	O
a	O
clinical	O
diagnosis	O
of	O
threatened	O
abortion	O
or	O
threatened	O
premature	O
labour	O
.	O

the	O
lymphocytes	O
of	O
women	O
with	O
threatened	O
abortion	O
or	O
threatened	O
premature	O
labour	O
showed	O
significantly	O
higher	O
cytotoxic	O
activity	O
(	O
p	O
less	O
than	O
0.000	O
)	O
and	O
significantly	O
lower	O
progesterone	O
binding	O
capacity	O
(	O
p	O
less	O
than	O
0.000	O
)	O
than	O
did	O
lymphocytes	B-cell_type
obtained	O
from	O
the	O
healthy	O
pregnant	O
women	O
.	O

significant	O
inverse	O
correlation	O
was	O
found	O
between	O
progesterone	O
binding	O
capacity	O
and	O
cytotoxic	O
activity	O
of	O
the	O
lymphocytes	O
(	O
p	O
less	O
than	O
0.000	O
)	O
,	O
but	O
the	O
progesterone	O
concentration	O
of	O
the	O
pregnancy	O
serum	O
appeared	O
to	O
have	O
no	O
influence	O
on	O
the	O
other	O
two	O
parameters	O
.	O

the	O
findings	O
indicate	O
that	O
intact	O
progesterone	O
binding	O
capacity	O
of	O
the	O
lymphocytes	B-cell_type
is	O
an	O
essential	O
factor	O
for	O
the	O
manifestation	O
of	O
the	O
blocking	O
effect	O
exerted	O
by	O
pregnancy	O
serum	O
on	O
lymphocyte	O
cytotoxicity	O
in	O
vitro	O
.	O

###MEDLINE:82166484

serum	O
sex	O
steroid	O
and	O
peptide	O
hormone	O
concentrations	O
,	O
and	O
endometrial	O
estrogen	O
and	O
progestin	B-protein
receptor	I-protein
levels	O
during	O
administration	O
of	O
human	B-protein
leukocyte	I-protein
interferon	I-protein
.	O

five	O
normally	O
cycling	O
healthy	O
women	O
were	O
given	O
daily	O
subcutaneous	O
injections	O
of	O
human	B-protein
leukocyte	I-protein
interferon	I-protein
(	O
0	O
x	O
00	O
(	O
0	O
)	O
units/day	O
)	O
from	O
the	O
0rd	O
through	O
00rd	O
day	O
of	O
the	O
menstrual	O
cycle	O
,	O
and	O
serum	O
steroid	O
and	O
peptide	O
hormone	O
concentrations	O
monitored	O
at	O
0-day	O
intervals	O
during	O
the	O
treatment	O
and	O
the	O
preceding	O
control	O
cycle	O
.	O

concentrations	O
of	O
cytosol	O
and	O
nuclear	B-protein
estrogen	I-protein
receptors	I-protein
(	O
erc	O
and	O
ern	B-protein
,	O
respectively	O
)	O
and	O
progestin	B-protein
receptors	I-protein
(	O
prc	O
and	O
prn	B-protein
)	O
were	O
also	O
measured	O
from	O
endometrial	O
biopsies	O
taken	O
on	O
the	O
00th	O
day	O
of	O
the	O
control	O
and	O
treatment	O
cycle	O
.	O

in	O
addition	O
,	O
an	O
extensive	O
monitoring	O
of	O
clinical	O
chemical	O
and	O
hematological	O
tests	O
from	O
the	O
blood	O
samples	O
were	O
performed	O
.	O

serum	O
estradiol	O
and	O
progesterone	O
concentrations	O
were	O
significantly	O
decreased	O
during	O
the	O
treatment	O
cycle	O
,	O
suggesting	O
that	O
interferon	B-protein
interacts	O
in	O
vivo	O
with	O
the	O
function	O
of	O
both	O
fsh	O
and	O
lh	O
.	O

no	O
significant	O
changes	O
were	O
observed	O
in	O
the	O
serum	O
peptide	O
hormone	O
concentrations	O
measured	O
(	O
fsh	O
,	O
lh	O
,	O
prolactin	B-protein
,	O
insulin	B-protein
,	O
growth	O
hormone	O
and	O
tsh	O
)	O
;	O
neither	O
were	O
the	O
levels	O
of	O
endometrial	O
erc	O
,	O
ern	B-protein
,	O
prc	O
and	O
prn	O
affected	O
by	O
interferon	B-protein
administration	O
.	O

as	O
expected	O
,	O
interferon	B-protein
administration	O
resulted	O
in	O
decreased	O
leukocyte	O
counts	O
.	O

moreover	O
,	O
an	O
increasing	O
tendency	O
in	O
the	O
activities	O
of	O
serum	B-protein
alkaline	I-protein
phosphatase	I-protein
and	O
gamma-glutamyltransferase	O
during	O
the	O
interferon	O
therapy	O
shows	O
that	O
interferon	B-protein
may	O
slightly	O
interfere	O
with	O
the	O
liver	O
function	O
.	O

these	O
results	O
suggest	O
that	O
one	O
of	O
the	O
mechanisms	O
by	O
which	O
interferon	B-protein
treatment	O
may	O
affect	O
the	O
growth	O
of	O
hormone-dependent	O
neoplasms	O
could	O
be	O
the	O
interaction	O
with	O
production	O
and/or	O
function	O
of	O
circulating	O
hormonal	O
compounds	O
.	O

###MEDLINE:82086319

[	O
glucocorticoid	B-protein
receptor	I-protein
level	O
in	O
the	O
blood	B-cell_type
leukocytes	I-cell_type
in	O
different	O
acute	O
diseases	O
]	O

content	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
cytosol	O
of	O
blood	B-cell_type
leukocytes	I-cell_type
,	O
concentration	O
of	O
cortisol	O
and	O
amount	O
of	O
leukocytes	B-cell_type
in	O
blood	O
were	O
studied	O
in	O
00	O
patients	O
with	O
acute	O
impairments	O
within	O
the	O
second	O
day	O
of	O
the	O
disease	O
.	O

content	O
of	O
receptors	O
in	O
cytosol	O
of	O
blood	B-cell_type
leukocytes	I-cell_type
was	O
studied	O
using	O
0h-triamcinolone	O
acetonide	O
.	O

distinct	O
increase	O
in	O
amount	O
of	O
the	O
leukocyte	B-protein
glucocorticoid	I-protein
receptors	I-protein
was	O
found	O
in	O
patients	O
with	O
poisoning	O
by	O
dichlorethane	B-protein
and	O
hypnotic	O
drugs	O
under	O
conditions	O
of	O
acute	O
myocardial	O
infarction	O
.	O

in	O
acute	O
pancreatitis	O
content	O
of	O
the	O
leukocyte	B-protein
receptors	I-protein
was	O
not	O
altered	O
as	O
compared	O
with	O
controls	O
.	O

concentration	O
of	O
endogenous	O
cortisol	O
was	O
increased	O
in	O
blood	O
of	O
all	O
the	O
patients	O
,	O
except	O
of	O
the	O
cases	O
of	O
acetate	O
intoxication	O
.	O

reverse	O
correlation	O
was	O
observed	O
between	O
concentration	O
of	O
cortisol	O
in	O
blood	O
and	O
content	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
leukocytes	B-cell_type
.	O

but	O
in	O
the	O
patients	O
with	O
acute	O
pancreatitis	O
the	O
decrease	O
in	O
content	O
of	O
leukocyte	B-protein
glucocorticoid	I-protein
receptors	I-protein
was	O
not	O
observed	O
although	O
there	O
was	O
an	O
increase	O
in	O
cortisol	O
concentration	O
in	O
blood	O
.	O

the	O
role	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
immunological	O
processes	O
under	O
conditions	O
of	O
purulent	O
complications	O
and	O
possibility	O
to	O
regulate	O
the	O
metabolism	O
in	O
leukocytes	B-cell_type

###MEDLINE:86034627

therapeutic	O
concentrations	O
of	O
glucocorticoids	O
suppress	O
the	O
antimicrobial	O
activity	O
of	O
human	B-cell_type
macrophages	I-cell_type
without	O
impairing	O
their	O
responsiveness	O
to	O
gamma	B-protein
interferon	I-protein
.	O

by	O
exposing	O
human	B-cell_type
blood-derived	I-cell_type
macrophages	I-cell_type
and	O
alveolar	B-cell_type
macrophages	I-cell_type
in	O
vitro	O
to	O
dexamethasone	O
,	O
we	O
showed	O
in	O
these	O
studies	O
that	O
glucocorticoids	O
markedly	O
suppress	O
the	O
antimicrobial	O
activity	O
of	O
macrophages	B-cell_type
but	O
not	O
macrophage	O
activation	O
by	O
lymphokines	B-protein
.	O

as	O
little	O
as	O
0.0	O
x	O
00	O
(	O
-0	O
)	O
mol/liter	O
of	O
dexamethasone	O
prevented	O
macrophages	B-cell_type
from	O
inhibiting	O
germination	O
of	O
aspergillus	O
spores	O
or	O
from	O
eliminating	O
ingested	O
bacteria	O
such	O
as	O
listeria	O
,	O
nocardia	O
,	O
or	O
salmonella	O
.	O

damage	O
to	O
macrophage	O
function	O
was	O
inhibited	O
by	O
progesterone	O
and	O
appeared	O
to	O
be	O
receptor-mediated	O
.	O

in	O
accordance	O
with	O
in	O
vivo	O
observations	O
,	O
dexamethasone	O
required	O
00-00	O
h	O
to	O
suppress	O
antimicrobial	O
activity	O
.	O

while	O
glucocorticoids	O
interfered	O
with	O
base-line	O
activity	O
of	O
macrophages	B-cell_type
,	O
dexamethasone	O
concentrations	O
comparable	O
to	O
drug	O
levels	O
in	O
patients	O
had	O
no	O
effect	O
on	O
macrophage	O
activation	O
.	O

proliferating	B-cell_type
lymphocytes	I-cell_type
and	O
gamma-interferon	B-protein
thus	O
increased	O
the	O
antimicrobial	O
activity	O
of	O
phagocytes	B-cell_type
exposed	O
to	O
glucocorticoids	O
over	O
that	O
of	O
control	B-cell_type
cells	I-cell_type
.	O

macrophage	O
activation	O
and	O
correction	O
of	O
the	O
dexamethasone	O
effect	O
by	O
gamma-interferon	B-protein
,	O
however	O
,	O
was	O
dependent	O
on	O
the	O
pathogen	O
.	O

the	O
lymphokine	B-protein
enhanced	O
the	O
antimicrobial	O
activity	O
of	O
dexamethasone-treated	B-cell_type
macrophages	I-cell_type
against	O
listeria	O
and	O
salmonella	O
but	O
not	O
against	O
aspergillus	O
or	O
nocardia	O
.	O

dexamethasone-induced	O
damage	O
to	O
the	O
antimicrobial	O
activity	O
of	O
human	B-cell_type
macrophages	I-cell_type
in	O
vitro	O
parallels	O
observations	O
that	O
glucocorticoids	O
render	O
laboratory	O
animals	O
susceptible	O
to	O
listeriosis	O
and	O
aspergillosis	O
by	O
damaging	O
resident	B-cell_type
macrophages	I-cell_type
.	O

suppression	O
of	O
macrophage	O
antimicrobial	O
activity	O
should	O
thus	O
be	O
considered	O
when	O
treating	O
patients	O
with	O
glucocorticoids	O
;	O
its	O
prevention	O
by	O
gamma-interferon	B-protein
might	O
be	O
beneficial	O
for	O
some	O
but	O
not	O
all	O
pathogens	O
.	O

###MEDLINE:85254470

interleukin	B-protein
0	I-protein
receptor	I-protein
(	O
tac	B-protein
antigen	O
)	O
expression	O
in	O
htlv-i-associated	O
adult	O
t-cell	O
leukemia	O
.	O

interleukin-0	B-protein
(	O
il-0	B-protein
)	O
is	O
a	O
lymphokine	B-protein
synthesized	O
by	O
some	O
t-cells	O
following	O
activation	O
.	O

resting	B-cell_type
t-cells	I-cell_type
do	O
not	O
express	O
il-0	B-protein
receptors	I-protein
,	O
but	O
receptors	O
are	O
rapidly	O
expressed	O
on	O
t-cells	B-cell_type
following	O
interaction	O
of	O
antigens	B-protein
,	O
mitogens	B-protein
,	O
or	O
monoclonal	B-protein
antibodies	I-protein
with	O
the	O
antigen-specific	B-protein
t-cell	I-protein
receptor	I-protein
complex	I-protein
.	O

using	O
anti-tac	O
,	O
a	O
monoclonal	B-protein
antibody	I-protein
that	O
recognizes	O
the	O
il-0	B-protein
receptor	I-protein
,	O
the	O
receptor	O
has	O
been	O
purified	O
and	O
shown	O
to	O
be	O
a	O
mr	O
00	O
,	O
000	O
peptide	O
that	O
is	O
posttranslationally	O
glycosylated	O
to	O
a	O
mr	O
00	O
,	O
000	O
mature	O
form	O
.	O

normal	O
resting	B-cell_type
t-cells	I-cell_type
and	O
most	O
leukemic	B-cell_line
t-cell	I-cell_line
populations	I-cell_line
do	O
not	O
express	O
il-0	B-protein
receptors	I-protein
;	O
however	O
,	O
the	O
leukemic	B-cell_type
cells	I-cell_type
of	O
the	O
00	O
patients	O
examined	O
who	O
had	O
human	O
t-cell	O
lymphotropic	O
virus-associated	O
adult	O
t-cell	O
leukemia	O
expressed	O
the	O
tac	B-protein
antigen	I-protein
.	O

in	O
human	O
t-cell	O
lymphotropic	O
virus-i	O
infected	B-cell_type
cells	I-cell_type
,	O
the	O
mr	O
00	O
,	O
000	O
long	B-DNA
open	I-DNA
reading	I-DNA
frame	I-DNA
protein	O
encoded	O
in	O
part	O
by	O
the	O
px	B-DNA
region	I-DNA
of	O
this	O
virus	O
may	O
act	O
as	O
a	B-protein
transacting	I-protein
transcriptional	I-protein
activator	I-protein
that	O
induces	O
il-0	B-DNA
receptor	I-DNA
gene	I-DNA
transcription	O
,	O
thus	O
providing	O
an	O
explanation	O
for	O
the	O
constant	O
association	O
of	O
il-0	B-protein
receptor	I-protein
expression	O
with	O
adult	O
t-cell	O
lymphotropic	O
virus-i	O
infection	O
of	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

the	O
constant	O
expression	O
of	O
large	O
numbers	O
of	O
il-0	B-protein
receptors	I-protein
which	O
may	O
be	O
aberrant	O
may	O
play	O
a	O
role	O
in	O
the	O
uncontrolled	O
growth	O
of	O
adult	B-cell_line
t-cell	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
.	O

two	O
patients	O
with	O
tac-positive	O
adult	O
t-cell	O
leukemia	O
have	O
been	O
treated	O
with	O
the	O
anti-tac	O
.	O

one	O
of	O
the	O
patients	O
had	O
0-	O
and	O
0-mo	O
remissions	O
of	O
his	O
leukemia	O
following	O
two	O
courses	O
of	O
therapy	O
with	O
this	O
monoclonal	B-protein
antibody	I-protein
directed	O
toward	O
this	O
growth	B-protein
factor	I-protein
receptor	I-protein
.	O

###MEDLINE:86121439

lymphocyte	B-protein
glucocorticoid	I-protein
receptor	I-protein
binding	O
in	O
depressed	O
patients	O
with	O
hypercortisolemia	O
.	O

despite	O
elevated	O
levels	O
of	O
serum	O
and	O
urinary	O
cortisol	O
,	O
patients	O
with	O
depressive	O
illness	O
manifest	O
none	O
of	O
the	O
clinical	O
stigmata	O
of	O
glucocorticoid	O
excess	O
.	O

this	O
hypercortisolemia	O
in	O
the	O
absence	O
of	O
clinical	O
effects	O
suggests	O
a	O
state	O
of	O
hormone	O
resistance	O
and	O
could	O
be	O
mediated	O
by	O
alterations	O
in	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O

earlier	O
studies	O
have	O
shown	O
that	O
small	O
doses	O
of	O
glucocorticoids	O
cause	O
a	O
decrease	O
in	O
glucocorticoid	B-protein
receptor	I-protein
binding	O
in	O
normal	B-cell_type
human	I-cell_type
lymphocytes	I-cell_type
.	O

white	B-cell_type
cells	I-cell_type
from	O
depressed	O
patients	O
with	O
significant	O
hypercortisolemia	O
would	O
be	O
expected	O
to	O
show	O
a	O
similar	O
change	O
in	O
receptor	O
concentration	O
if	O
peripheral	O
tissues	O
are	O
adequately	O
exposed	O
to	O
and	O
sensitive	O
to	O
the	O
hormone	O
.	O

in	O
this	O
study	O
we	O
compared	O
the	O
binding	O
of	O
[	O
0h	O
]	O
dexamethasone	O
to	O
lymphocytes	B-cell_type
from	O
normal	O
subjects	O
and	O
depressed	O
patients	O
with	O
hypercortisolemia	O
.	O

lymphocytes	B-cell_type
from	O
normal	O
subjects	O
had	O
a	O
mean	O
receptor	O
concentration	O
of	O
00.0	O
+/-	O
0.00	O
fm/00	O
(	O
0	O
)	O
cells	O
(	O
s.e.m.	B-protein
)	O
and	O
a	O
dissociation	O
constant	O
of	O
0.0	O
+/-	O
0.00	O
nm	O
.	O

lymphocytes	B-cell_type
from	O
depressed	O
patients	O
with	O
abnormal	O
0000	O
h	O
serum	O
cortisol	O
after	O
dexamethasone	O
had	O
a	O
mean	O
receptor	O
concentration	O
of	O
0.0	O
+/-	O
0.00	O
fm/00	O
(	O
0	O
)	O
cells	O
,	O
which	O
was	O
not	O
significantly	O
different	O
from	O
that	O
in	O
lymphocytes	B-cell_type
from	O
normal	O
subjects	O
or	O
from	O
depressed	O
subjects	O
with	O
normal	O
post-dexamethasone	O
cortisol	O
levels	O
(	O
0.0	O
+/-	O
0.00	O
fm/00	O
(	O
0	O
)	O
cells	O
)	O
.	O

lymphocytes	B-cell_type
from	O
depressed	O
patients	O
with	O
elevated	O
urinary	O
free	O
cortisol	O
excretion	O
(	O
ufc	B-protein
)	O
also	O
had	O
normal	O
receptor	O
concentration	O
and	O
binding	O
affinity	O
for	O
dexamethasone	O
.	O

the	O
lack	O
of	O
a	O
change	O
in	O
lymphocyte	B-protein
glucocorticoid	I-protein
receptor	I-protein
concentration	O
in	O
the	O
presence	O
of	O
cortisol	O
excess	O
suggests	O
the	O
possibility	O
that	O
hypercortisolemia	O
in	O
depressive	O
illness	O
represents	O
a	O
state	O
of	O
peripheral	O
glucocorticoid	O
resistance	O
.	O

###MEDLINE:85102467

structure	O
and	O
regulation	O
of	O
the	O
glucocorticoid	B-protein
hormone	I-protein
receptor	I-protein
.	O

the	O
glucocorticoid	B-protein
receptor	I-protein
is	O
an	O
intracellular	B-protein
protein	I-protein
which	O
possesses	O
three	O
distinct	O
domains	O
,	O
one	O
that	O
binds	O
agonist	O
and	O
antagonist	O
steroids	O
,	O
one	O
that	O
binds	O
dna	O
,	O
and	O
one	O
that	O
binds	O
anti-receptor	B-protein
antibodies	I-protein
and	O
is	O
required	O
for	O
glucocorticoid	O
modulation	O
of	O
gene	O
expression	O
.	O

in	O
intact	B-cell_type
cells	I-cell_type
,	O
receptor	O
number	O
,	O
affinity	O
and	O
activity	O
can	O
change	O
in	O
response	O
to	O
factors	O
that	O
bind	O
to	O
the	O
receptor	O
,	O
or	O
that	O
act	O
indirectly	O
through	O
ill-defined	O
mechanisms	O
which	O
may	O
include	O
resumption	O
or	O
arrest	O
of	O
cell	O
cycling	O
and	O
variations	O
in	O
intracellular	O
calcium	O
ion	O
concentrations	O
.	O

some	O
of	O
these	O
factors	O
appear	O
to	O
exert	O
their	O
effect	O
by	O
controlling	O
critical	O
receptor	O
properties	O
such	O
as	O
atp-dependent	O
phosphorylation	O
,	O
integrity	O
of	O
thiol	O
groups	O
,	O
and	O
exposure	O
of	O
key	B-protein
amino	I-protein
acid	I-protein
residues	I-protein
.	O

glucocorticoid	O
agonists	O
promote	O
the	O
'transformation	B-DNA
'	I-DNA
of	O
the	O
receptor	O
into	O
the	O
dna-binding	O
state	O
,	O
which	O
is	O
competent	O
for	O
modulating	O
gene	O
expression	O
.	O

glucocorticoid	O
antagonists	O
are	O
steroids	O
that	O
interact	O
with	O
the	O
receptor	O
but	O
either	O
fail	O
to	O
produce	O
a	O
stable	O
complex	O
or	O
produce	O
a	O
stable	O
but	O
inefficient	O
complex	O
.	O

although	O
substituent	O
groups	O
that	O
confer	O
agonist	O
or	O
antagonist	O
activity	O
to	O
the	O
steroid	O
have	O
been	O
identified	O
,	O
the	O
molecular	O
determinants	O
of	O
this	O
difference	O
at	O
the	O
receptor	O
level	O
remain	O
unknown	O
.	O

most	O
in	O
vitro	O
and	O
in	O
vivo	O
data	O
on	O
receptor	O
regulation	O
can	O
be	O
accommodated	O
by	O
postulating	O
the	O
existence	O
of	O
an	O
intracellular	O
cycle	O
that	O
involves	O
five	O
states	O
of	O
the	O
receptor	O
.	O

the	O
active	O
free	O
receptor	O
is	O
phosphorylated	O
,	O
reduced	O
,	O
and	O
presumably	O
oligomeric	O
(	O
state	O
a	O
)	O
.	O

following	O
binding	O
of	O
an	O
agonist	O
(	O
state	O
b	O
)	O
,	O
it	O
can	O
become	O
transformed	O
by	O
dissociation	O
into	O
its	O
subunits	O
and	O
dephosphorylation	O
(	O
state	O
c	O
)	O
.	O

the	O
transformed	B-protein
receptor	I-protein
then	O
interacts	O
with	O
chromatin	B-DNA
(	O
state	O
d	O
)	O
.	O

dissociation	O
of	O
the	O
steroid	O
and	O
oxidation	O
of	O
receptor	O
thiol	O
group	O
(	O
s	O
)	O
lead	O
to	O
the	O
inactive	B-protein
receptor	I-protein
form	I-protein
(	O
state	O
e	O
)	O
.	O

reduction	O
and	O
rephosphorylation	O
of	O
the	O
receptor	O
enable	O
it	O
to	O
bind	O
steroids	O
again	O
so	O
that	O
the	O
cycle	O
is	O
closed	O
.	O

###MEDLINE:84178365

thermodynamics	O
of	O
steroid	O
binding	O
to	O
the	O
human	O
glucocorticoid	B-protein
receptor	I-protein
.	O

the	O
thermodynamics	O
of	O
the	O
interaction	O
of	O
glucocorticoids	O
with	O
their	O
receptor	O
were	O
studied	O
in	O
cytosol	O
from	O
human	B-cell_line
lymphoblastoid	I-cell_line
cells	I-cell_line
.	O

the	O
rate	O
and	O
affinity	O
constants	O
of	O
dexamethasone	O
and	O
cortisol	O
between	O
0	O
degree	O
and	O
00	O
degrees	O
c	O
were	O
calculated	O
by	O
curve-fitting	O
from	O
time-course	O
and	O
equilibrium	O
kinetics	O
.	O

the	O
data	O
were	O
consistent	O
with	O
a	O
simple	O
reversible	O
bimolecular	O
interaction	O
.	O

arrhenius	O
and	O
va	O
n't	O
hoff	O
plots	O
were	O
curvilinear	O
for	O
both	O
steroids	O
.	O

at	O
equilibrium	O
,	O
the	O
solution	O
for	O
the	O
equation	B-DNA
delta	I-DNA
g	I-DNA
=	O
delta	B-protein
h	I-protein
-	I-protein
t	I-protein
x	I-protein
delta	I-protein
s	I-protein
(	I-protein
eqn.	I-protein
0	I-protein
)	O
was	O
(	O
in	O
kj	B-DNA
x	I-DNA
mol-0	I-DNA
)	I-DNA
-00	I-DNA
=	O
00	O
-	O
00	O
(	O
dexamethasone	O
)	O
and	O
-00	O
=	O
-0	O
-	O
00	O
(	O
cortisol	O
)	O
at	O
0	O
degree	O
c	O
.	O

enthalpy	O
and	O
entropy	O
changes	O
decreased	O
quasi-linearly	O
with	O
temperature	O
such	O
that	O
,	O
at	O
00	O
degrees	O
c	O
,	O
the	O
respective	O
values	O
were	O
-00	O
=	O
-00	O
+	O
00	O
and	O
-00	O
=	O
-00	B-DNA
+	I-DNA
0	I-DNA
.	O

thus	O
,	O
for	O
both	O
steroids	O
,	O
the	O
interaction	O
was	O
entropy-driven	O
at	O
low	O
temperature	O
and	O
became	O
entirely	O
enthalpy-driven	O
at	O
00	O
degrees	O
c	O
.	O

thermodynamic	O
values	O
for	O
the	O
transition	O
state	O
were	O
calculated	O
from	O
the	O
rate	O
constants	O
.	O

for	O
the	O
forward	O
reaction	O
,	O
eqn.	O
(	O
0	O
)	O
gave	O
00	O
=	O
00	O
-	O
00	O
(	O
dexamethasone	O
)	O
and	O
00	O
=	O
00	O
-	O
00	O
(	O
cortisol	O
)	O
at	O
0	O
degree	O
c	O
,	O
and	O
00	O
=	O
00	O
+	O
00	O
(	O
dexamethasone	O
)	O
and	O
00	O
=	O
00	O
+	O
00	O
(	O
cortisol	O
)	O
at	O
00	O
degrees	O
c	O
.	O

these	O
data	O
fit	O
quite	O
well	O
with	O
a	O
two-step	O
model	O
[	O
ross	B-protein
&	O
subramanian	B-protein
(	O
0000	O
)	O
biochemistry	O
00	O
,	O
0000-0000	O
]	O
proposed	O
for	O
ligand-protein	O
interactions	O
,	O
which	O
involves	O
a	O
partial	O
immobilization	O
of	O
the	O
reacting	O
species	O
governed	O
by	O
hydrophobic	B-protein
forces	I-protein
,	O
followed	O
by	O
stabilization	O
of	O
the	O
complex	O
by	O
short-range	O
interactions	O
.	O

on	O
the	O
basis	O
of	O
this	O
model	O
,	O
an	O
analysis	O
of	O
the	O
transition-state	O
thermodynamics	O
led	O
to	O
the	O
conclusion	O
that	O
no	O
more	O
than	O
half	O
of	O
the	O
steroid	O
molecular	O
area	O
is	O
engaged	O
in	O
the	O
binding	O
process	O
.	O

###MEDLINE:84238528

cell	O
cycle-related	O
changes	O
in	O
number	O
of	O
t-lymphocyte	O
receptors	O
for	O
glucocorticoids	O
and	O
insulin	B-protein
.	O

enriched	O
human	B-cell_type
peripheral	I-cell_type
t-lymphocytes	I-cell_type
were	O
stimulated	O
with	O
pha	B-protein
and	O
examined	O
for	O
variations	O
in	O
insulin	B-protein
and	O
glucocorticoid	O
(	O
dexamethasone	O
)	O
receptor	O
numbers	O
during	O
the	O
early	O
phases	O
of	O
the	O
cell	O
cycle	O
.	O

cells	O
in	O
g0	O
,	O
g0a	B-protein
and	O
g0b	O
phases	O
,	O
where	O
the	O
g0a	B-DNA
-	I-DNA
g0b	I-DNA
transition	O
is	O
an	O
interleukin	B-protein
0	I-protein
dependent	O
event	O
,	O
were	O
quantitated	O
by	O
flow	O
cytometry	O
.	O

few	O
but	O
significant	O
numbers	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
0000/cell	B-protein
)	O
and	O
no	O
insulin	B-protein
receptors	I-protein
(	O
-0/cell	B-protein
)	O
were	O
found	O
in	O
the	O
resting	O
(	O
g0	O
)	O
phase	O
.	O

as	O
cells	O
entered	O
the	O
g0a	O
phase	O
the	O
specific	O
binding	O
of	O
dexamethasone	O
increased	O
and	O
of	O
insulin	B-protein
took	O
place	O
.	O

although	O
the	O
specific	O
binding	O
further	O
increased	O
as	O
t-cells	B-cell_type
entered	O
the	O
g0b	O
phase	O
(	O
as	O
measured	O
at	O
00	O
h	O
of	O
incubation	O
and	O
using	O
hydroxyurea-treated	B-cell_line
cells	I-cell_line
)	O
,	O
the	O
major	O
changes	O
in	O
the	O
specific	O
binding	O
of	O
dexamethasone	O
took	O
place	O
during	O
the	O
period	O
00	O
-	O
00	O
h	O
after	O
stimulation	O
.	O

based	O
on	O
these	O
findings	O
,	O
it	O
is	O
concluded	O
that	O
both	O
receptor	O
types	O
(	O
cell	O
membrane	O
and	O
cytoplasmic	B-protein
receptors	I-protein
)	O
are	O
being	O
formed	O
and	O
increased	O
at	O
g0	O
phase	O
prior	O
to	O
cell	O
proliferation	O
,	O
indicating	O
the	O
importance	O
of	O
g0	O
phase	O
in	O
immunoregulation	O
.	O

###MEDLINE:83291326

glucocorticoid	B-protein
receptors	I-protein
and	O
cortico-sensitivity	O
in	O
a	O
human	B-cell_line
clonal	I-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
cm-sm	O
.	O

cm-sm	B-protein
is	O
a	O
clonal	B-cell_line
line	I-cell_line
of	O
human	B-cell_type
precursor	I-cell_type
mononuclear	I-cell_type
phagocytes	I-cell_type
inducible	O
to	O
macrophage	O
differentiation	O
in	O
response	O
to	O
the	O
tumor	B-DNA
promoter	I-DNA
phorbol	O
ester	O
00-o-tetradecanoyl-phorbol-00-acetate	O
(	O
tpa	O
)	O
.	O

untreated	B-cell_line
cm-sm	I-cell_line
cells	I-cell_line
contain	O
single	O
class	O
,	O
high-affinity	B-protein
(	I-protein
kd	I-protein
=	O
0.0	O
x	B-DNA
00	I-DNA
(	I-DNA
-0	I-DNA
)	I-DNA
m	I-DNA
)	I-DNA
glucocorticoid-specific	I-DNA
receptor	I-DNA
sites	I-DNA
(	O
approximately	O
00	O
,	O
000	O
per	O
cell	O
)	O
,	O
as	O
measured	O
by	O
a	O
whole	O
cell	O
assay	O
,	O
at	O
00	O
degrees	O
c	O
,	O
using	O
[	O
0h	O
]	O
triamcinolone	O
acetonide	O
(	O
ta	O
)	O
.	O

exposure	O
of	O
cm-sm	O
to	O
dexamethasone	O
(	O
dex	O
)	O
produced	O
a	O
progressive	O
,	O
dose-	O
and	O
time-related	O
series	O
of	O
changes	O
in	O
cm-sm	O
cell	O
growth	O
,	O
saturation	O
density	O
,	O
morphology	O
,	O
and	O
functional	O
properties	O
,	O
with	O
half-maximal	O
effects	O
at	O
about	O
00	O
(	O
-0	O
)	O
m	O
for	O
dex	O
.	O

ta-receptor	B-DNA
sites	I-DNA
rapidly	O
decreased	O
(	O
about	O
00	O
%	O
)	O
after	O
dex	O
treatment	O
,	O
without	O
any	O
apparent	O
change	O
in	O
steroid	O
specificity	O
and	O
affinity	O
.	O

after	O
0	O
days	O
in	O
culture	O
with	O
a	O
saturating	O
concentration	O
(	O
0.0	O
x	O
00	O
(	O
-0	O
)	O
m	O
)	O
of	O
hormone	O
,	O
the	O
cells	O
reached	O
a	O
saturation	O
density	O
of	O
about	O
0.0	O
x	O
00	O
(	O
0	O
)	O
viable	O
cells/ml	O
(	O
about	O
0.0	O
x	O
00	O
(	O
0	O
)	O
viable	O
cells/ml	O
in	O
the	O
controls	O
)	O
,	O
while	O
the	O
modal	O
volume	O
of	O
the	O
resulting	O
cell	O
population	O
was	O
approximately	O
00	O
%	O
,	O
as	O
compared	O
to	O
the	O
volume	O
of	O
untreated	B-cell_type
cells	I-cell_type
.	O

dex-treated	B-cell_type
cells	I-cell_type
appeared	O
less	O
differentiated	O
than	O
controls	O
,	O
as	O
assessed	O
by	O
combined	O
morphologic	O
,	O
antigenic	O
,	O
and	O
cytoenzymatic	O
analyses	O
.	O

dex	O
almost	O
completely	O
inhibited	O
tpa	O
activation	O
of	O
the	O
following	O
macrophage	O
functions	O
:	O
adherency	O
to	O
the	O
culture	O
plate	O
,	O
expression	O
of	O
lysosomal	B-protein
enzymes	I-protein
,	O
fc	B-protein
and	I-protein
c0	I-protein
receptors	I-protein
,	O
and	O
stimulation	O
of	O
phagocytosis	O
.	O

after	O
removal	O
of	O
dex	O
,	O
the	O
cells	O
,	O
within	O
a	O
few	O
passages	O
,	O
returned	O
to	O
a	O
state	O
apparently	O
identical	O
to	O
the	O
untreated	O
controls	O
and	O
could	O
be	O
induced	O
to	O
macrophage	O
differentiation	O
in	O
response	O
to	O
tpa	O
.	O

###MEDLINE:85152262

acute	O
lymphoblastic	O
leukemia	O
in	O
children	O
:	O
current	O
status	O
,	O
controversies	O
,	O
and	O
future	O
perspective	O
.	O

disease-free	O
survival	O
(	O
dfs	O
)	O
in	O
childhood	O
all	O
is	O
00	O
%	O
,	O
and	O
survival	O
in	O
good	O
,	O
average	O
,	O
and	O
poor	O
prognostic	O
groups	O
defined	O
by	O
initial	O
wbc	O
and	O
age	O
is	O
00	O
,	O
00	O
,	O
and	O
00	O
%	O
,	O
respectively	O
.	O

additional	O
immunological	O
,	O
morphological	O
,	O
biochemical	O
,	O
cytokinetic	O
,	O
and	O
cytogenetic	O
factors	O
have	O
been	O
identified	O
,	O
illustrating	O
the	O
heterogeneity	O
of	O
all	O
and	O
its	O
derivation	O
from	O
malignant	B-cell_line
clones	I-cell_line
at	O
various	O
stages	O
of	O
differentiation	O
and	O
with	O
varying	O
rates	O
of	O
proliferation	O
.	O

of	O
biologic	O
importance	O
,	O
these	O
factors	O
may	O
refine	O
further	O
the	O
characteristic	O
features	O
of	O
clinically-determined	O
prognostic	O
groups	O
.	O

multivariate	O
analysis	O
of	O
large	O
prospective	O
trials	O
with	O
homogeneous	O
therapy	O
will	O
be	O
required	O
to	O
determine	O
the	O
independent	O
prognostic	O
importance	O
of	O
these	O
factors	O
.	O

current	O
treatment	O
strategies	O
in	O
all	O
include	O
(	O
0	O
)	O
tailoring	O
therapy	O
and	O
its	O
intensity	O
to	O
prognostic	O
groups	O
;	O
(	O
0	O
)	O
multiple-drug	O
combinations	O
in	O
induction	O
;	O
(	O
0	O
)	O
early	O
use	O
of	O
intrathecal	O
(	O
it	O
)	O
methotrexate	O
(	O
mtx	O
)	O
;	O
(	O
0	O
)	O
cns	O
prophylaxis	O
with	O
it	O
mtx	O
alone	O
in	O
good	O
prognosis	O
patients	O
and	O
combined	O
cranial	O
radiation	O
(	O
cxrt	B-protein
)	O
,	O
0000	O
rads	O
plus	O
it	O
mtx	B-protein
,	I-protein
in	O
average	O
and	O
poor	O
prognosis	O
patients	O
.	O

current	O
studies	O
show	O
a	O
cns	O
relapse	O
rate	O
of	O
0	O
%	O
in	O
all	O
prognostic	O
groups	O
.	O

late	O
neuropsychological	O
defects	O
caused	O
by	O
cranial	O
xrt	O
and	O
it	O
mtx	O
have	O
prompted	O
programs	O
designed	O
to	O
reduce	O
the	O
potential	O
late	O
toxicity	O
of	O
cns	O
prophylaxis	O
.	O

more	O
pronounced	O
in	O
younger	O
children	O
,	O
these	O
abnormalities	O
include	O
decreased	O
iq	O
,	O
visual-motor	O
incoordination	O
,	O
poor	O
performance	O
in	O
mathematics	O
,	O
and	O
memory	O
dysfunction	O
.	O

until	O
0000	O
,	O
more	O
intensive	O
induction	O
,	O
consolidation	O
,	O
and	O
maintenance	O
therapy	O
had	O
failed	O
to	O
prolong	O
dfs	O
in	O
children	O
with	O
a	O
poor	O
prognosis	O
.	O

in	O
west	O
germany	O
(	O
berlin-frankfurt-muenster	B-protein
protocol	O
)	O
a	O
00	O
to	O
00	O
%	O
dfs	O
is	O
seen	O
in	O
all	O
patients	O
regardless	O
of	O
initial	O
wbc	O
,	O
suggesting	O
that	O
effective	O
therapy	O
will	O
override	O
prognostic	O
factors	O
.	O

ultra-high-dose	O
mtx	O
,	O
without	O
cranial	O
radiation	O
,	O
is	O
also	O
showing	O
promise	O
in	O
poor	O
prognosis	O
patients	O
.	O

other	O
issues	O
include	O
the	O
optimal	O
duration	O
of	O
therapy	O
,	O
the	O
role	O
of	O
testicular	O
biopsies	O
,	O
and	O
prophylactic	O
testicular	O
radiation	O
.	O

recent	O
studies	O
suggest	O
that	O
prognostic	O
factors	O
lose	O
their	O
significance	O
after	O
0	O
years	O
of	O
continuous	O
complete	O
remission	O
and	O
that	O
0	O
years	O
of	O
maintenance	O
therapy	O
is	O
adequate	O
.	O

bilateral	O
open-wedge	O
testicular	O
biopsies	O
have	O
identified	O
occult	O
testicular	O
disease	O
in	O
0	O
to	O
00	O
%	O
of	O
males	O
.	O

a	O
unified	O
approach	O
to	O
children	O
with	O
leukemia/lymphoma	O
,	O
a	O
group	O
with	O
a	O
particularly	O
poor	O
prognosis	O
,	O
utilizing	O
nhl-type	O
therapy	O
may	O
be	O
more	O
effective	O
than	O
conventional	O
all	O
therapy	O
.	O

(	O
abstract	O
truncated	O
at	O
000	O
words	O
)	O

###MEDLINE:82114943

glucocorticoid	B-protein
receptor	I-protein
and	O
in	O
vitro	O
sensitivity	O
to	O
steroid	O
hormones	O
in	O
human	O
lymphoproliferative	O
diseases	O
and	O
myeloid	O
leukemia	O
.	O

the	O
glucocorticoid	B-protein
receptor	I-protein
(	O
gr	B-protein
)	O
quantitation	O
by	O
a	O
whole-cell	O
assay	O
and/or	O
cytosol	O
technique	O
and	O
the	O
in	O
vitro	O
sensitivity	O
to	O
steroids	O
have	O
been	O
assessed	O
in	O
peripheral	B-cell_type
blood	I-cell_type
cells	I-cell_type
from	O
normal	O
donors	O
and	O
patients	O
with	O
chronic	O
lymphatic	O
leukemia	O
(	O
cll	B-cell_line
)	O
,	O
acute	O
lymphoblastic	O
leukemia	O
(	O
all	O
)	O
,	O
lymphosarcoma	B-cell_line
cell	I-cell_line
leukemia	I-cell_line
(	I-cell_line
lscl	I-cell_line
)	I-cell_line
,	I-cell_line
acute	I-cell_line
nonlymphatic	I-cell_line
leukemia	I-cell_line
(	I-cell_line
anll	I-cell_line
)	I-cell_line
,	O
and	O
chronic	O
myeloid	O
leukemia	O
(	O
cml	O
)	O
.	O

within	O
the	O
lymphoproliferative	O
diseases	O
,	O
all	O
cells	O
exhibited	O
the	O
highest	O
gr	B-protein
concentration	O
(	O
regardless	O
of	O
the	O
method	O
used	O
)	O
and	O
the	O
highest	O
in	O
vitro	O
inhibition	O
of	O
spontaneous	O
[	O
0h	O
]	O
thymidine	O
(	O
[	O
0h	O
]	O
tdr	B-protein
)	O
uptake	O
by	O
glucocorticoids	O
.	O

a	O
significant	O
relationship	O
between	O
gr	B-protein
concentration	O
(	O
whole-cell	O
assay	O
)	O
and	O
in	O
vitro	O
sensitivity	O
to	O
dexamethasone	O
was	O
also	O
found	O
.	O

on	O
the	O
contrary	O
,	O
cll	B-cell_line
cells	I-cell_line
presented	O
the	O
highest	O
sensitivity	O
to	O
glucocorticoids	O
in	O
pha-stimulated	B-cell_line
cell	I-cell_line
cultures	I-cell_line
.	O

cells	O
from	O
the	O
only	O
two	O
all	O
patients	O
who	O
did	O
not	O
undergo	O
a	O
remission	O
after	O
glucocorticoid-inclusive	O
chemotherapy	O
had	O
both	O
the	O
lowest	O
in	O
vitro	O
sensitivity	O
to	O
dexamethasone	O
and	O
the	O
lowest	O
gr	B-protein
concentration	O
with	O
whole-cell	O
assay	O
.	O

concerning	O
myeloid	O
leukemia	O
,	O
anll	O
patients	O
had	O
gr	B-protein
concentrations	O
slightly	O
higher	O
than	O
those	O
found	O
in	O
the	O
all	O
group	O
but	O
exhibited	O
the	O
lowest	O
degree	O
of	O
inhibition	O
of	O
spontaneous	O
[	O
0h	O
]	O
tdr	O
uptake	O
by	O
dexamethasone	O
(	O
stimulatory	O
effects	O
occurred	O
in	O
some	O
cases	O
)	O
.	O

cml	B-cell_type
cells	I-cell_type
exhibited	O
an	O
inhibition	O
degree	O
by	O
in	O
vitro	O
glucocorticoids	O
significantly	O
higher	O
than	O
that	O
of	O
anll	B-cell_type
cells	I-cell_type
but	O
not	O
different	O
from	O
that	O
of	O
lymphoproliferative	O
diseases	O
.	O

no	O
clear	O
relationship	O
among	O
gr	B-protein
pattern	O
,	O
in	O
vitro	O
cell	O
sensitivity	O
to	O
glucocorticoids	O
,	O
and	O
clinicohematologic	O
parameters	O
was	O
observed	O
in	O
myeloid	O
leukemia-bearing	O
patients	O
.	O

###MEDLINE:81265481

glucocorticoid	B-protein
receptors	I-protein
and	O
in	O
vitro	O
corticosensitivity	O
of	O
peanut-positive	B-cell_type
and	I-cell_type
peanut-negative	I-cell_type
human	I-cell_type
thymocyte	I-cell_type
subpopulations	I-cell_type
.	O

in	O
0	O
human	O
thymus	O
glands	O
,	O
the	O
immature	O
subset	O
of	O
thymocytes	B-cell_type
was	O
separated	O
from	O
the	O
more	O
mature	O
one	O
,	O
by	O
differential	O
peanut	B-protein
lectin	I-protein
agglutination	I-protein
.	O

these	O
0	O
cell	O
subpopulations	O
were	O
analyzed	O
for	O
glucocorticoid	B-protein
receptor	I-protein
content	O
by	O
using	O
a	O
whole	O
cell	O
assay	O
,	O
with	O
(	O
0h	O
)	O
-triamcinolone	O
acetonide	O
as	O
tracer	O
.	O

the	O
unagglutinated	B-cell_type
thymocytes	I-cell_type
(	O
peanut	B-protein
negative	I-protein
)	I-protein
contained	O
about	O
0	O
times	O
more	O
receptor	O
sites	O
per	O
cell	O
than	O
agglutinated	B-cell_type
(	I-cell_type
peanut	I-cell_type
positive	I-cell_type
)	I-cell_type
ones	I-cell_type
(	O
0000	O
+/-	O
0000	O
s.d.	O
verus	O
0000	O
+/-	O
000	O
s.d.	O
)	O
.	O

the	O
affinity	O
for	O
steroid	O
was	O
similar	O
in	O
both	O
cell	B-cell_line
subsets	I-cell_line
,	O
as	O
was	O
the	O
stereospecificity	O
for	O
glucocorticoids	O
,	O
the	O
time-course	O
of	O
steroid-receptor	O
association	O
,	O
and	O
cytoplasmic	O
to	O
nuclear	O
translocation	O
.	O

despite	O
the	O
greater	O
number	O
of	O
glucocorticoid	B-protein
receptor	I-protein
sites	I-protein
,	O
the	O
peanut-negative	O
thymocyte	O
subpopulation	O
did	O
not	O
differ	O
from	O
the	O
peanut-positive	O
one	O
in	O
its	O
sensitivity	O
to	O
the	O
inhibitory	O
effects	O
of	O
triamcinolone	O
acetonide	O
,	O
as	O
determined	O
by	O
measurements	O
of	O
the	O
incorporation	O
of	O
radiolabeled	O
precursors	O
of	O
protein	O
and	O
dna	O
.	O

moreover	O
,	O
the	O
peanut-negative	O
subset	O
appeared	O
more	O
resistant	O
in	O
vitro	O
to	O
the	O
steroid-induced	O
cell	O
lysis	O
as	O
compared	O
to	O
the	O
peanut-positive	O
one	O
.	O

thus	O
,	O
our	O
data	O
suggest	O
that	O
glucocorticoid	B-protein
receptor	I-protein
density	I-protein
and	I-protein
corticosensitivity	I-protein
are	O
not	O
directly	O
correlated	O
and	O
that	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptor	I-protein
sites	I-protein
may	O
be	O
dependent	O
on	O
the	O
degree	O
of	O
immunologic	O
maturation	O

###MEDLINE:86034662

defective	O
binding	O
and	O
function	O
of	O
0	B-protein
,	I-protein
00-dihydroxyvitamin	I-protein
d0	I-protein
receptors	I-protein
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
of	O
patients	O
with	O
end-organ	O
resistance	O
to	O
0	O
,	O
00-dihydroxyvitamin	O
d	O
.	O

lectin-induced	O
dna	O
synthesis	O
by	O
peripheral	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
from	O
00	O
normal	O
donors	O
was	O
inhibited	O
(	O
00-00	O
%	O
)	O
by	O
0	O
,	O
00-dihydroxyvitamin	O
d0	O
(	O
0	O
,	O
00	O
[	O
oh	O
]	O
0d0	O
)	O
at	O
physiological	O
concentrations	O
(	O
00	O
(	O
-00	B-DNA
)	I-DNA
-00	I-DNA
(	O
-0	O
)	O
m	O
)	O
.	O

the	O
lymphocytes	O
acquire	O
specific	O
receptors	O
for	O
0	O
,	O
00	O
(	O
oh	O
)	O
0d0	O
upon	O
activation	O
by	O
the	O
lectins	O
.	O

this	O
process	O
precedes	O
the	O
inhibitory	O
effect	O
of	O
0	O
,	O
00	O
(	O
oh	O
)	O
0d0	O
.	O

we	O
studied	O
lymphocytes	B-cell_type
from	O
six	O
patients	O
from	O
four	O
different	O
kindreds	O
with	O
the	O
syndrome	O
of	O
hereditary	O
end-organ	O
resistance	O
to	O
0	O
,	O
00	O
(	O
oh	O
)	O
0d	O
(	O
the	O
so-called	O
vitamin	O
d-dependent	O
rickets	O
type	O
ii	O
)	O
.	O

in	O
five	O
patients	O
(	O
three	O
kindreds	O
)	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
did	O
not	O
acquire	O
receptors	O
for	O
0	O
,	O
00	O
(	O
oh	O
)	O
0d0	O
upon	O
phytohemagglutinin-induced	O
activation	O
.	O

moreover	O
,	O
in	O
contrast	O
to	O
normal	B-cell_type
lymphocytes	I-cell_type
,	O
the	O
mitogenic	O
stimulation	O
of	O
these	O
patients	O
'	O
lymphocytes	B-cell_type
by	O
phytohemagglutinin	B-protein
and	O
concanavalin	O
a	O
was	O
not	O
inhibited	O
by	O
0	O
,	O
00	O
(	O
oh	O
)	O
0d0	O
.	O

activated	B-cell_type
lymphocytes	I-cell_type
of	O
the	O
sixth	O
patient	O
from	O
a	O
fourth	B-DNA
kindred	I-DNA
exhibited	O
normal	O
binding	O
of	O
[	O
0h	O
]	O
0	O
,	O
00	O
(	O
oh	O
)	O
0d0	O
but	O
the	O
hormone	O
failed	O
to	O
inhibit	O
the	O
mitogenic	O
stimulation	O
.	O

a	O
similar	O
pattern	O
of	O
the	O
vitamin	B-protein
d	I-protein
effector	I-protein
system	I-protein
was	O
previously	O
observed	O
in	O
fibroblasts	B-cell_type
cultured	O
from	O
skin	O
biopsies	O
of	O
the	O
same	O
group	O
of	O
patients	O
.	O

the	O
conclusions	O
from	O
these	O
findings	O
are	O
:	O
(	O
a	O
)	O
the	O
inhibition	O
of	O
mitogenic	O
stimulation	O
by	O
0	O
,	O
00	O
(	O
oh	O
)	O
0d0	O
is	O
mediated	O
by	O
specific	O
functional	O
receptors	O
to	O
the	O
hormone	O
;	O
and	O
(	O
b	O
)	O
the	O
receptors	O
for	O
0	O
,	O
00	O
(	O
oh	O
)	O
0d0	O
in	O
mononuclear	B-cell_type
cells	I-cell_type
are	O
probably	O
controlled	O
genetically	O
by	O
the	O
same	O
mechanisms	O
as	O
the	O
effector	O
system	O
in	O
well-characterized	O
target	O
organs	O
of	O
the	O
hormone	O
,	O
such	O
as	O
intestine	O
and	O
kidney	O
.	O

###MEDLINE:86021813

glucocorticoid	B-protein
receptors	I-protein
of	O
mononuclear	B-cell_type
leukocytes	I-cell_type
from	O
myasthenia	O
gravis	O
patients	O
.	O

the	O
present	O
study	O
was	O
performed	O
to	O
analyse	O
glucocorticoid	B-protein
receptor	I-protein
(	O
gr	B-protein
)	O
binding	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
(	O
mnl	B-cell_type
)	O
from	O
00	O
myasthenia	O
gravis	O
(	O
mg	O
)	O
patients	O
(	O
unoperated	O
patients	O
(	O
n	O
=	O
00	O
)	O
,	O
thymectomized	O
patients	O
(	O
n	O
=	O
00	O
)	O
and	O
patients	O
receiving	O
glucocorticoids	O
:	O
thymectomized	O
(	O
n	O
=	O
00	O
)	O
and	O
unoperated	O
(	O
n	O
=	O
0	O
]	O
.	O

a	O
whole	O
cell	O
binding	O
assay	O
with	O
0	O
(	O
h	O
)	O
dexamethasone	O
was	O
used	O
.	O

gr	B-protein
mean	O
values	O
were	O
significantly	O
higher	O
in	O
the	O
mnl	B-cell_type
of	O
mg	O
patients	O
(	O
thymectomized	B-cell_type
or	O
not	O
)	O
not	O
receiving	O
glucocorticoid	O
than	O
in	O
the	O
mnl	B-cell_type
of	O
healthy	O
donors	O
.	O

affinity	O
was	O
within	O
the	O
normal	O
range	O
.	O

sex	O
,	O
age	O
or	O
clinical	O
forms	O
of	O
illness	O
did	O
not	O
influence	O
the	O
results	O
.	O

in	O
patients	O
receiving	O
prednisone	O
(	O
pd	O
)	O
the	O
gr	B-protein
values	O
were	O
significantly	O
lower	O
than	O
in	O
mg	O
patients	O
without	O
pd	O
therapy	O
,	O
independent	O
of	O
pd	O
dose	O
or	O
time	O
of	O
administration	O
.	O

no	O
differences	O
in	O
receptor	O
binding	O
between	O
normal	O
subjects	O
and	O
mg	O
patients	O
receiving	O
pd	O
have	O
been	O
found	O
.	O

###MEDLINE:86125840

immunological	O
interference	O
of	O
high	O
dose	O
corticosteroids	O
.	O

high-dose	O
corticosteroids	O
(	O
hdc	B-protein
)	O
will	O
influence	O
cellular	O
as	O
well	O
as	O
humoral	O
participants	O
of	O
the	O
immune	O
response	O
.	O

the	O
lymphoid	O
tissue	O
will	O
decrease	O
in	O
size	O
and	O
weight	O
after	O
prolonged	O
treatment	O
with	O
hdc	B-protein
.	O

lymphocyte	O
functions	O
will	O
be	O
impaired	O
.	O

reduced	O
synthesis	O
of	O
b-	O
as	O
well	O
as	O
t-lymphocytes	B-cell_type
will	O
be	O
seen	O
.	O

the	O
inhibitory	O
effect	O
on	O
b-cell	O
function	O
can	O
be	O
observed	O
both	O
as	O
decreased	O
serum	O
levels	O
of	O
immunoglobulins	B-protein
and	O
as	O
impaired	O
binding	O
of	O
antibodies	B-protein
and	O
complement	O
to	O
the	O
cellular	O
surface	O
.	O

reduced	O
t-cell	O
function	O
indicated	O
by	O
impaired	O
stimulation	O
by	O
pha	B-protein
and	O
porkweed	O
as	O
well	O
as	O
by	O
impaired	O
lymphokinin	O
effects	O
on	O
leukocyte	O
migration	O
inhibition	O
has	O
been	O
reported	O
.	O

reduced	O
lymphocyte	O
adherence	O
to	O
antigen	O
and	O
suppressed	O
lymphocyte	O
reaction	O
have	O
also	O
been	O
observed	O
.	O

humoral	O
factors	O
involved	O
in	O
chemotaxis	O
,	O
opsonisation	O
,	O
phagocytosis	O
,	O
vascular	O
permeability	O
leading	O
to	O
leakage	O
of	O
fluid	O
and	O
cells	O
and	O
factors	O
involved	O
in	O
lysis	O
of	O
antigens	O
are	O
impaired	O
.	O

this	O
can	O
be	O
explained	O
partly	O
by	O
the	O
observed	O
reduced	O
complement	O
activation	O
via	O
the	O
alternative	O
as	O
well	O
as	O
the	O
classical	O
pathway	O
in	O
association	O
with	O
hdc	B-protein
therapy	O
.	O

acute	O
processes	O
with	O
increased	O
vascular	O
permeability	O
and	O
accumulation	O
of	O
leukocytes	B-cell_type
as	O
impairing	O
factors	O
could	O
be	O
influenced	O
beneficially	O
by	O
hdc	B-protein
therapy	O
.	O

this	O
positive	O
effect	O
can	O
be	O
seen	O
in	O
treatment	O
of	O
septic	O
shock	O
or	O
rejection	O
of	O
a	O
transplant	O
.	O

however	O
,	O
if	O
sepsis	O
or	O
rejection	O
is	O
not	O
rapidly	O
reversed	O
,	O
complications	O
such	O
as	O
multisystem	O
organ	O
failure	O
and	O
bacteremia	O
are	O
prone	O
to	O
appear	O
.	O

###MEDLINE:84282381

identification	O
of	O
human	B-protein
leukemic	I-protein
glucocorticoid	I-protein
receptors	I-protein
using	O
affinity	O
labeling	O
and	O
anti-human	O
glucocorticoid	B-protein
receptor	I-protein
antibodies	I-protein
.	O

antisera	O
raised	O
against	O
human	O
lymphoid	O
glucocorticoid	B-protein
receptors	I-protein
were	O
used	O
in	O
combination	O
with	O
the	O
glucocorticoid	B-protein
receptor	I-protein
affinity	O
label	O
[	O
0h	O
]	O
dexamethasone	O
00-mesylate	O
[	O
(	O
0h	O
]	O
dm	O
)	O
to	O
identify	O
the	O
glucocorticoid	B-protein
receptors	I-protein
of	O
the	O
human	B-cell_line
b-lymphoblastoid	I-cell_line
cell	I-cell_line
line	I-cell_line
im-0	B-cell_line
and	O
the	O
human	B-cell_line
t-cell	I-cell_line
leukemic	I-cell_line
cell	I-cell_line
line	I-cell_line
cem-c0	B-cell_line
.	O

antisera	O
were	O
obtained	O
following	O
immunization	O
of	O
new	O
zealand	O
white	O
rabbits	O
with	O
[	O
0h	O
]	O
triamcinolone	O
acetonide	O
[	O
(	O
0h	O
]	O
ta	O
)	O
-glucocorticoid	B-protein
receptor	I-protein
complexes	I-protein
partially	O
purified	O
by	O
two-stage	O
dna-cellulose	O
chromatography	O
.	O

the	O
presence	O
of	O
anti-human	O
glucocorticoid	B-protein
receptor	I-protein
antibodies	I-protein
was	O
verified	O
by	O
:	O
(	O
a	O
)	O
adsorption	O
of	O
[	O
0h	O
]	O
ta-receptor-antibody	B-protein
complexes	I-protein
to	O
protein	B-protein
a	I-protein
;	O
(	O
b	O
)	O
a	O
shift	O
to	O
higher	O
apparent	O
molecular	O
weight	O
in	O
the	O
elution	O
position	O
from	O
sephacryl	O
s000	B-protein
of	I-protein
[	I-protein
0h	I-protein
]	I-protein
ta-receptor	I-protein
complexes	I-protein
incubated	O
with	O
immune	O
serum	O
;	O
and	O
(	O
c	O
)	O
the	O
ability	O
of	O
immune	O
serum	O
to	O
displace	O
[	O
0h	O
]	O
ta-receptor	B-protein
complexes	I-protein
on	O
sucrose	O
gradients	O
.	O

these	O
antibodies	O
also	O
recognized	O
rat	B-cell_type
liver	I-cell_type
and	O
murine	B-cell_line
s00	I-cell_line
cell	I-cell_line
glucocorticoid	B-protein
receptors	I-protein
.	O

sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gel	O
electrophoresis	O
of	O
[	O
0h	O
]	O
dm-labeled	O
im-0	O
cytosol	O
identified	O
a	O
major	O
competable	O
band	O
with	O
a	O
molecular	O
weight	O
of	O
approximately	O
00	O
,	O
000	O
,	O
three	O
minor	O
competable	O
components	O
with	O
molecular	O
weights	O
of	O
approximately	O
00	O
,	O
000	O
,	O
approximately	O
00	O
,	O
000	O
,	O
and	O
approximately	O
00	O
,	O
000	O
,	O
and	O
at	O
least	O
00	O
other	O
noncompetable	O
components	O
.	O

following	O
immunoprecipitation	O
of	O
[	O
0h	O
]	O
dm-labeled	O
cytosol	O
with	O
immune	O
serum	O
,	O
only	O
the	O
mr	O
00	O
,	O
000	O
and	O
00	O
,	O
000	O
components	O
were	O
seen	O
.	O

sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gel	O
electrophoresis	O
of	O
[	O
0h	O
]	O
dm-labeled	B-cell_line
cem-c0	I-cell_line
cytosol	O
revealed	O
a	O
larger	O
number	O
of	O
[	O
0h	O
]	O
dm-labeled	O
components	O
.	O

however	O
,	O
after	O
immunoprecipitation	O
of	O
[	O
0h	O
]	O
dm-labeled	B-cell_line
cem-c0	I-cell_line
cytosol	O
,	O
a	O
predominant	O
competable	O
component	O
with	O
a	O
molecular	O
weight	O
of	O
00	O
,	O
000	O
was	O
easily	O
identified	O
.	O

this	O
component	O
was	O
markedly	O
diminished	O
when	O
cytosols	O
from	O
the	O
glucocorticoid	B-cell_line
receptor-deficient	I-cell_line
cell	I-cell_line
line	I-cell_line
icr-00	B-cell_line
were	O
used	O
.	O

thus	O
,	O
the	O
combination	O
of	O
affinity	O
labeling	O
and	O
anti-human	O
glucocorticoid	B-protein
receptor	I-protein
antibodies	I-protein
is	O
capable	O
of	O
providing	O
direct	O
physical	O
identification	O
of	O
human	O
lymphoid	O
glucocorticoid	B-protein
receptors	I-protein
.	O

###MEDLINE:84130660

effect	O
of	O
thymosin	B-protein
on	O
glucocorticoid	B-protein
receptor	I-protein
activity	O
and	O
glucocorticoid	O
sensitivity	O
of	O
human	B-cell_type
thymocytes	I-cell_type
.	O

incubation	O
with	O
thymosin	B-protein
fraction	O
0	O
,	O
(	O
tms	O
f0	O
at	O
000	O
micrograms/ml	O
)	O
a	O
partially	O
purified	O
thymic	O
factor	O
,	O
reduced	O
the	O
steroid	O
binding	O
activity	O
of	O
human	B-cell_type
infant	I-cell_type
thymocytes	I-cell_type
from	O
0.0	O
+/-	O
0.0	O
fmole/ml	O
to	O
0.0	O
+/-	O
0.0	O
fmole/ml	O
.	O

the	O
glucocorticoid	B-protein
receptor	I-protein
activity	O
in	O
normal	B-cell_type
infant	I-cell_type
thymocytes	I-cell_type
was	O
found	O
to	O
be	O
0	O
,	O
000	O
+/-	O
000	O
(	O
s.d.	B-DNA
)	I-DNA
sites	I-DNA
per	O
cell	O
with	O
dissociation	O
constant	O
of	O
0.0	O
+/-	O
0.0	O
x	O
00	O
(	O
-0	O
)	O
m	O
.	O

tms	O
f0	O
also	O
increased	O
the	O
resistance	O
of	O
human	B-cell_type
thymocytes	I-cell_type
to	O
the	O
cytolytic	O
effect	O
of	O
dexamethasone	O
(	O
0.0	O
x	O
00	O
(	O
-0	O
)	O
m	O
)	O
to	O
000.0	O
+/-	O
00.0	O
%	O
of	O
control	O
(	O
p	O
less	O
than	O
0.00	O
)	O
.	O

in	O
animals	O
,	O
medullary	B-cell_type
and	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
t	I-cell_type
cells	I-cell_type
are	O
more	O
resistant	O
to	O
glucocorticoids	O
than	O
immature	B-cell_type
thymic	I-cell_type
t	I-cell_type
cells	I-cell_type
.	O

the	O
results	O
show	O
that	O
thymosin	B-protein
can	O
induce	O
changes	O
consistent	O
with	O
differentiation	O
in	O
human	B-cell_type
thymocytes	I-cell_type
.	O

these	O
in	O
vitro	O
results	O
are	O
consistent	O
with	O
a	O
physiological	O
role	O
of	O
thymosin	B-protein
in	O
intrathymic	B-cell_type
t	I-cell_type
cell	I-cell_type
maturation	O
in	O
man	O
.	O

incubation	O
of	O
a	O
human	O
malignant	O
thymus	O
derived	O
t	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
molt	B-cell_line
0	I-cell_line
)	O
with	O
tms	O
f0	O
also	O
resulted	O
in	O
a	O
significant	O
reduction	O
of	O
the	O
number	O
of	O
steroid	B-protein
binding	I-protein
sites	I-protein
to	O
00.0	O
+/-	O
00.0	O
%	O
of	O
control	O
(	O
p	O
less	O
than	O
0.00	O
)	O
,	O
but	O
tms	O
f0	O
did	O
not	O
significantly	O
reduce	O
the	O
glucocorticoid	O
sensitivity	O
of	O
molt	B-cell_line
0	I-cell_line
cells	I-cell_line
.	O

###MEDLINE:84032920

specific	O
high-affinity	B-protein
receptors	I-protein
for	O
0	O
,	O
00-dihydroxyvitamin	O
d0	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
:	O
presence	O
in	O
monocytes	B-cell_type
and	O
induction	O
in	O
t	B-cell_type
lymphocytes	I-cell_type
following	O
activation	O
.	O

human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
have	O
high	O
affinity	O
binding	O
sites	O
for	O
0	O
,	O
00-	O
(	O
oh	O
)	O
0d0	O
(	O
kd	O
0.00	O
nm	O
,	O
sedimentation	O
coefficient	O
0.0s	O
)	O
.	O

resting	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
t	I-cell_type
lymphocytes	I-cell_type
,	O
however	O
,	O
do	O
not	O
have	O
a	O
demonstrable	O
0	O
,	O
00-	B-protein
(	I-protein
oh	I-protein
)	I-protein
0d0	I-protein
receptor	I-protein
.	O

after	O
activation	O
with	O
phytohemagglutinin	B-cell_line
the	I-cell_line
t	I-cell_line
cells	I-cell_line
exhibit	O
the	O
receptor	O
within	O
00	O
h	O
,	O
and	O
this	O
expression	O
is	O
blocked	O
by	O
cycloheximide	O
.	O

the	O
receptor	O
in	O
activated	B-cell_type
t	I-cell_type
lymphocytes	I-cell_type
has	O
a	O
sedimentation	O
coefficient	O
of	O
0.0s	O
and	O
a	O
high	O
affinity	O
(	O
kd	O
0.00	O
nm	O
)	O
for	O
the	O
ligand	O
.	O

###MEDLINE:83186675

effects	O
of	O
chronic	O
glucocorticoid	O
excess	O
in	O
man	O
on	O
insulin	B-protein
binding	O
to	O
circulating	B-cell_type
cells	I-cell_type
:	O
differences	O
between	O
endogenous	O
and	O
exogenous	O
hypercorticism	O
.	O

we	O
measured	O
[	O
000i	O
]	O
insulin	B-protein
binding	O
to	O
circulating	B-cell_type
monocytes	I-cell_type
or	O
erythrocytes	B-cell_type
from	O
00	O
patients	O
with	O
chronic	O
glucocorticoid	O
excess	O
,	O
0	O
chronically	O
treated	O
with	O
prednisone	O
and	O
0	O
with	O
adrenocortical	O
hyperfunction	O
.	O

with	O
monocytes	B-cell_type
,	O
[	O
000i	O
]	O
insulin	B-protein
binding	O
was	O
iincreased	O
in	O
all	O
patients	O
.	O

analysis	O
of	O
binding	O
data	O
indicated	O
that	O
increased	O
binding	O
in	O
patients	O
treated	O
with	O
prednisone	O
was	O
due	O
to	O
an	O
ncrease	O
in	O
receptor	O
concentration	O
,	O
whereas	O
in	O
patients	O
with	O
adrenocortical	O
hyperfunction	O
,	O
it	O
was	O
due	O
to	O
an	O
increase	O
in	O
receptor	O
affinity	O
.	O

with	O
erythrocytes	B-cell_type
from	O
patients	O
with	O
adrenocortical	O
hyperfunction	O
there	O
was	O
an	O
increase	O
in	O
receptor	O
affinity	O
and	O
a	O
decrease	O
in	O
receptor	O
concentration	O
,	O
so	O
that	O
the	O
binding	O
of	O
[	O
000i	O
]	O
insulin	B-protein
was	O
normal	O
.	O

the	O
disparity	O
of	O
results	O
between	O
endogenous	O
and	O
exogenous	O
hypercorticism	O
,	O
between	O
the	O
two	O
cell	O
types	O
,	O
and	O
between	O
the	O
present	O
studies	O
and	O
previous	O
studies	O
suggest	O
that	O
the	O
effects	O
of	O
glucocorticoid	O
excess	O
on	O
the	O
insulin	B-protein
receptor	I-protein
are	O
extremely	O
complex	O
and	O
wide-ranging	O
and	O
that	O
in	O
this	O
condition	O
,	O
extrapolations	O
in	O
humans	O
from	O
data	O
with	O
circulating	B-cell_type
cells	I-cell_type
to	O
liver	O
and	O
muscle	O
may	O
not	O
be	O
appropriate	O
.	O

###MEDLINE:83106949

reduced	O
level	O
of	O
cellular	O
glucocorticoid	B-protein
receptors	I-protein
in	O
patients	O
with	O
anorexia	O
nervosa	O
.	O

specific	O
glucocorticoid	B-protein
receptors	I-protein
were	O
measured	O
in	O
circulating	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
from	O
00	O
patients	O
with	O
anorexia	O
nervosa	O
and	O
00	O
healthy	O
control	O
subjects	O
.	O

cells	O
from	O
patients	O
were	O
found	O
to	O
contain	O
a	O
significantly	O
(	O
p	O
less	O
than	O
0.00	O
)	O
lower	O
level	O
of	O
glucocorticoid	B-protein
receptor	I-protein
(	O
0000	O
+/-	O
000	O
sites/cell	O
,	O
mean	O
+/-	O
se	B-protein
)	O
than	O
those	O
from	O
controls	O
(	O
0000	O
+/-	O
000	O
sites/cell	O
)	O
.	O

a	O
partial	O
glucocorticoid	B-protein
receptor	I-protein
defect	O
may	O
well	O
explain	O
the	O
abnormal	O
cortisol	O
metabolism	O
and	O
glucocorticoid	O
resistance	O
commonly	O
found	O
in	O
patients	O
with	O
anorexia	O
nervosa	O
.	O

###MEDLINE:82147031

regulation	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
in	O
human	B-cell_type
lymphocytes	I-cell_type
.	O

the	O
presence	O
of	O
a	O
glucocorticoid	B-protein
receptor	I-protein
in	O
human	B-cell_type
lymphocytes	I-cell_type
is	O
well	O
established	O
,	O
but	O
factors	O
affecting	O
its	O
regulation	O
have	O
not	O
been	O
described	O
.	O

using	O
a	O
competitive	O
binding	O
whole	O
cell	O
assay	O
,	O
we	O
have	O
examined	O
the	O
binding	O
of	O
[	O
0h	O
]	O
-dexamethasone	O
at	O
00	O
and	O
00	O
degrees	O
c	O
in	O
untreated	O
normal	O
subjects	O
and	O
in	O
healthy	O
subjects	O
taking	O
various	O
glucocorticoid	O
preparations	O
.	O

at	O
00	O
degrees	O
c	O
normal	O
human	B-cell_type
lymphocytes	I-cell_type
had	O
0000	O
binding	O
sites/cell	O
and	O
a	O
dissociation	O
constant	O
of	O
0	O
x	O
00	O
(	O
-0	O
)	O
m	O
.	O

the	O
administration	O
of	O
0	O
mg	O
of	O
dexamethasone	O
,	O
0	O
mg	O
of	O
prednisone	O
,	O
and	O
00.0	O
mg	O
of	O
cortisone	O
acetate	O
resulted	O
in	O
a	O
00	O
%	O
decrease	O
in	O
binding	B-DNA
sites	I-DNA
after	O
0	O
week	O
with	O
no	O
change	O
in	O
binding	O
affinity	O
.	O

no	O
changes	O
in	O
the	O
number	O
of	O
binding	B-DNA
sites	I-DNA
was	O
noted	O
before	O
0	O
week	O
and	O
the	O
diminished	O
number	O
persisted	O
for	O
0	O
week	O
after	O
discontinuation	O
of	O
glucocorticoid	O
treatment	O
.	O

lymphocytes	B-cell_type
from	O
hospitalized	O
patients	O
taking	O
00-00	O
mg	O
of	O
dexamethasone	O
daily	O
demonstrated	O
the	O
same	O
change	O
in	O
number	O
of	O
binding	B-DNA
sites	I-DNA
that	O
was	O
seen	O
in	O
normal	O
subjects	O
taking	O
0	O
mg	O
of	O
dexamethasone	O
.	O

when	O
binding	O
assays	O
were	O
carried	O
out	O
at	O
physiologic	O
temperature	O
there	O
was	O
the	O
same	O
decrease	O
in	O
number	O
of	O
binding	B-DNA
sites	I-DNA
after	O
dexamethasone	O
administration	O
,	O
and	O
in	O
addition	O
,	O
there	O
was	O
a	O
two-fold	O
increase	O
in	O
binding	O
affinity	O
.	O

glucocorticoid	O
administration	O
results	O
in	O
a	O
time-dependent	O
decrease	O
in	O
the	O
number	O
of	O
lymphocyte	B-protein
glucocorticoid	I-protein
binding	I-protein
sites	I-protein
that	O
is	O
independent	O
of	O
the	O
type	O
of	O
glucocorticoid	O
administered	O
.	O

this	O
is	O
the	O
first	O
in	O
vivo	O
demonstration	O
that	O
glucocorticoids	O
modulate	O
their	O
own	O
receptors	O
in	O
man	O
.	O

###MEDLINE:81209839

immunoglobulin	B-protein
localization	O
in	O
benign	O
and	O
malignant	O
lesions	O
of	O
the	O
human	O
mammary	O
gland	O
.	O

using	O
direct	O
imunofluorescence	O
,	O
lesions	O
from	O
000	O
human	O
breast	O
specimens	O
were	O
studied	O
for	O
the	O
presence	O
of	O
iga	B-protein
,	O
igm	B-protein
,	O
or	O
igg	B-protein
localization	O
.	O

the	O
lesions	O
included	O
benign	O
elements	O
from	O
00	O
subcutaneous	O
mastectomy	O
specimens	O
in	O
which	O
the	O
absence	O
of	O
simultaneous	O
breast	O
malignancy	O
was	O
documented	O
,	O
primary	O
breast	O
carcinomas	O
from	O
000	O
mastectomy	O
specimens	O
,	O
and	O
00	O
biopsies	O
containing	O
metastatic	O
breast	O
cancer	O
.	O

a	O
statistically	O
significant	O
association	O
of	O
iga	B-protein
and	O
igm	B-protein
with	O
benign	O
lesions	O
was	O
contrasted	O
to	O
the	O
association	O
of	O
igg	B-protein
with	O
malignant	O
lesions	O
.	O

in	O
both	O
primary	O
and	O
metastatic	O
lesions	O
,	O
igg	B-protein
localization	O
was	O
associated	O
with	O
estrogen-receptor-poor	O
primary	O
cancers	O
as	O
compared	O
with	O
estrogen-receptor-rich	O
primary	O
cancers	O
.	O

among	O
primary	O
breast	O
cancer	O
patients	O
,	O
igg	B-protein
localization	O
in	O
the	O
tumor	O
correlated	O
with	O
relative	O
lymphopenia	O
.	O

a	O
shorter	O
disease-free	O
interval	O
was	O
noted	O
in	O
association	O
with	O
igg	B-protein
localization	O
among	O
the	O
metastatic	O
breast	O
lesions	O
.	O

no	O
statistically	O
significant	O
association	O
between	O
stage	O
of	O
disease	O
and	O
immunoglobulin	B-protein
presence	O
was	O
demonstrable	O
.	O

moderate-to-severe	O
intraductal	O
epithelial	O
hyperplasias	O
were	O
more	O
often	O
associated	O
with	O
immunoglobulin	B-protein
g	I-protein
localization	O
that	O
were	O
other	O
benign	O
lesions	O

###MEDLINE:86027718

correlation	O
of	O
steroid	B-protein
receptors	I-protein
with	O
histologic	O
differentiation	O
in	O
mammary	O
carcinoma	O
.	O

a	O
singapore	O
experience	O
.	O

cancer	O
of	O
the	O
breast	O
is	O
the	O
most	O
common	O
tumor	O
in	O
females	O
in	O
singapore	O
,	O
with	O
the	O
rate	O
of	O
00.0	O
per	O
000	O
,	O
000	O
per	O
year	O
(	O
0000	O
estimate	O
)	O
,	O
which	O
is	O
predicted	O
to	O
increase	O
to	O
00.0	O
per	O
000	O
,	O
000	O
women	O
per	O
year	O
by	O
0000	O
.	O

a	O
detailed	O
histopathologic	O
review	O
of	O
00	O
primary	O
breast	O
cancer	O
tumors	O
analyzed	O
for	O
estrogen	B-protein
receptor	I-protein
(	O
er	B-protein
)	O
level	O
was	O
carried	O
out	O
and	O
a	O
variety	O
of	O
morphologic	O
features	O
correlated	O
with	O
er	B-protein
results	O
to	O
identify	O
any	O
factors	O
that	O
will	O
improve	O
the	O
management	O
and	O
prognosis	O
for	O
breast	O
cancer	O
.	O

cytosol	O
was	O
incubated	O
with	O
0h-estradiol	O
in	O
the	O
presence	O
and	O
absence	O
of	O
cold	O
diethylstilbestrol	O
,	O
and	O
bound	O
and	O
free	O
hormone	O
were	O
separated	O
by	O
dextran-coated	O
charcoal	O
method	O
.	O

tumors	O
binding	O
more	O
than	O
0	O
fmol/mg	O
cytosol	O
protein	O
were	O
classified	O
as	O
er	B-protein
-positive	O
.	O

progesterone	B-protein
receptor	I-protein
(	O
pr	B-protein
)	O
level	O
was	O
analyzed	O
in	O
some	O
specimens	O
with	O
the	O
use	O
of	O
a	O
similar	O
method	O
.	O

most	O
of	O
the	O
patients	O
were	O
chinese	O
(	O
00	O
%	O
)	O
.	O

three	O
patients	O
were	O
malays	O
,	O
one	O
was	O
indian	O
,	O
and	O
one	O
was	O
european	O
in	O
this	O
series	O
.	O

results	O
indicated	O
that	O
there	O
was	O
strong	O
correlation	O
between	O
er	B-protein
level	O
,	O
age	O
,	O
and	O
histologic	O
grade	O
of	O
the	O
tumors	O
.	O

no	O
correlation	O
existed	O
between	O
absence	O
or	O
presence	O
of	O
lymph	O
node	O
metastases	O
and	O
er	B-protein
.	O

although	O
there	O
was	O
a	O
trend	O
for	O
er	B-protein
-positive	O
tumors	O
to	O
have	O
a	O
low-grade	O
lymphocytic	O
infiltration	O
,	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O

###MEDLINE:85233509

mononuclear	B-cell_type
cells	I-cell_type
infiltrating	O
human	O
mammary	O
carcinomas	O
:	O
immunohistochemical	O
analysis	O
with	O
monoclonal	B-protein
antibodies	I-protein
.	O

breast	O
carcinomas	O
were	O
examined	O
by	O
the	O
immunoperoxidase	O
technique	O
using	O
antisera	O
specific	O
for	O
lymphocyte	B-cell_type
subsets	I-cell_type
,	O
monocytes	B-cell_type
,	O
nk	B-cell_type
cells	I-cell_type
and	O
major	B-protein
histocompatibility	I-protein
antigens	I-protein
(	B-protein
hla-a	I-protein
,	I-protein
-b	I-protein
,	I-protein
-c	I-protein
;	O
ia-like	O
)	O
.	O

sixty-four	O
per	O
cent	O
of	O
the	O
patients	O
had	O
a	O
moderate	O
or	O
strong	O
mononuclear	O
cell	O
infiltration	O
,	O
00	O
%	O
of	O
the	O
patients	O
without	O
mononuclear	B-cell_type
cell	I-cell_type
infiltration	O
had	O
receptors	O
for	O
estrogens	O
as	O
compared	O
to	O
00	O
%	O
of	O
the	O
patients	O
with	O
infiltration	O
.	O

the	O
majority	O
of	O
the	O
infiltrating	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
were	O
t	B-cell_type
cells	I-cell_type
;	O
generally	O
the	O
okt0	B-protein
cells	O
were	O
predominant	O
.	O

the	O
leu	O
0a/okt0	O
cell	O
ratio	O
was	O
not	O
related	O
to	O
histological	O
type	O
,	O
tumor	O
size	O
,	O
age	O
of	O
the	O
patient	O
or	O
presence	O
of	O
metastases	O
.	O

some	O
of	O
the	O
t	B-cell_type
cells	I-cell_type
had	O
the	O
ia	B-protein
antigen	I-protein
and	O
were	O
thus	O
probably	O
activated	O
.	O

the	O
b	B-cell_type
cells	I-cell_type
were	O
either	O
absent	O
or	O
less	O
numerous	O
than	O
the	O
t	B-cell_type
cells	I-cell_type
.	O

there	O
was	O
no	O
relation	O
between	O
their	O
distribution	O
and	O
the	O
various	O
parameters	O
studied	O
.	O

a	O
few	O
monocytes	O
were	O
heterogeneous	O
according	O
to	O
their	O
markers	O
(	O
okm	B-protein
i	I-protein
and	I-protein
acid	I-protein
phosphatase	I-protein
)	O
.	O

in	O
0	O
cases	O
only	O
there	O
was	O
a	O
strong	O
infiltration	O
of	O
mononuclear	B-cell_type
cells	I-cell_type
positive	O
for	O
acid	B-protein
phosphatase	I-protein
.	O

the	O
number	O
of	O
the	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
was	O
also	O
low	O
.	O

only	O
a	O
few	O
mononuclear	O
infiltrating	B-cell_type
cells	I-cell_type
had	O
receptors	O
for	O
transferrin	B-protein
.	O

there	O
was	O
a	O
positive	O
correlation	O
between	O
the	O
inflammatory	O
infiltration	O
and	O
the	O
presence	O
of	O
hla	B-protein
class-i	I-protein
antigens	I-protein
on	O
tumor	B-cell_line
cell	I-cell_line
s	I-cell_line
.	O

some	O
of	O
the	O
antisera	O
specific	O
for	O
lymphocyte	B-cell_type
subsets	I-cell_type
also	O
stained	O
the	O
breast	B-cell_type
carcinoma	I-cell_type
cells	I-cell_type
.	O

the	O
great	O
variations	O
in	O
the	O
subsets	O
of	O
mononuclear	B-cell_type
cells	I-cell_type
in	O
breast	O
carcinomas	O
may	O
correspond	O
to	O
various	O
systems	O
of	O
defense	O
against	O
neoplasm	O
.	O

###MEDLINE:85305500

a	O
case	O
of	O
male	O
pseudohermaphroditism	O
with	O
normal	O
androgen	B-DNA
receptor	I-DNA
binding	I-DNA
and	I-DNA
00	I-DNA
,	O
xyy	O
karyotype	O
.	O

a	O
case	O
of	O
male	O
pseudohermaphroditism	O
with	O
00	O
,	O
xyy	O
karyotype	O
in	O
blood	O
and	O
cutaneous	B-cell_line
fibroblasts	I-cell_line
is	O
described	O
.	O

the	O
plasma	O
testosterone	O
response	O
to	O
hcg	O
stimulation	O
was	O
slightly	O
below	O
the	O
normal	O
range	O
on	O
two	O
occasions	O
suggesting	O
a	O
deficit	O
of	O
gonadal	O
function	O
.	O

a	O
study	O
of	O
the	O
receptors	O
for	O
dihydrotestosterone	O
in	O
fibroblasts	B-cell_type
of	O
genital	O
and	O
nongenital	O
skin	O
showed	O
a	O
normal	O
concentration	O
of	O
receptors	O
in	O
genital	O
skin	O
;	O
0-alpha-reductase	O
activity	O
in	O
fibroblasts	B-cell_type
of	O
the	O
genital	O
skin	O
was	O
low	O
,	O
but	O
the	O
plasma	O
relationship	O
testosterone/dihydrotestosterone	O
under	O
hcg	O
stimulation	O
was	O
normal	O
.	O

the	O
diagnostic	O
possibility	O
of	O
a	O
complete	O
testicular	O
feminization	O
syndrome	O
with	O
normal	O
receptors	O
for	O
dihydrotestosterone	O
is	O
commented	O
on	O
.	O

###MEDLINE:84290642

0	O
,	O
00-dihydroxyvitamin	O
d0	O
inhibits	O
antigen-induced	O
t	O
cell	O
activation	O
.	O

the	O
proliferative	O
response	O
of	O
murine	O
spleen	O
and	O
thymus	B-cell_line
cells	I-cell_line
to	O
antigen	O
but	O
not	O
to	O
lectin	B-protein
was	O
inhibited	O
by	O
the	O
active	O
metabolite	O
of	O
vitamin	B-protein
d0	I-protein
,	O
0	O
,	O
00-	O
(	O
oh	O
)	O
0d0	O
.	O

to	O
directly	O
examine	O
the	O
effect	O
of	O
0	O
,	O
00-	O
(	O
oh	O
)	O
0d0	O
on	O
t	B-cell_type
cell	I-cell_type
activation	O
in	O
the	O
absence	O
of	O
other	O
complicating	O
interactions	O
,	O
we	O
utilized	O
a	O
panel	O
of	O
cloned	B-cell_line
ia-restricted	I-cell_line
t	I-cell_line
cell	I-cell_line
hybridomas	I-cell_line
that	O
secrete	O
il	B-protein
0	I-protein
on	O
activation	O
by	O
cloned	O
ia-bearing	O
stimulator	O
cells	O
(	O
ta0	O
)	O
or	O
when	O
stimulated	O
by	O
mitogen	B-protein
.	O

physiologic	O
concentrations	O
of	O
0	O
,	O
00-	O
(	O
oh	O
)	O
0d0	O
(	O
0.00	O
to	O
0.0	O
nm	O
)	O
inhibited	O
the	O
antigen-induced	O
secretion	O
of	O
il	B-protein
0	I-protein
by	O
several	O
of	O
these	O
t	B-cell_line
cell	I-cell_line
hybridomas	I-cell_line
.	O

this	O
inhibition	O
was	O
dependent	O
on	O
the	O
concentration	O
of	O
the	O
free	O
hormone	O
and	O
could	O
be	O
overcome	O
by	O
increasing	O
the	O
number	O
of	O
ia-bearing	O
stimulator	O
cells	O
used	O
.	O

pretreatment	O
of	O
the	O
t	B-cell_line
hybridoma	I-cell_line
but	O
not	O
the	O
ta0	O
stimulator	O
cell	O
with	O
0	O
,	O
00-	O
(	O
oh	O
)	O
0d0	O
resulted	O
in	O
inhibition	O
of	O
activation	O
.	O

these	O
results	O
are	O
consistent	O
with	O
the	O
finding	O
that	O
specific	O
0	O
,	O
00-	B-protein
(	I-protein
oh	I-protein
)	I-protein
0d0	I-protein
receptors	I-protein
are	O
present	O
on	O
the	O
t	B-cell_line
cell	I-cell_line
hybridomas	I-cell_line
but	O
are	O
lacking	O
in	O
ta0	B-cell_type
cells	I-cell_type
.	O

0	O
,	O
00-	O
(	O
oh	O
)	O
0d0	O
failed	O
,	O
however	O
,	O
to	O
inhibit	O
the	O
activation	O
of	O
the	O
t	B-cell_line
cell	I-cell_line
hybridomas	I-cell_line
by	O
lectin	B-protein
or	O
by	O
an	O
anti-thy-0	B-protein
antibody	I-protein
.	O

these	O
findings	O
suggest	O
that	O
0	O
,	O
00-	O
(	O
oh	O
)	O
0d0	O
may	O
be	O
interfering	O
with	O
early	O
events	O
of	O
antigen-induced	O
t	O
cell	O
activation	O
,	O
perhaps	O
by	O
hindering	B-cell_type
t	I-cell_type
cell	I-cell_type
recognition	O
of	O
the	O
relevant	O
antigen	O
on	O
stimulator	O
cell	O
surfaces	O
.	O

this	O
system	O
should	O
prove	O
useful	O
in	O
studying	O
the	O
molecular	O
mechanisms	O
by	O
which	O
0	O
,	O
00-	O
(	O
oh	O
)	O
0d0	O
acts	O
to	O
inhibit	O
t	O
cell	O
activation	O
and	O
subsequent	O
il	O
0	O
production	O
.	O

###MEDLINE:84106471

glucocorticoid	B-protein
receptors	I-protein
and	O
steroid	O
sensitivity	O
in	O
normal	O
and	O
neoplastic	B-cell_type
human	I-cell_type
lymphoid	I-cell_type
tissues	I-cell_type
:	O
a	O
review	O
.	O

the	O
determination	O
of	O
estrogen	O
and	O
progesterone	B-protein
receptors	I-protein
in	O
breast	O
cancer	O
has	O
been	O
shown	O
to	O
be	O
useful	O
in	O
predicting	O
the	O
response	O
to	O
endocrine	O
therapy	O
.	O

given	O
their	O
well-known	O
inhibitory	O
effects	O
on	O
lymphoid	B-cell_type
tissue	I-cell_type
,	O
glucocorticoids	O
have	O
been	O
used	O
widely	O
in	O
the	O
treatment	O
of	O
leukemia	O
.	O

given	O
these	O
facts	O
,	O
over	O
the	O
last	O
00	O
years	O
,	O
several	O
investigators	O
have	O
measured	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
normal	O
and	O
neoplastic	B-cell_type
lymphoid	I-cell_type
tissue	I-cell_type
to	O
see	O
whether	O
their	O
number	O
correlated	O
with	O
glucocorticoid	O
responsiveness	O
in	O
vitro	O
or	O
in	O
vivo	O
.	O

no	O
clear	O
correlation	O
could	O
be	O
established	O
between	O
the	O
level	O
of	O
glucocorticoid	B-protein
receptor	I-protein
and	O
the	O
in	O
vitro	O
action	O
of	O
steroids	O
in	O
normal	O
and	O
neoplastic	B-cell_type
lymphoid	I-cell_type
tissue	I-cell_type
.	O

in	O
contrast	O
,	O
attempts	O
to	O
correlate	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
in	O
acute	O
lymphocytic	O
leukemia	O
to	O
in	O
vivo	O
steroid	O
responsiveness	O
and	O
immunological	O
type	O
using	O
the	O
whole-cell-binding	O
assay	O
for	O
receptor	O
determination	O
and	O
selecting	O
the	O
patients	O
according	O
to	O
age	O
and	O
immunological	O
criteria	O
have	O
been	O
more	O
successful	O
.	O

###MEDLINE:84053675

[	O
glucocorticoid	B-protein
receptors	I-protein
in	O
normal	B-cell_type
human	I-cell_type
lymphocytes	I-cell_type
]	O

glucocorticoid	B-protein
(	I-protein
gc	I-protein
)	I-protein
receptors	I-protein
were	O
studied	O
in	O
intact	B-cell_type
lymphocytes	I-cell_type
from	O
00	O
donors	O
.	O

gc	O
binding	O
parameters	O
were	O
found	O
to	O
be	O
highly	O
reproducible	O
in	O
repeated	O
experiments	O
with	O
lymphocytes	B-cell_type
.	O

it	O
was	O
shown	O
that	O
gc	B-protein
receptors	I-protein
in	O
donors	O
'	O
lymphocytes	B-cell_type
could	O
be	O
distributed	O
into	O
two	O
different	O
classes	O
similarly	O
to	O
the	O
pattern	O
seen	O
in	O
skin	B-cell_type
fibroblasts	I-cell_type
.	O

human	B-cell_type
lymphocytes	I-cell_type
are	O
an	O
adequate	O
object	O
for	O
studying	O
genetically	O
determined	O
variability	O
of	O
gc	B-protein
receptors	I-protein
and	O
its	O
clinical	O
importance	O
.	O

###MEDLINE:83217486

specific	O
estrogen	B-DNA
binding	I-DNA
sites	I-DNA
in	O
human	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
and	O
thymic	B-cell_type
cells	I-cell_type
.	O

the	O
binding	O
of	O
estrogen	O
in	O
preparations	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
,	O
as	O
well	O
as	O
by	O
splenic	B-cell_type
and	I-cell_type
thymic	I-cell_type
cells	I-cell_type
is	O
demonstrated	O
by	O
three	O
different	O
approaches	O
(	O
dextran-coated	O
charcoal	O
method	O
,	O
whole	O
cell	O
assay	O
,	O
and	O
gel	O
filtration	O
on	O
a	O
sepharose	B-protein
0b	I-protein
column	O
)	O
.	O

scatchard	O
's	O
analysis	O
of	O
[	O
0h	O
]	O
-moxestrol	O
(	O
r0000	O
)	O
and	O
[	O
0h	O
]	O
-estradiol	O
binding	O
proves	O
the	O
existence	O
of	O
a	O
single	B-DNA
class	I-DNA
of	I-DNA
receptor	I-DNA
sites	I-DNA
having	O
a	O
dissociation	O
constant	O
of	O
0.00-0.0	O
x	O
00	O
(	O
-0	O
)	O
m	O
.	O

physicochemical	O
properties	O
of	O
the	O
binder	O
,	O
including	O
binding	O
capacity	O
and	O
steroid	O
specificity	O
,	O
are	O
quite	O
similar	O
to	O
those	O
reported	O
for	O
the	O
thymus	O
of	O
small	O
mammalian	O
species	O
or	O
human	B-cell_type
thymoma	I-cell_type
.	I-cell_type

###MEDLINE:83131778

administration	O
of	O
fibroblast	B-protein
interferon	I-protein
to	O
patients	O
with	O
advanced	O
breast	O
cancer	O
:	O
possible	O
effects	O
on	O
skin	O
metastasis	O
and	O
on	O
hormone	B-protein
receptors	I-protein
.	O

eleven	O
patients	O
with	O
metastasized	O
breast	O
cancer	O
received	O
0	O
intramuscular	O
injections	O
of	O
0	O
x	O
00	O
(	O
0	O
)	O
units	O
of	O
human	B-protein
fibroblast	I-protein
interferon	I-protein
over	O
a	O
period	O
of	O
00	O
days	O
.	O

the	O
injections	O
did	O
not	O
cause	O
local	O
irritation	O
or	O
inflammation	O
.	O

fever	O
occurred	O
in	O
only	O
0	O
of	O
the	O
00	O
patients	O
.	O

although	O
several	O
types	O
of	O
metastases	O
were	O
monitored	O
,	O
only	O
skin	B-cell_type
nodules	I-cell_type
consistently	O
(	O
00	O
out	O
of	O
00	O
patients	O
)	O
exhibited	O
changes	O
that	O
were	O
suggestive	O
of	O
a	O
therapeutic	O
effect	O
of	O
the	O
treatment	O
regimen	O
:	O
either	O
a	O
simple	O
decrease	O
in	O
size	O
of	O
some	O
nodules	O
or	O
central	O
necrosis	O
accompanied	O
by	O
an	O
inflammatory	O
reaction	O
.	O

nk-activity	O
of	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
was	O
significantly	O
increased	O
after	O
administration	O
of	O
the	O
first	O
dose	O
;	O
the	O
effect	O
of	O
subsequent	O
injections	O
was	O
less	O
clear	O
.	O

receptors	O
for	O
estrogens	O
and	O
progestogens	O
were	O
increased	O
in	O
the	O
tumor	O
biopsies	O
of	O
0	O
out	O
of	O
0	O
and	O
0	O
out	O
of	O
0	O
patients	O
tested	O
respectively	O
.	O

###MEDLINE:82098485

decreased	O
glucocorticoid	B-protein
receptor	I-protein
binding	O
in	O
adrenal	O
insufficiency	O
.	O

to	O
examine	O
the	O
effect	O
of	O
glucocorticoid	O
deficiency	O
on	O
the	O
glucocorticoid	B-protein
receptor	I-protein
,	O
we	O
examine	O
the	O
binding	O
of	O
[	O
0h	O
]	O
dexamethasone	O
to	O
lymphocytes	B-cell_type
in	O
normal	O
subjects	O
and	O
patients	O
with	O
adrenal	O
insufficiency	O
before	O
and	O
after	O
glucocorticoid	O
replacement	O
therapy	O
.	O

using	O
a	O
whole	O
cell	O
competitive	O
binding	O
assay	O
,	O
normal	B-cell_type
human	I-cell_type
lymphocytes	I-cell_type
had	O
0000	O
+/-	O
0000	O
(	O
mean	O
+/-	O
sd	O
)	O
binding	O
sites/cell	O
and	O
a	O
dissociation	O
constant	O
of	O
00	O
+/-	O
0	O
nm	O
.	O

lymphocytes	B-cell_type
from	O
patients	O
with	O
untreated	O
adrenal	O
insufficiency	O
had	O
fewer	O
binding	B-DNA
sites	I-DNA
(	O
0000	O
+/-000	O
)	O
and	O
a	O
0-fold	O
increase	O
in	O
binding	O
affinity	O
(	O
0.0	O
+/-	O
0.0	O
mm	O
)	O
.	O

the	O
administration	O
of	O
conventional	O
replacement	O
doses	O
of	O
cortisone	O
acetate	O
for	O
0	O
months	O
caused	O
no	O
change	O
in	O
receptor	O
number	O
,	O
but	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
binding	O
affinity	O
toward	O
normal	O
.	O

after	O
long	O
term	O
glucocorticoid	O
replacement	O
therapy	O
,	O
binding	O
parameters	O
were	O
similar	O
to	O
those	O
in	O
patients	O
before	O
treatment	O
.	O

the	O
physiological	O
implications	O
of	O
the	O
decreased	O
receptor	O
number	O
and	O
increased	O
binding	O
affinity	O
in	O
adrenal	O
insufficiency	O
remain	O
to	O
be	O
elucidated	O
.	O

###MEDLINE:81209206

glucocorticoid	B-protein
receptor	I-protein
concentrations	O
and	O
terminal	B-protein
transferase	I-protein
activity	O
as	O
indicators	O
of	O
prognosis	O
in	O
acute	O
non-lymphocytic	O
leukaemia	O
.	O

activity	O
of	O
terminal	B-protein
deoxynucleotidyl	I-protein
transferase	I-protein
(	O
tdt	O
)	O
,	O
adenosine	B-protein
deaminase	I-protein
,	O
and	O
0'nucleotidase	B-protein
and	O
the	O
cellular	O
concentration	O
of	O
glucocorticoid	O
(	O
dexamethasone	O
)	O
receptor	O
were	O
determined	O
in	O
00	O
patients	O
with	O
acute	O
non-lymphocytic	O
leukaemia	O
.	O

all	O
patients	O
were	O
treated	O
according	O
to	O
a	O
common	O
protocol	O
.	O

increased	O
activity	O
of	O
tdt	O
(	O
greater	O
than	O
0.0	O
unit/microgram	O
dna	O
)	O
was	O
found	O
in	O
00	O
patients	O
.	O

this	O
group	O
of	O
patients	O
was	O
shown	O
to	O
have	O
higher	O
remission	O
and	O
survival	O
rates	O
(	O
p	O
=	O
0.00	O
)	O
compared	O
with	O
patients	O
with	O
low	O
activity	O
of	O
tdt	O
.	O

the	O
glucocorticoid	B-protein
receptor	I-protein
concentration	O
of	O
the	O
leukaemic	B-cell_line
blast	I-cell_line
cells	I-cell_line
ranged	O
from	O
0	O
to	O
0.00	O
fmol/microgram	B-DNA
dna	I-DNA
.	O

thirteen	O
patients	O
had	O
blast	B-cell_type
cells	I-cell_type
with	O
a	O
glucocorticoid	B-protein
receptor	I-protein
concentration	O
over	O
0.00	O
fmol/microgram	B-DNA
dna	I-DNA
.	O

these	O
patients	O
had	O
significantly	O
increased	O
remission	O
and	O
survival	O
rates	O
(	O
p	O
=	O
0.000	O
)	O
compared	O
with	O
those	O
with	O
a	O
low	O
receptor	O
concentration	O
.	O

this	O
finding	O
can	O
not	O
be	O
explained	O
by	O
a	O
difference	O
in	O
sensitivity	O
to	O
glucocorticoids	O
since	O
these	O
were	O
not	O
used	O
as	O
therapeutic	O
agents	O
.	O

adenosine	B-protein
deaminase	I-protein
and	O
0'nucleotidase	O
activities	O
both	O
varied	O
within	O
two	O
orders	O
of	O
magnitude	O
.	O

no	O
correlation	O
could	O
be	O
found	O
between	O
activities	O
of	O
these	O
enzymes	B-protein
and	O
remission	O
or	O
survival	O
rate	O
.	O

these	O
results	O
show	O
that	O
measurements	O
of	O
tdt	O
activity	O
and	O
the	O
glucocorticoid	B-protein
receptor	I-protein
concentration	O
yield	O
valuable	O
prognostic	O
information	O
in	O
acute	B-cell_type
non-lymphocytic	I-cell_type
leukaemia	I-cell_type

###MEDLINE:85284782

[	O
0h	O
]	O
cortivazol	O
:	O
a	O
unique	O
high	O
affinity	O
ligand	O
for	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O

cortivazol	O
(	O
cvz	O
)	O
and	O
deacylcortivazol	B-protein
(	O
dac	B-protein
)	O
are	O
pyrazolosteroids	O
with	O
potent	O
glucocorticoid	O
activity	O
.	O

in	O
previous	O
work	O
we	O
showed	O
that	O
dac	B-protein
is	O
00-fold	O
more	O
potent	O
than	O
dexamethasone	O
(	O
dex	O
)	O
in	O
lysing	B-cell_type
leukemic	I-cell_type
lymphoblasts	I-cell_type
.	O

to	O
assess	O
the	O
interaction	O
between	O
these	O
atypical	O
steroids	O
and	O
the	O
glucocorticoid	B-protein
receptor	I-protein
,	O
we	O
examined	O
the	O
binding	O
of	O
[	O
0h	O
]	O
cvz	O
to	O
cytosol	O
from	O
glucocorticoid-sensitive	B-cell_line
and	I-cell_line
-resistant	I-cell_line
variants	I-cell_line
of	O
the	O
human	B-cell_line
leukemic	I-cell_line
cell	I-cell_line
line	I-cell_line
cem	I-cell_line
c0	I-cell_line
.	O

in	O
glucocorticoid-sensitive	B-cell_line
cells	I-cell_line
[	O
0h	O
]	O
cvz	O
causes	O
a	O
0-fold	O
induction	O
of	O
glutamine	B-protein
synthetase	I-protein
and	O
binds	O
to	O
a	O
protein	O
in	O
the	O
0.0	O
s	B-DNA
region	I-DNA
of	O
high	O
salt	O
sucrose	O
gradients	O
.	O

on	O
deae-cellulose	O
chromatography	O
,	O
[	O
0h	O
]	O
cvz-receptor	B-protein
complexes	I-protein
show	O
a	O
shift	O
from	O
high	O
(	O
0.00	O
m	O
kp	O
)	O
to	O
low	O
salt	O
(	O
0.00	O
m	O
kp	O
)	O
eluting	O
forms	O
upon	O
activation	O
.	O

cvz	O
competes	O
for	O
a	O
00	O
,	O
000-dalton	B-protein
protein	I-protein
labeled	O
by	O
[	O
0h	O
]	O
dexamethasone	O
mesylate	B-protein
.	O

scatchard	O
analysis	O
of	O
the	O
binding	O
of	O
[	O
0h	O
]	O
cvz	O
in	O
glucocorticoid-sensitive	B-cell_line
cells	I-cell_line
revealed	O
a	O
curvilinear	O
plot	O
which	O
resolved	O
into	O
high	O
(	O
0.0	O
nm	O
)	O
and	O
low	O
(	O
00	O
nm	O
)	O
affinity	O
components	O
.	O

the	O
receptor	O
concentration	O
of	O
the	O
low	O
affinity	O
site	O
(	O
0.00	O
pmol/mg	O
protein	O
)	O
was	O
approximately	O
twice	O
that	O
of	O
the	O
high	O
affinity	O
site	O
(	O
0.00	O
pmol/mg	O
protein	O
)	O
.	O

dissociation	O
experiments	O
with	O
dilution	O
and/or	O
excess	O
unlabeled	O
cvz	O
supported	O
the	O
presence	O
of	O
independent	O
sites	O
.	O

in	O
contrast	O
,	O
the	O
binding	O
of	O
[	O
0h	O
]	O
dex	O
to	O
c0	B-protein
cytosol	O
revealed	O
a	O
single	B-DNA
class	I-DNA
of	I-DNA
binding	I-DNA
sites	I-DNA
(	O
kd	O
=	O
0.0	O
nm	O
;	O
receptor	O
concentration	O
,	O
0.00	O
pmol/mg	O
protein	O
)	O
.	O

examination	O
of	O
the	O
binding	O
of	O
[	O
0h	O
]	O
cvz	O
using	O
00	O
(	O
-0	O
)	O
m	O
dex	O
as	O
the	O
competing	O
ligand	O
showed	O
that	O
dex	O
binds	O
only	O
to	O
the	O
low	O
affinity	O
site	O
detected	O
by	O
[	O
0h	O
]	O
cvz	O
.	O

in	O
cytosol	O
from	O
a	O
glucocorticoid-resistant	B-cell_line
cell	I-cell_line
line	I-cell_line
with	O
virtually	O
no	O
[	O
0h	O
]	O
dex	O
binding	O
,	O
[	O
0h	O
]	O
cvz	O
detected	O
a	O
single	O
high	O
affinity	O
binding	O
site	O
that	O
was	O
similar	O
in	O
dissociation	O
constant	O
(	O
0.0	O
nm	O
)	O
and	O
receptor	O
concentration	O
(	O
0.00	O
pmol/mg	O
protein	O
)	O
to	O
the	O
high	O
affinity	O
site	O
detected	O
in	O
the	O
glucocorticoid-sensitive	B-cell_line
cell	I-cell_line
line	I-cell_line
c0	I-cell_line
.	O

###MEDLINE:85266114

a	O
controlled	O
pore	O
glass	O
bead	O
assay	O
for	O
the	O
measurement	O
of	O
cytoplasmic	B-protein
and	I-protein
nuclear	I-protein
glucocorticoid	I-protein
receptors	I-protein
.	O

an	O
assay	O
for	O
the	O
quantitation	O
of	O
cytoplasmic	B-protein
and	I-protein
nuclear	I-protein
glucocorticoid	I-protein
receptors	I-protein
in	O
lymphoid	O
tissue	O
has	O
been	O
developed	O
using	O
controlled	O
pore	O
glass	O
(	O
cpg	O
)	O
beads	O
.	O

soluble	B-protein
receptor	I-protein
--	I-protein
0h-steroid	I-protein
complex	I-protein
(	O
cytosol	O
or	O
nuclear	O
extract	O
)	O
is	O
adsorbed	O
quantitatively	O
within	O
the	O
crevasses	O
of	O
porous	O
glass	O
beads	O
.	O

excess	O
labeled	O
steroid	O
as	O
well	O
as	O
most	O
non-specifically	O
bound	O
steroid	O
is	O
easily	O
washed	O
away	O
,	O
leaving	O
the	O
hormone-receptor	O
complex	O
retained	O
by	O
the	O
beads	O
.	O

bound	O
0h-steroid	B-protein
is	O
eluted	O
with	O
ethanol	O
and	O
measured	O
for	O
radioactivity	O
.	O

this	O
procedure	O
which	O
is	O
simple	O
,	O
rapid	O
,	O
and	O
highly	O
reproducible	O
is	O
carried	O
out	O
using	O
frozen	O
samples	O
(	O
stable	O
for	O
many	O
months	O
)	O
containing	O
as	O
few	O
as	O
0	O
x	O
00	O
(	O
0	O
)	O
cells	O
.	O

a	O
comparison	O
of	O
the	O
cpg	O
assay	O
to	O
dextran	O
coated	O
charcoal	O
and	O
a	O
whole	O
cell	O
assay	O
demonstrates	O
that	O
cpg	O
and	O
dextran	O
coated	O
charcoal	O
give	O
equivalent	O
measurements	O
of	O
cytosolic	B-protein
receptor	I-protein
concentration	O
,	O
while	O
the	O
cpg	O
and	O
whole	O
cell	O
assays	O
provide	O
equivalent	O
values	O
for	O
total	O
receptor	O
content	O
.	O

###MEDLINE:85186850

plasmacytoid	O
blast	O
crisis	O
in	O
b-cell	O
chronic	O
lymphocytic	O
leukemia	O
:	O
effect	O
of	O
estradiol	O
on	O
growth	O
and	O
differentiation	O
in	O
vitro	O
.	O

evolution	O
of	O
a	O
case	O
of	O
chronic	O
lymphocytic	O
leukemia	O
(	O
cll	B-cell_line
)	O
into	O
blast	O
crisis	O
was	O
found	O
to	O
be	O
characterized	O
by	O
three	O
unusual	O
features	O
(	O
0	O
)	O
the	O
phenotype	O
of	O
the	O
emerging	O
blast	B-cell_type
cells	I-cell_type
was	O
that	O
of	O
pre-plasmacytoid	B-cell_line
cells	I-cell_line
as	O
shown	O
by	O
plasma	B-cell_type
cell	I-cell_type
morphology	I-cell_type
and	O
an	O
immunological	O
phenotype	O
corresponding	O
partially	O
with	O
cll-	B-protein
or	O
intermediate	B-cell_type
b-cells	I-cell_type
,	O
partially	O
with	O
plasma	B-cell_type
cells	I-cell_type
(	O
terminal	B-protein
transferase	I-protein
-	O
,	O
common	O
acute	B-cell_type
lymphocytic	I-cell_type
leukemia	I-cell_type
antigen	I-cell_type
-	I-cell_type
,	I-cell_type
ia+	I-cell_type
,	O
surface	B-protein
immunoglobulin	I-protein
heavy	I-protein
chains	I-protein
-	O
,	O
surface	B-protein
kappa	I-protein
light	I-protein
chains	I-protein
+	O
,	O
intracytoplasmic	O
immunoglobulin	B-DNA
a+	I-DNA
and	I-DNA
g+	I-DNA
,	O
ba-0+	O
,	O
polyclonal	O
gammaglobulin	O
production	O
)	O
;	O
(	O
0	O
)	O
cytogenetic	O
analysis	O
of	O
spontaneous	B-cell_line
metaphases	I-cell_line
revealed	O
that	O
in	O
addition	O
to	O
the	O
typical	O
cll	O
abnormality	O
,	O
trisomy	O
00	O
,	O
in	O
all	O
of	O
the	O
cells	O
,	O
an	O
additional	O
translocation	O
between	O
chromosomes	B-DNA
00	O
and	O
00	O
was	O
present	O
in	O
00	O
%	O
with	O
a	O
presumptive	O
breakpoint	O
on	O
chromosome	B-DNA
00	I-DNA
(	O
q00-0	B-protein
)	O
never	O
described	O
before	O
(	O
commonly	B-DNA
q00	I-DNA
)	I-DNA
and	O
(	O
0	O
)	O
the	O
progression	O
of	O
the	O
disease	O
was	O
associated	O
with	O
a	O
striking	O
increase	O
in	O
the	O
expression	O
by	O
the	O
transformed	B-cell_line
cells	I-cell_line
of	O
specific	O
binding	O
sites	O
for	O
estradiol	O
(	O
e0	B-protein
)	O
due	O
to	O
an	O
actual	O
increase	O
in	O
total	O
cellular	B-protein
receptor	I-protein
proteins	I-protein
and	O
not	O
to	O
a	O
change	O
in	O
receptor	O
affinity	O
for	O
e0	O
.	O

the	O
functional	O
status	O
of	O
the	O
steroid	B-protein
receptors	I-protein
was	O
confirmed	O
by	O
nuclear	O
transfer	O
of	O
the	O
cytoplasmic	O
hormone-receptor	O
complex	O
upon	O
temperature	O
activation	O
.	O

since	O
the	O
rise	O
in	O
e0-receptor	O
display	O
paralleled	O
a	O
large	O
increase	O
in	O
the	O
proliferative	O
activity	O
of	O
the	O
cells	O
as	O
well	O
as	O
a	O
change	O
in	O
their	O
maturation	O
status	O
the	O
question	O
was	O
raised	O
as	O
to	O
whether	O
the	O
e0-receptor	O
should	O
be	O
considered	O
as	O
a	O
physiological	O
marker	O
of	O
growth	O
rate	O
or	O
of	O
cellular	O
differentiation	O
.	O

exposure	O
of	O
the	O
patient	O
's	O
blast	B-cell_type
cells	I-cell_type
to	O
e0	O
in	O
vitro	O
resulted	O
in	O
cessation	O
of	O
cell	O
growth	O
following	O
at	O
least	O
one	O
mitosis	O
after	O
addition	O
of	O
the	O
inducer	O
as	O
seen	O
from	O
the	O
replacement	O
of	O
the	O
large	O
blasts	O
by	O
small	O
cll-like	B-cell_type
cells	I-cell_type
without	O
definite	O
signs	O
of	O
alteration	O
of	O
the	O
differentiation	O
status	O
.	O

this	O
suggests	O
the	O
association	O
of	O
e0-receptor	O
expression	O
with	O
control	O
of	O
growth	O
rather	O
than	O
cell	O
maturation	O
.	O

###MEDLINE:84259121

multiple	O
forms	O
and	O
fragments	O
of	O
cytosolic	B-protein
glucocorticoid	I-protein
receptors	I-protein
from	O
human	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
and	O
normal	B-cell_type
lymphocytes	I-cell_type
.	O

therapy	O
with	O
glucocorticoids	O
is	O
generally	O
more	O
effective	O
in	O
acute	O
lymphoblastic	O
leukemia	O
than	O
in	O
other	O
types	O
of	O
human	O
leukemia	O
.	O

previous	O
studies	O
,	O
however	O
,	O
have	O
not	O
revealed	O
any	O
consistent	O
relationship	O
between	O
clinical	O
responsiveness	O
and	O
the	O
cellular	O
or	O
cytosolic	O
concentration	O
of	O
glucocorticoid-binding	B-DNA
sites	I-DNA
.	O

the	O
objectives	O
of	O
this	O
study	O
were	O
to	O
determine	O
whether	O
there	O
are	O
intrinsic	O
structural	O
differences	O
among	O
the	O
glucocorticoid	B-protein
receptors	I-protein
in	O
various	O
types	O
of	O
leukemic	B-cell_type
cells	I-cell_type
and	O
normal	B-cell_type
lymphocytes	I-cell_type
and	O
to	O
investigate	O
the	O
role	O
of	O
endogenous	O
peptidases	O
in	O
receptor	O
degradation	O
.	O

cytosols	O
were	O
prepared	O
from	O
fresh	O
or	O
rapidly	O
frozen	O
leukocytes	B-cell_type
from	O
0	O
healthy	O
adults	O
and	O
00	O
high-risk	O
leukemia	O
patients	O
(	O
median	O
white	B-cell_type
blood	I-cell_type
cell	I-cell_type
count	O
,	O
000	O
,	O
000	O
cells/microliter	O
;	O
median	O
age	O
,	O
00	O
years	O
)	O
.	O

receptors	O
were	O
labeled	O
with	O
[	O
0h	O
]	O
triamcinolone	O
acetonide	O
and	O
quantitated	O
by	O
charcoal-dextran	O
treatment	O
or	O
sephadex	O
lh-00	O
chromatography	O
.	O

mean	O
and	O
median	O
cytosolic	B-protein
receptor	I-protein
concentrations	O
in	O
00	O
acute	O
lymphoblastic	O
leukemia	O
specimens	O
lacking	O
the	O
standard	O
b-cell	O
or	O
t-cell	B-protein
markers	I-protein
(	O
``	O
null	O
cells	O
''	O
)	O
were	O
approximately	O
0-fold	O
higher	O
than	O
in	O
00	O
other	O
leukemic	B-cell_type
cell	I-cell_type
specimens	I-cell_type
.	O

no	O
other	O
consistent	O
differences	O
in	O
receptor	O
content	O
were	O
observed	O
.	O

agarose	O
filtration	O
and	O
ultracentrifugation	O
in	O
hypotonic	O
buffers	O
containing	O
00	O
mm	O
na0moo0	O
revealed	O
complexes	O
of	O
similar	O
size	O
and	O
shape	O
in	O
all	O
clinical	O
specimens	O
tested	O
and	O
two	O
established	B-cell_line
leukemic	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

they	O
had	O
stokes	O
radii	O
(	O
rs	O
)	O
of	O
0.0	O
+/-	O
0.0	O
(	O
s.d.	B-protein
)	O
nm	O
(	O
n	O
=	O
00	O
)	O
,	O
sedimentation	O
coefficients	O
of	O
0.0	O
+/-	O
0.0s	O
(	O
n	O
=	O
00	O
)	O
,	O
molecular	O
weights	O
of	O
approximately	O
000	O
,	O
000	O
,	O
and	O
axial	O
ratios	O
(	O
a/b	B-protein
)	O
of	O
approximately	O
00	O
.	O

in	O
hypertonic	O
,	O
molybdate-free	O
buffer	O
,	O
these	O
oligomeric	B-protein
complexes	I-protein
were	O
dissociated	O
into	O
subunits	O
with	O
rs	O
of	O
0.0	O
+/-	O
0.0	O
nm	O
(	O
n	O
=	O
00	O
)	O
and	O
a/b	O
of	O
00	O
to	O
00	O
,	O
as	O
observed	O
previously	O
for	O
other	O
receptors	O
.	O

fragmentation	O
of	O
the	O
oligomer	O
and	O
the	O
subunit	O
was	O
evident	O
in	O
some	O
cytosols	O
.	O

high	O
activities	O
of	O
peptidases	O
of	O
various	O
specificities	O
were	O
detected	O
in	O
leukemic	O
cell	O
cytosols	O
,	O
as	O
in	O
other	O
cytosols	O
,	O
by	O
fluorometric	O
assays	O
with	O
derivatives	O
of	O
0-amino-0-methylcoumarin	O
.	O

receptor	O
cleavage	O
by	O
these	O
and	O
other	O
endogenous	B-protein
enzymes	I-protein
may	O
account	O
for	O
previous	O
observations	O
of	O
``	O
abnormal	B-protein
''	I-protein
receptors	I-protein
in	O
cytosols	O
from	O
some	O
leukemic	B-cell_type
specimens	I-cell_type
.	O

we	O
conclude	O
that	O
intrinsic	O
structural	O
defects	O
in	O
the	O
receptors	O
are	O
unlikely	O
explanations	O
for	O
the	O
unresponsiveness	O
of	O
some	O
types	O
of	O
leukemia	O
to	O
steroid	O
therapy	O
.	O

###MEDLINE:84140373

glucocorticoid	B-protein
receptor	I-protein
number	O
and	O
intracellular	O
water	O
space	O
.	O

in	O
order	O
to	O
elucidate	O
the	O
relationship	O
between	O
cell	O
water	O
content	O
and	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
,	O
eleven	O
normal	O
and	O
malignant	B-cell_type
lymphoid	I-cell_type
or	I-cell_type
myelomonocytic	I-cell_type
cell	I-cell_type
types	I-cell_type
originating	O
from	O
mouse	O
,	O
rat	O
and	O
man	O
were	O
investigated	O
.	O

the	O
cellular	O
water	O
space	O
was	O
measured	O
with	O
0h0o	O
,	O
and	O
glucocorticoid	B-protein
receptor	I-protein
number	O
was	O
measured	O
in	O
a	O
whole-cell	O
binding	O
assay	O
with	O
[	O
0h	O
]	O
dexamethasone	O
at	O
00	O
and	O
00	O
degrees	O
c	O
.	O

the	O
intracellular	O
water	O
phase	O
concentration	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
around	O
00	O
nmol/l	O
cell	O
water	O
)	O
,	O
and	O
the	O
dependence	O
of	O
receptor	O
affinity	O
on	O
temperature	O
were	O
similar	O
in	O
normal	B-cell_type
and	I-cell_type
malignant	I-cell_type
rodent	I-cell_type
and	I-cell_type
human	I-cell_type
cells	I-cell_type
.	O

it	O
is	O
concluded	O
that	O
comparisons	O
of	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
are	O
best	O
made	O
on	O
the	O
basis	O
of	O
intracellular	O
receptor	O
concentrations	O
.	O

###MEDLINE:84001945

covalent	O
labeling	O
of	O
rat	B-cell_type
thymocyte	I-cell_type
and	O
human	O
lymphoid	O
glucocorticoid	B-protein
receptor	I-protein
.	O

lymphoid	B-cell_type
cells	I-cell_type
contain	O
specific	O
receptors	O
for	O
glucocorticoids	O
.	O

we	O
have	O
used	O
[	O
0h	O
]	O
dexamethasone-00-mesylate	O
to	O
label	O
covalently	O
glucocorticoid	B-protein
receptors	I-protein
in	O
rat	B-cell_type
thymic	I-cell_type
lymphocytes	I-cell_type
and	O
in	O
neoplastic	B-cell_type
cells	I-cell_type
obtained	O
from	O
patients	O
with	O
acute	B-cell_type
lymphoblastic	I-cell_type
leukemia	I-cell_type
and	I-cell_type
malignant	I-cell_type
lymphoma	I-cell_type
.	O

the	O
covalently	O
labeled	O
glucocorticoid	B-protein
receptors	I-protein
were	O
identified	O
by	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
in	O
the	O
presence	O
of	O
0.0	O
%	O
sodium	O
dodecyl	O
sulfate	O
)	O
.	O

in	O
cytosolic	O
fractions	O
prepared	O
from	O
rat	B-cell_type
thymic	I-cell_type
lymphocytes	I-cell_type
,	O
[	O
0h	O
]	O
-dexamethasone-00-mesylate	B-protein
labels	I-protein
a	I-protein
protein	I-protein
(	O
mr	B-protein
approximately	O
equal	O
to	O
00	O
,	O
000	O
)	O
which	O
was	O
identified	O
as	O
the	O
glucocorticoid	B-protein
receptor	I-protein
by	O
the	O
following	O
criteria	O
:	O
(	O
a	O
)	O
labeling	O
of	O
this	O
moiety	O
is	O
inhibited	O
by	O
treatment	O
with	O
a	O
000-fold	O
molar	O
excess	O
of	O
glucocorticoids	O
,	O
such	O
as	O
dexamethasone	O
and	O
triamcinolone	O
acetonide	O
;	O
and	O
(	O
b	O
)	O
the	O
covalently	O
labeled	O
mr	B-protein
approximately	O
equal	O
to	O
00	O
,	O
000	O
protein	O
is	O
activated	O
(	O
by	O
heating	O
at	O
00	O
degrees	O
for	O
00	O
min	O
)	O
to	O
a	O
form	O
that	O
binds	O
to	O
dna-cellulose	O
.	O

when	O
intact	B-cell_type
thymocytes	I-cell_type
are	O
treated	O
with	O
[	O
0h	O
]	O
dexamethasone-00-mesylate	B-protein
,	O
an	O
mr	B-protein
approximately	O
equal	O
to	O
00	O
,	O
000	O
moiety	O
is	O
also	O
labeled	O
covalently	O
.	O

approximately	O
00	O
%	O
of	O
the	O
glucocorticoid	B-protein
receptors	I-protein
can	O
be	O
labeled	O
covalently	O
when	O
intact	B-cell_type
thymocytes	I-cell_type
are	O
treated	O
with	O
000	O
nm	O
[	O
0h	O
]	O
dexamethasone-00-mesylate	B-protein
for	O
00	O
min	O
at	O
0	O
degrees	O
.	O

neoplastic	B-cell_type
cells	I-cell_type
from	O
acute	B-cell_type
lymphoblastic	I-cell_type
leukemia	I-cell_type
and	I-cell_type
malignant	I-cell_type
lymphoma	I-cell_type
were	O
treated	O
with	O
[	O
0h	O
]	O
dexamethasone-00-mesylate	B-protein
.	O

in	O
all	O
samples	O
,	O
an	O
mr	B-protein
approximately	O
equal	O
to	O
00	O
,	O
000	O
moiety	O
was	O
labeled	O
covalently	O
;	O
labeling	O
was	O
inhibited	O
by	O
excess	O
glucocorticoid	O
.	O

smaller	B-protein
moieties	I-protein
were	O
also	O
identified	O
by	O
competition	O
experiments	O
;	O
these	O
may	O
represent	O
proteolytic	O
fragments	O
of	O
the	O
mr	B-protein
approximately	O
equal	O
to	O
00	O
,	O
000	B-protein
receptor	I-protein
.	O

thus	O
,	O
in	O
rat	B-cell_type
and	I-cell_type
human	I-cell_type
lymphoid	I-cell_type
cells	I-cell_type
,	O
[	O
0h	O
]	O
dexamethasone-00-mesylate	B-protein
can	O
be	O
used	O
to	O
label	O
covalently	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O

###MEDLINE:83204609

the	O
association	O
of	O
cytosol	O
oestrogen	O
and	O
progesterone	B-protein
receptors	I-protein
with	O
histological	O
features	O
of	O
breast	O
cancer	O
and	O
early	O
recurrence	O
of	O
disease	O
.	O

two	O
hundred	O
and	O
eighty-eight	O
primary	O
breast	O
tumours	O
were	O
examined	O
for	O
the	O
presence	O
or	O
absence	O
of	O
oestrogen	O
(	O
rec	B-protein
)	O
and	O
progesterone	B-protein
(	I-protein
rpc	I-protein
)	I-protein
receptors	I-protein
.	O

analysis	O
has	O
shown	O
a	O
relative	O
interdependence	O
between	O
the	O
steroid	B-protein
receptor	I-protein
status	O
of	O
primary	O
breast	O
cancer	O
and	O
other	O
prognostic	O
variables	O
such	O
as	O
histological	O
grade	O
,	O
lymphocytic	O
infiltration	O
and	O
tumour	B-protein
elastosis	I-protein
.	O

there	O
were	O
significant	O
associations	O
between	O
epithelial	O
cellularity	O
,	O
stromal	O
fibrosis	O
and	O
the	O
value	O
of	O
rec	B-protein
in	O
those	O
tumours	O
in	O
which	O
the	O
receptor	O
was	O
present	O
.	O

cellularity	O
and	O
fibrosis	O
were	O
unrelated	O
to	O
the	O
presence	O
or	O
absence	O
of	O
oestrogen	B-protein
receptor	I-protein
.	O

by	O
contrast	O
,	O
neither	O
the	O
presence	O
or	O
absence	O
nor	O
the	O
value	O
of	O
rpc	B-protein
could	O
be	O
related	O
to	O
cellularity	O
or	O
fibrosis	O
.	O

the	O
value	O
of	O
rec	B-protein
and	O
rpc	O
analysis	O
as	O
an	O
indicator	O
of	O
prognosis	O
was	O
examined	O
in	O
a	O
sub-group	O
of	O
000	O
patients	O
receiving	O
no	O
additional	O
treatment	O
following	O
mastectomy	O
.	O

overall	O
relapse-free	O
survival	O
(	O
rfs	B-DNA
)	O
was	O
no	O
different	O
for	O
those	O
patients	O
with	O
receptors	O
compared	O
to	O
those	O
without	O
them	O
(	O
rec	B-protein
p	O
=	O
0.00	O
,	O
rpc	O
p	O
=	O
0.0	O
)	O
.	O

there	O
was	O
no	O
difference	O
in	O
rfs	B-protein
of	I-protein
receptor	I-protein
positive	O
and	O
negative	O
tumours	O
when	O
the	O
axillary	O
node	O
status	O
was	O
taken	O
into	O
account	O
.	O

###MEDLINE:82281646

clinical	O
implications	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
human	O
leukemia	O
.	O

normal	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
contain	O
glucocorticoid	B-protein
receptor	I-protein
.	O

a	O
variety	O
of	O
stimuli	O
that	O
activate	O
these	O
cells	O
also	O
induce	O
increases	O
in	O
receptor	O
concentration	O
.	O

similar	O
glucocorticoid	B-protein
receptors	I-protein
can	O
be	O
detected	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
from	O
patients	O
with	O
acute	O
lymphoblastic	O
leukemia	O
(	O
all	O
)	O
.	O

absence	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
(	O
usually	O
found	O
in	O
treated	O
patients	O
)	O
predicts	O
lack	O
of	O
glucocorticoid	O
responsiveness	O
.	O

furthermore	O
,	O
in	O
our	O
hands	O
,	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
correlate	O
with	O
the	O
duration	O
of	O
complete	O
remission	O
in	O
all	O
(	O
though	O
not	O
in	O
other	O
forms	O
of	O
leukemia	O
)	O
.	O

this	O
association	O
is	O
independent	O
of	O
cell	O
type	O
,	O
age	O
,	O
sex	O
,	O
or	O
initial	O
leukocyte	O
count	O
.	O

the	O
level	O
of	O
receptor	O
shows	O
a	O
negative	O
correlation	O
with	O
increasing	O
aggressiveness	O
of	O
the	O
tumor	B-protein
(	I-protein
null-cell	I-protein
leukemia	O
greater	O
than	O
t-cell	O
leukemia	O
greater	O
than	O
burkitt	B-cell_line
's	I-cell_line
lymphoma	I-cell_line
)	I-cell_line
.	O

###MEDLINE:83005500

corticosteroid-mediated	O
immunoregulation	O
in	O
man	O
.	O

glucocorticoids	O
have	O
profound	O
and	O
complex	O
effects	O
on	O
the	O
human	O
immune	O
response	O
.	O

however	O
,	O
the	O
precise	O
mechanisms	O
of	O
the	O
corticosteroid-induced	O
immunoregulation	O
in	O
man	O
have	O
not	O
been	O
precisely	O
defined	O
.	O

intracytoplasmic	O
corticosteroid-specific	B-protein
receptors	I-protein
appear	O
to	O
be	O
an	O
important	O
common	O
pathway	O
for	O
steroid-induced	O
changes	O
,	O
but	O
variations	O
of	O
receptor	O
parameters	O
do	O
not	O
account	O
for	O
the	O
multifaceted	O
effects	O
on	O
the	O
immune	O
system	O
.	O

human	B-cell_type
circulating	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
redistribute	O
out	O
of	O
the	O
intravascular	O
compartment	O
following	O
treatment	O
with	O
corticosteroids	O
.	O

although	O
certain	O
components	O
at	O
this	O
redistribution	O
phenomenon	O
have	O
been	O
well-characterized	O
,	O
the	O
importance	O
of	O
this	O
compartmental	O
cellular	O
shift	O
with	O
respect	O
to	O
the	O
mechanisms	O
of	O
corticosteroid-induced	O
immunoregulation	O
are	O
less	O
well-defined	O
.	O

recent	O
observations	O
that	O
activated	B-cell_type
lymphocytes	I-cell_type
may	O
be	O
sensitive	O
to	O
the	O
lytic	O
effects	O
of	O
glucocorticoids	O
suggest	O
that	O
under	O
certain	O
situations	O
the	O
elimination	O
of	O
selected	O
subsets	O
of	O
cells	O
may	O
be	O
a	O
relevant	O
mechanism	O
of	O
corticosteroid-mediated	O
immunoregulation	O
in	O
man	O
.	O

corticosteroid-mediated	O
effects	O
on	O
monocyte	O
function	O
may	O
be	O
an	O
important	O
mechanism	O
of	O
drug-induced	O
immunoregulation	O
in	O
monocyte-dependent	O
responses	O
.	O

in	O
some	O
experimental	O
conditions	O
,	O
corticosteroids	O
inhibit	O
interleukin	B-protein
0	I-protein
production	O
by	O
monocytes	B-cell_type
.	O

the	O
immunoregulatory	O
effects	O
of	O
corticosteroids	O
on	O
lymphocyte	O
immune	O
responses	O
are	O
complex	O
.	O

in	O
vitro	O
corticosteroids	O
appear	O
to	O
selectively	O
affect	O
early	O
immunoregulatory	O
events	O
as	O
opposed	O
to	O
altering	O
an	O
established	O
response	O
.	O

multiple	O
sites	O
of	O
steroid-induced	O
modulations	O
of	O
human	B-cell_type
b	I-cell_type
cell	I-cell_type
responses	O
have	O
been	O
defined	O
.	O

###MEDLINE:81260241

human	B-cell_line
lymphoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
glucocorticoids	O
:	O
ii	O
.	O

whole	O
cell	O
and	O
cytoplasmic	O
binding	O
properties	O
of	O
lymphoblastoid	B-cell_type
,	I-cell_type
leukaemia	I-cell_type
and	I-cell_type
lymphoma	I-cell_type
lines	I-cell_type
.	O

the	O
glucocorticoid	O
binding	O
properties	O
of	O
00	O
human	B-cell_line
lymphoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
hlcl	B-protein
)	O
have	O
been	O
investigated	O
.	O

the	O
specificity	O
of	O
steroid	O
binding	O
was	O
confirmed	O
with	O
various	O
glucocorticoid	O
agonists	O
and	O
antagonists	O
.	O

a	O
gradation	O
in	O
whole	O
cell	O
and	O
cytoplasmic	O
glucocorticoid	O
binding	O
capacity	O
was	O
observed	O
in	O
the	O
different	O
cell	O
line	O
types	O
:	O
lymphoblastoid	O
greater	O
than	O
lymphoma	O
greater	O
than	O
leukaemia	O
.	O

the	O
cytoplasmic	B-protein
receptors	I-protein
of	O
leukaemia	O
and	O
lymphoblastoid	B-cell_line
lines	I-cell_line
appeared	O
to	O
contain	O
both	O
proteinaceous	O
and	O
phospholipid	O
components	O
.	O

cytoplasmic	B-protein
steroid-receptor	I-protein
complexes	I-protein
exhibited	O
a	O
wide	O
range	O
of	O
sedimentation	O
coefficients	O
(	O
0.0-00.0s	B-protein
)	O
in	O
low	O
ionic	O
strength	O
buffer	O
but	O
there	O
was	O
no	O
correlation	O
with	O
cell	B-cell_line
line	I-cell_line
type	O
or	O
glucocorticoid	O
sensitivity	O
.	O

activation	O
of	O
these	O
complexes	O
by	O
heat	O
(	O
00	O
degrees	O
c	O
)	O
or	O
exposure	O
to	O
high	O
ionic	O
strength	O
buffer	O
(	O
0.0	O
m	O
nacl	O
)	O
induced	O
nuclear	O
binding	O
of	O
steroid	O
but	O
only	O
complexes	O
in	O
high	O
ionic	O
strength	O
buffer	O
manifested	O
changes	O
in	O
sedimentation	O
coefficient	O
.	O

no	O
correlation	O
was	O
observed	O
between	O
the	O
level	O
or	O
nature	O
of	O
glucocorticoid	O
binding	O
and	O
the	O
cytolethal	O
or	O
cytostatic	O
responsiveness	O
of	O
hlcl	O
to	O
glucocorticoid	O
treatment	O
in	O
vitro	O
.	O

the	O
resistance	O
to	O
cytolethal	O
effects	O
can	O
not	O
be	O
ascribed	O
to	O
a	O
failure	O
of	O
cells	O
to	O
take	O
up	O
and	O
bind	O
steroid	O
or	O
to	O
significant	O
differences	O
in	O
the	O
molecular	O
species	O
of	O
cytoplasmic	B-protein
receptors	I-protein
present	O
.	O

the	O
molecular	O
mechanisms	O
by	O
which	O
glucocorticoids	O
achieve	O
cytolethal	O
responses	O
in	O
human	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type

###MEDLINE:98281994

cd00	B-protein
-mediated	O
activation	O
in	O
cd00ra+	B-cell_type
and	I-cell_type
cd00ro+	I-cell_type
t	I-cell_type
cells	I-cell_type
:	O
enhanced	O
levels	O
of	O
reactive	O
oxygen	O
intermediates	O
and	O
c-rel	B-protein
nuclear	O
translocation	O
in	O
cd00ra+	B-cell_type
cells	I-cell_type
.	O

we	O
have	O
analyzed	O
the	O
effect	O
of	O
complete	O
t	O
cell	O
activation	O
(	O
anti-cd0	B-protein
plus	O
anti-cd00	B-protein
)	O
on	O
the	O
activation	O
of	O
nf-kappab	B-protein
in	O
cd00ra+	B-cell_type
(	I-cell_type
naive	I-cell_type
)	I-cell_type
and	I-cell_type
cd00ro+	I-cell_type
(	I-cell_type
memory/effector	I-cell_type
)	I-cell_type
t	I-cell_type
cells	I-cell_type
.	O

long	O
exposure	O
(	O
00	O
h	O
)	O
induced	O
stronger	O
nf-kappab	B-protein
dna	O
binding	O
in	O
cd00ra+	B-cell_type
cells	I-cell_type
than	O
in	O
cd00ro+	B-cell_type
cells	I-cell_type
.	O

analysis	O
of	O
the	O
nuclear	B-protein
c-rel	I-protein
protein	I-protein
indicated	O
that	O
after	O
anti-cd0+anti-cd00	O
stimulation	O
the	O
level	O
of	O
c-rel	B-protein
was	O
higher	O
in	O
cd00ra+	B-cell_type
cells	I-cell_type
.	O

analysis	O
of	O
the	O
cytoplasmic	B-protein
inhibitor	I-protein
ikappabalpha	B-protein
indicated	O
that	O
anti-cd0+anti-cd00	O
stimulation	O
induced	O
a	O
long-lasting	O
degradation	O
in	O
cd00ra+	B-cell_type
cells	I-cell_type
but	O
in	O
cd00ro+	B-cell_type
cells	I-cell_type
the	O
degradation	O
process	O
was	O
more	O
rapid	O
.	O

because	O
the	O
cd00	B-protein
costimulus	O
is	O
known	O
to	O
induce	O
the	O
production	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
rois	O
)	O
,	O
the	O
intracellular	O
roi	O
levels	O
in	O
cd00ra+	B-cell_type
and	I-cell_type
cd00ro+	I-cell_type
cells	I-cell_type
were	O
compared	O
by	O
flow	O
cytometry	O
.	O

rois	O
were	O
produced	O
in	O
both	O
cell	O
types	O
,	O
but	O
more	O
strongly	O
in	O
cd00ra+	B-cell_type
cells	I-cell_type
.	O

the	O
data	O
presented	O
in	O
this	O
study	O
further	O
emphasize	O
the	O
differences	O
between	O
cd00ra+	B-cell_type
and	I-cell_type
cd00ro+	I-cell_type
t	I-cell_type
lymphocytes	I-cell_type
in	O
roi-dependent	O
signaling	O
pathways	O
.	O

###MEDLINE:98282479

ikaros	B-protein
in	O
hemopoietic	B-cell_type
lineage	I-cell_type
determination	O
and	O
homeostasis	O
.	O

studies	O
on	O
the	O
molecular	O
mechanisms	O
that	O
control	O
hemopoietic	O
differentiation	O
have	O
focused	O
on	O
signaling	O
cascades	O
and	O
nuclear	B-protein
effectors	I-protein
that	O
drive	O
this	O
complex	O
developmental	O
system	O
in	O
a	O
regulated	O
fashion	O
.	O

here	O
we	O
review	O
the	O
role	O
of	O
ikaros	B-protein
,	O
the	O
founding	O
member	O
of	O
a	O
unique	O
family	O
of	O
zinc	B-protein
finger	I-protein
transcription	I-protein
factors	I-protein
in	O
this	O
developmental	O
process	O
.	O

studies	O
on	O
an	O
ikaros	B-protein
null	O
mutation	O
have	O
revealed	O
an	O
essential	O
role	O
for	O
this	O
factor	O
in	O
lymphoid	O
cell	O
fate	O
determination	O
and	O
at	O
subsequent	O
branch	O
points	O
of	O
the	O
t	O
cell	O
differentiation	O
pathway	O
.	O

differences	O
in	O
the	O
phenotypes	O
of	O
a	O
null	O
and	O
a	O
dominant	O
negative	O
(	O
dn	O
)	O
ikaros	B-protein
mutation	O
provide	O
insight	O
into	O
a	O
regulatory	O
network	O
through	O
which	O
ikaros	B-protein
proteins	I-protein
exert	O
their	O
effects	O
in	O
development	O
.	O

in	O
addition	O
a	O
comparative	O
analysis	O
of	O
the	O
hemopoietic	B-cell_line
stem	I-cell_line
cell	I-cell_line
and	I-cell_line
precursor	I-cell_line
compartment	I-cell_line
resulting	O
from	O
the	O
two	O
ikaros	B-DNA
mutations	I-DNA
reveals	O
a	O
profound	O
yet	O
not	O
absolute	O
requirement	O
for	O
ikaros	B-protein
in	O
the	O
production	O
and	O
differentiation	O
of	O
these	O
populations	O
.	O

###MEDLINE:98266173

overexpression	O
of	O
p00	B-protein
and	O
c-jun	B-protein
substitutes	O
for	O
b0-0	B-protein
costimulation	O
by	O
targeting	O
the	O
cd00re	B-DNA
within	O
the	O
il-0	B-DNA
promoter	I-DNA
.	O

the	O
role	O
of	O
rel	B-protein
and	I-protein
activation	I-protein
protein-0	I-protein
(	O
ap-0	B-protein
)	O
in	O
il-0	B-DNA
promoter	I-DNA
activity	O
in	O
b0-0-	B-protein
and	I-protein
leukocyte	I-protein
function-associated	I-protein
ag-0	I-protein
(	O
lfa.	O
0	O
)	O
-costimulated	B-cell_type
t	I-cell_type
cells	I-cell_type
has	O
been	O
evaluated	O
.	O

we	O
demonstrate	O
that	O
overexpression	O
of	O
c-jun	B-protein
but	O
not	O
c-fos	B-protein
increases	O
il-0	B-DNA
promoter	I-DNA
activity	O
in	O
both	O
b0-0-	B-cell_line
and	I-cell_line
lfa-0-costimulated	I-cell_line
jurkat	I-cell_line
t	I-cell_line
cells	I-cell_line
.	O

cotransfection	O
of	O
both	O
c-jun	B-DNA
and	O
c-fos	B-protein
substitutes	O
for	O
b0-0	B-protein
costimulation	O
in	O
driving	O
an	O
activation	B-protein
protein-0	I-protein
response	O
element	O
but	O
not	O
for	O
the	O
il-0	B-DNA
promoter	I-DNA
.	O

overexpression	O
of	O
rel	B-protein
proteins	I-protein
demonstrated	O
that	O
p00-expressing	B-cell_line
jurkat	I-cell_line
cells	I-cell_line
transcribed	O
equally	O
well	O
a	O
nuclear	B-DNA
factor	I-DNA
kappabeta	I-DNA
reporter	I-DNA
construct	I-DNA
when	O
costimulated	O
with	O
b0-0	B-protein
or	O
lfa-0	B-protein
,	O
but	O
transcription	O
of	O
il-0	B-DNA
promoter	I-DNA
or	O
cd00	B-DNA
response	I-DNA
element	I-DNA
(	O
cd00re	B-DNA
)	O
-driven	O
reporters	O
was	O
superior	O
in	O
b0-0-costimulated	B-cell_type
cells	I-cell_type
.	O

combined	O
expression	O
of	O
c-jun	B-protein
and	O
p00	B-protein
induced	O
vigorous	O
transcription	O
of	O
il-0	B-DNA
promoter-	I-DNA
and	I-DNA
cd00re-driven	I-DNA
reporter	I-DNA
constructs	I-DNA
in	O
both	O
lfa-0-	B-cell_line
and	I-cell_line
b0-0-costimulated	I-cell_line
jurkat	I-cell_line
cells	I-cell_line
.	O

mutating	O
the	O
cd00re	B-DNA
but	O
not	O
the	O
upstream	B-DNA
nuclear	I-DNA
factor	I-DNA
kappabeta-binding	I-DNA
site	I-DNA
in	O
the	O
il-0	B-DNA
promoter	I-DNA
reduced	O
b0-0	B-protein
-driven	O
transcription	O
>	O
00	O
%	O
.	O

the	O
results	O
implicates	O
a	O
major	O
role	O
of	O
the	O
cd00re	B-DNA
in	O
the	O
integration	O
of	O
p00	B-protein
/	O
c-jun	B-protein
-mediated	O
transcription	O
within	O
the	O
il-0	B-DNA
promoter	I-DNA
.	O

we	O
suggest	O
that	O
the	O
transition	O
from	O
an	O
autocrine	O
lfa-0	B-protein
-driven	O
immune	O
response	O
to	O
a	O
b0	O
--	O
induced	O
paracrine	O
immune	O
response	O
involves	O
the	O
activation	O
of	O
c-jun	B-protein
and	O
p00	B-protein
,	O
which	O
target	O
the	O
cd00re	B-DNA
region	O
of	O
the	O
il-0	B-DNA
promoter	I-DNA
.	O

###MEDLINE:98263946

defects	O
in	O
actin-cap	O
formation	O
in	O
vav-deficient	O
mice	O
implicate	O
an	O
actin	B-protein
requirement	O
for	O
lymphocyte	O
signal	O
transduction	O
.	O

background	O
:	O
antigen-receptor	O
interactions	O
on	O
lymphocytes	B-cell_type
result	O
in	O
local	O
clustering	O
of	O
actin	B-protein
,	I-protein
receptors	I-protein
and	O
signaling	B-protein
molecules	I-protein
into	O
an	O
asymmetric	B-protein
membrane	I-protein
structure	I-protein
termed	O
a	O
cap	B-DNA
.	I-DNA

although	O
actin	B-protein
polymerization	O
is	O
known	O
to	O
be	O
required	O
,	O
the	O
mechanisms	O
underlying	O
cap	O
formation	O
are	O
unclear	O
.	O

we	O
have	O
studied	O
the	O
events	O
underlying	O
cap	O
formation	O
using	O
mice	O
bearing	O
a	O
null	O
mutation	O
in	O
vav	B-protein
(	O
vav	B-protein
-/-	O
)	O
,	O
a	O
gene	O
that	O
encodes	O
a	O
guanine-nucleotide	B-protein
exchange	I-protein
factor	I-protein
for	O
the	O
gtpase	B-protein
rac	I-protein
.	O

results	O
:	O
lymphocytes	B-cell_type
from	O
vav	B-protein
-/-	O
mice	O
failed	O
to	O
form	O
t-cell	B-DNA
receptor	I-DNA
caps	I-DNA
following	O
activation	O
and	O
had	O
a	O
defective	O
actin	O
cytoskeleton	O
.	O

the	O
vav-/-	B-cell_line
t	I-cell_line
cells	I-cell_line
were	O
deficient	O
in	O
interleukin-0	B-protein
(	O
il-0	B-protein
)	O
production	O
and	O
proliferation	O
,	O
and	O
the	O
peak	O
of	O
ca0+	O
mobilization	O
was	O
reduced	O
although	O
of	O
normal	O
duration	O
.	O

activation	O
of	O
jun	B-protein
n-terminal	I-protein
kinase	I-protein
or	O
stress-activated	B-protein
kinase	I-protein
(	O
jnk	B-protein
or	O
sapk	B-protein
)	O
and	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
mapk	B-protein
)	O
and	O
the	O
induction	O
of	O
the	O
transcription	B-protein
factor	I-protein
nf-atc0	I-protein
and	O
egr-0	B-DNA
genes	I-DNA
was	O
normal	O
.	O

despite	O
the	O
reduced	O
ca0+	O
mobilization	O
,	O
translocation	O
of	O
cytoplasmic	O
nf-atc	B-protein
to	O
the	O
nucleus	O
was	O
normal	O
,	O
reflecting	O
that	O
the	O
lower	O
levels	O
of	O
ca0+	O
in	O
vav-/-	B-cell_line
cells	I-cell_line
were	O
still	O
sufficient	O
to	O
activate	O
calcineurin	B-protein
.	O

treatment	O
of	O
lymphocytes	B-cell_type
with	O
cytochalasin	O
d	O
,	O
which	O
blocks	O
actin	B-protein
polymerization	O
,	O
inhibited	O
cap	O
formation	O
and	O
produced	O
defects	O
in	O
signaling	O
and	O
il-0	B-protein
transcriptional	O
induction	O
in	O
response	O
to	O
antigen-receptor	O
signaling	O
that	O
were	O
nearly	O
identical	O
to	O
those	O
seen	O
in	O
vav-/-	B-cell_type
cells	I-cell_type
.	O

in	O
transfection	O
studies	O
,	O
either	O
constitutively	O
active	O
vav	B-protein
or	O
rac	B-protein
could	O
complement	O
constitutively	O
active	O
calcineurin	B-protein
to	O
activate	O
nf-at-dependent	O
transcription	O
.	O

conclusions	O
:	O
these	O
results	O
indicate	O
that	O
vav	B-protein
is	O
required	O
for	O
cap	O
formation	O
in	O
lymphocytes	B-cell_type
.	O

furthermore	O
,	O
the	O
correlation	O
between	O
cap	O
formation	O
,	O
il-0	B-protein
production	O
and	O
proliferation	O
supports	O
the	O
hypothesis	O
that	O
an	O
actin-dependent	O
pathway	O
is	O
a	O
source	O
of	O
specialized	O
growth	O
regulatory	O
signals	O
.	O

###MEDLINE:98248918

cd00	B-protein
-dependent	O
activation	O
of	O
human	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
by	O
bacteroides	O
fragilis	O
outer	O
membrane	O
.	O

we	O
studied	O
the	O
capacity	O
of	O
isolated	B-cell_type
bacteriodes	I-cell_type
fragilis	O
outer	O
membrane	O
,	O
b.	O
fragilis	O
nctc0000	O
lipopolysaccharide	O
(	O
lps	O
;	O
endotoxin	B-protein
)	O
,	O
and	O
b.	O
fragilis	O
nctc0000	B-protein
capsular	I-protein
polysaccharides	I-protein
to	O
activate	O
human	B-cell_line
umbilical	I-cell_line
vein	I-cell_line
endothelial	I-cell_line
cell	I-cell_line
(	I-cell_line
huvec	I-cell_line
)	I-cell_line
monolayers	I-cell_line
.	O

to	O
assess	O
huvec	B-cell_type
activation	O
,	O
e-selectin	B-protein
expression	O
was	O
measured	O
by	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
elisa	O
)	O
,	O
northern	O
blot	O
analysis	O
for	O
e-selectin-specific	B-RNA
mrna	I-RNA
,	O
and	O
electrophoretic	O
gel	O
mobility	O
shift	O
assay	O
(	O
emsa	O
)	O
for	O
nf-kappa	B-protein
b	I-protein
,	O
a	O
transcription	B-protein
factor	I-protein
necessary	O
for	O
e-selectin	B-protein
gene	O
activation	O
.	O

exposure	O
of	O
huvecs	B-cell_line
to	O
b.	O
fragilis	O
outer	O
membrane	O
fractions	O
,	O
separated	O
from	O
other	O
components	O
of	O
the	O
b.	O
fragilis	O
cell	O
wall	O
by	O
isopycnic	O
,	O
sucrose	O
gradient	O
centrifugation	O
,	O
significantly	O
increased	O
surface	O
expression	O
of	O
e-selectin	B-protein
and	O
induced	O
functional	O
endothelial	O
cell	O
-dependent	O
leukocyte	O
adhesion	O
.	O

b.	O
fragilis	O
outer	O
membranes	O
induced	O
translocation	O
of	O
nf-kappa	B-protein
b	I-protein
to	O
huvec	B-cell_type
nuclei	O
and	O
accumulation	O
of	O
e-selectin	B-RNA
mrna	I-RNA
in	O
huvec	B-cell_type
cytoplasm	O
.	O

e-selectin	B-protein
expression	O
induced	O
by	O
b.	O
fragilis	O
outer	O
membranes	O
was	O
not	O
blocked	O
by	O
polymixin	B-protein
b	I-protein
.	O

in	O
contrast	O
,	O
e-selectin	B-protein
expression	O
induced	O
by	O
outer	O
membrane	O
fractions	O
purified	O
from	O
e.	O
coli	O
was	O
competitively	O
inhibited	O
by	O
polymixin	B-protein
b	I-protein
.	O

neither	O
purified	B-protein
b.	I-protein
fragilis	I-protein
lps	O
,	O
a	O
prominent	O
constituent	O
of	O
the	O
outer	O
membrane	O
,	O
nor	O
purified	B-protein
b.	I-protein
fragilis	I-protein
capsular	I-protein
polysaccharides	I-protein
induced	O
huvec	B-cell_type
activation	O
.	O

two	O
different	O
monoclonal	B-protein
antibodies	I-protein
directed	O
against	O
human	O
cd00	B-protein
completely	O
inhibited	O
b.	O
fragilis	O
outer	O
membrane-induced	O
nf-kappa	B-protein
b	I-protein
activation	O
,	O
e-selectin	B-protein
transcription	O
,	O
and	O
e-selectin	B-protein
surface	O
expression	O
.	O

we	O
conclude	O
that	O
the	O
outer	O
membrane	O
component	O
of	O
the	O
b.	O
fragilis	O
cell	O
wall	O
contains	O
a	O
proinflammatory	B-protein
factor	I-protein
(	O
s	O
)	O
,	O
that	O
is	O
not	O
lps	O
,	O
which	O
induces	O
human	B-cell_type
endothelial	I-cell_type
cell	I-cell_type
activation	O
by	O
a	O
soluble	O
cd00	B-protein
-dependent	O
mechanism	O
.	O

###MEDLINE:98240931

nf-kappab	B-protein
protects	O
hiv-0-infected	B-cell_type
myeloid	I-cell_type
cells	I-cell_type
from	O
apoptosis	O
.	O

hiv-0	O
infection	O
of	O
primary	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
and	O
myeloid	B-cell_line
cell	I-cell_line
lines	I-cell_line
results	O
in	O
sustained	O
nf-kappab	B-protein
activation	O
.	O

recently	O
,	O
nf-kappab	B-protein
induction	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
protecting	O
cells	O
from	O
programmed	O
cell	O
death	O
.	O

in	O
the	O
present	O
study	O
,	O
we	O
sought	O
to	O
investigate	O
whether	O
constitutive	O
nf-kappab	B-protein
activity	O
in	O
chronically	B-cell_line
hiv-0-infected	I-cell_line
promonocytic	I-cell_line
u000	I-cell_line
(	O
u0-iiib	B-cell_line
)	O
and	O
myeloblastic	B-cell_line
plb-000	I-cell_line
(	I-cell_line
plb-iiib	I-cell_line
)	I-cell_line
cells	I-cell_line
affects	O
apoptotic	O
signaling	O
.	O

tnfalpha	B-protein
and	O
cycloheximide	O
caused	O
infected	B-cell_type
cells	I-cell_type
to	O
undergo	O
apoptosis	O
more	O
rapidly	O
than	O
parental	B-cell_line
u000	I-cell_line
and	I-cell_line
plb-000	I-cell_line
cells	I-cell_line
.	O

inhibition	O
of	O
tnfalpha	B-protein
-induced	O
nf-kappab	B-protein
activation	O
using	O
the	O
antioxidant	O
n-acetylcysteine	O
(	O
nac	O
)	O
resulted	O
in	O
increased	O
apoptosis	O
in	O
both	O
u000	B-cell_line
and	O
u0-iiib	B-cell_line
cells	I-cell_line
,	O
while	O
preactivation	O
of	O
nf-kappab	B-protein
with	O
the	O
non-apoptotic	B-protein
inducer	I-protein
il-0beta	B-protein
caused	O
a	O
relative	O
decrease	O
in	O
apoptosis	O
.	O

inhibition	O
of	O
constitutive	O
nf-kappab	B-protein
activity	O
in	O
u0-iiib	B-cell_line
and	O
plb-iiib	B-cell_line
cells	I-cell_line
also	O
induced	O
apoptosis	O
,	O
suggesting	O
that	O
nf-kappab	B-cell_type
protects	I-cell_type
cells	I-cell_type
from	O
a	O
persistent	O
apoptotic	O
signal	O
.	O

tnfalpha	B-protein
plus	O
nac	O
treatment	O
resulted	O
in	O
a	O
marked	O
decrease	O
in	O
bcl-0	B-protein
protein	O
levels	O
in	O
hiv-0-infected	B-cell_line
cells	I-cell_line
,	O
coupled	O
with	O
an	O
increase	O
in	O
bax	B-protein
protein	O
compared	O
to	O
uninfected	B-cell_type
cells	I-cell_type
,	O
suggesting	O
that	O
the	O
difference	O
in	O
susceptibility	O
to	O
tnfalpha	B-protein
-induced	O
apoptosis	O
may	O
relate	O
to	O
the	O
differences	O
in	O
relative	O
levels	O
of	O
bcl-0	B-protein
and	O
bax	B-protein
.	O

the	O
protective	O
role	O
of	O
nf-kappab	B-protein
in	O
blocking	O
tnfalpha-	B-protein
and	O
hiv-0-induced	O
apoptosis	O
was	O
supported	O
by	O
studies	O
in	O
jurkat	B-cell_line
t	I-cell_line
cells	I-cell_line
engineered	O
to	O
express	O
ikappab	B-protein
alpha	I-protein
repressor	I-protein
mutants	I-protein
(	O
td-ikappab	B-protein
)	O
under	O
the	O
control	O
of	O
a	O
tetracycline-responsive	B-DNA
promoter	I-DNA
.	O

cells	O
underwent	O
apoptosis	O
in	O
response	O
to	O
tnfalpha	B-protein
only	O
when	O
nf-kappab	B-protein
activation	O
was	O
inhibited	O
by	O
td-ikappab	O
expression	O
.	O

as	O
was	O
observed	O
for	O
the	O
u0-iiib	B-cell_line
cells	I-cell_line
,	O
tnfalpha	B-protein
treatment	O
also	O
induced	O
a	O
marked	O
decrease	O
in	O
bcl-0	B-protein
protein	O
levels	O
in	O
td-ikappab	B-cell_type
expressing	I-cell_type
cells	I-cell_type
.	O

these	O
experiments	O
demonstrate	O
that	O
apoptotic	O
signaling	O
is	O
perturbed	O
in	O
hiv-0-infected	O
u0-iiib	B-cell_line
cells	I-cell_line
and	O
indicate	O
that	O
nf-kappab	B-protein
activation	O
may	O
play	O
an	O
additional	O
protective	O
role	O
against	O
hiv-0-induced	O
apoptosis	O
in	O
myeloid	B-cell_type
cells	I-cell_type
.	O

###MEDLINE:98227977

human	B-cell_type
normal	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
b-lymphocytes	I-cell_type
are	O
deficient	O
in	O
dna-dependent	B-protein
protein	I-protein
kinase	I-protein
activity	O
due	O
to	O
the	O
expression	O
of	O
a	O
variant	O
form	O
of	O
the	O
ku00	B-protein
protein	I-protein
.	O

the	O
heterodimeric	O
ku	B-protein
protein	I-protein
,	O
which	O
comprises	O
a	O
00	B-protein
kda	I-protein
(	I-protein
ku00	I-protein
)	O
amd	O
a	O
00	B-protein
kda	I-protein
(	I-protein
ku00	I-protein
)	I-protein
subunits	I-protein
,	O
is	O
an	O
abundant	O
nuclear	B-protein
dna-binding	I-protein
protein	I-protein
which	O
binds	O
in	O
vitro	O
to	O
dna	B-protein
termini	I-protein
without	O
sequence	O
specificity	O
.	O

ku	B-protein
is	O
the	O
dna-targeting	O
component	O
of	O
the	O
large	O
catalytic	B-protein
sub-unit	I-protein
of	O
the	O
dna-dependent	B-protein
protein	I-protein
kinase	I-protein
complex	I-protein
(	O
dna-pk	B-protein
[	I-protein
cs	I-protein
]	I-protein
)	I-protein
,	O
that	O
plays	O
a	O
critical	O
role	O
in	O
mammalian	B-DNA
double-strand	I-DNA
break	I-DNA
repair	O
and	O
lymphoid	O
v	O
(	O
d	O
)	O
j	O
recombination	O
.	O

by	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
demonstrated	O
that	O
in	O
addition	O
to	O
the	O
major	O
ku	B-protein
x	I-protein
dna	I-protein
complex	I-protein
usually	O
detected	O
in	O
cell	B-cell_line
line	I-cell_line
extracts	O
,	O
a	O
second	O
complex	O
with	O
faster	O
electrophoretic	O
mobility	O
was	O
observed	O
in	O
normal	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
pbl	B-cell_type
)	O
extracts	O
.	O

the	O
presence	O
of	O
this	O
faster	O
migrating	O
complex	O
was	O
restricted	O
to	O
b	B-cell_type
cells	I-cell_type
among	O
the	O
circulating	B-cell_type
lymphocyte	I-cell_type
population	I-cell_type
.	O

western	O
blot	O
analysis	O
revealed	O
that	O
b	B-cell_type
cells	I-cell_type
express	O
a	O
variant	O
form	O
of	O
the	O
ku00	B-protein
protein	I-protein
with	O
an	O
apparent	O
molecular	O
weight	O
of	O
00	O
kda	O
,	O
and	O
not	O
the	O
00	O
kda-	O
full-length	B-protein
protein	I-protein
.	O

although	O
the	O
heterodimer	B-protein
ku00/variant-ku00	I-protein
binds	O
to	O
dna-ends	B-protein
,	O
this	O
altered	O
form	O
of	O
the	O
ku	B-protein
heterodimer	I-protein
has	O
a	O
decreased	O
ability	O
to	O
recruit	O
the	O
catalytic	B-protein
component	I-protein
of	O
the	O
complex	O
,	O
dna-pk	B-protein
(	I-protein
cs	I-protein
)	I-protein
,	O
which	O
contributes	O
to	O
an	O
absence	O
of	O
detectable	O
dna-pk	B-protein
activity	I-protein
in	O
b	B-cell_type
cells	I-cell_type
.	O

these	O
data	O
provide	O
a	O
molecular	O
basis	O
for	O
the	O
increased	O
sensitivity	O
of	O
b	B-cell_type
cells	I-cell_type
to	O
ionizing	O
radiation	O
and	O
identify	O
a	O
new	O
mechanism	O
of	O
regulation	O
of	O
dna-pk	B-protein
activity	I-protein
that	O
operates	O
in	O
vivo	O
.	O

###MEDLINE:98220845

co-stimulation	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
with	O
il-0	B-protein
and	O
anti-cd0	B-protein
monoclonal	I-protein
antibodies	I-protein
induces	O
phosphorylation	O
of	O
creb	B-protein
.	O

phosphorylation	O
of	O
the	O
camp-response	B-DNA
element	I-DNA
binding	O
protein	B-protein
creb	I-protein
within	O
0	O
h	O
of	O
cd0	B-protein
but	O
not	O
cd0	B-protein
cross-linking	O
of	O
human	B-cell_type
pbmc	I-cell_type
was	O
recently	O
demonstrated	O
.	O

the	O
absence	O
of	O
p-creb	B-protein
following	O
cd0	B-protein
cross-linking	O
was	O
unexpected	O
,	O
as	O
other	O
laboratories	O
reported	O
increased	O
phosphorylation	O
of	O
creb	B-protein
following	O
cd0	B-protein
cross-linking	O
of	O
the	O
jurkat	B-cell_line
lymphocyte	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

due	O
to	O
jurkat	B-cell_line
t-cells	I-cell_line
being	O
il-0-independent	O
,	O
it	O
was	O
postulated	O
that	O
il-0	B-protein
might	O
provide	O
a	O
necessary	O
co-stimulus	O
for	O
phosphorylation	O
of	O
creb	B-protein
in	O
primary	B-cell_type
lymphocytes	I-cell_type
.	O

therefore	O
,	O
p-creb	B-protein
was	O
evaluated	O
following	O
co-stimulation	O
of	O
human	B-cell_type
pbmc	I-cell_type
through	O
the	O
il-0	B-protein
and	O
cd0	B-protein
or	O
cd0	B-protein
receptors	I-protein
.	O

il-0	B-protein
did	O
not	O
further	O
augment	O
phosphorylation	O
of	O
creb	B-protein
following	O
cd0	B-protein
cross-linking	O
.	O

however	O
,	O
while	O
neither	O
il-0	B-protein
nor	O
cd0	B-protein
cross-linking	O
alone	O
induced	O
p-creb	B-protein
,	O
a	O
0.0-fold	O
increase	O
in	O
phosphorylation	O
of	O
creb	B-protein
within	O
0	O
h	O
of	O
il-0/cd0	O
co-stimulation	O
was	O
observed	O
.	O

phosphorylation	O
was	O
not	O
associated	O
with	O
the	O
induction	O
of	O
camp	O
,	O
and	O
inhibition	O
of	O
pka	B-protein
signaling	O
had	O
no	O
effect	O
on	O
p-creb	B-protein
.	O

consistent	O
with	O
signal	O
transduction	O
through	O
p00lck	B-protein
or	O
p00fyn	B-protein
,	O
inhibition	O
of	O
ptk	B-protein
signaling	O
reduced	O
phosphorylation	O
00	O
%	O
.	O

interestingly	O
,	O
inhibiting	O
pkc	B-protein
signaling	O
with	O
calphostin	O
c	O
further	O
increased	O
p-creb	B-protein
levels	O
0-fold	O
over	O
that	O
observed	O
in	O
il-0/cd0	B-cell_line
co-stimulated	I-cell_line
cells	I-cell_line
not	O
pretreated	O
with	O
a	O
pkc	B-protein
inhibitor	I-protein
.	O

in	O
contrast	O
to	O
previous	O
studies	O
performed	O
in	O
the	O
absence	O
of	O
exogenous	O
il-0	B-protein
,	O
no	O
increase	O
in	O
binding	O
of	O
creb	B-protein
to	O
a	O
00p-labeled	B-DNA
oligonucleotide	I-DNA
probe	I-DNA
was	O
observed	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

these	O
data	O
suggest	O
that	O
the	O
il-0	B-protein
and	O
cd0	B-protein
signaling	O
pathways	O
provide	O
a	O
necessary	O
and	O
co-operative	O
stimulus	O
promoting	O
phosphorylation	O
of	O
creb	B-protein
following	O
receptor	O
cross-linking	O
.	O

###MEDLINE:98211678

hiv-0	O
infection	O
induces	O
a	O
selective	O
reduction	O
in	O
stat0	B-protein
protein	O
expression	O
.	O

hiv-0	O
infection	O
is	O
accompanied	O
by	O
qualitative	O
and	O
quantitative	O
defects	O
in	O
cd0+	B-cell_type
t	I-cell_type
lymphocytes	I-cell_type
.	O

loss	O
of	O
immune	O
function	O
in	O
hiv	O
patients	O
is	O
usually	O
associated	O
with	O
a	O
profound	O
dysregulation	O
of	O
cytokine	B-protein
production	O
.	O

to	O
investigate	O
whether	O
cytokine	B-protein
signaling	O
defects	O
occur	O
during	O
hiv	O
infection	O
,	O
pha	B-protein
blasts	O
from	O
healthy	O
human	O
donors	O
were	O
infected	O
with	O
two	O
strains	O
of	O
hiv-0	O
and	O
screened	O
for	O
the	O
expression	O
of	O
stat	B-protein
proteins	I-protein
used	O
in	O
cytokine	B-protein
signaling	O
.	O

a	O
selective	O
decrease	O
in	O
stat0b	B-protein
was	O
seen	O
0	O
days	O
after	O
infection	O
with	O
the	O
bz000	O
dual-tropic	O
hiv	O
isolate	O
,	O
but	O
not	O
with	O
the	O
ba-l	O
,	O
m-tropic	O
strain	O
.	O

based	O
on	O
these	O
findings	O
,	O
purified	B-cell_type
t	I-cell_type
cells	I-cell_type
from	O
hiv-infected	O
patients	O
in	O
different	O
stages	O
of	O
disease	O
were	O
also	O
tested	O
for	O
stat	B-protein
expression	O
;	O
decreases	O
in	O
stat0a	B-protein
,	O
stat0b	B-protein
,	O
and	O
stat0alpha	B-protein
were	O
observed	O
in	O
all	O
patients	O
.	O

the	O
reduction	O
in	O
stats	B-protein
seen	O
in	O
vivo	O
and	O
in	O
vitro	O
after	O
hiv	O
infection	O
may	O
contribute	O
to	O
the	O
loss	O
of	O
t	B-cell_type
cell	I-cell_type
function	O
in	O
hiv	O
disease	O
.	O

###MEDLINE:98204128

transcription	B-protein
factors	I-protein
that	O
regulate	O
monocyte	O
/	O
macrophage	O
differentiation	O
.	O

although	O
all	O
the	O
cells	O
in	O
an	O
organism	O
contain	O
the	O
same	O
genetic	O
information	O
,	O
differences	O
in	O
the	O
cell	O
phenotype	O
arise	O
from	O
the	O
expression	O
of	O
lineage-specific	B-DNA
genes	I-DNA
.	O

during	O
myelopoiesis	O
,	O
external	O
differentiating	O
signals	O
regulate	O
the	O
expression	O
of	O
a	O
set	O
of	O
transcription	B-protein
factors	I-protein
.	O

the	O
combined	O
action	O
of	O
these	O
transcription	B-protein
factors	I-protein
subsequently	O
determines	O
the	O
expression	O
of	O
myeloid-specific	B-DNA
genes	I-DNA
and	O
the	O
generation	O
of	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
.	O

in	O
particular	O
,	O
the	O
transcription	B-protein
factor	I-protein
pu.0	B-protein
has	O
a	O
critical	O
role	O
in	O
this	O
process	O
.	O

we	O
review	O
the	O
contribution	O
of	O
several	O
transcription	B-protein
factors	I-protein
to	O
the	O
control	O
of	O
macrophage	O
development	O

###MEDLINE:21370255

transcription	B-protein
factor	I-protein
lklf	I-protein
is	O
sufficient	O
to	O
program	O
t	O
cell	O
quiescence	O
via	O
a	O
c-myc	B-DNA
--	O
dependent	O
pathway	O
.	O

t	B-cell_type
lymphocytes	I-cell_type
circulate	O
in	O
a	O
quiescent	O
state	O
until	O
they	O
encounter	O
cognate	O
antigen	O
bound	O
to	O
the	O
surface	O
of	O
an	O
antigen-presenting	B-cell_type
cell	I-cell_type
.	O

the	O
molecular	O
pathways	O
that	O
regulate	O
t	O
cell	O
quiescence	O
remain	O
largely	O
unknown	O
.	O

here	O
we	O
show	O
that	O
forced	O
expression	O
of	O
the	O
lung	B-protein
kruppel-like	I-protein
transcription	I-protein
factor	I-protein
(	O
lklf	B-protein
)	O
in	O
jurkat	B-cell_line
t	I-cell_line
cells	I-cell_line
is	O
sufficient	O
to	O
program	O
a	O
quiescent	B-cell_type
phenotype	I-cell_type
characterized	O
by	O
decreased	O
proliferation	O
,	O
reduced	O
cell	O
size	O
and	O
protein	O
synthesis	O
and	O
decreased	O
surface	O
expression	O
of	O
activation	O
markers	O
.	O

conversely	O
,	O
lklf-deficient	B-cell_type
peripheral	I-cell_type
t	I-cell_type
cells	I-cell_type
produced	O
by	O
gene	O
targeting	O
showed	O
increased	O
proliferation	O
,	O
increased	O
cell	O
size	O
and	O
enhanced	O
expression	O
of	O
surface	O
activation	O
markers	O
in	O
vivo	O
.	O

lklf	O
appeared	O
to	O
function	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
decreasing	O
expression	O
of	O
the	O
proto-oncogene	B-DNA
encoding	O
c-myc	B-DNA
.	O

forced	O
expression	O
of	O
lklf	B-protein
was	O
associated	O
with	O
markedly	O
decreased	O
c-myc	B-DNA
expression	O
.	O

in	O
addition	O
,	O
many	O
effects	O
of	O
lklf	O
expression	O
were	O
mimicked	O
by	O
expression	O
of	O
the	O
dominant-negative	B-protein
madmyc	I-protein
protein	I-protein
and	O
rescued	O
by	O
overexpression	O
of	O
c-myc	B-DNA
.	O

thus	O
,	O
lklf	B-protein
is	O
both	O
necessary	O
and	O
sufficient	O
to	O
program	O
quiescence	O
in	O
t	B-cell_type
cells	I-cell_type
and	O
functions	O
,	O
in	O
part	O
,	O
by	O
negatively	O
regulating	O
a	O
c-myc	B-DNA
--	O
dependent	O
pathway	O
.	O

###MEDLINE:21361184

htlv-0	B-protein
p00	I-protein
(	O
i	B-protein
)	I-protein
protein	I-protein
enhances	O
stat0	B-protein
activation	O
and	O
decreases	O
the	O
interleukin-0	B-protein
requirement	O
for	O
proliferation	O
of	O
primary	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

the	O
p00	B-protein
(	I-protein
i	I-protein
)	I-protein
protein	I-protein
,	O
encoded	O
by	O
the	O
px	B-DNA
open	I-DNA
reading	I-DNA
frame	I-DNA
i	O
of	O
the	O
human	B-DNA
t-lymphotropic	I-DNA
virus	I-DNA
type	I-DNA
0	I-DNA
(	O
htlv-0	O
)	O
,	O
is	O
a	O
hydrophobic	B-protein
protein	I-protein
that	O
localizes	O
to	O
the	O
endoplasmic	O
reticulum	O
and	O
the	O
golgi	O
.	O

although	O
p00	B-protein
(	O
i	O
)	O
contains	O
0	O
minimal	O
proline-rich	B-protein
,	I-protein
src	B-DNA
homology	I-DNA
0-binding	I-DNA
motifs	I-DNA
(	O
pxxp	B-protein
)	O
,	O
a	O
characteristic	O
commonly	O
found	O
in	O
proteins	O
involved	O
in	O
signaling	O
pathways	O
,	O
it	O
has	O
not	O
been	O
known	O
whether	O
p00	B-protein
(	O
i	O
)	O
has	O
a	O
role	O
in	O
modulating	O
intracellular	O
signaling	O
pathways	O
.	O

this	O
study	O
demonstrated	O
that	O
p00	B-protein
(	O
i	O
)	O
binds	O
to	O
the	O
cytoplasmic	B-protein
domain	I-protein
of	O
the	O
interleukin-0	B-protein
receptor	I-protein
(	O
il-0r	B-protein
)	I-protein
beta	I-protein
chain	I-protein
that	O
is	O
involved	O
in	O
the	O
recruitment	O
of	O
the	O
jak0	B-protein
and	O
jak0	B-protein
kinases	I-protein
.	O

as	O
a	O
result	O
of	O
this	O
interaction	O
,	O
p00	B-protein
(	O
i	O
)	O
increases	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
0	I-protein
(	O
stat0	B-protein
)	O
dna	O
binding	O
and	O
transcriptional	O
activity	O
and	O
this	O
effect	O
depends	O
on	O
the	O
presence	O
of	O
both	O
il-0r	B-protein
beta	I-protein
and	I-protein
gamma	I-protein
(	I-protein
c	I-protein
)	I-protein
chains	I-protein
and	O
jak0	B-protein
.	O

transduction	O
of	O
primary	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
pbmcs	B-cell_type
)	O
with	O
a	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
0-based	I-DNA
retroviral	B-DNA
vector	I-DNA
expressing	O
p00	B-protein
(	O
i	O
)	O
also	O
resulted	O
in	O
increased	O
stat0	B-protein
phosphorylation	O
and	O
dna	O
binding	O
.	O

however	O
,	O
p00	B-protein
(	O
i	O
)	O
could	O
increase	O
proliferation	O
of	O
human	B-cell_type
pbmcs	I-cell_type
only	O
after	O
stimulation	O
of	O
t-cell	B-protein
receptors	I-protein
by	O
treatment	O
of	O
cells	O
with	O
low	O
concentrations	O
of	O
alphacd0	B-protein
and	O
alphacd00	B-protein
antibodies	I-protein
.	O

in	O
addition	O
,	O
the	O
proliferative	O
advantage	O
of	O
p00	B-protein
(	O
i	O
)	O
-transduced	O
pbmcs	B-cell_type
was	O
evident	O
mainly	O
at	O
low	O
concentrations	O
of	O
il-0	B-protein
.	O

together	O
,	O
these	O
data	O
indicate	O
that	O
p00	B-protein
(	O
i	O
)	O
may	O
confer	O
a	O
proliferative	O
advantage	O
on	O
htlv-0-infected	B-cell_type
cells	I-cell_type
in	O
the	O
presence	O
of	O
suboptimal	O
antigen	O
stimulation	O
and	O
that	O
this	O
event	O
may	O
account	O
for	O
the	O
clonal	O
proliferation	O
of	O
infected	B-cell_type
t	I-cell_type
cells	I-cell_type
in	O
vivo	O
.	O

(	O
blood.	O
0000	O
;	O
00	O
:	O
000-000	O
)	O

###MEDLINE:21359034

single	O
dose	O
intranasal	O
administration	O
of	O
retinal	B-protein
autoantigen	I-protein
generates	O
a	O
rapid	O
accumulation	O
and	O
cell	O
activation	O
in	O
draining	O
lymph	O
node	O
and	O
spleen	O
:	O
implications	O
for	O
tolerance	O
therapy	O
.	O

background/aims	O
:	O
a	O
single	O
intranasal	O
delivery	O
of	O
retinal	B-protein
autoantigen	I-protein
suppresses	O
effectively	O
experimental	O
autoimmune	O
uveoretinitis	O
(	O
eau	O
)	O
.	O

to	O
further	O
unravel	O
underlying	O
mechanisms	O
the	O
authors	O
wished	O
to	O
determine	O
,	O
firstly	O
,	O
the	O
kinetics	O
of	O
antigen	O
delivery	O
and	O
,	O
secondly	B-protein
,	O
the	O
early	O
cellular	O
responses	O
involved	O
in	O
the	O
initial	O
stages	O
of	O
nasal	O
mucosal	O
tolerance	O
induction	O
.	O

methods	O
:	O
flow	O
cytometry	O
,	O
cell	O
proliferation	O
assays	O
,	O
and	O
microscopy	O
were	O
used	O
to	O
track	B-protein
antigen	I-protein
following	O
a	O
single	O
,	O
intranasal	O
dose	O
of	O
alexa-000	B-protein
labelled	I-protein
retinal	I-protein
antigen	I-protein
.	O

results	O
:	O
a	O
rapid	O
accumulation	O
of	O
antigen	O
within	O
both	O
superficial	O
cervical	O
lymph	O
nodes	O
(	O
scln	B-protein
)	O
and	O
spleen	O
was	O
observed	O
after	O
00	O
minutes	O
.	O

significant	O
proliferative	O
responses	O
to	O
irbp	B-protein
were	O
elicited	O
by	O
00	O
hours	O
indicating	O
that	O
systemic	O
priming	O
of	O
naive	B-cell_type
t	I-cell_type
cells	I-cell_type
to	O
retinal	B-protein
antigen	I-protein
had	O
occurred	O
.	O

cell	O
activation	O
was	O
further	O
confirmed	O
by	O
immunoprecipitation	O
studies	O
,	O
which	O
demonstrated	O
phosphorylation	O
of	O
stat0	B-protein
but	O
not	O
stat0	B-protein
in	O
both	O
lymph	O
nodes	O
and	O
spleen	O
.	O

however	O
,	O
at	O
00	O
hours	O
,	O
stat0	B-protein
heterodimerisation	O
with	O
stat	B-protein
0	I-protein
was	O
only	O
observed	O
in	O
spleen	O
.	O

conclusions	O
:	O
the	O
results	O
provide	O
novel	O
evidence	O
that	O
following	O
a	O
single	O
intranasal	O
application	O
rapid	O
transfer	O
of	O
antigen	O
occurs	O
.	O

resulting	O
t	O
cell	O
proliferation	O
develops	O
consequent	O
to	O
differential	O
cell	O
signalling	O
in	O
scln	B-protein
and	O
spleen	O
.	O

further	O
understanding	O
of	O
these	O
underlying	O
cellular	O
mechanisms	O
,	O
in	O
particular	O
as	O
is	O
inferred	O
by	O
the	O
results	O
the	O
contribution	O
of	O
local	O
versus	O
systemic	O
tolerance	O
induction	O
,	O
may	O
assist	O
in	O
strategies	O
to	O
clinically	O
apply	O
mucosal	O
tolerance	O
therapy	O
successfully	O
.	O

###MEDLINE:21351024

regulation	O
of	O
interleukin	B-protein
(	I-protein
il	I-protein
)	I-protein
-00	I-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
expression	O
on	O
cd0	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
t	I-cell_type
cells	I-cell_type
during	O
t	B-cell_type
helper	I-cell_type
(	I-cell_type
th	I-cell_type
)	I-cell_type
0/th0	I-cell_type
differentiation	O
.	O

critical	O
downregulatory	O
role	O
of	O
il-0	B-protein
.	O

interleukin	B-protein
(	I-protein
il	I-protein
)	I-protein
-00	I-protein
has	O
been	O
well	O
characterized	O
as	O
a	O
costimulatory	B-protein
factor	I-protein
for	O
the	O
induction	O
of	O
il-00-mediated	O
interferon	B-protein
(	I-protein
ifn	I-protein
)	I-protein
-gamma	I-protein
production	O
by	O
t	B-cell_type
helper	I-cell_type
(	I-cell_type
th	I-cell_type
)	I-cell_type
0	I-cell_type
cells	I-cell_type
,	O
but	O
also	O
can	O
induce	O
il-0	B-protein
production	O
and	O
thus	O
facilitate	O
the	O
differentiation	O
of	O
th0	B-cell_type
cells	I-cell_type
.	O

to	O
determine	O
the	O
mechanisms	O
by	O
which	O
il-00	B-protein
might	O
regulate	O
these	O
diametrically	O
distinct	O
immune	O
responses	O
,	O
we	O
have	O
analyzed	O
the	O
role	O
of	O
cytokines	B-protein
in	O
the	O
regulation	O
of	O
il-00	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
(	O
il-00ralpha	B-protein
)	O
expression	O
.	O

the	O
majority	O
of	O
peripheral	B-cell_type
cd0	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
t	I-cell_type
cells	I-cell_type
constitutively	O
expressed	O
the	O
il-00ralpha	O
.	O

upon	O
antigen	O
stimulation	O
in	O
the	O
presence	O
of	O
il-00	B-protein
,	O
marked	O
enhancement	O
of	O
il-00ralpha	B-protein
expression	O
was	O
observed	O
.	O

il-00	B-protein
-mediated	O
upregulation	O
of	O
il-00ralpha	B-protein
required	O
ifn-gamma	B-protein
.	O

activated	B-cell_type
cd0	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
t	I-cell_type
cells	I-cell_type
that	O
expressed	O
low	O
levels	O
of	O
il-00ralpha	B-protein
could	O
produce	O
ifn-gamma	B-protein
when	O
stimulated	O
with	O
the	O
combination	O
of	O
il-00	B-protein
and	O
il-00	B-protein
,	O
while	O
cd0	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
which	O
expressed	O
high	O
levels	O
of	O
il-00ralpha	B-protein
could	O
respond	O
to	O
il-00	B-protein
alone	O
.	O

in	O
contrast	O
,	O
t	B-cell_type
cell	I-cell_type
stimulation	O
in	O
the	O
presence	O
of	O
il-0	B-protein
resulted	O
in	O
a	O
downregulation	O
of	O
il-00ralpha	B-protein
expression	O
.	O

both	O
il-0	B-protein
(	O
-/	B-protein
)	O
-	O
and	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	I-protein
stat	I-protein
)	I-protein
0	I-protein
(	O
-/	B-cell_line
)	I-cell_line
-	I-cell_line
t	I-cell_line
cells	I-cell_line
expressed	O
higher	O
levels	O
of	O
il-00ralpha	B-protein
after	O
tcr	B-protein
stimulation	O
.	O

furthermore	O
,	O
activated	B-cell_type
t	I-cell_type
cells	I-cell_type
from	O
stat0	B-protein
(	O
-/	B-protein
)	O
-	O
mice	O
produced	O
more	O
ifn-gamma	B-protein
in	O
response	O
to	O
il-00	B-protein
than	O
wild-type	O
controls	O
.	O

thus	O
,	O
positive/negative	O
regulation	O
of	O
the	O
il-00ralpha	O
by	O
the	O
major	O
inductive	O
cytokines	B-protein
(	O
il-00	B-protein
and	O
il-0	B-protein
)	O
determines	O
the	O
capacity	O
of	O
il-00	B-protein
to	O
polarize	O
an	O
immune	O
response	O
.	O

###MEDLINE:21342532

glucocorticoid-regulated	B-protein
transcription	I-protein
factors	I-protein
.	O

glucocorticoids	O
are	O
the	O
most	O
effective	O
antiinflammatory	O
drugs	O
used	O
in	O
the	O
treatment	O
of	O
asthma	O
.	O

they	O
act	O
by	O
binding	O
to	O
a	O
specific	B-protein
receptor	I-protein
(	O
gr	B-protein
)	O
that	O
,	O
upon	O
activation	O
,	O
translocates	O
to	O
the	O
nucleus	O
and	O
either	O
increases	O
(	O
transactivates	O
)	O
or	O
decreases	O
(	O
transrepresses	B-DNA
)	I-DNA
gene	I-DNA
expression	O
.	O

inhibition	O
of	O
pro-inflammatory	B-protein
transcription	I-protein
factors	I-protein
such	O
as	O
activator	B-protein
protein	I-protein
(	I-protein
ap	I-protein
)	I-protein
-0	I-protein
,	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	O
transcription	O
(	O
stats	B-protein
)	O
,	O
nuclear	B-protein
factor	I-protein
of	O
activated	B-cell_type
t	I-cell_type
cells	I-cell_type
(	O
nfat	B-protein
)	O
and	O
nuclear	B-protein
factor	I-protein
(	O
nf	B-protein
)	I-protein
-kappa	I-protein
b	I-protein
is	O
thought	O
to	O
be	O
a	O
major	O
action	O
of	O
glucocorticoids	O
.	O

acetylation	O
of	O
histones	O
allows	O
unwinding	O
of	O
the	O
local	O
dna	O
structure	O
and	O
enables	O
rna	B-protein
polymerase	I-protein
ii	I-protein
to	O
enhance	O
gene	O
transcription	O
.	O

histone	B-protein
acetylation	O
is	O
regulated	O
by	O
a	O
balance	O
between	O
the	O
activity	O
of	O
histone	B-protein
acetyltransferases	I-protein
(	O
hats	B-protein
)	O
and	O
histone	B-protein
deacetylases	I-protein
(	O
hdacs	B-protein
)	O
.	O

gr	B-protein
acts	O
as	O
a	O
direct	O
inhibitor	O
of	O
nf-kappa	B-protein
b-induced	I-protein
hat	O
activity	O
and	O
also	O
by	O
recruiting	O
hdac0	B-protein
to	O
the	O
nf-kappa	B-protein
b/hat	I-protein
complex	I-protein
.	O

a	O
sub-group	O
of	O
patients	O
with	O
glucocorticoid-insensitive	O
asthma	O
have	O
an	O
inability	O
to	O
induce	O
histone	B-protein
acetylation	O
in	O
response	O
to	O
dexamethasone	O
suggesting	O
reduced	O
expression	O
of	O
a	O
gr-specific	O
hat	O
.	O

this	O
suggests	O
that	O
pharmacological	O
manipulation	O
of	O
specific	O
histone	O
acetylation	O
status	O
is	O
a	O
potentially	O
useful	O
approach	O
for	O
the	O
treatment	O
of	O
inflammatory	O
diseases	O
.	O

identification	O
of	O
the	O
precise	O
mechanism	O
by	O
which	O
activated	O
gr	B-protein
recruits	O
hdac0	B-protein
may	O
reveal	O
new	O
targets	O
for	O
the	O
development	O
of	O
drugs	O
that	O
may	O
dissociate	O
the	O
antiinflammatory	O
actions	O
of	O
glucocorticoids	O
from	O
their	O
side	O
effects	O
that	O
are	O
largely	O
due	O
to	O
gene	O
induction	O
.	O

copyright	O
academic	O
press	O
.	O

###MEDLINE:21336830

differential	O
ultraviolet-b-induced	O
immunomodulation	O
in	O
xpa	B-protein
,	O
xpc	O
,	O
and	O
csb	B-protein
dna	O
repair-deficient	O
mice	O
.	O

ultraviolet	B-protein
b	I-protein
irradiation	O
has	O
serious	O
consequences	O
for	O
cellular	O
immunity	O
and	O
can	O
suppress	O
the	O
rejection	O
of	O
skin	B-cell_type
tumors	I-cell_type
and	O
the	O
resistance	O
to	O
infectious	O
diseases	O
.	O

dna	O
damage	O
plays	O
a	O
crucial	O
role	O
in	O
these	O
immunomodulatory	O
effects	O
of	O
ultraviolet	B-protein
b	I-protein
,	O
as	O
impaired	O
repair	O
of	O
ultraviolet-b-induced	O
dna	O
damage	O
has	O
been	O
shown	O
to	O
cause	O
suppression	O
of	O
cellular	O
immunity	O
.	O

ultraviolet-b-induced	O
dna	O
damage	O
is	O
repaired	O
by	O
the	O
nucleotide	O
excision	O
repair	O
mechanism	O
very	O
efficiently	O
.	O

nucleotide	O
excision	O
repair	O
comprises	O
two	O
subpathways	B-protein
:	I-protein
transcription-coupled	I-protein
and	O
global	O
genome	O
repair	O
.	O

in	O
this	O
study	O
the	O
immunologic	O
consequences	O
of	O
specific	O
nucleotide	O
excision	O
repair	O
defects	O
in	O
three	O
mouse	O
models	O
,	O
xpa	B-protein
,	O
xpc	O
,	O
and	O
csb	B-protein
mutant	O
mice	O
,	O
were	O
investigated	O
.	O

xpa	O
mice	O
carry	O
a	O
total	O
nucleotide	O
excision	O
repair	O
defect	O
,	O
whereas	O
xpc	B-protein
and	O
csb	B-protein
mice	O
only	O
lack	O
global	O
genome	O
and	O
transcription-coupled	O
nucleotide	O
excision	O
repair	O
,	O
respectively	O
.	O

our	O
data	O
demonstrate	O
that	O
cellular	O
immune	O
parameters	O
in	O
xpa	B-protein
,	O
xpc	O
,	O
and	O
csb	O
mice	O
are	O
normal	O
compared	O
with	O
their	O
wild-type	B-DNA
(	I-DNA
control	I-DNA
)	I-DNA
littermates	I-DNA
.	O

this	O
may	O
indicate	O
that	O
the	O
reported	O
altered	O
cellular	O
responses	O
in	O
xeroderma	O
pigmentosum	O
patients	O
are	O
not	O
constitutive	O
but	O
could	O
be	O
due	O
to	O
external	O
factors	O
,	O
such	O
as	O
ultraviolet	B-protein
b	I-protein
.	O

upon	O
exposure	O
to	O
ultraviolet	B-protein
b	I-protein
,	O
only	O
xpa	O
mice	O
are	O
very	O
sensitive	O
to	O
ultraviolet-b-induced	O
inhibition	O
of	O
th0-mediated	O
contact	O
hypersensitivity	O
responses	O
and	O
interferon-gamma	B-protein
production	O
in	O
skin	O
draining	O
lymph	O
nodes	O
.	O

lipopolysaccharide-stimulated	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
and	O
interleukin-00	B-protein
production	O
are	O
significantly	O
augmented	O
in	O
both	O
xpa	O
and	O
csb	B-protein
mice	O
after	O
ultraviolet	B-protein
b	I-protein
exposure	O
.	O

lymph	O
node	O
cell	O
numbers	O
were	O
increased	O
very	O
significantly	O
in	O
xpa	B-protein
,	O
mildly	O
increased	O
in	O
csb	B-protein
,	O
and	O
not	O
in	O
xpc	O
mice	O
.	O

in	O
general	O
xpc	O
mice	O
do	O
not	O
exhibit	O
any	O
indication	O
of	O
enhanced	O
ultraviolet	B-protein
b	I-protein
susceptibility	O
with	O
regard	O
to	O
the	O
immune	O
parameters	O
analyzed	O
.	O

these	O
data	O
suggest	O
that	O
both	O
global	O
genome	O
repair	O
and	O
transcription-coupled	O
repair	O
are	O
needed	O
to	O
prevent	O
immunomodulation	O
by	O
ultraviolet	B-protein
b	I-protein
,	O
whereas	O
transcription-coupled	O
repair	O
is	O
the	O
major	O
dna	O
repair	O
subpathway	O
of	O
nucleotide	O
excision	O
repair	O
that	O
prevents	O
the	O
acute	O
ultraviolet-b-induced	O
effects	O
such	O
as	O
erythema	O
.	O

###MEDLINE:21328827

biomechanical	O
strain	O
induces	O
class	B-protein
a	I-protein
scavenger	I-protein
receptor	I-protein
expression	O
in	O
human	O
monocyte/macrophages	B-cell_type
and	O
thp-0	B-cell_line
cells	I-cell_line
:	O
a	O
potential	O
mechanism	O
of	O
increased	O
atherosclerosis	O
in	O
hypertension	O
.	O

background	O
:	O
although	O
hypertension	O
is	O
an	O
important	O
risk	O
factor	O
for	O
the	O
development	O
of	O
atherosclerosis	O
,	O
the	O
mechanisms	O
for	O
this	O
interaction	O
are	O
incompletely	O
described	O
.	O

previous	O
studies	O
have	O
suggested	O
that	O
biomechanical	O
strain	O
regulates	O
macrophage	B-cell_type
phenotype	I-cell_type
.	O

we	O
tested	O
the	O
hypothesis	O
that	O
biomechanical	O
strain	O
can	O
induce	O
expression	O
of	O
the	O
class	B-protein
a	I-protein
scavenger	I-protein
receptor	I-protein
(	O
sra	B-cell_type
)	O
,	O
an	O
important	O
lipoprotein	O
receptor	O
in	O
atherogenesis	O
.	O

methods	O
and	O
results	O
:	O
human	O
monocyte/macrophages	B-cell_type
or	O
thp-0	B-cell_line
cells	I-cell_line
were	O
cultured	O
in	O
a	O
device	O
that	O
imposes	B-cell_line
uniform	I-cell_line
biaxial	I-cell_line
cyclic	I-cell_line
0-hz	I-cell_line
strains	I-cell_line
of	O
0	O
%	O
,	O
0	O
%	O
,	O
0	O
%	O
,	O
or	O
0	O
%	O
,	O
and	O
sra	O
expression	O
was	O
analyzed	O
.	O

mechanical	O
strains	O
induced	O
sra	B-cell_type
mrna	O
(	O
0.0+/-0.0-fold	O
at	O
0	O
%	O
strain	O
for	O
00	O
hours	O
,	O
p	O
<	O
0.00	O
)	O
and	O
sra	B-cell_type
protein	O
in	O
thp-0	B-cell_line
cells	I-cell_line
in	O
an	O
amplitude-dependent	O
manner	O
.	O

this	O
induction	O
was	O
accompanied	O
by	O
augmented	O
expression	O
of	O
the	O
class	B-protein
b	I-protein
scavenger	I-protein
receptor	I-protein
cd00	B-protein
(	O
0.0+/-0.0-fold	B-protein
,	O
p	O
<	O
0.000	O
)	O
but	O
not	O
by	O
increased	O
peroxisome	B-protein
proliferator-activated	I-protein
receptor-gamma	I-protein
expression	O
.	O

to	O
evaluate	O
this	O
effect	O
in	O
vivo	O
,	O
apolipoprotein	B-protein
e	I-protein
(	O
-/-	O
)	O
mice	O
were	O
randomly	O
assigned	O
to	O
receive	O
standard	O
chow	O
,	O
a	O
high-cholesterol	O
diet	O
,	O
or	O
a	O
high-cholesterol	O
diet	O
with	O
hypertension	O
induced	O
by	O
angiotensin	B-protein
ii	I-protein
infusion	O
for	O
0	O
weeks	O
.	O

immunohistochemistry	O
revealed	O
that	O
among	O
macrophages	B-cell_type
in	O
atherosclerotic	O
lesions	O
of	O
the	O
aorta	O
,	O
the	O
proportion	O
of	O
macrophages	B-cell_type
with	O
sra	B-cell_type
expression	O
was	O
highest	O
in	O
hypertensive	O
animals	O
on	O
a	O
high-cholesterol	O
diet	O
(	O
00.0+/-0.0	O
%	O
,	O
versus	O
00.0+/-0.0	O
%	O
for	O
normotensive	O
animals	O
on	O
a	O
high-cholesterol	O
diet	O
and	O
0.0+/-0.0	O
%	O
for	O
animals	O
on	O
standard	O
chow	O
;	O
p	O
<	O
0.000	O
)	O
.	O

conclusions	O
:	O
biomechanical	O
strain	O
induces	O
sra	B-cell_type
expression	O
by	O
monocyte/macrophages	B-cell_type
,	O
suggesting	O
a	O
novel	O
mechanism	O
for	O
promotion	O
of	O
atherosclerosis	O
in	O
hypertensive	O
patients	O
.	O

###MEDLINE:21316949

high	O
glucose	O
induces	O
mcp-0	B-protein
expression	O
partly	O
via	O
tyrosine	O
kinase-ap-0	O
pathway	O
in	O
peritoneal	B-cell_type
mesothelial	I-cell_type
cells	I-cell_type
.	O

background	O
:	O
high	O
glucose	O
in	O
peritoneal	B-cell_type
dialysis	I-cell_type
solutions	I-cell_type
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
peritoneal	O
fibrosis	O
in	O
chronic	B-cell_type
ambulatory	I-cell_type
peritoneal	I-cell_type
dialysis	I-cell_type
(	O
capd	B-protein
)	O
patients	O
.	O

however	O
,	O
the	O
mechanisms	O
are	O
not	O
very	O
clear	O
.	O

peritoneal	B-cell_type
macrophages	I-cell_type
seem	O
to	O
participate	O
in	O
the	O
process	O
of	O
peritoneal	B-cell_type
fibrosis	I-cell_type
and	O
monocyte	B-protein
chemoattractant	I-protein
protein-0	I-protein
(	O
mcp-0	B-protein
)	O
plays	O
a	O
key	O
role	O
in	O
the	O
recruitment	O
of	O
monocytes	B-cell_type
toward	O
the	O
peritoneal	B-cell_type
cavity	I-cell_type
.	O

however	O
,	O
little	O
is	O
known	O
about	O
the	O
effect	O
of	O
high	O
glucose	O
on	O
mcp-0	B-protein
expression	O
and	O
its	O
signal	O
transduction	O
pathway	O
in	O
human	B-cell_type
peritoneal	I-cell_type
mesothelial	I-cell_type
cells	I-cell_type
.	O

methods	O
:	O
mesothelial	B-cell_type
cells	I-cell_type
were	O
cultured	O
with	O
glucose	O
(	O
0	O
to	O
000	O
mmol/l	O
)	O
or	O
mannitol	O
chronically	O
for	O
up	O
to	O
seven	O
days	O
.	O

mcp-0	B-protein
expression	O
of	O
mrna	B-RNA
and	O
protein	O
was	O
measured	O
by	O
northern	O
blot	O
analysis	O
and	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
elisa	O
)	O
.	O

chemotactic	O
activity	O
of	O
high-glucose-conditioned	O
culture	O
supernatant	O
was	O
measured	O
by	O
chemotactic	O
assay	O
.	O

to	O
examine	O
the	O
roles	O
of	O
the	O
transcription	B-protein
factors	I-protein
activator	B-protein
protein-0	I-protein
(	O
ap-0	B-protein
)	O
and	O
nuclear	B-protein
factor-kappab	I-protein
(	O
nf-kappab	B-protein
)	O
,	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
emsa	O
)	O
was	O
performed	O
.	O

results	O
:	O
glucose	O
induced	O
mcp-0	B-RNA
mrna	I-RNA
expression	O
in	O
a	O
time-	O
and	O
dose-dependent	O
manner	O
.	O

mcp-0	B-protein
protein	O
in	O
cell	B-cell_line
culture	I-cell_line
supernant	I-cell_line
was	O
also	O
increased	O
.	O

equivalent	O
concentrations	O
of	O
mannitol	O
had	O
no	O
significant	O
effect	O
.	O

high-glucose-conditioned	B-protein
supernatant	I-protein
possessed	O
an	O
increased	O
chemotactic	O
activity	O
for	O
monocytes	B-cell_type
,	O
which	O
was	O
neutralized	O
by	O
anti-mcp-0	B-protein
antibody	I-protein
.	O

emsa	O
revealed	O
that	O
glucose	O
increased	O
the	O
ap-0	B-protein
binding	O
activity	O
in	O
a	O
time-	O
and	O
dose-dependent	O
manner	O
,	O
but	O
not	O
nf-kappab	B-protein
.	O

curcumin	O
,	O
an	O
inhibitor	O
of	O
ap-0	B-protein
,	O
dose-dependently	O
suppressed	O
the	O
induction	O
of	O
mcp-0	B-RNA
mrna	I-RNA
by	O
high	O
glucose	O
.	O

tyrosine	B-protein
kinase	I-protein
inhibitors	I-protein
such	O
as	O
genistein	O
(	O
00.0	O
to	O
00	O
micromol/l	O
)	O
and	O
herbimycin	O
a	O
(	O
0.0	O
to	O
0	O
micromol/l	O
)	O
inhibited	O
the	O
high-glucose-induced	O
mcp-0	B-RNA
mrna	I-RNA
expression	O
in	O
a	O
dose-dependent	O
manner	O
,	O
and	O
also	O
suppressed	O
the	O
high-glucose-induced	O
ap-0	B-protein
binding	O
activity	O
.	O

conclusions	O
:	O
:	O
high	O
glucose	O
induced	O
mesothelial	O
mcp-0	B-protein
expression	O
partly	O
via	O
the	O
tyrosine	B-protein
kinase-	I-protein
ap-0	B-protein
pathway	O
.	O

###MEDLINE:21311861

signal	O
thresholds	O
and	O
modular	O
synergy	O
during	O
expression	O
of	O
costimulatory	B-protein
molecules	I-protein
in	O
b	B-cell_type
lymphocytes	I-cell_type
.	O

we	O
analyzed	O
intracellular	O
pathways	O
modulating	O
surface	O
densities	O
of	O
cd00	B-protein
and	O
cd00	B-protein
in	O
b	B-cell_type
cells	I-cell_type
activated	O
through	O
ligation	O
of	O
the	O
ag	B-protein
receptor	I-protein
,	O
and	O
the	O
adhesion	B-protein
molecule	I-protein
cd00	B-protein
.	O

whereas	O
b	B-protein
cell	I-protein
ag	I-protein
receptor	I-protein
(	O
bcr	B-protein
)	O
cross-linking	O
alone	O
stimulated	O
increased	O
expression	O
of	O
cd00	B-protein
,	O
up-regulation	O
of	O
cd00	B-protein
required	O
dual	O
stimulation	O
with	O
anti-igm	B-protein
and	O
anti-cd00	B-protein
.	O

the	O
principal	O
downstream	O
component	O
contributed	O
by	O
bcr	B-protein
signaling	O
,	O
toward	O
both	O
cd00	B-protein
and	O
cd00	B-protein
induction	O
,	O
was	O
the	O
elevated	O
concentration	O
of	O
free	O
cytoplasmic	B-protein
ca	I-protein
(	I-protein
0+	I-protein
)	I-protein
,	O
recruited	O
by	O
way	O
of	O
capacitative	O
influx	O
.	O

this	O
alone	O
was	O
sufficient	O
to	O
generate	O
an	O
increase	O
in	O
cd00	B-protein
levels	O
.	O

however	O
,	O
cd00	B-protein
enhancement	O
required	O
the	O
concerted	O
action	O
of	O
both	O
intracellular	O
ca	O
(	O
0+	O
)	O
concentration	O
and	O
cd00-initiated	O
pathways	O
.	O

the	O
nexus	O
between	O
anti-igm	B-protein
and	O
anti-cd00	B-protein
stimulation	O
,	O
in	O
the	O
context	O
of	O
cd00	B-protein
regulation	O
,	O
was	O
identified	O
to	O
involve	O
a	O
self-propagating	O
process	O
of	O
sequential	O
synergy	O
.	O

the	O
first	O
step	O
involved	O
amplified	O
accumulation	O
of	O
intracellular	O
camp	O
,	O
as	O
a	O
result	O
of	O
cross-talk	O
between	O
bcr	B-protein
-mobilized	O
ca	O
(	O
0+	O
)	O
and	O
cd00-derived	O
signals	O
.	O

this	O
then	O
facilitated	O
a	O
second	O
synergistic	O
interaction	O
between	O
ca	O
(	O
0+	O
)	O
and	O
camp	O
,	O
culminating	O
in	O
cd00	B-protein
expression	O
.	O

our	O
findings	O
of	O
distinct	O
signal	O
transducer	O
requirements	O
,	O
with	O
the	O
added	O
consequences	O
of	O
cross-talk	O
,	O
offers	O
an	O
explanation	O
for	O
variable	O
modulation	O
of	O
costimulatory	B-protein
molecule	I-protein
expression	O
in	O
response	O
to	O
diverse	O
physiological	O
stimuli	O
.	O

importantly	O
,	O
these	O
results	O
also	O
reveal	O
how	O
concentration	O
threshold	O
barriers	O
for	O
recruitment	O
of	O
individual	O
second	O
messengers	O
can	O
be	O
overcome	O
by	O
constructive	O
convergence	O
of	O
signaling	O
modules	O
.	O

###MEDLINE:21301916

the	O
role	O
of	O
epstein-barr	O
virus	O
in	O
neoplastic	O
transformation	O
.	O

in	O
this	O
review	O
,	O
we	O
focus	O
on	O
new	O
data	O
from	O
basic	O
,	O
translational	O
and	O
clinical	O
research	O
relating	O
to	O
the	O
epstein-barr	O
virus	O
(	O
ebv	O
)	O
.	O

beside	O
its	O
well-known	O
tropism	O
for	O
b	B-cell_type
lymphocytes	I-cell_type
and	O
epithelial	B-cell_type
cells	I-cell_type
,	O
ebv	O
also	O
infects	O
t	B-cell_type
lymphocytes	I-cell_type
,	O
monocytes	B-cell_type
and	O
granulocytes	B-cell_type
.	O

after	O
primary	O
infection	O
,	O
ebv	O
persists	O
throughout	O
the	O
life	O
span	O
in	O
resting	B-cell_type
memory	I-cell_type
b	I-cell_type
cells	I-cell_type
,	O
from	O
where	O
it	O
is	O
reactivated	O
upon	O
breakdown	O
of	O
cellular	O
immunity	O
.	O

in	O
the	O
process	O
of	O
neoplastic	O
transformation	O
,	O
the	O
ebv-encoded	B-protein
latent	I-protein
membrane	I-protein
protein	I-protein
0	I-protein
(	O
lmp0	B-protein
)	O
oncogene	O
represents	O
the	O
major	O
driving	O
force	O
.	O

lmp0	B-protein
acts	O
like	O
a	O
constitutively	B-protein
activated	I-protein
receptor	I-protein
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
family	I-protein
and	O
allows	O
the	O
amplification	O
or	O
bypassing	O
of	O
physiological	O
regulatory	O
signals	O
through	O
direct	O
and	O
indirect	O
interactions	O
with	O
proteins	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor-associated	I-protein
factor	I-protein
(	O
traf	B-protein
)	I-protein
family	I-protein
.	O

traf0	B-protein
-mediated	O
nf-kappab	B-protein
activation	O
,	O
ap-0	B-protein
induction	O
and	O
jak0	B-protein
/	O
stat	B-protein
activation	O
may	O
result	O
in	O
sustained	O
proliferation	O
leading	O
to	O
lymphoma	O
.	O

the	O
ability	O
of	O
lmp0	B-protein
to	O
suppress	O
germinal	O
center	O
formation	O
and	O
its	O
capacity	O
to	O
mediate	O
its	O
own	O
transcriptional	O
activation	O
shed	O
new	O
light	O
on	O
the	O
pathogenesis	O
of	O
ebv-associated	O
latency	O
type	O
ii	O
lymphoproliferations	O
like	O
hodgkin	O
's	O
disease	O
and	O
angioimmunoblastic	O
lymphadenopathy	O
.	O

the	O
carboxy	B-protein
terminus	I-protein
of	O
lmp0	B-protein
is	O
also	O
a	O
reliable	O
marker	O
for	O
individual	O
ebv	O
strain	O
identification	O
and	O
thus	O
offers	O
new	O
possibilities	O
in	O
tracing	O
the	O
molecular	O
events	O
leading	O
to	O
posttransplant	O
lymphoproliferative	O
disorders	O
(	O
ptlds	B-protein
)	O
.	O

cytotoxic	B-cell_type
t	I-cell_type
lymphocytes	I-cell_type
directed	O
against	O
well-characterized	O
epitopes	O
of	O
ebv	O
latency	O
genes	O
represent	O
an	O
already	O
successful	O
and	O
promising	O
therapeutic	O
approach	O
to	O
ebv-associated	O
lymphomas	O
,	O
in	O
particular	O
ptlds	O

###MEDLINE:21369576

interferon-alpha	B-protein
drives	O
t	O
cell-mediated	O
immunopathology	O
in	O
the	O
intestine	O
.	O

the	O
ability	O
of	O
interferon	B-protein
(	I-protein
ifn	I-protein
)	I-protein
-alpha	I-protein
to	O
induce	O
autoimmunity	O
and	O
exacerbate	O
th0	O
diseases	O
is	O
well	O
known	O
.	O

we	O
have	O
recently	O
described	O
enhanced	O
expression	O
of	O
ifn-alpha	B-protein
in	O
the	O
mucosa	O
of	O
patients	O
with	O
celiac	O
disease	O
(	O
cd	O
)	O
,	O
a	O
gluten-sensitive	O
th0-mediated	O
enteropathy	O
,	O
characterized	O
by	O
villous	O
atrophy	O
and	O
crypt	O
cell	O
hyperplasia	O
.	O

previous	O
studies	O
from	O
this	O
laboratory	O
have	O
shown	O
that	O
t	B-cell_type
cell	I-cell_type
activation	O
in	O
explant	B-cell_line
cultures	I-cell_line
of	O
human	O
fetal	O
gut	O
can	O
also	O
result	O
in	O
villous	O
atrophy	O
and	O
crypt	O
cell	O
hyperplasia	O
.	O

we	O
have	O
,	O
therefore	O
,	O
examined	O
changes	O
that	O
take	O
place	O
in	O
explant	B-cell_line
cultures	I-cell_line
of	O
human	O
fetal	O
gut	O
after	O
activation	O
of	O
t	B-cell_type
cells	I-cell_type
with	O
anti-cd0	B-protein
and/or	O
ifn-alpha	B-protein
.	O

we	O
show	O
that	O
activation	O
of	O
t	B-cell_type
cells	I-cell_type
with	O
anti-cd0	B-protein
alone	O
elicits	O
a	O
small	O
ifn-gamma	B-protein
and	O
tnf-alpha	B-protein
response	O
with	O
no	O
tissue	O
injury	O
.	O

similarly	O
,	O
no	O
changes	O
are	O
seen	O
in	O
explants	O
cultured	O
with	O
ifn-alpha	B-protein
alone	O
.	O

however	O
,	O
addition	O
of	O
ifn-alpha	B-protein
with	O
anti-cd0	B-protein
results	O
in	O
enhanced	O
th0	O
response	O
and	O
crypt	O
cell	O
hyperplasia	O
.	O

this	O
is	O
associated	O
with	O
enhanced	O
phosphorylation	O
of	O
stat0	B-protein
,	O
stat0	B-protein
,	O
and	O
fyn	B-protein
,	O
a	O
src	B-protein
homology	I-protein
tyrosine	I-protein
kinase	I-protein
,	O
which	O
interacts	O
with	O
both	O
tcr	B-protein
and	O
ifn-alpha	B-protein
signal	O
components	O
.	O

together	O
these	O
data	O
indicate	O
that	O
ifn-alpha	B-protein
can	O
facilitate	O
activation	O
of	O
th0-reactive	B-cell_type
cells	I-cell_type
in	O
the	O
gut	O
and	O
drive	O
immunopathology	O
.	O

###MEDLINE:21363766

suppression	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
production	O
by	O
camp	O
in	O
human	B-cell_type
monocytes	I-cell_type
:	O
dissociation	O
with	O
mrna	O
level	O
and	O
independent	O
of	O
interleukin-00	B-protein
.	O

background	O
:	O
elevation	O
of	O
cellular	O
camp	O
inhibits	O
lipopolysaccharide	O
(	O
lps	O
)	O
-stimulated	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
tnf-alpha	B-protein
)	O
production	O
and	O
increases	O
the	O
expression	O
of	O
interleukin	B-protein
(	I-protein
il	I-protein
)	I-protein
-00	I-protein
in	O
mononuclear	B-cell_type
cells	I-cell_type
.	O

tnf-alpha	B-protein
gene	O
expression	O
obligates	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor	I-protein
kappab	I-protein
(	O
nf-kappab	B-protein
)	O
.	O

exogenous	O
il-00	B-protein
inhibits	O
nf-kappab	B-protein
in	O
monocytes	B-cell_type
and	O
thus	O
attenuates	O
tnf-alpha	B-protein
production	O
.	O

we	O
examined	O
the	O
role	O
of	O
endogenous	O
il-00	B-protein
in	O
the	O
regulation	O
of	O
nf-kappab	B-protein
activation	O
and	O
tnf-alpha	B-protein
production	O
in	O
human	B-cell_type
monocytes	I-cell_type
by	O
camp	O
.	O

methods	O
:	O
human	B-cell_type
monocytes	I-cell_type
were	O
stimulated	O
with	O
escherichia	O
coli	O
lps	O
(	O
000	O
ng/ml	O
)	O
with	O
and	O
without	O
forskolin	O
(	O
fsk	O
,	O
00	O
microm	O
)	O
or	O
dibutyryl	O
cyclic	O
amp	O
(	O
dbcamp	O
,	O
000	O
microm	O
)	O
.	O

cytokine	B-protein
(	O
tnf-alpha	B-protein
and	O
il-00	B-protein
)	O
release	O
was	O
measured	O
by	O
immunoassay	O
.	O

tnf-alpha	B-RNA
mrna	I-RNA
was	O
measured	O
by	O
reverse	B-protein
transcription	I-protein
polymerase	I-protein
chain	I-protein
reaction	O
,	O
and	O
nf-kappab	B-protein
dna	O
binding	O
activity	O
was	O
assessed	O
by	O
gel	O
mobility	O
shift	O
assay	O
.	O

results	O
:	O
camp-elevating	O
agents	O
inhibited	O
lps-stimulated	O
tnf-alpha	B-protein
release	O
(	O
0.00	O
+/-	O
0.00	O
ng/00	O
(	O
0	O
)	O
cells	O
in	O
lps	O
+	O
dbcamp	O
and	O
0.00	O
+/-	O
0.00	O
ng/00	O
(	O
0	O
)	O
cells	O
in	O
lps	O
+	O
fsk	O
,	O
both	O
p	O
<	O
0.00	O
vs	O
0.00	O
+/-	O
0.00	O
ng/00	O
(	O
0	O
)	O
cells	O
in	O
lps	O
alone	O
)	O
.	O

conversely	O
,	O
camp	O
enhanced	O
lps-stimulated	O
il-00	B-protein
release	O
(	O
000	O
+/-	O
00.0	O
pg/00	O
(	O
0	O
)	O
cells	O
in	O
lps	O
+	O
dbcamp	O
and	O
000	O
+/-	O
00.0	O
pg/00	O
(	O
0	O
)	O
cells	O
in	O
lps	O
+	O
fsk	O
,	O
both	O
p	O
<	O
0.00	O
vs	O
00.0	O
+/-	O
00.0	O
pg/00	O
(	O
0	O
)	O
cells	O
in	O
lps	O
alone	O
)	O
.	O

neither	O
tnf-alpha	B-RNA
mrna	I-RNA
expression	O
nor	O
nf-kappab	B-protein
activation	O
stimulated	O
by	O
lps	O
was	O
inhibited	O
by	O
the	O
camp-elevating	O
agents	O
.	O

neutralization	O
of	O
il-00	B-protein
with	O
a	O
specific	O
antibody	O
did	O
not	O
attenuate	O
the	O
effect	O
of	O
camp-elevating	O
agents	O
on	O
tnf-alpha	B-protein
production	O
.	O

conclusion	O
:	O
the	O
results	O
indicate	O
that	O
camp	O
inhibits	O
lps-stimulated	O
tnf-alpha	B-protein
production	O
through	O
a	O
posttranscriptional	O
mechanism	O
that	O
is	O
independent	O
of	O
endogenous	O
il-00	B-protein
.	O

copyright	O
0000	O
academic	O
press	O
.	O

###MEDLINE:21359858

activation	O
of	O
the	O
p00	B-DNA
(	I-DNA
cip0/waf0	I-DNA
)	I-DNA
promoter	I-DNA
by	O
bone	O
morphogenetic	O
protein-0	O
in	O
mouse	B-cell_type
b	I-cell_type
lineage	I-cell_type
cells	I-cell_type
.	O

bmps	B-protein
exert	O
a	O
negative	O
growth	O
effect	O
on	O
various	O
types	O
of	O
cells	O
.	O

we	O
have	O
previously	O
reported	O
that	O
bmp-0	B-protein
inhibited	O
the	O
growth	O
of	O
hs-00	B-cell_line
mouse	I-cell_line
hybridoma	I-cell_line
cells	I-cell_line
by	O
inducing	O
p00	B-protein
(	O
cip0/waf0	B-protein
)	O
expression	O
.	O

in	O
the	O
present	O
study	O
,	O
we	O
demonstrated	O
that	O
bmp-0	B-protein
activated	O
the	O
mouse	B-DNA
p00	I-DNA
(	I-DNA
cip0/waf0	I-DNA
)	I-DNA
promoter	I-DNA
in	O
hs-00	B-cell_line
cells	I-cell_line
,	O
and	O
that	O
a	O
00-base	B-DNA
pair	I-DNA
(	I-DNA
b	I-DNA
)	I-DNA
region	I-DNA
of	O
the	O
promoter	O
(	O
-0000/-0000	B-protein
relative	O
to	O
the	O
tata	B-DNA
box	I-DNA
)	O
,	O
conserved	O
between	O
mice	O
and	O
humans	O
,	O
was	O
responsive	O
to	O
bmp-0	O
as	O
well	O
as	O
expression	O
of	O
smad0	B-protein
,	O
smad0	B-protein
,	O
and	O
constitutively	O
active	O
mutants	O
of	O
bmp	B-protein
type	I-protein
i	I-protein
receptors	I-protein
.	O

furthermore	O
,	O
an	O
oligonucleotide	O
containing	O
the	O
00-b	B-DNA
region	I-DNA
was	O
found	O
to	O
be	O
associated	O
with	O
smad0	B-protein
and	O
phosphorylated	O
smad0	O
in	O
the	O
nuclear	O
extract	O
of	O
bmp-0	O
-stimulated	O
hs-00	B-cell_line
cells	I-cell_line
.	O

these	O
results	O
suggested	O
that	O
bmp-0	B-protein
might	O
activate	O
p00	B-protein
(	O
cip0/waf0	B-protein
)	O
transcription	O
by	O
inducing	O
a	O
binding	O
of	O
smad0	B-protein
and	O
smad0	B-protein
to	O
the	O
00-b	B-DNA
region	I-DNA
in	O
hs-00	B-cell_line
cells	I-cell_line
.	O

###MEDLINE:21352151

dendritic	O
cell	O
development	O
from	O
common	B-cell_type
myeloid	I-cell_type
progenitors	I-cell_type
.	O

dendritic	B-cell_type
cells	I-cell_type
(	O
dcs	B-cell_type
)	O
are	O
professional	B-cell_type
antigen-presenting	I-cell_type
cells	I-cell_type
which	O
both	O
initiate	O
adaptive	O
immune	O
responses	O
and	O
control	O
tolerance	O
to	O
self-antigens	B-protein
.	O

it	O
has	O
been	O
suggested	O
that	O
these	O
different	O
effects	O
on	O
responder	B-cell_line
cells	I-cell_line
depend	O
on	O
subsets	O
of	O
dcs	B-cell_type
arising	O
from	O
either	O
myeloid	B-cell_type
or	I-cell_type
lymphoid	I-cell_type
hematopoietic	I-cell_type
origins	I-cell_type
.	O

in	O
this	O
model	O
,	O
cd0	B-protein
alpha+	O
mac-0-	O
dcs	B-cell_type
are	O
supposed	O
to	O
be	O
of	O
lymphoid	O
while	O
cd0	B-protein
alpha-	O
mac-0+	B-cell_type
dcs	B-cell_type
are	O
supposed	O
to	O
be	O
of	O
myeloid	B-cell_type
origin	I-cell_type
.	O

here	O
we	O
summarize	O
our	O
findings	O
that	O
both	O
cd0	B-protein
alpha+	I-protein
and	O
cd0	B-protein
alpha-	O
dcs	O
can	O
arise	O
from	O
clonogenic	O
common	O
myeloid	B-cell_type
progenitors	I-cell_type
(	O
cmps	B-protein
)	O
in	O
both	O
thymus	O
and	O
spleen	O
.	O

therefore	O
cd0	B-protein
alpha	I-protein
expression	O
dcs	O
does	O
not	O
indicate	O
a	O
lymphoid	O
origin	O
and	O
differences	O
among	O
cd0	B-protein
alpha+	O
and	O
cd0	B-protein
alpha-	O
dcs	O
might	O
rather	O
reflect	O
maturation	O
status	O
than	O
ontogeny	O
.	O

on	O
the	O
basis	O
of	O
transplantation	O
studies	O
,	O
it	O
seems	O
likely	O
that	O
most	O
of	O
the	O
dcs	O
in	O
secondary	O
lymphoid	O
organs	O
and	O
a	O
substantial	O
fraction	O
of	O
thymic	O
dcs	B-cell_type
are	O
myeloid-derived	O
.	O

###MEDLINE:21341822

macrophage	O
stimulation	O
with	O
murabutide	B-protein
,	O
an	O
hiv-suppressive	B-protein
muramyl	I-protein
peptide	I-protein
derivative	I-protein
,	O
selectively	O
activates	O
extracellular	B-protein
signal-regulated	I-protein
kinases	I-protein
0	O
and	O
0	O
,	O
c/ebpbeta	B-protein
and	O
stat0	B-protein
:	O
role	O
of	O
cd00	B-protein
and	O
toll-like	B-protein
receptors	I-protein
0	I-protein
and	I-protein
0	I-protein
.	O

the	O
smallest	B-DNA
unit	I-DNA
of	O
bacterial	O
peptidoglycans	O
known	O
to	O
be	O
endowed	O
with	O
biological	O
activities	O
is	O
muramyl	O
dipeptide	O
(	O
mdp	O
)	O
.	O

a	O
clinically	O
acceptable	O
synthetic	O
derivative	O
of	O
mdp	O
,	O
namely	O
murabutide	O
(	O
mb	B-protein
)	O
,	O
has	O
been	O
found	O
to	O
present	O
interesting	O
pharmacological	O
properties	O
and	O
to	O
suppress	O
hiv-0	O
replication	O
in	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
(	O
mdm	B-cell_type
)	O
.	O

we	O
have	O
addressed	O
the	O
signaling	O
events	O
activated	O
in	O
mdm	B-cell_type
following	O
stimulation	O
with	O
either	O
mb	O
or	O
the	O
potent	O
immunostimulant	O
lps	O
.	O

we	O
also	O
examined	O
whether	O
signaling	O
by	O
muramyl	O
peptides	O
involves	O
the	O
use	O
of	O
cell	B-protein
surface	I-protein
receptors	I-protein
,	O
including	O
cd00	B-protein
and	O
toll-like	B-protein
receptor	I-protein
0	I-protein
(	O
tlr0	B-protein
)	O
or	O
tlr0	B-protein
that	O
are	O
known	O
to	O
be	O
signal-transducing	B-protein
receptors	I-protein
for	O
other	O
bacterial	O
cell	O
wall	O
components	O
.	O

we	O
demonstrate	O
that	O
,	O
unlike	O
lps	O
,	O
the	O
safe	O
immunomodulator	O
mb	O
selectively	O
activates	O
extracellular	B-protein
signal-regulated	I-protein
kinases	I-protein
(	O
erk	B-protein
)	O
0/0	O
,	O
in	O
the	O
absence	O
of	O
detectable	O
jun	B-protein
n-terminal	I-protein
kinase	I-protein
(	O
jnk	B-protein
)	O
or	O
p00	B-protein
mitogen-activated	I-protein
kinase	I-protein
activation	O
.	O

furthermore	O
,	O
stat0	B-protein
activation	O
but	O
weak	O
or	O
no	O
activation	O
of	O
stat0	B-protein
or	O
stat0	B-protein
respectively	O
,	O
could	O
be	O
detected	O
in	O
mb-stimulated	B-cell_type
mdm	I-cell_type
.	O

using	O
monomac0	B-cell_line
cells	I-cell_line
,	O
we	O
observed	O
high	O
c/ebpbeta	B-protein
and	O
ap-0	B-protein
but	O
weaker	O
and	O
transient	O
nf-kappab	B-protein
activation	O
by	O
mb	O
.	O

moreover	O
,	O
the	O
truncated	O
form	O
of	O
c/ebpbeta	B-protein
,	O
known	O
to	O
repress	O
hiv-0	O
transcription	O
,	O
was	O
detected	O
in	O
extracts	O
from	O
mb-treated	B-cell_line
thp-0	I-cell_line
cells	I-cell_line
.	O

surprisingly	O
,	O
neither	O
mb	B-protein
nor	O
mdp	O
were	O
able	O
to	O
transduce	O
signals	O
via	O
cd00	B-protein
and	O
tlr0	B-protein
or	O
0	O
.	O

these	O
findings	O
present	O
major	O
differences	O
in	O
the	O
early	O
cell	O
activation	O
process	O
between	O
lps	O
and	O
muramyl	O
peptides	O
,	O
and	O
strongly	O
argue	O
for	O
the	O
implication	O
of	O
co-receptors	B-protein
other	O
than	O
tlr0	B-protein
and	O
tlr0	B-protein
in	O
mediating	O
the	O
signaling	O
events	O
induced	O
by	O
defined	O
subunits	O
of	O
bacterial	O
peptidoglycans	O
.	O

###MEDLINE:21336700

nuclear	B-protein
peroxisome	I-protein
proliferator-activated	I-protein
receptors	I-protein
alpha	I-protein
and	I-protein
gamma	I-protein
have	O
opposing	O
effects	O
on	O
monocyte	O
chemotaxis	O
in	O
endometriosis	O
.	O

the	O
peroxisome	B-protein
proliferator-activated	I-protein
receptors	I-protein
(	O
ppars	B-protein
)	O
alpha	B-protein
and	I-protein
gamma	I-protein
are	O
nuclear	B-protein
receptors	I-protein
that	O
play	O
important	O
roles	O
in	O
inflammatory	O
diseases	O
like	O
ulcerative	O
colitis	O
and	O
arthritis	O
.	O

in	O
this	O
study	O
,	O
we	O
examined	O
the	O
possible	O
role	O
of	O
ppars	B-protein
in	O
macrophage	O
attraction	O
into	O
the	O
peritoneal	O
cavity	O
of	O
patients	O
with	O
endometriosis	O
.	O

we	O
identified	O
ppar-alpha	B-protein
and	I-protein
-gamma	I-protein
messenger	B-RNA
rna	I-RNA
by	O
rt-pcr	O
and	O
protein	O
by	O
immunoblotting	O
of	O
lysates	O
of	O
peritoneal	B-cell_type
macrophages	I-cell_type
and	O
monocytic	B-cell_line
u000	I-cell_line
cells	I-cell_line
.	O

using	O
immunocytochemistry	O
,	O
we	O
localized	O
ppar-alpha	B-protein
and	I-protein
-gamma	I-protein
within	O
the	O
nuclei	O
of	O
both	O
cell	O
types	O
.	O

monocyte	O
chemotactic	O
activity	O
of	O
peritoneal	O
fluid	O
from	O
patients	O
with	O
endometriosis	O
was	O
quantified	O
in	O
boyden	O
chambers	O
.	O

migration	O
of	O
u000	B-cell_line
cells	I-cell_line
was	O
increased	O
by	O
wy	O
00000	O
and	O
reduced	O
by	O
rosiglitazone	O
.	O

peritoneal	O
fluid	O
from	O
patients	O
with	O
endometriosis	O
activated	O
u000	B-cell_line
cells	I-cell_line
transiently	O
transfected	O
with	O
a	O
ppar-alpha/gal0	B-DNA
luciferase	I-DNA
reporter	I-DNA
.	O

by	O
contrast	O
,	O
peritoneal	O
fluid	O
did	O
not	O
cause	O
significant	O
activation	O
of	O
ppar-gamma/gal0	B-DNA
constructs	I-DNA
.	O

the	O
u000	B-cell_line
cells	I-cell_line
transiently	O
transfected	O
with	O
a	O
ppar	O
response	O
element	O
luciferase	B-DNA
reporter	I-DNA
showed	O
disease	O
stage-dependent	O
up-regulation	O
when	O
treated	O
with	O
peritoneal	O
fluid	O
from	O
patients	O
with	O
endometriosis	O
.	O

treatment	O
with	O
peritoneal	O
fluid	O
from	O
healthy	O
controls	O
down-regulated	O
ppar	B-protein
response	O
element	O
transactivation	O
.	O

we	O
conclude	O
that	O
peritoneal	O
fluid	O
of	O
endometriosis	O
patients	O
contains	O
activators	B-protein
of	I-protein
ppar-alpha	I-protein
that	O
stimulate	O
macrophage	O
chemotaxis	O
.	O

inhibitors	O
of	O
ppar-alpha	B-protein
or	O
activators	O
of	O
ppar-gamma	B-protein
could	O
be	O
developed	O
for	O
the	O
treatment	O
of	O
inflammation	O
associated	O
with	O
endometriosis	O
.	O

###MEDLINE:21329192

long-term-impaired	O
expression	O
of	O
nuclear	B-protein
factor-kappa	I-protein
b	I-protein
and	O
i	B-protein
kappa	I-protein
b	I-protein
alpha	I-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
of	O
trauma	O
patients	O
.	O

nuclear	B-protein
factor	I-protein
(	O
nf	B-protein
)	I-protein
-kappa	I-protein
b	I-protein
expression	O
and	O
dimer	B-protein
characteristics	O
were	O
studied	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
pbmcs	B-cell_type
)	O
of	O
major-trauma	O
patients	O
and	O
healthy	O
controls	O
.	O

analysis	O
of	O
pbmcs	B-cell_type
on	O
days	O
0	O
,	O
0	O
,	O
0	O
,	O
and	O
00	O
after	O
trauma	O
revealed	O
that	O
expression	O
of	O
both	O
p00p00	B-protein
heterodimers	B-protein
and	O
p00p00	B-protein
homodimers	O
was	O
significantly	O
reduced	O
compared	O
with	O
that	O
in	O
controls	O
.	O

in	O
vitro	O
lipopolysaccharide	O
(	O
lps	O
)	O
stimulation	O
of	O
pbmcs	B-cell_type
induced	O
nf-kappa	B-protein
b	I-protein
translocation	O
.	O

however	O
,	O
throughout	O
the	O
survey	O
,	O
p00p00	B-protein
activation	O
remained	O
significantly	O
lower	O
in	O
trauma	O
patients	O
than	O
in	O
controls	O
.	O

after	O
lps	O
stimulation	O
in	O
vitro	O
,	O
the	O
p00p00/p00p00	O
ratio	O
was	O
significantly	O
lower	O
in	O
pbmcs	B-cell_type
from	O
trauma	O
patients	O
than	O
from	O
healthy	O
controls	O
.	O

the	O
ex	O
vivo	O
expression	O
of	O
i	B-protein
kappa	I-protein
b	I-protein
alpha	I-protein
was	O
higher	O
in	O
pbmcs	B-cell_type
of	O
controls	O
than	O
of	O
trauma	O
patients	O
.	O

lps	O
did	O
not	O
induce	O
i	B-protein
kappa	I-protein
b	I-protein
expression	O
in	O
pbmcs	B-cell_type
from	O
trauma	O
patients	O
,	O
but	O
strong	O
induction	O
was	O
obtained	O
with	O
staphylococci	O
,	O
suggesting	O
that	O
this	O
defect	O
is	O
not	O
universal	O
and	O
depends	O
on	O
the	O
nature	O
of	O
the	O
activating	O
signal	O
.	O

although	O
no	O
direct	O
correlation	O
was	O
found	O
between	O
levels	O
of	O
interleukin-00	B-protein
or	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
and	O
nf-kappa	B-protein
b	I-protein
,	O
these	O
immunosuppressive	O
cytokines	B-protein
were	O
significantly	O
elevated	O
in	O
trauma	O
patients	O
by	O
00	O
days	O
after	O
admission	O
.	O

the	O
long-term	O
low-basal	O
and	O
lps-induced	O
nuclear	O
translocation	O
of	O
nf-kappa	B-protein
b	I-protein
recalled	O
long-term	O
immunoparalysis	O
observed	O
in	O
patients	O
with	O
severe	O
inflammatory	O
stress	O
such	O
as	O
trauma	O
.	O

###MEDLINE:21317758

hepatic	O
ischemia-reperfusion	O
injury	O
.	O

background	O
:	O
the	O
morbidity	O
associated	O
with	O
liver	O
transplantation	O
and	O
major	O
hepatic	O
resections	O
is	O
partly	O
a	O
result	O
of	O
ischemia-reperfusion	O
injury	O
.	O

data	O
sources	O
:	O
the	O
entire	O
world	O
literature	O
on	O
the	O
subject	O
was	O
searched	O
via	O
medline	O
.	O

keywords	O
included	O
reperfusion	O
injury	O
,	O
transplantation	O
,	O
liver	O
resection	O
,	O
nitric	O
oxide	O
,	O
endothelin	O
,	O
cytokines	B-protein
,	O
kupffer	B-cell_type
cells	I-cell_type
,	O
ischemic/ischaemic	O
preconditioning	O
,	O
and	O
nuclear	B-protein
factor-kappa	I-protein
b	I-protein
.	O

conclusions	O
:	O
an	O
imbalance	O
between	O
endothelin	O
and	O
nitric	O
oxide	O
levels	O
results	O
in	O
failure	O
of	O
the	O
hepatic	O
microcirculation	O
at	O
the	O
onset	O
of	O
reperfusion	O
.	O

activation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
b	I-protein
in	O
the	O
liver	O
promotes	O
proinflammatory	B-protein
cytokine	I-protein
and	I-protein
adhesion	I-protein
molecule	I-protein
synthesis	O
.	O

these	O
result	O
in	O
oxygen-derived	O
free	O
radical	O
production	O
and	O
neutrophil	O
recruitment	O
,	O
further	O
contributing	O
to	O
cellular	O
injury	O
.	O

various	O
therapeutic	O
modalities	O
acting	O
on	O
the	O
above	O
mediators	O
have	O
been	O
successfully	O
used	O
to	O
attenuate	O
reperfusion	O
injury	O
in	O
animal	O
models	O
of	O
hepatic	O
transplantation	O
and	O
resection	O
.	O

application	O
of	O
the	O
knowledge	O
gained	O
from	O
animal	O
models	O
of	O
hepatic	O
ischemia-reperfusion	O
to	O
the	O
clinical	O
setting	O
will	O
improve	O
the	O
outcome	O
of	O
hepatic	O
surgery	O
.	O

###MEDLINE:21311876

down-regulation	O
of	O
il-00	B-DNA
p00	I-DNA
gene	I-DNA
in	O
plasmodium	O
berghei-infected	O
mice	O
.	O

we	O
analyzed	O
the	O
mechanism	O
that	O
causes	O
suppression	O
of	O
il-00	B-protein
p00	B-protein
gene	O
induction	O
during	O
plasmodium	B-protein
berghei	I-protein
infection	O
.	O

although	O
il-00	B-protein
together	O
with	O
ifn-gamma	B-protein
plays	O
an	O
important	O
role	O
in	O
protection	O
against	O
pathogenic	O
infection	O
,	O
the	O
il-00	B-protein
p00	I-protein
protein	I-protein
production	O
of	O
infected	B-cell_type
macrophages	I-cell_type
is	O
lower	O
than	O
that	O
by	O
the	O
uninfected	B-cell_type
macrophages	I-cell_type
.	O

we	O
showed	O
in	O
the	O
present	O
study	O
that	O
the	O
induction	O
of	O
il-00	B-DNA
p00	I-DNA
gene	I-DNA
but	O
not	O
il-00	B-DNA
p00	I-DNA
gene	I-DNA
in	O
macrophages	B-cell_type
of	O
p.	O
berghei-infected	O
mice	O
was	O
profoundly	O
inhibited	O
.	O

the	O
inhibition	O
was	O
induced	O
by	O
interaction	O
with	O
macrophages	B-cell_type
that	O
had	O
contacted	O
with	O
p.	O
berghei-infected	B-cell_type
erythrocytes	I-cell_type
and	O
was	O
mediated	O
by	O
a	O
soluble	B-protein
factor	I-protein
,	O
il-00	B-protein
.	O

there	O
was	O
comparable	O
activation	O
of	O
nf-kappab	B-protein
in	O
uninfected	B-cell_type
and	I-cell_type
infected	I-cell_type
cells	I-cell_type
.	O

the	O
induction	O
of	O
ifn-regulatory	B-DNA
factor-0	I-DNA
gene	I-DNA
was	O
comparable	O
in	O
transcription	O
level	O
in	O
uninfected	B-cell_type
and	I-cell_type
infected	I-cell_type
cells	I-cell_type
,	O
while	O
the	O
unidentified	B-protein
complex	I-protein
formation	O
of	O
ifn-regulatory	B-protein
factor-0	I-protein
was	O
observed	O
in	O
infected	B-cell_type
cells	I-cell_type
.	O

therefore	O
,	O
the	O
inhibition	O
of	O
the	O
il-00	B-DNA
p00	I-DNA
gene	I-DNA
induction	O
appeared	O
to	O
be	O
regulated	O
at	O
transcriptional	O
regulation	O
level	O
of	O
the	O
gene	O
.	O

###MEDLINE:21309954

the	O
friend	O
of	O
gata	B-protein
proteins	I-protein
u-shaped	O
,	O
fog-0	O
,	O
and	O
fog-0	O
function	O
as	O
negative	O
regulators	O
of	O
blood	O
,	O
heart	O
,	O
and	O
eye	O
development	O
in	O
drosophila	O
.	O

friend	O
of	O
gata	B-protein
(	O
fog	B-protein
)	O
proteins	O
regulate	O
gata	B-DNA
factor-activated	I-DNA
gene	I-DNA
transcription	O
.	O

during	O
vertebrate	O
hematopoiesis	O
,	O
fog	B-protein
and	O
gata	B-protein
proteins	I-protein
cooperate	O
to	O
promote	O
erythrocyte	O
and	O
megakaryocyte	O
differentiation	O
.	O

the	O
drosophila	O
fog	B-protein
homologue	O
u-shaped	O
(	O
ush	B-protein
)	O
is	O
expressed	O
similarly	O
in	O
the	O
blood	O
cell	O
anlage	O
during	O
embryogenesis	O
.	O

during	O
hematopoiesis	O
,	O
the	O
acute	O
myeloid	O
leukemia	O
0	O
homologue	O
lozenge	O
and	O
glial	B-cell_type
cells	I-cell_type
missing	O
are	O
required	O
for	O
the	O
production	O
of	O
crystal	O
cells	O
and	O
plasmatocytes	B-protein
,	O
respectively	O
.	O

however	O
,	O
additional	O
factors	O
have	O
been	O
predicted	O
to	O
control	O
crystal	O
cell	O
proliferation	O
.	O

in	O
this	O
report	O
,	O
we	O
show	O
that	O
ush	B-protein
is	O
expressed	O
in	O
hemocyte	B-cell_type
precursors	I-cell_type
and	O
plasmatocytes	O
throughout	O
embryogenesis	O
and	O
larval	O
development	O
,	O
and	O
the	O
gata	B-DNA
factor	I-DNA
serpent	I-DNA
is	O
essential	O
for	O
ush	O
embryonic	O
expression	O
.	O

furthermore	O
,	O
loss	O
of	O
ush	O
function	O
results	O
in	O
an	O
overproduction	O
of	O
crystal	O
cells	O
,	O
whereas	O
forced	O
expression	O
of	O
ush	B-protein
reduces	O
this	O
cell	B-cell_line
population	I-cell_line
.	O

murine	B-cell_line
fog-0	I-cell_line
and	I-cell_line
fog-0	I-cell_line
also	O
can	O
repress	O
crystal	O
cell	O
production	O
,	O
but	O
a	O
mutant	O
version	O
of	O
fog-0	O
lacking	O
a	O
conserved	B-DNA
motif	I-DNA
that	O
binds	O
the	O
corepressor	B-protein
c-terminal	B-protein
binding	I-protein
protein	I-protein
fails	O
to	O
affect	O
the	O
cell	B-cell_line
lineage	I-cell_line
.	O

the	O
gata	B-protein
factor	I-protein
pannier	I-protein
(	O
pnr	O
)	O
is	O
required	O
for	O
eye	O
and	O
heart	O
development	O
in	O
drosophila	O
.	O

when	O
ush	B-protein
,	O
fog-0	O
,	O
fog-0	O
,	O
or	O
mutant	O
fog-0	O
is	O
coexpressed	O
with	O
pnr	O
during	O
these	O
developmental	O
processes	O
,	O
severe	O
eye	O
and	O
heart	O
phenotypes	O
result	O
,	O
consistent	O
with	O
a	O
conserved	O
negative	O
regulation	O
of	O
pnr	O
function	O
.	O

these	O
results	O
indicate	O
that	O
the	O
fly	O
and	O
mouse	O
fog	B-protein
proteins	O
function	O
similarly	O
in	O
three	O
distinct	O
cellular	O
contexts	O
in	O
drosophila	O
,	O
but	O
may	O
use	O
different	O
mechanisms	O
to	O
regulate	O
genetic	O
events	O
in	O
blood	O
vs	O
.	O
cardial	O
or	O
eye	B-cell_type
cell	I-cell_type
lineages	I-cell_type

###MEDLINE:21376061

the	O
ring	B-DNA
finger	I-DNA
protein	I-DNA
siah-0	I-DNA
regulates	O
the	O
level	O
of	O
the	O
transcriptional	B-protein
coactivator	I-protein
obf-0	B-protein
.	O

the	O
transcriptional	B-protein
coactivator	I-protein
obf-0	B-protein
,	O
which	O
interacts	O
with	O
oct-0	B-protein
and	O
oct-0	B-protein
and	O
the	O
octamer	B-DNA
site	I-DNA
dna	O
,	O
has	O
been	O
shown	O
to	O
be	O
critical	O
for	O
development	O
of	O
a	O
normal	O
immune	O
response	O
and	O
the	O
formation	O
of	O
germinal	O
centers	O
in	O
secondary	O
lymphoid	O
organs	O
.	O

here	O
we	O
have	O
identified	O
the	O
ring	B-DNA
finger	I-DNA
protein	I-DNA
siah-0	I-DNA
as	O
a	O
protein	O
interacting	O
specifically	O
with	O
obf-0	B-protein
.	O

this	O
interaction	O
is	O
mediated	O
by	O
the	O
c-terminal	O
part	O
of	O
siah-0	B-protein
and	O
by	O
residues	O
in	O
the	O
n-terminus	O
of	O
obf-0	B-protein
,	O
partly	O
distinct	O
from	O
the	O
residues	O
required	O
for	O
formation	O
of	O
a	O
complex	O
with	O
the	O
oct	B-protein
pou	I-protein
domains	I-protein
and	O
the	O
dna	O
.	O

interaction	O
between	O
siah-0	B-protein
and	O
obf-0	B-protein
leads	O
to	O
downregulation	O
of	O
obf-0	B-protein
protein	O
level	O
but	O
not	O
mrna	B-RNA
,	O
and	O
to	O
a	O
corresponding	O
reduction	O
in	O
octamer	B-protein
site-dependent	I-protein
transcription	I-protein
activation	O
.	O

inhibition	O
of	O
the	O
ubiquitin-proteasome	O
pathway	O
in	O
b	B-cell_type
cells	I-cell_type
leads	O
to	O
elevated	O
levels	O
of	O
obf-0	B-protein
protein	O
.	O

furthermore	O
,	O
in	O
immunized	O
mice	O
,	O
obf-0	B-protein
protein	O
amounts	O
are	O
dramatically	O
increased	O
in	O
primary	B-cell_type
activated	I-cell_type
b	I-cell_type
cells	I-cell_type
,	O
without	O
concomitant	O
increase	O
in	O
obf-0	B-RNA
mrna	I-RNA
.	O

these	O
data	O
suggest	O
that	O
siah-0	B-protein
is	O
part	O
of	O
a	O
novel	B-protein
regulatory	I-protein
loop	I-protein
controlling	O
the	O
level	O
of	O
obf-0	B-protein
protein	O
in	O
b	B-cell_type
cells	I-cell_type
.	O

###MEDLINE:21370254

the	O
beta-catenin	B-protein
--	O
tcf-0	B-protein
pathway	O
ensures	O
cd0	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cd0	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
thymocyte	I-cell_type
survival	O
.	O

the	O
association	O
of	O
trans-acting	B-protein
t	I-protein
cell	I-protein
factors	I-protein
(	O
tcfs	B-protein
)	O
or	O
lymphoid	B-protein
enhancer	I-protein
factor	I-protein
0	I-protein
(	O
lef-0	B-protein
)	O
with	O
their	O
coactivator	O
beta-catenin	B-protein
mediates	O
transient	O
transcriptional	O
responses	O
to	O
extracellular	O
wnt	O
signals	O
.	O

we	O
show	O
here	O
that	O
t	B-cell_type
cell	I-cell_type
maturation	O
depends	O
on	O
the	O
presence	O
of	O
the	O
beta-catenin	B-protein
--	O
binding	O
domain	O
in	O
tcf-0	B-protein
.	O

this	O
domain	O
is	O
necessary	O
to	O
mediate	O
the	O
survival	O
of	O
immature	B-cell_line
cd0	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
cd0	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
double-positive	B-cell_type
(	I-cell_type
dp	I-cell_type
)	I-cell_type
thymocytes	I-cell_type
.	O

accelerated	O
spontaneous	O
thymocyte	O
death	O
in	O
the	O
absence	O
of	O
tcf-0	B-protein
correlates	O
with	O
aberrantly	O
low	O
expression	O
of	O
the	O
anti-apoptotic	B-protein
protein	I-protein
bcl-x	B-protein
(	I-protein
l	I-protein
)	I-protein
.	O

increasing	O
anti-apoptotic	B-protein
effectors	I-protein
in	O
thymocytes	B-cell_type
by	O
the	O
use	O
of	O
a	O
bcl-0	B-DNA
transgene	I-DNA
rescued	O
tcf-0-deficient	B-cell_type
dp	I-cell_type
thymocytes	I-cell_type
from	O
apoptosis	O
.	O

thus	O
,	O
tcf-0	B-protein
,	O
upon	O
association	O
with	O
beta-catenin	B-protein
,	O
transiently	O
ensures	O
the	O
survival	O
of	O
immature	B-cell_type
t	I-cell_type
cells	I-cell_type
,	O
which	O
enables	O
them	O
to	O
generate	O
and	O
edit	B-protein
t	I-protein
cell	I-protein
receptor	I-protein
(	O
tcr	B-protein
)	I-protein
alpha	I-protein
chains	I-protein
and	O
attempt	O
tcr	B-protein
-mediated	O
positive	O
selection	O
.	O

###MEDLINE:21361181

trail/apo0l	B-protein
ligand	I-protein
selectively	O
induces	O
apoptosis	O
and	O
overcomes	O
drug	O
resistance	O
in	O
multiple	O
myeloma	O
:	O
therapeutic	O
applications	O
.	O

multiple	O
myeloma	O
(	O
mm	O
)	O
remains	O
incurable	O
and	O
novel	O
treatments	O
are	O
urgently	O
needed	O
.	O

preclinical	O
in	O
vitro	O
and	O
in	O
vivo	O
evaluations	O
were	O
performed	O
to	O
assess	O
the	O
potential	O
therapeutic	O
applications	O
of	O
human	B-protein
recombinant	I-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
(	O
tnf	B-protein
)	I-protein
-related	I-protein
apoptosis-inducing	I-protein
ligand/apo0	I-protein
ligand	I-protein
(	O
trail/apo0l	B-protein
)	O
in	O
mm	O
.	O

trail/apo0l	O
potently	O
induced	O
apoptosis	O
of	O
mm	B-cell_line
cells	I-cell_line
from	O
patients	O
and	O
the	O
majority	O
of	O
mm	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
including	O
cells	O
sensitive	O
or	O
resistant	O
to	O
dexamethasone	O
(	O
dex	O
)	O
,	O
doxorubicin	O
(	O
dox	O
)	O
,	O
melphalan	O
,	O
and	O
mitoxantrone	O
.	O

trail/apo0l	O
also	O
overcame	O
the	O
survival	O
effect	O
of	O
interleukin	B-protein
0	I-protein
on	O
mm	B-cell_line
cells	I-cell_line
and	O
did	O
not	O
affect	O
the	O
survival	O
of	O
peripheral	B-cell_type
blood	I-cell_type
and	I-cell_type
bone	I-cell_type
marrow	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
purified	B-cell_type
b	I-cell_type
cells	I-cell_type
from	O
healthy	O
donors	O
.	O

the	O
status	O
of	O
the	O
trail	B-protein
receptors	O
(	O
assessed	O
by	O
immunoblotting	O
and	O
flow	O
cytometry	O
)	O
could	O
not	O
predict	O
trail	B-protein
sensitivity	O
of	O
mm	B-cell_line
cells	I-cell_line
.	O

the	O
anti-mm	O
activity	O
of	O
trail/apo0l	B-protein
was	O
confirmed	O
in	O
nu/xid/bg	O
mice	O
xenografted	O
with	O
human	B-cell_line
mm	I-cell_line
cells	I-cell_line
;	O
trail	B-protein
(	O
000	O
microg	O
intraperitoneally	O
daily	O
for	O
00	O
days	O
)	O
was	O
well	O
tolerated	O
and	O
significantly	O
suppressed	O
the	O
growth	O
of	O
plasmacytomas	O
.	O

dox	O
up-regulated	O
the	O
expression	O
of	O
the	O
trail	B-protein
receptor	B-protein
death	I-protein
receptor	I-protein
0	I-protein
(	O
dr0	B-protein
)	O
and	O
synergistically	O
enhanced	O
the	O
effect	O
of	O
trail	B-protein
not	O
only	O
against	O
mm	B-cell_line
cells	I-cell_line
sensitive	O
to	O
,	O
but	O
also	O
against	O
those	O
resistant	O
to	O
,	O
dex-	B-protein
or	O
dox-induced	O
apoptosis	O
.	O

nuclear	B-protein
factor	I-protein
(	O
nf	B-protein
)	I-protein
-kappab	I-protein
inhibitors	O
,	O
such	O
as	O
sn00	O
(	O
a	O
cell-permeable	O
inhibitor	O
of	O
the	O
nuclear	O
translocation	O
and	O
transcriptional	O
activity	O
of	O
nf-kappab	B-protein
)	O
or	O
the	O
proteasome	O
inhibitor	O
ps-000	O
,	O
enhanced	O
the	O
proapoptotic	O
activity	O
of	O
trail/apo0l	O
against	O
trail-sensitive	B-cell_line
mm	I-cell_line
cells	I-cell_line
,	O
whereas	O
sn00	O
reversed	O
the	O
trail	B-protein
resistance	O
of	O
arh-00	B-protein
and	O
im-0	B-cell_line
mm	I-cell_line
cells	I-cell_line
.	O

importantly	O
,	O
normal	B-cell_type
b	I-cell_type
lymphocytes	I-cell_type
were	O
not	O
sensitized	O
to	O
trail	B-protein
by	O
either	O
dox	O
,	O
sn00	O
,	O
or	O
ps-000	O
.	O

these	O
preclinical	O
studies	O
suggest	O
that	O
trail/apo0l	B-protein
can	O
overcome	O
conventional	O
drug	O
resistance	O
and	O
provide	O
the	O
basis	O
for	O
clinical	O
trials	O
of	O
trail	B-protein
-based	O
treatment	O
regimens	O
to	O
improve	O
outcome	O
in	O
patients	O
with	O
mm	O
.	O

(	O
blood.	O
0000	O
;	O
00	O
:	O
000-000	O
)	O

###MEDLINE:21357628

cd00	B-protein
costimulation	O
is	O
required	O
not	O
only	O
to	O
induce	O
il-00	B-protein
receptor	O
but	O
also	O
to	O
render	O
janus	B-protein
kinases/stat0	I-protein
responsive	O
to	O
il-00	B-protein
stimulation	O
in	O
tcr-triggered	B-cell_type
t	I-cell_type
cells	I-cell_type
.	O

the	O
activation	O
of	O
resting	B-cell_type
t	I-cell_type
cells	I-cell_type
for	O
the	O
acquisition	O
of	O
various	O
functions	O
depends	O
on	O
whether	O
cd00	B-protein
costimulatory	O
signals	O
are	O
provided	O
upon	O
t	B-protein
cell	I-protein
receptor	I-protein
stimulation	O
.	O

here	O
,	O
we	O
investigated	O
how	O
cd00	B-protein
costimulation	O
functions	O
to	O
allow	O
tcr	B-protein
-triggered	O
resting	B-cell_type
t	I-cell_type
cells	I-cell_type
to	O
acquire	O
il-00	B-protein
responsiveness	O
.	O

when	O
t	B-cell_type
cells	I-cell_type
are	O
stimulated	O
with	O
low	O
doses	O
of	O
anti-cd0	B-protein
mab	I-protein
,	O
cd00	B-protein
costimulation	O
was	O
required	O
for	O
the	O
optimal	O
levels	O
of	O
il-00	B-protein
receptor	I-protein
(	O
il-00r	B-protein
)	O
expression	O
.	O

however	O
,	O
stimulation	O
of	O
t	B-cell_type
cells	I-cell_type
with	O
high	O
doses	O
of	O
anti-cd0	B-protein
alone	O
induced	O
comparable	O
levels	O
of	O
il-00r	B-protein
expression	O
to	O
those	O
induced	O
upon	O
cd00	B-protein
costimulation	O
.	O

nevertheless	O
,	O
there	O
was	O
a	O
substantial	O
difference	O
in	O
il-00	B-protein
responsiveness	O
between	O
these	O
two	O
groups	O
of	O
t	B-cell_type
cells	I-cell_type
:	O
compared	O
to	O
anti-cd00-costimulated	B-cell_type
t	I-cell_type
cells	I-cell_type
,	O
t	B-cell_type
cells	I-cell_type
that	O
were	O
not	O
costimulated	O
with	O
anti-cd00	B-protein
exhibited	O
decreased	O
levels	O
of	O
janus	B-protein
kinases	I-protein
(	O
jak	B-protein
)	O
jak0/tyk0	O
and	O
stat0	B-protein
phosphorylation	O
and	O
ifn-y	O
production	O
following	O
il-00	B-protein
stimulation	O
.	O

importantly	O
,	O
stat0	B-protein
phosphorylation	O
following	O
il-0	B-protein
stimulation	O
was	O
not	O
decreased	O
in	O
anti-cd00-uncostimulated	B-cell_type
t	I-cell_type
cells	I-cell_type
.	O

these	O
resutls	O
indicate	O
that	O
cd00	B-protein
costimulation	O
not	O
only	O
contributes	O
to	O
up-regulating	O
il-00r	B-protein
expression	O
but	O
is	O
also	O
required	O
to	O
render	O
jaks/stat0	O
responsive	O
to	O
il-00	B-protein
stimulation	O
.	O

###MEDLINE:21351021

constitutively	O
activated	O
akt-0	B-protein
is	O
vital	O
for	O
the	O
survival	O
of	O
human	B-cell_type
monocyte-differentiated	I-cell_type
macrophages	I-cell_type
.	O

role	O
of	O
mcl-0	B-protein
,	O
independent	O
of	O
nuclear	B-protein
factor	I-protein
(	O
nf	B-protein
)	I-protein
-kappab	I-protein
,	O
bad	B-protein
,	O
or	O
caspase	O
activation	O
.	O

recent	O
data	O
from	O
mice	O
deficient	O
for	O
phosphatase	B-protein
and	O
tensin	B-protein
homologue	I-protein
deleted	O
from	O
chromosome	B-DNA
00	I-DNA
or	O
src	B-protein
homology	I-protein
0	I-protein
domain-containing	I-protein
0	I-protein
'	I-protein
inositol	I-protein
phosphatase	I-protein
,	I-protein
phosphatases	I-protein
that	O
negatively	O
regulate	O
the	O
phosphatidylinositol	B-protein
0-kinase	I-protein
(	O
pi0k	B-protein
)	O
pathway	O
,	O
revealed	O
an	O
increased	O
number	O
of	O
macrophages	B-cell_type
in	O
these	O
animals	O
,	O
suggesting	O
an	O
essential	O
role	O
for	O
the	O
pi0k	B-protein
pathway	O
for	O
macro-phage	O
survival	O
.	O

here	O
,	O
we	O
focused	O
on	O
the	O
role	O
of	O
the	O
pi0k-regulated	B-protein
serine/threonine	I-protein
kinase	I-protein
akt-0	I-protein
in	O
modulating	O
macrophage	O
survival	O
.	O

akt-0	O
was	O
constitutively	O
activated	O
in	O
human	B-cell_type
macrophages	I-cell_type
and	O
addition	O
of	O
the	O
pi0k	B-protein
inhibitor	O
,	O
ly000000	O
,	O
suppressed	O
the	O
activation	O
of	O
akt-0	B-protein
and	O
induced	O
cell	O
death	O
.	O

furthermore	O
,	O
suppression	O
of	O
akt-0	O
by	O
inhibition	O
of	O
pi0k	B-protein
or	O
a	O
dominant	O
negative	O
(	O
dn	O
)	O
akt-0	O
resulted	O
in	O
loss	O
of	O
mitochondrial	O
transmembrane	O
potential	O
,	O
activation	O
of	O
caspases-0	B-protein
and	O
-0	O
,	O
and	O
dna	O
fragmentation	O
.	O

the	O
effects	O
of	O
pi0k	B-protein
inhibition	O
were	O
reversed	O
by	O
the	O
ectopic	O
expression	O
of	O
constitutively	B-protein
activated	I-protein
akt-0	I-protein
or	O
bcl-x	B-protein
(	I-protein
l	I-protein
)	I-protein
.	O

inhibition	O
of	O
pi0k	B-protein
/akt-0	O
pathway	O
either	O
by	O
ly000000	O
or	O
dn	O
akt-0	O
had	O
no	O
effect	O
on	O
the	O
constitutive	O
or	O
inducible	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
(	O
nf	B-protein
)	I-protein
-kappab	I-protein
in	O
human	B-cell_type
macrophages	I-cell_type
.	O

however	O
,	O
after	O
inhibition	O
of	O
the	O
pi0k	B-protein
/	O
akt-0	O
pathway	O
,	O
a	O
marked	O
decrease	O
in	O
the	O
expression	O
of	O
the	O
antiapoptotic	B-protein
molecule	I-protein
mcl-0	B-protein
,	O
but	O
not	O
other	O
bcl-0	B-protein
family	I-protein
members	I-protein
was	O
observed	O
,	O
and	O
mcl-0	B-protein
rescued	O
macrophages	B-cell_type
from	O
ly000000-induced	O
cell	O
death	O
.	O

further	O
,	O
inhibition	O
of	O
mcl-0	O
by	O
antisense	O
oligonucleotides	O
,	O
also	O
resulted	O
in	O
macrophage	O
apoptosis	O
.	O

thus	O
,	O
our	O
findings	O
demonstrate	O
that	O
the	O
constitutive	O
activation	O
of	O
akt-0	B-protein
regulates	O
macrophage	O
survival	O
through	O
mcl-0	B-protein
,	O
which	O
is	O
independent	O
of	O
caspases	B-protein
,	O
nf-kappab	B-protein
,	O
or	O
bad	B-protein
.	O

###MEDLINE:21340428

grbeta	B-protein
expression	O
in	O
nasal	B-cell_type
polyp	I-cell_type
inflammatory	I-cell_type
cells	I-cell_type
and	O
its	O
relationship	O
to	O
the	O
anti-inflammatory	O
effects	O
of	O
intranasal	O
fluticasone	O
.	O

background	O
:	O
nasal	O
polyposis	O
disease	O
is	O
an	O
inflammatory	O
disorder	O
with	O
intense	O
eosinophilic	O
infiltration	O
of	O
respiratory	O
mucosa	O
that	O
is	O
often	O
difficult	O
to	O
control	O
with	O
topical	O
steroids	O
.	O

recent	O
evidence	O
suggests	O
that	O
overexpression	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
splice	I-protein
variant	I-protein
grbeta	B-protein
in	O
inflammatory	B-cell_type
cells	I-cell_type
might	O
contribute	O
to	O
steroid	O
insensitivity	O
in	O
diseases	O
such	O
as	O
asthma	O
.	O

objective	O
:	O
the	O
purposes	O
of	O
this	O
investigation	O
were	O
to	O
determine	O
whether	O
nasal	B-cell_type
polyp	I-cell_type
(	O
np	B-protein
)	O
inflammatory	O
cells	O
overexpress	O
grbeta	B-protein
and	O
to	O
examine	O
whether	O
grbeta	B-protein
overexpression	O
is	O
associated	O
with	O
insensitivity	O
to	O
the	O
potent	O
topical	O
steroid	O
fluticasone	O
propionate	O
(	O
fp	O
)	O
.	O

methods	O
:	O
biopsies	O
were	O
obtained	O
from	O
00	O
subjects	O
with	O
nps	O
before	O
and	O
0	O
weeks	O
after	O
treatment	O
with	O
intranasal	O
fp	O
.	O

middle	O
turbinates	O
biopsies	O
from	O
0	O
healthy	O
,	O
nonallergic	O
subjects	O
served	O
as	O
normal	O
controls	O
.	O

biopsies	O
were	O
immunostained	O
for	O
inflammatory	B-protein
cell	I-protein
markers	I-protein
as	O
well	O
as	O
grbeta	B-protein
and	O
probed	O
for	O
various	O
cytokine	B-RNA
mrna	I-RNA
.	O

the	O
anti-inflammatory	O
response	O
to	O
fp	O
was	O
examined	O
in	O
relation	O
to	O
pretreatment	O
levels	O
of	O
grbeta	B-protein
expression	O
.	O

results	O
:	O
the	O
total	O
numbers	O
of	O
inflammatory	B-cell_type
cells	I-cell_type
were	O
increased	O
in	O
nps	O
.	O

the	O
percentage	O
of	O
inflammatory	B-cell_type
cells	I-cell_type
expressing	O
grbeta	B-protein
was	O
also	O
increased	O
(	O
00.0	O
%	O
+/-	O
00.0	O
%	O
vs	O
00.0	O
%	O
+/-	O
0.0	O
%	O
,	O
p	O
=.000	O
)	O
.	O

grbeta	B-protein
expression	O
in	O
nps	B-protein
was	O
almost	O
exclusive	O
to	O
t	B-cell_type
lymphocytes	I-cell_type
,	O
eosinophils	B-cell_type
,	O
and	O
macrophages	B-cell_type
.	O

an	O
inverse	O
correlation	O
was	O
observed	O
between	O
the	O
baseline	O
inflammatory	O
cell	O
grbeta	B-protein
expression	O
and	O
the	O
reduction	O
after	O
fp	O
treatment	O
in	O
eg0-positive	B-cell_type
eosinophils	I-cell_type
,	O
cd0-positive	B-cell_type
t	I-cell_type
lymphocytes	I-cell_type
,	O
endothelial	O
vcam-0	B-protein
expression	O
,	O
and	O
il-0	B-cell_line
mrna-positive	I-cell_line
cells	I-cell_line
.	O

nps	O
that	O
were	O
``	O
fp-insensitive	O
''	O
in	O
terms	O
of	O
suppression	O
of	O
eosinophil	B-cell_type
numbers	O
(	O
major	B-protein
basic	I-protein
protein	I-protein
-positive	O
)	O
had	O
a	O
significantly	O
greater	O
percentage	O
of	O
grbeta-positive	B-cell_type
inflammatory	I-cell_type
cells	I-cell_type
,	O
a	O
higher	O
ratio	O
of	O
grbeta-positive/gralpha-positive	B-cell_type
cells	I-cell_type
,	O
and	O
increased	O
numbers	O
of	O
grbeta-positive	B-cell_type
eosinophils	I-cell_type
and	O
macrophages	B-cell_type
in	O
comparison	O
with	O
those	O
that	O
were	O
``	O
fp-sensitive.	O
''	O

``	B-cell_line
fp-insensitive	I-cell_line
''	I-cell_line
nps	I-cell_line
also	O
demonstrated	O
a	O
higher	O
percentage	O
of	O
il-0-positive	B-cell_type
inflammatory	I-cell_type
cells	I-cell_type
expressing	O
grbeta	B-protein
before	O
and	O
after	O
fp	O
treatment	O
.	O

conclusion	O
:	O
grbeta	B-protein
expression	O
appears	O
to	O
be	O
a	O
marker	O
of	O
steroid	O
insensitivity	O
in	O
nps	O
.	O

expression	O
of	O
grbeta	B-protein
by	O
np	B-protein
inflammatory	O
cells	O
,	O
particularly	O
t	B-cell_type
cells	I-cell_type
and	O
eosinophils	B-cell_type
,	O
might	O
render	O
them	O
resistant	O
to	O
suppression	O
by	O
topical	O
steroids	O
and	O
thereby	O
contribute	O
to	O
persistent	O
np	O
inflammation	O
.	O

###MEDLINE:21334898

transcriptional	O
regulation	O
of	O
galectin-00	B-protein
(	O
eosinophil	B-protein
charcot-leyden	I-protein
crystal	I-protein
protein	I-protein
)	O
:	O
a	O
gc	B-DNA
box	I-DNA
(	O
-00	O
to	O
-00	O
)	O
controls	O
butyric	O
acid	O
induction	O
of	O
gene	O
expression	O
.	O

galectin-00	O
(	O
gal-00	B-protein
,	O
also	O
known	O
as	O
charcot-leyden	B-protein
crystal	I-protein
protein	I-protein
)	O
is	O
a	O
member	O
of	O
the	O
galectin	B-protein
family	I-protein
of	O
beta-galactoside	B-protein
binding	I-protein
proteins	I-protein
that	O
is	O
expressed	O
uniquely	O
in	O
eosinophilic	O
and	O
basophilic	B-cell_type
leukocytes	I-cell_type
.	O

to	O
gain	O
a	O
better	O
understanding	O
of	O
galectin	B-DNA
gene	I-DNA
expression	O
,	O
we	O
present	O
an	O
analysis	O
of	O
the	O
transcriptional	O
regulation	O
of	O
the	O
gene	O
encoding	O
gal-00	O
.	O

analysis	O
of	O
the	O
minimal	B-DNA
promoter	I-DNA
revealed	O
nine	O
consensus-binding	B-DNA
sites	I-DNA
for	O
transcription	B-protein
factors	I-protein
,	O
including	O
several	O
that	O
are	O
also	O
found	O
in	O
the	O
minimal	B-DNA
promoters	I-DNA
of	O
galectins	B-protein
-0	I-protein
,	O
-0	O
,	O
and	O
-0	O
.	O

the	O
decrease	O
in	O
gal-00	B-DNA
promoter	I-DNA
activity	O
after	O
disruption	O
of	O
either	O
the	O
gc	B-DNA
box	I-DNA
(	O
-00	O
to	O
-00	O
)	O
or	O
the	O
oct	B-DNA
site	I-DNA
(	O
-000	O
to	O
-000	O
)	O
suggests	O
that	O
these	O
sites	O
,	O
along	O
with	O
the	O
previously	O
characterized	O
gata	B-DNA
and	I-DNA
eotf	I-DNA
sites	I-DNA
,	O
are	O
necessary	O
for	O
full	O
promoter	O
activity	O
.	O

by	O
supershift	O
analysis	O
,	O
we	O
demonstrate	O
binding	O
of	O
the	O
transcription	B-protein
factors	I-protein
sp0	B-protein
and	O
oct0	B-protein
to	O
the	O
consensus	B-DNA
gc	I-DNA
box	I-DNA
and	O
the	O
oct	B-DNA
site	I-DNA
,	O
respectively	O
.	O

similar	O
to	O
gal-0	B-protein
,	O
gal-00	O
expression	O
is	O
induced	O
by	O
butyric	O
acid	O
,	O
an	O
effect	O
that	O
is	O
lost	O
upon	O
ablation	O
of	O
the	O
gc	B-DNA
box	I-DNA
.	O

additionally	O
,	O
we	O
demonstrate	O
aml0	B-protein
binding	O
to	O
the	O
consensus	O
aml	O
site	O
and	O
yy0	B-protein
binding	O
to	O
the	O
inr	B-DNA
sequence	I-DNA
,	O
both	O
elements	O
functioning	O
as	O
silencers	O
in	O
the	O
gal-00	B-DNA
promoter	I-DNA
.	O

###MEDLINE:21328787

tumour-stromal	O
interactions	O
.	O

role	O
of	O
the	O
stroma	O
in	O
mammary	O
development	O
.	O

mammary	O
development	O
depends	O
on	O
branching	O
morphogenesis	O
,	O
namely	O
the	O
bifurcation	O
and	O
extension	O
of	O
ductal	O
growth	O
points	O
(	O
end	O
buds	O
)	O
and	O
secretory	O
lobules	O
into	O
a	O
more	O
or	O
less	O
fatty	O
stroma	O
.	O

because	O
breast	O
carcinomas	O
are	O
overwhelmingly	O
ductal	O
in	O
origin	O
,	O
this	O
review	O
focuses	O
on	O
stromal	O
influences	O
guiding	O
postnatal	O
ductal	O
development	O
and	O
there	O
is	O
only	O
the	O
briefest	O
account	O
of	O
the	O
role	O
of	O
embryonic	O
stroma	O
(	O
mesenchyme	B-cell_type
)	O
.	O

the	O
stroma	O
as	O
the	O
necessary	O
target	O
for	O
endocrine	B-cell_type
mammogens	I-cell_type
and	O
the	O
source	O
of	O
stimulatory	B-protein
growth	I-protein
factors	I-protein
is	O
described	O
and	O
the	O
importance	O
of	O
mammary	O
epithelium-induced	O
modifications	O
of	O
the	O
periductal	O
stroma	O
is	O
emphasized	O
.	O

evidence	O
is	O
presented	O
that	O
if	O
they	O
are	O
to	O
grow	O
,	O
end	O
buds	O
must	O
condition	O
proximal	O
fatty	O
stroma	O
by	O
recruiting	O
white	B-cell_type
blood	I-cell_type
cells	I-cell_type
as	O
well	O
as	O
inducing	O
stromal	O
cell	O
division	O
and	O
,	O
possibly	O
,	O
estrogen	B-protein
receptors	I-protein
.	O

the	O
induction	O
of	O
a	O
fibrous	O
stromal	O
tunic	O
around	O
the	O
end	O
bud	O
is	O
described	O
and	O
its	O
likely	O
role	O
as	O
a	O
complex	O
ductal	O
morphogen	O
is	O
discussed	O
;	O
a	O
possible	O
role	O
in	O
growth	O
inhibition	O
is	O
also	O
considered	O
.	O

although	O
the	O
signals	O
governing	O
fibrotic	O
induction	O
,	O
ductal	O
morphogenesis	O
,	O
and	O
growth	O
inhibition	O
are	O
unknown	O
,	O
a	O
role	O
for	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
is	O
highly	O
likely	O
and	O
is	O
discussed	O
.	O

finally	O
,	O
a	O
need	O
for	O
new	O
conceptual	O
and	O
experimental	O
approaches	O
to	O
understanding	O
stromal-epithelial	O
signaling	O
is	O
discussed	O
.	O

###MEDLINE:21313314

adipophilin	B-protein
is	O
a	O
sensitive	O
marker	O
for	O
lipid	O
loading	O
in	O
human	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
.	O

adipophilin	O
,	O
a	O
marker	O
of	O
lipid	O
accumulation	O
initially	O
described	O
in	O
adipocytes	B-cell_type
,	O
was	O
recently	O
shown	O
to	O
be	O
induced	O
in	O
macrophage	B-cell_type
foam	I-cell_type
cells	I-cell_type
.	O

we	O
found	O
that	O
even	O
freshly	B-cell_type
isolated	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
express	O
adipophilin	O
and	O
that	O
the	O
amount	O
of	O
adipophilin	B-protein
protein	I-protein
is	O
variable	O
in	O
monocytes	B-cell_type
from	O
different	O
healthy	O
individuals	O
.	O

however	O
,	O
the	O
physiological	O
expression	O
of	O
adipophilin	B-protein
does	O
not	O
correlate	O
with	O
the	O
levels	O
of	O
free	O
fatty	O
acids	O
,	O
cholesterylesters	B-protein
or	O
free	O
cholesterol	O
.	O

enzymatically	O
modified	O
low-density	B-protein
lipoprotein	I-protein
(	O
e-ldl	B-protein
)	O
induces	O
rapid	O
foam	O
cell	O
formation	O
in	O
monocytes	B-cell_type
and	O
upregulates	O
adipophilin	B-RNA
mrna	I-RNA
and	O
protein	O
within	O
0	O
h	O
of	O
incubation	O
.	O

this	O
rapid	O
induction	O
of	O
adipophilin	B-protein
is	O
accompanied	O
by	O
a	O
significant	O
increase	O
of	O
free	O
fatty	O
acids	O
in	O
monocytes	B-cell_type
incubated	O
with	O
e-ldl	O
.	O

adipophilin	B-protein
facilitates	O
the	O
uptake	O
of	O
free	O
fatty	O
acids	O
,	O
and	O
here	O
we	O
demonstrate	O
that	O
free	O
fatty	B-protein
acids	I-protein
increase	O
is	O
related	O
to	O
the	O
early	O
upregulation	O
of	O
adipophilin	O
expression	O
in	O
blood	B-cell_type
monocytes	I-cell_type
.	O

fatty	O
acids	O
are	O
ligands	O
for	O
peroxisome	B-protein
proliferator-activated	I-protein
receptor-gamma	I-protein
(	O
ppargamma	B-protein
)	O
,	O
and	O
the	O
upregulation	O
of	O
adipophilin	B-RNA
mrna	I-RNA
by	O
ppargamma	B-protein
agonists	O
like	O
00d-pgj	O
(	O
0	O
)	O
and	O
ciglitazone	B-protein
indicates	O
that	O
ppargamma	B-protein
may	O
mediate	O
the	O
induction	O
of	O
adipophilin	O
expression	O
in	O
human	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
.	O

###MEDLINE:21311859

constitutive	O
expression	O
of	O
mhc	B-DNA
class	I-DNA
ii	I-DNA
genes	I-DNA
in	O
melanoma	B-cell_type
cell	I-cell_type
lines	I-cell_type
results	O
from	O
the	O
transcription	B-protein
of	I-protein
class	I-protein
ii	I-protein
transactivator	I-protein
abnormally	O
initiated	O
from	O
its	O
b	B-DNA
cell-specific	I-DNA
promoter	I-DNA
.	O

in	B-cell_line
melanoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
two	O
different	O
patterns	O
of	O
mhc	B-protein
class	I-protein
ii	I-protein
expression	O
have	O
been	O
described	O
,	O
either	O
an	O
ifn	B-protein
gamma-inducible	I-protein
expression	O
of	O
hla-dr	B-protein
and	I-protein
hla-dp	I-protein
,	O
with	O
a	O
faint	O
or	O
null	O
expression	O
of	O
hla-dq	B-DNA
,	O
resembling	O
that	O
described	O
for	O
melanocytes	B-cell_type
,	O
or	O
a	O
constitutive	O
expression	O
,	O
i.e.	O
,	O
ifn-gamma	B-protein
independent	O
,	O
of	O
all	O
three	B-protein
hla-d	I-protein
isotypes	I-protein
.	O

as	O
this	O
latter	O
phenotype	O
has	O
been	O
associated	O
with	O
a	O
more	O
rapid	O
progression	O
of	O
melanoma	B-cell_type
tumors	I-cell_type
,	O
we	O
have	O
analyzed	O
in	O
different	O
melanoma	O
cell	O
lines	O
the	O
molecular	O
mechanisms	O
leading	O
to	O
this	O
abnormal	O
pattern	O
of	O
mhc	B-protein
class	I-protein
ii	I-protein
expression	O
.	O

in	O
agreement	O
with	O
the	O
evidence	O
of	O
a	O
coordinate	O
transcription	O
of	O
the	O
hla-d	B-DNA
genes	I-DNA
in	O
these	O
cell	B-cell_line
lines	I-cell_line
,	O
we	O
have	O
shown	O
the	O
constitutive	O
expression	O
of	O
ciita	B-protein
(	I-protein
class	I-protein
ii	I-protein
transactivator	I-protein
)	I-protein
transcripts	I-protein
,	O
ciita	B-DNA
being	O
known	O
as	O
the	O
master	O
switch	O
of	O
mhc	B-protein
class	I-protein
ii	I-protein
expression	O
.	O

unexpectedly	O
,	O
these	O
transcripts	O
initiate	O
from	O
promoter	B-DNA
iii	I-DNA
of	O
the	O
ciita	B-DNA
gene	I-DNA
,	O
a	O
promoter	O
that	O
is	O
mainly	O
used	O
constitutively	O
in	O
b	B-cell_type
lymphocytes	I-cell_type
.	O

this	O
expression	O
was	O
further	O
shown	O
to	O
occur	O
through	O
factor	O
(	O
s	O
)	O
acting	O
on	O
the	O
enhancer	B-DNA
located	O
upstream	B-DNA
of	I-DNA
ciita	I-DNA
promoter	I-DNA
iii	I-DNA
,	O
which	O
was	O
previously	O
described	O
in	O
epithelioid	B-cell_type
cells	I-cell_type
as	O
an	O
ifn-gamma-response	B-DNA
sequence	I-DNA
.	O

the	O
hypothesis	O
of	O
a	O
general	O
abnormality	O
of	O
the	O
ifn-gamma	B-protein
transduction	O
pathway	O
was	O
dismissed	O
.	O

constitutive	O
transcription	O
of	O
ciita	B-protein
from	O
promoter	B-DNA
iii	I-DNA
having	O
been	O
observed	O
in	O
unrelated	O
melanoma	O
cell	O
lines	O
,	O
we	O
propose	O
the	O
hypothesis	O
that	O
this	O
phenomenon	O
might	O
not	O
be	O
a	O
random	O
event	O
,	O
but	O
could	O
be	O
linked	O
to	O
the	O
neoplasic	O
state	O
of	O
the	O
melanoma	B-cell_type
cells	I-cell_type

###MEDLINE:21371733

caspase	B-protein
-mediated	O
calcineurin	B-protein
activation	O
contributes	O
to	O
il-0	B-protein
release	O
during	O
t	B-cell_type
cell	I-cell_type
activation	O
.	O

calcineurin	B-protein
,	O
a	O
ca	O
(	O
0+	O
)	O
/calmodulin-dependent	O
ser/thr	B-protein
phosphatase	I-protein
(	O
protein	B-protein
phosphatase	I-protein
0b	I-protein
)	O
,	O
plays	O
a	O
critical	O
role	O
in	O
il-0	B-protein
production	O
during	O
t	B-cell_type
cell	I-cell_type
activation	O
.	O

it	O
has	O
been	O
previously	O
reported	O
that	O
il-0	B-protein
release	O
in	O
activated	B-cell_line
jurkat	I-cell_line
t	I-cell_line
requires	O
caspase-like	O
activity	O
(	O
posmantur	O
et	O
al.	O
(	O
0000	O
)	O
exp.	O
cell.	O
res.	O
000	O
,	O
000-000	O
)	O
.	O

we	O
report	O
here	O
that	O
the	O
00-kda	B-protein
catalytic	I-protein
subunit	I-protein
of	O
calcineurin	B-protein
a	I-protein
(	O
cn	B-protein
a	O
)	O
was	O
partially	O
cleaved	O
to	O
a	O
00-kda	B-protein
form	I-protein
in	O
phytohemagglutinin	B-protein
a	I-protein
(	O
pha	B-protein
)	O
or	O
phorbol	O
ester	O
+	O
ionomycin	O
(	O
p	O
+	O
i	O
)	O
-activated	O
jurkat	B-cell_line
cells	I-cell_line
.	O

in	O
parallel	O
,	O
proteolytic	O
activation	O
of	O
upstream	B-protein
caspases	I-protein
(	O
caspase-0	B-protein
and	O
-0	O
)	O
as	O
well	O
as	O
effector	O
caspase-0	O
was	O
also	O
observed	O
.	O

cn	B-protein
a	O
cleavage	O
was	O
caspase	O
mediated	O
,	O
since	O
it	O
was	O
inhibitable	O
by	O
pan-caspase	B-protein
inhibitor	I-protein
cbz-asp-ch	I-protein
(	O
0	O
)	O
oc	O
(	O
o	O
)	O
-0	O
,	O
0-dichlorobenzene	O
(	O
z-d-dcb	B-protein
)	O
.	O

cn	B-protein
a	O
cleavage	O
was	O
also	O
observed	O
when	O
purified	O
calcineurin	B-protein
was	O
digested	O
in	O
vitro	O
with	O
caspase-0	B-protein
.	O

truncated	B-protein
cn	I-protein
a	I-protein
was	O
associated	O
with	O
enhanced	O
phosphatase	O
activity	O
and	O
reduced	O
calmodulin	B-protein
sensitivity	O
.	O

furthermore	O
,	O
in	O
pha	B-protein
or	O
p	O
+	O
i-activated	B-cell_line
jurkat	I-cell_line
cells	I-cell_line
,	O
dephosphorylation	O
of	O
calcineurin	B-protein
substrate	I-protein
nfatc	I-protein
(	O
a	O
transcription	B-protein
factor	I-protein
known	O
to	O
be	O
involved	O
in	O
transactivation	O
of	O
the	O
il-0	B-DNA
gene	I-DNA
)	O
,	O
was	O
also	O
suppressed	O
by	O
z-d-dcb	O
.	O

taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
caspase-mediated	O
cleavage	O
of	O
cn	B-protein
a	I-protein
contributes	O
to	O
il-0	B-protein
production	O
during	O
t	B-cell_type
cell	I-cell_type
activation	O
.	O

copyright	O
0000	O
academic	O
press	O
.	O

###MEDLINE:21363219

maturation	O
of	O
human	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
as	O
sulfasalazine	O
target	O
.	O

aim	O
:	O
sulfasalazine	O
,	O
a	O
nonsteroidal	O
anti-inflammatory	O
drug	O
,	O
is	O
effective	O
in	O
treating	O
some	O
autoimmune	O
diseases	O
,	O
but	O
its	O
mechanism	O
of	O
action	O
is	O
unclear	O
.	O

to	O
determine	O
whether	O
dendritic	B-cell_type
cells	I-cell_type
could	O
be	O
a	O
possible	O
target	O
of	O
the	O
drug	O
,	O
we	O
studied	O
the	O
effects	O
of	O
sulfasalazine	O
and	O
its	O
metabolites	O
,	O
aminosalicylate	B-protein
and	O
sulfapyridine	O
,	O
on	O
in	O
vitro	O
maturation	O
(	O
terminal	O
differentiation	O
)	O
of	O
human	B-cell_type
myeloid	I-cell_type
dendritic	I-cell_type
cells	I-cell_type
.	O

methods	O
:	O
we	O
prepared	O
immature	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
by	O
incubating	B-cell_type
cd00-positive	I-cell_type
cells	I-cell_type
in	O
the	O
presence	O
of	O
granulocyte-	B-protein
macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
and	O
interleukin	B-protein
(	I-protein
il	I-protein
)	I-protein
-0	I-protein
.	O

the	O
cells	O
were	O
matured	O
by	O
addition	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
tnf	B-protein
)	I-protein
-a	I-protein
,	O
il-0	B-protein
beta	I-protein
,	O
and	O
prostaglandin	O
e0	O
in	O
the	O
presence	O
of	O
sulfasalazine	O
or	O
its	O
metabolites	O
--	O
aminosalicylate	O
and	O
sulfapyridine	O
,	O
or	O
their	O
combinations	O
.	O

we	O
quantified	O
the	O
effect	O
of	O
drugs	O
on	O
the	O
dendritic	O
cell	O
characteristics	O
,	O
such	O
as	O
stimulation	O
of	O
autologous	O
and	O
allogeneic	O
pan-t	O
cell	O
proliferation	O
,	O
surface	O
marker	O
phenotype	O
,	O
il-00	B-protein
p00	B-protein
subunit	I-protein
secretion	O
,	O
and	O
activation	O
of	O
nuclear	B-protein
transcription	I-protein
factor	I-protein
(	O
nf	B-protein
)	I-protein
-kappa	I-protein
b	I-protein
.	O

results	O
:	O
dendritic	B-cell_type
cells	I-cell_type
treated	O
with	O
sulfasalazine	O
(	O
0.00	O
micromol/l	O
or	O
0.0	O
micromol/l	O
)	O
could	O
not	O
stimulate	O
t	B-cell_type
cells	I-cell_type
(	O
p	O
<	O
0.000	O
,	O
two-sided	O
paired	O
t-test	O
)	O
.	O

in	O
distinction	O
to	O
drug-free	B-cell_type
maturing	I-cell_type
dendritic	I-cell_type
cells	I-cell_type
,	O
0.0	O
micromol/l	O
sulfasalazine	O
upregulated	O
the	O
levels	O
of	O
cd00	B-protein
and	O
cd00	B-protein
and	O
downregulated	O
the	O
levels	O
of	O
cd00	B-protein
,	O
cd00	B-protein
,	O
and	O
cd00	B-protein
(	O
for	O
all	O
cd	O
markers	O
,	O
p	O
<	O
0.00	O
for	O
difference	O
between	O
measurements	O
in	O
the	O
absence	O
and	O
the	O
presence	O
of	O
sulfasalazine	O
)	O
.	O

from	O
concentration-dependent	O
changes	O
in	O
cd00	B-protein
expression	O
,	O
we	O
found	O
an	O
apparent	O
id00	O
>	O
>	O
0.0	O
micromol/l	O
sulfasalazine	O
.	O

the	O
apparent	O
id00	O
value	O
for	O
aminosalicylate-inhibited	O
maturation	O
was	O
0	O
micromol/l	O
.	O

sulfapyridine	O
had	O
no	O
effect	O
.	O

at	O
0.00	O
micromol/l	O
,	O
sulfasalazine	O
largely	O
inhibited	O
nf-kb	B-protein
activation	O
in	O
dendritic	B-cell_type
cells	I-cell_type
.	O

conclusion	O
:	O
maturing	B-cell_type
human	I-cell_type
dendritic	I-cell_type
cells	I-cell_type
are	O
hundred-fold	O
more	O
sensitive	O
to	O
sulfasalazine	O
than	O
t	B-cell_type
cells	I-cell_type
and	O
nk	B-cell_type
cells	I-cell_type
and	O
the	O
most	O
sensitive	O
human	B-cell_type
cells	I-cell_type
described	O
so	O
far	O
.	O

thus	O
,	O
dendritic	O
cell	O
maturation	O
is	O
an	O
important	O
target	O
of	O
sulfasalazine	O
.	O

because	O
of	O
the	O
role	O
of	O
dendritic	B-cell_type
cells	I-cell_type
in	O
(	O
auto	O
)	O
immunity	O
,	O
inhibition	O
of	O
their	O
maturation	O
might	O
provide	O
a	O
target	O
for	O
further	O
optimization	O
of	O
sulfasalazine	O
therapy	O
.	O

###MEDLINE:21359969

defective	O
function	O
of	O
the	O
proteasome	O
in	O
autoimmunity	O
:	O
involvement	O
of	O
impaired	O
nf-kappab	B-protein
activation	O
.	O

type	O
0	O
diabetes	O
(	O
also	O
known	O
as	O
insulin-dependent	O
diabetes	O
mellitus	O
or	O
juvenile-onset	O
diabetes	O
)	O
is	O
usually	O
caused	O
by	O
t	O
cell-mediated	O
autoimmunity	O
,	O
with	O
a	O
prediabetic	O
state	O
characterized	O
by	O
the	O
production	O
of	O
autoantibodies	B-protein
specific	O
for	O
proteins	O
expressed	O
by	O
pancreatic	B-cell_type
beta	I-cell_type
cells	I-cell_type
.	O

the	O
nonobese	O
patient	O
with	O
diabetes	O
(	O
nod	B-cell_type
)	O
mouse	O
is	O
a	O
spontaneous	O
model	O
of	O
type	O
0	O
diabetes	O
with	O
a	O
strong	O
genetic	O
component	O
that	O
maps	O
to	O
the	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
(	I-DNA
mhc	I-DNA
)	I-DNA
region	I-DNA
of	O
the	O
genome	O
.	O

a	O
specific	O
proteasome	O
defect	O
has	O
been	O
identified	O
in	O
nod	O
mouse	O
in	O
select	O
lymphocytic	B-cell_type
and	I-cell_type
monocytic	I-cell_type
lineages	I-cell_type
that	O
results	O
from	O
down-regulation	O
of	O
expression	O
of	O
the	O
proteasome	O
subunit	O
lmp0	B-protein
,	O
which	O
is	O
encoded	O
by	O
a	O
gene	O
in	O
the	O
mhc	B-DNA
genomic	I-DNA
region	I-DNA
.	O

this	O
defect	O
prevents	O
the	O
proteolytic	O
processing	O
required	O
for	O
the	O
production	O
and	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor-kappab	I-protein
(	O
nf-kappab	B-protein
)	O
,	O
which	O
plays	O
important	O
roles	O
in	O
immune	O
and	O
inflammatory	O
responses	O
,	O
as	O
well	O
as	O
increases	O
the	O
susceptibility	O
of	O
the	O
affected	B-cell_type
cells	I-cell_type
to	O
apoptosis	O
induced	O
by	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
tnf-alpha	B-protein
)	O
.	O

the	O
novel	O
role	O
of	O
the	O
proteasome	O
in	O
dysfunction	O
in	O
autoimmunity	O
is	O
presented	O
and	O
documented	O
to	O
be	O
both	O
tissue	O
and	O
developmental	O
stage	O
specific	O
.	O

we	O
propose	O
a	O
role	O
of	O
the	O
proteasome	O
as	O
a	O
step	O
in	O
disease	O
pathogenesis	O
and	O
tissue	O
targeting	O
.	O

###MEDLINE:21352808

down-regulation	O
of	O
tdt	O
transcription	O
in	O
cd0	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cd0	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
thymocytes	I-cell_type
by	O
ikaros	B-protein
proteins	I-protein
in	O
direct	O
competition	O
with	O
an	O
ets	B-protein
activator	I-protein
.	O

ikaros	B-protein
is	O
a	O
unique	O
regulator	O
of	O
lymphopoiesis	O
that	O
associates	O
with	O
pericentromeric	B-DNA
heterochromatin	I-DNA
and	O
has	O
been	O
implicated	O
in	O
heritable	O
gene	O
inactivation	O
.	O

binding	O
and	O
competition	O
experiments	O
demonstrate	O
that	O
ikaros	B-protein
dimers	I-protein
compete	O
with	O
an	O
ets	B-protein
activator	I-protein
for	O
occupancy	O
of	O
the	O
lymphocyte-specific	O
tdt	O
promoter	O
.	O

mutations	O
that	O
selectively	O
disrupt	O
ikaros	B-protein
binding	O
to	O
an	O
integrated	O
tdt	O
promoter	O
had	O
no	O
effect	O
on	O
promoter	O
function	O
in	O
a	O
cd0	B-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
cd0	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
thymocyte	I-cell_line
line	I-cell_line
.	O

however	O
,	O
these	O
mutations	O
abolished	O
down-regulation	O
on	O
differentiation	O
,	O
providing	O
evidence	O
that	O
ikaros	B-protein
plays	O
a	O
direct	O
role	O
in	O
repression	O
.	O

reduced	O
access	O
to	O
restriction	O
enzyme	O
cleavage	O
suggested	O
that	O
chromatin	O
alterations	O
accompany	O
down-regulation	O
.	O

the	O
ikaros-dependent	O
down-regulation	O
event	O
and	O
the	O
observed	O
chromatin	O
alterations	O
appear	O
to	O
precede	O
pericentromeric	O
repositioning	O
.	O

current	O
models	O
propose	O
that	O
the	O
functions	O
of	O
ikaros	B-protein
should	O
be	O
disrupted	O
by	O
a	O
small	B-protein
isoform	I-protein
that	O
retains	O
the	O
dimerization	B-protein
domain	I-protein
and	O
lacks	O
the	O
dna-binding	B-protein
domain	I-protein
.	O

surprisingly	O
,	O
in	O
the	O
cd0	B-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
cd0	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
thymocyte	I-cell_line
line	I-cell_line
,	O
overexpression	O
of	O
a	O
small	O
ikaros	B-protein
isoform	I-protein
had	O
no	O
effect	O
on	O
differentiation	O
or	O
on	O
the	O
pericentromeric	O
targeting	O
and	O
dna-binding	O
properties	O
of	O
ikaros	B-protein
.	O

rather	O
,	O
the	O
small	B-protein
isoform	I-protein
assembled	O
into	O
multimeric	B-protein
complexes	I-protein
with	O
dna-bound	O
ikaros	O
at	O
the	O
pericentromeric	O
foci	O
.	O

the	O
capacity	O
for	O
in	O
vivo	O
multimer	O
formation	O
suggests	O
that	O
interactions	O
between	O
ikaros	B-protein
dimers	I-protein
bound	O
to	O
the	O
tdt	O
promoter	O
and	O
those	O
bound	O
to	O
pericentromeric	B-DNA
repeat	I-DNA
sequences	I-DNA
may	O
contribute	O
to	O
the	O
pericentromeric	O
repositioning	O
of	O
the	O
inactive	B-DNA
gene	I-DNA
.	O

###MEDLINE:21341829

type	B-protein
i	I-protein
interferons	I-protein
and	O
il-00	B-protein
:	O
convergence	O
and	O
cross-regulation	O
among	O
mediators	O
of	O
cellular	O
immunity	O
.	O

therapeutic	O
use	O
of	O
type	B-protein
i	I-protein
ifn	I-protein
(	O
ifn-alpha/beta	B-protein
)	O
has	O
become	O
common	O
.	O

many	O
of	O
the	O
diverse	O
diseases	O
targeted	O
are	O
marked	O
by	O
pathogenetic	O
abnormalities	O
in	O
cell-mediated	O
immunity	O
(	O
cmi	O
)	O
,	O
these	O
cellular	O
immune	O
responses	O
either	O
causing	O
injury	O
to	O
the	O
host	O
,	O
lacking	O
sufficient	O
vigor	O
for	O
virus	O
or	O
tumor	O
clearance	O
,	O
or	O
both	O
.	O

in	O
general	O
,	O
therapeutic	O
efficacy	O
is	O
limited	O
.	O

it	O
is	O
thus	O
notable	O
that	O
the	O
pleiotropic	O
effects	O
of	O
type	B-protein
i	I-protein
ifn	I-protein
on	O
cmi	O
remain	O
poorly	O
understood	O
.	O

we	O
characterized	O
the	O
effects	O
of	O
type	B-protein
i	I-protein
ifn	I-protein
on	O
the	O
production	O
of	O
il-00	B-protein
,	O
the	O
central	O
immunoregulatory	B-protein
cytokine	I-protein
of	O
the	O
cd0	B-DNA
(	I-DNA
+	I-DNA
)	I-DNA
t	I-DNA
cell	I-DNA
arm	I-DNA
of	O
cmi	O
.	O

we	O
show	O
that	O
type	B-protein
i	I-protein
ifn	I-protein
are	O
potent	O
inhibitors	O
of	O
il-00	B-protein
production	O
by	O
human	B-cell_type
monocytes/macrophages	I-cell_type
.	O

the	O
underlying	O
mechanism	O
involves	O
transcriptional	O
inhibition	O
of	O
the	O
il-00p00	B-DNA
gene	I-DNA
,	O
marked	O
by	O
down-regulation	O
of	O
pu.0	B-protein
binding	O
activity	O
at	O
the	O
upstream	B-DNA
ets	I-DNA
site	I-DNA
of	O
the	O
il-00p00	B-DNA
promoter	I-DNA
.	O

type	B-protein
i	I-protein
ifn	I-protein
have	O
previously	O
been	O
shown	O
to	O
be	O
able	O
to	O
substitute	O
for	O
il-00	B-protein
in	O
driving	O
ifn-gamma	B-protein
production	O
from	O
t	B-cell_type
and	I-cell_type
nk	I-cell_type
cells	I-cell_type
.	O

the	O
ability	O
of	O
ifn-alpha/beta	B-protein
to	O
suppress	O
il-00	B-protein
production	O
while	O
up-regulating	O
ifn-gamma	B-protein
production	O
suggests	O
a	O
possible	O
mechanistic	O
basis	O
for	O
the	O
difficulties	O
of	O
employing	O
these	O
cytokines	B-protein
in	O
diseases	O
involving	O
abnormalities	O
of	O
cmi	O
.	O

###MEDLINE:21336723

nuclear	B-protein
factor-kappab	I-protein
suppressive	O
and	O
inhibitor-kappab	O
stimulatory	O
effects	O
of	O
troglitazone	O
in	O
obese	O
patients	O
with	O
type	O
0	O
diabetes	O
:	O
evidence	O
of	O
an	O
antiinflammatory	O
action	O
?	O

it	O
has	O
been	O
shown	O
recently	O
that	O
troglitazone	O
exerts	O
an	O
anti-inflammatory	O
effect	O
,	O
in	O
vitro	O
,	O
and	O
in	O
experimental	O
animals	O
.	O

to	O
test	O
these	O
properties	O
in	O
humans	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
troglitazone	O
on	O
the	O
proinflammatory	B-protein
transcription	I-protein
factor	I-protein
nuclear	I-protein
factor-kappab	I-protein
and	O
its	O
inhibitory	B-protein
protein	I-protein
ikappab	B-protein
in	O
mononuclear	B-cell_type
cells	I-cell_type
(	O
mnc	B-cell_type
)	O
and	O
plasma	B-protein
soluble	I-protein
intracellular	I-protein
adhesion	I-protein
molecule-0	I-protein
,	O
monocyte	B-protein
chemoattractant	I-protein
protein-0	I-protein
,	O
plasminogen	B-protein
activator	I-protein
inhibitor-0	I-protein
,	O
and	O
c-reactive	B-protein
protein	I-protein
.	O

we	O
also	O
examined	O
the	O
effect	O
of	O
troglitazone	O
on	O
reactive	O
oxygen	O
species	O
generation	O
,	O
p00	B-protein
(	I-protein
phox	I-protein
)	I-protein
subunit	I-protein
expression	O
,	O
0-hydroxyoctadecadienoic	O
acid	O
(	O
0-hode	B-protein
)	O
,	O
00-hode	O
,	O
o-tyrosine	O
,	O
and	O
m-tyrosine	O
in	O
obese	O
patients	O
with	O
type	O
0	O
diabetes	O
.	O

seven	O
obese	O
patients	O
with	O
type	O
0	O
diabetes	O
were	O
treated	O
with	O
troglitazone	O
(	O
000	O
mg/day	O
)	O
for	O
0	O
weeks	O
.	O

blood	O
samples	O
were	O
obtained	O
at	O
weekly	O
intervals	O
.	O

nuclear	B-protein
factor-kappab	I-protein
binding	O
activity	O
in	O
mnc	B-cell_type
nuclear	O
extracts	O
was	O
significantly	O
inhibited	O
after	O
troglitazone	O
treatment	O
at	O
week	O
0	O
and	O
continued	O
to	O
be	O
inhibited	O
up	O
to	O
week	O
0	O
.	O

on	O
the	O
other	O
hand	O
,	O
ikappab	B-protein
protein	I-protein
levels	O
increased	O
significantly	O
after	O
troglitazone	O
treatment	O
at	O
week	O
0	O
,	O
and	O
this	O
increase	O
persisted	O
throughout	O
the	O
study	O
.	O

plasma	B-protein
monocyte	I-protein
chemoattractant	I-protein
protein-0	I-protein
and	O
soluble	B-protein
intracellular	I-protein
adhesion	I-protein
molecule-0	I-protein
concentrations	O
did	O
not	O
decrease	O
significantly	O
after	O
troglitazone	O
treatment	O
,	O
although	O
there	O
was	O
a	O
trend	O
toward	O
inhibition	O
.	O

reactive	O
oxygen	O
species	O
generation	O
by	O
polymorphonuclear	B-cell_type
cells	I-cell_type
and	O
mnc	B-cell_type
,	O
p00	B-protein
(	I-protein
phox	I-protein
)	I-protein
subunit	I-protein
protein	O
quantities	O
,	O
plasminogen	B-protein
activator	I-protein
inhibitor-0	I-protein
,	O
and	O
c-reactive	B-protein
protein	I-protein
levels	O
decreased	O
significantly	O
after	O
troglitazone	O
intake	O
.	O

00-hode/linoleic	O
acid	O
and	O
0-hode/linoleic	O
acid	O
ratios	O
also	O
decreased	O
after	O
troglitazone	O
intake	O
.	O

however	O
,	O
o-tyrosine/phenylalanine	B-protein
and	O
m-tyrosine/phenylalanine	O
ratios	O
did	O
not	O
change	O
significantly	O
.	O

these	O
data	O
show	O
that	O
troglitazone	O
has	O
profound	O
antiinflammatory	O
effects	O
in	O
addition	O
to	O
antioxidant	O
effects	O
in	O
obese	O
type	O
0	O
diabetics	O
;	O
these	O
effects	O
may	O
be	O
relevant	O
to	O
the	O
recently	O
described	O
beneficial	O
antiatherosclerotic	O
effects	O
of	O
troglitazone	O
at	O
the	O
vascular	O
level	O
.	O

###MEDLINE:21329455

ox00	O
stimulation	O
by	O
gp00/ox00	B-protein
ligand	I-protein
enhances	O
productive	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
0	I-DNA
infection	O
.	O

ox00	O
is	O
a	O
member	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
tnf	B-protein
)	I-protein
receptor	I-protein
superfamily	I-protein
and	O
known	O
to	O
be	O
an	O
important	O
costimulatory	B-protein
molecule	I-protein
expressed	O
on	O
activated	B-cell_type
t	I-cell_type
cells	I-cell_type
.	O

to	O
investigate	O
the	O
role	O
of	O
costimulation	O
of	O
ox00	O
in	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
0	I-DNA
(	O
hiv-0	O
)	O
infection	O
by	O
its	O
natural	O
ligand	O
,	O
gp00	B-protein
,	O
the	O
ox00-transfected	B-cell_line
ach-0	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
ach-0/ox00	O
,	O
chronically	O
infected	O
with	O
hiv-0	O
,	O
was	O
cocultured	O
with	O
paraformaldehyde	B-cell_line
(	I-cell_line
pfa	I-cell_line
)	I-cell_line
-fixed	I-cell_line
gp00-transfected	I-cell_line
mouse	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
sv-t0/gp00	O
.	O

the	O
results	O
showed	O
that	O
hiv-0	O
production	O
was	O
strongly	O
induced	O
.	O

this	O
was	O
followed	O
by	O
apparent	O
apoptosis	O
,	O
and	O
both	O
processes	O
were	O
specifically	O
inhibited	O
by	O
the	O
gp00	B-protein
-specific	I-protein
neutralizing	I-protein
monoclonal	I-protein
antibody	I-protein
0a0	I-protein
.	O

endogenous	B-protein
tnf	I-protein
alpha	I-protein
(	O
tnf-alpha	B-protein
)	O
and	O
tnf-beta	B-protein
production	O
were	O
not	O
involved	O
in	O
the	O
enhanced	O
hiv-0	O
production	O
.	O

furthermore	O
,	O
enhanced	O
hiv-0	O
transcription	O
in	O
gp00	B-protein
-stimulated	O
ach-0/ox00	B-cell_line
cells	I-cell_line
was	O
dependent	O
on	O
the	O
kappa	B-DNA
b	I-DNA
site	I-DNA
of	O
the	O
hiv-0	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
,	O
and	O
the	O
ox00-gp00	B-protein
interaction	I-protein
activated	I-protein
nf-kappa	I-protein
b	I-protein
consisting	O
of	O
p00	B-protein
and	O
p00	B-protein
subunits	I-protein
.	O

when	O
primary	B-cell_type
activated	I-cell_type
cd0	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
t	I-cell_type
cells	I-cell_type
acutely	O
infected	O
with	O
hiv-0	B-DNA
(	I-DNA
nl0-0	I-DNA
)	I-DNA
(	I-DNA
cxcr0-using	I-DNA
t-cell-line-tropic	I-DNA
)	O
were	O
cocultured	O
with	O
pfa-fixed	B-protein
gp00	I-protein
(	O
+	O
)	O
human	B-cell_line
t-cell	I-cell_line
leukemia	I-cell_line
virus	I-cell_line
type	I-cell_line
0-bearing	I-cell_line
mt-0	I-cell_line
cells	I-cell_line
or	O
sv-t0/gp00	B-cell_line
cells	I-cell_line
,	O
hiv-0	O
production	O
was	O
also	O
markedly	O
enhanced	O
.	O

the	O
enhancement	O
was	O
again	O
significantly	O
inhibited	O
by	O
0a0	O
.	O

the	O
present	O
study	O
first	O
shows	O
that	O
ox00-gp00	O
interaction	O
stimulates	O
hiv-0	O
expression	O
and	O
suggests	O
that	O
ox00	O
triggering	O
by	O
gp00	B-protein
may	O
play	O
an	O
important	O
role	O
in	O
enhancing	O
hiv-0	O
production	O
in	O
both	O
acutely	O
and	O
latently	B-cell_type
infected	I-cell_type
cd0	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
t	I-cell_type
cells	I-cell_type
in	O
vivo	O
.	O

###MEDLINE:21319877

troglitazone	O
,	O
a	O
ppargamma	B-protein
ligand	I-protein
,	O
inhibits	O
osteopontin	B-DNA
gene	I-DNA
expression	O
in	O
human	B-cell_line
monocytes/macrophage	I-cell_line
thp-0	I-cell_line
cells	I-cell_line
.	O

peroxizome	B-protein
proliferator-activated	I-protein
receptor-gamma	I-protein
(	O
ppargamma	B-protein
)	O
is	O
a	O
member	O
of	O
the	O
nuclear	B-protein
receptor	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
that	O
regulate	O
adipocyte	B-cell_type
differentiation	O
.	O

recent	O
studies	O
indicate	O
that	O
liganded	B-protein
ppargamma	I-protein
not	O
only	O
promotes	O
differentiation	O
but	O
also	O
inhibits	O
the	O
activation	O
of	O
macrophages	B-cell_type
.	O

osteopontin	B-protein
,	O
a	O
component	O
of	O
extracellular	O
matrix	O
,	O
is	O
synthesized	O
by	O
macrophages	B-cell_type
in	O
atherosclerotic	O
plaques	O
.	O

in	O
this	O
study	O
,	O
we	O
examined	O
whether	O
ppargamma	B-protein
ligand	O
regulates	O
osteopontin	B-DNA
gene	I-DNA
expression	O
in	O
thp-0	B-cell_line
cells	I-cell_line
,	O
a	O
cell	B-cell_line
line	I-cell_line
derived	O
from	O
human	B-cell_line
monocytic	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
which	O
can	O
differentiate	O
to	O
macrophage	O
upon	O
stimulation	O
with	O
phorbol	O
ester	O
pma	O
.	O

northern	O
blot	O
analysis	O
showed	O
that	O
osteopontin	B-protein
expression	O
is	O
markedly	O
induced	O
in	O
response	O
to	O
pma	O
.	O

troglitazone	O
,	O
a	O
ppargamma	B-protein
ligand	I-protein
,	O
dramatically	O
attenuated	O
the	O
pma-induced	O
osteopontin	B-protein
expression	O
.	O

transient	O
transfection	O
assays	O
of	O
the	O
human	O
osteopontin	B-DNA
promoter/luciferase	I-DNA
construct	I-DNA
which	O
contains	O
a	O
0'-flanking	B-DNA
region	I-DNA
between	O
-0000	O
and	O
+00	O
relative	O
to	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
demonstrate	O
that	O
either	O
treatment	O
with	O
troglitazone	O
or	O
cotransfection	O
of	O
ppargamma	B-protein
expression	O
vector	O
inhibits	O
osteopontin	B-DNA
promoter	I-DNA
activity	O
.	O

these	O
data	O
indicate	O
that	O
troglitazone	O
reduces	O
osteopontin	B-DNA
gene	I-DNA
expression	O
at	O
transcriptional	O
level	O
through	O
ppargamma	B-protein
activation	O
,	O
and	O
suggest	O
the	O
role	O
of	O
troglitazone	O
in	O
inhibiting	O
the	O
ability	O
of	O
macrophages	B-cell_type
to	O
produce	O
extracellular	O
matrix	O
,	O
which	O
is	O
particularly	O
relevant	O
to	O
atherosclerotic	O
plaque	O
formation	O
.	O

###MEDLINE:21311880

transcription	B-protein
factor	I-protein
nf-kappa	I-protein
b	I-protein
regulates	O
ig	B-DNA
lambda	I-DNA
light	I-DNA
chain	I-DNA
gene	I-DNA
rearrangement	O
.	O

the	O
tissue-	O
and	O
stage-specific	O
assembly	O
of	O
ig	B-DNA
and	I-DNA
tcr	I-DNA
genes	I-DNA
is	O
mediated	O
by	O
a	O
common	B-DNA
v	I-DNA
(	O
d	O
)	O
j	O
recombinase	O
complex	O
in	O
precursor	B-cell_type
lymphocytes	I-cell_type
.	O

directed	O
alterations	O
in	O
the	O
accessibility	O
of	O
v	O
,	O
d	O
,	O
and	O
j	B-DNA
gene	I-DNA
segments	I-DNA
target	O
the	O
recombinase	O
to	O
specific	O
ag	B-protein
receptor	I-protein
loci	O
.	O

accessibility	O
within	O
a	O
given	O
locus	O
is	O
regulated	O
by	O
the	O
functional	O
interaction	O
of	O
transcription	B-protein
factors	I-protein
with	O
cognate	B-DNA
enhancer	I-DNA
elements	I-DNA
and	O
correlates	O
with	O
the	O
transcriptional	O
activity	O
of	O
unrearranged	O
gene	O
segments	O
.	O

as	O
demonstrated	O
in	O
our	O
prior	O
studies	O
,	O
rearrangement	O
of	O
the	O
igkappa	B-DNA
locus	I-DNA
is	O
regulated	O
by	O
the	O
inducible	B-protein
transcription	I-protein
factor	I-protein
nf-kappab	B-protein
.	O

in	O
contrast	O
to	O
the	O
igkappa	B-DNA
locus	I-DNA
,	O
known	O
transcriptional	B-DNA
control	I-DNA
elements	I-DNA
in	O
the	O
iglambda	B-DNA
locus	I-DNA
lack	O
functional	O
nf-kappab	B-DNA
binding	I-DNA
sites	I-DNA
.	O

consistent	O
with	O
this	O
observation	O
,	O
the	O
expression	O
of	O
assembled	O
iglambda	B-DNA
genes	I-DNA
in	O
mature	B-cell_type
b	I-cell_type
cells	I-cell_type
has	O
been	O
shown	O
to	O
be	O
nf-kappab	B-protein
independent	O
.	O

nonetheless	O
,	O
we	O
now	O
show	O
that	O
specific	O
repression	O
of	O
nf-kappab	B-protein
inhibits	O
germline	B-DNA
transcription	O
and	O
recombination	O
of	O
iglambda	B-DNA
gene	I-DNA
segments	I-DNA
in	O
precursor	B-cell_type
b	I-cell_type
cells	I-cell_type
.	O

molecular	O
analyses	O
indicate	O
that	O
the	O
block	O
in	O
nf-kappab	B-protein
impairs	O
iglambda	O
rearrangement	O
at	O
the	O
level	O
of	O
recombinase	O
accessibility	O
.	O

in	O
contrast	O
,	O
the	O
activities	O
of	O
known	O
iglambda	B-DNA
promoter	I-DNA
and	I-DNA
enhancer	I-DNA
elements	I-DNA
are	O
unaffected	O
in	O
the	O
same	O
cellular	O
background	O
.	O

these	O
findings	O
expand	O
the	O
range	O
of	O
nf-kappab	B-protein
action	O
in	O
precursor	B-cell_type
b	I-cell_type
cells	I-cell_type
beyond	O
igkappa	O
to	O
include	O
the	O
control	O
of	O
recombinational	O
accessibility	O
at	O
both	O
l	B-DNA
chain	I-DNA
loci	I-DNA
.	O

moreover	O
,	O
our	O
results	O
strongly	O
suggest	O
the	O
existence	O
of	O
a	O
novel	B-DNA
iglambda	I-DNA
regulatory	I-DNA
element	I-DNA
that	O
is	O
either	O
directly	O
or	O
indirectly	O
activated	O
by	O
nf-kappab	B-protein
during	O
the	O
early	O
stages	O
of	O
b	B-cell_type
cell	I-cell_type
development	O
.	O

###MEDLINE:21391971

transcription	B-protein
factor	I-protein
stat0a	I-protein
is	O
a	O
substrate	O
of	O
bruton	B-protein
's	I-protein
tyrosine	I-protein
kinase	I-protein
in	O
b	B-cell_type
cells	I-cell_type
.	O

stat0a	B-protein
is	O
a	O
molecular	O
regulator	O
of	O
proliferation	O
,	O
differentiation	O
,	O
and	O
apoptosis	O
in	O
lymphohematopoietic	B-cell_type
cells	I-cell_type
.	O

here	O
we	O
show	O
that	O
stat0a	B-protein
can	O
serve	O
as	O
a	O
functional	O
substrate	O
of	O
bruton	B-protein
's	I-protein
tyrosine	I-protein
kinase	I-protein
(	O
btk	B-protein
)	O
.	O

purified	O
recombinant	O
btk	B-protein
was	O
capable	O
of	O
directly	O
binding	O
purified	B-protein
recombinant	I-protein
stat0a	I-protein
with	O
high	O
affinity	O
(	O
k	O
(	O
d	O
)	O
=	O
00	O
nm	O
)	O
,	O
as	O
determined	O
by	O
surface	O
plasmon	O
resonance	O
using	O
a	O
biacore	O
biosensor	O
system	O
.	O

btk	B-protein
was	O
also	O
capable	O
of	O
tyrosine-phosphorylating	B-protein
ectopically	O
expressed	O
recombinant	B-protein
stat0a	I-protein
on	O
tyr	O
(	O
000	O
)	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
in	O
a	O
janus	B-protein
kinase	I-protein
0	I-protein
-independent	O
fashion	O
.	O

btk	B-protein
phosphorylated	O
the	O
y000f	O
,	O
y000f	O
,	O
and	O
y000f	O
,	O
y000f	B-protein
mutants	I-protein
but	O
not	O
the	O
y000f	B-protein
mutant	I-protein
of	O
stat0a	B-protein
.	O

stat0a	B-protein
mutations	O
in	O
the	O
src	B-protein
homology	I-protein
0	I-protein
(	O
sh0	B-protein
)	O
and	O
sh0	B-protein
domains	I-protein
did	O
not	O
alter	O
the	O
btk	B-protein
-mediated	O
tyrosine	O
phosphorylation	O
.	O

recombinant	O
btk	B-protein
proteins	O
with	O
mutant	B-protein
pleckstrin	I-protein
homology	I-protein
,	I-protein
sh0	I-protein
,	I-protein
or	I-protein
sh0	I-protein
domains	I-protein
were	O
capable	O
of	O
phosphorylating	O
stat0a	B-protein
,	O
whereas	O
recombinant	O
btk	B-protein
proteins	O
with	O
sh0/kinase	B-protein
domain	I-protein
mutations	O
were	O
not	O
.	O

in	O
pull-down	O
experiments	O
,	O
only	O
full-length	O
btk	B-protein
and	O
its	O
sh0/kinase	B-protein
domain	I-protein
(	O
but	O
not	O
the	O
pleckstrin	O
homology	O
,	O
sh0	B-protein
,	O
or	O
sh0	B-protein
domains	I-protein
)	O
were	O
capable	O
of	O
binding	O
stat0a	B-protein
.	O

ectopically	O
expressed	O
btk	B-DNA
kinase	I-DNA
domain	I-DNA
was	O
capable	O
of	O
tyrosine-phosphorylating	B-protein
stat0a	I-protein
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

btk	B-protein
-mediated	O
tyrosine	O
phosphorylation	O
of	O
ectopically	O
expressed	O
wild	B-protein
type	I-protein
(	I-protein
but	I-protein
not	I-protein
tyr	I-protein
(	I-protein
000	I-protein
)	I-protein
mutant	I-protein
)	I-protein
stat0a	I-protein
enhanced	O
its	O
dna	O
binding	O
activity	O
.	O

in	O
btk	B-protein
-competent	O
chicken	B-cell_type
b	I-cell_type
cells	I-cell_type
,	O
anti-igm-stimulated	O
tyrosine	O
phosphorylation	O
of	O
stat0	B-protein
protein	I-protein
was	O
prevented	O
by	O
pretreatment	O
with	O
the	O
btk	B-protein
inhibitor	O
lfm-a00	O
but	O
not	O
by	O
pretreatment	O
with	O
the	O
jak0	B-protein
inhibitor	O
hi-p000	O
.	O

b	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
ligation	O
resulted	O
in	O
enhanced	O
tyrosine	O
phosphorylation	O
of	O
stat0	B-protein
in	O
btk	B-protein
-deficient	O
chicken	B-cell_type
b	I-cell_type
cells	I-cell_type
reconstituted	O
with	O
wild	O
type	O
human	O
btk	B-protein
but	O
not	O
in	O
btk	B-protein
-deficient	O
chicken	B-cell_type
b	I-cell_type
cells	I-cell_type
reconstituted	O
with	O
kinase-inactive	B-protein
mutant	I-protein
btk	B-protein
.	O

similarly	O
,	O
anti-igm	B-protein
stimulation	O
resulted	O
in	O
enhanced	O
tyrosine	O
phosphorylation	O
of	O
stat0a	B-protein
in	O
btk	B-protein
-competent	O
b	B-cell_type
cells	I-cell_type
from	O
wild	O
type	O
mice	O
but	O
not	O
in	O
btk	B-protein
-deficient	O
b	B-cell_type
cells	I-cell_type
from	O
xid	O
mice	O
.	O

in	O
contrast	O
to	O
b	B-cell_type
cells	I-cell_type
from	O
xid	O
mice	O
,	O
b	B-cell_type
cells	I-cell_type
from	O
jak0	B-protein
knockout	O
mice	O
showed	O
a	O
normal	O
stat0a	B-protein
phosphorylation	O
response	O
to	O
anti-igm	B-protein
stimulation	O
.	O

these	O
findings	O
provide	O
unprecedented	O
experimental	O
evidence	O
that	O
btk	B-protein
plays	O
a	O
nonredundant	O
and	O
pivotal	O
role	O
in	O
b	B-protein
cell	I-protein
antigen	I-protein
receptor-mediated	O
stat0a	B-protein
activation	O
in	O
b	B-cell_type
cells	I-cell_type

###MEDLINE:21291437

role	O
of	O
t-bet	O
in	O
commitment	O
of	O
th0	B-cell_type
cells	I-cell_type
before	O
il-00	B-protein
-dependent	O
selection	O
.	O

how	O
cytokines	B-protein
control	O
differentiation	O
of	O
helper	B-cell_type
t	I-cell_type
(	I-cell_type
th	I-cell_type
)	I-cell_type
cells	I-cell_type
is	O
controversial	O
.	O

we	O
show	O
that	O
t-bet	B-protein
,	O
without	O
apparent	O
assistance	O
from	O
interleukin	B-protein
00	I-protein
(	O
il-00	B-protein
)	O
/	O
stat0	B-protein
,	O
specifies	O
th0	B-cell_type
effector	I-cell_type
fate	I-cell_type
by	O
targeting	O
chromatin	B-DNA
remodeling	O
to	O
individual	O
interferon-gamma	B-protein
(	O
ifn-gamma	B-protein
)	O
alleles	O
and	O
by	O
inducing	O
il-00	B-protein
receptor	I-protein
beta0	I-protein
expression	O
.	O

subsequently	O
,	O
it	O
appears	O
that	O
il-00	B-protein
/	O
stat0	B-protein
serves	O
two	O
essential	O
functions	O
in	O
the	O
development	O
of	O
th0	B-cell_type
cells	I-cell_type
:	O
as	O
growth	O
signal	O
,	O
inducing	O
survival	O
and	O
cell	O
division	O
;	O
and	O
as	O
trans-activator	B-protein
,	O
prolonging	O
ifn-gamma	B-protein
synthesis	O
through	O
a	O
genetic	O
interaction	O
with	O
the	O
coactivator	O
,	O
creb-binding	B-protein
protein	I-protein
.	O

these	O
results	O
suggest	O
that	O
a	O
cytokine	B-protein
does	O
not	O
simply	O
induce	O
th	O
fate	O
choice	O
but	O
instead	O
may	O
act	O
as	O
an	O
essential	O
secondary	O
stimulus	O
that	O
mediates	O
selective	O
survival	O
of	O
a	O
lineage	O
.	O

###MEDLINE:21286476

stat0	B-protein
is	O
necessary	O
and	O
sufficient	O
for	O
il-0	B-protein
's	O
role	O
in	O
th0	O
differentiation	O
and	O
cell	O
expansion	O
.	O

il-0	B-protein
plays	O
a	O
critical	O
role	O
in	O
the	O
differentiation	O
of	O
t	B-cell_type
cr-stimulated	I-cell_type
naive	I-cell_type
cd0	I-cell_type
t	I-cell_type
cells	I-cell_type
to	O
the	O
th0	B-cell_type
phenotype	I-cell_type
.	O

in	O
response	O
to	O
il-0	B-protein
,	O
the	O
il-0r	B-protein
activates	O
a	O
set	O
of	O
phosphotyrosine	B-protein
binding	I-protein
domain-containing	I-protein
proteins	I-protein
,	O
including	O
insulin	B-protein
receptor	I-protein
substrate	I-protein
0/0	I-protein
,	O
shc	B-protein
,	O
and	O
il-0r	B-protein
interacting	I-protein
protein	I-protein
,	O
as	O
well	O
as	O
stat0	B-protein
.	O

stat0	B-protein
has	O
been	O
shown	O
to	O
be	O
required	O
for	O
th0	O
differentiation	O
.	O

to	O
determine	O
the	O
roles	O
of	O
the	O
phosphotyrosine	B-protein
binding	I-protein
adaptors	I-protein
in	O
th0	O
differentiation	O
,	O
we	O
prepared	O
a	O
retrovirus	O
containing	O
a	O
mutant	O
of	O
the	O
human	B-protein
(	I-protein
h	I-protein
)	I-protein
il-0r	I-protein
alpha-chain	I-protein
,	O
y000f	O
,	O
which	O
is	O
unable	O
to	O
recruit	O
these	O
adaptors	O
.	O

the	O
mutant	O
hil-0ralpha	O
,	O
as	O
well	O
as	O
the	O
wild-type	B-cell_line
(	I-cell_line
wt	I-cell_line
)	I-cell_line
hil-0ralpha	I-cell_line
,	O
was	O
introduced	O
into	O
naive	B-cell_type
cd0	I-cell_type
t	I-cell_type
cells	I-cell_type
.	O

upon	O
hil-0	B-protein
stimulation	O
,	O
y000f	O
worked	O
as	O
well	O
as	O
the	O
wt	O
hil-0ralpha	O
in	O
driving	O
th0	O
differentiation	O
,	O
as	O
measured	O
by	O
gata0	B-protein
up-regulation	O
and	O
il-0	B-protein
production	O
.	O

furthermore	O
,	O
il-0-driven	O
cell	O
expansion	O
was	O
also	O
normal	O
in	O
the	O
cells	O
infected	O
with	O
y000f	O
,	O
although	O
cells	O
infected	O
with	O
y000f	O
were	O
not	O
capable	O
of	O
phosphorylating	O
insulin	B-protein
receptor	I-protein
substrate	I-protein
0	I-protein
.	O

these	O
results	O
suggest	O
that	O
the	O
signal	O
pathway	O
mediated	O
by	O
y000	O
is	O
dispensable	O
for	O
both	O
il-0	B-protein
-driven	O
th0	O
differentiation	O
and	O
cell	O
expansion	O
.	O

both	O
wt	O
and	O
y000f	O
hil-0ralpha	O
lose	O
the	O
ability	O
to	O
drive	O
th0	O
differentiation	O
and	O
cell	O
expansion	O
in	O
stat0-knockout	B-cell_type
cd0	I-cell_type
t	I-cell_type
cells	I-cell_type
.	O

a	O
constitutively	B-protein
activated	I-protein
form	I-protein
of	O
stat0	B-protein
introduced	O
into	O
cd0	B-cell_type
t	I-cell_type
cells	I-cell_type
resulted	O
in	O
both	O
th0	O
differentiation	O
and	O
enhanced	O
cell	O
expansion	O
.	O

thus	O
,	O
activated	O
stat0	B-protein
is	O
necessary	O
and	O
sufficient	O
to	O
mediate	O
both	O
il-0	B-protein
-driven	O
th0	O
differentiation	O
and	O
cell	O
expansion	O
in	O
cd0	B-cell_type
t	I-cell_type
cells	I-cell_type
.	O

###MEDLINE:21278505

the	O
effect	O
of	O
hiv-0	B-protein
regulatory	I-protein
proteins	I-protein
on	O
cellular	O
genes	O
:	O
derepression	O
of	O
the	O
il-0	B-DNA
promoter	I-DNA
by	O
tat	B-protein
.	O

in	O
hiv-infected	O
individuals	O
dysregulation	O
of	O
the	O
immune	O
system	O
is	O
characterized	O
by	O
severe	O
disorders	O
of	O
the	O
cytokine	B-protein
network	I-protein
.	O

increase	O
secretion	O
of	O
il-0	B-protein
,	O
the	O
major	B-protein
t	I-protein
cell	I-protein
growth	I-protein
and	I-protein
differentiation	I-protein
cytokine	I-protein
,	O
may	O
play	O
a	O
decisive	O
role	O
in	O
sensitization	O
of	O
t	B-cell_type
cells	I-cell_type
for	O
activation	O
induced	O
apoptosis	O
and	O
indirect	O
death	O
of	O
activated	B-cell_type
t	I-cell_type
cells	I-cell_type
through	O
augmented	O
virus	O
replication	O
.	O

we	O
investigated	O
the	O
cause	O
of	O
enhanced	O
il-0	B-protein
secretion	O
and	O
found	O
that	O
the	O
hiv	B-DNA
tat	I-DNA
induces	O
this	O
effect	O
.	O

we	O
demonstrate	O
that	O
increased	O
il-0	B-protein
secretion	O
is	O
due	O
to	O
tat	B-protein
-enhanced	O
il-0	B-DNA
promoter	I-DNA
activation	O
.	O

tat	B-protein
derepresses	I-protein
and	O
activates	O
the	O
distal	B-DNA
ap-0	I-DNA
site	I-DNA
(	O
position	O
-000	O
to	O
-000	O
)	O
in	O
the	O
il-0	B-DNA
promoter	I-DNA
.	O

in	O
nonstimulated	B-cell_type
t	I-cell_type
cells	I-cell_type
a	O
repressor	B-protein
complex	I-protein
containing	O
nf-il0	B-protein
,	O
junb	B-protein
,	O
c-fos	B-DNA
and	O
fra-0	B-DNA
is	O
formed	O
on	O
the	O
ap-0	B-DNA
(	I-DNA
il-0/d	I-DNA
)	I-DNA
site	I-DNA
and	O
represses	O
il-0	B-DNA
promoter	I-DNA
activity	O
.	O

after	O
t	B-cell_type
cell	I-cell_type
activation	O
,	O
a	O
heterodimeric	B-protein
activator	I-protein
containing	O
p00	B-protein
and	O
c-jun	B-protein
binds	O
to	O
the	O
ap-0	B-DNA
(	I-DNA
il-0/d	I-DNA
)	I-DNA
site	I-DNA
.	O

hiv	B-protein
tat	I-protein
enhances	O
activation	O
of	O
nf-kappab	B-protein
and	O
consequently	O
,	O
activates	O
the	O
ap-0	B-DNA
(	I-DNA
il-0/d	I-DNA
)	I-DNA
site	I-DNA
.	O

our	O
data	O
provide	O
evidence	O
for	O
a	O
novel	O
mechanism	O
by	O
which	O
hiv	B-protein
tat	I-protein
dysregulates	I-protein
il-0	B-protein
production	O
and	O
therefore	O
may	O
contribute	O
to	O
the	O
hiv-0	O
infection	O
in	O
a	O
way	O
yet	O
to	O
be	O
clarified	O
.	O

###MEDLINE:21272363

transforming	B-protein
growth	I-protein
factor-beta0	I-protein
interferes	O
with	O
thrombopoietin-induced	O
signal	O
transduction	O
in	O
megakaryoblastic	O
and	O
erythroleukemic	B-cell_line
cells	I-cell_line
.	O

objective	O
:	O
thrombopoietin	B-protein
(	O
tpo	B-protein
)	O
and	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
(	O
0	O
)	O
(	O
tgf-beta	B-protein
(	O
0	O
)	O
)	O
have	O
been	O
shown	O
to	O
exert	O
opposite	O
effects	O
on	O
proliferation	O
and	O
megakaryocytic	O
differentiation	O
of	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O

to	O
determine	O
whether	O
tgf-beta	B-protein
(	O
0	O
)	O
interferes	O
directly	O
with	O
tpo	B-protein
-induced	O
signal	O
transduction	O
in	O
hematopoietic	B-cell_type
cells	I-cell_type
,	O
we	O
compared	O
the	O
regulatory	O
effects	O
in	O
the	O
tpo	B-protein
-responsive	O
cell	B-cell_line
lines	I-cell_line
mo-0e	B-cell_line
and	O
hel	B-cell_line
.	O

materials	O
and	O
methods	O
:	O
the	O
cells	O
were	O
stimulated	O
by	O
000	O
ng/ml	O
tpo	B-protein
and/or	O
000	O
ng/ml	O
tgf-beta0	B-protein
and	O
analyzed	O
for	O
proliferation	O
(	O
0h	O
thymidine	O
incorporation	O
)	O
,	O
viability	O
(	O
trypan	O
blue	O
exclusion	O
)	O
,	O
and	O
protein	O
expression	O
and	O
phosphorylation	O
(	O
western	O
blot	O
)	O
.	O

results	O
:	O
tpo	B-protein
enhanced	O
the	O
proliferation	O
of	O
mo-0e	B-cell_line
cells	I-cell_line
as	O
determined	O
by	O
0h-thymidine	O
incorporation	O
,	O
whereas	O
tgf-beta0	B-protein
suppressed	O
baseline	O
cell	O
growth	O
and	O
antagonized	O
the	O
proliferative	O
effect	O
of	O
tpo	B-protein
.	O

tpo	B-protein
-induced	O
proliferation	O
also	O
was	O
reduced	O
by	O
a	O
specific	O
inhibitor	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
mapk	B-protein
)	O
pathway	O
(	O
pd000000	O
)	O
,	O
which	O
inhibits	O
activation	O
of	O
the	O
mapk	B-protein
extracellular	I-protein
signal-regulated	I-protein
kinases	I-protein
(	O
erk	B-protein
)	O
erk0	B-protein
and	O
erk0	B-protein
,	O
and	O
ag000	O
,	O
an	O
inhibitor	O
of	O
janus	B-protein
kinase-0	I-protein
,	O
which	O
completely	O
blocked	O
tpo	B-protein
-induced	O
proliferation	O
.	O

as	O
demonstrated	O
by	O
western	O
blotting	O
,	O
tgf-beta0	B-protein
reduced	O
the	O
tpo	B-protein
-stimulated	O
erk0	B-protein
/	O
erk0	B-protein
and	O
stat0	B-protein
phosphorylation	O
in	O
mo-0e	B-cell_line
and	I-cell_line
hel	I-cell_line
cells	I-cell_line
.	O

this	O
effect	O
was	O
completely	O
reversed	O
by	O
preincubation	O
with	O
a	O
tyrosine	B-protein
phosphatase	I-protein
inhibitor	I-protein
(	O
na0vo0	B-protein
)	O
,	O
which	O
suggests	O
that	O
tgf-beta0	B-protein
activated	O
a	O
phosphatase	O
.	O

although	O
stat0	B-protein
also	O
was	O
activated	O
by	O
tpo	B-protein
,	O
stat0	B-protein
activation	O
remained	O
unaltered	O
by	O
tgf-beta0	B-protein
.	O

conclusion	O
:	O
taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
tgf-beta0	B-protein
modulates	O
tpo	B-protein
-mediated	O
effects	O
on	O
megakaryocytic	O
proliferation	O
by	O
interfering	O
with	O
tpo	B-protein
-induced	O
signal	O
transduction	O
,	O
particularly	O
by	O
reducing	O
the	O
activities	O
of	O
mapk	B-protein
erk0/erk0	O
and	O
stat0	B-protein
.	O

###MEDLINE:21347972

invariant	B-protein
chain	I-protein
induces	O
b	O
cell	O
maturation	O
by	O
activating	O
a	O
taf	B-protein
(	O
ii	O
)	O
000-nf-kappab	O
-dependent	O
transcription	O
program	O
.	O

early	O
stages	O
of	O
b	B-cell_type
cell	I-cell_type
development	O
occur	O
in	O
the	O
bone	O
marrow	O
,	O
resulting	O
in	O
formation	O
of	O
immature	B-cell_type
b	I-cell_type
cells	I-cell_type
.	O

from	O
there	O
these	O
immature	B-cell_type
cells	I-cell_type
migrate	O
to	O
the	O
spleen	O
where	O
they	O
differentiate	O
to	O
mature	B-cell_type
cells	I-cell_type
.	O

this	O
final	O
maturation	O
step	O
is	O
crucial	O
for	O
the	O
b	B-cell_type
cells	I-cell_type
to	O
become	O
responsive	O
to	O
antigens	B-protein
and	O
to	O
participate	O
in	O
the	O
immune	O
response	O
.	O

recently	O
,	O
invariant	B-protein
chain	I-protein
(	O
ii	O
)	O
,	O
a	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
class	I-protein
ii	I-protein
chaperone	I-protein
,	O
as	O
well	O
as	O
the	O
transcription	B-protein
factors	I-protein
c-rel	B-protein
and	O
p00/rela	B-protein
,	O
were	O
found	O
to	O
play	O
a	O
role	O
in	O
the	O
final	O
antigen-independent	O
differentiation	O
stage	O
of	O
b	B-cell_type
cells	I-cell_type
in	O
the	O
spleen	O
.	O

in	O
this	O
study	O
,	O
we	O
investigated	O
a	O
possible	O
link	O
between	O
ii	O
-dependent	O
b	O
cell	O
maturation	O
and	O
the	O
nf-kappab	B-protein
pathway	O
.	O

our	O
studies	O
indicate	O
that	O
ii	O
-induced	O
b	O
cell	O
maturation	O
involves	O
activation	O
of	O
transcription	O
mediated	O
by	O
the	O
nf-kappab	B-protein
p00/rela	B-protein
homodimer	I-protein
and	O
requires	O
the	O
b	B-protein
cell-enriched	I-protein
coactivator	I-protein
tbp-associated	B-protein
factor	I-protein
(	O
ii	O
)	O
000	O
.	O

###MEDLINE:21258442

androgens	O
indirectly	O
accelerate	O
thymocyte	O
apoptosis	O
.	O

apoptotic	O
processes	O
,	O
or	O
the	O
disturbance	O
of	O
the	O
natural	O
regulation	O
of	O
these	O
processes	O
,	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
autoimmune	O
diseases	O
(	O
aid	O
)	O
.	O

women	O
are	O
,	O
in	O
general	O
,	O
more	O
susceptible	O
than	O
men	O
to	O
develop	O
aid	O
like	O
rheumatoid	O
arthritis	O
.	O

androgens	O
and	O
glucocorticoids	O
,	O
in	O
contrast	O
to	O
oestrogens	O
,	O
have	O
favourable	O
effects	O
in	O
aid	O
models	O
as	O
well	O
as	O
in	O
human	O
aid	O
.	O

it	O
is	O
known	O
that	O
glucocorticoids	O
(	O
gc	O
)	O
,	O
used	O
for	O
treatment	O
of	O
aid	B-protein
,	O
increase	O
apoptosis	O
in	O
the	O
thymus	O
resulting	O
in	O
decreased	O
numbers	O
of	O
cd0+	B-cell_type
cd0+	I-cell_type
thymocytes	I-cell_type
.	O

it	O
was	O
asked	O
whether	O
androgens	O
,	O
in	O
contrast	O
to	O
oestrogens	O
,	O
exert	O
their	O
favourable	O
effects	O
in	O
the	O
treatment	O
of	O
aid	O
by	O
a	O
mechanism	O
comparable	O
to	O
that	O
described	O
for	O
gc	O
by	O
eliminating	O
the	O
apoptosis	O
prone	O
cd0+	B-cell_type
cd0+	I-cell_type
population	I-cell_type
in	O
the	O
thymus	O
.	O

although	O
both	O
androgens	O
and	O
oestrogens	O
proved	O
thymolytic	O
,	O
a	O
significantly	O
decreased	O
percentage	O
of	O
cd0+	B-cell_type
cd0+	I-cell_type
thymocytes	I-cell_type
was	O
observed	O
by	O
flow	O
cytometry	O
after	O
treatment	O
of	O
mice	O
with	O
the	O
androgen	O
methyltestosterone	O
,	O
but	O
not	O
with	O
the	O
oestrogen	O
ethinylestradiol	O
.	O

to	O
investigate	O
whether	O
the	O
observed	O
thymolytic	O
effects	O
were	O
due	O
to	O
the	O
presence	O
of	O
hormone	B-protein
receptors	I-protein
on	O
thymocytes	B-cell_type
,	O
cells	O
were	O
isolated	O
from	O
the	O
thymus	O
and	O
incubated	O
with	O
androgens	O
or	O
oestrogens	O
to	O
measure	O
apoptosis	O
.	O

several	O
techniques	O
were	O
used	O
to	O
determine	O
thymocyte	O
apoptosis	O
in	O
vitro	O
,	O
but	O
no	O
enhanced	O
apoptotic	O
signal	O
was	O
observed	O
.	O

using	O
the	O
very	O
sensitive	O
tunel	O
assay	O
,	O
no	O
direct	O
effect	O
of	O
androgens	O
on	O
thymocytes	B-cell_type
in	O
vitro	O
could	O
be	O
observed	O
.	O

this	O
is	O
in	O
sharp	O
contrast	O
to	O
the	O
high	O
signal	O
observed	O
with	O
gc	O
.	O

therefore	O
,	O
upon	O
in	O
vivo	O
androgen	O
treatment	O
,	O
other	O
cells	O
containing	O
androgen	B-protein
receptors	I-protein
than	O
thymocytes	B-cell_type
are	O
probably	O
involved	O
in	O
inducing	O
the	O
increase	O
in	O
thymic	O
apoptosis	O
.	O

to	O
study	O
the	O
role	O
of	O
the	O
androgen	B-protein
receptor	I-protein
on	O
thymocyte	O
apoptosis	O
,	O
androgen	B-protein
receptor	I-protein
mutant	I-protein
(	O
tfm/y	B-protein
)	O
mice	O
were	O
treated	O
with	O
androgens	O
.	O

no	O
alterations	O
of	O
thymocyte	O
subpopulations	O
were	O
seen	O
,	O
suggesting	O
that	O
changes	O
in	O
the	O
percentage	O
of	O
cd0+	B-cell_type
cd0+	I-cell_type
thymocytes	I-cell_type
after	O
administration	O
of	O
androgens	O
depend	O
on	O
the	O
presence	O
of	O
functional	O
androgen	B-protein
receptors	I-protein
.	O

thus	O
,	O
it	O
is	O
concluded	O
that	O
androgens	O
indirectly	O
accelerate	O
thymocyte	O
apoptosis	O
in	O
vivo	O
.	O

###MEDLINE:21256403

inhibition	O
of	O
the	O
transcription	B-protein
factors	I-protein
ap-0	B-protein
and	O
nf-kappab	B-protein
in	O
cd0	B-cell_type
t	I-cell_type
cells	I-cell_type
by	O
peroxisome	B-protein
proliferator-activated	I-protein
receptor	I-protein
gamma	I-protein
ligands	I-protein
.	O

the	O
peroxisome	B-protein
proliferator-activated	I-protein
receptor	I-protein
gamma	I-protein
(	O
ppargamma	B-protein
)	O
,	O
a	O
member	O
of	O
the	O
nuclear	B-protein
hormone	I-protein
receptor	I-protein
superfamily	I-protein
,	O
is	O
essential	O
for	O
adipocyte	B-cell_type
differentiation	O
and	O
glucose	O
homeostasis	O
.	O

ppargamma	B-protein
has	O
been	O
found	O
recently	O
to	O
regulate	O
macrophage	O
activation	O
in	O
response	O
to	O
mitogens	B-protein
and	O
inflammation	O
.	O

our	O
study	O
shows	O
ppargamma	B-protein
to	O
be	O
preferentially	O
expressed	O
in	O
the	O
nuclei	O
of	O
resting	B-cell_type
t	I-cell_type
cells	I-cell_type
and	O
to	O
increase	O
upon	O
activation	O
of	O
t	B-cell_type
cells	I-cell_type
by	O
either	O
anti-cd0	B-protein
and	O
anti-cd00	B-protein
or	O
phorbol	O
myristyl	O
acetate	O
(	O
pma	O
)	O
.	O

we	O
also	O
found	O
the	O
ppargamma	B-protein
ligand	O
ciglitizone	O
to	O
attenuate	O
the	O
activation	O
of	O
t	B-cell_type
cells	I-cell_type
by	O
inhibiting	O
cytokine	B-DNA
gene	I-DNA
expression	O
and	O
anti-cd0	B-protein
and	O
anti-cd00	B-protein
or	O
pma-induced	O
proliferative	O
responses	O
.	O

inhibition	O
of	O
both	O
the	O
proliferative	O
response	O
and	O
inflammatory	O
cytokine	O
expression	O
in	O
cd0	B-cell_type
t	I-cell_type
cells	I-cell_type
was	O
correlated	O
with	O
suppression	O
of	O
the	O
activated	B-protein
transcription	I-protein
factors	I-protein
ap0	B-protein
and	O
nf-kappab	B-protein
.	O

ppargamma	B-protein
ligands	O
also	O
strongly	O
inhibited	O
sea-induced	B-cell_type
vbeta0	I-cell_type
t	I-cell_type
cell	I-cell_type
activation	O
in	O
vivo	O
.	O

these	O
results	O
,	O
together	O
with	O
previous	O
findings	O
of	O
the	O
inhibitory	O
effect	O
of	O
ppargamma	B-protein
ligands	O
on	O
activated	B-cell_type
macrophages	I-cell_type
,	O
provide	O
clear	O
evidence	O
for	O
ppargamma	B-protein
as	O
a	O
negative	O
regulator	O
of	O
the	O
inflammatory	O
activation	O
of	O
both	O
macrophage	O
and	O
t	B-cell_type
cells	I-cell_type
.	O

ppargamma	B-protein
may	O
thus	O
be	O
a	O
potential	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
autoimmunity	O
.	O

###MEDLINE:21240684

a	O
prominent	O
role	O
for	O
activator	B-protein
protein-0	I-protein
in	O
the	O
transcription	O
of	O
the	O
human	B-protein
0b0	I-protein
(	O
cd000	B-protein
)	O
gene	O
in	O
nk	B-cell_type
cells	I-cell_type
.	O

the	O
cell	B-protein
surface	I-protein
glycoprotein	I-protein
0b0	I-protein
(	O
cd000	B-protein
)	O
of	O
the	O
ig	B-protein
superfamily	I-protein
is	O
involved	O
in	O
the	O
regulation	O
of	O
nk	B-cell_type
and	I-cell_type
t	I-cell_type
lymphocyte	I-cell_type
functions	O
.	O

we	O
have	O
recently	O
identified	O
cd00	B-protein
as	O
the	O
high	O
affinity	O
counterreceptor	O
for	O
0b0	O
in	O
both	O
mice	O
and	O
humans	O
.	O

the	O
cytoplasmic	B-protein
domain	I-protein
of	O
0b0	B-protein
associates	O
with	O
src	B-protein
homology	I-protein
0	I-protein
domain-containing	I-protein
protein	I-protein
or	O
signaling	B-protein
lymphocyte	I-protein
activation	I-protein
molecule-associated	I-protein
protein	I-protein
,	O
whose	O
mutation	O
is	O
the	O
underlying	O
genetic	O
defect	O
in	O
the	O
x-linked	O
lymphoproliferative	O
syndrome	O
.	O

in	O
this	O
study	O
,	O
we	O
report	O
the	O
molecular	O
cloning	O
and	O
characterization	O
of	O
the	O
human	B-DNA
0b0	I-DNA
(	I-DNA
h0b0	I-DNA
)	I-DNA
promoter	I-DNA
.	O

through	O
primer	O
extension	O
analysis	O
,	O
we	O
found	O
that	O
the	O
transcription	O
of	O
the	O
h0b0	B-DNA
gene	I-DNA
initiates	O
at	O
multiple	B-DNA
start	I-DNA
sites	I-DNA
.	O

we	O
isolated	O
h0b0	B-cell_line
genomic	I-cell_line
clones	I-cell_line
and	O
pcr	O
amplified	O
the	O
0	B-DNA
'	I-DNA
untranslated	I-DNA
region	I-DNA
containing	O
the	O
promoter	B-DNA
elements	I-DNA
.	O

we	O
have	O
identified	O
a	O
functional	O
ap-0	B-DNA
site	I-DNA
that	O
lies	O
between	O
(	O
-000	O
to	O
-000	O
)	O
through	O
transient	O
transfection	O
analysis	O
in	O
yt	B-cell_line
cells	I-cell_line
,	O
a	O
human	B-cell_line
nk	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

emsas	O
with	O
abs	B-protein
specific	O
for	O
various	O
protein	B-protein
factors	I-protein
of	O
the	O
ap-0	B-protein
family	I-protein
revealed	O
that	O
multiple	O
members	O
of	O
the	O
jun	B-protein
family	I-protein
are	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
h0b0	B-DNA
gene	I-DNA
.	O

mutation	O
of	O
the	O
ap-0	B-DNA
site	I-DNA
not	O
only	O
abolishes	O
protein/dna	O
interactions	O
but	O
also	O
promoter	O
activity	O
.	O

these	O
results	O
demonstrate	O
a	O
significant	O
role	O
for	O
ap-0	B-protein
in	O
the	O
transcriptional	O
regulation	O
of	O
the	O
h0b0	B-DNA
gene	I-DNA
.	O

###MEDLINE:21240402

functional	O
correction	O
of	O
fa-c	B-cell_type
cells	I-cell_type
with	O
fancc	B-protein
suppresses	O
the	O
expression	O
of	O
interferon	B-DNA
gamma-inducible	I-DNA
genes	I-DNA
.	O

because	O
hematopoietic	B-cell_type
cells	I-cell_type
derived	O
from	O
fanconi	O
anemia	O
(	O
fa	B-protein
)	O
patients	O
of	O
the	O
c-complementation	O
group	O
(	O
fa-c	B-protein
)	O
are	O
hypersensitive	O
to	O
the	O
inhibitory	O
effects	O
of	O
interferon	B-protein
gamma	I-protein
(	O
ifngamma	B-protein
)	O
,	O
the	O
products	O
of	O
certain	O
ifngamma-inducible	B-DNA
genes	I-DNA
known	O
to	O
influence	O
hematopoietic	O
cell	O
survival	O
were	O
quantified	O
.	O

high	O
constitutive	O
expression	O
of	O
the	O
ifngamma-inducible	B-DNA
genes	I-DNA
,	O
ifn-stimulated	B-protein
gene	I-protein
factor	I-protein
0	I-protein
gamma	I-protein
subunit	I-protein
(	O
isgf0gamma	O
)	O
,	O
ifn	B-protein
regulatory	I-protein
factor-0	I-protein
(	O
irf-0	B-protein
)	O
,	O
and	O
the	O
cyclin-dependent	B-protein
kinase	I-protein
inhibitor	I-protein
p00	I-protein
(	O
waf0	B-protein
)	O
was	O
found	O
in	O
fancc	B-cell_line
mutant	I-cell_line
b	I-cell_line
lymphoblasts	I-cell_line
,	O
low-density	O
bone	B-cell_type
marrow	I-cell_type
cells	I-cell_type
,	O
and	O
murine	B-cell_line
embryonic	I-cell_line
fibroblasts	I-cell_line
.	O

paradoxically	O
,	O
these	O
cells	O
do	O
not	O
activate	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	I-protein
stat	I-protein
)	I-protein
0	I-protein
properly	O
.	O

in	O
an	O
attempt	O
to	O
clarify	O
mechanisms	O
by	O
which	O
fa-c	B-cell_type
cells	I-cell_type
overexpress	O
ifngamma-inducible	O
genes	O
in	O
the	O
face	O
of	O
defective	O
stat0	B-protein
phosphorylation	O
,	O
it	O
was	O
reasoned	O
that	O
decreased	O
levels	O
of	O
activated	O
stat0	B-protein
might	O
result	O
in	O
reduced	O
expression	O
of	O
a	O
hematopoietic	B-protein
ifngamma-responsive	I-protein
protein	I-protein
that	O
normally	O
modulates	O
expression	O
of	O
other	O
ifngamma-responsive	B-DNA
genes	I-DNA
.	O

levels	O
of	O
the	O
ifngamma	B-DNA
-inducible	I-DNA
factor	I-DNA
ifn	I-DNA
consensus	I-DNA
sequence	I-DNA
binding	O
protein	O
(	O
icsbp	B-protein
)	O
,	O
a	O
negative	O
trans-acting	B-protein
regulator	I-protein
of	O
some	O
ifngamma-inducible	B-DNA
genes	I-DNA
,	O
were	O
quantified	O
.	O

icsbp	B-protein
levels	O
were	O
reduced	O
in	O
fa-c	B-cell_type
b	I-cell_type
lymphoblasts	I-cell_type
and	O
mefs	B-cell_type
.	O

however	O
,	O
enforced	O
expression	O
of	O
icsbp	B-protein
failed	O
to	O
down-regulate	O
irf-0	B-protein
,	O
isgf0gamma	O
,	O
and	O
p00	B-protein
(	O
waf0	B-protein
)	O
.	O

thus	O
,	O
the	O
fancc	B-protein
protein	I-protein
functions	O
to	O
modulate	O
expression	O
of	O
a	O
family	O
of	O
genes	O
that	O
in	O
normal	B-cell_type
cells	I-cell_type
are	O
inducible	O
only	O
by	O
specific	O
environmental	O
cues	O
for	O
apoptosis	O
or	O
mitogenic	O
inhibition	O
,	O
but	O
it	O
does	O
so	O
independently	O
of	O
the	O
classic	O
ifn-stat0	O
pathway	O
and	O
is	O
not	O
the	O
direct	O
result	O
of	O
reduced	O
icsbp	B-protein
expression	O
.	O

###MEDLINE:21235950

a	O
genetic	O
investigation	O
of	O
e0a	B-protein
function	O
in	O
lymphocyte	O
development	O
.	O

lymphocytes	B-cell_type
are	O
derived	O
from	O
hematopoietic	B-cell_type
stem	I-cell_type
cells	I-cell_type
(	O
hsc	B-cell_type
)	O
following	O
a	O
series	O
of	O
regulated	O
differentiation	O
events	O
.	O

multipotent	O
hscs	O
become	O
committed	O
to	O
the	O
b	B-cell_type
cell	I-cell_type
lineage	I-cell_type
in	O
bone	O
marrow	O
and	O
the	O
t	B-cell_type
cell	I-cell_type
lineage	I-cell_type
in	O
the	O
thymus	O
after	O
receiving	O
appropriate	O
signals	O
from	O
the	O
corresponding	O
microenvironment	O
.	O

these	O
committed	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
must	O
then	O
undergo	O
v	O
(	O
d	O
)	O
j	O
recombination	O
at	O
the	O
immunoglobulin	B-DNA
gene	I-DNA
or	I-DNA
t	I-DNA
cell	I-DNA
receptor	I-DNA
gene	I-DNA
locus	I-DNA
resulting	O
in	O
clonal	O
production	O
of	O
functional	O
b	B-cell_type
or	I-cell_type
t	I-cell_type
lymphocytes	I-cell_type
,	O
respectively	O
.	O

lymphocyte	O
commitment	O
and	O
differentiation	O
are	O
accompanied	O
by	O
programmed	O
gene	O
expression	O
or	O
repression	O
events	O
which	O
are	O
driven	O
by	O
lineage	O
and	O
stage	O
specific	O
transcription	B-protein
factors	I-protein
.	O

the	O
basic-helix-loop-helix	B-protein
(	I-protein
bhlh	I-protein
)	I-protein
transcription	I-protein
factors	I-protein
encoded	O
by	O
the	O
e0a	B-DNA
gene	I-DNA
are	O
involved	O
in	O
several	O
differentiation	O
events	O
during	O
b	B-cell_type
and	I-cell_type
t	I-cell_type
cell	I-cell_type
development	O
,	O
including	O
lineage	O
commitment	O
,	O
initiation	O
of	O
v	O
(	O
d	O
)	O
j	O
recombination	O
,	O
and	O
antigen	B-protein
receptor	I-protein
mediated	O
proliferation	O
and	O
differentiation	O
.	O

several	O
recent	O
reviews	O
have	O
provided	O
a	O
comprehensive	O
discussion	O
of	O
biochemical	O
,	O
cellular	O
,	O
and	O
genetic	O
research	O
on	O
e0a	B-protein
function	O
in	O
lymphocyte	O
development	O
(	O
0	O
,	O
0	O
)	O
.	O

here	O
,	O
we	O
only	O
discuss	O
some	O
of	O
the	O
genetic	O
approaches	O
our	O
laboratory	O
(	O
except	O
where	O
it	O
is	O
noted	O
)	O
has	O
undertaken	O
to	O
investigate	O
the	O
molecular	O
pathways	O
mediated	O
by	O
e0a	B-protein
transcription	I-protein
factors	I-protein
in	O
lymphocyte	O
development	O

###MEDLINE:21301738

d000	O
inhibits	O
ionizing	O
radiation-induced	O
oxidative	O
damage	O
by	O
acting	O
as	O
a	O
potent	O
antioxidant	O
.	O

tricyclodecan-0-yl-xanthogenate	O
(	O
d000	O
)	O
has	O
been	O
extensively	O
studied	O
in	O
biological	O
systems	O
and	O
exhibits	O
a	O
variety	O
of	O
biological	O
functions	O
,	O
including	O
antiviral	O
,	O
antitumor	O
,	O
and	O
anti-inflammatory	O
activities	O
.	O

most	O
of	O
these	O
activities	O
have	O
been	O
largely	O
attributed	O
to	O
the	O
inhibitory	O
effect	O
of	O
d000	O
on	O
phosphatidylcholine-specific	B-protein
phospholipase	I-protein
c	I-protein
.	O

however	O
,	O
as	O
a	O
xanthate	O
derivative	O
,	O
d000	O
is	O
a	O
strong	O
electrolyte	O
and	O
readily	O
dissociates	O
to	O
xanthate	O
anions	O
and	O
cations	O
of	O
alkali	B-DNA
metals	I-DNA
in	O
solution	O
.	O

xanthate	O
anions	O
and	O
protonated	O
xanthic	O
acid	O
contain	O
a	O
free	O
thiol	O
moiety	O
and	O
are	O
highly	O
reductive	O
.	O

this	O
implies	O
that	O
d000	O
and	O
other	O
xanthate	O
derivatives	O
may	O
function	O
as	O
potent	O
antioxidants	O
.	O

indeed	O
,	O
we	O
found	O
that	O
d000	O
inhibited	O
the	O
fenton	O
reaction-induced	O
oxidation	O
of	O
dihydrorhodamine	B-protein
000	I-protein
in	O
a	O
dose-dependent	O
manner	O
similar	O
to	O
that	O
of	O
pyrrolidinedithiocarbamate	O
,	O
a	O
well	O
known	O
antioxidant	O
.	O

in	O
addition	O
,	O
d000	O
inhibited	O
the	O
formation	O
of	O
the	O
alpha-phenyl-tert-butylnitrone-free	O
radical	O
spin	O
adducts	O
and	O
lipid	O
peroxidation	O
of	O
synaptosomal	O
membranes	O
by	O
the	O
fenton	O
reagents	O
.	O

furthermore	O
,	O
preincubation	O
of	O
lymphocytes	B-cell_type
with	O
d000	O
resulted	O
in	O
a	O
significant	O
diminution	O
of	O
ionizing	O
radiation	O
(	O
ir	O
)	O
-induced	O
0	O
)	O
production	O
of	O
reactive	O
oxygen	O
species	O
;	O
0	O
)	O
decrease	O
in	O
intracellular	O
reduced	O
glutathione	O
;	O
0	O
)	O
oxidative	O
damage	O
to	O
proteins	O
and	O
lipids	O
;	O
and	O
0	O
)	O
activation	O
of	O
nuclear	B-protein
factor-kappab	I-protein
.	O

moreover	O
,	O
when	O
d000	O
(	O
00	O
mg/kg	O
i.v.	O
)	O
was	O
administered	O
to	O
mice	O
00	O
min	O
prior	O
to	O
total	O
body	O
ir	O
(	O
0.0	O
and	O
0.0	O
gy	O
)	O
,	O
it	O
protected	O
the	O
mice	O
from	O
ir-induced	O
lethality	O
.	O

thus	O
,	O
these	O
results	O
indicate	O
that	O
d000	O
is	O
a	O
potent	O
antioxidant	O
and	O
has	O
the	O
ability	O
to	O
inhibit	O
ir-induced	O
cellular	O
oxidative	O
stress	O
.	O

###MEDLINE:21369994

inhibition	O
of	O
ap-0	B-protein
by	O
the	O
glucocorticoid-inducible	B-protein
protein	I-protein
gilz	I-protein
.	O

the	O
immunosuppressive	O
effects	O
of	O
glucocorticoids	O
arise	O
largely	O
by	O
inhibition	O
of	O
cytokine	B-DNA
gene	I-DNA
expression	O
,	O
which	O
has	O
been	O
ascribed	O
to	O
interference	O
between	O
the	O
glucocorticoid	B-protein
receptor	I-protein
and	O
transcription	B-protein
factors	I-protein
such	O
as	O
ap-0	B-protein
and	O
nf-kappa	B-protein
b	I-protein
as	O
well	O
as	O
by	O
competition	O
for	O
common	B-protein
coactivators	I-protein
.	O

here	O
we	O
show	O
that	O
glucocorticoid-induced	O
inhibition	O
of	O
interleukin-0	B-RNA
mrna	I-RNA
expression	O
in	O
activated	B-cell_type
normal	I-cell_type
t	I-cell_type
cells	I-cell_type
required	O
new	O
protein	O
synthesis	O
,	O
suggesting	O
that	O
this	O
phenomenon	O
is	O
secondary	O
to	O
expression	O
of	O
glucocorticoid-regulated	B-DNA
genes	I-DNA
.	O

one	O
of	O
the	O
most	O
prominent	O
glucocorticoid-induced	O
genes	O
is	O
glucocorticoid-induced	O
leucine	B-protein
zipper	I-protein
(	O
gilz	B-protein
)	O
,	O
which	O
has	O
been	O
reported	O
to	O
inhibit	O
activation-induced	O
up-regulation	O
of	O
fas	B-protein
ligand	I-protein
(	O
fasl	B-RNA
)	I-RNA
mrna	I-RNA
.	O

indeed	O
,	O
transient	O
expression	O
of	O
gilz	O
in	O
jurkat	B-cell_line
t	I-cell_line
cells	I-cell_line
blocked	O
induction	O
of	O
a	O
reporter	B-DNA
construct	I-DNA
driven	O
by	O
the	O
fasl	B-DNA
promoter	I-DNA
.	O

this	O
could	O
be	O
accounted	O
for	O
by	O
gilz	O
-mediated	O
inhibition	O
of	O
egr-0	B-protein
and	O
egr-0	B-protein
,	O
nfat/ap-0	B-protein
-inducible	I-protein
transcription	I-protein
factors	I-protein
that	O
bind	O
a	O
regulatory	B-DNA
element	I-DNA
in	O
the	O
fasl	B-DNA
promoter	I-DNA
and	O
up-regulate	O
fasl	B-protein
expression	O
.	O

gilz	O
also	O
potently	O
inhibited	O
ap-0-driven	B-DNA
and	I-DNA
il-0	I-DNA
promoter-driven	I-DNA
reporter	I-DNA
constructs	I-DNA
,	O
and	O
recombinant	B-protein
gilz	I-protein
specifically	O
interacted	O
with	O
c-fos	B-protein
and	O
c-jun	B-protein
in	O
vitro	O
and	O
inhibited	O
the	O
binding	O
of	O
active	O
ap-0	B-protein
to	O
its	O
target	O
dna	O
.	O

whereas	O
homodimerization	O
of	O
gilz	B-protein
required	O
the	O
presence	O
of	O
its	O
leucine	B-protein
zipper	I-protein
,	O
the	O
interaction	O
with	O
c-fos	B-protein
and	O
c-jun	B-protein
occurred	O
through	O
the	O
n-terminal	B-protein
00-amino	I-protein
acid	I-protein
region	I-protein
of	O
gilz	O
.	O

thus	O
,	O
gilz	B-protein
represents	O
a	O
glucocorticoid-induced	O
gene	O
product	O
that	O
can	O
inhibit	O
a	O
variety	O
of	O
activation-induced	O
events	O
,	O
at	O
least	O
in	O
part	O
by	O
direct	O
interference	O
with	O
ap-0	B-protein
,	O
and	O
is	O
therefore	O
a	O
candidate	O
for	O
a	O
mediator	O
of	O
glucocorticoid-induced	O
immunosuppression	O
.	O

###MEDLINE:21286460

pharmacokinetic	O
differences	O
between	O
a	O
t	B-protein
cell-tolerizing	I-protein
and	O
a	O
t	O
cell-activating	O
peptide	O
.	O

vaccination	O
with	O
a	O
peptide	O
representing	O
a	O
ctl	O
epitope	O
from	O
the	O
human	O
papillomavirus	O
(	O
hpv	O
)	O
00	O
e0	B-protein
protein	I-protein
induces	O
a	O
specific	O
ctl	O
response	O
that	O
prevents	O
the	O
outgrowth	O
of	O
hpv00	O
e0-expressing	O
tumors	O
.	O

in	O
contrast	O
,	O
vaccination	O
with	O
a	O
peptide	O
encoding	O
an	O
adenovirus	B-protein
type	I-protein
0	I-protein
(	O
ad0	B-protein
)	O
e0a	B-protein
ctl	O
epitope	O
results	O
in	O
ctl	O
tolerance	O
and	O
enhanced	O
growth	O
of	O
an	O
ad0	O
e0a-expressing	O
tumor	O
.	O

it	O
is	O
unclear	O
why	O
these	O
peptides	O
induce	O
such	O
opposite	O
effects	O
.	O

to	O
determine	O
whether	O
a	O
difference	O
in	O
pharmacokinetics	O
can	O
explain	O
the	O
functional	O
contrasts	O
,	O
tritiated	O
ad0	B-protein
e0a	B-protein
and	O
hpv00	O
e0	O
peptides	O
were	O
injected	O
into	O
mice	O
.	O

results	O
show	O
that	O
the	O
tolerizing	O
peptide	O
spread	O
through	O
the	O
body	O
00	O
times	O
faster	O
than	O
the	O
activating	O
peptide	O
and	O
was	O
cleared	O
at	O
least	O
0	O
times	O
faster	O
.	O

the	O
hpv00	O
e0	O
peptide	O
kinetics	O
correlated	O
with	O
the	O
kinetics	O
of	O
hpv00	O
e0	O
-specific	O
ctl	O
induction	O
.	O

in	O
contrast	O
,	O
ad0	O
e0a	O
peptide	O
injection	O
resulted	O
in	O
physical	O
deletion	O
of	O
preexisting	O
ad0	O
e0a	B-protein
-specific	O
ctls	B-cell_type
within	O
00	O
h	O
after	O
injection	O
.	O

this	O
tolerization	O
occurred	O
at	O
the	O
time	O
when	O
the	O
peptide	O
reached	O
its	O
maximum	O
peptide	O
concentration	O
in	O
the	O
organs	O
.	O

these	O
data	O
suggest	O
that	O
ubiquitous	O
expression	O
of	O
the	O
tolerizing	O
ad0	O
e0a	O
peptide	O
within	O
a	O
short	O
period	O
of	O
time	O
causes	O
activation-induced	O
cell	O
death	O
of	O
ad0	B-protein
e0a	B-protein
-specific	O
ctls	B-cell_type
.	O

therefore	O
,	O
information	O
on	O
the	O
pharmacokinetics	O
of	O
peptides	O
is	O
vital	O
for	O
the	O
safety	O
and	O
efficacy	O
of	O
peptide-based	O
vaccines	O
.	O

###MEDLINE:21278495

smad0	B-protein
and	O
smad0	B-protein
mediate	O
transforming	B-protein
growth	I-protein
factor-beta0	I-protein
-induced	O
iga	B-protein
expression	O
in	O
murine	B-cell_type
b	I-cell_type
lymphocytes	I-cell_type
.	O

transforming	B-protein
growth	I-protein
factor	I-protein
(	O
tgf	B-protein
)	I-protein
-beta0	I-protein
is	O
well	O
established	O
as	O
a	O
critical	O
iga	B-protein
isotype	O
switching	O
factor	O
and	O
smad	B-protein
molecules	I-protein
have	O
been	O
reported	O
to	O
act	O
as	O
transducers	O
and	O
transcriptional	B-protein
factors	I-protein
in	O
the	O
expression	O
of	O
tgf-beta0	B-protein
-targeted	O
genes	O
.	O

we	O
examined	O
the	O
involvement	O
of	O
smad	B-protein
proteins	I-protein
in	O
tgf-beta0	B-protein
-induced	O
iga	B-protein
expression	O
.	O

first	O
,	O
we	O
found	O
that	O
tgf-beta0	B-protein
significantly	O
increases	O
endogenous	O
germ-line	B-RNA
(	I-RNA
gl	I-RNA
)	I-RNA
alpha	I-RNA
transcripts	I-RNA
by	O
lps-stimulated	O
ch00.lx.0000	B-DNA
(	I-DNA
mu	I-DNA
(	I-DNA
+	I-DNA
)	I-DNA
)	O
b	B-cell_line
lymphoma	I-cell_line
cells	I-cell_line
.	O

to	O
investigate	O
its	O
signaling	O
mechanisms	O
,	O
the	O
lymphoma	B-cell_line
cell	I-cell_line
line	I-cell_line
was	O
transfected	O
with	O
pfl0	O
that	O
contains	O
the	O
tgf-beta-responsive	B-DNA
element	I-DNA
of	O
the	O
glalpha	B-DNA
promoter	I-DNA
,	O
and	O
stimulated	O
with	O
tgf-beta0	B-protein
.	O

similar	O
to	O
endogenous	O
glalpha	B-RNA
transcripts	I-RNA
,	O
tgf-beta0	B-protein
induces	O
glalpha	B-DNA
promoter	I-DNA
activity	O
and	O
overexpression	O
of	O
smad0	B-protein
markedly	O
enhances	O
the	O
promoter	O
activity	O
.	O

this	O
activity	O
is	O
further	O
augmented	O
by	O
cotransfected	O
smad0	B-protein
.	O

on	O
the	O
other	O
hand	O
,	O
smad0	B-protein
substantially	O
abrogates	O
the	O
synergistic	O
effect	O
of	O
smad0/0	O
on	O
glalpha	B-DNA
promoter	I-DNA
activity	O
.	O

in	O
addition	O
,	O
overexpression	O
of	O
smad0/0	B-protein
enhances	O
tgf-beta0	B-protein
-induced	O
endogenous	B-RNA
glalpha	I-RNA
transcripts	I-RNA
in	O
normal	B-cell_line
spleen	I-cell_line
b	I-cell_line
cell	I-cell_line
s	I-cell_line
.	O

finally	O
,	O
in	O
the	O
presence	O
of	O
tgf-beta0	B-protein
,	O
overexpression	O
of	O
smad0/0	B-protein
selectively	O
increases	O
both	O
surface	O
iga	B-protein
expression	O
and	O
iga	B-protein
production	O
.	O

the	O
results	O
from	O
the	O
present	O
study	O
indicate	O
that	O
smad0	B-protein
,	O
smad0	B-protein
,	O
and	O
smad0	B-protein
,	O
at	O
least	O
in	O
part	O
,	O
serve	O
as	O
mediators	O
linking	O
tgf-beta0	B-protein
to	O
transcriptional	O
regulation	O
of	O
iga	B-protein
switching	O
related	O
gene	O
and	O
regulation	O
of	O
iga	B-protein
class	O
switching	O
.	O

###MEDLINE:21264350

the	O
translesion	B-protein
dna	I-protein
polymerase	I-protein
zeta	I-protein
plays	O
a	O
major	O
role	O
in	O
ig	B-protein
and	O
bcl-0	B-protein
somatic	O
hypermutation	O
.	O

ig	B-protein
somatic	O
mutations	O
would	O
be	O
introduced	O
by	O
a	O
polymerase	O
(	O
pol	B-protein
)	O
while	O
repairing	O
dna	O
outside	O
main	O
dna	O
replication	O
.	O

we	O
show	O
that	O
human	B-cell_type
b	I-cell_type
cells	I-cell_type
constitutively	O
express	O
the	O
translesion	O
pol	B-protein
zeta	O
,	O
which	O
effectively	O
extends	O
dna	O
past	O
mismatched	O
bases	O
(	O
mispair	O
extender	O
)	O
,	O
and	O
pol	B-DNA
eta	I-DNA
,	O
which	O
bypasses	O
dna	O
lesions	O
in	O
an	O
error-free	O
fashion	O
.	O

upon	O
b	B-protein
cell	I-protein
receptor	I-protein
(	O
bcr	B-protein
)	O
engagement	O
and	O
coculture	O
with	O
activated	B-cell_type
cd0+	I-cell_type
t	I-cell_type
cells	I-cell_type
,	O
these	O
lymphocytes	B-cell_type
upregulated	O
pol	B-DNA
zeta	I-DNA
,	I-DNA
downregulated	O
pol	B-DNA
eta	I-DNA
,	O
and	O
mutated	O
the	O
ig	B-DNA
and	I-DNA
bcl-0	I-DNA
genes	I-DNA
.	O

inhibition	O
of	O
the	O
pol	B-DNA
zeta	I-DNA
rev0	I-DNA
catalytic	O
subunit	O
by	O
specific	O
phosphorothioate-modified	O
oligonucleotides	O
impaired	O
ig	O
and	O
bcl-0	B-protein
hypermutation	O
and	O
uv	O
damage-induced	O
dna	O
mutagenesis	O
,	O
without	O
affecting	O
cell	O
cycle	O
or	O
viability	O
.	O

thus	O
,	O
pol	B-protein
zeta	O
plays	O
a	O
critical	O
role	O
in	O
ig	B-protein
and	O
bcl-0	B-protein
hypermutation	O
,	O
perhaps	O
facilitated	O
by	O
the	O
downregulation	O
of	O
pol	B-DNA
eta	I-DNA
.	O

###MEDLINE:21260138

molecular	O
mechanism	O
of	O
cell	O
cycle	O
progression	O
induced	O
by	O
the	O
oncogene	O
product	O
tax	O
of	O
human	B-protein
t-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
i	I-protein
.	O

the	O
trans-activator	B-protein
protein	B-protein
tax	I-protein
of	O
human	B-protein
t-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
i	I-protein
(	O
htlv-i	O
)	O
plays	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
adult	O
t-cell	O
leukemia	O
through	O
,	O
at	O
least	O
in	O
part	O
,	O
its	O
ability	O
to	O
stimulate	O
cell	O
growth	O
.	O

we	O
previously	O
reported	O
that	O
tax	B-protein
induced	O
cell	O
cycle	O
progression	O
from	O
g0/g0	O
phase	O
to	O
s	O
and	O
g0/m	O
phases	O
in	O
human	B-cell_line
t-cell	I-cell_line
line	I-cell_line
kit	O
000	O
cells	O
.	O

to	O
elucidate	O
molecular	O
mechanism	O
of	O
tax	B-protein
-induced	O
cell	O
cycle	O
progression	O
,	O
we	O
systematically	O
examined	O
the	O
effects	O
of	O
tax	B-protein
on	O
biochemical	O
events	O
associated	O
with	O
cell	O
cycle	O
progression	O
.	O

introduction	O
of	O
tax	B-protein
into	O
resting	O
kit	O
000	O
cells	O
induced	O
activation	O
of	O
the	O
g0/s	O
transition	O
regulation	O
cascade	O
consisting	O
of	O
activation	O
of	O
cyclin	B-protein
dependent	I-protein
kinase	I-protein
0	I-protein
(	O
cdk0	B-protein
)	O
and	O
cdk0	B-protein
,	O
phosphorylation	O
of	O
the	O
rb	B-protein
family	I-protein
proteins	I-protein
and	O
an	O
increase	O
in	O
free	O
e0f	B-protein
.	O

the	O
kinase	O
activation	O
was	O
found	O
to	O
result	O
from	O
tax	B-protein
-induced	O
expression	O
of	O
genes	O
for	O
cell	B-protein
cycle	I-protein
regulatory	I-protein
molecules	I-protein
including	O
cyclin	B-protein
d0	I-protein
,	O
cyclin	B-protein
e	I-protein
,	O
e0f0	B-protein
,	O
cdk0	B-protein
,	O
cdk0	B-protein
and	O
cdk0	B-protein
,	O
and	O
tax	B-protein
-induced	O
reduction	O
of	O
cdk	B-protein
inhibitors	I-protein
p00	I-protein
(	O
ink0d	B-protein
)	O
and	O
p00	B-protein
(	I-protein
kip0	I-protein
)	I-protein
.	O

these	O
modulations	O
by	O
tax	B-protein
always	O
paralleled	O
the	O
ability	O
of	O
tax	B-protein
to	O
activate	O
the	O
nf-kappab	B-protein
transcription	O
pathway	O
.	O

these	O
results	O
indicate	O
the	O
important	O
role	O
of	O
tax	B-protein
-mediated	O
trans-activation	O
of	O
the	O
genes	O
for	O
cell	B-protein
cycle	I-protein
regulatory	I-protein
molecules	I-protein
in	O
tax	B-protein
-induced	O
cell	O
cycle	O
progression	O
.	O

###MEDLINE:21347936

cot	B-protein
kinase	I-protein
induces	O
cyclooxygenase-0	B-protein
expression	O
in	O
t	B-cell_type
cells	I-cell_type
through	O
activation	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	O
activated	B-cell_type
t	I-cell_type
cells	I-cell_type
.	O

cyclooxygenase-0	B-protein
(	O
cox-0	B-protein
)	O
is	O
induced	O
in	O
human	B-cell_type
t	I-cell_type
lymphocytes	I-cell_type
upon	O
t	B-protein
cell	I-protein
receptor	I-protein
triggering	O
.	O

here	O
we	O
report	O
that	O
cot	B-protein
kinase	I-protein
,	O
a	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
kinase	I-protein
kinase	I-protein
involved	O
in	O
t	B-cell_type
cell	I-cell_type
activation	O
,	O
up-regulates	O
cox-0	B-DNA
gene	I-DNA
expression	O
in	O
jurkat	B-cell_line
t	I-cell_line
cells	I-cell_line
.	O

induction	O
of	O
cox-0	B-DNA
promoter	I-DNA
activity	O
by	O
cot	B-protein
kinase	I-protein
occurred	O
mainly	O
through	O
activation	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	O
activated	B-cell_type
t	I-cell_type
cells	I-cell_type
(	O
nfat	B-protein
)	O
.	O

mutation	O
of	O
the	O
distal	B-DNA
(	I-DNA
-000/-00	I-DNA
)	O
and	O
proximal	O
(	O
-00/-00	B-DNA
)	I-DNA
nfat	I-DNA
response	I-DNA
elements	I-DNA
in	O
the	O
cox-0	B-DNA
promoter	I-DNA
abolished	O
the	O
activation	O
induced	O
by	O
cot	B-protein
kinase	I-protein
.	O

even	O
more	O
,	O
coexpression	O
of	O
a	O
dominant	O
negative	O
version	O
of	O
nfat	B-protein
inhibited	O
cot	B-protein
kinase	I-protein
-mediated	O
cox-0	B-DNA
promoter	I-DNA
activation	O
,	O
whereas	O
cotransfection	O
of	O
a	O
constitutively	O
active	O
version	O
of	O
the	O
calcium-dependent	B-protein
phosphatase	I-protein
calcineurin	B-protein
synergizes	O
with	O
cot	B-protein
kinase	I-protein
in	O
the	O
up-regulation	O
of	O
cox-0	B-DNA
promoter	I-DNA
-driven	O
transcription	O
.	O

strikingly	O
,	O
cot	B-protein
kinase	I-protein
increased	O
transactivation	O
mediated	O
by	O
a	O
gal0-nfat	B-protein
fusion	I-protein
protein	I-protein
containing	O
the	O
n-terminal	B-protein
transactivation	I-protein
domain	I-protein
of	O
nfatp	B-protein
.	O

in	O
contrast	O
to	O
phorbol	O
ester	O
plus	O
calcium	O
ionophore	O
a00000	O
,	O
cot	B-protein
kinase	I-protein
increases	O
both	O
cox-0	B-DNA
promoter	I-DNA
activity	O
and	O
nfat	B-protein
-mediated	O
transactivation	O
in	O
a	O
cyclosporin	O
a-independent	O
manner	O
.	O

these	O
data	O
indicate	O
that	O
cot	B-protein
kinase	I-protein
up-regulates	O
cox-0	B-DNA
promoter	I-DNA
-driven	O
transcription	O
through	O
the	O
nfat	B-DNA
response	I-DNA
elements	I-DNA
,	O
being	O
the	O
cot	B-protein
kinase	I-protein
-induced	O
nfat	B-protein
-dependent	O
transactivation	O
presumably	O
implicated	O
in	O
this	O
up-regulation	O
.	O

###MEDLINE:21240683

positive	O
and	O
negative	O
roles	O
of	O
the	O
trans-acting	B-protein
t	I-protein
cell	I-protein
factor-0	I-protein
for	O
the	O
acquisition	O
of	O
distinct	O
ly-00	B-protein
mhc	I-protein
class	I-protein
i	I-protein
receptors	I-protein
by	O
nk	B-cell_type
cells	I-cell_type
.	O

members	O
of	O
the	O
ly-00	B-DNA
gene	I-DNA
family	I-DNA
code	O
for	O
class	B-protein
i	I-protein
mhc-specific	I-protein
receptors	I-protein
that	O
regulate	O
nk	O
cell	O
function	O
.	O

due	O
to	O
a	O
combinatorial	O
distribution	O
of	O
ly-00	B-protein
receptors	I-protein
,	O
nk	B-cell_type
cells	I-cell_type
display	O
considerable	O
clonal	O
heterogeneity	O
.	O

the	O
acquisition	O
of	O
one	O
ly-00	B-protein
receptor	I-protein
,	O
ly-00a	B-protein
is	O
strictly	O
dependent	O
on	O
the	O
transcriptional	O
trans-acting	B-protein
factor	I-protein
t	I-protein
cell-specific	I-protein
factor-0	I-protein
(	O
tcf-0	B-protein
)	O
.	O

indeed	O
,	O
tcf-0	B-protein
binds	O
to	O
two	O
sites	O
in	O
the	O
ly-00a	B-DNA
promoter	I-DNA
and	O
regulates	O
its	O
activity	O
,	O
suggesting	O
that	O
the	O
ly-00a	B-DNA
gene	I-DNA
is	O
a	O
direct	O
tcf-0	B-protein
target	O
.	O

tcf-0	B-protein
deficiency	O
resulted	O
in	O
the	O
altered	O
usage	O
of	O
additional	O
ly-00	B-protein
receptors	I-protein
.	O

we	O
show	O
in	O
this	O
study	O
,	O
using	O
tcf-0	B-protein
beta	I-protein
(	O
0	O
)	O
-microglobulin	O
double-deficient	O
mice	O
,	O
that	O
these	O
repertoire	O
alterations	O
are	O
not	O
due	O
to	O
ly-00/mhc	B-protein
class	I-protein
i	I-protein
interactions	O
.	O

our	O
findings	O
rather	O
suggest	O
a	O
tcf-0	B-protein
-dependent	O
,	O
cell	O
autonomous	O
effect	O
on	O
the	O
acquisition	O
of	O
multiple	B-protein
ly-00	I-protein
receptors	I-protein
.	O

besides	O
reduced	O
receptor	O
usage	O
(	O
ly-00a	B-protein
and	O
d	O
)	O
,	O
we	O
also	O
observed	O
no	O
effect	O
(	O
ly-00c	B-protein
)	O
and	O
significantly	O
expanded	O
(	O
ly-00g	B-protein
and	O
i	B-protein
)	I-protein
receptor	I-protein
usage	O
in	O
the	O
absence	O
of	O
tcf-0	B-protein
.	O

these	O
effects	O
did	O
not	O
in	O
all	O
cases	O
correlate	O
with	O
the	O
presence	O
of	O
tcf	B-DNA
binding	I-DNA
sites	I-DNA
in	O
the	O
respective	O
proximal	B-DNA
promoter	I-DNA
.	O

therefore	O
,	O
besides	O
tcf-0	B-protein
binding	O
to	O
the	O
proximal	B-DNA
promoter	I-DNA
,	O
ly-00	O
acquisition	O
may	O
also	O
be	O
regulated	O
by	O
tcf-0	B-protein
binding	O
to	O
more	O
distant	O
cis-acting	B-DNA
elements	I-DNA
and/or	O
by	O
regulating	O
the	O
expression	O
of	O
additional	O
trans-acting	B-protein
factors	I-protein
.	O

consistent	O
with	O
the	O
observed	O
differential	O
,	O
positive	O
or	O
negative	O
role	O
of	O
tcf-0	B-protein
for	O
ly-00	B-protein
receptor	I-protein
acquisition	O
,	O
reporter	B-DNA
gene	I-DNA
assays	O
revealed	O
the	O
presence	O
of	O
an	O
inducing	O
as	O
well	O
as	O
a	O
repressing	O
tcf	B-DNA
site	I-DNA
in	O
certain	O
proximal	B-DNA
ly-00	I-DNA
promoters	I-DNA
.	O

these	O
findings	O
reveal	O
an	O
important	O
role	O
of	O
tcf-0	B-protein
for	O
the	O
formation	O
of	O
the	O
nk	B-protein
cell	I-protein
receptor	I-protein
repertoire	I-protein
.	O

###MEDLINE:21240390

ligation	O
of	O
cd00b	B-protein
and	O
cd00c	B-DNA
beta	I-DNA
(	O
0	O
)	O
integrins	O
by	O
antibodies	B-protein
or	O
soluble	O
cd00	B-protein
induces	O
macrophage	B-protein
inflammatory	I-protein
protein	I-protein
0alpha	O
(	O
mip-0alpha	B-protein
)	O
and	O
mip-0beta	B-protein
production	O
in	O
primary	B-cell_type
human	I-cell_type
monocytes	I-cell_type
through	O
a	O
pathway	O
dependent	O
on	O
nuclear	B-protein
factor-kappab	I-protein
.	O

chemokines	B-protein
and	O
adhesion	B-protein
molecules	I-protein
such	O
as	O
integrins	B-protein
play	O
a	O
major	O
part	O
in	O
the	O
trafficking	O
,	O
extravasation	O
,	O
and	O
recruitment	O
of	O
leukocytes	B-cell_type
to	O
inflammatory	O
sites	O
.	O

this	O
study	O
investigated	O
the	O
effects	O
of	O
beta	O
(	O
0	O
)	O
integrin	B-protein
engagement	O
on	O
chemokine	B-protein
production	O
by	O
freshly	B-cell_type
isolated	I-cell_type
human	I-cell_type
monocytes	I-cell_type
.	O

we	O
found	O
that	O
ligation	O
of	O
cd00b	B-protein
or	O
cd00c	B-DNA
but	O
not	O
cd00a	B-protein
alpha	B-protein
chains	I-protein
of	O
beta	O
(	O
0	O
)	O
integrins	O
by	O
antibodies	B-protein
or	O
soluble	B-protein
cd00	I-protein
(	O
scd00	B-protein
)	I-protein
fusion	I-protein
proteins	I-protein
rapidly	O
induced	O
transcription	O
and	O
secretion	O
of	O
interleukin	B-protein
0	I-protein
,	O
macrophage	B-protein
inflammatory	I-protein
protein	I-protein
(	O
mip	O
)	O
0alpha	O
,	O
and	O
mip-0beta	B-protein
.	O

because	O
the	O
promoters	O
of	O
these	O
chemokine	B-protein
genes	O
contain	O
kappab	B-DNA
binding	I-DNA
sites	I-DNA
,	O
we	O
assessed	O
the	O
possible	O
role	O
of	O
nuclear	B-protein
factor-kappab	I-protein
(	O
nf-kappab	B-protein
)	O
in	O
controlling	O
induction	O
of	O
the	O
genes	O
through	O
beta	O
(	O
0	O
)	O
integrin	B-protein
engagement	O
.	O

electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
scd00	B-protein
or	O
antibodies	B-protein
to	O
cd00b	B-protein
or	O
to	O
cd00c	B-DNA
up-regulated	O
dna-binding	O
activity	O
of	O
nf-kappab	B-protein
.	O

activation	O
of	O
nf-kappab	B-protein
was	O
accompanied	O
by	O
degradation	O
of	O
its	O
cytosolic	B-protein
inhibitor	I-protein
ikappab-alpha	B-protein
.	O

blockade	O
of	O
depletion	O
of	O
ikappab-alpha	B-protein
by	O
proteasome	B-protein
inhibitors	O
(	O
proteasome	B-protein
inhibitor	O
i	O
or	O
acetyl-leucinyl-leucinyl-norleucinal	B-protein
)	O
led	O
to	O
concomitant	O
inhibition	O
of	O
nf-kappab	B-protein
dna-binding	O
activity	O
and	O
expression	O
of	O
mip-0alpha	B-protein
and	O
mip-0beta	B-protein
messenger	B-RNA
rna	I-RNA
induced	O
by	O
beta	O
(	O
0	O
)	O
integrin	B-protein
ligation	O
.	O

these	O
results	O
suggest	O
that	O
triggering	O
of	O
cd00b	B-protein
or	O
cd00c	B-DNA
beta	I-DNA
(	O
0	O
)	O
integrin	O
on	O
primary	B-cell_type
human	I-cell_type
monocytes	I-cell_type
provides	O
activation	O
signals	O
leading	O
to	O
nuclear	O
translocation	O
of	O
nf-kappab	B-protein
and	O
subsequent	O
secretion	O
of	O
mip-0alpha	B-protein
and	O
mip-0beta	B-protein
that	O
may	O
have	O
an	O
important	O
role	O
in	O
recruitment	O
of	O
other	O
inflammatory	O
cells	O
during	O
initiation	O
of	O
an	O
inflammatory	O
response	O

###MEDLINE:21293129

synergistic	O
transcriptional	O
activation	O
of	O
human	B-protein
acyl-coenzyme	I-protein
a	I-protein
:	O
cholesterol	O
acyltransterase-0	O
gene	O
by	O
interferon-gamma	B-protein
and	O
all-trans-retinoic	O
acid	O
thp-0	B-cell_line
cells	I-cell_line
.	O

acyl-coenzyme	B-protein
a	I-protein
:	O
cholesterol	O
acyltransferase	O
(	O
acat	B-protein
)	O
is	O
an	O
intracellular	B-protein
enzyme	I-protein
involved	O
in	O
cellular	O
cholesterol	O
homeostasis	O
and	O
in	O
atherosclerotic	O
foam	O
cell	O
formation	O
.	O

human	O
acat-0	B-DNA
gene	I-DNA
contains	O
two	O
promoters	B-DNA
(	O
p0	B-DNA
and	O
p0	B-DNA
)	O
,	O
each	O
located	O
in	O
a	O
different	O
chromosome	O
(	O
0	O
and	O
0	O
)	O
(	O
li	O
,	O
b.	O
l.	O
,	O
li	O
,	O
x.	O
l.	O
,	O
duan	O
,	O
z.	O
j.	O
,	O
lee	O
,	O
o.	O
,	O
lin	B-cell_type
,	O
s.	O
,	O
ma	O
,	O
z.	O
m.	O
,	O
chang	O
,	O
c.	O
c.	O
,	O
yang	B-protein
,	I-protein
x.	I-protein
y.	I-protein
,	O
park	B-protein
,	O
j.	O
p.	O
,	O
mohandas	O
,	O
t.	O
k.	O
,	O
noll	O
,	O
w.	O
,	O
chan	O
,	O
l.	O
,	O
and	O
chang	O
,	O
t.	O
y.	O
(	O
0000	O
)	O
j.	O
biol	O
chem.	O
000	O
,	O
00000-00000	O
)	O
.	O

interferon-gamma	B-protein
(	O
ifn-gamma	B-protein
)	O
,	O
a	O
cytokine	B-protein
that	O
exerts	O
many	O
pro-atherosclerotic	O
effects	O
in	O
vivo	O
,	O
causes	O
up-regulation	O
of	O
acat-0	B-RNA
mrna	I-RNA
in	O
human	B-cell_type
blood	I-cell_type
monocyte-derived	I-cell_type
macrophages	I-cell_type
and	O
macrophage-like	B-cell_type
cells	I-cell_type
but	O
not	O
in	O
other	O
cell	O
types	O
.	O

to	O
examine	O
the	O
molecular	O
nature	O
of	O
this	O
observation	O
,	O
we	O
identified	O
within	O
the	O
acat-0	B-DNA
p0	I-DNA
promoter	I-DNA
a	O
000-base	B-DNA
pair	I-DNA
core	I-DNA
region	I-DNA
.	O

this	O
region	O
contains	O
0	O
sp0	B-DNA
elements	I-DNA
and	O
an	O
ifn-gamma	B-DNA
activated	I-DNA
sequence	I-DNA
(	O
gas	B-DNA
)	O
that	O
overlaps	O
with	O
the	O
second	B-DNA
sp0	I-DNA
element	I-DNA
.	O

in	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
thp-0	I-cell_line
cell	I-cell_line
,	O
the	O
combination	O
of	O
ifn-gamma	B-protein
and	O
all-trans-retinoic	O
acid	O
(	O
a	O
known	O
differentiation	O
agent	O
)	O
enhances	O
the	O
acat-0	B-DNA
p0	I-DNA
promoter	I-DNA
but	O
not	O
the	O
p0	B-DNA
promoter	I-DNA
.	O

additional	O
experiments	O
showed	O
that	O
all-trans-retinoic	O
acid	O
causes	O
large	O
induction	O
of	O
the	O
transcription	B-protein
factor	I-protein
stat0	B-protein
,	O
while	O
ifn-gamma	B-protein
causes	O
activation	O
of	O
stat0	B-protein
such	O
that	O
it	O
binds	O
to	O
the	O
gas/sp0	B-DNA
site	I-DNA
in	O
the	O
acat-0	B-DNA
p0	I-DNA
promoter	I-DNA
.	O

our	O
work	O
provides	O
a	O
molecular	O
mechanism	O
to	O
account	O
for	O
the	O
effect	O
of	O
ifn-gamma	B-protein
in	O
causing	O
transcriptional	O
activation	O
of	O
acat-0	B-DNA
in	O
macrophage-like	B-cell_type
cells	I-cell_type
.	O

###MEDLINE:21288911

inhaled	O
nitric	O
oxide	O
down-regulates	O
intrapulmonary	O
nitric	O
oxide	O
production	O
in	O
lipopolysaccharide-induced	O
acute	O
lung	O
injury	O
.	O

objective	O
:	O
to	O
examine	O
whether	O
inhaled	O
nitric	O
oxide	O
(	O
no	O
)	O
affected	O
the	O
intrapulmonary	O
production	O
of	O
no	O
,	O
reactive	O
oxygen	O
species	O
,	O
and	O
nuclear	B-protein
factor-kappab	I-protein
in	O
a	O
lipopolysaccharide	O
(	O
lps	O
)	O
-induced	O
model	O
of	O
acute	O
lung	O
injury	O
.	O

design	O
:	O
prospective	O
,	O
randomized	O
,	O
laboratory	O
study	O
.	O

setting	O
:	O
experimental	O
laboratory	O
at	O
a	O
biomedical	O
institute	O
.	O

subjects	O
:	O
twenty	O
male	O
rabbits	O
weighing	O
0.0-0.0	O
kg	O
.	O

interventions	O
:	O
saline	O
or	O
lps	O
(	O
0	O
mg/kg	O
of	O
body	O
weight	O
)	O
was	O
administered	O
intravenously	O
with	O
or	O
without	O
no	O
inhalation	O
(	O
00	O
ppm	O
)	O
in	O
each	O
group	O
of	O
five	O
rabbits	O
.	O

measurements	O
and	O
main	O
results	O
:	O
lps	O
increased	O
the	O
lung	O
leak	O
index	O
,	O
the	O
neutrophils	B-cell_type
and	O
no	O
levels	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
,	O
and	O
no	O
levels	O
produced	O
by	O
resting	B-cell_type
and	I-cell_type
stimulated	I-cell_type
alveolar	I-cell_type
macrophages	I-cell_type
.	O

inhaled	O
no	O
decreased	O
the	O
lung	O
leak	O
index	O
,	O
the	O
neutrophils	B-cell_type
and	O
no	O
levels	O
as	O
measured	O
by	O
nitrite	O
levels	O
in	O
the	O
lavage	O
fluid	O
,	O
and	O
no	O
produced	O
by	O
the	O
resting	B-cell_type
and	I-cell_type
stimulated	I-cell_type
alveolar	I-cell_type
macrophages	I-cell_type
.	O

inhaled	O
no	O
also	O
blocked	O
the	O
activities	O
of	O
reactive	O
oxygen	O
species	O
and	O
nuclear	B-protein
factor-kappab	I-protein
binding	O
to	O
dna	O
in	O
lavage	B-cell_type
cells	I-cell_type
and	O
in	O
alveolar	B-cell_type
macrophages	I-cell_type
.	O

conclusion	O
:	O
inhaled	O
no	O
attenuates	O
lps-induced	O
acute	O
lung	O
injury	O
,	O
possibly	O
by	O
decreasing	O
no	O
production	O
in	O
the	O
lungs	O
.	O

the	O
mechanism	O
of	O
reducing	O
no	O
production	O
resulting	O
from	O
inhaled	O
no	O
may	O
involve	O
,	O
in	O
part	O
,	O
the	O
activities	O
of	O
reactive	O
oxygen	O
species	O
and/or	O
nuclear	B-protein
factor-kappab	I-protein
.	O

###MEDLINE:21286431

treatment	O
of	O
allergic	O
airway	O
inflammation	O
and	O
hyperresponsiveness	O
by	O
antisense-induced	O
local	O
blockade	O
of	O
gata-0	B-protein
expression	O
.	O

recent	O
studies	O
in	O
transgenic	O
mice	O
have	O
revealed	O
that	O
expression	O
of	O
a	O
dominant	O
negative	O
form	O
of	O
the	O
transcription	B-protein
factor	I-protein
gata-0	I-protein
in	O
t	B-cell_type
cells	I-cell_type
can	O
prevent	O
t	B-protein
helper	I-protein
cell	I-protein
type	I-protein
0	I-protein
(	O
th0	B-cell_line
)	O
-mediated	O
allergic	O
airway	O
inflammation	O
in	O
mice	O
.	O

however	O
,	O
it	O
remains	O
unclear	O
whether	O
gata-0	B-protein
plays	O
a	O
role	O
in	O
the	O
effector	O
phase	O
of	O
allergic	O
airway	O
inflammation	O
and	O
whether	O
antagonizing	O
the	O
expression	O
and/or	O
function	O
of	O
gata-0	B-protein
can	O
be	O
used	O
for	O
the	O
therapy	O
of	O
allergic	O
airway	O
inflammation	O
and	O
hyperresponsiveness	O
.	O

here	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
locally	O
antagonizing	O
gata-0	B-protein
function	O
in	O
a	O
murine	O
model	O
of	O
asthma	O
.	O

we	O
could	O
suppress	O
gata-0	B-protein
expression	O
in	O
interleukin	B-protein
(	I-protein
il	I-protein
)	I-protein
-0	I-protein
-producing	O
t	B-cell_type
cells	I-cell_type
in	O
vitro	O
and	O
in	O
vivo	O
by	O
an	O
antisense	O
phosphorothioate	O
oligonucleotide	O
overlapping	O
the	O
translation	B-DNA
start	I-DNA
site	I-DNA
of	O
gata-0	B-protein
,	O
whereas	O
nonsense	O
control	O
oligonucleotides	O
were	O
virtually	O
inactive	O
.	O

in	O
a	O
murine	O
model	O
of	O
asthma	O
associated	O
with	O
allergic	O
pulmonary	O
inflammation	O
and	O
hyperresponsiveness	O
in	O
ovalbumin	B-protein
(	I-protein
ova	I-protein
)	O
-sensitized	O
mice	O
,	O
local	O
intranasal	O
administration	O
of	O
fluorescein	B-protein
isothiocyanate-labeled	I-protein
gata-0	B-protein
antisense	O
oligonucleotides	O
led	O
to	O
dna	O
uptake	O
in	O
lung	B-cell_type
cells	I-cell_type
associated	O
with	O
a	O
reduction	O
of	O
intracellular	O
gata-0	B-protein
expression	O
.	O

such	O
intrapulmonary	O
blockade	O
of	O
gata-0	B-protein
expression	O
caused	O
an	O
abrogation	O
of	O
signs	O
of	O
lung	O
inflammation	O
including	O
infiltration	O
of	O
eosinophils	B-cell_type
and	O
th0	B-protein
cytokine	I-protein
production	O
.	O

furthermore	O
,	O
treatment	O
with	O
antisense	O
but	O
not	O
nonsense	O
oligonucleotides	O
induced	O
a	O
significant	O
reduction	O
of	O
airway	O
hyperresponsiveness	O
in	O
ova-sensitized	O
mice	O
to	O
levels	O
comparable	O
to	O
saline-treated	O
control	O
mice	O
,	O
as	O
assessed	O
by	O
both	O
enhanced	O
pause	O
(	O
penh	B-protein
)	O
responses	O
and	O
pulmonary	O
resistance	O
determined	O
by	O
body	O
plethysmography	O
.	O

these	O
data	O
indicate	O
a	O
critical	O
role	O
for	O
gata-0	B-protein
in	O
the	O
effector	O
phase	O
of	O
a	O
murine	O
asthma	O
model	O
and	O
suggest	O
that	O
local	O
delivery	O
of	O
gata-0	B-protein
antisense	O
oligonucleotides	O
may	O
be	O
a	O
novel	O
approach	O
for	O
the	O
treatment	O
of	O
airway	O
hyperresponsiveness	O
such	O
as	O
in	O
asthma	O
.	O

this	O
approach	O
has	O
the	O
potential	O
advantage	O
of	O
suppressing	O
the	O
expression	O
of	O
various	O
proinflammatory	B-protein
th0	I-protein
cytokines	I-protein
simultaneously	O
rather	O
than	O
suppressing	O
the	O
activity	O
of	O
a	O
single	O
cytokine	O
.	O

###MEDLINE:21276281

t	B-cell_type
helper-cell	I-cell_type
phenotype	I-cell_type
regulates	O
atherosclerosis	O
in	O
mice	O
under	O
conditions	O
of	O
mild	O
hypercholesterolemia	O
.	O

background	O
:	O
t	B-cell_type
cells	I-cell_type
are	O
implicated	O
in	O
atherosclerosis	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
genetic	O
control	O
or	O
molecular	O
pathways	O
,	O
especially	O
under	O
conditions	O
of	O
mild	O
hypercholesterolemia	O
.	O

methods	O
and	O
results	O
:	O
balb/c	O
mice	O
,	O
making	O
a	O
cd0+	B-cell_line
th0	I-cell_line
(	I-cell_line
il-0+	I-cell_line
)	O
cell	O
response	O
,	O
express	O
both	O
mhc	B-protein
class	I-protein
ii	I-protein
antigens	I-protein
(	O
ia	O
(	O
d	O
)	O
,	O
ie	B-DNA
(	O
d	O
)	O
)	O
and	O
are	O
atherosclerosis-resistant	O
.	O

c00bl/0	O
mice	O
produce	O
a	O
cd0+	O
th0	B-protein
(	I-protein
interferon	I-protein
[	O
ifn	B-protein
]	O
gamma+	O
)	O
response	O
,	O
express	O
ia	O
(	O
b	O
)	O
but	O
no	O
ie	B-DNA
,	O
and	O
are	O
atherosclerosis-prone	O
.	O

to	O
evaluate	O
t	B-cell_type
helper-cell	I-cell_type
phenotype	I-cell_type
in	O
fatty	O
streak	O
formation	O
,	O
wild-type	O
c00bl/0	O
mice	O
(	O
ia	O
(	O
b	O
)	O
+ie-	O
)	O
and	O
transgenic	O
mice	O
,	O
either	O
ab	O
(	O
o	O
)	O
,	O
ia	O
(	O
b	O
)	O
-ie-	O
;	O
abealpha	O
,	O
ia-ie	B-protein
(	I-protein
k	I-protein
)	I-protein
+	O
;	O
or	O
bl	O
:	O
tg	O
:	O
ealpha	B-cell_line
,	I-cell_line
ia	I-cell_line
(	I-cell_line
b	I-cell_line
)	I-cell_line
+ie	I-cell_line
(	I-cell_line
k	I-cell_line
)	I-cell_line
+	I-cell_line
,	I-cell_line
were	O
fed	O
a	O
high-cholesterol	O
diet	O
for	O
00	O
weeks	O
and	O
evaluated	O
histomorphometrically	O
for	O
aortic	O
lesions	O
.	O

lesion	O
size	O
in	O
ab	O
(	O
o	O
)	O
,	O
abealpha	O
,	O
and	O
bl	O
:	O
tg	O
:	O
ealpha	O
strains	O
was	O
decreased	O
by	O
00	O
%	O
,	O
00	O
%	O
,	O
and	O
00	O
%	O
,	O
respectively	O
,	O
compared	O
with	O
wild-type	B-cell_line
,	O
correlating	O
with	O
decreased	O
th0	O
and	O
increased	O
th0	O
expression	O
and	O
suggesting	O
that	O
t	B-cell_type
helper-cell	I-cell_type
phenotype	I-cell_type
is	O
important	O
in	O
fatty	O
lesion	O
development	O
.	O

decreasing	O
th0	B-cell_type
cells	I-cell_type
by	O
antibodies	B-protein
(	O
alpha-cd0	B-protein
)	O
or	O
cytokines	B-protein
(	O
il-0	B-protein
)	O
also	O
caused	O
>	O
/=00	O
%	O
reductions	O
in	O
lesion	O
size	O
.	O

immunohistology	O
revealed	O
ifn-gamma	B-protein
,	O
but	O
not	O
il-0	B-protein
,	O
colocalized	O
with	O
activated	B-cell_type
macrophages	I-cell_type
.	O

confirming	O
these	O
findings	O
in	O
a	O
different	O
mouse	O
strain	O
,	O
balb/c	O
stat	B-protein
0	I-protein
knockout	O
mice	O
(	O
th0	O
cell-deficient	O
)	O
developed	O
aortic	O
lesions	O
comparable	O
to	O
c00bl/0	O
mice	O
on	O
the	O
same	O
diet	O
.	O

conclusions	O
:	O
in	O
mildly	O
hypercholesterolemic	O
c00bl/0	O
mice	O
,	O
presence	O
of	O
ia	O
(	O
b	O
)	O
and	O
absence	O
of	O
ie	O
regulated	O
cd0+	B-cell_type
t	I-cell_type
helper-cell	I-cell_type
phenotype	I-cell_type
;	O
fatty	O
lesions	O
were	O
proportional	O
to	O
ifngamma+	B-cell_type
th0	I-cell_type
cells	I-cell_type
in	O
both	O
c00bl/0	O
and	O
balb/c	B-cell_line
strains	I-cell_line
.	O

ifn-gamma	B-protein
may	O
participate	O
through	O
macrophage	O
activation	O
,	O
whereas	O
il-0	B-protein
may	O
act	O
to	O
limit	O
th0-cell	O
response	O
.	O

###MEDLINE:21269099

requirement	O
for	O
p00	B-protein
and	O
p00/p00	B-protein
mitogen-activated	I-protein
protein	I-protein
kinases	I-protein
in	O
rage	B-protein
-mediated	O
nuclear	B-protein
factor-kappab	I-protein
transcriptional	O
activation	O
and	O
cytokine	B-protein
secretion	O
.	O

advanced	O
glycation	O
end	O
product	O
(	O
age	O
)	O
activation	O
of	O
the	O
signal-transducing	B-protein
receptor	I-protein
for	O
age	O
(	O
rage	B-protein
)	O
has	O
been	O
linked	O
to	O
a	O
proinflammatory	O
phenotypic	O
change	O
within	O
cells	O
.	O

however	O
,	O
the	O
precise	O
intracellular	O
signaling	O
pathways	O
involved	O
have	O
not	O
been	O
elucidated	O
.	O

we	O
demonstrate	O
here	O
that	O
human	B-protein
serum	I-protein
albumin	I-protein
modified	O
with	O
n	O
(	O
varepsilon	B-protein
)	O
-	O
(	O
carboxymethyl	O
)	O
lysine	O
(	O
cml	O
)	O
,	O
a	O
major	O
age	O
adduct	O
that	O
progressively	O
accumulates	O
with	O
aging	O
,	O
diabetes	O
,	O
and	O
renal	O
failure	O
,	O
induced	O
nuclear	B-protein
factor	I-protein
(	O
nf	B-DNA
)	I-DNA
-kappab	I-DNA
-driven	I-DNA
reporter	I-DNA
gene	I-DNA
expression	O
in	O
human	B-cell_line
monocytic	I-cell_line
thp-0	I-cell_line
cells	I-cell_line
.	O

the	O
nf-kappab	B-protein
response	O
was	O
blocked	O
with	O
a	O
synthetic	O
peptide	O
corresponding	O
to	O
the	O
putative	O
ligand-binding	B-protein
domain	I-protein
of	O
rage	B-protein
,	O
with	O
anti-	O
rage	B-protein
antiserum	O
,	O
and	O
by	O
coexpression	O
of	O
truncated	B-protein
receptors	I-protein
lacking	O
the	O
intracellular	B-protein
domain	I-protein
.	O

signal	O
transduction	O
from	O
rage	B-protein
to	O
nf-kappab	B-protein
involved	O
the	O
generation	O
of	O
reactive	O
oxygen	O
species	O
,	O
since	O
reporter	B-DNA
gene	I-DNA
expression	O
was	O
blocked	O
with	O
the	O
antioxidant	O
n-acetyl-l-cysteine	O
.	O

cml-modified	B-protein
albumin	I-protein
produced	O
rapid	O
transient	O
activation	O
of	O
tyrosine	O
phosphorylation	O
,	O
extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
0	I-protein
and	O
0	O
,	O
and	O
p00	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
(	O
mapk	B-protein
)	O
,	O
but	O
not	O
c-jun	B-protein
nh	I-protein
(	I-protein
0	I-protein
)	I-protein
-terminal	I-protein
kinase	I-protein
.	O

rage	B-protein
-mediated	O
nf-kappab	B-protein
activation	O
was	O
suppressed	O
by	O
the	O
selective	O
p00	B-protein
mapk	I-protein
inhibitor	O
sb000000	O
and	O
by	O
coexpression	O
of	O
a	O
kinase-dead	B-protein
p00	I-protein
dominant-negative	I-protein
mutant	I-protein
.	O

activation	O
of	O
nf-kappab	B-protein
by	O
cml-modified	B-protein
albumin	I-protein
increased	O
secretion	O
of	O
proinflammatory	B-protein
cytokines	I-protein
(	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
interleukin-0beta	B-protein
,	O
and	O
monocyte	B-protein
chemoattractant	I-protein
protein-0	I-protein
)	O
severalfold	O
,	O
and	O
inhibition	O
of	O
p00	B-protein
mapk	I-protein
blocked	O
these	O
increases	O
.	O

these	O
results	O
indicate	O
that	O
p00	B-protein
mapk	I-protein
activation	O
mediates	O
rage	B-protein
-induced	O
nf-kappab	B-protein
-dependent	O
secretion	O
of	O
proinflammatory	B-protein
cytokines	I-protein
and	O
suggest	O
that	O
accelerated	O
inflammation	O
may	O
be	O
a	O
consequence	O
of	O
cellular	O
activation	O
induced	O
by	O
this	O
receptor	O
.	O

###MEDLINE:21261983

antigen-receptor	O
cross-linking	O
and	O
lipopolysaccharide	O
trigger	O
distinct	O
phosphoinositide	B-protein
0-kinase	I-protein
-dependent	O
pathways	O
to	O
nf-kappa	B-protein
b	I-protein
activation	O
in	O
primary	B-cell_type
b	I-cell_type
cells	I-cell_type
.	O

the	O
nf-kappab/rel	B-protein
transcription	I-protein
factors	I-protein
play	O
an	O
important	O
role	O
in	O
the	O
expression	O
of	O
genes	O
involved	O
in	O
b	B-cell_type
cell	I-cell_type
development	O
,	O
differentiation	O
and	O
function	O
.	O

nuclear	O
nf-kappab	B-protein
is	O
induced	O
in	O
b	B-cell_type
cells	I-cell_type
by	O
engagement	O
of	O
either	O
the	O
bcr	B-protein
or	O
cd00	B-protein
or	O
by	O
stimulation	O
with	O
lipopolysaccharide	O
(	O
lps	O
)	O
.	O

despite	O
the	O
importance	O
of	O
nf-kappab	B-protein
to	O
b	B-cell_type
cell	I-cell_type
function	O
,	O
little	O
is	O
known	O
about	O
the	O
signaling	O
pathways	O
leading	O
to	O
nf-kappab	B-protein
activation	O
.	O

in	O
this	O
report	O
we	O
address	O
the	O
role	O
of	O
phosphoinositide	B-protein
0'-kinase	I-protein
(	O
pi	B-protein
0-kinase	I-protein
)	O
in	O
bcr	B-protein
-	O
and	O
lps-induced	O
nf-kappab	B-protein
activation	O
using	O
populations	O
of	O
primary	B-cell_type
murine	I-cell_type
resting	I-cell_type
b	I-cell_type
cells	I-cell_type
.	O

using	O
the	O
specific	O
pharmacological	O
inhibitors	O
of	O
pi	B-protein
0-kinase	I-protein
,	O
wortmannin	O
and	O
ly000000	O
,	O
we	O
demonstrate	O
that	O
pi	B-protein
0-kinase	I-protein
activity	O
is	O
vital	O
for	O
bcr	B-protein
-induced	O
nf-kappab	B-protein
dna-binding	O
activity	O
.	O

furthermore	O
,	O
we	O
show	O
that	O
this	O
is	O
achieved	O
via	O
protein	B-protein
kinase	I-protein
c	I-protein
-dependent	O
degradation	O
of	O
ikappabalpha	B-protein
.	O

similar	O
analyses	O
reveal	O
that	O
pi	B-protein
0-kinase	I-protein
is	O
also	O
critical	O
in	O
triggering	O
nf-kappab	B-protein
dna-binding	O
activity	O
and	O
ikappabalpha	B-protein
degradation	O
following	O
lps	O
stimulation	O
.	O

interestingly	O
,	O
a	O
pkc	B-protein
inhibitor	I-protein
which	O
blocked	O
the	O
bcr	B-protein
-induced	O
ikappabalpha	B-protein
degradation	O
had	O
no	O
effect	O
on	O
the	O
degradation	O
of	O
ikappabalpha	B-protein
after	O
lps	O
stimulation	O
.	O

taken	O
together	O
,	O
our	O
results	O
indicate	O
the	O
involvement	O
of	O
pi	B-protein
0-kinase	I-protein
in	O
at	O
least	O
two	O
distinct	O
signaling	O
pathways	O
leading	O
to	O
activation	O
of	O
nf-kappab	B-protein
in	O
b	B-cell_type
cells	I-cell_type
.	O

###MEDLINE:21259893

tetramer-guided	O
epitope	O
mapping	O
:	O
rapid	O
identification	O
and	O
characterization	O
of	O
immunodominant	O
cd0+	B-cell_type
t	I-cell_type
cell	I-cell_type
epitopes	O
from	O
complex	B-protein
antigens	I-protein
.	O

t	O
cell	O
responses	O
to	O
ags	B-protein
involve	O
recognition	O
of	O
selected	O
peptide	O
epitopes	O
contained	O
within	O
the	O
antigenic	O
protein	O
.	O

in	O
this	O
report	O
,	O
we	O
describe	O
a	O
new	O
approach	O
for	O
direct	O
identification	O
of	O
cd0+	B-cell_type
t	I-cell_type
cell	I-cell_type
epitopes	O
of	O
complex	B-protein
ags	I-protein
that	O
uses	O
human	B-protein
class	I-protein
ii	I-protein
tetramers	I-protein
to	O
identify	O
reactive	O
cells	O
.	O

with	O
a	O
panel	O
of	O
00	O
overlapping	O
peptides	O
covering	O
the	O
entire	B-DNA
sequence	I-DNA
of	O
the	O
vp00	B-protein
protein	O
,	O
a	O
major	B-protein
ag	I-protein
for	O
hsv-0	O
,	O
we	O
generated	O
a	O
panel	O
of	O
class	B-protein
ii	I-protein
mhc	I-protein
tetramers	I-protein
loaded	O
with	O
peptide	O
pools	O
that	O
were	O
used	O
to	O
stain	O
peripheral	B-cell_type
lymphocytes	I-cell_type
of	O
an	O
hsv-0	O
infected	O
individual	O
.	O

with	O
this	O
approach	O
,	O
we	O
identified	O
four	O
new	O
dra0*0000/drb0*0000-	O
and	O
two	O
dra0*0000/drb0*0000-restricted	O
,	O
vp00-specific	B-protein
epitopes	I-protein
.	O

by	O
using	O
tetramers	O
to	O
sort	O
individual	O
cells	O
,	O
we	O
easily	O
obtained	O
a	O
large	O
number	O
of	O
clones	O
specific	O
to	O
these	O
epitopes	O
.	O

although	O
dra0*0000/drb0*0000	B-protein
and	O
dra0*0000/drb0*0000	B-protein
are	O
structurally	O
very	O
similar	O
,	O
nonoverlapping	B-protein
vp00	I-protein
epitopes	I-protein
were	O
identified	O
,	O
illustrating	O
high	O
selectivity	O
of	O
individual	O
allele	O
polymorphisms	O
within	O
common	O
mhc	B-protein
variants	I-protein
.	O

this	O
rapid	O
approach	O
to	O
detecting	B-cell_type
cd0+	I-cell_type
t	I-cell_type
cell	I-cell_type
epitopes	O
from	O
complex	B-protein
ags	I-protein
can	O
be	O
applied	O
to	O
any	O
known	B-protein
ag	I-protein
that	O
gives	O
a	O
t	O
cell	O
response	O
.	O

###MEDLINE:21250583

localized	O
pancreatic	O
nf-kappab	B-protein
activation	O
and	O
inflammatory	O
response	O
in	O
taurocholate-induced	O
pancreatitis	O
.	O

transcription	B-protein
factor	I-protein
nuclear	I-protein
factor-kappab	I-protein
(	O
nf-kappab	B-protein
)	O
is	O
activated	O
in	O
cerulein	O
pancreatitis	O
and	O
mediates	O
cytokine	B-protein
expression	O
.	O

the	O
role	O
of	O
transcription	B-protein
factor	I-protein
activation	O
in	O
other	O
models	O
of	O
pancreatitis	O
has	O
not	O
been	O
established	O
.	O

here	O
we	O
report	O
upregulation	O
of	O
nf-kappab	B-protein
and	O
inflammatory	B-protein
molecules	I-protein
,	O
and	O
their	O
correlation	O
with	O
local	O
pancreatic	O
injury	O
,	O
in	O
a	O
model	O
of	O
severe	O
pancreatitis	O
.	O

rats	O
received	O
intraductal	O
infusion	O
of	O
taurocholate	O
or	O
saline	O
,	O
and	O
the	O
pancreatic	O
head	O
and	O
tail	O
were	O
analyzed	O
separately	O
.	O

nf-kappab	B-protein
and	O
activator	B-protein
protein-0	I-protein
(	O
ap-0	B-protein
)	O
activation	O
were	O
assessed	O
by	O
gel	O
shift	O
assay	O
,	O
and	O
mrna	B-RNA
expression	O
of	O
interleukin-0	B-protein
,	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
kc	O
,	O
monocyte	B-protein
chemoattractant	I-protein
protein-0	I-protein
,	O
and	O
inducible	B-protein
nitric	I-protein
oxide	I-protein
synthase	I-protein
was	O
assessed	O
by	O
semiquantitative	O
rt-pcr	O
.	O

morphological	O
damage	O
and	O
trypsin	B-protein
activation	O
were	O
much	O
greater	O
in	O
the	O
pancreatic	O
head	O
than	O
tail	O
,	O
in	O
parallel	O
with	O
a	O
stronger	O
activation	O
of	O
nf-kappab	B-protein
and	O
cytokine	B-RNA
mrna	I-RNA
.	O

saline	O
infusion	O
mildly	O
affected	O
these	O
parameters	O
.	O

ap-0	B-protein
was	O
strongly	O
activated	O
in	O
both	O
pancreatic	O
segments	O
after	O
either	O
taurocholate	O
or	O
saline	O
infusion	O
.	O

nf-kappab	B-protein
inhibition	O
with	O
n-acetylcysteine	O
ameliorated	O
the	O
local	O
inflammatory	O
response	O
.	O

correlation	O
between	O
localized	O
nf-kappab	B-protein
activation	O
,	O
cytokine	B-protein
upregulation	O
,	O
and	O
tissue	O
damage	O
suggests	O
a	O
key	O
role	O
for	O
nf-kappab	B-protein
in	O
the	O
development	O
of	O
the	O
inflammatory	O
response	O
of	O
acute	O
pancreatitis	O
.	O

###MEDLINE:21240664

cd00	B-protein
tyrosine	I-protein
phosphatase	I-protein
controls	O
common	B-protein
gamma-chain	I-protein
cytokine	B-protein
-mediated	O
stat	B-protein
and	I-protein
extracellular	I-protein
signal-related	I-protein
kinase	I-protein
phosphorylation	O
in	O
activated	B-cell_type
human	I-cell_type
lymphoblasts	I-cell_type
:	O
inhibition	O
of	O
proliferation	O
without	O
induction	O
of	O
apoptosis	O
.	O

the	O
objective	O
of	O
this	O
study	O
was	O
to	O
test	O
whether	O
cd00	B-protein
signals	O
can	O
influence	O
signaling	O
processes	O
in	O
activated	B-cell_type
human	I-cell_type
lymphoblasts	I-cell_type
.	O

to	O
this	O
end	O
,	O
we	O
generated	O
lymphoblasts	B-cell_type
which	O
proliferate	O
in	O
response	O
to	O
common	B-protein
gamma-chain	I-protein
cytokines	B-protein
,	O
but	O
readily	O
undergo	O
apoptosis	O
after	O
cytokine	B-protein
withdrawal	O
.	O

in	O
experiments	O
with	O
the	O
cd00r0	B-cell_type
mab	I-cell_type
uchl-0	I-cell_type
,	O
but	O
not	O
control	O
cd00	B-protein
mabs	I-protein
,	O
we	O
found	O
significant	O
inhibition	O
of	O
proliferation	O
.	O

interestingly	O
,	O
the	O
pan-cd00	B-protein
mab	I-protein
gap0.0	B-protein
,	O
which	O
is	O
most	O
effective	O
in	O
inhibition	O
of	O
okt-0-mediated	O
proliferation	O
in	O
quiescent	B-cell_type
lymphocytes	I-cell_type
,	O
was	O
ineffective	O
in	O
lymphoblasts	B-cell_type
.	O

addition	O
of	O
cd0	B-protein
mab	I-protein
okt-0	B-protein
had	O
no	O
influence	O
on	O
il-0-mediated	O
proliferation	O
(	O
with	O
or	O
without	O
uchl-0	O
)	O
.	O

in	O
contrast	O
,	O
after	O
addition	O
of	O
okt-0	B-protein
to	O
il-0	B-protein
-	O
and	O
il-0	B-protein
-stimulated	O
proliferation	O
assays	O
,	O
uchl-0	O
signals	O
could	O
not	O
significantly	O
alter	O
cellular	O
proliferation	O
.	O

we	O
did	O
not	O
find	O
induction	O
of	O
apoptosis	O
following	O
cd00r0	O
signaling	O
.	O

in	O
western	O
blots	O
using	O
mabs	B-protein
detecting	O
phosphorylated	B-protein
stat-0	I-protein
,	O
stat-0	B-protein
,	O
stat-0	B-protein
,	O
or	O
extracellular	B-protein
signal-related	I-protein
kinase	I-protein
0/0	I-protein
,	O
we	O
found	O
that	O
cd00r0	O
signaling	O
could	O
effectively	O
diminish	O
phosphorylation	O
of	O
these	O
intracellular	O
signaling	O
components	O
.	O

using	O
rt-pcr	O
,	O
we	O
found	O
that	O
cd00r0	O
signaling	O
inhibited	O
il-0	B-RNA
mrna	I-RNA
production	O
without	O
major	O
influence	O
on	O
il-00	B-protein
,	O
il-0	B-protein
,	O
or	O
ifn-gamma	B-RNA
mrna	I-RNA
levels	O
.	O

costimulation	O
with	O
okt-0	B-protein
and	O
il-0	B-protein
optimally	O
induced	O
secretion	O
of	O
ifn-gamma	B-protein
,	O
tnf-alpha	B-protein
,	O
and	O
il-0	B-protein
,	O
which	O
was	O
not	O
decreased	O
by	O
cd00	B-protein
signals	O
.	O

in	O
conclusion	O
,	O
we	O
illustrate	O
that	O
cd00r0	O
signals	O
control	O
early	O
cytokine	B-protein
receptor-associated	O
signaling	O
processes	O
and	O
mrna	B-RNA
and	O
dna	O
synthesis	O
in	O
activated	B-cell_type
human	I-cell_type
lymphoblasts	I-cell_type
.	O

furthermore	O
,	O
we	O
show	O
the	O
existence	O
of	O
cd00	B-protein
epitopes	I-protein
(	O
gap0.0	B-protein
)	O
,	O
which	O
are	O
active	O
and	O
critical	O
for	O
signaling	O
in	O
quiescent	B-cell_type
lymphocytes	I-cell_type
,	O
but	O
are	O
nonfunctional	O
in	O
activated	B-cell_type
human	I-cell_type
lymphoblasts	I-cell_type
.	O

###MEDLINE:21240752

pax0	B-protein
determines	O
the	O
identity	O
of	O
b	B-cell_type
cells	I-cell_type
from	O
the	O
beginning	O
to	O
the	O
end	O
of	O
b-lymphopoiesis	O
.	O

despite	O
being	O
one	O
of	O
the	O
most	O
intensively	O
studied	O
cell	O
types	O
,	O
the	O
molecular	O
basis	O
of	O
b	B-cell_type
cell	I-cell_type
specification	O
is	O
largely	O
unknown	O
.	O

the	O
pax0	B-DNA
gene	I-DNA
encoding	O
the	O
transcription	B-protein
factor	I-protein
bsap	B-protein
is	O
required	O
for	O
progression	O
of	O
b-lymphopoiesis	O
beyond	O
the	O
pro-b	B-cell_type
cell	I-cell_type
stage	I-cell_type
.	O

pax0-deficient	B-cell_line
pro-b	I-cell_line
cells	I-cell_line
are	O
,	O
however	O
,	O
not	O
yet	O
committed	O
to	O
the	O
b-lymphoid	B-cell_type
lineage	I-cell_type
,	O
but	O
instead	O
have	O
a	O
broad	O
lymphomyeloid	O
developmental	O
potential	O
.	O

pax0	B-protein
appears	O
to	O
mediate	O
b-lineage	O
commitment	O
by	O
repressing	O
the	O
transcription	O
of	O
non-b-lymphoid	B-DNA
genes	I-DNA
and	O
by	O
simultaneously	O
activating	O
the	O
expression	O
of	O
b-lineage-specific	B-DNA
genes	I-DNA
.	O

pax0	B-protein
thus	O
functions	O
both	O
as	O
a	O
transcriptional	B-protein
repressor	I-protein
and	I-protein
activator	I-protein
,	O
depending	O
on	O
its	O
interactions	O
with	O
corepressors	O
of	O
the	O
groucho	B-protein
protein	I-protein
family	I-protein
or	O
with	O
positive	O
regulators	O
such	O
as	O
the	O
tata-binding	B-protein
protein	I-protein
.	O

once	O
committed	O
to	O
the	O
b-lineage	B-cell_type
,	I-cell_type
b	I-cell_type
cells	I-cell_type
require	O
pax0	B-protein
function	O
to	O
maintain	O
their	O
b-lymphoid	O
identity	O
throughout	O
b	B-cell_type
cell	I-cell_type
development	O

###MEDLINE:21295479

partners	O
in	O
transcription	O
:	O
nfat	B-protein
and	O
ap-0	B-protein
.	O

combinatorial	O
regulation	O
is	O
a	O
powerful	O
mechanism	O
that	O
enables	O
tight	O
control	O
of	O
gene	O
expression	O
,	O
via	O
integration	O
of	O
multiple	O
signaling	O
pathways	O
that	O
induce	O
different	O
transcription	B-protein
factors	I-protein
required	O
for	O
enhanceosome	O
assembly	O
.	O

the	O
four	O
calcium-regulated	B-protein
transcription	I-protein
factors	I-protein
of	O
the	O
nfat	B-protein
family	I-protein
act	O
synergistically	O
with	O
ap-0	B-protein
(	I-protein
fos/jun	I-protein
)	I-protein
proteins	I-protein
on	O
composite	B-DNA
dna	I-DNA
elements	I-DNA
which	O
contain	O
adjacent	O
nfat	B-protein
and	O
ap-0	B-DNA
binding	I-DNA
sites	I-DNA
,	O
where	O
they	O
form	O
highly	O
stable	O
ternary	B-protein
complexes	I-protein
to	O
regulate	O
the	O
expression	O
of	O
diverse	O
inducible	B-DNA
genes	I-DNA
.	O

concomitant	O
induction	O
of	O
nfat	B-protein
and	O
ap-0	B-protein
requires	O
concerted	O
activation	O
of	O
two	O
different	O
signaling	O
pathways	O
:	O
calcium/calcineurin	O
,	O
which	O
promotes	O
nfat	B-protein
dephosphorylation	O
,	O
nuclear	O
translocation	O
and	O
activation	O
;	O
and	O
protein	B-protein
kinase	I-protein
c	I-protein
(	O
pkc	B-protein
)	O
/ras	O
,	O
which	O
promotes	O
the	O
synthesis	O
,	O
phosphorylation	O
and	O
activation	O
of	O
members	O
of	O
the	O
fos	B-protein
and	I-protein
jun	I-protein
families	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O

a	O
fifth	O
member	O
of	O
the	O
nfat	B-protein
family	I-protein
,	O
nfat0	B-protein
,	O
controls	O
the	O
cellular	O
response	O
to	O
osmotic	O
stress	O
,	O
by	O
a	O
mechanism	O
that	O
requires	O
dimer	B-protein
formation	O
and	O
is	O
independent	O
of	O
calcineurin	B-protein
or	O
of	O
interaction	O
with	O
ap-0	B-protein
.	O

pharmacological	O
interference	O
with	O
thenfat	O
:	O
ap-0	B-protein
interaction	O
may	O
be	O
useful	O
in	O
selective	O
manipulation	O
of	O
the	O
immune	O
response	O
.	O

balanced	O
activation	O
of	O
nfat	B-protein
and	O
ap-0	B-protein
is	O
known	O
to	O
be	O
required	O
for	O
productive	O
immune	O
responses	O
,	O
but	O
the	O
role	O
of	O
nfat	B-protein
:	O
ap-0	B-protein
interactions	O
in	O
other	O
cell	O
types	O
and	O
biological	O
processes	O
remains	O
to	O
be	O
understood	O
.	O

###MEDLINE:21286716

cytokine	B-protein
production	O
by	O
vgamma	B-protein
(	I-protein
+	I-protein
)	I-protein
-t-cell	O
subsets	O
is	O
an	O
important	O
factor	O
determining	O
cd0	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
-th-cell	I-cell_type
phenotype	I-cell_type
and	O
susceptibility	O
of	O
balb/c	O
mice	O
to	O
coxsackievirus	O
b0-induced	O
myocarditis	O
.	O

two	O
coxsackievirus	B-DNA
b0	I-DNA
(	I-DNA
cvb0	I-DNA
)	I-DNA
variants	I-DNA
(	O
h0	B-cell_line
and	O
h000a0	B-protein
)	O
differ	O
by	O
a	O
single	O
amino	O
acid	O
mutation	O
in	O
the	O
vp0	B-protein
capsid	I-protein
protein	I-protein
.	O

h0	B-protein
induces	O
severe	O
myocarditis	O
in	O
balb/c	O
mice	O
,	O
but	O
h000a0	B-protein
is	O
amyocarditic	O
.	O

infection	O
with	O
h0	B-cell_line
,	O
but	O
not	O
h000a0	O
,	O
preferentially	O
activates	O
vgamma0	O
vdelta0	B-cell_line
cells	I-cell_line
,	O
which	O
are	O
strongly	O
positive	O
for	O
gamma	B-protein
interferon	I-protein
(	O
ifn-gamma	B-protein
)	O
,	O
whereas	O
vgamma0	B-cell_line
vdelta0	I-cell_line
cells	I-cell_line
are	O
increased	O
in	O
both	O
h0	O
and	O
h000a0	O
virus-infected	O
animals	O
.	O

depletion	O
of	O
vgamma0	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
using	O
monoclonal	B-protein
anti-vgamma0	I-protein
antibody	I-protein
enhanced	O
myocarditis	O
and	O
cd0	B-protein
(	O
+	O
)	O
-	O
,	O
ifn-gamma	B-protein
(	O
+	O
)	O
-cell	O
responses	O
in	O
both	O
h0-	O
and	O
h000a0-infected	O
mice	O
yet	O
decreased	O
the	O
cd0	B-protein
(	O
+	O
)	O
-	O
,	O
il-0	B-protein
(	O
+	O
)	O
-cell	O
response	O
.	O

depleting	O
vgamma0	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
suppressed	O
myocarditis	O
and	O
reduced	O
cd0	B-protein
(	O
+	O
)	O
ifn-gamma	B-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
cells	I-cell_line
but	O
increased	O
cd0	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
il-0	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
t	I-cell_type
cells	I-cell_type
.	O

the	O
role	O
of	O
cytokine	B-protein
production	O
by	O
vgamma0	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
and	I-cell_type
vgamma0	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
t	I-cell_type
cells	I-cell_type
was	O
investigated	O
by	O
adoptively	O
transferring	O
these	O
cells	O
isolated	O
from	O
h0-infected	O
balb/c	O
stat0	B-protein
knockout	O
(	O
stat0ko	B-protein
)	O
(	O
defective	O
in	O
ifn-gamma	B-protein
expression	O
)	O
or	O
balb/c	B-cell_line
stat0ko	I-cell_line
(	O
defective	O
in	O
il-0	B-protein
expression	O
)	O
mice	O
into	O
h0	B-protein
virus-infected	O
wild-type	O
balb/c	O
recipients	O
.	O

vgamma0	O
and	O
vgamma0	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
t	I-cell_type
cells	I-cell_type
from	O
stat0ko	O
mice	O
expressed	O
il-0	B-protein
but	O
no	O
or	O
minimal	O
ifn-gamma	B-protein
,	O
whereas	O
these	O
cell	O
populations	O
derived	O
from	O
stat0ko	O
mice	O
expressed	O
ifn-gamma	B-protein
but	O
no	O
il-0	B-protein
.	O

stat0ko	B-cell_line
vgamma0	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
cells	I-cell_line
(	O
il-0	B-protein
(	O
+	O
)	O
)	O
suppress	O
myocarditis	O
.	O

stat0ko	B-cell_line
vgamma0	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
cells	I-cell_line
(	O
ifn-gamma	B-protein
(	O
+	O
)	O
)	O
were	O
not	O
inhibitory	O
.	O

stat0ko	B-cell_line
vgamma0	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
cells	I-cell_line
(	O
ifn-gamma	B-protein
(	O
+	O
)	O
)	O
significantly	O
enhanced	O
myocarditis	O
.	O

stat0ko	B-cell_line
vgamma0	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
cells	I-cell_line
(	O
il-0	B-protein
(	O
+	O
)	O
)	O
neither	O
inhibited	O
nor	O
enhanced	O
disease	O
.	O

these	O
results	O
show	O
that	O
distinct	O
gammadelta-t-cell	O
subsets	O
control	O
myocarditis	O
susceptibility	O
and	O
bias	O
the	O
cd0	B-DNA
(	I-DNA
+	I-DNA
)	I-DNA
-th-cell	I-DNA
response	O
.	O

the	O
cytokines	B-protein
produced	O
by	O
the	O
vgamma	O
subpopulation	O
have	O
a	O
significant	O
influence	O
on	O
the	O
cd0	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
-th-cell	I-cell_type
phenotype	I-cell_type
.	O

###MEDLINE:21282637

plasmin	O
-induced	O
expression	O
of	O
cytokines	B-protein
and	O
tissue	B-protein
factor	I-protein
in	O
human	B-cell_type
monocytes	I-cell_type
involves	O
ap-0	B-protein
and	O
ikkbeta	B-protein
-mediated	O
nf-kappab	B-protein
activation	O
.	O

it	O
was	O
previously	O
shown	O
that	O
plasmin	B-protein
activates	O
human	B-cell_type
peripheral	I-cell_type
monocytes	I-cell_type
in	O
terms	O
of	O
lipid	O
mediator	O
release	O
and	O
chemotactic	O
migration	O
.	O

here	O
it	O
is	O
demonstrated	O
that	O
plasmin	B-protein
induces	O
proinflammatory	B-protein
cytokine	I-protein
release	O
and	O
tissue	B-protein
factor	I-protein
(	O
tf	B-protein
)	O
expression	O
by	O
monocytes	B-cell_type
.	O

plasmin	O
0.000	O
to	O
0.00	O
cta	O
u/ml	O
,	O
but	O
not	O
active	O
site-blocked	B-protein
plasmin	I-protein
,	O
triggered	O
concentration-dependent	O
expression	O
of	O
mrna	O
for	O
interleukin-0alpha	B-protein
(	O
il-0alpha	B-protein
)	O
,	O
il-0beta	B-protein
,	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
tnf-alpha	B-protein
)	O
,	O
and	O
tf	B-protein
with	O
maximum	O
responses	O
after	O
0	O
hours	O
.	O

plasmin	O
-mediated	O
mrna	O
expression	O
was	O
inhibited	O
in	O
a	O
concentration-dependent	O
manner	O
by	O
the	O
lysine	O
analogue	O
trans-0-	O
(	O
aminomethyl	O
)	O
cyclohexane-0-carboxylic	O
acid	O
(	O
t-amca	B-protein
)	O
.	O

increases	O
in	O
mrna	O
levels	O
were	O
followed	O
by	O
concentration-	O
and	O
time-dependent	O
release	O
of	O
il-0alpha	B-protein
,	O
il-0beta	B-protein
and	O
tnf-alpha	B-protein
and	O
by	O
tf	B-protein
expression	O
on	O
monocyte	O
surfaces	O
.	O

neither	O
cytokines	B-protein
nor	O
tf	B-protein
could	O
be	O
detected	O
when	O
monocytes	B-cell_type
were	O
preincubated	O
with	O
actinomycin	O
d	O
or	O
cycloheximide	O
.	O

electrophoretic	O
mobility	O
shift	O
assays	O
indicated	O
plasmin	O
-induced	O
activation	O
of	O
nf-kappab	B-protein
;	O
dna-binding	B-protein
complexes	I-protein
were	O
composed	O
of	O
p00	B-protein
,	O
p00	B-protein
,	O
and	O
c-rel	B-protein
,	O
as	O
shown	O
by	O
supershift	O
experiments	O
.	O

nuclear	O
translocation	O
of	O
nf-kappab/rel	B-protein
proteins	I-protein
coincided	O
with	O
ikappabalpha	B-protein
degradation	O
.	O

at	O
variance	O
with	O
endotoxic	O
lipopolysaccharide	O
,	O
plasmin	B-protein
elicited	O
the	O
rapid	O
degradation	O
of	O
another	O
cytoplasmic	B-protein
nf-kappab	I-protein
inhibitor	I-protein
,	O
p000	B-protein
.	O

proteolysis	O
of	O
nf-kappab	B-protein
inhibitors	O
was	O
apparently	O
due	O
to	O
transient	O
activation	O
of	O
ikappab	B-protein
kinase	I-protein
(	O
ikk	B-protein
)	I-protein
beta	I-protein
that	O
reached	O
maximum	O
activity	O
at	O
0	O
hour	O
after	O
plasmin	O
stimulation	O
.	O

in	O
addition	O
,	O
ap-0	B-protein
binding	O
was	O
increased	O
in	O
plasmin	B-cell_line
-treated	I-cell_line
monocytes	I-cell_line
,	O
with	O
most	O
complexes	O
composed	O
of	O
jund	B-protein
,	O
c-fos	B-DNA
,	O
and	O
fosb	B-protein
.	O

these	O
findings	O
further	O
substantiate	O
the	O
role	O
of	O
plasmin	O
as	O
a	O
proinflammatory	B-protein
activator	I-protein
of	O
human	B-cell_type
monocytes	I-cell_type
and	O
reveal	O
an	O
important	O
new	O
link	O
between	O
the	O
plasminogen-plasmin	O
system	O
and	O
inflammation	O
.	O

(	O
blood.	O
0000	O
;	O
00	O
:	O
0000-0000	O
)	O

###MEDLINE:21272376

stat0	B-protein
is	O
constitutively	O
active	O
in	O
some	O
patients	O
with	O
polycythemia	O
rubra	O
vera	O
.	O

objective	O
:	O
polycythemia	O
vera	O
is	O
a	O
clonal	O
stem	O
cell	O
disorder	O
characterized	O
by	O
hyperproliferation	O
of	O
the	O
erythroid	B-cell_type
,	I-cell_type
myeloid	I-cell_type
,	I-cell_type
and	I-cell_type
megakaryocytic	I-cell_type
lineages	I-cell_type
.	O

while	O
it	O
has	O
been	O
shown	O
that	O
progenitor	B-cell_type
cells	I-cell_type
of	O
p.	O
vera	O
patients	O
are	O
hypersensitive	O
to	O
several	O
growth	B-protein
factors	I-protein
including	O
erythropoietin	B-protein
,	O
insulin-like	B-protein
growth	I-protein
factor-0	I-protein
,	O
thrombopoietin	B-protein
,	O
interleukin-0	B-protein
,	O
and	O
granulocyte/monocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
,	O
the	O
molecular	O
pathogenesis	O
of	O
this	O
disease	O
remains	O
unknown	O
.	O

growth	B-protein
factor	I-protein
hypersensitivity	O
could	O
be	O
mediated	O
by	O
changes	O
in	O
signal	O
transduction	O
pathways	O
.	O

we	O
therefore	O
investigated	O
a	O
common	O
downstream	O
effector	O
of	O
cytokines	B-protein
,	O
the	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	O
transcription	O
(	O
stats	B-protein
)	O
.	O

a	O
constitutive	O
activation	O
of	O
stat	B-protein
factors	I-protein
could	O
explain	O
the	O
increased	O
proliferation	O
of	O
p.	O
vera	O
cells	O
even	O
in	O
the	O
absence	O
of	O
growth	B-protein
factor	I-protein
stimulation	O
.	O

methods	O
:	O
peripheral	B-cell_type
granulocytes	I-cell_type
from	O
patients	O
with	O
p.	O
vera	O
and	O
from	O
healthy	O
volunteers	O
were	O
assayed	O
for	O
stat0	B-protein
,	O
0	O
,	O
and	O
0	O
dna	O
binding	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

results	O
:	O
four	O
of	O
00	O
p.	O
vera	O
patients	O
analyzed	O
showed	O
constitutive	O
stat0	B-protein
dna	O
binding	O
in	O
unstimulated	B-cell_type
peripheral	I-cell_type
granulocytes	I-cell_type
,	O
while	O
none	O
of	O
the	O
00	O
healthy	O
volunteers	O
tested	O
did	O
.	O

none	O
of	O
the	O
subjects	O
showed	O
constitutive	O
stat0	B-protein
or	O
stat0	B-protein
activity	O
.	O

western	O
blotting	O
demonstrated	O
that	O
,	O
in	O
the	O
three	O
patients	O
,	O
stat0	B-protein
is	O
constitutively	O
phosphorylated	O
on	O
tyr	B-protein
000	I-protein
,	O
whereas	O
it	O
is	O
unphosphorylated	O
in	O
the	O
other	O
patients	O
and	O
in	O
controls	O
.	O

interestingly	O
,	O
constitutive	O
stat0	B-protein
activity	O
did	O
not	O
correlate	O
with	O
the	O
duration	O
of	O
disease	O
or	O
the	O
treatment	O
regimen	O
.	O

it	O
was	O
observed	O
in	O
a	O
recently	O
diagnosed	O
patient	O
and	O
in	O
two	O
patients	O
treated	O
only	O
with	O
phlebotomy	O
.	O

conclusion	O
:	O
our	O
data	O
suggest	O
that	O
constitutive	O
phosphorylation	O
and	O
activation	O
of	O
stat0	B-protein
is	O
not	O
a	O
secondary	O
event	O
induced	O
by	O
mutagenizing	O
agents	O
or	O
by	O
prolonged	O
hyperproliferation	O
of	O
hematopoietic	B-cell_type
cells	I-cell_type
,	O
but	O
rather	O
represents	O
a	O
primary	O
molecular	O
aberration	O
.	O

constitutively	O
active	O
stat0	B-protein
may	O
contribute	O
to	O
the	O
growth	B-protein
factor	I-protein
hypersensitivity	O
of	O
p.	O
vera	O
cells	O
.	O

###MEDLINE:21359415

identification	O
of	O
phosphorylation	O
sites	O
for	O
bruton	B-protein
's	I-protein
tyrosine	I-protein
kinase	I-protein
within	O
the	O
transcriptional	O
regulator	O
bap/tfii-i	O
.	O

bruton	B-protein
's	I-protein
tyrosine	I-protein
kinase	I-protein
(	O
btk	B-protein
)	O
,	O
a	O
member	O
of	O
the	O
tec	B-cell_type
family	O
of	O
cytosolic	B-protein
kinases	I-protein
,	O
is	O
essential	O
for	O
b	B-cell_type
cell	I-cell_type
development	O
and	O
function	O
.	O

bap/tfii-i	O
,	O
a	O
protein	O
implicated	O
in	O
transcriptional	O
regulation	O
,	O
is	O
associated	O
with	O
btk	B-protein
in	O
b	B-cell_type
cells	I-cell_type
and	O
is	O
transiently	O
phosphorylated	O
on	O
tyrosine	O
following	O
b	B-protein
cell	I-protein
receptor	I-protein
engagement	O
.	O

bap/tfii-i	B-protein
is	O
a	O
substrate	O
for	O
btk	B-protein
in	O
vitro	O
and	O
is	O
hyperphosphorylated	O
on	O
tyrosine	O
upon	O
coexpression	O
with	O
btk	B-protein
in	O
mammalian	B-cell_type
cells	I-cell_type
.	O

in	O
an	O
effort	O
to	O
understand	O
the	O
physiologic	O
consequences	O
of	O
bap/tfii-i	O
tyrosine	O
phosphorylation	O
following	O
b	B-protein
cell	I-protein
receptor	I-protein
stimulation	O
,	O
site-directed	O
mutagenesis	O
and	O
phosphopeptide	O
mapping	O
were	O
used	O
to	O
locate	O
the	O
predominant	O
sites	O
of	O
bap/tfii-i	O
phosphorylation	O
by	O
btk	B-protein
in	O
vitro	O
.	O

these	O
residues	O
,	O
tyr000	O
,	O
tyr000	O
,	O
and	O
tyr000	O
,	O
were	O
also	O
found	O
to	O
be	O
the	O
major	B-DNA
sites	I-DNA
for	O
btk	B-protein
-dependent	O
phosphorylation	O
of	O
bap/tfii-i	O
in	O
vivo	O
.	O

residues	O
tyr000	O
and	O
tyr000	O
are	O
contained	O
within	O
the	O
loop	O
regions	O
of	O
adjacent	B-DNA
helix-loop-helix-like	I-DNA
repeats	I-DNA
within	O
bap/tfii-i	O
.	O

mutation	O
of	O
either	O
tyr000	O
,	O
tyr000	O
,	O
or	O
tyr000	O
to	O
phenylalanine	O
reduced	O
transcription	O
from	O
a	O
c-fos	B-DNA
promoter	I-DNA
relative	O
to	O
wild-type	O
bap/tfii-i	O
in	O
transfected	O
cos-0	B-cell_line
cells	I-cell_line
,	O
consistent	O
with	O
the	O
interpretation	O
that	O
phosphorylation	O
at	O
these	O
sites	O
contributes	O
to	O
transcriptional	O
activation	O
.	O

phosphorylation	O
of	O
bap/tfii-i	O
by	O
btk	B-protein
may	O
link	O
engagement	O
of	O
receptors	B-protein
such	O
as	O
surface	B-protein
immunoglobulin	I-protein
to	O
modulation	O
of	O
gene	O
expression	O
.	O

###MEDLINE:21261560

expression	O
of	O
interferon	B-protein
consensus	I-protein
sequence	I-protein
binding	I-protein
protein	I-protein
induces	O
potent	O
immunity	O
against	O
bcr/abl-induced	O
leukemia	O
.	O

mice	O
deficient	O
in	O
the	O
interferon	B-protein
consensus	I-protein
sequence	I-protein
binding	I-protein
protein	I-protein
(	O
icsbp	B-protein
)	O
develop	O
a	O
disease	O
resembling	O
chronic	O
myeloid	O
leukemia	O
(	O
cml	O
)	O
,	O
which	O
in	O
humans	O
is	O
caused	O
by	O
the	O
bcr/abl	O
oncoprotein	B-protein
.	O

interferon-alpha	B-protein
(	O
ifn-alpha	B-protein
)	O
induces	O
icsbp	B-protein
expression	O
and	O
is	O
an	O
effective	O
therapy	O
for	O
cml	O
.	O

this	O
study	O
examined	O
whether	O
enforced	O
expression	O
of	O
icsbp	B-protein
might	O
antagonize	O
bcr/abl-induced	O
leukemia	O
;	O
results	O
demonstrated	O
that	O
icsbp-modified	B-cell_line
cells	I-cell_line
generated	O
a	O
protective	O
cd0	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cytotoxic	I-cell_type
t-cell	I-cell_type
response	O
against	O
bcr/abl-transformed	B-cell_line
baf0	I-cell_line
cells	I-cell_line
in	O
a	O
murine	B-cell_line
leukemia	I-cell_line
model	I-cell_line
.	O

icsbp	B-protein
expression	O
represents	O
a	O
novel	O
means	O
of	O
stimulating	O
a	O
host	B-DNA
immune	I-DNA
response	I-DNA
to	I-DNA
bcr/abl	I-DNA
(	O
+	O
)	O
leukemia	B-cell_type
cells	I-cell_type
and	O
a	O
potential	O
strategy	O
for	O
immunotherapy	O
of	O
cml	O
.	O

(	O
blood.	O
0000	O
;	O
00	O
:	O
0000-0000	O
)	O

###MEDLINE:21259876

a	O
transcriptional	O
block	O
in	O
the	O
il-0	B-DNA
promoter	I-DNA
at	O
the	O
-000	B-DNA
ap-0	I-DNA
site	I-DNA
in	O
effector	B-cell_type
cd0+	I-cell_type
t	I-cell_type
cells	I-cell_type
.	O

both	O
cd0+	B-cell_type
and	I-cell_type
cd0+	I-cell_type
t	I-cell_type
cells	I-cell_type
that	O
produce	O
il-0	B-protein
in	O
response	O
to	O
ag	B-protein
recognition	O
have	O
been	O
isolated	O
.	O

however	O
,	O
most	O
effector	B-cell_type
cd0+	I-cell_type
t	I-cell_type
cells	I-cell_type
recovered	O
after	O
exposure	O
to	O
ag	B-protein
do	O
not	O
produce	O
sufficient	O
il-0	B-protein
to	O
sustain	O
growth	O
,	O
and	O
depend	O
on	O
cd0+	B-cell_type
t	I-cell_type
helper	I-cell_type
cells	I-cell_type
for	O
this	O
obligate	O
growth	B-protein
factor	I-protein
.	O

il-0	B-protein
expression	O
in	O
cd0+	B-cell_type
t	I-cell_type
cells	I-cell_type
is	O
primarily	O
controlled	O
at	O
the	O
level	O
of	O
transcription	O
,	O
but	O
mechanisms	O
restricting	O
il-0	B-protein
production	O
in	O
cd0+	B-cell_type
t	I-cell_type
cells	I-cell_type
have	O
not	O
been	O
elucidated	O
.	O

to	O
evaluate	O
transcriptional	O
regulation	O
of	O
the	O
il-0	B-DNA
gene	I-DNA
in	O
cd0+	B-cell_type
t	I-cell_type
cells	I-cell_type
,	O
we	O
stably	O
transfected	O
reporter	B-DNA
genes	I-DNA
into	O
ag	B-protein
-specific	O
cd0+	B-cell_line
t	I-cell_line
cell	I-cell_line
clones	I-cell_line
.	O

cd00+	B-cell_type
cd0	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
t	I-cell_type
cells	I-cell_type
unable	O
to	O
transcribe	O
the	O
il-0	B-DNA
gene	I-DNA
in	O
response	O
to	O
antigenic	O
stimulation	O
had	O
a	O
block	O
in	O
transactivation	O
of	O
the	O
-000	B-DNA
cd00	I-DNA
response	I-DNA
element	I-DNA
(	O
cd00re	B-DNA
)	O
/ap-0	B-protein
site	O
of	O
the	O
il-0	B-DNA
promoter	I-DNA
,	O
but	O
did	O
transactivate	O
the	O
composite	B-DNA
nfat/ap-0	I-DNA
and	I-DNA
oct/ap-0	I-DNA
sites	I-DNA
,	O
and	O
a	O
consensus	B-DNA
ap-0	I-DNA
motif	I-DNA
.	O

mutation	O
of	O
the	O
nonconsensus	B-DNA
-000	I-DNA
ap-0	I-DNA
site	I-DNA
to	O
a	O
consensus	B-DNA
ap-0	I-DNA
site	I-DNA
,	O
or	O
insertion	O
of	O
a	O
cd00re/ap-0	B-DNA
consensus	I-DNA
site	I-DNA
upstream	I-DNA
of	O
the	O
native	B-DNA
-000	I-DNA
cd00re/ap-0	I-DNA
site	I-DNA
restored	O
transactivation	O
of	O
the	O
altered	O
promoter	O
.	O

these	O
results	O
suggest	O
that	O
the	O
defect	O
at	O
the	O
-000	B-DNA
site	I-DNA
may	O
reflect	O
the	O
absence	O
or	O
inactivity	O
of	O
a	O
required	O
factor	O
rather	O
than	O
repression	O
of	O
the	O
il-0	B-DNA
promoter	I-DNA
.	O

###MEDLINE:21250679

stem	B-protein
cell	I-protein
factor	I-protein
and	O
interleukin-0	B-protein
induce	O
stepwise	O
generation	O
of	O
erythroid	B-cell_type
precursor	I-cell_type
cells	I-cell_type
from	O
a	O
basic	B-protein
fibroblast	I-protein
growth	I-protein
factor	I-protein
-dependent	O
hematopoietic	B-cell_line
stem	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
a-0	B-protein
.	O

a	O
m	B-cell_line
ultipotent	I-cell_line
immature	I-cell_line
myeloid	I-cell_line
cell	I-cell_line
population	I-cell_line
was	O
produced	O
from	O
a	O
basic	B-protein
fibroblast	I-protein
growth	I-protein
factor	I-protein
(	O
bfgf	O
)	O
-dependent	O
hematopoietic	B-cell_line
stem	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
a-0	B-protein
,	O
when	O
cultured	O
with	O
stem	B-protein
cell	I-protein
factor	I-protein
(	O
scf	B-protein
)	O
replacing	O
bfgf	O
.	O

those	O
cells	O
were	O
positive	O
for	O
stem	B-protein
cell	I-protein
markers	I-protein
,	O
c-kit	B-protein
and	O
cd00	B-protein
,	O
and	O
a	O
myeloid	O
cell	O
marker	O
,	O
f0/00	O
.	O

some	O
cell	O
fractions	O
were	O
also	O
positive	O
for	O
mac-0	B-protein
,	O
a	O
macrophage	O
marker	O
or	O
gr-0	B-protein
,	O
a	O
granulocytic	O
maker	O
,	O
but	O
negative	O
for	O
an	O
erythroid	O
marker	O
ter000	O
.	O

they	O
also	O
showed	O
the	O
expression	O
of	O
mrna	O
for	O
the	O
myeloid-specific	O
pu.0	B-protein
but	O
did	O
not	O
that	O
for	O
the	O
erythroid-specific	O
gata-0	B-protein
.	O

among	O
various	O
cytokines	B-protein
,	O
interleukin-0	B-protein
(	O
il-0	B-protein
)	O
induced	O
erythroid	B-cell_type
precursor	I-cell_type
cells	I-cell_type
that	O
expressed	O
the	O
erythroid-specific	O
gata-0	B-protein
and	O
beta-major	B-protein
globin	I-protein
.	O

the	O
quantitative	O
analysis	O
showed	O
that	O
erythroid	B-cell_type
precursor	I-cell_type
cells	I-cell_type
were	O
newly	O
produced	O
from	O
the	O
immature	B-cell_type
myeloid	I-cell_type
cells	I-cell_type
by	O
cultivation	O
with	O
il-0	B-protein
.	O

scf	B-protein
and	O
il-0	B-protein
induced	O
stepwise	O
generation	O
of	O
erythroid	B-cell_type
precursor	I-cell_type
cells	I-cell_type
from	O
an	O
a-0	O
hematopoietic	B-cell_line
stem	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

copyright	O
0000	O
academic	O
press	O
.	O

###MEDLINE:21240651

distinct	O
bmi-0	O
and	O
ezh0	O
expression	O
patterns	O
in	O
thymocytes	B-cell_type
and	O
mature	B-cell_type
t	I-cell_type
cells	I-cell_type
suggest	O
a	O
role	O
for	O
polycomb	B-DNA
genes	I-DNA
in	O
human	B-cell_type
t	I-cell_type
cell	I-cell_type
differentiation	O
.	O

bmi-0	B-protein
and	I-protein
ezh0	I-protein
polycomb-group	I-protein
(	I-protein
pcg	I-protein
)	I-protein
proteins	I-protein
belong	O
to	O
two	O
distinct	O
protein	B-protein
complexes	I-protein
involved	O
in	O
the	O
regulation	O
of	O
hematopoiesis	O
.	O

using	O
unique	O
pcg-specific	O
antisera	O
and	O
triple	O
immunofluorescence	O
,	O
we	O
found	O
that	O
mature	B-cell_type
resting	I-cell_type
peripheral	I-cell_type
t	I-cell_type
cells	I-cell_type
expressed	O
bmi-0	O
,	O
whereas	O
dividing	B-cell_type
blasts	I-cell_type
were	O
ezh0	B-protein
(	I-protein
+	I-protein
)	I-protein
.	O

by	O
contrast	O
,	O
subcapsular	B-cell_type
immature	I-cell_type
double-negative	I-cell_type
(	I-cell_type
dn	I-cell_type
)	I-cell_type
(	O
cd0	B-protein
(	O
-	O
)	O
/cd0	B-protein
(	O
-	O
)	O
)	O
t	B-cell_type
cells	I-cell_type
in	O
the	O
thymus	O
coexpressed	O
bmi-0	O
and	O
ezh0	B-protein
or	O
were	O
bmi-0	O
single	O
positive	O
.	O

their	O
descendants	O
,	O
double-positive	O
(	O
dp	B-DNA
;	O
cd0	B-protein
(	I-protein
+	I-protein
)	I-protein
/cd0	I-protein
(	O
+	O
)	O
)	O
cortical	B-cell_type
thymocytes	I-cell_type
,	O
expressed	O
ezh0	O
without	O
bmi-0	O
.	O

most	O
ezh0	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
dn	I-cell_type
and	I-cell_type
dp	I-cell_type
thymocytes	I-cell_type
were	O
dividing	O
,	O
while	O
dn	O
bmi-0	O
(	O
+	O
)	O
/ezh0	O
(	O
-	O
)	O
thymocytes	B-cell_type
were	O
resting	O
and	O
proliferation	O
was	O
occasionally	O
noted	O
in	O
dn	O
bmi-0	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
/ezh0	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
.	O

maturation	O
of	O
dp	B-DNA
cortical	O
thymocytes	B-cell_type
to	O
single-positive	B-cell_type
(	O
cd0	B-protein
(	I-protein
+	I-protein
)	I-protein
/cd0	I-protein
(	O
-	O
)	O
or	O
cd0	B-protein
(	I-protein
+	I-protein
)	I-protein
/cd0	I-protein
(	O
-	O
)	O
)	O
medullar	B-cell_type
thymocytes	I-cell_type
correlated	O
with	O
decreased	O
detectability	O
of	O
ezh0	B-protein
and	O
continued	O
relative	O
absence	O
of	O
bmi-0	O
.	O

our	O
data	O
show	O
that	O
bmi-0	B-protein
and	O
ezh0	O
expression	O
in	O
mature	B-cell_type
peripheral	I-cell_type
t	I-cell_type
cells	I-cell_type
is	O
mutually	O
exclusive	O
and	O
linked	O
to	O
proliferation	O
status	O
,	O
and	O
that	O
this	O
pattern	O
is	O
not	O
yet	O
established	O
in	O
thymocytes	B-cell_type
of	O
the	O
cortex	O
and	O
medulla	O
.	O

t	B-protein
cell	I-protein
stage-specific	I-protein
pcg	I-protein
expression	O
profiles	O
suggest	O
that	O
pcg	B-DNA
genes	I-DNA
contribute	O
to	O
regulation	O
of	O
t	B-cell_type
cell	I-cell_type
differentiation	O
.	O

they	O
probably	O
reflect	O
stabilization	O
of	O
cell	B-DNA
type-specific	I-DNA
gene	I-DNA
expression	O
and	O
irreversibility	O
of	O
lineage	O
choice	O
.	O

the	O
difference	O
in	O
pcg	B-protein
expression	O
between	O
medullar	B-cell_type
thymocytes	I-cell_type
and	O
mature	O
interfollicular	B-cell_type
t	I-cell_type
cells	I-cell_type
indicates	O
that	O
additional	O
maturation	O
processes	O
occur	O
after	O
thymocyte	O
transportation	O
from	O
the	O
thymus	O
.	O

###MEDLINE:21240749

stepwise	O
lineage	O
restriction	O
of	O
progenitors	O
in	O
lympho-myelopoiesis	O
.	O

it	O
has	O
long	O
been	O
controversial	O
whether	O
hematopoiesis	O
progresses	O
through	O
ordered	O
stages	O
of	O
determination	O
as	O
in	O
embryonic	O
development	O
.	O

this	O
is	O
due	O
to	O
the	O
absence	O
of	O
a	O
methodology	O
capable	O
of	O
exactly	O
determining	O
the	O
developmental	O
potential	O
of	O
hematopoietic	B-cell_type
stem/progenitor	I-cell_type
cells	I-cell_type
.	O

the	O
multilineage	B-cell_type
progenitor	I-cell_type
(	O
mlp	B-protein
)	O
assay	O
enabled	O
us	O
to	O
discriminate	O
among	O
seven	O
types	O
of	O
hematopoietic	B-cell_type
progenitors	I-cell_type
,	O
which	O
are	O
multipotent	O
progenitor	O
p-mtb	O
(	O
capable	O
of	O
generating	O
myeloid	B-cell_type
,	I-cell_type
t	I-cell_type
and	I-cell_type
b	I-cell_type
cells	I-cell_type
)	O
,	O
bipotent	B-cell_type
progenitors	I-cell_type
p-mt	O
,	O
p-mb	B-protein
and	O
p-tb	B-protein
,	O
and	O
unipotent	B-cell_line
progenitors	I-cell_line
p-m	I-cell_line
,	I-cell_line
p-t	I-cell_line
and	I-cell_line
p-b	I-cell_line
.	O

among	O
these	O
seven	O
types	O
,	O
the	O
p-tb	O
type	O
progenitor	O
was	O
found	O
to	O
be	O
absent	O
.	O

these	O
findings	O
indicate	O
that	O
the	O
process	O
of	O
lineage	O
commitment	O
proceeds	O
through	O
an	O
ordered	O
but	O
not	O
random	O
process	O
.	O

by	O
extending	O
the	O
area	O
of	O
investigation	O
to	O
include	O
the	O
erythroid	B-cell_type
lineage	I-cell_type
,	O
more	O
convincing	O
evidence	O
for	O
the	O
ordered	O
process	O
was	O
obtained	O
.	O

detailed	O
and	O
exact	O
illustration	O
of	O
the	O
process	O
of	O
hematopoiesis	O
will	O
provide	O
an	O
opportunity	O
to	O
revive	O
hematopoiesis	O
as	O
one	O
of	O
the	O
most	O
fascinating	O
targets	O
of	O
research	O
in	O
developmental	O
biology	O

###MEDLINE:21226883

epstein-barr	O
virus	O
and	O
its	O
glycoprotein-000	O
upregulate	O
il-0	B-protein
in	O
human	B-cell_type
b-lymphocytes	I-cell_type
via	O
cd00	B-protein
,	O
involving	O
activation	O
of	O
nf-kappab	B-protein
and	O
different	O
signaling	O
pathways	O
.	O

epstein-barr	O
virus	O
(	O
ebv	O
)	O
is	O
a	O
ubiquitous	O
and	O
highly	O
immunotropic	O
gamma	O
herpesvirus	O
that	O
infects	O
more	O
than	O
00	O
%	O
of	O
humans	O
worldwide	O
.	O

its	O
pathogenicity	O
leads	O
to	O
a	O
number	O
of	O
diseases	O
including	O
tumors	O
that	O
result	O
from	O
ebv	O
's	O
ability	O
to	O
readily	O
transform	O
b-lymphocytes	B-cell_type
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
epithelial	B-cell_type
cells	I-cell_type
.	O

ebv	O
utilizes	O
cd00/cr0	O
as	O
its	O
receptor	O
on	O
b	B-cell_type
cells	I-cell_type
to	O
initiate	O
the	O
infection	O
process	O
.	O

ebv	O
binds	O
to	O
cr0	B-protein
through	O
its	O
major	B-protein
envelope	I-protein
glycoprotein-000	I-protein
(	O
gp000	B-protein
)	O
and	O
is	O
also	O
a	O
remarkable	O
immunomodulating	O
agent	O
.	O

we	O
had	O
previously	O
shown	O
that	O
ebv	O
is	O
capable	O
of	O
modulating	O
the	O
synthesis	O
of	O
a	O
number	O
of	O
cytokines	B-protein
.	O

we	O
now	O
show	O
that	O
while	O
both	O
purified	B-protein
recombinant	I-protein
gp000	I-protein
(	O
rgp000	B-protein
)	O
and	O
ebv	O
upregulate	O
il-0	B-RNA
mrna	I-RNA
synthesis	O
in	O
b	B-cell_type
cells	I-cell_type
,	O
ebv-induced	O
il-0	B-DNA
gene	I-DNA
activation	O
occurs	O
for	O
a	O
significantly	O
longer	O
period	O
of	O
time	O
(	O
i.e.	O
00	O
hours	O
for	O
ebv	O
as	O
compared	O
to	O
0	O
hours	O
for	O
rgp000	B-protein
)	O
.	O

moreover	O
,	O
the	O
half-life	O
of	O
ebv-induced	O
il-0	B-RNA
mrna	I-RNA
was	O
also	O
significantly	O
longer	O
(	O
00	O
hours	O
)	O
than	O
that	O
of	O
mrna	O
induced	O
by	O
rgp000	B-protein
(	O
about	O
0	O
hours	O
)	O
.	O

both	O
ebv	O
and	O
gp000	B-protein
enhance	O
the	O
binding	O
of	O
the	O
nf-kappab	B-protein
transcription	I-protein
factor	I-protein
,	O
as	O
determined	O
by	O
band-shift	O
and	O
augment	O
nf-kappab	B-protein
-mediated	O
activation	O
of	O
a	O
cat	B-DNA
reporter	I-DNA
plasmid	I-DNA
.	O

furthermore	O
,	O
we	O
demonstrate	O
that	O
while	O
the	O
activation	O
of	O
il-0	B-DNA
gene	I-DNA
expression	O
by	O
gp000	B-protein
is	O
mediated	O
primarily	O
by	O
the	O
protein	B-protein
kinase	I-protein
c	I-protein
pathway	O
,	O
ebv	O
can	O
mediate	O
its	O
effects	O
through	O
multiple	O
signaling	O
pathways	O
.	O

to	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
report	O
showing	O
that	O
the	O
binding	O
of	O
a	O
herpesvirus	B-protein
envelope	I-protein
glycoprotein	I-protein
to	O
cr0	B-protein
on	O
human	B-cell_type
b	I-cell_type
cells	I-cell_type
results	O
in	O
the	O
activation	O
of	O
the	O
nf-kappab	B-protein
transcription	I-protein
factor	I-protein
leading	O
to	O
the	O
upregulation	O
of	O
il-0	B-DNA
gene	I-DNA
expression	O
in	O
these	O
lymphocytes	B-cell_type
.	O

copyright	O
0000	O
academic	O
press	O
.	O

###MEDLINE:21216559

gene-	B-protein
and	O
tissue-specificity	O
of	O
mutation	O
in	O
big	O
blue	O
rats	O
treated	O
with	O
the	O
hepatocarcinogen	O
n-hydroxy-0-acetylaminofluorene	O
.	O

in	O
a	O
previous	O
study	O
,	O
we	O
found	O
that	O
treating	O
transgenic	O
big	O
blue	O
rats	O
with	O
the	O
hepatocarcinogen	B-DNA
n-hydroxy-0-acetylaminofluorene	O
(	O
n-oh-aaf	B-protein
)	O
produced	O
the	O
same	O
major	O
dna	O
adduct	O
in	O
the	O
target	O
liver	O
and	O
the	O
nontarget	B-cell_type
spleen	I-cell_type
lymphocytes	I-cell_type
and	O
bone	B-cell_type
marrow	I-cell_type
cells	I-cell_type
,	O
induced	O
laci	B-DNA
mutants	I-DNA
in	O
the	O
liver	O
,	O
and	O
induced	O
much	O
lower	O
frequencies	O
of	O
l	O
aci	O
and	O
hprt	B-DNA
mutants	I-DNA
in	O
spleen	B-cell_type
lymphocytes	I-cell_type
.	O

in	O
the	O
present	O
study	O
,	O
sequence	O
analysis	O
was	O
conducted	O
on	O
laci	B-DNA
dna	I-DNA
and	I-DNA
hprt	I-DNA
cdna	I-DNA
from	O
the	O
mutants	O
,	O
to	O
determine	O
the	O
mutational	O
specificity	O
of	O
n-oh-aaf	O
in	O
the	O
rat	O
.	O

all	O
the	O
mutation	O
spectra	O
from	O
n-oh-aaf-treated	O
rats	O
differed	O
significantly	O
from	O
corresponding	O
mutation	O
profiles	O
from	O
untreated	O
animals	O
(	O
p	O
=	O
0.00	O
to	O
p	O
<	O
0.0000	O
)	O
.	O

although	O
there	O
were	O
similarities	O
among	O
the	O
mutational	O
patterns	O
derived	O
from	O
n-oh-aaf-treated	O
rats	O
(	O
e.g.	O
,	O
g	B-protein
:	I-protein
c	I-protein
--	O
>	O
t	O
:	O
a	O
transversion	O
was	O
the	O
most	O
common	O
mutation	O
in	O
all	O
mutation	O
sets	O
)	O
,	O
there	O
were	O
significant	O
differences	O
in	O
the	O
patterns	O
of	O
basepair	O
substitution	O
and	O
frameshift	O
mutation	O
between	O
the	O
liver	O
and	O
spleen	O
lymphocyte	O
laci	B-DNA
mutants	I-DNA
(	O
p	O
=	O
0.00	O
)	O
and	O
between	O
the	O
spleen	O
lymphocyte	O
laci	B-DNA
and	I-DNA
hprt	I-DNA
mutants	I-DNA
(	O
p	O
=	O
0.00	O
)	O
.	O

also	O
,	O
multiplex	O
pcr	O
analysis	O
of	O
genomic	O
dna	O
from	O
the	O
hprt	B-DNA
mutants	I-DNA
indicated	O
that	O
00	O
%	O
of	O
mutants	O
from	O
treated	O
rats	O
had	O
major	O
deletions	O
in	O
the	O
hprt	B-DNA
gene	I-DNA
;	O
no	O
corresponding	O
incidence	O
of	O
large	O
deletions	O
was	O
evident	O
among	O
laci	B-DNA
mutations	I-DNA
.	O

all	O
the	O
mutation	O
profiles	O
reflect	O
the	O
general	O
mutational	O
specificity	O
of	O
the	O
major	B-protein
dna	I-protein
adduct	I-protein
formed	O
by	O
n-oh-aaf	O
.	O

the	O
differences	O
between	O
n-oh-aaf	O
mutation	O
in	O
the	O
endogenous	B-DNA
gene	I-DNA
and	I-DNA
transgene	I-DNA
can	O
be	O
partially	O
explained	O
by	O
the	O
structures	O
of	O
the	O
two	O
genes	O
.	O

the	O
tissue-specificity	O
of	O
the	O
mutation	O
spectra	O
may	O
contribute	O
to	O
targeting	O
tumor	O
formation	O
to	O
the	O
liver	O
.	O

environ.	O
mol.	O
mutagen.	O
00	O
:	O
000-000	O
,	O
0000	O
.	O

published	O
0000	O
wiley-liss	O
,	O
inc	O
.	O

###MEDLINE:21214521

caspase	B-protein
-dependent	O
cleavage	O
of	O
the	O
hematopoietic	B-protein
specific	I-protein
adaptor	I-protein
protein	I-protein
gads	I-protein
alters	O
signalling	O
from	O
the	O
t	B-protein
cell	I-protein
receptor	I-protein
.	O

gads	B-protein
is	O
a	O
sh0	B-protein
and	I-protein
sh0	I-protein
domain	I-protein
-containing	O
,	O
hematopoietic-specific	B-protein
adaptor	I-protein
protein	I-protein
that	O
functions	O
in	O
signalling	O
from	O
the	O
t	B-protein
cell	I-protein
receptor	I-protein
.	O

gads	B-protein
acts	O
by	O
linking	O
slp-00	B-protein
,	O
bound	O
by	O
the	O
carboxy-terminal	B-protein
gads	I-protein
sh0	I-protein
domain	I-protein
,	O
to	O
tyrosine	O
phosphorylated	O
lat	B-protein
which	O
contains	O
binding	B-DNA
sites	I-DNA
for	O
the	O
gads	B-protein
sh0	I-protein
domain	I-protein
.	O

gads	B-protein
is	O
distinguished	O
from	O
grb0	B-protein
and	O
the	O
closely	O
related	O
grap	B-protein
protein	I-protein
by	O
the	O
presence	O
of	O
a	O
000	O
amino	O
acid	O
unique	O
region	O
between	O
the	O
sh0	B-protein
domain	I-protein
and	O
the	O
carboxy	B-protein
terminal	I-protein
sh0	I-protein
domain	I-protein
.	O

here	O
we	O
demonstrate	O
that	O
the	O
unique	O
region	O
of	O
gads	B-protein
contains	O
a	O
capase	O
cleavage	O
site	O
.	O

induction	O
of	O
apoptosis	O
in	O
lymphocytes	B-cell_type
results	O
in	O
detectable	O
gads	O
cleavage	O
by	O
00	O
min	O
.	O

gads	O
cleavage	O
is	O
blocked	O
in	O
vivo	O
by	O
treating	O
cells	O
with	O
a	O
caspase	B-protein
0	I-protein
inhibitor	I-protein
.	O

a	O
putative	B-protein
caspase	I-protein
0	I-protein
cleavage	I-protein
site	I-protein
was	O
identified	O
within	O
the	O
unique	O
region	O
and	O
mutation	O
of	O
this	O
site	O
prevented	O
gads	O
cleavage	O
in	O
vitro	O
,	O
and	O
in	O
vivo	O
.	O

the	O
gads	B-protein
cleavage	I-protein
products	I-protein
retained	O
the	O
predicted	O
binding	O
specificity	O
for	O
slp-00	B-protein
and	O
lat	B-protein
.	O

expression	O
of	O
the	O
gads	B-protein
cleavage	I-protein
products	I-protein
in	O
jurkat	B-cell_line
t	I-cell_line
cells	I-cell_line
inhibited	O
nfat	B-protein
activation	O
following	O
tcr	B-DNA
cross	I-DNA
linking	O
.	O

these	O
findings	O
indicate	O
that	O
cleavage	O
of	O
gads	O
in	O
vivo	O
could	O
function	O
to	O
alter	O
signalling	O
downstream	O
of	O
the	O
t	B-protein
cell	I-protein
receptor	I-protein
by	O
disrupting	O
cross	O
talk	O
between	O
slp-00	B-protein
and	O
lat	B-protein
.	O

###MEDLINE:21347868

targeting	O
of	O
p000	B-protein
to	O
the	O
interleukin-0	B-DNA
promoter	I-DNA
via	O
creb-rel	O
cross-talk	O
during	O
mitogen	B-protein
and	O
oncogenic	O
molecular	O
signaling	O
in	O
activated	B-cell_type
t-cells	I-cell_type
.	O

in	O
this	O
report	O
,	O
we	O
explore	O
the	O
mechanisms	O
of	O
targeting	O
of	O
p000	B-protein
to	O
the	O
interleukin-0	B-DNA
(	I-DNA
il-0	I-DNA
)	I-DNA
promoter	I-DNA
in	O
response	O
to	O
mitogenic	O
and	O
oncogenic	O
molecular	O
signals	O
.	O

recruitment	O
of	O
p000	B-protein
by	O
camp-responsive	B-protein
element-binding	I-protein
protein-rel	I-protein
cross-talk	O
at	O
the	O
composite	B-DNA
cd00	I-DNA
response	I-DNA
element	I-DNA
(	O
cd00re	B-DNA
)	O
-	O
tre	B-DNA
element	O
of	O
the	O
il-0	B-DNA
promoter	I-DNA
is	O
essential	O
for	O
promoter	O
inducibility	O
during	O
t-cell	O
activation	O
,	O
and	O
cd00re-tre	B-protein
is	O
the	O
exclusive	O
target	O
of	O
the	O
human	B-protein
t-cell	I-protein
lymphotropic	I-protein
virus	I-protein
type	I-protein
i	I-protein
oncoprotein	I-protein
tax	B-protein
.	O

the	O
intrinsic	O
histone	B-protein
acetyltransferase	I-protein
activity	O
of	O
p000	B-protein
is	O
dispensable	O
for	O
activation	O
of	O
the	O
il-0	B-DNA
promoter	I-DNA
,	O
and	O
the	O
n-terminal	B-protein
000	I-protein
residues	I-protein
contain	O
the	O
minimal	O
structural	O
requirements	O
for	O
synergistic	O
transactivation	O
of	O
the	O
cd00re-tre	O
,	O
the	O
il-0	B-DNA
promoter	I-DNA
,	O
and	O
endogenous	O
il-0	B-DNA
gene	I-DNA
expression	O
.	O

mutational	O
analysis	O
of	O
p000	B-protein
reveals	O
differential	O
structural	O
requirements	O
for	O
the	O
n-terminal	B-protein
p000	I-protein
module	I-protein
by	O
individual	O
cis-elements	B-DNA
within	O
the	O
il-0	B-DNA
promoter	I-DNA
.	O

these	O
findings	O
provide	O
evidence	O
that	O
p000	B-protein
assembles	O
at	O
the	O
il-0	B-DNA
promoter	I-DNA
to	O
form	O
an	O
enhanceosome-like	O
signal	O
transduction	O
target	O
that	O
is	O
centrally	O
integrated	O
at	O
the	O
cd00re-tre	B-DNA
element	I-DNA
of	O
the	O
il-0	B-DNA
promoter	I-DNA
through	O
specific	O
protein	O
module-targeted	O
associations	O
in	O
activated	B-cell_type
t-cells	I-cell_type
.	O

###MEDLINE:21203274

regulation	O
of	O
cytokine	B-protein
production	O
in	O
t-cell	O
responses	O
to	O
inhalant	O
allergen	O
:	O
gata-0	B-protein
expression	O
distinguishes	O
between	O
th0-	O
and	O
th0-polarized	O
immunity	O
.	O

background	O
:	O
the	O
precise	O
nature	O
of	O
allergen-specific	O
cytokine	O
responses	O
in	O
atopics	O
versus	O
non-atopics	B-protein
,	O
in	O
particular	O
the	O
'th0	B-DNA
polarity	I-DNA
'	I-DNA
of	O
responses	O
in	O
non-atopics	B-protein
,	O
remains	O
controversial	O
.	O

this	O
is	O
due	O
in	O
part	O
to	O
the	O
relative	O
insensitivity	O
of	O
cytokine	B-protein
detection	O
systems	O
,	O
and	O
associated	O
variations	O
in	O
kinetics	O
of	O
cytokine	B-protein
production	O
and	O
catabolism	O
in	O
in	O
vitro	O
culture	O
systems	O
.	O

as	O
an	O
alternative	O
to	O
cytokine	B-protein
measurement	O
,	O
this	O
study	O
focuses	O
on	O
expression	O
of	O
the	O
transcription	B-protein
factor	I-protein
gata-0	I-protein
for	O
analysis	O
of	O
allergen-specific	B-cell_line
th	I-cell_line
cell	I-cell_line
responses	O
.	O

methods	O
:	O
cord	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
were	O
th0-	O
or	O
th0-polarized	O
by	O
culture	O
in	O
il-00-	O
or	O
il-0-employing	O
established	O
methods	O
;	O
pbmc	B-cell_type
from	O
house	O
dust	O
mite	O
(	O
hdm	O
)	O
-sensitive	O
atopics	O
and	O
controls	O
were	O
stimulated	O
overnight	O
with	O
hdm	O
;	O
cytokine	B-protein
production	O
was	O
measured	O
by	O
elisa	O
and	O
gata-0	B-RNA
mrna	I-RNA
expression	O
by	O
pcr	O
.	O

results	O
:	O
cytokine	B-protein
-driven	O
th0	O
polarization	O
of	O
naive	B-cell_type
t	I-cell_type
cells	I-cell_type
is	O
associated	O
with	O
marked	O
upregulation	O
of	O
gata-0	B-protein
expression	O
,	O
whereas	O
a	O
reciprocal	O
expression	O
pattern	O
accompanies	O
differentiation	O
towards	O
the	O
th0	B-protein
cytokine	I-protein
phenotype	O
.	O

in	O
t	B-cell_type
cells	I-cell_type
from	O
hdm	B-cell_line
skin	I-cell_line
prick	I-cell_line
test-positive	I-cell_line
(	O
hdm-spt+/hdm-ige+	B-protein
)	O
volunteers	O
,	O
overnight	O
stimulation	O
results	O
in	O
marked	O
upregulation	O
of	O
gata-0	B-protein
expression	O
,	O
compared	O
to	O
an	O
equally	O
marked	O
downregulation	O
of	O
expression	O
in	O
t	B-cell_type
cells	I-cell_type
from	O
spt-/ige-	O
subjects	O
.	O

in	O
subjects	O
who	O
are	O
hdm-spt+	O
but	O
ige-	B-protein
,	O
gata-0	B-protein
expression	O
levels	O
remained	O
relatively	O
stable	O
during	O
culture	O
with	O
hdm	O
.	O

conclusions	O
:	O
upregulation	O
of	O
gata-0	B-protein
expression	O
in	O
pbmc	B-cell_type
is	O
a	O
hallmark	O
of	O
the	O
early	O
phase	O
of	O
th0	O
recall	O
responses	O
to	O
specific	O
allergen	O
in	O
atopics	O
.	O

the	O
reciprocal	O
expression	O
pattern	O
observed	O
in	O
hdm-specific	O
recall	O
responses	O
of	O
non-atopics	B-protein
provides	O
independent	O
confirmation	O
of	O
the	O
presence	O
of	O
underlying	O
th0-like	O
immunity	O
in	O
these	O
subjects	O
.	O

the	O
parallel	O
findings	O
in	O
neonatal	B-cell_type
t	I-cell_type
cells	I-cell_type
suggest	O
that	O
the	O
same	O
approach	O
may	O
be	O
utilized	O
for	O
monitoring	O
the	O
progress	O
of	O
allergen-specific	O
th0/th0	O
memory	O
development	O
during	O
early	O
childhood	O
,	O
and	O
hence	O
in	O
assessment	O
of	O
risk	O
for	O
future	O
allergic	O
disease	O
.	O

copyright	O
0000	O
s.	B-protein
karger	I-protein
ag	I-protein
,	O
basel	O

###MEDLINE:21210813

the	O
heat	O
shock	O
response	O
reduces	O
myelin	O
oligodendrocyte	B-protein
glycoprotein	I-protein
-induced	O
experimental	O
autoimmune	O
encephalomyelitis	O
in	O
mice	O
.	O

the	O
stress	O
response	O
(	O
sr	B-protein
)	O
can	O
block	O
inflammatory	O
gene	O
expression	O
by	O
preventing	O
activation	O
of	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor-kappa	I-protein
b	I-protein
(	O
nf-kappab	B-protein
)	O
.	O

as	O
inflammatory	O
gene	O
expression	O
contributes	O
to	O
the	O
pathogenesis	O
of	O
demyelinating	O
diseases	O
,	O
we	O
tested	O
the	O
effects	O
of	O
the	O
sr	O
on	O
the	O
progression	O
of	O
the	O
demyelinating	O
disease	O
experimental	O
autoimmune	O
encephalomyelitis	O
(	O
eae	O
)	O
.	O

eae	O
was	O
actively	O
induced	O
in	O
c00bl/0	O
mice	O
using	O
an	O
encephalitogenic	B-protein
myelin	I-protein
oligodendrocyte	I-protein
glycoprotein	I-protein
(	O
mog	B-protein
(	O
00-00	O
)	O
)	O
peptide	O
.	O

whole	O
body	O
hyperthermia	O
was	O
used	O
to	O
induce	O
a	O
heat	B-DNA
shock	I-DNA
response	I-DNA
(	I-DNA
hsr	I-DNA
)	O
in	O
immunized	O
mice	O
0	O
days	O
after	O
the	O
booster	B-protein
mog	I-protein
(	O
00-00	O
)	O
peptide	O
injection	O
.	O

the	O
hsr	B-DNA
reduced	O
the	O
incidence	O
of	O
eae	O
by	O
00	O
%	O
,	O
delayed	O
disease	O
onset	O
by	O
0	O
days	O
,	O
and	O
attenuated	O
disease	O
severity	O
.	O

the	O
hsr	B-DNA
attenuated	O
leukocyte	O
infiltration	O
into	O
cns	O
assessed	O
by	O
quantitation	O
of	O
perivascular	B-cell_type
infiltrates	I-cell_type
,	O
and	O
by	O
reduced	O
staining	O
for	O
cd0	B-cell_type
and	I-cell_type
cd00	I-cell_type
immunopositive	I-cell_type
t-cells	I-cell_type
.	O

t-cell	O
activation	O
,	O
assessed	O
by	O
the	O
production	O
of	O
interferon	B-protein
gamma	I-protein
(	O
ifngamma	B-protein
)	O
in	O
response	O
to	O
mog	B-protein
(	O
00-00	O
)	O
,	O
was	O
also	O
decreased	O
by	O
the	O
hsr	B-DNA
.	O

the	O
hsr	B-DNA
reduced	O
inflammatory	O
gene	O
expression	O
in	O
the	O
brain	O
that	O
normally	O
occurs	O
during	O
eae	O
,	O
including	O
the	O
early	O
increase	O
in	O
rantes	B-protein
(	O
regulated	O
on	O
activation	O
of	O
normal	O
t-cell	B-protein
expressed	I-protein
and	I-protein
secreted	I-protein
)	O
expression	O
,	O
and	O
the	O
later	O
expression	O
of	O
the	O
inducible	O
form	O
of	O
nitric	B-protein
oxide	I-protein
synthase	I-protein
.	O

the	O
early	O
activation	O
of	O
transcription	B-protein
factor	I-protein
nf-kappab	B-protein
was	O
also	O
blocked	O
by	O
the	O
hsr	O
.	O

the	O
finding	O
that	O
the	O
sr	O
reduces	O
inflammation	O
in	O
the	O
brain	O
and	O
the	O
clinical	O
severity	O
of	O
eae	O
opens	O
a	O
novel	O
therapeutic	O
approach	O
for	O
prevention	O
of	O
autoimmune	O
diseases	O
.	O

###MEDLINE:21188582

in	O
vivo	O
detection	O
of	O
intracellular	O
signaling	O
pathways	O
in	O
developing	B-cell_type
thymocytes	I-cell_type
.	O

information	O
regarding	O
the	O
intracellular	O
signaling	O
processes	O
that	O
occur	O
during	O
the	O
development	O
of	O
t	B-cell_type
cells	I-cell_type
has	O
largely	O
been	O
obtained	O
with	O
the	O
use	O
of	O
transgenic	O
mouse	O
models	O
,	O
which	O
although	O
providing	O
invaluable	O
information	O
are	O
time	O
consuming	O
and	O
costly	O
.	O

to	O
this	O
end	O
,	O
we	O
have	O
developed	O
a	O
novel	O
system	O
that	O
facilitates	O
the	O
in	O
vivo	O
analysis	O
of	O
signal	O
transduction	O
pathways	O
during	O
t-lymphocyte	O
development	O
.	O

this	O
approach	O
uses	O
reporter-plasmids	O
for	O
the	O
detection	O
of	O
intracellular	O
signals	O
mediated	O
by	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
or	O
cyclic	B-protein
amp-dependent	I-protein
protein	I-protein
kinase	I-protein
.	O

reporter-plasmids	O
are	O
transfected	O
into	O
thymocytes	B-cell_type
in	O
fetal	B-cell_line
thymic	I-cell_line
organ	I-cell_line
culture	I-cell_line
by	O
accelerated	O
dna/particle	B-DNA
bombardment	I-DNA
(	I-DNA
gene	I-DNA
gun	B-DNA
)	O
,	O
and	O
the	O
activation	O
of	O
a	O
signaling	O
pathway	O
is	O
determined	O
in	O
the	O
form	O
of	O
a	O
standard	O
luciferase	O
assay	O
.	O

importantly	O
,	O
this	O
powerful	O
technique	O
preserves	O
the	O
structural	O
integrity	O
of	O
the	O
thymus	O
,	O
and	O
will	O
provide	O
an	O
invaluable	O
tool	O
to	O
study	O
how	O
thymocytes	B-cell_type
respond	O
to	O
normal	O
environmental	O
stimuli	O
encountered	O
during	O
differentiation	O
within	O
the	O
thymic	O
milieu	O
.	O

thus	O
,	O
this	O
method	O
allows	O
for	O
the	O
monitoring	O
of	O
signals	O
that	O
occur	O
in	O
a	O
biological	O
time	O
frame	O
,	O
such	O
as	O
during	O
differentiation	O
,	O
and	O
within	O
the	O
natural	O
environment	O
of	O
differentiating	B-cell_type
cells	I-cell_type
.	O

###MEDLINE:21185796

core-binding	B-protein
factor	I-protein
beta	I-protein
(	O
cbfbeta	B-protein
)	O
,	O
but	O
not	O
cbfbeta-smooth	B-protein
muscle	I-protein
myosin	I-protein
heavy	I-protein
chain	I-protein
,	O
rescues	O
definitive	O
hematopoiesis	O
in	O
cbfbeta	O
-deficient	O
embryonic	B-cell_type
stem	I-cell_type
cells	I-cell_type
.	O

core-binding	B-protein
factor	I-protein
beta	I-protein
(	O
cbfbeta	B-protein
)	O
is	O
the	O
non-dna-binding	B-protein
subunit	I-protein
of	O
the	O
heterodimeric	B-protein
cbfs	I-protein
.	O

genes	O
encoding	O
cbfbeta	O
(	O
cbfb	B-protein
)	O
,	O
and	O
one	O
of	O
the	O
dna-binding	B-protein
cbfalpha	I-protein
subunits	I-protein
,	O
runx0	O
(	O
also	O
known	O
as	O
cbfalpha0	B-protein
,	O
aml0	B-protein
,	O
and	O
pebp0alphab	B-protein
)	O
,	O
are	O
required	O
for	O
normal	O
hematopoiesis	O
and	O
are	O
also	O
frequent	O
targets	O
of	O
chromosomal	O
translocations	O
in	O
acute	O
leukemias	O
in	O
humans	O
.	O

homozygous	O
disruption	O
of	O
either	O
the	O
runx0	B-DNA
or	I-DNA
cbfb	I-DNA
gene	I-DNA
in	O
mice	O
results	O
in	O
embryonic	O
lethality	O
at	O
midgestation	O
due	O
to	O
hemorrhaging	O
in	O
the	O
central	O
nervous	O
system	O
,	O
and	O
severely	O
impairs	O
fetal	O
liver	O
hematopoiesis	O
.	O

results	O
of	O
this	O
study	O
show	O
that	O
cbfb-deficient	B-cell_line
mouse	I-cell_line
embryonic	I-cell_line
stem	I-cell_line
(	I-cell_line
es	I-cell_line
)	I-cell_line
cells	I-cell_line
can	O
differentiate	O
into	O
primitive	B-cell_type
erythroid	I-cell_type
colonies	I-cell_type
in	O
vitro	O
,	O
but	O
are	O
impaired	O
in	O
their	O
ability	O
to	O
produce	O
definitive	O
erythroid	B-cell_line
and	I-cell_line
myeloid	I-cell_line
colonies	I-cell_line
,	O
mimicking	O
the	O
in	O
vivo	O
defect	O
.	O

definitive	O
hematopoiesis	O
is	O
restored	O
by	O
ectopic	O
expression	O
of	O
full-length	B-DNA
cbfb	I-DNA
transgenes	I-DNA
,	O
as	O
well	O
as	O
by	O
a	O
transgene	O
encoding	O
only	O
the	O
heterodimerization	B-protein
domain	I-protein
of	O
cbfbeta	O
.	O

in	O
contrast	O
,	O
the	O
cbfbeta	O
-	O
smooth	B-protein
muscle	I-protein
myosin	I-protein
heavy	I-protein
chain	I-protein
(	O
smmhc	B-protein
)	I-protein
fusion	I-protein
protein	I-protein
generated	O
by	O
the	O
inv	O
(	O
00	O
)	O
associated	O
with	O
acute	B-cell_type
myeloid	I-cell_type
leukemias	I-cell_type
(	O
m0eo	O
)	O
can	O
not	O
rescue	O
definitive	O
hematopoiesis	O
by	O
cbfb-deficient	B-cell_line
es	I-cell_line
cells	I-cell_line
.	O

sequences	O
responsible	O
for	O
the	O
inability	O
of	O
cbfbeta	O
-smmhc	O
to	O
rescue	O
definitive	O
hematopoiesis	O
reside	O
in	O
the	O
smmhc	B-protein
portion	I-protein
of	O
the	O
fusion	B-protein
protein	I-protein
.	O

results	O
also	O
show	O
that	O
the	O
cbfbeta-smmhc	B-protein
fusion	I-protein
protein	I-protein
transdominantly	I-protein
inhibits	O
definitive	O
hematopoiesis	O
,	O
but	O
not	O
to	O
the	O
same	O
extent	O
as	O
homozygous	O
loss	O
of	O
runx0	B-cell_line
or	I-cell_line
cbfb	I-cell_line
.	O

cbfbeta-smmhc	O
preferentially	O
inhibits	O
the	O
differentiation	O
of	O
myeloid	B-cell_type
lineage	I-cell_type
cells	I-cell_type
,	O
while	O
increasing	O
the	O
number	O
of	O
blastlike	B-cell_type
cells	I-cell_type
in	O
culture	O
.	O

###MEDLINE:21184079

the	O
latency	O
pattern	O
of	O
epstein-barr	O
virus	O
infection	O
and	O
viral	O
il-00	B-protein
expression	O
in	O
cutaneous	O
natural	B-cell_type
killer/t-cell	I-cell_type
lymphomas	I-cell_type
.	O

the	O
nasal	O
type	O
,	O
extranodal	B-cell_type
natural	I-cell_type
killer	I-cell_type
or	O
t	O
(	O
nk/t	B-cell_type
)	I-cell_type
-cell	I-cell_type
lymphoma	I-cell_type
is	O
usually	O
associated	O
with	O
latent	O
epstein-barr	O
virus	O
(	O
ebv	O
)	O
infection	O
.	O

in	O
order	O
to	O
elucidate	O
the	O
ebv	B-DNA
gene	I-DNA
expression	O
patterns	O
in	O
vivo	O
,	O
we	O
examined	O
eight	O
patients	O
with	O
cutaneous	O
ebv-related	B-cell_type
nk/t-cell	I-cell_type
lymphomas	I-cell_type
,	O
including	O
six	O
patients	O
with	O
a	O
nk-cell	O
phenotype	O
and	O
two	O
patients	O
with	O
a	O
t-cell	O
phenotype	O
.	O

the	O
implication	O
of	O
ebv	O
in	O
the	O
skin	O
lesions	O
was	O
determined	O
by	O
the	O
presence	O
of	O
ebv-dna	O
,	O
ebv-encoded	B-protein
nuclear	I-protein
rna	I-protein
(	I-protein
eber	I-protein
)	I-protein
and	O
a	O
clonality	O
of	O
ebv-dna	B-DNA
fragments	I-DNA
containing	O
the	O
terminal	O
repeats	O
.	O

transcripts	O
of	O
ebv-encoded	B-RNA
genes	I-RNA
were	O
screened	O
by	O
reverse	B-protein
transcription-	I-protein
polymerase	I-protein
chain	I-protein
reaction	O
(	O
rt-pcr	O
)	O
,	O
and	O
confirmed	O
by	O
southern	O
blot	O
hybridization	O
.	O

the	O
expression	O
of	O
ebv-related	B-protein
antigens	I-protein
was	O
examined	O
by	O
immunostaining	O
using	O
paraffin-embedded	O
tissue	O
sections	O
and	O
cell	O
pellets	O
of	O
ebv-positive	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

our	O
study	O
demonstrated	O
that	O
all	O
samples	O
from	O
the	O
patients	O
contained	O
ebv	B-protein
nuclear	I-protein
antigen	I-protein
(	O
ebna	B-protein
)	O
-0	O
mrna	O
which	O
was	O
transcribed	O
using	O
the	O
q	B-DNA
promoter	I-DNA
,	O
whereas	O
both	O
the	O
q	B-DNA
promoter	I-DNA
and	O
another	O
upstream	B-DNA
promoter	I-DNA
(	O
cp/wp	B-protein
)	O
were	O
used	O
in	O
ebv-positive	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
b00.0	O
,	O
raji	B-cell_line
and	O
jiyoye	O
.	O

latent	B-protein
membrane	I-protein
protein-0	I-protein
(	O
lmp-0	B-protein
)	O
mrna	O
was	O
detected	O
in	O
seven	O
of	O
eight	O
patients	O
and	O
all	O
cell	B-cell_line
lines	I-cell_line
,	O
whereas	O
ebna-0	B-RNA
transcripts	I-RNA
were	O
found	O
only	O
in	O
the	O
cell	B-cell_line
lines	I-cell_line
.	O

immunostaining	O
showed	O
no	O
lmp-0	B-protein
,	O
ebna-0	B-protein
or	O
zebra	B-protein
antigens	I-protein
in	O
the	O
paraffin-embedded	O
tissue	O
sections	O
,	O
although	O
they	O
were	O
positive	O
in	O
the	O
cell	B-cell_line
line	I-cell_line
cells	I-cell_line
.	O

latent	O
bhrf0	B-protein
transcripts	O
encoding	O
bcl-0	B-protein
homologue	I-protein
and	O
bcrf0	B-RNA
transcripts	I-RNA
encoding	O
viral	B-DNA
interleukin	I-DNA
(	I-DNA
vil	I-DNA
)	I-DNA
-00	I-DNA
were	O
detected	O
in	O
one	O
and	O
two	O
of	O
eight	O
patients	O
,	O
respectively	O
.	O

a	O
patient	O
with	O
nk-cell	O
lymphoma	O
expressing	O
both	O
transcripts	O
died	O
of	O
rapid	O
progression	O
of	O
the	O
illness	O
.	O

our	O
results	O
indicate	O
that	O
the	O
restricted	O
expression	O
of	O
the	O
latency-associated	B-DNA
ebv	I-DNA
genes	I-DNA
and	O
the	O
production	O
of	O
vil-00	B-protein
and	O
bcl-0	B-protein
homologue	I-protein
may	O
favour	O
tumour	O
growth	O
,	O
evading	O
the	O
host	O
immune	O
surveillance	O
.	O

copyright	O
0000	O
cancer	O
research	O
campaign	O
.	O

###MEDLINE:21238271

oxidized	B-protein
alkyl	I-protein
phospholipids	O
are	O
specific	O
,	O
high	O
affinity	O
peroxisome	B-protein
proliferator-activated	I-protein
receptor	I-protein
gamma	I-protein
ligands	I-protein
and	O
agonists	O
.	O

synthetic	O
high	O
affinity	O
peroxisome	B-protein
proliferator-activated	I-protein
receptor	I-protein
(	O
ppar	B-protein
)	O
agonists	O
are	O
known	O
,	O
but	O
biologic	O
ligands	O
are	O
of	O
low	O
affinity	O
.	O

oxidized	B-protein
low	I-protein
density	I-protein
lipoprotein	I-protein
(	O
oxldl	B-protein
)	O
is	O
inflammatory	O
and	O
signals	O
through	O
ppars	B-protein
.	O

we	O
showed	O
,	O
by	O
phospholipase	B-protein
a	I-protein
(	O
0	O
)	O
digestion	O
,	O
that	O
ppargamma	B-protein
agonists	O
in	O
oxldl	B-protein
arise	O
from	O
the	O
small	O
pool	O
of	O
alkyl	O
phosphatidylcholines	O
in	O
ldl	B-protein
.	O

we	O
identified	O
an	O
abundant	O
oxidatively	O
fragmented	O
alkyl	O
phospholipid	O
in	O
oxldl	B-protein
,	O
hexadecyl	B-protein
azelaoyl	I-protein
phosphatidylcholine	I-protein
(	O
azpc	B-protein
)	O
,	O
as	O
a	O
high	O
affinity	O
ligand	O
and	O
agonist	O
for	O
ppargamma	B-protein
.	O

[	O
(	O
0	O
)	O
h	O
]	O
azpc	O
bound	O
recombinant	B-protein
ppargamma	I-protein
with	O
an	O
affinity	O
(	O
k	B-protein
(	I-protein
d	I-protein
)	I-protein
(	I-protein
(	I-protein
app	I-protein
)	O
)	O
approximately	O
00	O
nm	O
)	O
that	O
was	O
equivalent	O
to	O
rosiglitazone	O
(	O
brl00000	O
)	O
,	O
and	O
competition	O
with	O
rosiglitazone	O
showed	O
that	O
binding	O
occurred	O
in	O
the	O
ligand-binding	O
pocket	O
.	O

azpc	O
induced	O
ppre	B-DNA
reporter	I-DNA
gene	I-DNA
expression	O
,	O
as	O
did	O
rosiglitazone	O
,	O
with	O
a	O
half-maximal	O
effect	O
at	O
000	O
nm	O
.	O

overexpression	O
of	O
pparalpha	B-protein
or	O
ppargamma	B-protein
revealed	O
that	O
azpc	B-protein
was	O
a	O
specific	O
ppargamma	B-protein
agonist	O
.	O

the	O
scavenger	O
receptor	O
cd00	B-protein
is	O
encoded	O
by	O
a	O
ppre-responsive	B-DNA
gene	I-DNA
,	O
and	O
azpc	O
enhanced	O
expression	O
of	O
cd00	B-protein
in	O
primary	B-cell_type
human	I-cell_type
monocytes	I-cell_type
.	O

we	O
found	O
that	O
anti-cd00	B-protein
inhibited	O
azpc	O
uptake	O
,	O
and	O
it	O
inhibited	O
ppre	O
reporter	O
induction	O
.	O

results	O
with	O
a	O
small	B-protein
molecule	I-protein
phospholipid	O
flippase	O
mimetic	O
suggest	O
azpc	O
acts	O
intracellularly	O
and	O
that	O
cellular	O
azpc	O
accumulation	O
was	O
efficient	O
.	O

thus	O
,	O
certain	O
alkyl	O
phospholipid	O
oxidation	O
products	O
in	O
oxldl	B-protein
are	O
specific	O
,	O
high	O
affinity	O
extracellular	O
ligands	O
and	O
agonists	O
for	O
ppargamma	B-protein
that	O
induce	O
ppar-responsive	O
genes	O

###MEDLINE:21326158

regulation	O
of	O
the	O
human	B-DNA
mat0b	I-DNA
gene	I-DNA
encoding	O
the	O
regulatory	B-protein
beta	I-protein
subunit	I-protein
of	O
methionine	B-DNA
adenosyltransferase	I-DNA
,	I-DNA
mat	I-DNA
ii	I-DNA
.	O

methionine	O
adenosyltransferase	O
(	O
mat	B-protein
)	O
catalyzes	O
the	O
biosynthesis	O
of	O
s-adenosylmethionine	O
(	O
adomet	O
)	O
,	O
a	O
key	O
molecule	O
in	O
transmethylation	O
reactions	O
and	O
polyamine	O
biosynthesis	O
.	O

the	O
mat	B-protein
ii	I-protein
isozyme	I-protein
consists	O
of	O
a	O
catalytic	B-protein
alpha0	I-protein
and	O
a	O
regulatory	B-protein
beta	I-protein
subunit	I-protein
.	O

down-regulation	O
of	O
the	O
mat	B-protein
ii	I-protein
beta	I-protein
subunit	I-protein
expression	O
causes	O
a	O
0-00-fold	O
increase	O
in	O
intracellular	O
adomet	O
levels	O
.	O

to	O
understand	O
the	O
mechanism	O
by	O
which	O
the	O
beta	B-protein
subunit	I-protein
expression	O
is	O
regulated	O
,	O
we	O
cloned	O
the	O
mat0b	B-DNA
gene	I-DNA
,	O
determined	O
its	O
organization	O
,	O
characterized	O
its	O
0'-flanking	B-DNA
sequences	I-DNA
,	O
and	O
elucidated	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
regulation	O
of	O
its	O
promoter	O
.	O

transcription	O
of	O
the	O
mat0b	B-DNA
gene	I-DNA
initiates	O
at	O
position	B-DNA
-000	I-DNA
relative	O
to	O
the	O
translation	B-DNA
start	I-DNA
site	I-DNA
.	O

promoter	O
deletion	O
analysis	O
defined	O
a	O
minimal	B-DNA
promoter	I-DNA
between	O
positions	B-DNA
+00	I-DNA
and	I-DNA
+00	I-DNA
base	I-DNA
pairs	I-DNA
,	O
a	O
gc-rich	B-DNA
region	I-DNA
.	O

inclusion	O
of	O
the	O
sequences	O
between	O
-0	O
and	O
+00	O
enhanced	O
promoter	O
activity	O
;	O
this	O
was	O
primarily	O
because	O
of	O
an	O
sp0	B-DNA
recognition	I-DNA
site	I-DNA
at	O
+0/+00	O
.	O

the	O
inclusion	O
of	O
sequences	O
up	O
to	O
position	B-DNA
-000	I-DNA
provided	O
full	O
activity	O
;	O
this	O
was	O
attributed	O
to	O
a	O
tata	B-DNA
at	I-DNA
-00	I-DNA
.	O

the	O
sp0	B-DNA
site	I-DNA
at	O
position	B-DNA
+0	I-DNA
was	O
key	O
for	O
the	O
formation	O
of	O
protein.dna	B-protein
complexes	I-protein
.	O

mutation	O
of	O
both	O
the	O
sp0	B-DNA
site	I-DNA
at	O
+0	O
and	O
the	O
tata	B-DNA
at	I-DNA
-00	I-DNA
reduced	O
promoter	O
activity	O
to	O
its	O
minimal	O
level	O
.	O

supershift	O
assays	O
showed	O
no	O
effect	O
of	O
the	O
anti-sp0	B-protein
antibody	I-protein
on	O
complex	O
formation	O
,	O
whereas	O
the	O
anti-sp0	B-protein
antibody	I-protein
had	O
a	O
strong	O
effect	O
on	O
protein.dna	B-protein
complex	I-protein
formation	O
,	O
suggesting	O
that	O
sp0	B-protein
is	O
one	O
of	O
the	O
main	O
factors	O
binding	O
to	O
this	O
sp0	B-DNA
site	I-DNA
.	O

chromatin	O
immunoprecipitation	O
assays	O
supported	O
the	O
involvement	O
of	O
both	O
sp0	B-protein
and	O
sp0	B-protein
in	O
complexes	O
formed	O
on	O
the	O
mat0b	B-DNA
promoter	I-DNA
.	O

the	O
data	O
show	O
that	O
the	O
0'-untranslated	B-DNA
sequences	I-DNA
play	O
an	O
important	O
role	O
in	O
regulating	O
the	O
mat0b	B-DNA
gene	I-DNA
and	O
identifies	O
the	O
sp0	B-DNA
site	I-DNA
at	O
+0	O
as	O
a	O
potential	O
target	O
for	O
modulating	O
mat0b	O
expression	O
,	O
a	O
process	O
that	O
can	O
have	O
a	O
major	O
effect	O
on	O
intracellular	O
adomet	O
levels	O
.	O

###MEDLINE:21225972

molecular	O
pathogenesis	O
of	O
influenza	O
a	O
virus	O
infection	O
and	O
virus-induced	O
regulation	O
of	O
cytokine	B-DNA
gene	I-DNA
expression	O
.	O

despite	O
vaccines	O
and	O
antiviral	O
substances	O
influenza	O
still	O
causes	O
significant	O
morbidity	O
and	O
mortality	O
world	O
wide	O
.	O

better	O
understanding	O
of	O
the	O
molecular	O
mechanisms	O
of	O
influenza	O
virus	O
replication	O
,	O
pathogenesis	O
and	O
host	O
immune	O
responses	O
is	O
required	O
for	O
the	O
development	O
of	O
more	O
efficient	O
means	O
of	O
prevention	O
and	O
treatment	O
of	O
influenza	O
.	O

influenza	O
a	O
virus	O
,	O
which	O
replicates	O
in	O
epithelial	B-cell_type
cells	I-cell_type
and	O
leukocytes	B-cell_type
,	O
regulates	O
host	O
cell	O
transcriptional	O
and	O
translational	O
systems	O
and	O
activates	O
,	O
as	O
well	O
as	O
downregulates	O
apoptotic	O
pathways	O
.	O

influenza	O
a	O
virus	O
infection	O
results	O
in	O
the	O
production	O
of	O
chemotactic	O
(	O
rantes	B-protein
,	O
mip-0	B-protein
alpha	I-protein
,	O
mcp-0	B-protein
,	O
mcp-0	B-protein
,	O
and	O
ip-00	B-protein
)	O
,	O
pro-inflammatory	B-protein
(	I-protein
il-0	I-protein
beta	I-protein
,	O
il-0	B-protein
,	O
il-00	B-protein
,	O
and	O
tnf-alpha	B-protein
)	O
,	O
and	O
antiviral	B-protein
(	I-protein
ifn-alpha/beta	I-protein
)	I-protein
cytokines	I-protein
.	O

cytokine	B-DNA
gene	I-DNA
expression	O
is	O
associated	O
with	O
the	O
activation	O
of	O
nf-kappa	B-protein
b	I-protein
,	O
ap-0	B-protein
,	O
stat	B-protein
and	I-protein
irf	I-protein
signal	I-protein
transducing	I-protein
molecules	I-protein
in	O
influenza	B-cell_type
a	I-cell_type
virus-infected	I-cell_type
cells	I-cell_type
.	O

in	O
addition	O
of	O
upregulating	O
cytokine	B-DNA
gene	I-DNA
expression	O
,	O
influenza	O
a	O
virus	O
infection	O
activates	O
caspase-0	B-protein
enzyme	I-protein
,	O
which	O
is	O
involved	O
in	O
the	O
proteolytic	O
processing	O
of	O
proil-0	B-protein
beta	I-protein
and	O
proil-00	O
into	O
their	O
biologically	O
active	O
forms	O
.	O

influenza	O
a	O
virus-induced	O
ifn-alpha/beta	B-protein
is	O
essential	O
in	O
host	O
's	O
antiviral	O
defence	O
by	O
activating	O
the	O
expression	O
of	O
antiviral	O
mx	O
,	O
pkr	B-protein
and	O
oligoadenylate	B-protein
synthetase	I-protein
genes	O
.	O

ifn-alpha/beta	B-protein
also	O
prolongs	O
t	O
cell	O
survival	O
,	O
upregulates	O
il-00	B-protein
and	O
il-00	B-protein
receptor	O
gene	O
expression	O
and	O
together	O
with	O
il-00	B-protein
stimulates	O
nk	B-cell_type
and	I-cell_type
t	I-cell_type
cell	I-cell_type
ifn-gamma	B-protein
production	O
and	O
the	O
development	O
of	O
th0-type	O
immune	O
response	O
.	O

###MEDLINE:21216558

comparison	O
of	O
hprt	B-protein
and	O
laci	B-protein
mutant	O
frequency	O
with	O
dna	B-protein
adduct	I-protein
formation	O
in	O
n-hydroxy-0-acetylaminofluorene-treated	O
big	O
blue	O
rats	O
.	O

n-hydroxy-0-acetylaminofluorene	O
(	O
n-oh-aaf	B-protein
)	O
is	O
the	O
proximate	O
carcinogenic	O
metabolite	O
of	O
the	O
powerful	O
rat	O
liver	O
carcinogen	O
0-acetylaminofluorene	O
.	O

in	O
this	O
study	O
,	O
transgenic	O
big	O
blue	O
(	O
r	B-protein
)	O
rats	O
were	O
used	O
to	O
examine	O
the	O
relationship	O
between	O
in	O
vivo	O
mutagenicity	O
and	O
dna	B-protein
adduct	I-protein
formation	O
by	O
n-oh-aaf	O
in	O
the	O
target	O
liver	O
compared	O
with	O
that	O
in	O
nontarget	B-cell_type
tissues	I-cell_type
.	O

male	O
rats	O
were	O
given	O
one	O
,	O
two	O
,	O
or	O
four	O
doses	O
of	O
00	O
mg	O
n-oh-aaf/kg	O
body	O
weight	O
by	O
i.p.	O
injection	O
at	O
0-day	O
intervals	O
,	O
and	O
groups	O
of	O
treated	O
and	O
control	O
rats	O
were	O
euthanized	O
up	O
to	O
00	O
weeks	O
after	O
beginning	O
the	O
dosing	O
.	O

mutant	O
frequencies	O
were	O
measured	O
in	O
the	O
spleen	O
lymphocyte	O
hprt	B-DNA
gene	I-DNA
,	O
and	O
laci	B-protein
mutant	O
frequencies	O
were	O
determined	O
in	O
the	O
liver	O
and	O
spleen	B-cell_type
lymphocytes	I-cell_type
.	O

at	O
0	O
weeks	O
after	O
beginning	O
the	O
dosing	O
,	O
the	O
hprt	B-DNA
mutant	I-DNA
frequency	O
in	O
spleen	B-cell_type
lymphocytes	I-cell_type
from	O
the	O
four-dose	O
group	O
was	O
00.0	O
x	O
00	O
(	O
-0	O
)	O
compared	O
with	O
0.0	O
x	O
00	O
(	O
-0	O
)	O
in	O
control	O
animals	O
.	O

also	O
at	O
0	O
weeks	O
,	O
rats	O
given	O
one	O
,	O
two	O
,	O
or	O
four	O
doses	O
of	O
n-oh-aaf	B-protein
had	O
laci	B-protein
mutant	O
frequencies	O
in	O
the	O
liver	O
of	O
00.0	O
,	O
000.0	O
,	O
and	O
000.0	O
x	O
00	O
(	O
-0	O
)	O
,	O
respectively	O
,	O
compared	O
with	O
a	O
control	O
frequency	O
of	O
00.0	O
x	O
00	O
(	O
-0	O
)	O
;	O
rats	O
given	O
four	O
doses	O
had	O
laci	B-protein
mutant	O
frequencies	O
in	O
spleen	B-cell_type
lymphocytes	I-cell_type
of	O
00.0	O
x	O
00	O
(	O
-0	O
)	O
compared	O
with	O
a	O
control	O
frequency	O
of	O
00.0	O
x	O
00	O
(	O
-0	O
)	O
.	O

additional	O
rats	O
were	O
evaluated	O
for	O
dna	B-protein
adduct	I-protein
formation	O
in	O
the	O
liver	O
,	O
spleen	B-cell_type
lymphocytes	I-cell_type
,	O
and	O
bone	O
marrow	O
by	O
(	O
00	O
)	O
p-postlabeling	O
.	O

adduct	O
analysis	O
was	O
conducted	O
0	O
day	O
after	O
one	O
,	O
two	O
,	O
and	O
four	O
treatments	O
with	O
n-oh-aaf	B-protein
,	O
0	O
days	O
after	O
one	O
treatment	O
,	O
and	O
0	O
days	O
after	O
two	O
treatments	O
.	O

n-	B-protein
(	I-protein
deoxyguanosin-0-yl	I-protein
)	I-protein
-0-aminofluorene	I-protein
was	O
the	O
major	B-protein
dna	I-protein
adduct	I-protein
identified	O
in	O
all	O
the	O
tissues	O
examined	O
.	O

adduct	O
concentrations	O
increased	O
with	O
total	O
dose	O
to	O
maximum	O
values	O
in	O
samples	O
taken	O
0	O
day	O
after	O
two	O
doses	O
,	O
and	O
remained	O
essentially	O
the	O
same	O
after	O
four	O
doses	O
.	O

in	O
samples	O
taken	O
after	O
four	O
doses	O
,	O
adduct	O
levels	O
were	O
000	O
,	O
00	O
,	O
and	O
0	O
fmol/microg	O
of	O
dna	O
in	O
liver	O
,	O
spleen	B-cell_type
lymphocytes	I-cell_type
,	O
and	O
bone	O
marrow	O
,	O
respectively	O
.	O

the	O
results	O
indicate	O
that	O
the	O
extent	O
of	O
both	O
dna	B-protein
adduct	I-protein
formation	O
and	O
mutant	O
induction	O
correlates	O
with	O
the	O
organ	O
specificity	O
for	O
n-oh-aaf	O
carcinogenesis	O
in	O
the	O
rat	O
.	O

environ.	O
mol.	O
mutagen.	O
00	O
:	O
000-000	O
,	O
0000	O
.	O

published	O
0000	O
wiley-liss	O
,	O
inc	O
.	O

###MEDLINE:21214517

expression	O
of	O
mad0	B-protein
in	O
t	B-cell_type
cells	I-cell_type
leads	O
to	O
reduced	O
thymic	O
cellularity	O
and	O
impaired	O
mitogen-induced	O
proliferation	O
.	O

to	O
investigate	O
mad0	B-protein
function	O
in	O
vivo	O
,	O
transgenic	O
mice	O
were	O
generated	O
that	O
express	O
a	O
mad0	B-protein
transgene	O
in	O
t	B-cell_type
lineage	I-cell_type
cells	I-cell_type
under	O
the	O
control	O
of	O
the	O
proximal	B-DNA
lck	I-DNA
promoter	I-DNA
.	O

thymus	O
size	O
in	O
lck-mad0	O
transgenic	O
mice	O
is	O
drastically	O
reduced	O
although	O
representation	O
of	O
the	O
various	B-cell_line
thymocyte	I-cell_line
sub	I-cell_line
populations	I-cell_line
appears	O
normal	O
.	O

to	O
investigate	O
more	O
closely	O
any	O
effects	O
of	O
mad0	B-protein
expression	O
on	O
thymocytes	B-cell_type
,	O
we	O
examined	O
thymic	O
selection	O
using	O
mhc	B-cell_type
class	I-cell_type
i-restricted	I-cell_type
h-y-tcr	I-cell_type
transgenic	O
mice	O
.	O

mad0	B-protein
expression	O
in	O
vivo	O
reduces	O
the	O
efficiency	O
of	O
positive	O
selection	O
.	O

furthermore	O
,	O
thymocytes	B-cell_type
and	O
splenic	B-cell_type
t	I-cell_type
cells	I-cell_type
from	O
lck-mad0	O
transgenic	O
mice	O
display	O
a	O
profound	O
proliferative	O
defect	O
in	O
response	O
to	O
activation	O
with	O
either	O
pma/ionomycin	O
or	O
immobilized	B-protein
anti-cd0/cd00	I-protein
antibody	I-protein
.	O

this	O
proliferative	O
defect	O
is	O
not	O
reversed	O
by	O
addition	O
of	O
exogenous	O
il-0	B-protein
and	O
is	O
p00-independent	O
.	O

the	O
growth	O
inhibition	O
caused	O
by	O
mad0	B-protein
is	O
overcome	O
by	O
expression	O
of	O
active	O
c-myc	O
.	O

###MEDLINE:21213531

differential	O
requirement	O
for	O
the	O
transcription	B-protein
factor	I-protein
pu.0	B-protein
in	O
the	O
generation	O
of	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
versus	O
b	B-cell_type
and	I-cell_type
t	I-cell_type
cells	I-cell_type
.	O

pu.0	B-protein
is	O
a	O
member	O
of	O
the	O
ets	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
required	O
for	O
the	O
development	O
of	O
various	O
lymphoid	B-cell_type
and	I-cell_type
myeloid	I-cell_type
cell	I-cell_type
lineages	I-cell_type
,	O
but	O
its	O
role	O
in	O
natural	B-cell_type
killer	I-cell_type
(	I-cell_type
nk	I-cell_type
)	I-cell_type
cell	I-cell_type
development	O
is	O
not	O
known	O
.	O

the	O
study	O
shows	O
that	O
pu.0	B-protein
is	O
expressed	O
in	O
nk	B-cell_type
cells	I-cell_type
and	O
that	O
,	O
on	O
cell	O
transfer	O
into	O
alymphoid	B-protein
rag0/gammac	I-protein
(	O
-/-	O
)	O
mice	O
,	O
hematopoietic	B-cell_type
progenitors	I-cell_type
of	O
pu.0	B-protein
(	O
-/-	O
)	O
fetal	B-cell_type
liver	I-cell_type
cells	I-cell_type
could	O
generate	O
functional	O
nk	B-cell_type
cells	I-cell_type
but	O
not	O
b	B-cell_type
or	I-cell_type
t	I-cell_type
cells	I-cell_type
.	O

nevertheless	O
,	O
the	O
numbers	O
of	O
bone	B-cell_type
marrow	I-cell_type
nk	I-cell_type
cell	I-cell_type
precursors	I-cell_type
and	O
splenic	B-cell_type
mature	I-cell_type
nk	I-cell_type
cells	I-cell_type
were	O
reduced	O
compared	O
to	O
controls	O
.	O

moreover	O
,	O
pu.0	B-protein
(	O
-/-	O
)	O
nk	B-cell_type
cells	I-cell_type
displayed	O
reduced	O
expression	O
of	O
the	O
receptors	O
for	O
stem	B-protein
cell	I-protein
factor	I-protein
and	O
interleukin	B-protein
(	I-protein
il	I-protein
)	I-protein
-0	I-protein
,	O
suggesting	O
a	O
nonredundant	O
role	O
for	O
pu.0	B-protein
in	O
regulating	O
the	O
expression	O
of	O
these	O
cytokine	B-DNA
receptor	I-DNA
genes	I-DNA
during	O
nk	B-cell_type
cell	I-cell_type
development	O
.	O

pu.0	B-protein
(	O
-/-	O
)	O
nk	B-cell_type
cells	I-cell_type
also	O
showed	O
defective	O
expression	O
of	O
inhibitory	B-protein
and	I-protein
activating	I-protein
members	I-protein
of	O
the	O
ly00	B-DNA
family	I-DNA
and	O
failed	O
to	O
proliferate	O
in	O
response	O
to	O
il-0	B-protein
and	O
il-00	B-protein
.	O

thus	O
,	O
despite	O
the	O
less	O
stringent	O
requirement	O
for	O
pu.0	B-protein
in	O
nk	B-cell_type
cell	I-cell_type
development	O
compared	O
to	O
b	B-cell_type
and	I-cell_type
t	I-cell_type
cells	I-cell_type
,	O
pu.0	B-protein
regulates	O
nk	O
cell	O
differentiation	O
and	O
homeostasis	O
.	O

###MEDLINE:21203088

benzene-extracted	O
components	O
are	O
important	O
for	O
the	O
major	O
activity	O
of	O
diesel	O
exhaust	O
particles	O
:	O
effect	O
on	O
interleukin-0	B-DNA
gene	I-DNA
expression	O
in	O
human	B-cell_type
bronchial	I-cell_type
epithelial	I-cell_type
cells	I-cell_type
.	O

epidemiologic	O
and	O
experimental	O
studies	O
suggest	O
that	O
diesel	O
exhaust	O
particles	O
(	O
deps	B-protein
)	O
may	O
be	O
related	O
to	O
increasing	O
respiratory	O
mortality	O
and	O
morbidity	O
.	O

we	O
have	O
shown	O
that	O
deps	B-protein
augmented	O
the	O
production	O
of	O
inflammatory	B-protein
cytokines	I-protein
by	O
human	O
airway	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
in	O
vitro	O
.	O

to	O
better	O
understand	O
the	O
mechanisms	O
of	O
their	O
proinflammatory	O
activities	O
,	O
we	O
studied	O
the	O
effects	O
of	O
several	O
components	O
extracted	O
from	O
deps	B-protein
on	O
interleukin	B-protein
(	I-protein
il	I-protein
)	I-protein
-0	I-protein
expression	O
in	O
human	B-cell_line
bronchial	I-cell_line
epithelial	I-cell_line
cell	I-cell_line
line	I-cell_line
beas-0b	B-cell_line
and	O
normal	O
human	O
airway	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
obtained	O
from	O
very	O
peripheral	O
airways	O
by	O
an	O
ultrathin	O
bronchoscope	O
.	O

we	O
used	O
several	O
agents	O
active	O
on	O
signal	O
transduction	O
pathways	O
in	O
cytokine	B-protein
expression	O
,	O
such	O
as	O
the	O
protein	B-protein
kinase	I-protein
c	I-protein
inhibitor	O
staurosporin	O
,	O
antioxidant	O
agents	O
including	O
n-acetyl	O
cysteine	O
(	O
nac	O
)	O
and	O
pyrrolidine	O
dithiocarbamate	O
(	O
pdtc	O
)	O
,	O
and	O
p00	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
(	O
mapk	B-protein
)	O
inhibitor	O
sb000000	O
.	O

benzene-extracted	O
components	O
showed	O
effects	O
mimicking	O
deps	B-protein
on	O
il-0	B-DNA
gene	I-DNA
expression	O
,	O
release	O
of	O
several	O
cytokines	B-protein
(	O
il-0	B-protein
;	O
granulocyte	B-protein
macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
;	O
and	O
regulated	O
on	O
activation	O
,	O
normal	B-cell_type
t	I-cell_type
cells	I-cell_type
expressed	O
and	O
secreted	O
)	O
and	O
nuclear	B-protein
factor	I-protein
(	O
nf	B-protein
)	I-protein
-kappa	I-protein
b	I-protein
activation	O
.	O

we	O
also	O
found	O
that	O
nac	O
,	O
pdtc	O
,	O
and	O
sb000000	O
suppressed	O
the	O
activities	O
of	O
deps	B-protein
and	O
their	O
benzene	O
extracts	O
,	O
suggesting	O
the	O
roles	O
of	O
oxidants-mediated	O
nf-kappa	B-protein
b	I-protein
activation	O
and	O
p00mapk	B-protein
pathways	O
.	O

finally	O
,	O
benzo	O
[	O
a	O
]	O
pyrene	O
,	O
one	O
of	O
the	O
important	O
compounds	O
included	O
in	O
the	O
benzene	O
component	O
,	O
replicated	O
the	O
activities	O
shown	O
by	O
deps	B-protein
.	O

###MEDLINE:21195296

the	O
nuclear	B-protein
receptor	I-protein
ppar	B-protein
gamma	O
is	O
expressed	O
by	O
mouse	B-cell_type
t	I-cell_type
lymphocytes	I-cell_type
and	O
ppar	B-protein
gamma	O
agonists	O
induce	O
apoptosis	O
.	O

peroxisome	B-protein
proliferator-activated	I-protein
receptor	I-protein
(	O
ppar	B-protein
)	O
-gamma	O
is	O
a	O
nuclear	B-protein
hormone	I-protein
receptor	I-protein
that	O
serves	O
as	O
a	O
trans	O
factor	O
to	O
regulate	O
lipid	O
metabolism	O
.	O

intense	O
interest	O
is	O
focused	O
on	O
ppar-gamma	B-protein
and	O
its	O
ligands	O
owing	O
to	O
its	O
putative	O
role	O
in	O
adipocyte	B-cell_type
differentiation	O
.	O

little	O
is	O
known	O
,	O
however	O
,	O
about	O
the	O
functions	O
of	O
ppar-gamma	B-protein
in	O
the	O
immune	O
system	O
,	O
especially	O
in	O
t	B-cell_type
lymphocytes	I-cell_type
.	O

we	O
demonstrate	O
that	O
both	O
naive	B-cell_type
and	I-cell_type
activated	I-cell_type
ovalbumin-specific	I-cell_type
t	I-cell_type
cells	I-cell_type
from	O
do00.00-transgenic	O
mice	O
express	O
ppar-gamma	B-RNA
mrna	I-RNA
and	O
protein	O
.	O

in	O
order	O
to	O
determine	O
the	O
function	O
of	O
ppar-gamma	B-protein
,	O
t	B-cell_type
cells	I-cell_type
were	O
stimulated	O
with	O
phorbol	O
00-myristate	O
00-acetate	O
and	O
ionomycin	O
or	O
antigen	O
and	O
antigen-presenting	B-cell_type
cells	I-cell_type
.	O

simultaneous	O
exposure	O
to	O
ppar-gamma	B-protein
ligands	O
(	O
e.g.	O
00-deoxy-delta	O
(	O
00	O
,	O
00	O
)	O
-prostaglandin	O
j	O
(	O
0	O
)	O
,	O
troglitazone	O
)	O
showed	O
drastic	O
inhibition	O
of	O
proliferation	O
and	O
significant	O
decreases	O
in	O
cell	O
viability	O
.	O

the	O
decrease	O
in	O
cell	O
viability	O
was	O
due	O
to	O
apoptosis	O
of	O
the	O
t	B-cell_type
lymphocytes	I-cell_type
,	O
and	O
occurred	O
only	O
when	O
cells	O
were	O
treated	O
with	O
ppar-gamma	B-protein
,	O
and	O
not	O
ppar-alpha	B-protein
agonists	O
,	O
revealing	O
specificity	O
of	O
this	O
response	O
for	O
ppar-gamma	B-protein
.	O

these	O
observations	O
suggest	O
that	O
ppar-gamma	B-protein
agonists	O
play	O
an	O
important	O
role	O
in	O
regulating	O
t	O
cell-mediated	O
immune	O
responses	O
by	O
inducing	O
apoptosis	O
.	O

t	O
cell	O
death	O
via	O
ppar-gamma	B-protein
ligation	O
may	O
act	O
as	O
a	O
potent	O
anti-inflammatory	O
signal	O
in	O
the	O
immune	O
system	O
,	O
and	O
ligands	O
could	O
possibly	O
be	O
used	O
to	O
control	O
disorders	O
in	O
which	O
excessive	O
inflammation	O
occurs	O
.	O

###MEDLINE:21188436

suppression	O
of	O
lung	O
inflammation	O
in	O
rats	O
by	O
prevention	O
of	O
nf-kappab	B-protein
activation	O
in	O
the	O
liver	O
.	O

activation	O
of	O
nf-kappab	B-protein
and	O
production	O
of	O
nf-kappab	B-protein
-dependent	O
chemokines	O
are	O
thought	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
neutrophilic	O
lung	O
inflammation	O
.	O

calpain-0	B-protein
inhibitor	I-protein
(	O
ci-0	B-protein
)	O
blocks	O
activation	O
of	O
nf-kappab	B-protein
by	O
preventing	O
proteolysis	O
of	O
the	O
inhibitory	B-protein
protein	I-protein
ikappab-alpha	B-protein
by	O
the	O
ubiquitin/proteasome	O
pathway	O
.	O

we	O
hypothesized	O
that	O
inhibition	O
of	O
proteasome	B-protein
function	O
with	O
ci-0	B-protein
would	O
block	O
nf-kappab	B-protein
activation	O
in	O
vivo	O
after	O
intraperitoneal	O
(	O
i.p.	O
)	O
treatment	O
with	O
bacterial	O
lipopolysaccharide	O
(	O
lps	O
)	O
,	O
and	O
that	O
nf-kappab	B-protein
inhibition	O
would	O
be	O
associated	O
with	O
suppression	O
of	O
chemokine	B-protein
gene	O
expression	O
and	O
attenuation	O
of	O
neutrophilic	O
alveolitis	O
.	O

we	O
treated	O
rats	O
with	O
a	O
single	O
i.p.	O
injection	O
of	O
ci-0	B-protein
(	O
00	O
mg/kg	O
)	O
two	O
hours	O
prior	O
to	O
i.p.	O
lps	O
(	O
0	O
mg/kg	O
)	O
.	O

treatment	O
with	O
cl-0	B-protein
prevented	O
degradation	O
of	O
ikappab-alpha	B-protein
and	O
activation	O
of	O
nf-kappab	B-protein
in	O
the	O
liver	O
in	O
response	O
to	O
lps	O
;	O
however	O
,	O
cl-0	O
treatment	O
had	O
no	O
detected	O
effect	O
on	O
nf-kappab	B-protein
activation	O
in	O
lung	O
tissue	O
.	O

ci-0	O
treatment	O
prior	O
to	O
lps	O
resulted	O
in	O
00	O
%	O
lower	O
mip-0	B-protein
concentration	O
in	O
lung	O
lavage	O
fluid	O
compared	O
to	O
rats	O
treated	O
with	O
vehicle	O
prior	O
to	O
lps	O
(	O
000	O
+/-	O
000	O
pg/ml	O
vs.	O
000	O
+/-000	O
pg/ml	O
,	O
p	O
<	O
0.00	O
)	O
.	O

in	O
addition	O
,	O
ci-0	O
treatment	O
substantially	O
inhibited	O
lps-induced	O
neutrophilic	O
alveolitis	O
(	O
0.0+	O
/-	O
0.0	O
x	O
00	O
(	O
0	O
)	O
vs.	O
00.0	O
+/-	O
00.0	O
x	O
00	O
(	O
0	O
)	O
lung	B-cell_type
lavage	I-cell_type
neutrophils	I-cell_type
,	O
p	O
<	O
0.00	O
)	O
.	O

these	O
data	O
indicate	O
that	O
nf-kappab	B-protein
inhibition	O
in	O
the	O
liver	O
can	O
alter	O
lung	O
inflammation	O
induced	O
by	O
systemic	O
lps	O
treatment	O
and	O
suggest	O
that	O
a	O
liver-lung	O
interaction	O
contributes	O
to	O
the	O
inflammatory	O
response	O
of	O
the	O
lung	O
.	O

###MEDLINE:21186394

notch0	B-protein
regulates	O
maturation	O
of	O
cd0+	B-cell_type
and	I-cell_type
cd0+	I-cell_type
thymocytes	I-cell_type
by	O
modulating	O
tcr	B-protein
signal	O
strength	O
.	O

notch	O
signaling	O
regulates	O
cell	O
fate	O
decisions	O
in	O
multiple	B-cell_type
lineages	I-cell_type
.	O

we	O
demonstrate	O
in	O
this	O
report	O
that	O
retroviral	O
expression	O
of	O
activated	O
notch0	B-protein
in	O
mouse	B-cell_type
thymocytes	I-cell_type
abrogates	O
differentiation	O
of	O
immature	B-cell_type
cd0+cd0+	I-cell_type
thymocytes	I-cell_type
into	O
both	O
cd0	B-cell_type
and	I-cell_type
cd0	I-cell_type
mature	I-cell_type
single-positive	I-cell_type
t	I-cell_type
cells	I-cell_type
.	O

the	O
ability	O
of	O
notch0	B-protein
to	O
inhibit	O
t	O
cell	O
development	O
was	O
observed	O
in	O
vitro	O
and	O
in	O
vivo	O
with	O
both	O
normal	O
and	O
tcr	B-protein
transgenic	O
thymocytes	B-cell_type
.	O

notch0	B-protein
-mediated	O
developmental	O
arrest	O
was	O
dose	O
dependent	O
and	O
was	O
associated	O
with	O
impaired	O
thymocyte	O
responses	O
to	O
tcr	B-protein
stimulation	O
.	O

notch0	B-protein
also	O
inhibited	O
tcr-mediated	O
signaling	O
in	O
jurkat	B-cell_line
t	I-cell_line
cells	I-cell_line
.	O

these	O
data	O
indicate	O
that	O
constitutively	O
active	O
notch0	B-protein
abrogates	O
cd0+	B-protein
and	O
cd0+	O
maturation	O
by	O
interfering	O
with	O
tcr	B-protein
signal	O
strength	O
and	O
provide	O
an	O
explanation	O
for	O
the	O
physiological	O
regulation	O
of	O
notch	O
expression	O
during	O
thymocyte	O
development	O
.	O

###MEDLINE:21184078

expression	O
of	O
sart0	B-protein
antigen	I-protein
and	O
induction	O
of	O
ctls	B-cell_type
by	O
sart0-derived	O
peptides	O
in	O
breast	O
cancer	O
patients	O
.	O

we	O
recently	O
reported	O
the	O
sart0	B-protein
tumour-rejection	I-protein
antigen	I-protein
as	O
possessing	O
tumour	B-protein
epitopes	I-protein
capable	O
of	O
inducing	O
hla-class	B-cell_type
i-restricted	I-cell_type
cytotoxic	I-cell_type
t	I-cell_type
lymphocytes	I-cell_type
(	O
ctls	B-cell_type
)	O
.	O

this	O
study	O
investigated	O
expression	O
of	O
the	O
sart0	B-protein
antigen	I-protein
in	O
breast	O
cancer	O
to	O
explore	O
an	O
appropriate	O
molecule	O
for	O
use	O
in	O
specific	O
immunotherapy	O
of	O
breast	O
cancer	O
patients	O
.	O

the	O
sart0	B-protein
antigen	I-protein
was	O
detected	O
in	O
all	O
of	O
the	O
breast	O
cancer	O
cell	O
lines	O
tested	O
,	O
00	O
of	O
00	O
(	O
00	O
%	O
)	O
breast	O
cancer	O
tissue	O
samples	O
,	O
and	O
0	O
of	O
0	O
non-tumourous	O
breast	O
tissue	O
samples	O
.	O

sart0	O
derived	O
peptides	O
at	O
positions	B-DNA
000-000	I-DNA
and	O
000-000	B-protein
induced	O
hla-a00	O
restricted	O
ctls	B-cell_type
that	O
reacted	O
to	O
breast	B-cell_type
cancer	I-cell_type
cells	I-cell_type
from	O
the	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
pbmcs	B-cell_type
)	O
of	O
breast	O
cancer	O
patients	O
.	O

therefore	O
,	O
the	O
sart0	B-protein
antigen	I-protein
and	O
its	O
peptides	O
could	O
be	O
an	O
appropriate	O
molecule	O
for	O
use	O
in	O
specific	O
immunotherapy	O
of	O
the	O
majority	O
of	O
hla-a00-positive	O
breast	O
cancer	O
patients	O

###MEDLINE:21232503

autostimulation	O
of	O
the	O
epstein-barr	B-DNA
virus	I-DNA
brlf0	I-DNA
promoter	B-DNA
is	O
mediated	O
through	O
consensus	B-DNA
sp0	I-DNA
and	I-DNA
sp0	I-DNA
binding	I-DNA
sites	I-DNA
.	O

as	O
an	O
essential	O
step	O
in	O
the	O
lytic	O
cascade	O
,	O
the	O
rta	B-protein
homologues	O
of	O
gammaherpesviruses	O
all	O
activate	O
their	O
own	O
expression	O
.	O

consistent	O
with	O
this	O
biologic	O
function	O
,	O
the	O
epstein-barr	B-protein
virus	I-protein
(	I-protein
ebv	I-protein
)	I-protein
rta	I-protein
protein	I-protein
powerfully	I-protein
stimulates	O
the	O
promoter	O
of	O
its	O
own	O
gene	O
,	O
rp	O
,	O
in	O
ebv-positive	B-cell_line
b	I-cell_line
cells	I-cell_line
in	O
transient-transfection	O
reporter-based	O
assays	O
.	O

we	O
analyzed	O
the	O
activity	O
of	O
rpcat	O
in	O
response	O
to	O
rta	B-protein
by	O
deletional	O
and	O
site-directed	O
mutagenesis	O
.	O

two	O
cognate	B-DNA
sp0	I-DNA
binding	I-DNA
sites	I-DNA
located	O
at	O
-000	O
and	O
-00	O
relative	O
to	O
the	O
transcriptional	B-DNA
start	I-DNA
site	I-DNA
proved	O
crucial	O
for	O
rta-mediated	O
activation	O
.	O

previously	O
described	O
binding	B-DNA
sites	I-DNA
for	O
the	O
cellular	B-protein
transcription	I-protein
factor	I-protein
zif000	B-protein
and	O
the	O
viral	B-protein
transactivator	I-protein
zebra	B-protein
were	O
found	O
to	O
be	O
dispensable	O
for	O
activation	O
of	O
rpcat	O
by	O
rta	B-protein
.	O

gel	O
shift	O
analysis	O
,	O
using	O
extracts	O
of	O
b	B-cell_type
cells	I-cell_type
in	O
latency	O
or	O
induced	O
into	O
the	O
lytic	O
cycle	O
,	O
identified	O
sp0	B-protein
and	O
sp0	B-protein
as	O
the	O
predominant	O
cellular	B-protein
proteins	I-protein
bound	O
to	O
rp	O
near	O
-00	O
.	O

during	O
the	O
lytic	O
cycle	O
,	O
zebra	B-protein
bound	O
rp	O
near	O
the	O
sp0/sp0	B-DNA
site	I-DNA
.	O

the	O
binding	O
of	O
sp0	B-protein
and	O
sp0	B-protein
to	O
rp	O
correlated	O
with	O
the	O
reporter	O
activities	O
in	O
the	O
mutagenesis	O
study	O
,	O
establishing	O
a	O
direct	O
link	O
between	O
transcriptional	O
activation	O
of	O
rp	O
by	O
rta	B-protein
and	O
dna	O
binding	O
by	O
sp0	B-protein
and/or	O
sp0	B-protein
.	O

the	O
relative	O
abundance	O
or	O
functional	O
state	O
of	O
the	O
cellular	O
sp0	B-protein
and	O
sp0	B-protein
transcription	I-protein
factors	I-protein
may	O
be	O
altered	O
in	O
response	O
to	O
stimuli	O
that	O
induce	O
the	O
brlf0	B-DNA
promoter	O
and	O
thereby	O
contribute	O
to	O
the	O
activation	O
of	O
the	O
viral	O
lytic	O
cycle	O
.	O

###MEDLINE:21221189

gene	O
transfer	O
of	O
antisense	O
hypoxia	O
inducible	B-protein
factor-0	I-protein
alpha	I-protein
enhances	O
the	O
therapeutic	O
efficacy	O
of	O
cancer	O
immunotherapy	O
.	O

solid	O
tumors	O
meet	O
their	O
demands	O
for	O
nascent	O
blood	O
vessels	O
and	O
increased	O
glycolysis	O
,	O
to	O
combat	O
hypoxia	O
,	O
by	O
activating	O
multiple	O
genes	O
involved	O
in	O
angiogenesis	O
and	O
glucose	O
metabolism	O
.	O

hypoxia	O
inducible	B-protein
factor-0	I-protein
(	O
hif-0	B-protein
)	O
is	O
a	O
constitutively	O
expressed	O
basic	B-protein
helix-loop-helix	I-protein
transcription	I-protein
factor	I-protein
,	O
formed	O
by	O
the	O
assembly	O
of	O
hif-0alpha	B-protein
and	I-protein
hif-0beta	I-protein
(	O
arnt	B-protein
)	O
,	O
that	O
is	O
stablized	O
in	O
response	O
to	O
hypoxia	O
,	O
and	O
rapidly	O
degraded	O
under	O
normoxic	O
conditions	O
.	O

it	O
activates	O
the	O
transcription	O
of	O
genes	O
important	O
for	O
maintaining	O
oxygen	O
homeostasis	O
.	O

here	O
,	O
we	O
demonstrate	O
that	O
engineered	O
down-regulation	O
of	O
hif-0alpha	B-DNA
by	O
intratumoral	O
gene	O
transfer	O
of	O
an	O
antisense	O
hif-0alpha	B-DNA
plasmid	I-DNA
leads	O
to	O
the	O
down-regulation	O
of	O
vegf	B-protein
,	O
and	O
decreased	O
tumor	B-cell_type
microvessel	I-cell_type
density	I-cell_type
.	O

antisense	O
hif-0alpha	B-DNA
monotherapy	O
resulted	O
in	O
the	O
complete	O
and	O
permanent	O
rejection	O
of	O
small	O
(	O
0.0	O
cm	O
in	O
diameter	O
)	O
el-0	B-cell_type
tumors	I-cell_type
,	O
which	O
is	O
unusual	O
for	O
an	O
anti-angiogenic	O
agent	O
where	O
transient	O
suppression	O
of	O
tumor	O
growth	O
is	O
the	O
norm	O
.	O

it	O
induced	O
nk	O
cell	O
-dependent	O
rejection	O
of	O
tumors	O
,	O
but	O
failed	O
to	O
stimulate	O
systemic	O
t	O
cell	O
-mediated	O
anti-tumor	O
immunity	O
,	O
and	O
synergized	O
with	O
b0-0-mediated	O
immunotherapy	O
to	O
cause	O
the	O
nk	B-cell_type
cell	I-cell_type
and	I-cell_type
cd0	I-cell_type
t	I-cell_type
cell	I-cell_type
-dependent	O
rejection	O
of	O
larger	O
el-0	B-cell_type
tumors	I-cell_type
(	O
0.0	O
cm	O
in	O
diameter	O
)	O
that	O
were	O
refractory	O
to	O
monotherapies	O
.	O

mice	O
cured	O
of	O
their	O
tumors	O
by	O
combination	O
therapy	O
resisted	O
a	O
rechallenge	O
with	O
parental	B-cell_line
tumor	I-cell_line
cells	I-cell_line
,	O
indicating	O
systemic	O
antitumor	O
immunity	O
had	O
been	O
achieved	O
.	O

in	O
summary	O
,	O
whilst	O
intensive	O
investigations	O
are	O
in	O
progress	O
to	O
target	O
the	O
many	O
hif-0	B-protein
effectors	I-protein
,	O
the	O
results	O
herein	O
indicate	O
that	O
blocking	O
hypoxia-inducible	O
pathways	O
and	O
enhancing	O
nk-mediated	O
antitumor	O
immunity	O
by	O
targeting	O
hif-0	O
itself	O
may	O
be	O
advantageous	O
,	O
especially	O
when	O
combined	O
with	O
cancer	O
immunotherapy	O
.	O

###MEDLINE:21214420

runx0	O
:	O
a	O
novel	O
oncogenic	O
effector	O
revealed	O
by	O
in	O
vivo	O
complementation	O
and	O
retroviral	O
tagging	O
.	O

the	O
runx0	O
(	O
cbfa0	B-protein
,	O
pebp0alphaa	O
,	O
aml0	B-DNA
)	I-DNA
gene	I-DNA
was	O
previously	O
identified	O
as	O
a	O
frequent	O
target	O
for	O
transcriptional	O
activation	O
by	O
proviral	O
insertion	O
in	O
t-cell	B-cell_type
lymphomas	I-cell_type
of	O
cd0-myc	O
transgenic	O
mice	O
.	O

we	O
have	O
recently	O
shown	O
that	O
over-expression	O
of	O
the	O
full-length	O
,	O
most	O
highly	O
expressed	O
runx0	B-protein
isoform	I-protein
in	O
the	O
thymus	O
perturbs	O
t-cell	O
development	O
,	O
leads	O
to	O
development	O
of	O
spontaneous	O
lymphomas	O
at	O
low	O
frequency	O
and	O
is	O
strongly	O
synergistic	O
with	O
myc	B-protein
.	O

to	O
gain	O
further	O
insight	O
into	O
the	O
relationship	O
of	O
runx0	O
to	O
other	O
lymphomagenic	O
pathways	O
,	O
we	O
tested	O
the	O
effect	O
of	O
combining	O
the	O
cd0-runx0	B-DNA
transgene	I-DNA
either	O
with	O
a	O
pim0	B-DNA
transgene	I-DNA
(	O
e	B-DNA
(	I-DNA
mu	I-DNA
)	I-DNA
-pim0	I-DNA
)	O
or	O
with	O
the	O
p00	B-protein
null	O
genotype	O
,	O
as	O
each	O
of	O
these	O
displays	O
independent	O
synergy	O
with	O
myc	B-protein
.	O

in	O
both	O
cases	O
we	O
observed	O
synergistic	O
tumour	O
development	O
.	O

however	O
,	O
runx0	B-protein
appeared	O
to	O
have	O
a	O
dominant	O
effect	O
on	O
the	O
tumour	O
phenotype	O
in	O
each	O
case	O
,	O
with	O
most	O
tumours	O
conforming	O
to	O
the	O
cd0	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
,	I-cell_type
cd0	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
,	I-cell_type
cd0	I-cell_type
(	I-cell_type
+/-	I-cell_type
)	I-cell_type
phenotype	I-cell_type
seen	O
in	O
cd0-runx0	O
mice	O
.	O

neonatal	O
infection	O
of	O
cd0-runx0	O
mice	O
with	O
moloney	O
murine	O
leukaemia	O
virus	O
(	O
moloney	O
mlv	O
)	O
also	O
led	O
to	O
a	O
dramatic	O
acceleration	O
of	O
tumour	O
onset	O
.	O

analysis	O
of	O
known	O
moloney	O
mlv	O
target	O
genes	O
in	O
these	O
lymphomas	O
showed	O
a	O
high	O
frequency	O
of	O
rearrangement	O
at	O
c-myc	B-DNA
or	O
n-myc	B-protein
(	O
00	O
%	O
)	O
,	O
and	O
a	O
significant	O
number	O
at	O
pim0	B-protein
or	I-protein
pim0	I-protein
(	O
00	O
%	O
)	O
,	O
and	O
at	O
pal0/gfi0	B-protein
(	O
00	O
%	O
)	O
.	O

these	O
results	O
indicate	O
that	O
runx0	B-protein
makes	O
a	O
distinct	O
contribution	O
to	O
t-cell	O
lymphoma	O
development	O
which	O
does	O
not	O
coincide	O
with	O
any	O
of	O
the	O
oncogene	O
complementation	O
groups	O
previously	O
identified	O
by	O
retroviral	O
tagging	O
.	O

###MEDLINE:21214119

the	O
involvement	O
of	O
tnf-alpha	B-protein
-related	O
apoptosis-inducing	B-protein
ligand	I-protein
in	O
the	O
enhanced	O
cytotoxicity	O
of	O
ifn-beta	B-protein
-stimulated	O
human	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
to	O
tumor	B-cell_type
cells	I-cell_type
.	O

tnf-alpha	B-protein
-related	O
apoptosis-inducing	B-protein
ligand	I-protein
(	O
trail	B-protein
)	O
is	O
characterized	O
by	O
its	O
preferential	O
induction	O
of	O
apoptosis	O
of	O
tumor	B-cell_type
cells	I-cell_type
but	O
not	O
normal	B-cell_type
cells	I-cell_type
.	O

dendritic	B-cell_type
cells	I-cell_type
(	O
dcs	B-cell_type
)	O
,	O
besides	O
their	O
role	O
as	O
apcs	B-cell_type
,	O
now	O
have	O
been	O
demonstrated	O
to	O
exert	O
cytotoxicity	O
or	O
cytostasis	O
on	O
some	O
tumor	B-cell_type
cells	I-cell_type
.	O

here	O
,	O
we	O
report	O
that	O
both	O
human	B-cell_type
cd00	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
stem	I-cell_type
cell	I-cell_type
-derived	O
dcs	O
(	O
cd00dcs	B-protein
)	O
and	O
human	B-cell_type
cd00	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
monocyte	I-cell_type
-derived	O
dcs	O
(	O
modcs	B-protein
)	O
express	O
trail	B-protein
and	O
exhibit	O
cytotoxicity	O
to	O
some	O
types	O
of	O
tumor	B-cell_type
cells	I-cell_type
partially	O
through	O
trail	B-protein
.	O

moderate	O
expression	O
of	O
trail	B-protein
appeared	O
on	O
cd00dcs	O
from	O
the	O
0th	O
day	O
of	O
culture	O
and	O
was	O
also	O
seen	O
on	O
freshly	B-cell_type
isolated	I-cell_type
monocytes	I-cell_type
.	O

the	O
level	O
of	O
trail	B-protein
expression	O
remained	O
constant	O
until	O
dc	B-cell_type
maturation	O
.	O

trail	B-protein
expression	O
on	O
immature	B-cell_line
cd00dcs	I-cell_line
or	I-cell_line
modcs	I-cell_line
was	O
greatly	O
up-regulated	O
after	O
ifn-beta	B-protein
stimulation	O
.	O

moreover	O
,	O
ifn-beta	B-protein
could	O
strikingly	O
enhance	O
the	O
ability	O
of	O
cd00dcs	B-protein
or	O
modcs	O
to	O
kill	O
trail-sensitive	B-cell_type
tumor	I-cell_type
cells	I-cell_type
,	O
but	O
lps	O
did	O
not	O
have	O
such	O
an	O
effect	O
.	O

the	O
up-regulation	O
of	O
trail	B-protein
on	O
ifn-beta	B-protein
-stimulated	O
dcs	B-cell_type
partially	O
contributed	O
to	O
the	O
increased	O
cytotoxicity	O
of	O
dcs	B-cell_type
:	O
pretreatment	O
of	O
trail-sensitive	B-cell_type
tumor	I-cell_type
cells	I-cell_type
with	O
caspase-0	B-protein
inhibitor	I-protein
could	O
significantly	O
increase	O
their	O
resistance	O
to	O
the	O
cytotoxicity	O
of	O
ifn-beta	B-protein
-stimulated	O
dcs	B-cell_type
:	O
in	O
contrast	O
,	O
nf-kappab	B-protein
inhibitor	O
could	O
significantly	O
increase	O
the	O
sensitivity	O
of	O
tumor	B-cell_type
cells	I-cell_type
to	O
the	O
killing	O
by	O
nonstimulated	O
or	O
lps-stimulated	O
dcs	B-cell_type
:	O
our	O
studies	O
demonstrate	O
that	O
ifn-beta	B-protein
-stimulated	O
dcs	B-cell_type
are	O
functionally	O
cytotoxic	O
.	O

thus	O
,	O
an	O
innate	O
mechanism	O
of	O
dc-mediated	O
antitumor	O
immunity	O
might	O
exist	O
in	O
vivo	O
in	O
which	O
dcs	B-cell_type
act	O
as	O
effectors	O
to	O
directly	O
kill	O
tumor	B-cell_type
cells	I-cell_type
partially	O
via	O
trail	B-protein
.	O

subsequently	O
,	O
dcs	B-cell_type
act	O
as	O
apcs	B-cell_type
involved	O
in	O
the	O
uptake	O
,	O
processing	O
,	O
and	O
presentation	O
of	O
apoptotic	O
tumor	B-protein
ags	I-protein
to	O
cross-prime	B-cell_line
cd0	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
ctl	I-cell_line
cells	I-cell_line
.	O

###MEDLINE:21205813

tumor	B-cell_type
cells	I-cell_type
regulate	O
the	O
lytic	O
activity	O
of	O
tumor-specific	O
cytotoxic	B-cell_type
t	I-cell_type
lymphocytes	I-cell_type
by	O
modulating	O
the	O
inhibitory	O
natural	B-protein
killer	I-protein
receptor	I-protein
function	O
.	O

tumor-infiltrating	B-cell_type
p00+	I-cell_type
t	I-cell_type
cells	I-cell_type
from	O
a	O
renal	O
tumor	O
were	O
specifically	O
expanded	O
in	O
response	O
to	O
tumor	O
cell	O
stimulation	O
and	O
cloned	O
.	O

these	O
p00+	B-cell_line
t	I-cell_line
cells	I-cell_line
were	O
found	O
to	O
express	O
a	O
memory	B-cell_type
phenotype	I-cell_type
and	O
corresponded	O
to	O
clonal	O
tcrbv0	O
t-cell	O
expansion	O
.	O

functionally	O
,	O
p00	B-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
ctls	I-cell_line
displayed	O
a	O
low	O
lytic	O
activity	O
for	O
hla-a0	B-protein
tumor	O
and	O
normal	B-cell_type
cells	I-cell_type
.	O

however	O
,	O
this	O
lytic	O
activity	O
was	O
significantly	O
increased	O
after	O
blockade	O
of	O
p00	B-protein
with	O
specific	O
monoclonal	B-protein
antibodies	I-protein
.	O

interestingly	O
,	O
we	O
demonstrated	O
that	O
stimulation	O
by	O
tumor	B-cell_type
cells	I-cell_type
was	O
required	O
to	O
trigger	O
the	O
inhibitory	O
effect	O
of	O
p00	B-protein
on	O
the	O
lytic	O
activity	O
of	O
antigen-specific	B-cell_type
ctls	I-cell_type
and	O
that	O
stimulation	O
of	O
the	O
inhibitory	O
function	O
of	O
p00	B-protein
by	O
tumor	B-cell_type
cells	I-cell_type
correlated	O
with	O
an	O
inhibition	O
of	O
nuclear	B-protein
factor-kappab	I-protein
activation	O
in	O
p00+	O
tumor-specific	O
ctls	B-cell_type
.	O

###MEDLINE:21198003

t-cell	B-protein
factor-0	I-protein
expression	O
during	O
human	B-cell_type
natural	I-cell_type
killer	I-cell_type
cell	I-cell_type
development	O
and	O
in	O
circulating	B-cell_type
cd00	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
bright	I-cell_type
natural	I-cell_type
killer	I-cell_type
cells	I-cell_type
.	O

transcription	B-protein
factors	I-protein
are	O
essential	O
to	O
govern	O
differentiation	O
along	O
the	O
lymphoid	B-cell_type
lineage	I-cell_type
from	O
uncommitted	B-cell_type
hematopoietic	I-cell_type
stem	I-cell_type
cells	I-cell_type
.	O

although	O
many	O
of	O
these	O
transcription	B-protein
factors	I-protein
have	O
putative	O
roles	O
based	O
on	O
murine	O
knockout	O
experiments	O
,	O
their	O
function	O
in	O
human	O
lymphoid	O
development	O
is	O
less	O
known	O
and	O
was	O
studied	O
further	O
.	O

transcription	B-protein
factor	I-protein
expression	O
in	O
fresh	B-cell_type
and	I-cell_type
cultured	I-cell_type
adult	I-cell_type
human	I-cell_type
bone	I-cell_type
marrow	I-cell_type
and	I-cell_type
umbilical	I-cell_type
cord	I-cell_type
blood	I-cell_type
progenitors	I-cell_type
was	O
evaluated	O
.	O

we	O
found	O
that	O
fresh	B-cell_type
cd00	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
lin	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
cells	I-cell_type
that	O
are	O
human	B-protein
leukocyte	I-protein
antigen	I-protein
(	O
hla	B-protein
)	I-protein
-dr	I-protein
(	O
-	O
)	O
or	O
cd00	B-protein
(	O
-	O
)	O
constitutively	O
express	O
gata-0	B-protein
but	O
not	O
t-cell	B-protein
factor-0	I-protein
(	O
tcf-0	B-protein
)	O
or	O
id-0	B-protein
.	O

culture	O
with	O
the	O
murine	B-cell_line
fetal	I-cell_line
liver	I-cell_line
cell	I-cell_line
line	I-cell_line
aft000	B-cell_line
and	O
defined	O
cytokines	B-protein
was	O
capable	O
of	O
inducing	O
tcf-0	B-RNA
mrna	I-RNA
.	O

however	O
,	O
no	O
t-cell	B-DNA
receptor	I-DNA
gene	I-DNA
rearrangement	O
was	O
identified	O
in	O
cultured	B-cell_line
progeny	I-cell_line
.	O

id-0	B-protein
,	O
a	O
basic	B-protein
helix	I-protein
loop	I-protein
helix	I-protein
factor	I-protein
with	O
dominant	O
negative	O
function	O
for	O
t-cell	B-protein
differentiation	I-protein
transcription	I-protein
factors	I-protein
,	O
also	O
was	O
upregulated	O
and	O
may	O
explain	O
unsuccessful	O
t-cell	O
maturation	O
.	O

to	O
better	O
understand	O
the	O
developmental	O
link	O
between	O
natural	B-cell_type
killer	I-cell_type
(	I-cell_type
nk	I-cell_type
)	I-cell_type
cells	I-cell_type
derived	O
from	O
progenitors	B-cell_type
,	O
we	O
studied	O
nk	B-cell_type
cell	I-cell_type
subsets	I-cell_type
circulating	O
in	O
blood	O
.	O

cd00	B-protein
(	O
+bright	B-protein
)	O
,	O
but	O
not	O
cd00	B-protein
(	O
+dim	B-protein
)	O
,	O
nk	B-cell_type
cells	I-cell_type
constitutively	O
express	O
tcf-0	B-protein
by	O
reverse	B-protein
transcriptase	I-protein
polymerase	I-protein
chain	I-protein
reaction	O
and	O
western	O
blot	O
analysis	O
.	O

the	O
tcf-0	B-protein
isoform	I-protein
found	O
in	O
cd00	B-protein
(	O
+bright	B-cell_line
)	I-cell_line
cells	I-cell_line
,	O
which	O
express	O
lectin	B-protein
but	O
not	O
immunoglobulin	B-DNA
class	I-DNA
i	I-DNA
recognizing	O
inhibitory	B-protein
receptors	I-protein
,	O
was	O
identical	O
to	O
that	O
induced	O
in	O
nk	B-cell_type
cell	I-cell_type
differentiation	O
culture	O
and	O
was	O
distinctly	O
different	O
from	O
isoforms	O
in	O
t	B-cell_type
cells	I-cell_type
.	O

these	O
results	O
suggest	O
that	O
tcf-0	B-protein
does	O
not	O
target	O
human	B-DNA
killer	I-DNA
immunoglobulin	I-DNA
receptor	I-DNA
genes	I-DNA
,	O
tcf-0	B-protein
is	O
uniquely	O
expressed	O
in	O
circulating	B-cell_type
cd00	I-cell_type
(	I-cell_type
+bright	I-cell_type
)	I-cell_type
nk	I-cell_type
cells	I-cell_type
,	O
and	O
specific	O
tcf-0	B-protein
isoforms	I-protein
may	O
play	O
an	O
important	O
role	O
in	O
regulating	O
nk	O
differentiation	O
from	O
a	O
common	O
nk/t-cell	O
progenitor	O
.	O

###MEDLINE:21293104

transcriptional	O
activation	O
by	O
a	O
matrix	O
associating	O
region-binding	B-protein
protein	I-protein
.	O

contextual	O
requirements	O
for	O
the	O
function	O
of	O
bright	O
.	O

bright	B-protein
(	I-protein
b	I-protein
cell	I-protein
regulator	I-protein
of	O
igh	B-protein
transcription	O
)	O
is	O
a	O
b	O
cell	O
-specific	O
,	O
matrix	O
associating	O
region-binding	B-protein
protein	I-protein
that	O
transactivates	O
gene	O
expression	O
from	O
the	O
igh	B-DNA
intronic	I-DNA
enhancer	I-DNA
(	O
e	B-DNA
mu	I-DNA
)	I-DNA
.	O

we	O
show	O
here	O
that	O
bright	O
has	O
multiple	O
contextual	O
requirements	O
to	O
function	O
as	O
a	O
transcriptional	O
activator	O
.	O

bright	O
can	O
not	O
transactivate	O
via	O
out	O
of	O
context	O
,	O
concatenated	B-DNA
binding	I-DNA
sites	I-DNA
.	O

transactivation	O
is	O
maximal	O
on	O
integrated	O
substrates	O
.	O

two	O
of	O
the	O
three	O
previously	O
identified	O
binding	B-DNA
sites	I-DNA
in	O
e	B-protein
mu	I-protein
are	O
required	O
for	O
full	O
bright	O
transactivation	O
.	O

the	O
bright	B-DNA
dna	I-DNA
binding	I-DNA
domain	I-DNA
defined	O
a	O
new	O
family	O
,	O
which	O
includes	O
swi0	B-DNA
,	O
a	O
component	O
of	O
the	O
swi.snf	B-protein
complex	I-protein
shown	O
to	O
have	O
high	O
mobility	O
group-like	O
dna	O
binding	O
characteristics	O
.	O

similar	O
to	O
one	O
group	O
of	O
high	B-protein
mobility	I-protein
group	I-protein
box	I-protein
proteins	I-protein
,	O
bright	O
distorts	B-DNA
e	I-DNA
mu	I-DNA
binding	I-DNA
site	I-DNA
-containing	O
dna	O
on	O
binding	O
,	O
supporting	O
the	O
concept	O
that	O
it	O
mediates	O
e	B-protein
mu	I-protein
remodeling	O
.	O

transfection	O
studies	O
further	O
implicate	O
bright	O
in	O
facilitating	O
spatially	O
separated	O
promoter-enhancer	O
interactions	O
in	O
both	O
transient	O
and	O
stable	O
assays	O
.	O

finally	O
,	O
we	O
show	O
that	O
overexpression	O
of	O
bright	O
leads	O
to	O
enhanced	O
dnase	B-protein
i	I-protein
sensitivity	O
of	O
the	O
endogenous	B-protein
e	I-protein
mu	I-protein
matrix	O
associating	O
regions	O
.	O

these	O
data	O
further	O
suggest	O
that	O
bright	O
may	O
contribute	O
to	O
increased	O
gene	O
expression	O
by	O
remodeling	O
the	O
immunoglobulin	B-DNA
locus	I-DNA
during	O
b	B-cell_type
cell	I-cell_type
development	O
.	O

###MEDLINE:21185814

analysis	O
of	O
bcl-0	B-protein
mutations	O
in	O
classic	O
hodgkin	O
disease	O
of	O
the	O
b-	O
and	O
t-cell	O
type	O
.	O

bcl-0	B-protein
is	O
essential	O
for	O
germinal	O
center	O
formation	O
and	O
thus	O
for	O
affinity	O
maturation	O
of	O
immunoglobulin	B-DNA
(	I-DNA
ig	I-DNA
)	I-DNA
genes	I-DNA
by	O
somatic	O
mutations	O
.	O

the	O
0'-noncoding	B-DNA
region	I-DNA
of	O
the	O
bcl-0	B-DNA
gene	I-DNA
is	O
even	O
a	O
target	O
for	O
the	O
mutation	O
machinery	O
.	O

translocations	O
of	O
the	O
bcl-0	B-DNA
gene	I-DNA
to	O
heterologous	B-DNA
promoters	I-DNA
and	O
mutations	O
of	O
its	O
0'-noncoding	B-DNA
regulatory	I-DNA
region	I-DNA
were	O
reported	O
to	O
be	O
potential	O
mechanisms	O
for	O
deregulating	O
bcl-0	B-protein
expression	O
and	O
for	O
playing	O
a	O
role	O
in	O
the	O
genesis	O
of	O
non-hodgkin	O
lymphoma	O
.	O

in	O
line	O
with	O
this	O
hypothesis	O
is	O
the	O
observation	O
that	O
b-cell	O
lymphoma	O
with	O
somatic	O
mutations	O
,	O
such	O
as	O
diffuse	O
large	O
b-cell	O
lymphoma	O
and	O
follicular	O
lymphoma	O
,	O
also	O
carry	O
bcl-0	B-protein
mutations	O
,	O
some	O
of	O
which	O
are	O
recurrently	O
detectable	O
.	O

classic	O
hodgkin	O
disease	O
(	O
chd	O
)	O
is	O
also	O
derived	O
from	O
b	B-cell_type
cells	I-cell_type
with	O
high	O
loads	O
of	O
somatic	O
mutations	O
and	O
thus	O
a	O
further	O
candidate	O
for	O
bcl-0	B-protein
mutations	O
.	O

to	O
determine	O
the	O
presence	O
and	O
potential	O
role	O
of	O
bcl-0	B-protein
mutations	O
in	O
chd	O
,	O
the	O
0'-noncoding	O
bcl-0	B-protein
proportion	O
of	O
single	O
hodgkin	B-cell_line
and	I-cell_line
reed-sternberg	I-cell_line
(	I-cell_line
hrs	I-cell_line
)	I-cell_line
cells	I-cell_line
from	O
0	O
cases	O
of	O
chd	O
and	O
0	O
cases	O
of	O
hd-derived	B-cell_line
cell	I-cell_line
lines	I-cell_line
was	O
analyzed	O
.	O

all	O
b-cell-derived	O
hd	O
cases	O
and	O
cell	B-cell_line
lines	I-cell_line
harbored	O
bcl-0	B-protein
mutations	O
.	O

in	O
contrast	O
,	O
both	O
t-cell-derived	O
hd	O
cases	O
and	O
cell	B-cell_line
lines	I-cell_line
were	O
devoid	O
of	O
bcl-0	B-protein
mutations	O
.	O

with	O
only	O
one	O
exception	O
,	O
there	O
were	O
no	O
lymphoma-specific	O
recurrent	O
bcl-0	B-protein
mutations	O
detected	O
,	O
and	O
bcl-0	B-protein
protein	I-protein
was	O
absent	O
from	O
the	O
hrs	O
cells	O
of	O
most	O
cases	O
.	O

in	O
conclusion	O
,	O
(	O
0	O
)	O
somatic	O
bcl-0	B-protein
mutations	O
are	O
restricted	O
to	O
chd	O
cases	O
of	O
b-cell	B-cell_line
origin	I-cell_line
,	O
and	O
(	O
0	O
)	O
the	O
bcl-0	B-protein
mutations	O
represent	O
mostly	O
irrelevant	O
somatic	O
base	O
substitutions	O
without	O
consequences	O
for	O
bcl-0	B-protein
protein	I-protein
expression	O
and	O
the	O
pathogenesis	O
of	O
chd	O
.	O

###MEDLINE:21184779

gadd00gamma	B-protein
is	O
dispensable	O
for	O
normal	O
mouse	O
development	O
and	O
t-cell	O
proliferation	O
.	O

gadd00gamma	O
,	O
a	O
family	O
member	O
of	O
the	O
growth	O
arrest	O
and	O
dna	B-DNA
damage-inducible	I-DNA
gene	I-DNA
family	I-DNA
00	I-DNA
(	O
gadd00	B-protein
)	O
,	O
is	O
strongly	O
induced	O
by	O
interleukin-0	B-protein
(	O
il-0	B-protein
)	O
in	O
peripheral	B-cell_type
t	I-cell_type
cells	I-cell_type
.	O

while	O
in	O
most	O
tissues	O
all	O
gadd00	B-protein
family	I-protein
members	I-protein
are	O
expressed	O
,	O
gadd00gamma	B-protein
is	O
the	O
only	O
member	O
that	O
is	O
induced	O
by	O
il-0	B-protein
.	O

here	O
we	O
show	O
that	O
the	O
il-0	B-protein
-induced	O
expression	O
of	O
gadd00gamma	B-protein
is	O
dependent	O
on	O
a	O
signaling	O
pathway	O
mediated	O
by	O
the	O
tyrosine	B-protein
kinase	I-protein
jak0	B-protein
and	O
the	O
transcription	B-protein
factors	I-protein
stat0a	B-protein
and	O
stat0b	B-protein
(	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	O
transcription	O
)	O
.	O

previous	O
studies	O
with	O
ectopically	O
overexpressed	O
gadd00gamma	O
in	O
various	B-cell_line
cell	I-cell_line
lines	I-cell_line
implicated	O
its	O
function	O
in	O
negative	O
growth	O
control	O
.	O

to	O
analyze	O
the	O
physiological	O
role	O
of	O
gadd00gamma	O
we	O
used	O
homologous	O
recombination	O
to	O
generate	O
mice	O
lacking	O
gadd00gamma	O
.	O

gadd00gamma	O
-deficient	O
mice	O
develop	O
normally	O
,	O
are	O
indistinguishable	O
from	O
their	O
littermates	O
,	O
and	O
are	O
fertile	O
.	O

furthermore	O
,	O
hematopoiesis	O
in	O
mice	O
lacking	O
gadd00gamma	B-protein
is	O
not	O
impaired	O
and	O
gadd00gamma	O
-deficient	O
t	B-cell_type
lymphocytes	I-cell_type
show	O
normal	O
responses	O
to	O
il-0	B-protein
.	O

these	O
data	O
demonstrate	O
that	O
gadd00gamma	B-protein
is	O
not	O
essential	O
for	O
normal	O
mouse	O
development	O
and	O
hematopoiesis	O
,	O
possibly	O
due	O
to	O
functional	O
redundancy	O
among	O
the	O
gadd00	B-protein
family	I-protein
members	I-protein
.	O

gadd00gamma	B-protein
is	O
also	O
dispensable	O
for	O
il-0	B-protein
-induced	O
t-cell	O
proliferation	O
.	O

###MEDLINE:21179339

decreased	O
expression	O
of	O
c-myc	B-DNA
family	I-DNA
genes	I-DNA
in	O
thymuses	O
from	O
myasthenia	O
gravis	O
patients	O
.	O

the	O
thymus	O
is	O
a	O
critical	O
organ	O
for	O
the	O
elimination	O
of	O
autoreactive	B-cell_type
t	I-cell_type
cells	I-cell_type
by	O
apoptosis	O
.	O

we	O
studied	O
the	O
expression	O
of	O
apoptosis-associated	B-DNA
genes	I-DNA
,	O
bcl-xl	B-protein
,	O
bad	B-protein
,	O
caspase-0	B-protein
,	O
and	O
c-myc	B-DNA
family	I-DNA
genes	I-DNA
in	O
myasthenia	O
gravis	B-cell_line
(	I-cell_line
mg	I-cell_line
)	I-cell_line
thymuses	I-cell_line
.	O

we	O
observed	O
that	O
the	O
mrna	O
levels	O
of	O
myc	B-protein
family	O
genes	O
,	O
c-myc	B-DNA
and	O
max	B-protein
,	O
were	O
markedly	O
reduced	O
in	O
mg	O
thymuses	O
.	O

these	O
results	O
indicate	O
that	O
c-myc	B-protein
-mediated	O
signaling	O
is	O
abnormal	O
in	O
mg	O
thymuses	O
.	O

the	O
levels	O
of	O
molecules	O
whose	O
expressions	O
are	O
associated	O
with	O
myc	B-protein
,	O
such	O
as	O
stam	B-protein
,	O
prothymosin-alpha	O
,	O
and	O
nfkappab	B-protein

###MEDLINE:21174076

immunohistochemical	O
detection	O
of	O
interferon-gamma-producing	B-cell_type
cells	I-cell_type
in	O
dermatophytosis	O
.	O

skin	O
lesions	O
of	O
dermatophytosis	O
are	O
thought	O
to	O
be	O
a	O
result	O
of	O
a	O
t	B-cell_type
cell	I-cell_type
-dependent	O
inflammatory	O
response	O
that	O
is	O
mediated	O
by	O
various	O
cytokines	B-protein
.	O

we	O
examined	O
whether	O
ifn-gamma-positive	B-cell_type
cells	I-cell_type
(	O
as	O
expression	O
of	O
th0	O
response	O
)	O
were	O
present	O
in	O
the	O
skin	O
lesions	O
of	O
dermatophytosis	O
in	O
situ	O
by	O
immunohistochemical	O
techniques	O
.	O

mixtures	O
of	O
cd0-positive	B-cell_type
t	I-cell_type
cells	I-cell_type
and	O
cd0-positive	B-cell_type
t	I-cell_type
cells	I-cell_type
were	O
found	O
to	O
be	O
present	O
in	O
the	O
dermal	B-cell_type
infiltrates	I-cell_type
of	O
the	O
lesions	O
.	O

considerable	O
numbers	O
of	O
cd0a-positive	B-cell_line
cells	I-cell_line
were	O
detected	O
in	O
the	O
upper	O
dermis	O
and	O
epidermis	B-cell_type
.	O

a	O
marked	O
accumulation	O
of	O
cd00-positive	B-cell_type
cells	I-cell_type
was	O
found	O
in	O
the	O
upper	O
dermis	O
.	O

ifn-gamma-positive	B-cell_line
cells	I-cell_line
were	O
present	O
in	O
the	O
upper	O
dermis	O
of	O
the	O
lesions	O
.	O

the	O
pattern	O
of	O
ifn-gamma	B-protein
staining	O
appeared	O
to	O
be	O
intracellular	O
in	O
mononuclear	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O

the	O
staining	O
was	O
considered	O
to	O
be	O
highly	O
specific	O
because	O
it	O
could	O
be	O
completely	O
blocked	O
by	O
preabsorption	O
with	O
recombinant	O
ifn-gamma	B-protein
.	O

our	O
data	O
support	O
the	O
hypothesis	O
that	O
the	O
skin	O
lesions	O
of	O
dermatophytosis	O
may	O
be	O
associated	O
with	O
a	O
th0	O
response	O
.	O

th0	O
response	O
,	O
which	O
is	O
characterized	O
by	O
ifn-gamma	B-protein
release	O
,	O
is	O
thought	O
to	O
be	O
involved	O
in	O
the	O
host	O
defense	O
against	O
dermatophytes	O
and	O
to	O
reflect	O
cutaneous	O
reaction	O
in	O
dermatophytosis	O
.	O

###MEDLINE:21170151

regulation	O
of	O
the	O
helix-loop-helix	B-protein
proteins	I-protein
,	O
e0a	B-protein
and	O
id0	B-protein
,	O
by	O
the	O
ras	B-protein
-	I-protein
erk	I-protein
mapk	I-protein
cascade	O
.	O

activation	O
of	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
mapk	B-protein
)	O
pathways	O
leads	O
to	O
cellular	O
differentiation	O
and/or	O
proliferation	O
in	O
a	O
wide	O
variety	O
of	O
cell	O
types	O
,	O
including	O
developing	B-cell_type
thymocytes	I-cell_type
.	O

the	O
basic	B-protein
helix-loop-helix	I-protein
(	I-protein
bhlh	I-protein
)	I-protein
proteins	I-protein
e00	B-protein
and	O
e00	B-protein
and	O
an	O
inhibitor	B-protein
hlh	I-protein
protein	I-protein
,	O
id0	B-protein
,	O
play	O
key	O
roles	O
in	O
thymocyte	O
differentiation	O
.	O

we	O
show	O
here	O
that	O
e0a	B-protein
dna	O
binding	O
is	O
lowered	O
in	O
primary	B-cell_type
immature	I-cell_type
thymocytes	I-cell_type
consequent	O
to	O
t	B-protein
cell	I-protein
receptor	I-protein
(	O
tcr	B-protein
)	O
-mediated	O
ligation	O
.	O

whereas	O
expression	O
of	O
e0a	B-protein
mrna	I-protein
and	I-protein
protein	I-protein
are	O
unaltered	O
,	O
id0	B-RNA
transcripts	I-RNA
are	O
rapidly	O
induced	O
upon	O
signaling	O
from	O
the	O
tcr	B-protein
.	O

activation	O
of	O
id0	B-protein
transcription	O
is	O
regulated	O
in	O
a	O
dose-dependent	O
manner	O
by	O
the	O
extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
(	I-protein
erk	I-protein
)	I-protein
mapk	I-protein
module	I-protein
.	O

these	O
observations	O
directly	O
connect	O
the	O
erk	B-protein
mapk	I-protein
cascade	O
and	O
hlh	B-protein
proteins	I-protein
in	O
a	O
linear	O
pathway	O
.	O

###MEDLINE:21158232

retinoic	O
acid	O
up-regulates	O
myeloid	O
icam-0	B-protein
expression	O
and	O
function	O
in	O
a	O
cell-specific	O
fashion	O
--	O
evidence	O
for	O
retinoid	O
signaling	O
pathways	O
in	O
the	O
mast	B-cell_type
cell	I-cell_type
lineage	I-cell_type
.	O

investigation	O
of	O
mast	B-cell_type
cell	I-cell_type
responsiveness	O
toward	O
retinoic	O
acid	O
(	O
ra	O
)	O
revealed	O
selective	O
promotion	O
of	O
icam-0	B-protein
expression	O
in	O
the	O
human	B-cell_type
mast	I-cell_type
cell	I-cell_type
line	O
hmc-0	B-cell_type
.	O

this	O
process	O
was	O
dose-	O
and	O
time-dependent	O
and	O
detectable	O
by	O
flow	O
cytometry	O
,	O
western	O
blot	O
analysis	O
,	O
elisa	O
,	O
and	O
northern	O
blot	O
analysis	O
.	O

icam-0	B-protein
modulation	O
was	O
found	O
to	O
be	O
cell-type	O
dependent	O
,	O
detectable	O
also	O
for	O
hl-00	B-cell_line
cells	I-cell_line
and	O
monocytes	B-cell_type
but	O
not	O
u-000	B-cell_line
and	O
only	O
weakly	O
for	O
ku000	B-cell_type
cells	I-cell_type
.	O

terminally	B-cell_type
differentiated	I-cell_type
skin	I-cell_type
mast	I-cell_type
cells	I-cell_type
also	O
failed	O
to	O
up-modulate	O
their	O
icam-0	B-protein
,	O
suggesting	O
the	O
requirement	O
for	O
some	O
degree	O
of	O
immaturity	O
for	O
the	O
process	O
.	O

ra-mediated	O
effects	O
on	O
icam-0	B-protein
expression	O
,	O
studied	O
in	O
parallel	O
,	O
were	O
clearly	O
distinct	O
from	O
those	O
on	O
icam-0	B-protein
.	O

investigation	O
of	O
retinoid	B-protein
receptor	I-protein
expression	O
,	O
known	O
to	O
mediate	O
intracellular	O
ra	O
signaling	O
,	O
revealed	O
presence	O
of	O
rar	B-protein
alpha	I-protein
,	O
rar	B-protein
gamma	I-protein
,	O
rxr	B-protein
beta	I-protein
,	O
and	O
rxr	B-protein
gamma	I-protein
transcripts	I-protein
in	O
all	O
cell	B-cell_line
lines	I-cell_line
studied	O
,	O
and	O
hmc-0	B-cell_type
cells	O
were	O
the	O
only	O
line	O
lacking	O
rxr	B-protein
alpha	I-protein
.	O

rar	B-protein
beta	I-protein
,	O
not	O
expressed	O
at	O
baseline	O
,	O
was	O
induced	O
by	O
ra	O
in	O
a	O
fashion	O
obviously	O
correlating	O
with	O
icam-0	B-protein
up-regulation	O
.	O

increased	O
icam-0	B-protein
expression	O
was	O
of	O
functional	O
significance	O
,	O
such	O
that	O
processes	O
stimulated	O
or	O
co-stimulated	O
via	O
icam-0	B-protein
(	O
homotypic	O
aggregation	O
,	O
il-0	B-protein
secretion	O
)	O
were	O
clearly	O
enhanced	O
upon	O
ra	O
pretreatment	O
,	O
suggesting	O
that	O
ra	O
may	O
contribute	O
via	O
hitherto	O
unrecognized	O
pathways	O
to	O
immune	O
function	O
and	O
host	O
defense	O
.	O

###MEDLINE:21155831

cd00	B-protein
and	O
t	B-cell_type
cell	I-cell_type
co-stimulation	O
.	O

over	O
the	O
last	O
decade	O
the	O
concept	O
of	O
t	B-cell_type
cell	I-cell_type
co-stimulation	O
has	O
emerged	O
to	O
take	O
a	O
central	O
role	O
in	O
the	O
process	O
of	O
t	B-cell_type
cell	I-cell_type
activation	O
.	O

however	O
,	O
the	O
exact	O
definition	O
of	O
co-stimulation	O
is	O
still	O
unclear	O
.	O

in	O
this	O
review	O
,	O
we	O
re-examine	O
the	O
concept	O
of	O
co-stimulation	O
.	O

we	O
suggest	O
that	O
while	O
co-stimulation	O
is	O
important	O
,	O
there	O
is	O
little	O
evidence	O
to	O
link	O
co-stimulation	O
with	O
t	B-cell_type
cell	I-cell_type
anergy	O
.	O

we	O
then	O
suggest	O
a	O
framework	O
for	O
studying	O
co-stimulation	O
.	O

focusing	O
on	O
recent	O
advances	O
in	O
our	O
understanding	O
of	O
cd00	B-protein
,	O
we	O
discuss	O
four	O
areas	O
of	O
t	B-cell_type
cell	I-cell_type
activation	O
where	O
co-stimulation	O
may	O
play	O
a	O
role	O
.	O

###MEDLINE:21154038

regulation	O
of	O
activator	B-protein
protein-0	I-protein
and	O
nf-kappa	B-protein
b	I-protein
in	O
cd0+	B-cell_type
t	I-cell_type
cells	I-cell_type
exposed	O
to	O
peripheral	O
self-antigens	B-protein
.	O

the	O
transcriptional	O
events	O
that	O
control	B-cell_type
t	I-cell_type
cell	I-cell_type
tolerance	O
to	O
peripheral	O
self	O
ags	O
are	O
still	O
unknown	O
.	O

in	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
regulation	O
of	O
ap-0	B-protein
-	O
and	O
nf-kappa	B-protein
b	I-protein
-mediated	O
transcription	O
during	O
in	O
vivo	O
induction	O
of	O
tolerance	O
to	O
a	O
self	O
ag	O
expressed	O
exclusively	O
on	O
hepatocytes	B-cell_type
.	O

naive	B-cell_type
cd0	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
desire	I-cell_type
(	O
des	O
)	O
(	O
+	O
)	O
t	B-cell_type
cells	I-cell_type
isolated	O
from	O
the	O
des	O
tcr-transgenic	O
mice	O
that	O
are	O
specific	O
for	O
the	O
h-0k	B-protein
(	I-protein
b	I-protein
)	I-protein
class	I-protein
i	I-protein
ag	I-protein
were	O
transferred	O
into	O
alb-k	B-protein
(	I-protein
b	I-protein
)	O
-transgenic	O
mice	O
that	O
express	O
the	O
h-0k	B-protein
(	I-protein
b	I-protein
)	I-protein
ag	I-protein
on	O
hepatocytes	B-cell_type
only	O
.	O

tolerance	O
develops	O
in	O
these	O
mice	O
.	O

we	O
found	O
that	O
the	O
self-reactive	B-cell_type
cd0	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
des	O
(	O
+	O
)	O
t	B-cell_type
cells	I-cell_type
were	O
transiently	O
activated	O
,	O
then	O
became	O
unresponsive	O
and	O
were	O
further	O
deleted	O
.	O

in	O
contrast	O
to	O
cd0	B-protein
(	O
+	O
)	O
des	O
(	O
+	O
)	O
t	B-cell_type
cells	I-cell_type
activated	O
in	O
vivo	O
with	O
apcs	B-cell_type
,	O
which	O
express	O
high	O
ap-0	B-protein
and	O
high	O
nf-kappa	B-protein
b	I-protein
transcriptional	O
activity	O
,	O
the	O
unresponsive	O
cd0	B-protein
(	I-protein
+	I-protein
)	I-protein
des	O
(	O
+	O
)	O
t	B-cell_type
cells	I-cell_type
expressed	O
no	O
ap-0	B-protein
and	O
only	O
weak	O
nf-kappa	B-protein
b	I-protein
transcriptional	O
activity	O
.	O

the	O
differences	O
in	O
nf-kappa	B-protein
b	I-protein
transcriptional	O
activity	O
correlated	O
with	O
the	O
generation	O
of	O
distinct	O
nf-kappa	B-protein
b	I-protein
complexes	I-protein
.	O

indeed	O
,	O
in	O
vivo	O
primed	B-cell_line
t	I-cell_line
cells	I-cell_line
predominantly	O
express	O
p00/p00	B-protein
and	O
p00/p00	B-protein
dimers	I-protein
,	O
whereas	O
these	O
p00-containing	B-protein
complexes	I-protein
are	O
barely	O
detectable	O
in	O
tolerant	B-cell_type
t	I-cell_type
cells	I-cell_type
that	O
express	O
p00-	O
and	O
c-rel-containing	B-protein
complexes	I-protein
.	O

these	O
observations	O
suggest	O
that	O
fine	O
regulation	O
of	O
nf-kappa	B-protein
b	I-protein
complex	I-protein
formation	O
may	O
determine	O
t	B-cell_type
cell	I-cell_type
fate	I-cell_type
.	O

###MEDLINE:21145240

transcriptional	O
regulation	O
in	O
lymphocytes	B-cell_type
.	O

lymphocytes	B-cell_type
have	O
been	O
used	O
to	O
investigate	O
many	O
cellular	O
processes	O
,	O
including	O
lineage	O
commitment	O
,	O
differentiation	O
,	O
proliferation	O
and	O
apoptosis	O
.	O

the	O
transcription	B-protein
factors	I-protein
that	O
mediate	O
these	O
processes	O
are	O
often	O
expressed	O
broadly	O
in	O
many	O
cell	O
types	O
.	O

the	O
emerging	O
theme	O
is	O
one	O
of	O
cell-type-specific	O
regulation	O
,	O
affecting	O
not	O
only	O
the	O
functional	O
activation	O
of	O
transcription	B-protein
factors	I-protein
but	O
also	O
their	O
access	O
to	O
appropriate	O
regions	O
of	O
dna	O
.	O

###MEDLINE:21133063

existence	O
of	O
retinoic	O
acid-receptor	O
-independent	O
retinoid	B-protein
x-receptor	I-protein
-dependent	O
pathway	O
in	O
myeloid	O
cell	O
function	O
.	O

we	O
previously	O
reported	O
that	O
er-00000	O
(	O
0-	O
[	O
0	O
,	O
0	O
,	O
0	O
,	O
0	O
,	O
0	O
,	O
00-hexahydro-0	O
,	O
0	O
,	O
00	O
,	O
00-tetramethyl-0-	O
(	O
0-pyridylmethyl	O
)	O
anthra	O
[	O
0	O
,	O
0-b	O
]	O
pyrrol-0-yl	O
]	O
benzoic	O
acid	O
)	O
is	O
a	O
potent	O
antagonist	O
of	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
(	O
rar	B-protein
)	O
,	O
and	O
er-00000	O
(	O
(	O
0e	O
,	O
0e	O
,	O
0e	O
)	O
-0-	O
[	O
0-	O
(	O
0-methylethyl	B-protein
)	O
-0-chloro-0	O
,	O
0	O
,	O
0	O
,	O
0-tetrahydroquinolin-0-yl	O
]	O
-0-fluoro-0-methyl-0	O
,	O
0	O
,	O
0-nonatrienoic	O
acid	O
)	O
is	O
a	O
novel	O
retinoid	B-protein
x	I-protein
receptor	I-protein
(	O
rxr	B-protein
)	O
-specific	O
agonist	O
.	O

by	O
using	O
these	O
compounds	O
,	O
we	O
investigated	O
whether	O
distinct	O
rar	B-protein
-dependent	O
and	O
rxr	B-protein
-dependent	O
pathways	O
operate	O
to	O
mediate	O
the	O
diverse	O
activities	O
of	O
retinoids	O
,	O
particularly	O
,	O
the	O
effects	O
of	O
the	O
rxr	B-protein
pathway	O
on	O
cellular	O
function	O
.	O

er-00000	O
completely	O
antagonized	O
hl00	B-cell_line
cell	O
differentiation	O
induced	O
by	O
all-trans-retinoic	O
acid	O
(	O
atra	O
)	O
.	O

however	O
,	O
the	O
differentiation	O
induced	O
by	O
the	O
er-00000	O
was	O
not	O
antagonized	O
at	O
all	O
by	O
the	O
rar	B-protein
antagonist	I-protein
,	O
but	O
was	O
inhibited	O
by	O
an	O
rxr	B-protein
homodimer	I-protein
antagonist	O
(	O
lgd000000	B-protein
,	O
(	O
0e	O
,	O
0e	O
,	O
0z	O
)	O
-0-	O
(	O
0-n-propoxy-0	B-protein
,	O
0	B-RNA
,	I-RNA
0	I-RNA
,	I-RNA
0-tetrahydro-0	I-RNA
,	I-RNA
0	I-RNA
,	I-RNA
0	I-RNA
,	I-RNA
0-tetramethylnaphthalen-0-yl	I-RNA
)	I-RNA
-0-methylocta-0	I-RNA
,	I-RNA
0	I-RNA
,	I-RNA
0-trienoic	I-RNA
acid	I-RNA
)	O
.	O

its	O
agonistic	O
action	O
on	O
rxr/rar	B-protein
heterodimer	I-protein
,	O
on	O
the	O
other	O
hand	O
,	O
was	O
neutralized	O
by	O
the	O
rar	B-protein
antagonist	I-protein
.	O

during	O
hl00	B-cell_line
cell	I-cell_line
differentiation	O
,	O
atra	O
induced	O
rarbeta	B-RNA
mrna	I-RNA
,	O
while	O
the	O
rxr	B-protein
had	O
no	O
effect	O
.	O

interestingly	O
,	O
a	O
functional	O
rxr	B-protein
-pathway	I-protein
was	O
also	O
seen	O
in	O
lipopolysaccharide-induced	O
inhibition	O
of	O
mouse	B-cell_type
splenocyte	I-cell_type
proliferation	O
.	O

these	O
results	O
strongly	O
suggest	O
the	O
existence	O
of	O
a	O
pharmacological	O
rxr	B-protein
-dependent	O
pathway	O
that	O
is	O
activated	O
by	O
a	O
ligand	O
that	O
can	O
bind	O
to	O
rxr	B-protein
.	O

###MEDLINE:21136373

targeting	O
src	B-protein
homology	I-protein
0	I-protein
domain-containing	I-protein
tyrosine	I-protein
phosphatase	I-protein
(	O
shp-0	B-protein
)	O
into	O
lipid	B-protein
rafts	I-protein
inhibits	O
cd0	B-protein
-induced	O
t	O
cell	O
activation	O
.	O

to	O
study	O
the	O
mechanism	O
by	O
which	O
protein	B-protein
tyrosine	I-protein
phosphatases	I-protein
(	O
ptps	B-protein
)	O
regulate	O
cd0	B-protein
-induced	O
tyrosine	O
phosphorylation	O
,	O
we	O
investigated	O
the	O
distribution	O
of	O
ptps	B-protein
in	O
subdomains	O
of	O
plasma	O
membrane	O
.	O

we	O
report	O
here	O
that	O
the	O
bulk	O
ptp	O
activity	O
associated	O
with	O
t	B-cell_type
cell	I-cell_type
membrane	O
is	O
present	O
outside	O
the	O
lipid	O
rafts	O
,	O
as	O
determined	O
by	O
sucrose	O
density	O
gradient	O
sedimentation	O
.	O

in	O
jurkat	B-cell_line
t	I-cell_line
cells	I-cell_line
,	O
approximately	O
0	O
--	O
00	O
%	O
of	O
src	B-protein
homology	I-protein
0	I-protein
domain-containing	I-protein
tyrosine	I-protein
phosphatase	I-protein
(	O
shp-0	B-protein
)	O
is	O
constitutively	O
associated	O
with	O
plasma	O
membrane	O
,	O
and	O
nearly	O
00	O
%	O
of	O
shp-0	B-protein
is	O
translocated	O
to	O
plasma	O
membrane	O
after	O
vanadate	O
treatment	O
.	O

similar	O
to	O
transmembrane	B-protein
ptp	I-protein
,	O
cd00	B-protein
,	O
the	O
membrane-associated	O
populations	O
of	O
shp-0	B-protein
and	O
shp-0	B-protein
are	O
essentially	O
excluded	O
from	O
lipid	B-protein
rafts	I-protein
,	O
where	O
other	O
signaling	O
molecules	O
such	O
as	O
lck	B-protein
,	O
linker	O
for	O
activation	O
of	O
t	B-cell_type
cells	I-cell_type
,	O
and	O
cd0	B-protein
zeta	I-protein
are	O
enriched	O
.	O

we	O
further	O
demonstrated	O
that	O
cd0	B-protein
-induced	O
tyrosine	O
phosphorylation	O
of	O
these	O
substrates	O
is	O
largely	O
restricted	O
to	O
lipid	O
rafts	O
,	O
unless	O
ptps	B-protein
are	O
inhibited	O
.	O

it	O
suggests	O
that	O
a	O
restricted	O
partition	O
of	O
ptps	O
among	O
membrane	O
subdomains	O
may	O
regulate	O
protein	O
tyrosine	O
phosphorylation	O
in	O
t	B-cell_type
cell	I-cell_type
membrane	O
.	O

to	O
test	O
this	O
hypothesis	O
,	O
we	O
targeted	O
shp-0	B-protein
into	O
lipid	O
rafts	O
by	O
using	O
the	O
n-terminal	B-protein
region	I-protein
of	O
lck	B-protein
(	O
residues	O
0	O
--	O
00	O
)	O
.	O

the	O
results	O
indicate	O
that	O
the	O
expression	O
of	O
lck/shp-0	B-protein
chimera	I-protein
inside	O
lipid	O
rafts	O
profoundly	O
inhibits	O
cd0	B-protein
-induced	O
tyrosine	O
phosphorylation	O
of	O
cd0	B-protein
zeta/epsilon	I-protein
,	O
il-0	B-protein
generation	O
,	O
and	O
nuclear	O
mobilization	O
of	O
nf-at	B-protein
.	O

collectively	O
,	O
these	O
results	O
suggest	O
that	O
the	O
exclusion	O
of	O
ptps	O
from	O
lipid	O
rafts	O
may	O
be	O
a	O
mechanism	O
that	O
potentiates	O
tcr	B-protein
/	O
cd0	B-protein
activation	O

###MEDLINE:21136244

an	O
instructive	O
component	O
in	O
t	B-cell_line
helper	I-cell_line
cell	I-cell_line
type	I-cell_line
0	I-cell_line
(	O
th0	B-cell_line
)	O
development	O
mediated	O
by	O
gata-0	B-protein
.	O

although	O
interleukin	B-protein
(	I-protein
il	I-protein
)	I-protein
-00	I-protein
and	O
il-0	B-protein
polarize	O
naive	B-cell_type
cd0	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
t	I-cell_type
cells	I-cell_type
toward	O
t	B-cell_line
helper	I-cell_line
cell	I-cell_line
type	I-cell_line
0	I-cell_line
(	I-cell_line
th0	I-cell_line
)	I-cell_line
or	I-cell_line
th0	I-cell_line
phenotypes	I-cell_line
,	O
it	O
is	O
not	O
known	O
whether	O
cytokines	B-protein
instruct	O
the	O
developmental	O
fate	O
in	O
uncommitted	B-cell_type
progenitors	I-cell_type
or	O
select	O
for	O
outgrowth	O
of	O
cells	O
that	O
have	O
stochastically	O
committed	O
to	O
a	O
particular	O
fate	O
.	O

to	O
distinguish	O
these	O
instructive	O
and	O
selective	O
models	O
,	O
we	O
used	O
surface	O
affinity	O
matrix	O
technology	O
to	O
isolate	O
committed	B-cell_type
progenitors	I-cell_type
based	O
on	O
cytokine	B-protein
secretion	O
phenotype	O
and	O
developed	O
retroviral-based	O
tagging	O
approaches	O
to	O
directly	O
monitor	O
individual	O
progenitor	O
fate	O
decisions	O
at	O
the	O
clonal	O
and	O
population	O
levels	O
.	O

we	O
observe	O
il-0	B-protein
-dependent	O
redirection	O
of	O
phenotype	O
in	O
cells	O
that	O
have	O
already	O
committed	O
to	O
a	O
non-il-0-producing	O
fate	O
,	O
inconsistent	O
with	O
predictions	O
of	O
the	O
selective	O
model	O
.	O

further	O
,	O
retroviral	O
tagging	O
of	O
naive	B-cell_type
progenitors	I-cell_type
with	O
the	O
th0-specific	B-protein
transcription	I-protein
factor	I-protein
gata-0	B-protein
provided	O
direct	O
evidence	O
for	O
instructive	O
differentiation	O
,	O
and	O
no	O
evidence	O
for	O
the	O
selective	O
outgrowth	O
of	O
cells	O
committed	O
to	O
either	O
the	O
th0	O
or	O
th0	B-cell_type
fate	I-cell_type
.	O

these	O
data	O
would	O
seem	O
to	O
exclude	O
selection	O
as	O
an	O
exclusive	O
mechanism	O
in	O
th0	B-cell_type
/	O
th0	O
differentiation	O
,	O
and	O
support	O
an	O
instructive	O
model	O
of	O
cytokine-driven	O
transcriptional	O
programming	O
of	O
cell	O
fate	O
decisions	O
.	O

###MEDLINE:21131863

in	O
vitro-activated	O
human	O
lupus	B-cell_type
t	I-cell_type
cells	I-cell_type
express	O
normal	O
estrogen	B-protein
receptor	I-protein
proteins	I-protein
which	O
bind	O
to	O
the	O
estrogen	B-DNA
response	I-DNA
element	I-DNA
.	O

we	O
have	O
shown	O
that	O
estrogen	B-protein
receptor	I-protein
(	O
eralpha	B-protein
,	O
erbeta	B-protein
)	O
transcripts	O
are	O
expressed	O
in	O
sle	O
and	O
normal	B-cell_type
t	I-cell_type
cells	I-cell_type
.	O

in	O
this	O
study	O
,	O
t	B-cell_type
cell	I-cell_type
nuclear	O
extracts	O
from	O
female	O
lupus	O
patients	O
and	O
normal	O
donors	O
were	O
tested	O
for	O
biologically	O
active	O
er	B-protein
proteins	I-protein
capable	O
of	O
binding	O
to	O
the	O
human	O
estrogen	B-DNA
response	I-DNA
element	I-DNA
(	O
here	O
)	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

when	O
peripheral	B-cell_type
blood	I-cell_type
t	I-cell_type
cells	I-cell_type
were	O
stimulated	O
with	O
00beta-estradiol	O
(	O
e0	B-protein
)	O
,	O
pma	O
and	O
ionomycin	O
,	O
two	O
major	O
retarded	O
bands	O
in	O
t	B-cell_type
cell	I-cell_type
nuclear	O
extracts	O
exhibited	O
a	O
migration	O
pattern	O
similar	O
to	O
slow	O
migrating	O
protein-ere	B-protein
complexes	I-protein
in	O
human	B-cell_type
breast	I-cell_type
cancer	I-cell_type
cell	I-cell_type
extracts	I-cell_type
.	O

t	B-cell_type
cells	I-cell_type
cultured	O
only	O
with	O
e0	B-protein
did	O
not	O
have	O
these	O
complexes	O
.	O

the	O
formation	O
of	O
the	O
complexes	O
was	O
inhibited	O
by	O
competition	O
with	O
the	O
here	O
cold	O
oligonucleotide	O
and	O
partially	O
with	O
anti-eralpha	B-protein
antibodies	I-protein
.	O

there	O
was	O
no	O
notable	O
difference	O
in	O
the	O
migration	O
pattern	O
of	O
ere-binding	B-protein
proteins	I-protein
between	O
the	O
sle	O
and	O
normal	B-cell_type
t	I-cell_type
cell	I-cell_type
extracts	I-cell_type
.	O

together	O
,	O
these	O
results	O
suggest	O
that	O
activated	B-cell_type
human	I-cell_type
t	I-cell_type
cells	I-cell_type
,	O
whether	O
lupus-derived	B-protein
or	O
normal-derived	B-protein
,	O
contain	O
biologically	O
active	O
eralpha	B-protein
proteins	I-protein
.	O

other	O
factors	O
may	O
be	O
responsible	O
for	O
differential	O
sensitivity	O
of	O
lupus	B-cell_type
t	I-cell_type
cells	I-cell_type
to	O
estrogen	O
.	O

###MEDLINE:21115153

mechanism	O
of	O
the	O
inhibitory	O
effect	O
of	O
protease	B-protein
inhibitor	O
on	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
production	O
of	O
monocytes	B-cell_type
.	O

if	O
the	O
inflammatory	O
response	O
becomes	O
excessive	O
or	O
uncontrolled	O
by	O
some	O
stimuli	O
,	O
inappropriate	O
inflammatory	O
responses	O
occur	O
.	O

monocytes	B-cell_type
are	O
extremely	O
important	O
cells	O
for	O
regulating	O
the	O
cytokine	B-protein
network	I-protein
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
tnfalpha	B-protein
)	O
and	O
interleukin-	B-protein
(	I-protein
il	I-protein
)	I-protein
00	I-protein
,	O
which	O
are	O
mainly	O
synthesized	O
by	O
monocytes	B-cell_type
,	O
are	O
representative	O
cytokines	O
that	O
play	O
a	O
central	O
role	O
in	O
the	O
cytokine	B-protein
network	I-protein
.	O

protease	O
inhibitors	O
such	O
as	O
gabexate	O
mesilate	O
(	O
gm	O
)	O
and	O
ulinastatin	O
(	O
uti	O
)	O
have	O
been	O
shown	O
to	O
have	O
various	O
beneficial	O
effects	O
by	O
inhibiting	O
the	O
activation	O
of	O
leukocytes	B-cell_type
,	O
but	O
the	O
mechanism	O
for	O
this	O
has	O
yet	O
to	O
be	O
fully	O
elucidated	O
.	O

in	O
this	O
study	O
we	O
investigated	O
the	O
mechanism	O
of	O
the	O
inhibitory	O
effect	O
of	O
protease	O
inhibitors	O
on	O
the	O
proinflammatory	B-protein
cytokine	I-protein
production	O
of	O
lipopolysaccharide-	B-protein
(	O
lps	O
)	O
stimulated	B-cell_type
monocytes	I-cell_type
.	O

lps-stimulated	B-cell_line
monocytes	I-cell_line
were	O
treated	O
with	O
gm	O
or	O
uti	O
.	O

the	O
value	O
of	O
tnfalpha	B-protein
and	O
il-00	B-protein
in	O
the	O
culture	O
medium	O
of	O
monocytes	B-cell_type
was	O
measured	O
and	O
each	O
mrna	O
expression	O
was	O
assayed	O
.	O

the	O
inhibitory	O
effect	O
of	O
protease	O
inhibitors	O
on	O
the	O
activity	O
of	O
intracellular	O
signal	O
transduction	O
pathways	O
such	O
as	O
protein	B-protein
kinase	I-protein
c	I-protein
(	O
pkc	B-protein
)	O
and	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
b	I-protein
(	O
nfkappab	B-protein
)	O
were	O
also	O
evaluated	O
.	O

gm	O
decreased	O
the	O
tnfalpha	B-protein
production	O
of	O
lps-stimulated	B-cell_line
monocytes	I-cell_line
as	O
shown	O
by	O
the	O
inhibition	O
of	O
mrna	O
expression	O
and	O
increased	O
the	O
il-00	B-protein
production	O
of	O
lps-stimulated	B-cell_type
monocytes	I-cell_type
.	O

gm	O
also	O
suppressed	O
the	O
nfkappab	B-protein
activity	O
of	O
lps-stimulated	B-cell_type
monocytes	I-cell_type
.	O

uti	O
decreased	O
the	O
tnfalpha	B-protein
production	O
of	O
lps-stimulated	B-cell_type
monocytes	I-cell_type
,	O
but	O
did	O
not	O
inhibit	O
the	O
tnfalpha	B-protein
mrna	O
expression	O
.	O

the	O
present	O
study	O
shows	O
that	O
the	O
inhibitory	O
effect	O
of	O
gm	O
on	O
the	O
tnfalpha	B-protein
production	O
of	O
activated	B-cell_type
human	I-cell_type
monocytes	I-cell_type
is	O
mediated	O
by	O
the	O
suppression	O
of	O
nfkappab	B-protein
activation	O
,	O
while	O
the	O
mechanism	O
of	O
uti	O
inhibiting	O
tnfalpha	B-protein
production	O
of	O
human	B-cell_type
monocytes	I-cell_type
may	O
be	O
due	O
to	O
the	O
inhibition	O
of	O
either	O
the	O
translation	O
or	O
secretion	O
of	O
tnfalpha	B-protein
.	O

###MEDLINE:21084706

homocysteine	O
stimulates	O
the	O
expression	O
of	O
monocyte	B-protein
chemoattractant	I-protein
protein-0	I-protein
in	O
endothelial	B-cell_type
cells	I-cell_type
leading	O
to	O
enhanced	O
monocyte	O
chemotaxis	O
.	O

hyperhomocysteinemia	O
has	O
been	O
identified	O
as	O
an	O
independent	O
risk	O
factor	O
for	O
atherosclerosis	O
.	O

the	O
infiltration	O
of	O
monocytes	B-cell_type
into	O
the	O
arterial	O
wall	O
is	O
one	O
of	O
the	O
key	O
events	O
during	O
atherogenesis	O
.	O

monocyte	B-protein
chemoattractant	I-protein
protein-0	I-protein
(	O
mcp-0	B-protein
)	O
is	O
a	O
potent	B-protein
chemokine	I-protein
that	O
stimulates	O
the	O
migration	O
of	O
monocytes	B-cell_type
into	O
the	O
intima	O
of	O
the	O
arterial	O
wall	O
.	O

the	O
mechanism	O
by	O
which	O
increased	O
monocyte	O
infiltration	O
occurs	O
in	O
atherosclerotic	O
lesions	O
in	O
patients	O
with	O
hyperhomocysteinemia	O
has	O
not	O
been	O
delineated	O
.	O

the	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
homocysteine	O
on	O
mcp-0	B-protein
production	O
in	O
endothelial	B-cell_type
cells	I-cell_type
.	O

cells	O
were	O
incubated	O
with	O
homocysteine	O
.	O

the	O
secretion	O
of	O
mcp-0	B-protein
protein	O
was	O
significantly	O
increased	O
(	O
000	O
%	O
as	O
compared	O
to	O
the	O
control	O
)	O
in	O
cells	O
treated	O
with	O
pathological	O
concentrations	O
of	O
homocysteine	O
.	O

such	O
effect	O
was	O
accompanied	O
by	O
an	O
increased	O
expression	O
of	O
mcp-0	B-RNA
mrna	I-RNA
(	O
000	O
%	O
as	O
compared	O
to	O
the	O
control	O
)	O
in	O
endothelial	B-cell_type
cells	I-cell_type
which	O
resulted	O
in	O
enhanced	O
monocyte	O
chemotaxis	O
.	O

the	O
p00	B-protein
map	I-protein
kinase	I-protein
as	O
well	O
as	O
other	O
members	O
of	O
the	O
p00	B-protein
map	I-protein
kinase	I-protein
pathway	O
,	O
including	O
mkk0	B-protein
,	O
mkk0	B-protein
,	O
atf-0	B-protein
and	O
elk-0	B-protein
,	O
were	O
activated	O
in	O
homocysteine-treated	B-cell_type
cells	I-cell_type
.	O

homocysteine-induced	O
mcp-0	B-protein
expression	O
and	O
subsequent	O
monocyte	O
chemotaxis	O
were	O
blocked	O
by	O
a	O
p00	B-protein
map	I-protein
kinase	I-protein
inhibitor	I-protein
(	O
sb000000	O
)	O
suggesting	O
that	O
the	O
p00	B-protein
map	I-protein
kinase	I-protein
pathway	O
might	O
be	O
involved	O
in	O
homocysteine-induced	O
mcp-0	B-protein
expression	O
in	O
endothelial	B-cell_type
cells	I-cell_type
.	O

in	O
contrast	O
,	O
staurosporine	O
,	O
a	O
protein	B-protein
kinase	I-protein
c	I-protein
inhibitor	I-protein
,	O
had	O
no	O
effect	O
on	O
homocysteine-induced	O
mcp-0	B-protein
expression	O
.	O

in	O
conclusion	O
,	O
our	O
results	O
indicate	O
that	O
homocysteine	O
stimulates	O
mcp-0	B-protein
expression	O
in	O
endothelial	B-cell_type
cells	I-cell_type
leading	O
to	O
enhanced	O
monocyte	O
chemotaxis	O
.	O

###MEDLINE:21031071

inducible	O
resistance	O
to	O
fas-mediated	O
apoptosis	O
in	O
b	B-cell_type
cells	I-cell_type
.	O

apoptosis	O
produced	O
in	O
b	B-cell_type
cells	I-cell_type
through	O
fas	B-protein
(	O
apo-0	B-protein
,	O
cd00	B-protein
)	O
triggering	O
is	O
regulated	O
by	O
signals	O
derived	O
from	O
other	O
surface	B-protein
receptors	I-protein
:	O
cd00	B-protein
engagement	O
produces	O
upregulation	O
of	O
fas	B-protein
expression	O
and	O
marked	O
susceptibility	O
to	O
fas	B-protein
-induced	O
cell	O
death	O
,	O
whereas	O
antigen	B-protein
receptor	I-protein
engagement	O
,	O
or	O
il-0r	B-protein
engagement	O
,	O
inhibits	O
fas	B-protein
killing	O
and	O
in	O
so	O
doing	O
induces	O
a	O
state	O
of	O
fas	B-protein
-resistance	I-protein
,	O
even	O
in	O
otherwise	O
sensitive	O
,	O
cd00	B-protein
-stimulated	O
targets	O
.	O

surface	B-protein
immunoglobulin	I-protein
and	O
il-0r	B-protein
utilize	O
at	O
least	O
partially	O
distinct	O
pathways	O
to	O
produce	O
fas	B-protein
-resistance	I-protein
that	O
differentially	O
depend	O
on	O
pkc	B-protein
and	O
stat0	B-protein
,	O
respectively	O
.	O

further	O
,	O
surface	B-protein
immunoglobulin	I-protein
signaling	O
for	O
inducible	O
fas	B-protein
-resistance	I-protein
bypasses	I-protein
btk	B-protein
,	O
requires	O
nf-kappab	B-protein
,	O
and	O
entails	O
new	O
macromolecular	O
synthesis	O
.	O

terminal	O
effectors	O
of	O
b	B-protein
cell	I-protein
fas	I-protein
-resistance	I-protein
include	O
the	O
known	O
anti-apoptotic	B-protein
gene	I-protein
products	I-protein
,	O
bcl-xl	B-protein
and	O
flip	O
,	O
and	O
a	O
novel	O
anti-apoptotic	O
gene	O
that	O
encodes	O
faim	O
(	O
fas	B-protein
apoptosis	O
inhibitory	O
molecule	O
)	O
.	O

faim	O
was	O
identified	O
by	O
differential	O
display	O
and	O
exists	O
in	O
two	O
alternatively	O
spliced	O
forms	O
;	O
faim-s	O
is	O
broadly	O
expressed	O
,	O
but	O
faim-l	O
expression	O
is	O
tissue-specific	O
.	O

the	O
faim	B-DNA
sequence	I-DNA
is	O
highly	O
evolu-	O
tionarily	O
conserved	O
,	O
suggesting	O
an	O
important	O
role	O
for	O
this	O
molecule	O
throughout	O
phylogeny	O
.	O

inducible	O
resistance	O
to	O
fas	B-protein
killing	O
is	O
hypothesized	O
to	O
protect	O
foreign	B-cell_type
antigen-specific	I-cell_type
b	I-cell_type
cells	I-cell_type
during	O
potentially	O
hazardous	O
interactions	O
with	O
fasl-bearing	B-cell_type
t	I-cell_type
cells	I-cell_type
,	O
whereas	O
autoreactive	B-cell_type
b	I-cell_type
cells	I-cell_type
fail	O
to	O
become	O
fas	B-protein
-resistant	O
and	O
are	O
deleted	O
via	O
fas	B-protein
-dependent	O
cytotoxicity	O
.	O

inadvertent	O
or	O
aberrant	O
acquisition	O
of	O
fas	B-protein
-resistance	I-protein
may	O
permit	O
autoreactive	B-cell_type
b	I-cell_type
cells	I-cell_type
to	O
escape	O
fas	B-protein
deletion	O
,	O
and	O
malignant	B-cell_type
lymphocytes	I-cell_type
to	O
impede	O
anti-tumor	O
immunity	O
.	O

###MEDLINE:21142766

stromal	O
cell-derived	O
factor	B-protein
0	I-protein
alpha	I-protein
-induced	O
chemotaxis	O
in	O
t	B-cell_type
cells	I-cell_type
is	O
mediated	O
by	O
nitric	O
oxide	O
signaling	O
pathways	O
.	O

stromal	O
cell-derived	O
factor	B-protein
0	I-protein
alpha	I-protein
(	O
sdf0	B-protein
alpha	I-protein
)	O
and	O
its	O
cognate	O
chemokine	B-protein
receptor	I-protein
cxcr0	B-protein
act	O
as	O
potent	O
chemoattractants	O
and	O
regulate	O
trafficking	O
and	O
homing	O
of	O
hematopoietic	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
and	O
lymphocytes	B-cell_type
.	O

however	O
,	O
the	O
molecular	O
mechanisms	O
regulating	O
sdf0	B-protein
alpha	I-protein
-driven	O
cell	O
migration	O
are	O
not	O
well	O
defined	O
.	O

in	O
this	O
study	O
,	O
we	O
have	O
explored	O
the	O
roles	O
of	O
the	O
second	O
messenger	O
no	O
and	O
the	O
transcription	B-protein
factor	I-protein
nf-kappa	I-protein
b	I-protein
in	O
sdf0	B-protein
alpha	I-protein
-induced	O
t	O
cell	O
migration	O
.	O

sdf0	B-protein
alpha	I-protein
treatment	O
of	O
jurkat	B-cell_line
t	I-cell_line
cells	I-cell_line
increased	O
the	O
activity	O
of	O
no	B-protein
synthase	I-protein
,	O
which	O
catalyzes	O
the	O
generation	O
of	O
no	O
.	O

we	O
observed	O
that	O
pretreatment	O
of	O
jurkat	B-cell_line
cells	I-cell_line
or	O
activated	O
pbls	B-cell_type
with	O
several	O
no	O
donors	O
significantly	O
enhanced	O
the	O
sdf0	B-protein
alpha	I-protein
-induced	O
migration	O
,	O
whereas	O
various	O
inhibitors	O
of	O
no	B-protein
synthase	I-protein
markedly	O
abrogated	O
the	O
chemotactic	O
response	O
in	O
a	O
concentration-dependent	O
manner	O
.	O

furthermore	O
,	O
we	O
observed	O
that	O
inhibitors	O
of	O
the	O
transcription	B-protein
factor	I-protein
nf-kappa	I-protein
b	I-protein
,	O
which	O
is	O
linked	O
to	O
no	O
signaling	O
pathways	O
,	O
also	O
significantly	O
blocked	O
the	O
sdf0	B-protein
alpha	I-protein
-induced	O
chemotactic	O
response	O
.	O

however	O
,	O
these	O
compounds	O
did	O
not	O
have	O
a	O
significant	O
effect	O
on	O
sdf0	B-protein
alpha	I-protein
-induced	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
activity	O
.	O

in	O
addition	O
,	O
the	O
map/erk	B-protein
kinase	I-protein
kinase	I-protein
inhibitor	I-protein
pd00000	O
did	O
not	O
abrogate	O
sdf0	B-protein
alpha	I-protein
-induced	O
chemotaxis	O
.	O

akt	B-protein
,	O
which	O
has	O
been	O
shown	O
to	O
mediate	O
no	O
production	O
,	O
was	O
also	O
phosphorylated	O
upon	O
sdf0	B-protein
alpha	I-protein
stimulation	O
.	O

these	O
studies	O
suggest	O
that	O
no-related	O
signaling	O
pathways	O
may	O
mediate	O
sdf0	B-protein
alpha	I-protein
-induced	O
chemotaxis	O
,	O
but	O
not	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
activation	O
.	O

###MEDLINE:21110357

the	O
lack	O
of	O
nf-kappa	B-protein
b	I-protein
transactivation	O
and	O
pkc	B-protein
epsilon	O
expression	O
in	O
cd0	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cd0	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
thymocytes	I-cell_type
correlates	O
with	O
negative	O
selection	O
.	O

deletion	O
of	O
autoreactive	B-cell_type
thymocytes	I-cell_type
at	O
the	O
dp	B-DNA
stage	O
is	O
the	O
basis	O
for	O
tolerance	O
to	O
thymus-expressed	O
self	O
antigens	O
.	O

in	O
this	O
study	O
we	O
investigated	O
whether	O
distinct	O
signalling	O
pathways	O
are	O
induced	O
in	O
dp	B-DNA
thymocytes	O
as	O
compared	O
to	O
mature	B-cell_type
t	I-cell_type
cells	I-cell_type
upon	O
stimulation	O
with	O
antigen	O
.	O

using	O
triple	O
transgenic	O
mice	O
expressing	O
a	O
tcr	B-DNA
transgene	I-DNA
,	O
dominant	B-protein
negative	I-protein
ras/mek	I-protein
proteins	I-protein
and	O
a	O
reporter	B-DNA
gene	I-DNA
construct	I-DNA
with	O
ap-0	B-protein
or	O
nf-kappa	B-protein
b	I-protein
binding	I-protein
sites	I-protein
,	O
we	O
showed	O
a	O
complete	O
lack	O
of	O
transcriptional	O
activity	O
of	O
nf-kappa	B-protein
b	I-protein
but	O
not	O
ap-0	B-protein
in	O
dp	B-DNA
thymocytes	O
,	O
whereas	O
both	O
were	O
transcriptionally	O
active	O
in	O
mature	B-cell_type
t	I-cell_type
cells	I-cell_type
after	O
antigenic	O
stimulation	O
.	O

lack	O
of	O
nf-kappa	B-protein
b	I-protein
induction	O
correlated	O
with	O
increased	O
death	O
in	O
response	O
to	O
antigen	O
.	O

ap-0	B-protein
induction	O
was	O
dependent	O
on	O
the	O
integrity	O
of	O
the	O
ras/mek	O
pathway	O
indicating	O
that	O
this	O
pathway	O
was	O
activated	O
in	O
the	O
dp	B-DNA
thymocytes	O
.	O

in	O
contrast	O
,	O
we	O
found	O
a	O
complete	O
lack	O
of	O
constitutive	O
expression	O
of	O
the	O
epsilon	O
isoform	O
of	O
protein	B-protein
kinase	I-protein
c	I-protein
(	O
pkc	B-protein
)	O
in	B-cell_type
dp	I-cell_type
thymocytes	I-cell_type
,	O
although	O
it	O
was	O
present	O
in	O
mature	B-cell_type
thymocytes	I-cell_type
and	O
peripheral	B-cell_type
t	I-cell_type
cells	I-cell_type
.	O

taken	O
together	O
the	O
results	O
suggest	O
that	O
the	O
lack	O
of	O
pkc	B-protein
epsilon	O
in	O
dp	B-DNA
thymocytes	O
could	O
lead	O
to	O
the	O
absence	O
of	O
nf-kappa	B-protein
b	I-protein
activity	O
after	O
antigenic	O
stimulation	O
contributing	O
to	O
negative	O
selection	O
.	O

cell	O
death	O
and	O
differentiation	O
(	O
0000	O
)	O
0	O
,	O
0000	O
-	O
0000	O
.	O

###MEDLINE:21099673

cd0	B-protein
stimulation	O
leads	O
to	O
the	O
delayed	O
and	O
prolonged	O
activation	O
of	O
stat0	B-protein
in	O
t	B-cell_type
cells	I-cell_type
but	O
not	O
nk	B-cell_type
cells	I-cell_type
.	O

objective	O
:	O
t	B-cell_type
lymphocytes	I-cell_type
can	O
be	O
activated	O
by	O
soluble	B-protein
factors	I-protein
such	O
as	O
cytokines	B-protein
or	O
through	O
direct	O
cell-cell	O
interactions	O
.	O

although	O
cytokine	B-protein
receptors	I-protein
are	O
known	O
to	O
signal	O
through	O
stat	B-protein
family	I-protein
transcription	I-protein
factors	I-protein
,	O
the	O
mechanisms	O
by	O
which	O
other	O
cell-surface	B-protein
molecules	I-protein
,	O
such	O
as	O
cd0	B-protein
,	O
transduce	O
signals	O
is	O
unclear	O
.	O

the	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
stimulation	O
of	O
t	B-cell_type
cells	I-cell_type
through	O
cd0	B-protein
recapitulates	O
aspects	O
of	O
cytokine	B-protein
-induced	O
t-cell	O
activation	O
by	O
use	O
of	O
stat	B-protein
transcription	I-protein
factors	I-protein
.	O

materials	O
and	O
methods	O
:	O
t	B-cell_type
cells	I-cell_type
were	O
treated	O
with	O
anti-cd0	B-protein
antibodies	I-protein
or	O
cells	O
bearing	O
the	O
natural	O
cd0	B-protein
ligand	I-protein
cd00	B-protein
,	O
after	O
which	O
signaling	O
through	O
stat	B-protein
transcription	I-protein
factors	I-protein
was	O
assessed	O
.	O

results	O
:	O
stimulation	O
of	O
cd0	B-protein
on	O
primary	B-cell_type
t	I-cell_type
lymphocytes	I-cell_type
leads	O
to	O
the	O
tyrosine	O
phosphorylation	O
,	O
nuclear	O
translocation	O
,	O
and	O
dna	O
binding	O
of	O
stat0	B-protein
.	O

in	O
contrast	O
to	O
stimulation	O
by	O
cytokines	B-protein
,	O
the	O
activation	O
of	O
stat0	B-protein
in	O
response	O
to	O
cd0	B-protein
ligation	O
is	O
delayed	O
and	O
does	O
not	O
involve	O
jak	B-protein
kinases	I-protein
.	O

furthermore	O
,	O
while	O
stat	B-protein
phosphorylation	O
induced	O
by	O
cytokines	B-protein
is	O
generally	O
transient	O
,	O
stat0	B-protein
phosphorylation	O
following	O
cd0	B-protein
stimulation	O
persists	O
for	O
a	O
period	O
of	O
days	O
.	O

transcription	O
of	O
key	O
target	B-DNA
genes	I-DNA
such	O
as	O
irf0	B-protein
and	O
c-fos	B-protein
proceeds	O
with	O
delayed	O
kinetics	O
following	O
cd0	B-protein
stimulation	O
,	O
suggesting	O
that	O
this	O
unique	O
pattern	O
of	O
stat	B-protein
activation	O
may	O
lead	O
to	O
a	O
distinct	O
cellular	O
response	O
following	O
cd0	B-protein
ligation	O
.	O

this	O
pathway	O
appears	O
to	O
be	O
restricted	O
to	O
t	B-cell_type
cells	I-cell_type
,	O
as	O
stimulation	O
of	O
cd0	B-protein
on	O
nk	B-cell_type
cells	I-cell_type
does	O
not	O
lead	O
to	O
stat0	B-protein
activation	O
.	O

conclusion	O
:	O
stimulation	O
of	O
t	B-cell_type
cells	I-cell_type
through	O
cell-surface	B-protein
molecules	I-protein
such	O
as	O
cd0	B-protein
involves	O
activation	O
of	O
stat	B-protein
transcription	I-protein
factors	I-protein
,	O
thus	O
recapitulating	O
elements	O
of	O
cytokine	B-protein
signaling	O
.	O

###MEDLINE:21109735

nfatc0	O
and	O
nfatc0	B-protein
together	O
control	O
both	O
t	B-cell_type
and	I-cell_type
b	I-cell_type
cell	I-cell_type
activation	O
and	O
differentiation	O
.	O

nfat	B-protein
transcription	I-protein
factors	I-protein
play	O
critical	O
roles	O
in	O
gene	O
transcription	O
during	O
immune	O
responses	O
.	O

to	O
investigate	O
further	O
the	O
two	O
most	O
prominent	O
nfat	B-protein
family	I-protein
members	I-protein
,	O
nfatc0	B-protein
and	O
nfatc0	B-protein
,	O
we	O
generated	O
mice	O
bearing	O
lymphoid	O
systems	O
devoid	O
of	O
both	O
.	O

doubly	B-cell_line
deficient	I-cell_line
t	I-cell_line
cells	I-cell_line
displayed	O
cell	B-protein
surface	I-protein
markers	I-protein
of	O
activation	O
yet	O
were	O
significantly	O
deficient	O
in	O
the	O
development	O
of	O
multiple	O
effector	O
functions	O
,	O
including	O
th	B-protein
cytokine	I-protein
production	O
,	O
surface	B-protein
effector	I-protein
molecule	I-protein
expression	O
,	O
and	O
cytolytic	O
activity	O
.	O

nevertheless	O
,	O
doubly	B-cell_line
deficient	I-cell_line
b	I-cell_line
cells	I-cell_line
were	O
hyperactivated	O
,	O
as	O
evidenced	O
by	O
extremely	O
elevated	O
serum	O
igg0	O
and	O
ige	B-protein
,	O
as	O
well	O
as	O
plasma	O
cell	O
expansion	O
and	O
infiltration	O
of	O
end	O
organs	O
.	O

thus	O
,	O
in	O
t	B-cell_type
cells	I-cell_type
,	O
nfatc0	B-protein
and	O
nfatc0	B-protein
are	O
dispensable	O
for	O
inflammatory	O
reactivity	O
but	O
are	O
required	O
for	O
effector	O
differentiation	O
,	O
while	O
in	O
b	B-cell_type
cells	I-cell_type
,	O
nfats	O
regulate	O
both	O
normal	O
homeostasis	O
and	O
differentiation	O
.	O

###MEDLINE:21105279

epstein-barr	B-protein
virus	I-protein
immediate-early	I-protein
protein	I-protein
bzlf0	B-protein
is	O
sumo-0	O
modified	O
and	O
disrupts	O
promyelocytic	O
leukemia	O
bodies	O
.	O

although	O
the	O
immediate-early	B-protein
proteins	I-protein
of	O
both	O
herpes	B-protein
simplex	I-protein
virus	I-protein
(	I-protein
hsv	I-protein
)	I-protein
and	O
cytomegalovirus	O
(	O
cmv	O
)	O
are	O
known	O
to	O
modify	O
promyelocytic	O
leukemia	O
(	O
pml	B-protein
)	O
(	O
nd00	B-protein
)	O
bodies	O
in	O
the	O
nucleus	O
of	O
the	O
host	O
cell	O
,	O
it	O
has	O
been	O
unclear	O
whether	O
lytic	O
infection	O
with	O
gamma	O
herpesviruses	O
induces	O
a	O
similar	O
effect	O
.	O

the	O
pml	B-protein
protein	I-protein
is	O
induced	O
by	O
interferon	B-protein
,	O
involved	O
in	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
class	I-DNA
i	I-DNA
presentation	O
,	O
and	O
necessary	O
for	O
certain	O
types	O
of	O
apoptosis	O
.	O

therefore	O
,	O
it	O
is	O
likely	O
that	O
pml	B-protein
bodies	I-protein
function	O
in	O
an	O
antiviral	O
capacity	O
.	O

sumo-0	O
modification	O
of	O
pml	B-protein
is	O
known	O
to	O
be	O
required	O
for	O
the	O
formation	O
of	O
pml	B-protein
bodies	O
.	O

to	O
examine	O
whether	O
epstein-barr	O
virus	O
(	O
ebv	O
)	O
lytic	O
replication	O
interferes	O
with	O
pml	B-protein
bodies	I-protein
,	O
we	O
expressed	O
the	O
ebv	B-DNA
immediate-early	I-DNA
genes	I-DNA
bzlf0	B-DNA
(	O
z	B-protein
)	O
and	O
brlf0	B-protein
(	O
r	B-protein
)	O
in	O
ebv-positive	B-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
examined	O
pml	B-protein
localization	O
.	O

both	O
z	B-protein
and	O
r	O
expression	O
resulted	O
in	O
pml	B-protein
dispersion	O
in	O
ebv-positive	B-cell_line
cells	I-cell_line
.	O

z	B-protein
but	O
not	O
r	O
expression	O
is	O
sufficient	O
to	O
disrupt	O
pml	B-protein
bodies	O
in	O
ebv-negative	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

we	O
show	O
that	O
dispersion	O
of	O
pml	B-protein
bodies	O
by	O
z	B-protein
requires	O
a	O
portion	O
of	O
the	O
transcriptional	O
activation	O
domain	O
of	O
z	B-protein
but	O
not	O
the	O
dna-binding	O
function	O
.	O

as	O
was	O
previously	O
reported	O
for	O
the	O
hsv-0	O
icp0	B-protein
and	O
cmv	B-protein
ie0	I-protein
proteins	I-protein
,	O
z	B-protein
reduces	O
the	O
amount	O
of	O
sumo-0-modified	O
pml	O
.	O

we	O
also	O
found	O
that	O
z	B-protein
itself	O
is	O
sumo-0	B-protein
modified	O
(	O
through	O
amino	O
acid	O
00	O
)	O
and	O
that	O
z	B-protein
competes	O
with	O
pml	B-cell_type
for	O
limiting	O
amounts	O
of	O
sumo-0	B-protein
.	O

these	O
results	O
suggest	O
that	O
disruption	O
of	O
pml	B-protein
bodies	I-protein
is	O
important	O
for	O
efficient	O
lytic	O
replication	O
of	O
ebv	O
.	O

furthermore	O
,	O
z	B-protein
may	O
potentially	O
alter	O
the	O
function	O
of	O
a	O
variety	O
of	O
cellular	B-protein
proteins	I-protein
by	O
inhibiting	O
sumo-0	B-protein
modification	O

###MEDLINE:21136001

suppression	O
of	O
nuclear	B-protein
factor-kappab	I-protein
and	O
stimulation	O
of	O
inhibitor	B-protein
kappab	I-protein
by	O
troglitazone	O
:	O
evidence	O
for	O
an	O
anti-inflammatory	O
effect	O
and	O
a	O
potential	O
antiatherosclerotic	O
effect	O
in	O
the	O
obese	O
.	O

to	O
elucidate	O
whether	O
troglitazone	O
exerts	O
an	O
antiinflammatory	O
effect	O
in	O
humans	O
,	O
in	O
vivo	O
,	O
we	O
investigated	O
the	O
suppression	O
of	O
nuclear	B-protein
factor	I-protein
kappab	I-protein
(	O
nfkappab	B-protein
)	O
in	O
mononuclear	B-cell_type
cells	I-cell_type
(	O
mnc	B-cell_type
)	O
by	O
this	O
drug	O
.	O

we	O
measured	O
intranuclear	O
nfkappab	B-protein
,	O
total	O
cellular	O
nfkappab	B-protein
,	O
inhibitor	B-protein
kappab	I-protein
(	O
ikappab	B-protein
)	I-protein
alpha	I-protein
,	O
reactive	O
oxygen	O
species	O
(	O
ros	O
)	O
generation	O
,	O
and	O
p00	B-protein
(	I-protein
phox	I-protein
)	I-protein
subunit	I-protein
(	O
a	O
key	O
component	O
protein	O
of	O
nicotinamide	O
adenine	O
dinucleotide	O
phosphate	O
oxidase	O
)	O
in	O
mnc	B-cell_type
.	O

plasma	B-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
(	O
tnf	B-protein
)	I-protein
-alpha	I-protein
,	O
soluble	O
intercellular	B-protein
adhesion	I-protein
molecule-0	I-protein
(	O
sicam-0	O
)	O
,	O
monocyte	B-protein
chemoattractant	I-protein
protein-0	I-protein
(	O
mcp-0	B-protein
)	O
,	O
plasminogen	B-protein
activator	I-protein
inhibitor	I-protein
type	I-protein
0	I-protein
(	O
pai-0	B-protein
)	O
,	O
c-reactive	B-protein
protein	I-protein
(	O
crp	O
)	O
,	O
and	O
interleukin	B-protein
(	I-protein
il	I-protein
)	I-protein
-00	I-protein
(	O
antiinflammatory	O
cytokine	B-protein
)	O
concentrations	O
were	O
also	O
measured	O
as	O
mediators	O
of	O
inflammatory	O
activity	O
that	O
are	O
regulated	O
by	O
the	O
proinflammatory	B-protein
transcription	I-protein
factor	I-protein
nfkappab	B-protein
.	O

seven	O
nondiabetic	O
obese	O
patients	O
were	O
given	O
000	O
mg	O
troglitazone	O
daily	O
for	O
0	O
weeks	O
.	O

blood	O
samples	O
were	O
collected	O
before	O
and	O
at	O
weekly	O
intervals	O
thereafter	O
.	O

mnc	B-cell_type
were	O
separated	O
;	O
and	O
the	O
levels	O
of	O
intranuclear	O
nfkappab	B-protein
,	O
total	O
cellular	O
nfkappab	B-protein
,	O
ikappabalpha	B-protein
,	O
and	O
p00	B-protein
(	I-protein
phox	I-protein
)	I-protein
subunit	I-protein
and	O
ros	O
generation	O
were	O
determined	O
.	O

plasma	O
was	O
used	O
to	O
measure	O
insulin	B-protein
glucose	O
,	O
tnfalpha	B-protein
,	O
sicam	O
,	O
mcp-0	B-protein
,	O
pai-0	B-protein
,	O
crp	O
,	O
and	O
il-00	B-protein
.	O

plasma	O
insulin	O
concentrations	O
fell	O
significantly	O
at	O
week	O
0	O
,	O
from	O
00.0	O
+/-	O
00.0	O
to	O
00.0	O
+/-	O
00.0	O
mu/l	O
(	O
p	O
<	O
0.00	O
)	O
and	O
remained	O
low	O
throughout	O
0	O
weeks	O
.	O

plasma	O
glucose	O
concentrations	O
did	O
not	O
alter	O
significantly	O
.	O

there	O
was	O
a	O
fall	O
in	O
intranuclear	O
nfkappab	B-protein
,	O
total	O
cellular	O
nfkappab	B-protein
,	O
and	O
p00	B-protein
(	I-protein
phox	I-protein
)	I-protein
subunit	I-protein
,	O
with	O
an	O
increase	O
in	O
cellular	O
ikappabalpha	B-protein
at	O
week	O
0	O
,	O
which	O
persisted	O
until	O
week	O
0	O
.	O

there	O
was	O
a	O
parallel	O
fall	O
in	O
ros	O
generation	O
by	O
mnc	B-cell_type
at	O
week	O
0	O
;	O
this	O
progressed	O
and	O
persisted	O
until	O
week	O
0	O
(	O
p	O
<	O
0.000	O
)	O
.	O

plasma	O
tnf-alpha	B-protein
,	O
sicam-0	O
,	O
mcp-0	B-protein
,	O
and	O
pai-0	B-protein
concentrations	O
fell	O
significantly	O
at	O
week	O
0	O
.	O

plasma	O
il-00	B-protein
concentration	O
increased	O
significantly	O
,	O
whereas	O
plasma	O
crp	O
concentrations	O
decreased	O
.	O

we	O
conclude	O
that	O
troglitazone	O
has	O
an	O
antiinflammatory	O
action	O
that	O
may	O
contribute	O
to	O
its	O
putative	O
antiatherosclerotic	O
effects	O
.	O

###MEDLINE:21153258

tyrosine	O
phosphorylation-dependent	O
activation	O
of	O
nf-kappa	B-protein
b	I-protein
.	O

requirement	O
for	O
p00	B-protein
lck	I-protein
and	I-protein
zap-00	I-protein
protein	B-protein
tyrosine	I-protein
kinases	I-protein
.	O

phosphorylation	O
of	O
the	O
n-terminal	B-protein
domain	I-protein
of	O
i	B-protein
kappa	I-protein
b	I-protein
inhibitory	I-protein
subunits	I-protein
induces	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nf-kappa	I-protein
b	I-protein
.	O

although	O
serine	O
phosphorylation	O
has	O
been	O
shown	O
to	O
induce	O
ubiquitination	O
and	O
subsequent	O
proteasome-mediated	O
degradation	O
of	O
i	B-protein
kappa	I-protein
b-alpha	I-protein
,	O
little	O
is	O
known	O
about	O
the	O
mechanisms	O
that	O
lead	O
to	O
release	O
of	O
active	O
nf-kappa	B-protein
b	I-protein
in	O
t	B-cell_type
cells	I-cell_type
as	O
a	O
consequence	O
of	O
tyrosine	O
phosphorylation	O
of	O
i	B-protein
kappa	I-protein
b-alpha	I-protein
[	O
imbert	B-protein
,	O
v.	O
,	O
rupec	O
,	O
r.a.	O
,	O
livolsi	O
,	O
a.	O
,	O
pahl	O
,	O
h.l.	O
,	O
traenckner	O
,	O
b.m.	O
,	O
mueller-dieckmann	O
,	O
c.	O
,	O
farahifar	O
,	O
d.	O
,	O
rossi	O
,	O
b.	O
,	O
auberger	O
,	O
p.	O
,	O
baeuerle	O
,	O
p.	O
&	O
peyron	B-protein
,	O
j.f.	O
(	O
0000	O
)	O
cell	O
00	O
,	O
000	O
--	O
000	O
]	O
.	O

the	O
involvement	O
of	O
the	O
tyrosine	B-protein
kinases	I-protein
p00	B-protein
(	O
lck	B-protein
)	O
and	O
zap-00	B-protein
in	O
this	O
reaction	O
is	O
demonstrated	O
here	O
using	O
specific	O
pharmacological	O
inhibitors	O
and	O
jurkat	B-cell_line
mutants	I-cell_line
unable	O
to	O
express	O
these	O
kinases	O
.	O

although	O
the	O
inhibitors	O
prevented	O
both	O
pervanadate-induced	O
phosphorylation	O
of	O
i	B-protein
kappa	I-protein
b-alpha	I-protein
on	O
tyr00	O
and	O
nf-kappa	B-protein
b	I-protein
activation	O
,	O
we	O
observed	O
that	O
,	O
in	O
p00	B-protein
(	O
lck	B-protein
)	O
-deficient	O
jurkat	B-cell_line
mutants	I-cell_line
,	O
nf-kappa	B-protein
b	I-protein
could	O
still	O
associate	O
with	O
i	B-protein
kappa	I-protein
b-alpha	I-protein
despite	O
phosphorylation	O
on	O
tyr00	O
.	O

furthermore	O
,	O
the	O
sh0	B-protein
domain	I-protein
of	O
p00	B-protein
(	O
lck	B-protein
)	O
appeared	O
to	O
be	O
required	O
for	O
pervanadate-induced	O
nf-kappa	B-protein
b	I-protein
activation	O
but	O
not	O
for	O
tyr00	O
phosphorylation	O
.	O

these	O
results	O
show	O
that	O
p00	B-protein
(	O
lck	B-protein
)	O
and	O
zap-00	B-protein
are	O
key	O
components	O
of	O
the	O
signaling	O
pathway	O
that	O
leads	O
to	O
phosphotyrosine-dependent	O
nf-kappa	B-protein
b	I-protein
activation	O
in	O
t	B-cell_type
cells	I-cell_type
and	O
confirm	O
that	O
tyrosine	B-protein
kinases	I-protein
must	O
control	O
at	O
least	O
two	O
different	O
steps	O
to	O
induce	O
activation	O
of	O
nf-kappa	B-protein
b	I-protein
.	O

finally	O
,	O
we	O
show	O
that	O
h	O
(	O
0	O
)	O
o	O
(	O
0	O
)	O
,	O
which	O
stimulates	O
p00	B-protein
(	O
lck	B-protein
)	O
and	O
zap-00	B-protein
in	O
t	B-cell_type
cells	I-cell_type
,	O
is	O
an	O
activator	O
of	O
nf-kappa	B-protein
b	I-protein
through	O
tyrosine	O
phosphorylation	O
of	O
i	B-protein
kappa	I-protein
b-alpha	I-protein
.	O

###MEDLINE:21163376

specific	O
missense	O
mutations	O
in	O
nemo	O
result	O
in	O
hyper-igm	O
syndrome	O
with	O
hypohydrotic	O
ectodermal	O
dysplasia	O
.	O

the	O
gene	O
that	O
encodes	O
nuclear	B-protein
factor	I-protein
kappab	I-protein
(	O
nf-kappab	B-protein
)	O
essential	O
modulator	O
(	O
or	O
nemo	B-protein
,	O
also	O
known	O
as	O
ikkgamma	B-protein
)	O
is	O
required	O
for	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nf-kappab	B-protein
.	O

we	O
describe	O
mutations	O
in	O
the	O
putative	B-protein
zinc-finger	I-protein
domain	I-protein
of	O
nemo	O
that	O
result	O
in	O
an	O
x-linked	O
primary	O
immunodeficiency	O
characterized	O
by	O
hyper-igm	O
syndrome	O
and	O
hypohydrotic	O
ectodermal	O
dysplasia	O
(	O
xhm-ed	B-protein
)	O
.	O

these	O
mutations	O
prevent	O
cd00	B-protein
ligand	I-protein
(	O
cd00l	B-protein
)	O
-mediated	O
degradation	O
of	O
inhibitor	O
of	O
nf-kappab	B-protein
alpha	I-protein
(	O
ikappab-alpha	B-protein
)	O
and	O
account	O
for	O
the	O
following	O
observations	O
:	O
b	B-cell_type
cells	I-cell_type
from	O
xhm-ed	O
patients	O
are	O
unable	O
to	O
undergo	O
immunoglobulin	B-DNA
class-switch	I-DNA
recombination	O
and	O
antigen-presenting	B-cell_type
cells	I-cell_type
(	O
apcs	B-cell_type
)	O
are	O
unable	O
to	O
synthesize	O
the	O
nf-kappab-regulated	B-protein
cytokines	I-protein
interleukin	B-protein
00	I-protein
(	O
il-00	B-protein
)	O
or	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
tnf-alpha	B-protein
)	O
when	O
stimulated	O
with	O
cd00l	B-protein
.	O

nevertheless	O
,	O
innate	O
immunity	O
is	O
preserved	O
in	O
xhm-ed	O
patients	O
because	O
apcs	B-cell_type
retain	O
the	O
capacity	O
to	O
respond	O
to	O
stimulation	O
by	O
lipopolysaccharide	O
or	O
staphylococcus	O
aureus	O
cowan	O
's	O
antigen	O
(	O
sac	O
)	O
.	O

overall	O
,	O
the	O
phenotype	O
observed	O
in	O
xhm-ed	O
patients	O
shows	O
that	O
the	O
putative	B-protein
zinc-finger	I-protein
domain	I-protein
of	O
nemo	B-protein
has	O
a	O
regulatory	O
function	O
and	O
demonstrates	O
the	O
definite	O
requirement	O
of	O
cd00	B-protein
-mediated	O
nf-kappab	B-protein
activation	O
for	O
b	B-protein
cell	I-protein
immunoglobulin	I-protein
class-switching	I-protein
.	O

###MEDLINE:21079795

granulocytic	O
differentiation	O
of	O
human	B-cell_line
nb0	I-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
induced	O
by	O
all-trans	O
retinoic	O
acid	O
metabolites	O
.	O

the	O
metabolism	O
of	O
all-trans	O
retinoic	O
acid	O
(	O
atra	O
)	O
has	O
been	O
reported	O
to	O
be	O
partly	O
responsible	O
for	O
the	O
in	O
vivo	O
resistance	O
to	O
atra	O
seen	O
in	O
the	O
treatment	O
of	O
human	B-cell_line
acute	I-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
(	I-cell_line
apl	I-cell_line
)	I-cell_line
.	O

however	O
,	O
atra	O
metabolism	O
appears	O
to	O
be	O
involved	O
in	O
the	O
growth	O
inhibition	O
of	O
several	O
cancer	O
cell	O
lines	O
in	O
vitro	O
.	O

the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
in	O
vitro	O
activity	O
of	O
the	O
principal	O
metabolites	O
of	O
atra	O
[	O
0-hydroxy-retinoic	B-RNA
acid	I-RNA
(	I-RNA
0-oh-ra	I-RNA
)	I-RNA
,	I-RNA
00-hydroxy-retinoic	I-RNA
acid	I-RNA
(	I-RNA
00-oh-ra	I-RNA
)	I-RNA
,	I-RNA
0-oxo-retinoic	I-RNA
acid	I-RNA
(	I-RNA
0-oxo-ra	I-RNA
)	I-RNA
,	I-RNA
and	I-RNA
0	I-RNA
,	I-RNA
0-epoxy-retinoic	I-RNA
acid	I-RNA
(	O
0	O
,	O
0-epoxy-ra	B-protein
)	O
]	O
in	O
nb0	B-cell_line
,	O
a	O
human	B-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
that	O
exhibits	O
the	O
apl	O
diagnostic	O
t	O
(	O
00	O
;	O
00	O
)	O
chromosomal	O
translocation	O
and	O
expresses	O
the	O
pml-rar	B-protein
alpha	I-protein
fusion	I-protein
protein	I-protein
.	O

we	O
established	O
that	O
the	O
four	O
atra	O
metabolites	O
were	O
indeed	O
formed	O
by	O
the	O
nb0	B-cell_line
cells	I-cell_line
in	O
vitro	O
.	O

nb0	O
cell	O
growth	O
was	O
inhibited	O
(	O
00-00	O
%	O
at	O
000	O
h	O
)	O
and	O
cell	O
cycle	O
progression	O
in	O
the	O
g0	O
phase	O
(	O
00-00	O
%	O
at	O
000	O
h	O
)	O
was	O
blocked	O
by	O
atra	O
and	O
all	O
of	O
the	O
metabolites	O
at	O
0	O
microm	O
concentration	O
.	O

atra	O
and	O
its	O
metabolites	O
could	O
induce	O
nb0	B-cell_line
cells	I-cell_line
differentiation	O
with	O
similar	O
activity	O
,	O
as	O
evaluated	O
by	O
cell	O
morphology	O
,	O
by	O
the	O
nitroblue	O
tetrazolium	O
reduction	O
test	O
(	O
00-00	O
%	O
at	O
000	O
h	O
)	O
or	O
by	O
the	O
expression	O
of	O
the	O
maturation	O
specific	O
cell	O
surface	O
marker	O
cd00c	B-DNA
.	O

in	O
addition	O
,	O
nuclear	O
body	O
reorganization	O
to	O
macropunctated	O
structures	O
,	O
as	O
well	O
as	O
the	O
degradation	O
of	O
pml-rar	B-protein
alpha	I-protein
,	O
was	O
found	O
to	O
be	O
similar	O
for	O
atra	O
and	O
all	O
of	O
its	O
metabolites	O
.	O

comparison	O
of	O
the	O
relative	O
potency	O
of	O
the	O
retinoids	O
using	O
the	O
nitroblue	O
tetrazolium	O
reduction	O
test	O
showed	O
effective	O
concentrations	O
required	O
to	O
differentiate	O
00	O
%	O
of	O
cells	O
in	O
00	O
h	O
as	O
follows	O
:	O
atra	O
,	O
00.0	O
+/-	O
0.0	O
nm	O
;	O
0-oxo-ra	O
,	O
00.0	O
+/-	O
0.0	O
nm	O
;	O
00-oh-ra	O
,	O
00.0	O
+/-	O
0.0	O
nm	O
;	O
0-oh-ra	O
,	O
00.0	O
+/-	O
0.0	O
nm	O
;	O
and	O
0	O
,	O
0-epoxy-ra	O
,	O
00.0	O
+/-	O
0.0	O
nm	O
.	O

the	O
atra	O
metabolites	O
were	O
found	O
to	O
exert	O
their	O
differentiation	O
effects	O
via	O
the	O
rar	B-protein
alpha	I-protein
nuclear	I-protein
receptors	I-protein
,	O
because	O
the	O
rar	B-RNA
alpha-specific	I-RNA
antagonist	I-RNA
bms000	I-RNA
blocked	O
metabolite-induced	O
cd00c	B-DNA
expression	O
in	O
nb0	B-cell_line
cells	I-cell_line
.	O

these	O
data	O
demonstrate	O
that	O
the	O
principal	O
atra	O
phase	O
0	O
metabolites	O
can	O
elicit	O
leukemia	O
cell	O
growth	O
inhibition	O
and	O
differentiation	O
in	O
vitro	O
through	O
the	O
rar	B-protein
alpha	I-protein
signaling	O
pathway	O
,	O
and	O
they	O
suggest	O
that	O
these	O
metabolites	O
may	O
play	O
a	O
role	O
in	O
atra	O
antileukemic	O
activity	O
in	O
vivo	O
.	O

###MEDLINE:21108585

expression	O
of	O
oestrogen	O
and	O
progesterone	B-protein
receptors	I-protein
by	O
mast	B-cell_type
cells	I-cell_type
alone	O
,	O
but	O
not	O
lymphocytes	B-cell_type
,	O
macrophages	B-cell_type
or	O
other	O
immune	O
cells	O
in	O
human	O
upper	O
airways	O
.	O

background	O
:	O
nasal	B-cell_type
polyposis	I-cell_type
often	O
coexists	O
with	O
asthma	O
in	O
airway	O
inflammatory	O
conditions	O
characterised	O
by	O
the	O
infiltration	O
of	O
a	O
range	O
of	O
immune	B-cell_type
cells	I-cell_type
.	O

a	O
potentially	O
important	O
role	O
for	O
ovarian	O
hormones	O
has	O
been	O
implicated	O
in	O
airway	O
inflammation	O
but	O
the	O
cellular	O
target	O
for	O
such	O
action	O
is	O
not	O
known	O
.	O

methods	O
:	O
expression	O
of	O
oestrogen	B-protein
receptors	I-protein
(	O
er	B-protein
)	O
and	O
progesterone	B-protein
receptors	I-protein
(	O
pr	B-protein
)	O
was	O
examined	O
using	O
immunohistochemistry	O
in	O
formalin	O
fixed	O
nasal	O
polyp	O
tissues	O
from	O
00	O
subjects	O
.	O

the	O
cells	O
positive	O
for	O
er	B-protein
or	O
pr	B-protein
were	O
confirmed	O
by	O
spatial	O
location	O
,	O
dual	O
immunolabelling	O
,	O
and	O
histochemical	O
staining	O
.	O

results	O
:	O
consistent	O
with	O
the	O
known	O
features	O
of	O
nasal	B-cell_type
polyps	I-cell_type
,	I-cell_type
cd0+	I-cell_type
(	I-cell_type
t	I-cell_type
helper/inducer	I-cell_type
)	O
,	O
cd0+	B-cell_type
(	I-cell_type
cytotoxic/suppressor	I-cell_type
)	I-cell_type
,	I-cell_type
cd00+	I-cell_type
(	I-cell_type
macrophages	I-cell_type
)	O
,	O
mast	B-cell_type
cells	I-cell_type
,	O
eosinophils	B-cell_type
and	O
neutrophils	B-cell_type
were	O
all	O
clearly	O
detected	O
by	O
their	O
relevant	O
monoclonal	B-protein
antibodies	I-protein
or	O
appropriate	O
histochemical	O
staining	O
,	O
but	O
only	O
mast	B-cell_type
cells	I-cell_type
tested	O
positive	O
for	O
er	B-protein
/pr	O
labelling	O
with	O
their	O
polyclonal	O
and	O
monoclonal	B-protein
antibodies	I-protein
.	O

the	O
frequencies	O
for	O
expression	O
were	O
00.0	O
%	O
for	O
er	B-protein
positive	O
and	O
00.0	O
%	O
for	O
pr	B-protein
positive	O
cells	O
.	O

the	O
expression	O
of	O
er	B-protein
/	O
pr	B-protein
was	O
independent	O
of	O
patient	O
sex	O
and	O
age	O
but	O
was	O
highly	O
correlated	O
with	O
the	O
numbers	O
of	O
mast	B-cell_type
cells	I-cell_type
(	O
r	B-protein
=	O
0.000	O
,	O
p	O
<	O
0.000	O
for	O
er	B-protein
;	O
r	O
=	O
0.000	O
,	O
p	O
<	O
0.000	O
for	O
pr	B-protein
)	O
.	O

fewer	O
than	O
0	O
%	O
of	O
mast	B-cell_type
cells	I-cell_type
were	O
found	O
to	O
be	O
negative	O
for	O
er	B-protein
/	O
pr	B-protein
expression	O
.	O

conclusions	O
:	O
mast	B-cell_type
cells	I-cell_type
alone	O
,	O
but	O
not	O
lymphocytes	B-cell_type
,	O
macrophages	B-cell_type
,	O
or	O
other	O
immune	B-cell_type
cells	I-cell_type
,	O
express	O
er	B-protein
/	O
pr	B-protein
in	O
human	O
upper	O
airways	O
.	O

numerous	O
er/pr	B-cell_type
positive	I-cell_type
mast	I-cell_type
cells	I-cell_type
exist	O
in	O
nasal	B-cell_type
polyps	I-cell_type
,	O
indicating	O
that	O
this	O
may	O
be	O
a	O
major	O
route	O
for	O
the	O
involvement	O
of	O
sex	O
hormones	O
in	O
airway	O
inflammation	O
when	O
exposed	O
to	O
the	O
higher	O
and	O
varying	O
concentration	O
of	O
oestrogen	O
and	O
progesterone	O
characteristic	O
of	O
females	O
.	O

###MEDLINE:21093289

nf	B-protein
kappa	I-protein
b	I-protein
signaling	O
in	O
posthypoxic	O
endothelial	B-cell_type
cells	I-cell_type
:	O
relevance	O
to	O
e-selectin	B-protein
expression	O
and	O
neutrophil	O
adhesion	O
.	O

our	O
previous	O
studies	O
have	O
implicated	O
the	O
nuclear	B-protein
transcription	I-protein
factor	I-protein
kappa	I-protein
b	I-protein
(	O
nf	B-protein
kappa	I-protein
b	I-protein
)	O
in	O
the	O
regulation	O
of	O
adhesion	B-protein
molecule	I-protein
expression	O
in	O
endothelial	B-cell_type
cells	I-cell_type
exposed	O
to	O
anoxia-reoxygenation	O
(	O
a/r	O
)	O
or	O
a	O
redox	O
imbalance	O
.	O

the	O
objectives	O
of	O
this	O
study	O
were	O
(	O
0	O
)	O
to	O
define	O
the	O
kinetics	O
of	O
nf	B-protein
kappa	I-protein
b	I-protein
activation	O
by	O
examining	O
i	B-protein
kappa	I-protein
b	I-protein
alpha	I-protein
degradation	O
and	O
the	O
nuclear	O
translocation	O
of	O
p00	B-protein
in	O
response	O
to	O
a/r	O
or	O
redox	O
imbalance	O
(	O
induced	O
by	O
treatment	O
of	O
cells	O
with	O
diamide	O
and	O
buthionine	O
sulfoximine	O
)	O
and	O
(	O
0	O
)	O
to	O
determine	O
whether	O
the	O
signal	O
for	O
i	B-protein
kappa	I-protein
b	I-protein
alpha	I-protein
degradation	O
,	O
nuclear	O
translocation	O
of	O
p00	B-protein
,	O
and	O
e-selectin	B-protein
-mediated	O
neutrophil	O
adhesion	O
is	O
related	O
to	O
the	O
activity	O
of	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
(	O
ptk	B-protein
)	O
,	O
protein	B-protein
tyrosine	I-protein
phosphatase	I-protein
(	O
ptpase	B-protein
)	O
and/or	O
protein	B-protein
kinase	I-protein
c	I-protein
(	O
pkc	B-protein
)	O
.	O

the	O
results	O
demonstrate	O
that	O
both	O
a/r	O
and	O
redox	O
imbalance	O
led	O
to	O
i	B-protein
kappa	I-protein
b	I-protein
alpha	I-protein
degradation	O
within	O
00	O
min	O
and	O
the	O
concomitant	O
appearance	O
of	O
p00	B-protein
in	O
the	O
nucleus	O
,	O
consistent	O
with	O
rapid	O
cytosolic	O
activation	O
of	O
nf	B-protein
kappa	I-protein
b	I-protein
and	O
subsequent	O
nuclear	O
translocation	O
of	O
the	O
activated	B-protein
p00	I-protein
subunit	I-protein
.	O

inhibition	O
of	O
pkc	B-protein
blocked	O
i	B-protein
kappa	I-protein
b	I-protein
alpha	I-protein
degradation	O
and	O
p00	B-protein
translocation	O
in	O
a/r-challenged	B-protein
,	O
but	O
not	O
redox-altered	O
,	O
endothelial	B-cell_type
cells	I-cell_type
.	O

however	O
,	O
both	O
a/r-	B-protein
and	O
redox-induced	B-protein
nf	I-protein
kappa	I-protein
b	I-protein
activation	O
was	O
blocked	O
by	O
inhibition	O
of	O
ptk	B-protein
.	O

similarly	O
,	O
a/r-induced	O
e-selectin	B-protein
expression	O
and	O
neutrophil-endothelial	O
cell	O
adhesion	O
were	O
blocked	O
by	O
inhibition	O
of	O
pkc	B-protein
or	O
ptk	B-protein
,	O
while	O
only	O
ptk	B-protein
inhibited	O
the	O
redox-induced	O
adhesion	O
response	O
.	O

pretreatment	O
of	O
cells	O
with	O
n-acetyl	O
cysteine	O
effectively	O
blocked	O
a/r-	B-protein
or	O
redox-induced	B-protein
i	I-protein
kappa	I-protein
b	I-protein
degradation	O
and	O
significantly	O
attenuated	O
the	O
respective	O
neutrophil	O
adhesion	O
responses	O
.	O

collectively	O
,	O
these	O
findings	O
indicate	O
that	O
a/r-induced	O
e-selectin	B-protein
expression	O
and	O
neutrophil-endothelial	O
cell	O
adhesion	O
are	O
mediated	O
by	O
both	O
pkc	B-protein
and	O
ptk	B-protein
,	O
which	O
signal	O
rapid	O
activation	O
of	O
nf	B-protein
kappa	I-protein
b	I-protein
.	O

this	O
a/r-induced	O
nf	B-protein
kappa	I-protein
b	I-protein
signaling	O
response	O
appears	O
to	O
be	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
intracellular	O
redox	O
imbalance	O
.	O

copyright	O
0000	O
s.	B-protein
karger	I-protein
ag	I-protein
,	O
basel	O

###MEDLINE:21100758

induction	O
of	O
apoptosis	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
by	O
the	O
herbicide	B-protein
0	I-protein
,	O
0-dichlorophenoxyacetic	O
acid	O
.	O

dimethylammonium	O
salt	O
of	O
0	O
,	O
0-dichlorophenoxyacetic	B-protein
acid	I-protein
(	I-protein
dma-0	I-protein
,	O
0-d	O
)	O
is	O
a	O
widely	O
used	O
herbicide	O
that	O
is	O
considered	O
moderately	O
toxic	O
.	O

in	O
the	O
present	O
study	O
we	O
found	O
that	O
dma-0	B-protein
,	O
0-d	O
is	O
able	O
to	O
cause	O
apoptosis	O
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
of	O
healthy	O
individuals	O
and	O
jurkat	B-cell_line
t	I-cell_line
cells	I-cell_line
.	O

apoptosis	O
induced	O
by	O
dma-0	B-protein
,	O
0-d	O
was	O
dose	O
and	O
time	O
dependent	O
,	O
independent	O
of	O
fas	B-protein
,	O
tnf	B-protein
receptor	I-protein
0	I-protein
or	O
the	O
aromatic	B-protein
hydrocarbon	I-protein
receptor	I-protein
,	O
and	O
involved	O
disruption	O
of	O
the	O
mitochondrial	O
transmembrane	O
potential	O
and	O
activation	O
of	O
caspase-0	B-protein
.	O

zvad-fmk	O
,	O
a	O
broad-spectrum	O
inhibitor	O
of	O
caspases	B-protein
,	O
blocked	O
dma-0	O
,	O
0-d-induced	O
apoptosis	O
completely	O
.	O

while	O
an	O
inhibitor	O
of	O
caspase-0	B-protein
,	O
as	O
well	O
as	O
caspase-0	B-protein
and	O
caspase-0	B-protein
inhibitors	O
in	O
combination	O
,	O
strongly	O
blocked	O
dma-0	O
,	O
0-d-induced	O
apoptosis	O
,	O
an	O
inhibitor	O
of	O
caspase-0	B-protein
had	O
a	O
moderate	O
inhibitory	O
effect	O
.	O

unlike	O
fas	B-protein
-mediated	O
apoptosis	O
,	O
the	O
initiator	O
caspase	O
,	O
caspase-0	B-protein
,	O
was	O
not	O
involved	O
in	O
dma-0	B-protein
,	O
0-d-induced	O
apoptosis	O
.	O

transfection	O
of	O
jurkat	B-cell_line
cells	I-cell_line
with	O
bcl-0	B-protein
prevented	O
dma-0	O
,	O
0-d-induced	O
disruption	O
of	O
the	O
mitochondrial	O
transmembrane	O
potential	O
and	O
led	O
to	O
a	O
complete	O
blockage	O
of	O
apoptosis	O
.	O

our	O
data	O
indicate	O
that	O
dma-0	B-cell_type
,	I-cell_type
0-d	I-cell_type
kills	I-cell_type
human	I-cell_type
lymphocytes	I-cell_type
by	O
initiating	O
apoptosis	O
via	O
a	O
direct	O
effect	O
on	O
mitochondria	O
.	O

the	O
activation	O
of	O
caspases	B-protein
occurs	O
downstream	O
of	O
mitochondrial	O
damage	O
,	O
and	O
the	O
dysfunction	O
of	O
mitochondria	O
appears	O
to	O
be	O
sufficient	O
for	O
triggering	O
all	O
downstream	O
events	O
leading	O
to	O
apoptosis	O
.	O

###MEDLINE:21036309

inhibition	O
of	O
th0	O
differentiation	O
by	O
il-0	B-protein
is	O
mediated	O
by	O
socs0	O
.	O

interleukin	B-protein
0	I-protein
(	O
il-0	B-protein
)	O
is	O
a	O
cytokine	B-protein
produced	O
by	O
immune	O
and	O
nonimmune	B-cell_type
cells	I-cell_type
and	O
exhibits	O
functional	O
pleiotropy	O
and	O
redundancy	O
.	O

il-0	B-protein
plays	O
an	O
important	O
role	O
in	O
the	O
differentiation	O
of	O
several	O
cell	O
types	O
.	O

here	O
,	O
we	O
describe	O
a	O
novel	O
function	O
of	O
il-0	B-protein
:	O
the	O
negative	O
regulation	O
of	O
cd0	B-cell_type
+	I-cell_type
th0	I-cell_type
cell	I-cell_type
differentiation	O
.	O

while	O
il-0	B-protein
-directed	O
cd0	B-protein
+	O
th0	O
differentiation	O
is	O
mediated	O
by	O
il-0	B-protein
,	O
inhibition	O
of	O
th0	O
differentiation	O
by	O
il-0	B-protein
is	O
independent	O
of	O
il-0	B-protein
.	O

il-0	B-protein
upregulates	O
suppressor	O
of	O
cytokine	B-protein
signaling	I-protein
0	I-protein
(	O
socs0	B-protein
)	O
expression	O
in	O
activated	B-cell_type
cd0+	I-cell_type
t	I-cell_type
cells	I-cell_type
,	O
thereby	O
interfering	O
with	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
0	I-protein
(	O
stat0	B-protein
)	O
phosphorylation	O
induced	O
by	O
interferon	B-protein
gamma	I-protein
(	O
ifngamma	B-protein
)	O
.	O

inhibition	O
of	O
ifngamma	B-protein
receptor-mediated	O
signals	O
by	O
il-0	B-protein
prevents	O
autoregulation	O
of	O
ifngamma	B-protein
gene	O
expression	O
by	O
ifngamma	B-protein
during	O
cd0+	B-cell_type
t	I-cell_type
cell	I-cell_type
activation	O
,	O
thereby	O
preventing	O
th0	O
differentiation	O
.	O

thus	O
,	O
il-0	B-protein
promotes	O
cd0	B-protein
+	O
th0	O
differentiation	O
and	O
inhibits	O
th0	O
differentiation	O
by	O
two	O
independent	O
molecular	O
mechanisms	O
.	O

###MEDLINE:21105220

interaction	O
between	O
ccaat/enhancer	B-protein
binding	I-protein
protein	I-protein
and	O
cyclic	B-protein
amp	I-protein
response	I-protein
element	I-protein
binding	I-protein
protein	I-protein
0	I-protein
regulates	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
0	I-DNA
transcription	O
in	O
cells	O
of	O
the	O
monocyte/macrophage	B-cell_type
lineage	I-cell_type
.	O

recent	O
observations	O
have	O
shown	O
two	O
ccaat/enhancer	B-protein
binding	I-protein
protein	I-protein
(	O
c/ebp	B-DNA
)	I-DNA
binding	I-DNA
sites	I-DNA
to	O
be	O
critically	O
important	O
for	O
efficient	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
0	I-DNA
(	O
hiv-0	O
)	O
replication	O
within	O
cells	O
of	O
the	O
monocyte/macrophage	B-cell_type
lineage	I-cell_type
,	O
a	O
cell	O
type	O
likely	O
involved	O
in	O
transport	O
of	O
the	O
virus	O
to	O
the	O
brain	O
.	O

additionally	O
,	O
sequence	O
variation	O
at	O
c/ebp	B-DNA
site	I-DNA
i	O
,	O
which	O
lies	O
immediately	O
upstream	O
of	O
the	O
distal	B-DNA
nuclear	I-DNA
factor	I-DNA
kappa	I-DNA
b	I-DNA
site	I-DNA
and	O
immediately	O
downstream	O
of	O
a	O
binding	B-DNA
site	I-DNA
for	O
activating	O
transcription	B-protein
factor	I-protein
(	O
atf	B-protein
)	O
/	O
cyclic	B-protein
amp	I-protein
response	I-protein
element	I-protein
binding	I-protein
protein	I-protein
(	O
creb	B-protein
)	O
,	O
has	O
been	O
shown	O
to	O
affect	O
hiv-0	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
ltr	B-DNA
)	O
activity	O
.	O

given	O
that	O
c/ebp	B-protein
proteins	I-protein
have	O
been	O
shown	O
to	O
interact	O
with	O
many	O
other	O
transcription	B-protein
factors	I-protein
including	O
members	O
of	O
the	O
atf/creb	B-protein
family	I-protein
,	O
we	O
proceeded	O
to	O
determine	O
whether	O
an	O
adjacent	B-DNA
atf/creb	I-DNA
binding	I-DNA
site	I-DNA
could	O
affect	O
c/ebp	B-protein
protein	I-protein
binding	O
to	O
c/ebp	B-DNA
site	I-DNA
i	O
.	O

electrophoretic	O
mobility	O
shift	O
analyses	O
indicated	O
that	O
selected	O
atf/creb	B-protein
site	I-protein
variants	O
assisted	O
in	O
the	O
recruitment	O
of	O
c/ebp	B-protein
proteins	I-protein
to	O
an	O
adjacent	O
,	O
naturally	O
occurring	O
,	O
low-affinity	O
c/ebp	B-DNA
site	I-DNA
.	O

this	O
biophysical	O
interaction	O
appears	O
to	O
occur	O
via	O
at	O
least	O
two	O
mechanisms	O
.	O

first	O
,	O
low	O
amounts	O
of	O
creb-0	B-protein
and	O
c/ebp	B-protein
appear	O
to	O
heterodimerize	O
and	O
bind	O
to	O
a	O
site	O
consisting	O
of	O
a	O
half	O
site	O
from	O
both	O
the	O
atf/creb	B-protein
and	I-protein
c/ebp	I-protein
binding	I-protein
sites	I-protein
.	O

in	O
addition	O
,	O
creb-0	B-protein
homodimers	I-protein
bind	O
to	O
the	O
atf/creb	B-protein
site	I-protein
and	O
recruit	O
c/ebp	B-protein
dimers	I-protein
to	O
their	O
cognate	O
weak	O
binding	B-DNA
sites	I-DNA
.	O

this	O
interaction	O
is	O
reciprocal	O
,	O
since	O
c/ebp	B-protein
dimer	I-protein
binding	O
to	O
a	O
strong	O
c/ebp	B-DNA
site	I-DNA
leads	O
to	O
enhanced	O
creb-0	O
recruitment	O
to	O
atf/creb	B-protein
sites	I-protein
that	O
are	O
weakly	O
bound	O
by	O
creb	B-protein
.	O

sequence	O
variation	O
at	O
both	O
c/ebp	B-DNA
and	I-DNA
atf/creb	I-DNA
sites	I-DNA
affects	O
the	O
molecular	O
interactions	O
involved	O
in	O
mediating	O
both	O
of	O
these	O
mechanisms	O
.	O

most	O
importantly	O
,	O
sequence	O
variation	O
at	O
the	O
atf/creb	B-protein
binding	I-protein
site	I-protein
affected	O
basal	O
ltr	B-DNA
activity	O
as	O
well	O
as	O
ltr	B-DNA
function	O
following	O
interleukin-0	B-protein
stimulation	O
,	O
a	O
treatment	O
that	O
leads	O
to	O
increases	O
in	O
c/ebp	B-protein
activation	O
.	O

thus	O
,	O
hiv-0	B-DNA
ltr	I-DNA
atf/creb	I-DNA
binding	I-DNA
site	I-DNA
sequence	O
variation	O
may	O
modulate	O
cellular	O
signaling	O
at	O
the	O
viral	B-DNA
promoter	I-DNA
through	O
the	O
c/ebp	B-protein
pathway	I-protein

###MEDLINE:21134520

selective	O
inhibition	O
of	O
interleukin-0	B-DNA
gene	I-DNA
expression	O
in	O
human	B-cell_type
t	I-cell_type
cells	I-cell_type
by	O
aspirin	O
.	O

previous	O
studies	O
indicated	O
that	O
aspirin	O
(	O
acetylsalicylic	O
acid	O
[	O
asa	O
]	O
)	O
can	O
have	O
profound	O
immunomodulatory	O
effects	O
by	O
regulating	O
cytokine	B-DNA
gene	I-DNA
expression	O
in	O
several	O
types	O
of	O
cells	O
.	O

this	O
study	O
is	O
the	O
first	O
in	O
which	O
concentrations	O
of	O
asa	O
in	O
the	O
therapeutic	O
range	O
were	O
found	O
to	O
significantly	O
reduce	O
interleukin	B-protein
(	I-protein
il	I-protein
)	I-protein
-0	I-protein
secretion	O
and	O
rna	O
expression	O
in	O
freshly	B-cell_type
isolated	I-cell_type
and	I-cell_type
mitogen-primed	I-cell_type
human	I-cell_type
cd0+	I-cell_type
t	I-cell_type
cells	I-cell_type
.	O

in	O
contrast	O
,	O
asa	O
did	O
not	O
affect	O
il-00	B-protein
,	O
interferon-gamma	B-protein
,	O
and	O
il-0	B-protein
expression	O
.	O

asa	O
inhibited	O
il-0	B-protein
,	O
but	O
not	O
il-0	B-protein
,	O
promoter-driven	O
chloramphenicol	B-protein
acetyltransferase	I-protein
expression	O
in	O
transiently	B-cell_line
transfected	I-cell_line
jurkat	I-cell_line
t	I-cell_line
cells	I-cell_line
.	O

the	O
structurally	O
unrelated	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
indomethacin	O
and	O
flurbiprofen	O
did	O
not	O
affect	O
cytokine	B-DNA
gene	I-DNA
expression	O
in	O
t	B-cell_type
cells	I-cell_type
,	O
whereas	O
the	O
weak	O
cyclo-oxygenase	O
inhibitor	O
salicylic	O
acid	O
was	O
at	O
least	O
as	O
effective	O
as	O
asa	O
in	O
inhibiting	O
il-0	B-DNA
expression	I-DNA
and	I-DNA
promoter	I-DNA
activity	O
.	O

the	O
inhibitory	O
effect	O
of	O
asa	O
on	O
il-0	B-protein
transcription	O
was	O
not	O
mediated	O
by	O
decreased	O
nuclear	O
expression	O
of	O
the	O
known	O
salicylate	O
target	O
nuclear	B-protein
factor	I-protein
(	O
nf	B-protein
)	I-protein
-kappab	I-protein
and	O
was	O
accompanied	O
by	O
reduced	O
binding	O
of	O
an	O
inducible	B-protein
factor	I-protein
to	O
an	O
il-0	B-DNA
promoter	I-DNA
region	I-DNA
upstream	I-DNA
of	O
,	O
but	O
not	O
overlapping	O
,	O
the	O
nf	B-protein
of	I-protein
activated	I-protein
t	I-protein
cells-	I-protein
and	O
nf-kappab-binding	B-DNA
p0	I-DNA
element	I-DNA
.	O

it	O
is	O
concluded	O
that	O
anti-inflammatory	O
salicylates	O
,	O
by	O
means	O
of	O
a	O
previously	O
unrecognized	O
mechanism	O
of	O
action	O
,	O
can	O
influence	O
the	O
nature	O
of	O
adaptive	O
immune	O
responses	O
by	O
selectively	O
inhibiting	O
the	O
expression	O
of	O
il-0	B-protein
,	O
a	O
critical	O
effector	O
of	O
these	O
responses	O
,	O
in	O
cd0+	B-cell_type
t	I-cell_type
cells	I-cell_type
.	O

###MEDLINE:21121146

molecular	O
and	O
cellular	O
mediators	O
of	O
interleukin-0	B-protein
-dependent	O
acute	O
inflammatory	O
arthritis	O
.	O

objective	O
:	O
to	O
examine	O
the	O
molecular	O
and	O
cellular	O
mechanisms	O
in	O
a	O
model	O
of	O
acute	O
inflammatory	O
monarticular	O
arthritis	O
induced	O
by	O
methylated	O
bovine	O
serum	B-protein
albumin	I-protein
(	O
mbsa	B-protein
)	O
and	O
interleukin-0	B-protein
(	O
il-0	B-protein
)	O
.	O

methods	O
:	O
mice	O
were	O
injected	O
intraarticularly	O
with	O
mbsa	O
on	O
day	O
0	O
and	O
subcutaneously	O
with	O
recombinant	B-protein
human	I-protein
il-0beta	I-protein
on	O
days	O
0-0	O
.	O

at	O
day	O
0	O
,	O
knee	O
joints	O
were	O
removed	O
and	O
assessed	O
histologically	O
.	O

flow	O
cytometry	O
and	O
rnase	B-protein
protection	O
were	O
used	O
to	O
analyze	O
il-0	B-protein
-dependent	O
events	O
.	O

results	O
:	O
c00bl/0	O
(	O
b0	B-protein
)	O
,	O
000/sv	O
,	O
and	O
(	O
b0	B-protein
x	O
000/	B-cell_line
sv	I-cell_line
)	I-cell_line
f0	I-cell_line
hybrid	I-cell_line
mice	O
,	O
all	O
h-0b	O
strains	O
,	O
were	O
susceptible	O
to	O
mbsa	O
/il-0-induced	O
arthritis	O
,	O
whereas	O
c0h/hej	O
(	O
h-0k	B-protein
)	O
mice	O
were	O
not	O
.	O

b0	O
mice	O
lacking	O
t	B-cell_type
and	I-cell_type
b	I-cell_type
cells	I-cell_type
(	O
rag0-/-	B-protein
)	O
or	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
(	O
mhc	B-protein
)	I-protein
class	I-protein
ii	I-protein
antigens	I-protein
(	O
mhcii-/-	B-protein
)	O
,	O
and	O
b0	B-protein
mice	O
treated	O
with	O
a	O
cd0+	B-protein
t	I-protein
cell-depleting	I-protein
monoclonal	I-protein
antibody	I-protein
,	O
were	O
resistant	O
to	O
disease	O
.	O

in	O
contrast	O
,	O
b	O
cell-deficient	O
(	O
mumt/	O
mumt	O
)	O
mice	O
developed	O
arthritis	O
at	O
an	O
incidence	O
and	O
severity	O
similar	O
to	O
that	O
of	O
controls	O
.	O

relb-deficient	O
(	O
relb-/-	B-protein
)	O
bone	O
marrow	O
chimeric	O
mice	O
had	O
arthritis	O
that	O
was	O
significantly	O
reduced	O
in	O
incidence	O
and	O
severity	O
.	O

in	O
b0	O
mice	O
,	O
flow	O
cytometry	O
demonstrated	O
an	O
il-0-dependent	B-cell_type
leukocyte	I-cell_type
infiltration	O
into	O
the	O
synovial	O
compartment	O
and	O
rnase	B-protein
protection	O
assays	O
revealed	O
induction	O
of	O
messenger	B-RNA
rna	I-RNA
(	I-RNA
mrna	I-RNA
)	O
for	O
the	O
chemokines	B-protein
monocyte	B-protein
chemoattractant	I-protein
protein	I-protein
0	I-protein
,	O
macrophage	B-protein
inhibitory	I-protein
protein	I-protein
0	I-protein
(	O
mip-0	B-protein
)	O
,	O
rantes	B-protein
,	O
mip-0alpha	B-protein
,	O
and	O
mip-0beta	B-protein
,	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

conclusion	O
:	O
arthritis	O
induced	O
by	O
mbsa	O
/	O
il-0	B-protein
is	O
strain	O
specific	O
and	O
dependent	O
on	O
cd0+	B-cell_type
t	I-cell_type
lymphocytes	I-cell_type
and	O
at	O
least	O
partially	O
on	O
relb	B-protein
,	O
but	O
not	O
on	O
b	B-cell_type
lymphocytes	I-cell_type
or	O
antibody	O
.	O

il-0	B-protein
contributes	O
to	O
leukocyte	O
recruitment	O
to	O
the	O
synovium	O
and	O
directly	O
induces	O
chemokine	B-protein
mrna	O
production	O
by	O
synovial	B-cell_type
cells	I-cell_type
.	O

this	O
model	O
of	O
acute	O
monarticular	O
arthritis	O
is	O
particularly	O
suitable	O
for	O
further	O
investigations	O
into	O
cell-mediated	O
immunity	O
in	O
arthritis	O
and	O
the	O
role	O
of	O
il-0	B-protein
.	O

###MEDLINE:21124335

positive	O
and	O
negative	O
regulation	O
of	O
granulopoiesis	O
by	O
endogenous	B-protein
raralpha	I-protein
.	O

acute	O
promyelocytic	O
leukemia	O
(	O
apl	B-cell_line
)	O
is	O
always	O
associated	O
with	O
chromosomal	O
translocations	O
that	O
disrupt	O
the	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
alpha	I-protein
(	O
raralpha	B-protein
)	O
gene	O
.	O

whether	O
these	O
translocations	O
relate	O
to	O
a	O
role	O
for	O
endogenous	B-protein
raralpha	I-protein
in	O
normal	O
granulopoiesis	O
remains	O
uncertain	O
because	O
most	O
studies	O
addressing	O
this	O
question	O
have	O
used	O
non-physiological	O
overexpression	O
systems	O
.	O

granulocyte	O
differentiation	O
in	O
cells	O
derived	O
from	O
raralpha-deficient	B-protein
(	I-protein
raralpha	I-protein
(	O
-/-	O
)	O
)	O
mice	O
was	O
studied	O
and	O
evaluated	O
in	O
the	O
context	O
of	O
agonist-bound	B-protein
and	O
ligand-free	B-protein
raralpha	I-protein
.	O

our	O
results	O
demonstrate	O
that	O
raralpha	B-protein
is	O
dispensable	O
for	O
granulopoiesis	O
,	O
as	O
raralpha	B-protein
(	O
-/-	O
)	O
mice	O
have	O
a	O
normal	O
granulocyte	O
population	O
despite	O
an	O
impaired	O
ability	O
to	O
respond	O
to	O
retinoids	O
.	O

however	O
,	O
although	O
it	O
is	O
not	O
absolutely	O
required	O
,	O
raralpha	B-protein
can	O
bidirectionally	O
modulate	O
granulopoiesis	O
.	O

raralpha	B-protein
stimulates	O
differentiation	O
in	O
response	O
to	O
exogenous	O
retinoic	O
acid	O
.	O

furthermore	O
,	O
endogenous	O
retinoids	O
control	O
granulopoiesis	O
in	O
vivo	O
,	O
as	O
either	O
vitamin	O
a-deficient	O
mice	O
or	O
animals	O
treated	O
with	O
an	O
rar	B-protein
antagonist	I-protein
accumulate	O
more	O
immature	B-cell_type
granulocytes	I-cell_type
in	O
their	O
bone	O
marrow	O
.	O

conversely	O
,	O
raralpha	B-protein
acts	O
to	O
limit	O
differentiation	O
in	O
the	O
absence	O
of	O
ligand	O
because	O
granulocyte	B-cell_type
precursors	I-cell_type
from	O
raralpha	B-protein
(	O
-/-	O
)	O
mice	O
differentiate	O
earlier	O
in	O
culture	O
.	O

thus	O
,	O
the	O
block	O
in	O
granulopoiesis	O
exerted	O
by	O
raralpha	B-protein
fusion	B-protein
proteins	I-protein
expressed	O
in	O
apl	B-cell_type
cells	I-cell_type
may	O
correspond	O
to	O
an	O
amplification	O
of	O
a	O
normal	O
function	O
of	O
unliganded	B-protein
raralpha	I-protein
.	O

###MEDLINE:21077029

expression	O
and	O
function	O
of	O
a	O
stem	O
cell	O
promoter	O
for	O
the	O
murine	B-DNA
cbfalpha0	I-DNA
gene	I-DNA
:	O
distinct	O
roles	O
and	O
regulation	O
in	O
natural	B-cell_type
killer	I-cell_type
and	I-cell_type
t	I-cell_type
cell	I-cell_type
development	O
.	O

the	O
runt	B-protein
family	I-protein
transcription	I-protein
factor	I-protein
cbfalpha0	I-protein
(	O
aml0	B-protein
,	O
pebp0alphab	O
,	O
or	O
runx0	B-protein
)	O
is	O
required	O
by	O
hematopoietic	B-cell_type
stem	I-cell_type
cells	I-cell_type
and	O
expressed	O
at	O
high	O
levels	O
in	O
t-lineage	B-cell_type
cells	I-cell_type
.	O

in	O
human	B-cell_type
t	I-cell_type
cells	I-cell_type
cbfalpha0	O
is	O
usually	O
transcribed	O
from	O
a	O
different	O
promoter	O
(	O
distal	B-DNA
promoter	I-DNA
)	O
than	O
in	O
myeloid	B-cell_type
cells	I-cell_type
(	O
proximal	B-DNA
promoter	I-DNA
)	O
,	O
but	O
the	O
developmental	O
and	O
functional	O
significance	O
of	O
this	O
promoter	B-DNA
switch	I-DNA
has	O
not	O
been	O
known	O
.	O

here	O
,	O
we	O
report	O
that	O
both	O
coding	B-DNA
and	I-DNA
noncoding	I-DNA
sequences	I-DNA
of	O
the	O
distal	B-DNA
0	I-DNA
'	I-DNA
end	I-DNA
are	O
highly	O
conserved	O
between	O
the	O
human	O
and	O
the	O
murine	B-DNA
genes	I-DNA
,	O
and	O
the	O
distal	B-DNA
promoter	I-DNA
is	O
responsible	O
for	O
the	O
overwhelming	O
majority	O
of	O
cbfalpha0	O
expression	O
in	O
murine	B-cell_type
hematopoietic	I-cell_type
stem	I-cell_type
cells	I-cell_type
as	O
well	O
as	O
in	O
t	B-cell_type
cells	I-cell_type
.	O

distal	B-DNA
promoter	I-DNA
activity	O
is	O
maintained	O
throughout	O
t	B-cell_type
cell	I-cell_type
development	O
and	O
at	O
lower	O
levels	O
in	O
b	B-cell_type
cell	I-cell_type
development	O
,	O
but	O
downregulated	O
in	O
natural	B-cell_type
killer	I-cell_type
cell	I-cell_type
development	O
.	O

the	O
distal	B-protein
n-terminal	I-protein
isoform	I-protein
binds	O
to	O
functionally	O
important	O
regulatory	B-DNA
sites	I-DNA
from	O
known	O
target	B-DNA
genes	I-DNA
with	O
two-	O
to	O
threefold	O
higher	O
affinity	O
than	O
the	O
proximal	O
n-terminal	B-protein
isoform	I-protein
.	O

neither	O
full-length	B-protein
isoform	I-protein
alters	O
growth	O
of	O
a	O
myeloid	B-cell_line
cell	I-cell_line
line	I-cell_line
under	O
nondifferentiating	O
conditions	O
,	O
but	O
the	O
proximal	B-DNA
isoform	I-DNA
selectively	O
delays	O
mitotic	O
arrest	O
of	O
the	O
cell	B-cell_line
line	I-cell_line
under	O
differentiating	O
conditions	O
,	O
resulting	O
in	O
the	O
generation	O
of	O
greater	O
numbers	O
of	O
neutrophils	B-cell_type
.	O

###MEDLINE:21115099

constitutive	O
pi0-k	B-protein
activity	O
is	O
essential	O
for	O
proliferation	O
,	O
but	O
not	O
survival	O
,	O
of	O
theileria	B-cell_type
parva-transformed	I-cell_type
b	I-cell_type
cells	I-cell_type
.	O

theileria	O
is	O
an	O
intracellular	O
parasite	O
that	O
causes	O
lymphoproliferative	O
disorders	O
in	O
cattle	O
,	O
and	O
infection	O
of	O
leucocytes	B-cell_type
induces	O
a	O
transformed	B-cell_type
phenotype	I-cell_type
similar	O
to	O
tumour	B-cell_type
cells	I-cell_type
,	O
but	O
the	O
mechanisms	O
by	O
which	O
the	O
parasite	O
induces	O
this	O
phenotype	O
are	O
not	O
understood	O
.	O

here	O
,	O
we	O
show	O
that	O
infected	B-cell_type
b	I-cell_type
lymphocytes	I-cell_type
display	O
constitutive	O
phosphoinositide	B-protein
0-kinase	I-protein
(	O
pi0-k	B-protein
)	O
activity	O
,	O
which	O
appears	O
to	O
be	O
necessary	O
for	O
proliferation	O
,	O
but	O
not	O
survival	O
.	O

importantly	O
,	O
we	O
demonstrate	O
that	O
one	O
mechanism	O
by	O
which	O
pi0-k	B-protein
mediates	O
the	O
proliferation	O
of	O
infected	B-cell_type
b	I-cell_type
lymphocytes	I-cell_type
is	O
through	O
the	O
induction	O
of	O
a	O
granulocyte-monocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
gm-csf	B-protein
)	O
-dependent	O
autocrine	O
loop	O
.	O

pi0-k	B-protein
induction	O
of	O
gm-csf	B-protein
appears	O
to	O
be	O
at	O
the	O
transcriptional	O
level	O
and	O
,	O
consistently	O
,	O
we	O
demonstrate	O
that	O
pi0-k	B-protein
is	O
also	O
involved	O
in	O
the	O
constitutive	O
induction	O
of	O
ap-0	B-protein
and	O
nf-kappab	B-protein
,	O
which	O
characterizes	O
theileria-infected	B-cell_type
leucocytes	I-cell_type
.	O

taken	O
together	O
,	O
our	O
results	O
highlight	O
a	O
novel	O
strategy	O
exploited	O
by	O
the	O
intracellular	O
parasite	O
theileria	O
to	O
induce	O
continued	O
proliferation	O
of	O
its	O
host	O
leucocyte	O
.	O

###MEDLINE:21099489

lymphokine	B-protein
dependence	O
of	O
stat0	B-protein
activation	O
produced	O
by	O
surface	B-protein
immunoglobulin	I-protein
cross-linking	O
and	O
by	O
phorbol	O
ester	O
plus	O
calcium	O
ionophore	O
treatment	O
in	O
b	B-cell_type
cells	I-cell_type
.	O

stimulation	O
of	O
b	B-cell_type
cells	I-cell_type
by	O
surface	B-protein
immunoglobulin	I-protein
(	O
sig	B-protein
)	O
triggering	O
,	O
or	O
through	O
the	O
mitogenic	O
combination	O
of	O
phorbol	O
ester	O
and	O
calcium	O
ionophore	O
,	O
is	O
accompanied	O
by	O
activation	O
of	O
stat	B-protein
transcription	I-protein
factors	I-protein
.	O

the	O
mechanism	O
responsible	O
for	O
the	O
delayed	O
nuclear	O
accumulation	O
of	O
phosphorylated	O
stat0	B-protein
was	O
examined	O
in	O
detail	O
,	O
focusing	O
on	O
the	O
role	O
of	O
b	B-protein
cell-derived	I-protein
lymphokines	I-protein
.	O

sig	B-protein
-induced	O
activation	O
of	O
stat0	B-protein
was	O
partially	O
inhibited	O
in	O
b	B-cell_type
cells	I-cell_type
obtained	O
from	O
il-0-	O
or	O
il-00-deficient	O
mice	O
,	O
and	O
was	O
partially	O
blocked	O
by	O
neutralizing	B-protein
antibodies	I-protein
directed	O
against	O
either	O
of	O
these	O
lymphokines	B-protein
.	O

sig	B-protein
-induced	O
stat0	B-protein
activation	O
was	O
completely	O
inhibited	O
by	O
combining	O
il-0-	O
and	O
il-00-specific	B-protein
neutralizing	I-protein
antibodies	I-protein
,	O
or	O
by	O
adding	O
individual	O
neutralizing	B-protein
antibodies	I-protein
to	O
b	B-cell_type
cells	I-cell_type
obtained	O
from	O
lymphokine-deficient	O
animals	O
.	O

in	O
contrast	O
,	O
il-00	B-protein
alone	O
appeared	O
to	O
account	O
for	O
stat0	B-protein
activation	O
resulting	O
from	O
b	B-cell_type
cell	I-cell_type
stimulation	O
with	O
phorbol	O
ester	O
and	O
calcium	O
ionophore	O
.	O

in	O
keeping	O
with	O
these	O
results	O
,	O
soluble	O
il-0	B-protein
and	O
il-00	B-protein
were	O
found	O
in	O
supernatant	O
fluid	O
obtained	O
from	O
stimulated	B-cell_type
b	I-cell_type
cells	I-cell_type
.	O

this	O
work	O
indicates	O
that	O
a	O
lymphokine	B-protein
pathway	O
is	O
responsible	O
for	O
stat0	B-protein
activation	O
that	O
occurs	O
late	O
after	O
b	B-cell_type
cell	I-cell_type
stimulation	O
,	O
and	O
points	O
out	O
differences	O
in	O
b	B-cell_type
cell	I-cell_type
activation	O
that	O
result	O
from	O
stimulation	O
through	O
the	O
antigen	B-protein
receptor	I-protein
and	O
through	O
pharmacological	O
mimicry	O
of	O
signaling	B-protein
mediators	I-protein
.	O

###MEDLINE:21092954

transcription	B-protein
factor	I-protein
ap-0	B-protein
is	O
a	O
ligand	O
for	O
immunoglobulin-kappa	B-DNA
promoter	I-DNA
e-box	B-DNA
elements	I-DNA
.	O

immunoglobulin	B-protein
(	I-protein
ig	I-protein
)	I-protein
-kappa	I-protein
promoters	I-protein
from	O
humans	O
and	O
mice	O
share	O
conserved	O
sequences	O
.	O

the	O
octamer	B-DNA
element	I-DNA
is	O
common	O
to	O
all	O
ig	B-DNA
promoters	I-DNA
and	O
pivotal	O
for	O
their	O
function	O
.	O

however	O
,	O
other	O
conserved	B-DNA
sequence	I-DNA
motifs	I-DNA
,	O
that	O
differ	O
between	O
ig	B-DNA
variable	I-DNA
gene	I-DNA
families	I-DNA
,	O
are	O
required	O
for	O
normal	O
promoter	O
function	O
.	O

these	O
conserved	B-DNA
motifs	I-DNA
do	O
not	O
stimulate	O
transcription	O
in	O
the	O
absence	O
of	O
an	O
octamer	O
.	O

one	O
example	O
is	O
an	O
e-box	B-DNA
of	I-DNA
the	I-DNA
e00/e00	I-DNA
type	I-DNA
(	I-DNA
0'-cagctg-0	I-DNA
'	I-DNA
)	I-DNA
,	O
which	O
is	O
found	O
in	O
all	O
promoters	O
of	O
the	O
human	B-DNA
and	I-DNA
murine	I-DNA
ig-kappa	I-DNA
gene	I-DNA
subgroups/families	O
,	O
with	O
the	O
exception	O
of	O
subgroups	O
ii	O
and	O
vi	B-protein
and	O
their	O
related	O
murine	B-protein
families	I-protein
.	O

in	O
the	O
present	O
study	O
we	O
show	O
that	O
the	O
ubiquitously	B-protein
expressed	I-protein
transcription	I-protein
factor	I-protein
ap-0	B-protein
,	O
and	O
not	O
e00	B-protein
,	O
interacts	O
specifically	O
with	O
the	O
kappa	B-DNA
promoter	I-DNA
e-boxes	O
when	O
tested	O
in	O
electrophoretic	O
mobility-shift	O
assays	O
using	O
nuclear	O
extracts	O
derived	O
from	O
human	B-cell_line
and	I-cell_line
murine	I-cell_line
b-cell	I-cell_line
lines	I-cell_line
.	O

furthermore	O
,	O
ap-0	B-protein
,	O
unlike	O
e00	B-protein
,	O
did	O
not	O
act	O
as	O
a	O
transactivator	O
,	O
which	O
is	O
in	O
agreement	O
with	O
previous	O
studies	O
on	O
intact	O
kappa	B-DNA
promoters	I-DNA
,	O
showing	O
that	O
transcription	O
is	O
absent	O
when	O
the	O
octamer	B-DNA
element	I-DNA
has	O
been	O
mutated	O
.	O

based	O
on	O
these	O
data	O
,	O
and	O
the	O
conservation	O
of	O
the	O
0'-cagctg-0	B-DNA
'	I-DNA
motif	I-DNA
among	O
human	B-DNA
and	I-DNA
murine	I-DNA
kappa	I-DNA
promoters	I-DNA
,	O
we	O
propose	O
that	O
ap-0	B-protein
is	O
the	O
major	O
ligand	O
for	O
ig-kappa	B-DNA
promoter	I-DNA
e-boxes	B-DNA
.	O

###MEDLINE:21108989

a	O
00-mer	O
peptide	O
(	O
rqikiwfqnrrmkwkk	B-protein
)	O
from	O
antennapedia	B-DNA
preferentially	O
targets	O
the	O
class	B-protein
i	I-protein
pathway	O
.	O

translocation	O
of	O
antigenic	O
peptides	O
into	O
the	O
cytosol	O
of	O
antigen	B-cell_type
presenting	I-cell_type
cells	I-cell_type
facilitates	O
proteosomal	O
processing	O
and	O
loading	O
into	O
class	B-protein
i	I-protein
molecules	I-protein
for	O
mhc	B-protein
presentation	O
on	O
the	O
cell	O
surface	O
.	O

the	O
dna	B-DNA
binding	I-DNA
domain	I-DNA
of	O
the	O
drosophila	B-protein
transcription	I-protein
factor	I-protein
(	O
antennapedia	B-DNA
)	O
,	O
a	O
00	B-protein
amino	I-protein
acid	I-protein
protein	I-protein
,	O
is	O
rapidly	O
taken	O
up	O
by	O
cells	O
and	O
has	O
been	O
fused	O
to	O
selected	O
antigens	O
to	O
enhance	O
their	O
immunogenicity	O
.	O

we	O
now	O
demonstrate	O
that	O
a	O
00	O
amino	O
acid	O
peptide	O
from	O
antennapedia	B-DNA
can	O
facilitate	O
the	O
cytoplasmic	O
uptake	O
of	O
ctl	O
epitope	O
0-mer	O
peptides	O
.	O

synthetic	O
peptides	O
were	O
made	O
containing	O
the	O
00-mer	O
antennapedia	B-protein
peptide	I-protein
linked	O
in	O
tandem	O
to	O
the	O
ovalbumin	O
siinfekl	O
ctl	O
peptide	O
.	O

the	O
peptide	O
complex	O
was	O
shown	O
to	O
rapidly	O
internalise	O
into	O
apcs	B-cell_type
by	O
confocal	O
microscopy	O
.	O

this	O
peptide	O
induced	O
ctl	O
in	O
c00bl/0	O
mice	O
and	O
protected	O
them	O
against	O
growth	O
of	O
an	O
ovalbumin	O
expressing	O
tumour	O
cell	B-cell_line
line	I-cell_line
(	O
e.g0-ova	B-protein
)	O
.	O

the	O
ability	O
of	O
the	O
hybrid	O
peptide	O
to	O
be	O
processed	O
and	O
presented	O
by	O
apcs	B-cell_type
was	O
similar	O
,	O
whether	O
the	O
siinfekl	B-DNA
sequence	I-DNA
was	O
appended	O
at	O
the	O
c-terminus	B-protein
or	O
n-terminus	O
of	O
the	O
antennapedia	B-protein
peptide	I-protein
.	O

the	O
production	O
of	O
synthetic	O
peptides	O
containing	O
other	O
ctl	O
peptide	O
epitopes	O
may	O
be	O
useful	O
for	O
priming	O
ctls	B-cell_type
in	O
vitro	O
and	O
in	O
vivo	O

###MEDLINE:21100729

bone	B-cell_type
marrow	I-cell_type
cells	I-cell_type
promote	O
th0	O
polarization	O
and	O
inhibit	O
virus-specific	O
ctl	O
generation	O
.	O

this	O
laboratory	O
recently	O
reported	O
that	O
human	B-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
(	O
bmc	B-cell_type
)	O
inhibit	O
the	O
generation	O
of	O
virus-specific	B-cell_line
ctl	I-cell_line
in	O
culture	O
.	O

the	O
culture	O
supernatants	O
contained	O
increased	O
levels	O
of	O
prostaglandin	B-protein
e	I-protein
(	O
0	O
)	O
(	O
pge	O
(	O
0	O
)	O
)	O
(	O
shown	O
to	O
favor	O
th0	O
cell	O
development	O
)	O
and	O
also	O
inhibited	O
ebv-ctl	O
effector	O
cell	O
development	O
.	O

in	O
this	O
study	O
,	O
we	O
obtained	O
pbl	B-cell_type
from	O
epstein-barr	B-protein
virus	I-protein
(	I-protein
ebv	I-protein
)	I-protein
igg	I-protein
antibody	I-protein
positive	O
kidney	O
transplant	O
recipients	O
(	O
r	B-protein
)	O
and	O
their	O
living-related	O
donors	O
(	O
lrd	O
)	O
one	O
year	O
after	O
renal	O
transplantation	O
.	O

ebv-specific	O
ctl	O
were	O
then	O
generated	O
in	O
vitro	O
by	O
stimulating	O
pbl	B-cell_type
with	O
autologous	B-cell_line
ebv-transformed	I-cell_line
b	I-cell_line
cells	I-cell_line
(	O
ebv-b	B-cell_line
)	I-cell_line
in	O
the	O
presence	O
or	O
absence	O
of	O
autologous	B-cell_type
bmc	I-cell_type
.	O

the	O
addition	O
of	O
bmc	B-cell_type
to	O
the	O
ebv-ctl	O
generation	O
cultures	O
increased	O
the	O
intracellular	O
expression	O
in	O
cd0+	B-cell_type
cells	I-cell_type
of	O
il-0	B-protein
,	O
-0	O
,	O
-0	O
,	O
-00	O
,	O
and	O
-00	O
.	O

these	O
cd0+	B-cell_line
cells	I-cell_line
also	O
expressed	O
increased	O
levels	O
of	O
the	O
th0	B-protein
associated	I-protein
receptor	I-protein
ccr0	I-protein
.	O

inhibition	O
was	O
even	O
observed	O
by	O
preparing	O
ebv-ctl	O
generating	O
cultures	O
in	O
trans-wells	O
that	O
separated	O
the	O
autologous	O
bmc	O
from	O
the	O
pbl	B-cell_type
+	O
ebv-b	O
.	O

it	O
was	O
then	O
observed	O
that	O
cd0+	B-cell_type
cells	I-cell_type
obtained	O
after	O
0	O
days	O
of	O
culture	O
in	O
the	O
presence	O
of	O
autologous	B-cell_type
bmc	I-cell_type
could	O
be	O
used	O
as	O
inhibitors	O
of	O
ebv-ctl	O
generation	O
.	O

protein	B-protein
kinase	I-protein
a	I-protein
(	O
pka	B-protein
)	O
,	O
a	O
camp	B-protein
kinase	I-protein
that	O
is	O
involved	O
in	O
the	O
upregulation	O
of	O
th0	B-protein
cytokine	I-protein
activity	O
,	O
was	O
increased	O
in	O
ebv-ctl	B-cell_line
cultures	I-cell_line
by	O
the	O
presence	O
of	O
bmc	B-cell_type
.	O

additionally	O
,	O
il-0-mediated	O
signal	O
transduction	O
and	O
activation	O
of	O
transcription	O
(	O
stat-0	B-protein
)	O
phosphorylation	O
was	O
slightly	O
increased	O
.	O

these	O
results	O
show	O
that	O
the	O
bmc	O
inhibition	O
is	O
mediated	O
by	O
soluble	B-protein
factors	I-protein
(	O
cytokines	B-protein
)	O
and	O
that	O
cell-cell	O
contact	O
in	O
this	O
autologous	O
system	O
is	O
not	O
required	O
,	O
so	O
that	O
bmc	B-cell_type
(	O
at	O
least	O
partially	O
,	O
via	O
cytokine	B-protein
production	O
)	O
promote	O
th0	O
polarization	O
in	O
culture	O
.	O

moreover	O
,	O
th0	B-cell_type
cells	I-cell_type
induced	O
by	O
culturing	O
with	O
autologous	B-cell_type
bmc	I-cell_type
directly	O
inhibit	O
ebv-ctl	O
generation	O
,	O
and	O
th0	B-cell_type
associated	O
pka	B-protein
,	O
ccr0	B-protein
,	O
and	O
stat-0	B-protein
phosphorylation	O
are	O
enhanced	O
by	O
bmc	B-cell_type
.	O

###MEDLINE:21103296

reduction	O
in	O
dna	O
binding	O
activity	O
of	O
the	O
transcription	B-protein
factor	I-protein
pax-0a	B-protein
in	O
b	B-cell_type
lymphocytes	I-cell_type
of	O
aged	O
mice	O
.	O

aging	O
has	O
been	O
associated	O
with	O
intrinsic	O
changes	O
of	O
the	O
humoral	O
immune	O
response	O
,	O
which	O
may	O
lead	O
to	O
an	O
increased	O
occurrence	O
of	O
autoimmune	O
disorders	O
and	O
pathogenic	O
susceptibility	O
.	O

the	O
transcription	B-protein
factor	I-protein
pax-0	I-protein
is	O
a	O
key	O
regulator	O
of	O
b	B-cell_type
cell	I-cell_type
development	O
.	O

pax-0a/b	B-protein
cell-specific	I-protein
activator	I-protein
protein	I-protein
and	O
an	O
alternatively	B-protein
spliced	I-protein
isoform	I-protein
,	O
pax-0d	B-protein
,	O
may	O
have	O
opposing	O
functions	O
in	O
transcriptional	O
regulation	O
due	O
to	O
the	O
lack	O
of	O
a	O
transactivation	B-protein
domain	I-protein
in	O
pax-0d	B-protein
.	O

to	O
study	O
b	B-cell_type
cell	I-cell_type
-specific	O
changes	O
that	O
occur	O
during	O
the	O
aging	O
process	O
,	O
we	O
investigated	O
expression	O
patterns	O
of	O
pax-0a	B-protein
and	O
0d	O
in	O
mature	B-cell_type
b	I-cell_type
cells	I-cell_type
of	O
young	O
and	O
aged	O
mice	O
.	O

rnase	B-protein
protection	O
assays	O
showed	O
a	O
similar	O
transcriptional	O
pattern	O
for	O
both	O
age	O
groups	O
that	O
indicates	O
that	O
aging	O
has	O
no	O
affect	O
on	O
transcription	O
initiation	O
or	O
alternative	O
splicing	O
for	O
either	O
isoform	O
.	O

in	O
contrast	O
,	O
a	O
significant	O
reduction	O
in	O
the	O
dna	O
binding	O
activity	O
of	O
pax-0a	B-protein
but	O
not	O
pax-0d	B-protein
protein	O
was	O
observed	O
in	O
aged	O
b	B-cell_type
cells	I-cell_type
in	O
vitro	O
,	O
while	O
western	O
blot	O
analyses	O
showed	O
that	O
similar	O
levels	O
of	O
pax-0a	B-protein
and	O
0d	O
proteins	O
were	O
present	O
in	O
both	O
age	O
groups	O
.	O

the	O
observed	O
decrease	O
in	O
pax-0a	B-protein
binding	O
activity	O
correlated	O
with	O
changes	O
in	O
expression	O
of	O
two	O
pax-0	B-DNA
target	I-DNA
genes	I-DNA
in	O
aged	O
b	B-cell_type
cells	I-cell_type
.	O

expression	O
of	O
the	O
ig	B-DNA
j	I-DNA
chain	I-DNA
and	O
the	O
secreted	B-RNA
form	I-RNA
of	O
ig	B-protein
mu	I-protein
,	O
which	O
are	O
both	O
known	O
to	O
be	O
suppressed	O
by	O
pax-0a	B-protein
in	O
mature	B-cell_type
b	I-cell_type
cells	I-cell_type
,	O
were	O
increased	O
in	O
b	B-cell_type
cells	I-cell_type
of	O
aged	O
mice	O
.	O

together	O
,	O
our	O
studies	O
suggest	O
that	O
changes	O
associated	O
with	O
the	O
aging	O
phenotype	O
cause	O
posttranslational	O
modification	O
(	O
s	O
)	O
of	O
pax-0a	B-protein
but	O
not	O
pax-0d	B-protein
,	O
which	O
may	O
lead	O
to	O
an	O
abnormal	B-cell_type
b	I-cell_type
cell	I-cell_type
phenotype	I-cell_type
in	O
aged	O
mice	O
,	O
associated	O
with	O
elevated	O
levels	O
of	O
j	B-protein
chain	I-protein
,	O
and	O
secretion	O
of	O
igm	B-protein

###MEDLINE:21103247

nf-kappa	B-protein
b/rel	I-protein
participation	O
in	O
the	O
lymphokine-dependent	O
proliferation	O
of	O
t	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O

proliferative	O
responses	O
of	O
lymphoid	B-cell_type
cells	I-cell_type
to	O
il-0	B-protein
and	O
il-0	B-protein
depend	O
on	O
activation	O
of	O
the	O
cells	O
,	O
but	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
activation	O
enhances	O
cellular	O
competence	O
to	O
respond	O
to	O
cytokines	B-protein
is	O
not	O
fully	O
understood	O
.	O

the	O
nf-kappab/rel	B-protein
family	I-protein
represents	O
one	O
signal	O
transduction	O
pathway	O
induced	O
during	O
such	O
activation	O
.	O

we	O
show	O
in	O
this	O
study	O
that	O
inhibition	O
of	O
nf-kappab	B-protein
through	O
the	O
expression	O
of	O
an	O
ikappabalpha	B-protein
(	I-protein
inhibitory	I-protein
protein	I-protein
that	O
dissociates	O
from	O
nf-kappab	B-protein
)	O
mutant	O
refractory	O
to	O
signal-induced	O
degradation	O
(	O
ikappabalpha	B-protein
(	O
deltan	B-protein
)	O
)	O
interfered	O
with	O
the	O
acquisition	O
of	O
competence	O
to	O
proliferate	O
in	O
response	O
to	O
il-0	B-protein
as	O
well	O
as	O
il-0	B-protein
.	O

thymocytes	B-cell_type
and	O
t	B-cell_type
cells	I-cell_type
from	O
ikappabalpha	B-protein
(	O
deltan	B-protein
)	O
transgenic	O
mice	O
expressed	O
normal	O
levels	O
of	O
il-0r	B-protein
subunits	I-protein
.	O

however	O
,	O
transgenic	B-cell_type
cells	I-cell_type
exhibited	O
a	O
dramatic	O
defect	O
in	O
stat0a	B-protein
activation	O
treatment	O
with	O
il-0	B-protein
,	O
and	O
a	O
similar	O
defect	O
was	O
observed	O
for	O
il-0	B-protein
-induced	O
stat0	B-protein
.	O

in	O
contrast	O
,	O
t	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
with	O
inhibition	O
of	O
nf-kappab	B-protein
showed	O
normal	O
insulin	B-protein
receptor	I-protein
substrate-0	I-protein
phosphorylation	O
and	O
only	O
a	O
modest	O
decrease	O
in	O
stat0	B-protein
activation	O
and	O
insulin	B-protein
receptor	I-protein
substrate-0	I-protein
phosphorylation	O
after	O
il-0	B-protein
stimulation	O
.	O

these	O
results	O
indicate	O
that	O
the	O
nf-kappab/rel/ikappabalpha	O
system	O
can	O
regulate	O
cytokine	B-protein
receptor	I-protein
capacitation	O
through	O
effects	O
on	O
the	O
induction	O
of	O
downstream	O
signaling	O
by	O
the	O
stat	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
.	O

###MEDLINE:21111553

bms-000000	O
,	O
a	O
novel	O
retinoid	B-protein
receptor	I-protein
antagonist	I-protein
,	O
is	O
a	O
potent	O
testicular	O
toxin	O
.	O

bms-000000	O
is	O
a	O
synthetic	O
retinoid	O
that	O
acts	O
as	O
an	O
antagonist	O
at	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
alpha	I-protein
,	I-protein
beta	I-protein
,	O
and	O
gamma	O
.	O

in	O
sprague	O
dawley	O
rats	O
at	O
daily	O
oral	O
doses	O
of	O
00	O
,	O
00	O
,	O
or	O
000	O
mg/kg	O
for	O
0	O
month	O
,	O
bms-000000	O
produced	O
increases	O
in	O
leukocyte	O
counts	O
,	O
alkaline	B-protein
phosphatase	I-protein
and	O
alanine	O
aminotransferase	O
levels	O
,	O
and	O
marked	O
testicular	O
degeneration	O
and	O
atrophy	O
at	O
all	O
doses	O
.	O

significant	O
overt	O
signs	O
of	O
toxicity	O
and	O
deaths	O
occurred	O
at	O
000	O
mg/kg	O
,	O
whereas	O
body-weight	O
and	O
food-consumption	O
decreases	O
occurred	O
at	O
00	O
and	O
000	O
mg/kg	O
.	O

when	O
bms-000000	O
was	O
administered	O
to	O
male	O
rats	O
at	O
daily	O
doses	O
ranging	O
from	O
00.0	O
to	O
000	O
mg/kg	O
for	O
0	O
week	O
,	O
only	O
minimal	O
testicular	O
changes	O
occurred	O
at	O
all	O
doses	O
,	O
shortly	O
after	O
the	O
dosing	O
period	O
.	O

however	O
,	O
after	O
a	O
0-month	O
drug-free	O
observation	O
period	O
,	O
marked	O
testicular	O
atrophy	O
was	O
evident	O
at	O
all	O
doses	O
.	O

bms-000000	O
was	O
then	O
administered	O
at	O
doses	O
of	O
0	O
,	O
00	O
,	O
or	O
00	O
mg/kg	O
to	O
male	O
rats	O
for	O
0	O
,	O
0	O
,	O
or	O
0	O
consecutive	O
days	O
.	O

dose-	O
and	O
duration-dependent	O
testicular	O
toxicity	O
that	O
occurred	O
after	O
a	O
0-month	O
observation	O
period	O
did	O
not	O
recover	O
,	O
and	O
,	O
in	O
some	O
cases	O
,	O
was	O
more	O
severe	O
0	O
months	O
after	O
the	O
last	O
dose	O
.	O

in	O
rabbits	O
administered	O
bms-000000	O
at	O
oral	O
doses	O
of	O
0	O
,	O
00	O
,	O
or	O
00	O
mg/kg	O
for	O
0	O
week	O
,	O
testicular	O
degeneration	O
and	O
atrophy	O
were	O
evident	O
in	O
the	O
high-dose	O
group	O
at	O
0	O
month	O
following	O
treatment	O
.	O

these	O
studies	O
indicate	O
that	O
retinoid	B-protein
antagonists	I-protein
can	O
selectively	O
produce	O
progressive	O
and	O
prolonged	O
testicular	O
toxicity	O
after	O
single	O
or	O
repeated	O
oral	O
doses	O
that	O
are	O
otherwise	O
well	O
tolerated	O
.	O

###MEDLINE:20216392

sequential	O
involvement	O
of	O
nfat	B-protein
and	O
egr	B-protein
transcription	I-protein
factors	I-protein
in	O
fasl	B-protein
regulation	O
.	O

the	O
critical	O
function	O
of	O
nfat	B-protein
proteins	I-protein
in	O
maintaining	O
lymphoid	O
homeostasis	O
was	O
revealed	O
in	O
mice	O
lacking	O
both	O
nfatp	B-protein
and	O
nfat0	B-protein
(	O
dko	B-protein
)	O
.	O

dko	O
mice	O
exhibit	O
increased	O
lymphoproliferation	O
,	O
decreased	O
activation-induced	O
cell	O
death	O
,	O
and	O
impaired	O
induction	O
of	O
fasl	B-protein
.	O

the	O
transcription	B-protein
factors	I-protein
egr0	B-protein
and	O
egr0	B-protein
are	O
potent	O
activators	O
of	O
fasl	B-protein
expression	O
.	O

here	O
we	O
find	O
that	O
egr0	B-protein
and	O
egr0	B-protein
are	O
nfat	B-DNA
target	I-DNA
genes	I-DNA
.	O

activation	O
of	O
fasl	B-protein
occurs	O
via	O
the	O
nfat	B-protein
-dependent	O
induction	O
of	O
egr0	B-protein
,	O
as	O
demonstrated	O
by	O
the	O
ability	O
of	O
exogenously	O
provided	O
nfatp	B-protein
to	O
restore	O
egr	B-DNA
-dependent	I-DNA
fasl	I-DNA
promoter	I-DNA
activity	O
in	O
dko	B-cell_type
lymph	I-cell_type
node	I-cell_type
cells	I-cell_type
.	O

further	O
,	O
egr0	B-protein
expression	O
is	O
enriched	O
in	O
th0	B-cell_type
cells	I-cell_type
,	O
suggesting	O
a	O
molecular	O
basis	O
for	O
the	O
known	O
preferential	O
expression	O
of	O
fasl	B-protein
in	O
the	O
th0	O
versus	O
th0	B-cell_type
subset	I-cell_type
.	O

###MEDLINE:21028948

mechanisms	O
and	O
clinical	O
relevance	O
of	O
nongenomic	O
glucocorticoid	O
actions	O
.	O

glucocorticoids	O
have	O
profound	O
anti-inflammatory	O
and	O
immunosuppressive	O
actions	O
when	O
used	O
therapeutically	O
.	O

the	O
therapeutic	O
dose	O
is	O
quite	O
variable	O
and	O
depends	O
on	O
the	O
disease	O
,	O
but	O
ranges	O
from	O
very	O
low	O
to	O
extremely	O
high	O
.	O

the	O
rationale	O
for	O
the	O
use	O
of	O
various	O
dosage	O
regimens	O
for	O
specific	O
clinical	O
indications	O
is	O
the	O
existence	O
of	O
three	O
distinct	O
,	O
therapeutically	O
relevant	O
effects	O
:	O
genomic	O
,	O
specific	O
nongenomic	O
and	O
unspecific	O
nongenomic	O
.	O

genomic	O
effects	O
are	O
mediated	O
by	O
cytosolic	B-protein
receptors	I-protein
that	O
alter	O
expression	O
of	O
specific	O
genes	O
.	O

specific	O
nongenomic	O
effects	O
occur	O
within	O
a	O
few	O
minutes	O
and	O
are	O
mediated	O
by	O
steroid-selective	B-protein
membrane	I-protein
receptors	I-protein
.	O

unspecific	O
nongenomic	O
effects	O
occur	O
within	O
seconds	O
,	O
but	O
only	O
at	O
high	O
glucocorticoid	O
dosages	O
,	O
and	O
seem	O
to	O
result	O
from	O
direct	O
interactions	O
with	O
biological	O
membranes	O
.	O

for	O
unspecific	O
nongenomic	O
effects	O
,	O
methylprednisolone	O
and	O
other	O
glucocorticoids	O
have	O
been	O
shown	O
to	O
inhibit	O
cation	O
cycling	O
across	O
the	O
plasma	O
membrane	O
,	O
but	O
to	O
have	O
little	O
effect	O
on	O
protein	O
synthesis	O
.	O

thus	O
,	O
glucocorticoids	O
could	O
diminish	O
or	O
prevent	O
the	O
acute	O
immune	O
response	O
by	O
interfering	O
with	O
processes	O
such	O
as	O
the	O
rise	O
in	O
intracellular	O
ca0+	O
concentration	O
.	O

it	O
is	O
proposed	O
that	O
the	O
additional	O
therapeutic	O
benefit	O
of	O
higher	O
doses	O
is	O
obtained	O
via	O
these	O
nongenomic	O
effects	O
.	O

###MEDLINE:21026273

high	O
glucose-induced	O
intercellular	B-protein
adhesion	I-protein
molecule-0	I-protein
(	O
icam-0	B-protein
)	O
expression	O
through	O
an	O
osmotic	O
effect	O
in	O
rat	B-cell_type
mesangial	I-cell_type
cells	I-cell_type
is	O
pkc-nf-kappa	O
b-dependent	O
.	O

aims/hypothesis	O
:	O
infiltration	O
of	O
mononuclear	B-cell_type
cells	I-cell_type
and	O
glomerular	O
enlargement	O
accompanied	O
by	O
glomerular	O
cell	O
proliferation	O
are	O
very	O
early	O
characteristics	O
of	O
the	O
pathophysiology	O
of	O
diabetes	O
.	O

to	O
clarify	O
the	O
mechanism	O
of	O
early	O
diabetic	O
nephropathy	O
,	O
we	O
measured	O
[	O
0h	O
]	O
-thymidine	O
incorporation	O
and	O
cell	O
numbers	O
to	O
show	O
the	O
influence	O
of	O
a	O
high	O
ambient	O
glucose	O
concentration	O
and	O
the	O
osmotic	O
effect	O
on	O
rat	B-cell_type
mesangial	I-cell_type
cell	I-cell_type
proliferation	O
.	O

we	O
also	O
measured	O
the	O
effect	O
of	O
high	O
glucose	O
on	O
the	O
expression	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-0	I-protein
and	O
vascular	B-protein
adhesion	I-protein
molecule-0	I-protein
by	O
flow	O
cytometry	O
and	O
semiquantitative	O
rt-pcr	O
in	O
mesangial	B-cell_type
cells	I-cell_type
and	O
the	O
adhesion	O
of	O
leukocytes	B-cell_type
to	O
mesangial	B-cell_type
cells	I-cell_type
.	O

methods/results	B-cell_line
:	I-cell_line
cells	I-cell_line
exposed	O
to	O
high	O
d-glucose	O
(	O
00	O
mmol/l	O
)	O
caused	O
an	O
increase	O
in	O
[	O
0h	O
]	O
-thymidine	O
incorporation	O
and	O
cell	O
numbers	O
at	O
00	O
and	O
00	O
h	O
and	O
normalized	O
at	O
00	O
h	O
(	O
p	O
<	O
0.00	O
)	O
,	O
whereas	O
these	O
changes	O
were	O
not	O
found	O
in	O
high	O
mannitol	O
(	O
00	O
mmol/l	O
)	O
,	O
il-0	B-protein
beta	I-protein
,	O
or	O
tnf	B-protein
alpha	I-protein
-stimulated	O
mesangial	B-cell_type
cells	I-cell_type
.	O

cells	O
exposed	O
to	O
high-glucose	O
(	O
00	O
,	O
00	O
,	O
or	O
00	O
mmol/l	O
)	O
or	O
osmotic	O
agents	O
(	O
l-glucose	O
,	O
raffinose	O
and	O
mannitol	O
)	O
showed	O
that	O
intercellular	B-protein
adhesion	I-protein
molecule-0	I-protein
expression	O
began	O
to	O
increase	O
after	O
00	O
h	O
,	O
reached	O
its	O
maximum	O
at	O
00	O
and	O
00	O
h	O
and	O
gradually	O
decreased	O
afterwards	O
.	O

the	O
stimulatory	O
effects	O
of	O
high	O
glucose	O
and	O
high	O
mannitol	O
on	O
mrna	O
expression	O
were	O
observed	O
as	O
early	O
as	O
0	O
h	O
and	O
reached	O
its	O
maximum	O
at	O
00	O
h	O
.	O

up-regulation	O
of	O
icam-0	B-RNA
protein	I-RNA
and	I-RNA
mrna	I-RNA
was	O
also	O
found	O
in	O
il-0-beta	B-cell_line
and	I-cell_line
tnf-alpha	I-cell_line
-stimulated	I-cell_line
mesangial	I-cell_line
cells	I-cell_line
.	O

neither	O
vascular	B-protein
adhesion	I-protein
molecule-0	I-protein
protein	O
nor	O
mrna	B-RNA
expression	O
was	O
,	O
however	O
,	O
affected	O
by	O
high	O
glucose	O
and	O
high	O
mannitol	O
.	O

notably	O
,	O
the	O
protein	B-protein
kinase	I-protein
c	I-protein
inhibitors	I-protein
calphostin	O
c	O
and	O
staurosporine	O
reduced	O
high	O
glucose-	O
or	O
high	O
mannitol-induced	O
intercellular	B-protein
adhesion	I-protein
molecule-0	I-protein
mrna	O
expression	O
and	O
high	O
glucose-induced	O
proliferation	O
.	O

furthermore	O
,	O
the	O
nf-kappa	B-protein
b	I-protein
inhibitor	O
n-tosyl-l-phenylalanine	O
chloromethyl	O
ketone	O
reduced	O
high	O
glucose-	O
or	O
high	O
mannitol-induced	O
intercellular	B-protein
adhesion	I-protein
molecule-0	I-protein
mrna	O
expression	O
and	O
high	O
glucose-induced	O
proliferation	O
.	O

results	O
showed	O
that	O
high	O
glucose	O
(	O
00	O
,	O
00	O
mmol/l	O
)	O
or	O
high	O
concentrations	O
of	O
osmotic	O
agents	O
remarkably	O
increased	O
the	O
number	O
of	O
adherent	B-cell_type
leukocytes	I-cell_type
to	O
mesangial	B-cell_type
cells	I-cell_type
(	O
p	O
<	O
0.00	O
)	O
compared	O
with	O
control	B-cell_type
cells	I-cell_type
(	O
0	O
mmol/l	O
d-glucose	O
)	O
.	O

functional	O
blocking	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-0	I-protein
on	O
mesangial	B-cell_type
cells	I-cell_type
with	O
rat	O
intercellular	B-protein
adhesion	I-protein
molecule-0	I-protein
monoclonal	B-protein
antibody	I-protein
,	O
calphostin	O
c	O
,	O
staurosporine	O
,	O
or	O
n-tosyl-l-phenylalanine	O
chloromethyl	O
ketone	O
significantly	O
inhibited	O
high	O
glucose-	O
or	O
high	O
mannitol-induced	O
increase	O
in	O
leukocyte	O
adhesion	O
(	O
p	O
<	O
<	O
0.00	O
)	O
.	O

conclusion/interpretation	O
:	O
these	O
results	O
suggest	O
that	O
high	O
glucose	O
can	O
upregulate	O
intercellular	B-protein
adhesion	I-protein
molecule-0	I-protein
protein	O
and	O
mrna	B-RNA
expression	O
but	O
not	O
vascular	B-protein
adhesion	I-protein
molecule-0	I-protein
expression	O
in	O
mesangial	B-cell_type
cells	I-cell_type
and	O
promote	O
leukocyte	O
adhesion	O
through	O
up-regulation	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-0	I-protein
through	O
osmotic	O
effect	O
,	O
possibly	O
depending	O
on	O
the	O
protein	B-protein
kinase	I-protein
c	I-protein
nuclear	I-protein
factor-kappa	I-protein
b	I-protein
(	O
pkc	B-protein
-	O
nf-kappa	B-protein
b	I-protein
)	O
pathway	O
.	O

high	O
glucose	O
itself	O
can	O
also	O
promote	O
mesangial	O
cell	O
proliferation	O
through	O
the	O
pkc-nf-kappa	B-protein
b	I-protein
pathways	O
.	O

we	O
conclude	O
that	O
hyperglycaemia	O
in	O
itself	O
seems	O
to	O
be	O
an	O
important	O
factor	O
in	O
the	O
development	O
of	O
early	O
diabetic	O
nephropathy	O
.	O

###MEDLINE:20582375

combined	O
corticosteroid/	B-protein
granulocyte	I-protein
colony-stimulating	I-protein
factor	I-protein
(	O
g-csf	B-protein
)	O
therapy	O
in	O
the	O
treatment	O
of	O
severe	O
congenital	O
neutropenia	O
unresponsive	O
to	O
g-csf	B-protein
:	O
activated	O
glucocorticoid	B-protein
receptors	I-protein
synergize	O
with	O
g-csf	B-protein
signals	O
.	O

more	O
than	O
00	O
%	O
of	O
patients	O
with	O
severe	O
congenital	O
neutropenia	O
(	O
scn	O
)	O
respond	O
to	O
granulocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
g-csf	B-protein
)	O
therapy	O
.	O

the	O
basis	O
for	O
the	O
refractory	O
state	O
in	O
the	O
remaining	O
patients	O
is	O
unknown	O
.	O

to	O
address	O
this	O
issue	O
,	O
we	O
studied	O
a	O
child	O
with	O
scn	O
who	O
was	O
totally	O
unresponsive	O
to	O
g-csf	B-protein
and	O
had	O
a	O
novel	O
point	O
mutation	O
in	O
the	O
extracellular	B-protein
domain	I-protein
of	O
the	O
g-csf	B-protein
receptor	I-protein
(	O
gcsf-r	B-protein
)	O
.	O

marrow	O
stromal	O
support	O
of	O
granulopoiesis	O
was	O
evaluated	O
by	O
plating	B-cell_line
cd00	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
cells	I-cell_line
on	O
preformed	O
stromal	B-cell_type
layers	I-cell_type
.	O

nonadherent	B-cell_line
cells	I-cell_line
were	O
harvested	O
and	O
assayed	O
in	O
clonogenic	O
assays	O
for	O
granulocytic	O
colony	O
production	O
.	O

the	O
in	O
vitro	O
effect	O
of	O
g-csf	B-protein
and	O
corticosteroids	O
on	O
granulopoiesis	O
was	O
evaluated	O
in	O
clonogenic	O
assays	O
of	O
marrow	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
,	O
by	O
proliferation	O
studies	O
of	O
the	O
murine	B-cell_line
myeloid	I-cell_line
cell	I-cell_line
line	I-cell_line
00d	B-cell_line
expressing	O
the	O
patient	O
's	O
mutated	B-protein
g-csfr	I-protein
,	O
and	O
by	O
measuring	O
stat0	B-protein
activation	O
in	O
nuclear	O
extracts	O
from	O
stimulated	B-cell_type
cells	I-cell_type
.	O

patient	O
's	O
stroma	O
supported	O
granulopoiesis	O
derived	O
from	O
control	B-cell_type
marrow	I-cell_type
cd00	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
in	O
a	O
normal	O
manner	O
.	O

normal	O
stroma	O
,	O
however	O
,	O
failed	O
to	O
induce	O
granulopoiesis	O
from	O
patient	O
's	O
cd00	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
.	O

clonogenic	O
assays	O
of	O
the	O
patient	O
's	O
marrow	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
incorporating	O
either	O
g-csf	B-protein
or	O
hydrocortisone	O
produced	O
little	O
neutrophil	O
growth	O
.	O

in	O
contrast	O
,	O
inclusion	O
of	O
both	O
g-csf	B-protein
and	O
hydrocortisone	O
in	O
the	O
cytokine	O
``	O
cocktail	O
''	O
markedly	O
increased	O
the	O
neutrophil	O
numbers	O
.	O

proliferation	O
of	O
00d	O
cells	O
expressing	O
the	O
mutated	B-protein
receptor	I-protein
and	O
stat0	B-protein
activation	O
were	O
improved	O
by	O
a	O
combination	O
of	O
g-csf	B-protein
and	O
dexamethasone	O
.	O

when	O
small	O
daily	O
doses	O
of	O
oral	O
prednisone	O
were	O
then	O
administered	O
to	O
the	O
patient	O
with	O
conventional	O
doses	O
of	O
subcutaneous	O
g-csf	B-protein
,	O
the	O
patient	O
responded	O
with	O
increased	O
neutrophil	O
numbers	O
and	O
with	O
a	O
complete	O
reversal	O
of	O
the	O
infectious	O
problems	O
.	O

these	O
data	O
provide	O
insight	O
into	O
scn	O
unresponsive	O
to	O
standard	O
g-csf	B-protein
treatment	O
and	O
to	O
the	O
potential	O
corrective	O
action	O
of	O
combined	O
treatment	O
with	O
g-csf	B-protein
and	O
corticosteroids	O
through	O
synergistic	O
activation	O
of	O
stat0	B-protein
.	O

###MEDLINE:20580277

human	O
renal	O
mesangial	B-cell_type
cells	I-cell_type
are	O
a	O
target	O
for	O
the	O
anti-inflammatory	O
action	O
of	O
0-cis	O
retinoic	O
acid	O
.	O

mesangial	B-cell_type
cells	I-cell_type
play	O
an	O
active	O
role	O
in	O
the	O
inflammatory	O
response	O
to	O
glomerular	O
injury	O
.	O

we	O
have	O
studied	O
in	O
cultured	B-cell_line
human	I-cell_line
mesangial	I-cell_line
cells	I-cell_line
(	O
chmc	B-protein
)	O
several	O
effects	O
of	O
0-cis	O
retinoic	O
acid	O
(	O
0-cra	B-protein
)	O
,	O
an	O
activator	O
of	O
both	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
(	O
rars	B-protein
)	O
and	O
retinoid	B-protein
x	I-protein
receptors	I-protein
(	O
rxrs	B-protein
)	O
.	O

0-cra	O
inhibited	O
foetal	O
calf	O
serum-induced	O
chmc	O
proliferation	O
.	O

it	O
also	O
prevented	O
chmc	O
death	O
induced	O
by	O
the	O
inflammatory	O
mediator	O
h	O
(	O
0	O
)	O
o	O
(	O
0	O
)	O
.	O

this	O
preventive	O
effect	O
was	O
not	O
due	O
to	O
any	O
increase	O
in	O
h	O
(	O
0	O
)	O
o	O
(	O
0	O
)	O
catabolism	O
and	O
it	O
persisted	O
even	O
when	O
both	O
catalase	B-protein
and	O
glutathione	O
synthesis	O
were	O
inhibited	O
.	O

finally	O
,	O
0-cra	O
diminished	O
monocyte	O
adhesion	O
to	O
fcs-stimulated	O
chmc	O
.	O

interestingly	O
,	O
the	O
retinoid	O
also	O
inhibited	O
in	O
fcs-stimulated	B-cell_type
cells	I-cell_type
the	O
protein	O
expression	O
of	O
two	O
mesangial	B-protein
adhesion	I-protein
molecules	I-protein
,	O
fibronectin	B-protein
and	O
osteopontin	B-protein
,	O
but	O
it	O
did	O
not	O
modify	O
the	O
protein	O
expression	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-0	I-protein
and	O
vascular	B-protein
adhesion	I-protein
molecule-0	I-protein
.	O

all	O
major	O
rars	B-protein
and	O
rxrs	B-protein
isotypes	O
were	O
expressed	O
in	O
chmc	B-protein
regardless	O
of	O
the	O
presence	O
or	O
absence	O
of	O
0-cra	O
.	O

transcripts	O
to	O
rar-alpha	B-protein
,	O
rar-beta	B-protein
and	O
rxr-alpha	B-protein
increased	O
after	O
incubation	O
with	O
0-cra	O
whereas	O
rxr-gamma	B-protein
was	O
inhibited	O
,	O
suggesting	O
a	O
major	O
role	O
for	O
rars	B-protein
and	O
rxrs	B-protein
in	O
0-cra-anti-inflammatory	O
effects	O
.	O

0-cra	O
was	O
toxic	O
only	O
at	O
00	O
microm	O
(	O
a	O
concentration	O
00	O
-	O
0000	O
times	O
higher	O
than	O
required	O
for	O
the	O
effects	O
above	O
)	O
.	O

cell	O
death	O
occurred	O
by	O
apoptosis	O
,	O
whose	O
onset	O
was	O
associated	O
with	O
a	O
pronounced	O
increase	O
in	O
catalase	B-protein
activity	O
and	O
reduced	O
glutathione	O
content	O
,	O
being	O
more	O
effectively	O
induced	O
by	O
all-trans	O
retinoic	O
acid	O
.	O

modulation	O
of	O
the	O
oxidant/antioxidant	O
balance	O
failed	O
to	O
inhibit	O
apoptosis	O
.	O

we	O
conclude	O
that	O
mesangial	B-cell_type
cells	I-cell_type
might	O
be	O
a	O
target	O
for	O
the	O
treatment	O
of	O
inflammatory	O
glomerulopathies	O
with	O
0-cra	O
.	O

###MEDLINE:21011862

expression	O
of	O
mammalian	O
defensin	O
genes	O
.	O

antimicrobial	O
peptides	O
are	O
a	O
prevalent	O
mechanism	O
of	O
host	O
defense	O
found	O
throughout	O
nature	O
.	O

in	O
mammals	O
,	O
defensins	B-protein
are	O
among	O
the	O
most	O
abundant	O
of	O
these	O
broad-spectrum	O
antibiotics	O
,	O
and	O
are	O
expressed	O
in	O
epithelial	B-cell_type
and	I-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
.	O

the	O
defensin	O
peptides	O
are	O
especially	O
abundant	O
in	O
neutrophils	B-cell_type
;	O
however	O
,	O
gene	O
expression	O
is	O
limited	O
to	O
the	O
promyelocyte	O
stage	O
.	O

in	O
epithelial	B-cell_type
cells	I-cell_type
,	O
defensin	B-protein
genes	O
are	O
found	O
as	O
both	O
constitutively	O
expressed	O
and	O
inducible	O
.	O

induction	O
has	O
been	O
observed	O
in	O
vitro	O
by	O
stimulation	O
with	O
bacterial	O
lipopolysaccharide	O
as	O
well	O
as	O
inflammatory	B-protein
mediators	I-protein
.	O

in	O
vivo	O
,	O
up-regulation	O
of	O
several	O
defensin	O
genes	O
occurs	O
in	O
both	O
infectious	O
and	O
inflammatory	O
states	O
.	O

gene	O
regulation	O
occurs	O
via	O
signal	O
transduction	O
pathways	O
common	O
to	O
other	O
innate	O
immune	O
responses	O
,	O
utilizing	O
transcription	B-protein
factors	I-protein
such	O
as	O
nuclear	B-protein
factor	I-protein
(	O
nf	B-protein
)	I-protein
-kappab	I-protein
and	O
nf	B-protein
interleukin-0	I-protein
.	O

together	O
,	O
the	O
data	O
suggest	O
a	O
broad-based	O
innate	O
host	O
defense	O
whereby	O
potent	O
antimicrobial	O
peptides	O
are	O
present	O
to	O
prevent	O
initial	O
colonization	O
by	O
pathogenic	O
microorganisms	O
.	O

in	O
addition	O
,	O
the	O
recognition	O
of	O
bacteria	O
coupled	O
with	O
a	O
nascent	O
inflammatory	O
response	O
can	O
bolster	O
this	O
defense	O
by	O
a	O
coordinated	O
up-regulation	O
of	O
the	O
peptides	O
.	O

###MEDLINE:20571908

multiple	O
signals	O
required	O
for	O
cyclic	B-protein
amp-responsive	I-protein
element	I-protein
binding	I-protein
protein	I-protein
(	O
creb	B-protein
)	I-protein
binding	I-protein
protein	I-protein
interaction	O
induced	O
by	O
cd0/cd00	B-protein
costimulation	O
.	O

the	O
optimal	O
activation	O
of	O
camp-responsive	B-protein
element	I-protein
binding	I-protein
protein	I-protein
(	O
creb	B-protein
)	O
,	O
similar	O
to	O
the	O
full	O
activation	O
of	O
t	B-cell_type
lymphocytes	I-cell_type
,	O
requires	O
the	O
stimulation	O
of	O
both	O
cd0	B-protein
and	O
cd00	B-protein
.	O

using	O
a	O
reporter	O
system	O
to	O
detect	O
interaction	O
of	O
creb	B-protein
and	O
creb-binding	B-protein
protein	I-protein
(	O
cbp	B-protein
)	O
,	O
in	O
this	O
study	O
we	O
found	O
that	O
creb	B-protein
binds	O
to	O
cbp	B-protein
only	O
by	O
engagement	O
of	O
both	O
cd0	B-protein
and	O
cd00	B-protein
.	O

cd0/cd00	B-protein
-promoted	O
creb	B-protein
-	O
cbp	B-protein
interaction	O
was	O
dependent	O
on	O
p00	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
(	O
mapk	B-protein
)	O
and	O
calcium/calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
(	I-protein
camk	I-protein
)	I-protein
iv	I-protein
in	O
addition	O
to	O
the	O
previously	O
identified	O
extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
pathway	O
.	O

extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
,	O
camkiv	B-protein
,	O
and	O
p00	B-protein
mapk	I-protein
were	O
also	O
the	O
kinases	O
involved	O
in	O
creb	B-protein
ser	O
(	O
000	O
)	O
phosphorylation	O
induced	O
by	O
cd0/cd00	B-protein
.	O

a	O
reconstitution	O
experiment	O
illustrated	O
that	O
optimum	O
creb	B-protein
-	O
cbp	B-protein
interaction	O
and	O
creb	B-protein
trans-activation	O
were	O
attained	O
when	O
these	O
three	O
kinase	O
pathways	O
were	O
simultaneously	O
activated	O
in	O
t	B-cell_type
cells	I-cell_type
.	O

our	O
results	O
demonstrate	O
that	O
coordinated	O
activation	O
of	O
different	O
kinases	O
leads	O
to	O
full	O
activation	O
of	O
creb	B-protein
.	O

notably	O
,	O
cd00	B-protein
ligation	O
activated	O
p00	B-protein
mapk	I-protein
and	O
camkiv	B-protein
,	O
the	O
kinases	O
stimulated	O
by	O
cd0	B-protein
engagement	O
,	O
suggesting	O
that	O
cd00	B-protein
acts	O
by	O
increasing	O
the	O
activation	O
extent	O
of	O
p00	B-protein
mapk	I-protein
and	O
camkiv	B-protein
.	O

these	O
results	O
support	O
the	O
model	O
of	O
a	O
minimum	O
activation	O
threshold	O
for	O
creb	B-protein
-	O
cbp	B-protein
interaction	O
that	O
can	O
be	O
reached	O
only	O
when	O
both	O
cd0	B-protein
and	O
cd00	B-protein
are	O
stimulated	O
.	O

###MEDLINE:20570937

the	O
murine	B-DNA
il-0	I-DNA
promoter	I-DNA
contains	O
distal	B-DNA
regulatory	I-DNA
elements	I-DNA
responsive	O
to	O
the	O
ah	B-protein
receptor	I-protein
,	O
a	O
member	O
of	O
the	O
evolutionarily	O
conserved	O
bhlh-pas	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
.	O

signaling	O
through	O
the	O
tcr	B-protein
and	O
costimulatory	O
signals	O
primarily	O
control	O
transcription	O
of	O
the	O
il-0	B-DNA
gene	I-DNA
in	O
naive	B-cell_type
t	I-cell_type
cells	I-cell_type
.	O

the	O
minimal	B-DNA
promoter	I-DNA
necessary	O
for	O
this	O
expression	O
lies	O
proximal	O
,	O
between	O
-000	O
and	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
.	O

we	O
had	O
previously	O
shown	O
that	O
activation	O
of	O
the	O
arylhydrocarbon	B-protein
receptor	I-protein
(	O
ahr	B-protein
)	O
,	O
a	O
member	O
of	O
the	O
bhlh-pas	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
,	O
leads	O
to	O
increased	O
mrna	B-RNA
expression	O
of	O
il-0	B-protein
in	O
murine	B-cell_type
fetal	I-cell_type
thymocytes	I-cell_type
.	O

the	O
ahr	B-protein
is	O
abundant	O
in	O
the	O
thymus	O
and	O
may	O
play	O
a	O
role	O
for	O
the	O
development	O
of	O
the	O
immune	O
system	O
.	O

moreover	O
,	O
its	O
overactivation	O
by	O
chemicals	O
such	O
as	O
dioxins	O
leads	O
to	O
immunosuppression	O
and	O
thymic	O
involution	O
.	O

binding	O
motifs	O
for	O
the	O
liganded	O
ahr	B-protein
can	O
be	O
identified	O
in	O
the	O
distal	B-DNA
region	I-DNA
-0000	I-DNA
to	I-DNA
-000	I-DNA
of	O
the	O
mouse	B-DNA
il-0	I-DNA
promoter	I-DNA
.	O

we	O
show	O
here	O
that	O
these	O
dna	B-DNA
motifs	I-DNA
,	O
the	O
so-called	O
dioxin	O
response	O
elements	O
,	O
after	O
binding	O
to	O
the	O
liganded	O
ahr	B-protein
are	O
sufficient	O
to	O
transactivate	O
luciferase	B-protein
expression	O
in	O
a	O
reporter	B-DNA
gene	I-DNA
system	O
.	O

the	O
il-0	B-DNA
gene	I-DNA
can	O
be	O
induced	O
by	O
the	O
ahr	B-protein
also	O
in	O
thymocytes	B-cell_type
in	O
vivo	O
after	O
injection	O
of	O
0	O
,	O
0	O
,	O
0	O
,	O
0-tetrachlorodibenzo-p-dioxin	O
,	O
a	O
potent	O
ligand	O
of	O
the	O
ahr	B-protein
.	O

the	O
ahr	B-protein
mediates	O
the	O
il-0	B-protein
induction	O
as	O
shown	O
with	O
ahr	B-protein
-deficient	O
mice	O
.	O

however	O
,	O
in	O
spleen	B-cell_type
cells	I-cell_type
in	O
vitro	O
costimulation	O
via	O
the	O
tcr	B-protein
is	O
necessary	O
for	O
optimal	O
il-0	B-DNA
gene	I-DNA
induction	O
.	O

thus	O
,	O
the	O
il-0	B-DNA
promoter	I-DNA
region	I-DNA
contains	O
novel	O
distal	B-DNA
regulatory	I-DNA
elements	I-DNA
that	O
can	O
be	O
addressed	O
by	O
the	O
ahr	B-protein
to	O
induce	O
il-0	B-protein
and	O
can	O
cooperate	O
with	O
the	O
proximal	B-DNA
promoter	I-DNA

###MEDLINE:21103162

visualization	O
of	O
syk-antigen	B-protein
receptor	I-protein
interactions	O
using	O
green	O
fluorescent	O
protein	O
:	O
differential	O
roles	O
for	O
syk	B-protein
and	O
lyn	B-protein
in	O
the	O
regulation	O
of	O
receptor	O
capping	O
and	O
internalization	O
.	O

the	O
cross-linking	O
of	O
the	O
b	B-protein
cell	I-protein
ag	I-protein
receptor	I-protein
(	O
bcr	B-protein
)	O
is	O
coupled	O
to	O
the	O
stimulation	O
of	O
multiple	O
intracellular	O
signal	O
transduction	O
cascades	O
via	O
receptor-associated	B-protein
,	I-protein
protein	I-protein
tyrosine	I-protein
kinases	I-protein
of	O
both	O
the	O
src	B-protein
and	O
syk	B-protein
families	I-protein
.	O

to	O
monitor	O
changes	O
in	O
the	O
subcellular	O
distribution	O
of	O
syk	B-protein
in	O
b	B-cell_type
cells	I-cell_type
responding	O
to	O
bcr	B-protein
cross-linking	O
,	O
we	O
expressed	O
in	O
syk	B-protein
-deficient	O
dt00	B-cell_type
b	I-cell_type
cells	I-cell_type
a	O
fusion	B-protein
protein	I-protein
consisting	O
of	O
syk	B-protein
coupled	O
to	O
green	O
fluorescent	O
protein	O
.	O

treatment	O
of	O
these	O
cells	O
with	O
anti-igm	B-protein
abs	I-protein
leads	O
to	O
the	O
recruitment	O
of	O
the	O
kinase	O
from	O
cytoplasmic	O
and	O
nuclear	O
compartments	O
to	O
the	O
site	O
of	O
the	O
cross-linked	B-protein
receptor	I-protein
at	O
the	O
plasma	O
membrane	O
.	O

the	O
syk-receptor	B-protein
complexes	I-protein
aggregate	O
into	O
membrane	O
patches	O
that	O
redistribute	O
to	O
form	O
a	O
cap	B-DNA
at	I-DNA
one	I-DNA
pole	I-DNA
of	O
the	O
cell	O
.	O

syk	B-protein
is	O
not	O
demonstrably	O
associated	O
with	O
the	O
internalized	O
receptor	O
.	O

catalytically	O
active	O
syk	B-protein
promotes	O
and	O
stabilizes	O
the	O
formation	O
of	O
tightly	O
capped	O
bcr	O
complexes	O
at	O
the	O
plasma	O
membrane	O
.	O

lyn	B-protein
is	O
not	O
required	O
for	O
the	O
recruitment	O
of	O
syk	B-protein
to	O
the	O
cross-linked	B-protein
receptor	I-protein
,	O
but	O
is	O
required	O
for	O
the	O
internalization	O
of	O
the	O
clustered	O
bcr	O
complexes	O
.	O

in	O
the	O
absence	O
of	O
lyn	B-protein
,	O
receptor-syk	B-protein
complexes	I-protein
at	O
the	O
plasma	O
membrane	O
are	O
long	O
lived	O
,	O
and	O
the	O
receptor-mediated	O
activation	O
of	O
the	O
nf-at	B-protein
transcription	I-protein
factor	I-protein
is	O
enhanced	O
.	O

thus	O
,	O
lyn	B-protein
appears	O
to	O
function	O
to	O
negatively	O
regulate	O
aspects	O
of	O
bcr	B-protein
-dependent	O
signaling	O
by	O
stimulating	B-protein
receptor	I-protein
internalization	O
and	O
down-regulation	O
.	O

###MEDLINE:21093708

renal	O
interstitial	O
fibrosis	O
is	O
reduced	O
in	O
angiotensin	B-protein
ii	I-protein
type	I-protein
0a	I-protein
receptor	I-protein
-deficient	O
mice	O
.	O

unilateral	O
ureteral	O
obstruction	O
(	O
uuo	O
)	O
results	O
in	O
tubulointerstitial	O
fibrosis	O
of	O
the	O
affected	O
kidney	O
by	O
stimulating	O
the	O
renin-angiotensin	O
system	O
.	O

this	O
study	O
established	O
a	O
uuo	O
model	O
in	O
angiotensin	B-protein
type	I-protein
0a	I-protein
receptor	I-protein
(	O
at0a	O
)	O
deficient	O
(	O
mutant	O
)	O
mice	O
to	O
elucidate	O
the	O
role	O
of	O
angiotensin	B-protein
ii	I-protein
through	O
at0a	O
on	O
the	O
fibrosis	O
of	O
the	O
obstructed	O
kidney	O
(	O
obk	B-protein
)	O
.	O

the	O
relative	O
volume	O
of	O
the	O
tubulointerstitium	B-cell_type
was	O
measured	O
by	O
an	O
image	O
analyzer	O
;	O
deposition	O
of	O
collagen	B-protein
types	O
iii	O
and	O
iv	O
and	O
monocyte	O
/	O
macrophage	O
infiltration	O
were	O
histologically	O
examined	O
using	O
specific	O
antibodies	O
.	O

also	O
determined	O
were	O
the	O
mrna	O
levels	O
of	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
by	O
northern	O
blot	O
analysis	O
.	O

nuclear	B-protein
factor-kappab	I-protein
activity	O
was	O
assessed	O
by	O
gel	O
shift	O
assay	O
.	O

uuo	O
in	O
wild	O
mice	O
resulted	O
in	O
a	O
marked	O
expansion	O
of	O
relative	O
volume	O
of	O
the	O
tubulointerstitium	B-cell_type
,	O
together	O
with	O
increased	O
deposition	O
of	O
collagen	B-protein
types	O
iii	O
and	O
iv	O
and	O
number	O
of	O
infiltrated	O
monocytes	B-cell_type
/	O
macrophages	B-cell_type
in	O
the	O
interstitium	O
,	O
relative	O
to	O
sham-operated	O
mice	O
.	O

in	O
comparison	O
,	O
these	O
changes	O
were	O
significantly	O
lower	O
in	O
mutant	O
mice	O
with	O
uuo	O
.	O

the	O
mrna	O
level	O
of	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
was	O
significantly	O
higher	O
in	O
the	O
obk	O
of	O
wild	O
mice	O
with	O
uuo	O
compared	O
with	O
sham-operated	O
mice	O
.	O

in	O
contrast	O
,	O
the	O
increase	O
in	O
mrna	O
level	O
in	O
the	O
obk	O
of	O
mutant	O
mice	O
was	O
significantly	O
less	O
than	O
in	O
wild	O
mice	O
.	O

finally	O
,	O
uuo	O
resulted	O
in	O
activation	O
of	O
nuclear	B-protein
factor-kappab	I-protein
in	O
wild	O
mice	O
but	O
was	O
inhibited	O
in	O
the	O
obk	O
of	O
mutant	O
mice	O
.	O

the	O
results	O
provide	O
direct	O
evidence	O
that	O
angiotensin	B-protein
ii	I-protein
acting	O
via	O
the	O
at0a	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
development	O
of	O
tubulointerstitial	O
fibrosis	O
in	O
uuo	O
.	O

###MEDLINE:20219263

hla-dq	B-protein
tetramers	I-protein
identify	O
epitope-specific	B-cell_type
t	I-cell_type
cells	I-cell_type
in	O
peripheral	B-cell_type
blood	I-cell_type
of	O
herpes	B-protein
simplex	I-protein
virus	I-protein
type	I-protein
0-infected	I-protein
individuals	O
:	O
direct	O
detection	O
of	O
immunodominant	O
antigen-responsive	B-cell_type
cells	I-cell_type
.	O

ag-specific	B-cell_type
cd0+	I-cell_type
t	I-cell_type
cells	I-cell_type
are	O
present	O
in	O
peripheral	B-cell_type
blood	I-cell_type
in	O
low	O
frequency	O
,	O
where	O
they	O
undergo	O
recruitment	O
and	O
expansion	O
during	O
immune	O
responses	O
and	O
in	O
the	O
pathogenesis	O
of	O
numerous	O
autoimmune	O
diseases	O
.	O

mhc	B-protein
tetramers	I-protein
,	O
which	O
constitute	O
a	O
labeled	O
mhc-peptide	B-protein
ligand	I-protein
suitable	O
for	O
binding	O
to	O
the	O
ag-specific	B-protein
receptor	I-protein
on	O
t	B-cell_type
cells	I-cell_type
,	O
provide	O
a	O
novel	O
approach	O
for	O
the	O
detection	O
and	O
characterization	O
of	O
such	O
rare	O
cells	O
.	O

in	O
this	O
study	O
,	O
we	O
utilized	O
this	O
technology	O
to	O
identify	O
hla	O
dq	O
-restricted	O
ag-specific	B-cell_type
t	I-cell_type
cells	I-cell_type
in	O
the	O
peripheral	O
blood	O
of	O
human	O
subjects	O
and	O
to	O
identify	O
immunodominant	B-protein
epitopes	I-protein
associated	O
with	O
viral	O
infection	O
.	O

peptides	O
representing	O
potential	O
epitope	O
regions	O
of	O
the	O
vp00	B-protein
protein	O
from	O
hsv-0	O
were	O
loaded	O
onto	O
recombinant	O
dq0000	O
molecules	O
to	O
generate	O
a	O
panel	O
of	O
ag-specific	O
dq0000	O
tetramers	O
.	O

vp00	B-protein
ag	B-protein
-specific	O
dq-restricted	B-cell_line
t	I-cell_line
cells	I-cell_line
were	O
identified	O
and	O
expanded	O
from	O
the	O
peripheral	O
blood	O
of	O
hsv-0-infected	O
individuals	O
,	O
representing	O
two	O
predominant	O
epitope	O
specificities	O
.	O

although	O
the	O
vp00	O
000-000	O
peptide	O
has	O
a	O
lower	O
binding	O
affinity	O
for	O
dq0000	O
molecules	O
than	O
the	O
vp00	O
00-00	O
peptide	O
,	O
t	B-cell_type
cells	I-cell_type
that	O
recognized	O
the	O
vp00	O
000-000	O
peptide	O
occurred	O
at	O
a	O
much	O
higher	O
frequency	O
than	O
those	O
that	O
were	O
specific	O
for	O
the	O
vp00	O
00-00	O
peptide	O
.	O

###MEDLINE:20584588

down-regulation	O
of	O
bob.0/obf.0	B-protein
and	O
oct0	B-protein
in	O
classical	O
hodgkin	O
disease	O
but	O
not	O
in	O
lymphocyte	O
predominant	O
hodgkin	O
disease	O
correlates	O
with	O
immunoglobulin	B-protein
transcription	O
.	O

in	O
contrast	O
to	O
the	O
tumor	B-cell_type
cells	I-cell_type
(	O
l	B-cell_type
&	I-cell_type
h	I-cell_type
cells	I-cell_type
)	O
of	O
lymphocyte	O
predominant	O
hodgkin	O
disease	O
(	O
lphd	B-protein
)	O
,	O
hodgkin	B-cell_line
and	I-cell_line
reed-sternberg	I-cell_line
(	I-cell_line
hrs	I-cell_line
)	I-cell_line
cells	I-cell_line
of	O
classical	O
hodgkin	O
disease	O
(	O
chd	O
)	O
are	O
unable	O
to	O
transcribe	O
immunoglobulin	B-protein
,	O
despite	O
the	O
presence	O
of	O
rearranged	B-DNA
immunoglobulin	I-DNA
genes	I-DNA
.	O

although	O
initial	O
studies	O
have	O
suggested	O
crippling	O
immunoglobulin	B-DNA
gene	I-DNA
mutations	O
to	O
be	O
the	O
cause	O
of	O
absent	O
immunoglobulin	O
expression	O
in	O
chd	O
,	O
recent	O
work	O
of	O
our	O
group	O
has	O
demonstrated	O
an	O
impaired	O
activation	O
of	O
the	O
immunoglobulin	B-DNA
promoter	I-DNA
as	O
a	O
superior	O
mechanism	O
.	O

as	O
immunoglobulin	B-protein
transcription	O
is	O
mainly	O
regulated	O
by	O
the	O
b-cell	B-protein
transcription	I-protein
factors	I-protein
oct0	B-protein
and	O
bob.0/obf.0	B-protein
,	O
we	O
analyzed	O
00	O
cases	O
of	O
lphd	O
,	O
00	O
cases	O
of	O
chd	O
,	O
and	O
0	O
hodgkin	O
disease	O
cell	O
lines	O
for	O
the	O
expression	O
of	O
these	O
transcription	B-protein
factors	I-protein
and	O
also	O
in	O
parallel	O
for	O
immunoglobulin	B-protein
expression	O
.	O

our	O
results	O
demonstrate	O
an	O
absence	O
of	O
oct0	B-protein
and/or	O
bob.0/obf.0	B-protein
in	O
chd	O
and	O
a	O
striking	O
overexpression	O
of	O
oct0	B-protein
in	O
lphd	O
.	O

immunoglobulin	B-protein
expression	O
was	O
lacking	O
in	O
chd	O
but	O
present	O
in	O
lphd	O
.	O

furthermore	O
,	O
the	O
reintroduction	O
of	O
bob.0/obf.0	B-protein
and	O
oct0	B-protein
into	O
cultured	O
hrs	O
cells	O
restored	O
the	O
activity	O
of	O
cotransduced	B-DNA
immunoglobulin	I-DNA
promoter	I-DNA
constructs	I-DNA
.	O

our	O
findings	O
dismiss	O
the	O
concept	O
that	O
the	O
different	O
immunoglobulin	O
expression	O
in	O
chd	O
and	O
lphd	B-protein
is	O
due	O
to	O
disrupting	O
mutations	O
of	O
immunoglobulin	B-DNA
v	I-DNA
genes	I-DNA
in	O
chd	O
but	O
is	O
most	O
likely	O
due	O
to	O
a	O
down-regulation	O
of	O
oct0	B-protein
and/or	O
bob.0/obf.0	B-protein
.	O

this	O
study	O
further	O
revealed	O
oct0	B-protein
as	O
a	O
new	O
and	O
valuable	O
marker	O
for	O
the	O
identification	O
of	O
l	B-cell_type
&	I-cell_type
h	I-cell_type
cells	I-cell_type
and	O
their	O
distinction	O
from	O
hrs	O
cells	O
.	O

the	O
impairment	O
of	O
immunoglobulin	B-protein
transcription	O
with	O
a	O
down-regulated	O
synthesis	O
of	O
oct0	B-protein
and	O
bob.0/obf.0	B-protein
is	O
the	O
first	O
established	O
general	O
recurrent	O
defect	O
found	O
in	O
hrs	O
cells	O
.	O

###MEDLINE:20584330

constitutive	O
expression	O
of	O
nf-kappa	B-protein
b	I-protein
is	O
a	O
characteristic	O
feature	O
of	O
mycosis	O
fungoides	O
:	O
implications	O
for	O
apoptosis	O
resistance	O
and	O
pathogenesis	O
.	O

the	O
nf-kappa	B-protein
b	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
is	O
an	O
important	O
regulator	O
of	O
genes	O
expressed	O
during	O
inflammatory	O
responses	O
,	O
immunoglobulin	B-protein
(	O
ig	B-protein
)	O
class	O
switching	O
,	O
cellular	O
differentiation	O
,	O
and	O
apoptosis	O
.	O

recently	O
,	O
members	O
of	O
the	O
nf-kappab	B-protein
family	I-protein
,	O
including	O
p00	B-protein
(	O
rel	B-protein
a	I-protein
)	O
,	O
have	O
been	O
implicated	O
in	O
promoting	O
survival	O
of	O
various	O
hematopoeitic	B-cell_type
neoplasms	I-cell_type
,	O
including	O
t	B-cell_type
cell	I-cell_type
malignancies	I-cell_type
such	O
as	O
adult	B-cell_line
t	I-cell_line
cell	I-cell_line
leukemia-lymphoma	I-cell_line
.	O

we	O
investigated	O
the	O
expression	O
of	O
active	O
nf-kappa	B-protein
b	I-protein
p00	I-protein
(	O
rel	B-protein
a	I-protein
)	O
in	O
cases	O
of	O
mycosis	O
fungoides	O
(	O
mf	O
)	O
and	O
the	O
effect	O
of	O
chemical	O
inhibitors	O
of	O
nf-kappa	B-protein
b	I-protein
on	O
apoptosis	O
in	O
cutaneous	B-cell_line
t	I-cell_line
cell	I-cell_line
lymphoma	I-cell_line
(	I-cell_line
ctcl	I-cell_line
)	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

paraffin-embedded	O
tissues	O
from	O
00	O
cutaneous	O
lesions	O
and	O
a	O
single	O
lymph	O
node	O
biopsy	O
from	O
patients	O
diagnosed	O
with	O
mf	O
were	O
evaluated	O
for	O
p00	B-protein
(	I-protein
rel	I-protein
a	I-protein
)	O
expression	O
by	O
using	O
a	O
monoclonal	B-protein
mouse	I-protein
antibody	I-protein
that	O
detects	O
the	O
activated	O
form	O
of	O
p00	B-protein
(	I-protein
rel	I-protein
a	I-protein
)	O
.	O

apoptosis	O
after	O
treatment	O
with	O
the	O
nf-kappa	B-protein
b	I-protein
inhibitors	I-protein
gliotoxin	O
,	O
mg000	O
,	O
bay	O
00-0000	O
,	O
and	O
bay	O
00-0000	O
was	O
quantitatively	O
measured	O
in	O
the	O
ctcl	B-cell_line
cell	I-cell_line
lines	I-cell_line
hut-00	B-cell_line
and	O
hh	O
by	O
propidium	O
iodide	O
(	O
pi	B-DNA
)	O
/cell	O
cycle	O
analysis	O
for	O
detection	O
of	O
a	O
hypodiploid	B-protein
(	I-protein
sub-g	I-protein
(	O
0	O
)	O
)	O
population	O
and	O
by	O
determination	O
of	O
increased	O
annexin	O
v/0-amino-actinomycin	O
d	O
(	O
0-aad	B-protein
)	O
expression	O
.	O

nuclear	O
extracts	O
from	O
ctcl	B-cell_type
cells	I-cell_type
before	O
and	O
after	O
chemical	O
inhibition	O
were	O
analyzed	O
for	O
nf-kappa	B-protein
b	I-protein
nuclear	O
dna-binding	O
activity	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
emsa	O
)	O
with	O
quantitative	O
densitometry	O
.	O

nuclear	O
expression	O
of	O
p00	B-protein
(	I-protein
rel	I-protein
a	I-protein
)	O
before	O
and	O
after	O
treatment	O
with	O
the	O
various	O
inhibitory	O
compounds	O
was	O
measured	O
by	O
immunofluorescence	O
staining	O
in	O
each	O
ctcl	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

neoplastic	B-cell_type
t	I-cell_type
lymphocytes	I-cell_type
from	O
00	O
of	O
00	O
cases	O
of	O
mf	O
showed	O
strong	O
nuclear	O
and	O
cytoplasmic	O
expression	O
of	O
active	O
p00	B-protein
(	I-protein
rel	I-protein
a	I-protein
)	O
.	O

compared	O
with	O
untreated	B-cell_line
control	I-cell_line
cells	I-cell_line
,	O
a	O
marked	O
increase	O
in	O
apoptosis	O
,	O
a	O
significant	O
decrease	O
in	O
nf-kappa	B-protein
b	I-protein
dna-binding	O
activity	O
,	O
and	O
a	O
marked	O
decrease	O
in	O
nuclear	B-protein
p00	I-protein
(	O
rel	B-protein
a	I-protein
)	O
expression	O
were	O
seen	O
in	O
cells	O
from	O
both	O
ctcl	B-cell_line
cell	I-cell_line
lines	I-cell_line
after	O
chemical	O
nf-kappa	B-protein
b	I-protein
inhibition	O
.	O

these	O
data	O
show	O
that	O
the	O
active	O
form	O
of	O
nf-kappa	B-protein
b	I-protein
p00	I-protein
(	O
rel	B-protein
a	I-protein
)	O
is	O
commonly	O
expressed	O
in	O
neoplastic	B-cell_type
t	I-cell_type
lymphocytes	I-cell_type
in	O
patients	O
with	O
mf	O
.	O

in	O
ctcl	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
the	O
significant	O
decrease	O
in	O
nuclear	B-protein
nf-kappa	I-protein
b	I-protein
expression	O
and	O
the	O
marked	O
increase	O
in	O
spontaneous	O
apoptosis	O
caused	O
by	O
chemical	O
nf-kappa	B-protein
b	I-protein
inhibition	O
suggest	O
a	O
critical	O
role	O
for	O
nf-kappa	B-protein
b	I-protein
in	O
the	O
pathogenesis	O
and	O
tumor	O
cell	O
maintenance	O
of	O
ctcls	O
.	O

hum	O
pathol	O
00	O
:	O
0000-0000	O
.	O

###MEDLINE:21066742

human	B-protein
t-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
0	I-protein
tax	I-protein
protein	I-protein
activates	O
transcription	O
through	O
ap-0	B-DNA
site	I-DNA
by	O
inducing	O
dna	O
binding	O
activity	O
in	O
t	B-cell_type
cells	I-cell_type
.	O

human	B-protein
t-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
0	I-protein
(	I-protein
htlv-0	I-protein
)	I-protein
tax	I-protein
protein	I-protein
induces	O
the	O
expression	O
of	O
various	O
family	O
members	O
of	O
the	O
transcription	B-protein
factor	I-protein
ap-0	B-protein
,	O
such	O
as	O
c-jun	B-protein
,	O
jund	B-protein
,	O
c-fos	B-DNA
,	O
and	O
fra-0	B-DNA
,	O
at	O
the	O
level	O
of	O
rna	O
expression	O
in	O
t	B-cell_type
cells	I-cell_type
.	O

we	O
examined	O
the	O
activity	O
of	O
tax	B-protein
in	O
transcription	O
through	O
ap-0-binding	B-DNA
sites	I-DNA
(	O
ap-0	B-DNA
site	I-DNA
)	O
in	O
t	B-cell_type
cells	I-cell_type
.	O

transient	O
transfection	O
studies	O
showed	O
that	O
tax	B-protein
activated	O
the	O
expression	O
of	O
a	O
luciferase	B-DNA
gene	I-DNA
regulated	O
by	O
two	O
copies	O
of	O
an	O
ap-0	B-DNA
site	I-DNA
in	O
the	O
human	B-cell_line
jurkat	I-cell_line
t-cell	I-cell_line
line	I-cell_line
.	O

tax	B-protein
activates	O
the	O
expression	O
of	O
viral	O
and	O
cellular	O
genes	O
through	O
two	O
different	O
enhancers	O
:	O
a	O
camp-responsive	B-DNA
(	I-DNA
cre	I-DNA
)	I-DNA
-like	I-DNA
element	I-DNA
and	O
a	O
kappab	B-DNA
element	I-DNA
.	O

two	O
tax	B-protein
mutants	I-protein
differentially	O
activated	O
expression	O
of	O
these	O
two	O
elements	O
.	O

tax000	O
preferentially	O
activated	O
the	O
kappab	B-DNA
element	I-DNA
but	O
not	O
the	O
cre-like	O
one	O
,	O
whereas	O
taxm00	B-protein
showed	O
the	O
reverse	O
.	O

in	O
addition	O
,	O
tax000	B-protein
and	O
tax	B-protein
,	O
but	O
not	O
taxm00	O
,	O
converted	O
cell	O
growth	O
of	O
a	O
mouse	B-cell_line
t-cell	I-cell_line
line	I-cell_line
from	O
being	O
interleukin	B-protein
(	I-protein
il	I-protein
)	I-protein
-0-dependent	I-protein
to	O
being	O
il-0-independent	O
.	O

unlike	O
the	O
wild-type	B-protein
tax	I-protein
,	O
tax000	B-protein
and	O
taxm00	B-protein
only	O
weakly	O
activated	O
the	O
ap-0	B-DNA
site	I-DNA
in	O
the	O
t-cell	B-cell_line
line	I-cell_line
.	O

thus	O
,	O
tax	B-protein
seems	O
to	O
activate	O
the	O
ap-0	B-DNA
site	I-DNA
via	O
mechanisms	O
distinct	O
from	O
those	O
of	O
kappab	B-protein
or	O
cre-like	B-DNA
elements	I-DNA
,	O
and	O
the	O
activation	O
of	O
the	O
ap-0	B-DNA
site	I-DNA
is	O
dispensable	O
for	O
il-0-independent	O
growth	O
of	O
ctll-0	B-cell_line
.	O

electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
tax	B-protein
induced	O
strong	O
binding	O
activity	O
to	O
an	O
ap-0	B-DNA
site	I-DNA
in	O
ctll-0	B-cell_line
,	O
whereas	O
tax000	B-protein
did	O
not	O
,	O
indicating	O
that	O
the	O
induction	O
of	O
binding	O
activity	O
to	O
the	O
ap-0	B-DNA
site	I-DNA
is	O
essential	O
for	O
the	O
transcriptional	O
activation	O
by	O
tax	B-protein
.	O

the	O
binding	B-protein
complex	I-protein
induced	O
by	O
tax	B-protein
in	O
ctll-0	B-cell_line
contained	O
jund	B-protein
and	O
fra-0	B-DNA
.	O

other	O
ap-0	B-protein
proteins	I-protein
were	O
undetectable	O
.	O

activation	O
of	O
transcription	O
through	O
the	O
ap-0	B-DNA
site	I-DNA
in	O
jurkat	B-cell_line
cells	I-cell_line
by	O
jund	B-protein
and/or	O
fra-0	B-DNA
was	O
weak	O
.	O

c-jun	B-protein
,	O
junb	B-protein
,	O
and	O
c-fos	B-protein
activation	O
was	O
greater	O
,	O
although	O
the	O
level	O
was	O
still	O
less	O
than	O
that	O
with	O
tax	B-protein
.	O

thus	O
,	O
the	O
induction	O
of	O
ap-0	B-RNA
mrna	I-RNA
by	O
tax	B-protein
may	O
not	O
be	O
sufficient	O
for	O
a	O
complete	O
activation	O
of	O
ap-0	B-DNA
site	I-DNA
by	O
tax	B-protein
.	O

our	O
results	O
suggest	O
that	O
tax	B-protein
activates	O
the	O
transcription	O
of	O
cellular	O
genes	O
with	O
ap-0	B-DNA
sites	I-DNA
by	O
inducing	O
the	O
dna-binding	O
activity	O
of	O
ap-0	B-protein
proteins	I-protein
in	O
t	B-cell_type
cells	I-cell_type
,	O
a	O
mechanism	O
distinct	O
from	O
those	O
of	O
cre-like	B-DNA
and	I-DNA
kappab	I-DNA
elements	I-DNA
.	O

copyright	O
0000	O
academic	O
press	O
.	O

###MEDLINE:20578233

strict	O
control	O
of	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
0	I-DNA
replication	O
by	O
a	O
genetic	O
switch	O
:	O
tet	O
for	O
tat	B-protein
.	O

live-attenuated	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
0	I-DNA
(	I-DNA
hiv-0	I-DNA
)	I-DNA
variants	I-DNA
have	O
shown	O
great	O
promise	O
as	O
aids	O
vaccines	O
,	O
but	O
continued	O
replication	O
can	O
lead	O
to	O
the	O
selection	O
of	O
faster-replicating	O
variants	O
that	O
are	O
pathogenic	O
.	O

we	O
therefore	O
designed	O
hiv-0	B-DNA
genomes	I-DNA
that	O
replicate	O
exclusively	O
upon	O
addition	O
of	O
the	O
nontoxic	O
effector	O
doxycycline	O
(	O
dox	O
)	O
.	O

this	O
was	O
achieved	O
by	O
replacement	O
of	O
the	O
viral	O
tar-tat	O
system	O
for	O
transcriptional	O
activation	O
by	O
the	O
escherichia	O
coli-derived	O
tet	O
system	O
for	O
inducible	O
gene	O
expression	O
.	O

these	O
designer	O
``	O
hiv-rtta	O
''	O
viruses	O
replicate	O
in	O
a	O
strictly	O
dox-dependent	O
manner	O
both	O
in	O
a	O
t-cell	B-cell_line
line	I-cell_line
and	O
in	O
primary	B-cell_type
blood	I-cell_type
cells	I-cell_type
,	O
and	O
the	O
rate	O
of	O
replication	O
can	O
be	O
fine-tuned	O
by	O
simple	O
variation	O
of	O
the	O
dox	O
concentration	O
.	O

these	O
hiv-rtta	O
viruses	O
provide	O
a	O
tool	O
to	O
perform	O
genetics	O
,	O
e.g.	O
,	O
selection	O
and	O
optimization	O
experiments	O
,	O
with	O
the	O
e.	O
coli-derived	O
tet	O
reagents	O
in	O
a	O
eukaryotic	O
background	O
.	O

furthermore	O
,	O
such	O
viruses	O
may	O
represent	O
improved	O
vaccine	O
candidates	O
because	O
their	O
replication	O
can	O
be	O
turned	O
on	O
and	O
off	O
at	O
will	O
.	O

###MEDLINE:21011278

synovial	O
fluid	O
induced	O
nuclear	B-protein
factor-kappab	I-protein
dna	O
binding	O
in	O
a	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

objective	O
:	O
to	O
determine	O
the	O
effects	O
of	O
synovial	B-cell_type
fluids	I-cell_type
(	O
sf	O
)	O
on	O
dna	O
binding	O
activity	O
of	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor-kappab	I-protein
(	O
nf-kappab	B-protein
)	O
in	O
the	O
mono	B-cell_line
mac	I-cell_line
0	I-cell_line
monocytic/macrophage	O
cell	B-cell_line
line	I-cell_line
as	O
a	O
model	O
for	O
the	O
interaction	O
between	O
sf	O
and	O
synovial	B-cell_type
tissue	I-cell_type
macrophages	I-cell_type
in	O
arthritis	O
.	O

methods	O
:	O
mono	B-cell_line
mac	I-cell_line
0	I-cell_line
cells	I-cell_line
were	O
incubated	O
with	O
sf	O
from	O
the	O
knee	O
joints	O
of	O
human	O
subjects	O
with	O
rheumatoid	O
arthritis	O
(	O
ra	O
)	O
,	O
undifferentiated	O
seronegative	O
oligoarthritis	O
,	O
and	O
osteoarthritis	O
(	O
oa	O
)	O
.	O

nuclear	O
extracts	O
prepared	O
from	O
the	O
mono	B-cell_line
mac	I-cell_line
0	I-cell_line
cells	I-cell_line
and	O
ra	B-cell_type
synovial	I-cell_type
tissue	I-cell_type
were	O
analyzed	O
by	O
electrophoretic	O
mobility	O
shift	O
analysis	O
(	O
emsa	O
)	O
for	O
nf-kappab	B-protein
dna	I-protein
binding	I-protein
proteins	I-protein
.	O

results	O
:	O
induction	O
of	O
nf-kappab	B-protein
dna	O
binding	O
by	O
the	O
p00	B-protein
(	I-protein
rela	I-protein
)	I-protein
/p00	I-protein
heterodimer	I-protein
was	O
observed	O
in	O
response	O
to	O
incubation	O
of	O
mono	B-cell_line
mac	I-cell_line
0	I-cell_line
cells	I-cell_line
with	O
sf	O
(	O
00	O
%	O
in	O
culture	O
medium	O
)	O
from	O
0	O
of	O
0	O
subjects	O
with	O
ra	O
,	O
0	O
of	O
0	O
with	O
oa	O
,	O
and	O
none	O
of	O
0	O
with	O
undifferentiated	O
seronegative	O
oligoarthritis	O
.	O

incubation	O
of	O
sf	O
with	O
neutralizing	B-protein
antibodies	I-protein
against	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
tnf-alpha	B-protein
)	O
,	O
but	O
not	O
antibodies	B-protein
against	O
interleukin	B-protein
0	I-protein
(	O
il-0	B-protein
)	O
,	O
significantly	O
reduced	O
the	O
induction	O
of	O
p00/p00	B-protein
binding	O
activity	O
in	O
sf	O
from	O
subjects	O
with	O
ra	O
and	O
oa	O
.	O

unexpectedly	O
,	O
a	O
slowly	O
migrating	O
sf	O
inducible	O
nf-kappab	B-protein
-binding	I-protein
complex	I-protein
was	O
observed	O
in	O
emsa	O
of	O
mono	B-cell_line
mac	I-cell_line
0	I-cell_line
cells	I-cell_line
after	O
incubation	O
with	O
sf	O
from	O
0	O
of	O
0	O
ra	O
and	O
0	O
of	O
0	O
oa	O
subjects	O
.	O

the	O
induction	O
of	O
this	O
complex	O
by	O
sf	O
was	O
not	O
affected	O
by	O
neutralization	O
of	O
tnf-alpha	B-protein
or	O
il-0	B-protein
in	O
sf	O
,	O
and	O
the	O
complex	O
was	O
not	O
inducible	O
by	O
tnf-alpha	B-protein
,	O
il-0beta	B-protein
,	O
tnf-alpha	B-protein
/	O
il-0beta	B-protein
,	O
il-0	B-protein
,	O
platelet	B-cell_type
derived	O
growth	B-protein
factor	I-protein
,	O
lipopolysaccharide	O
,	O
or	O
tetradecanoyl	O
phorbol	O
acetate	O
.	O

the	O
slowly	O
migrating	O
complex	O
could	O
not	O
be	O
supershifted	O
with	O
antibodies	O
against	O
nf-kappab	B-protein
,	O
jun	B-protein
,	O
or	O
the	O
transcriptional	B-protein
coactivators	I-protein
p000	B-protein
or	O
cbp	B-protein
.	O

a	O
nf-kappab-binding	B-protein
complex	I-protein
with	O
similar	O
slow	O
mobility	O
was	O
observed	O
in	O
nuclear	O
extracts	O
prepared	O
from	O
fresh	O
human	O
ra	O
synovial	O
tissue	O
.	O

conclusion	O
:	O
biological	O
activity	O
of	O
tnf-alpha	B-protein
in	O
sf	O
from	O
ra	O
and	O
oa	O
subjects	O
is	O
capable	O
of	O
inducing	O
p00/p00	B-protein
nf-kappab	B-protein
dna	O
binding	O
activity	O
in	O
macrophages	B-cell_type
.	O

a	O
property	O
of	O
sf	O
that	O
is	O
independent	O
of	O
tnf-alpha	B-protein
and	O
other	O
cytokines	B-protein
is	O
responsible	O
for	O
the	O
induction	O
of	O
a	O
novel	O
slowly	O
migrating	O
nf-kappab-binding	B-DNA
complex	I-DNA
.	I-DNA

soluble	O
mediators	O
in	O
sf	O
of	O
subjects	O
with	O
ra	O
and	O
oa	O
can	O
therefore	O
modulate	O
binding	O
of	O
nuclear	B-protein
proteins	I-protein
to	O
the	O
nf-kappab	B-DNA
binding	I-DNA
site	I-DNA
in	O
macrophages	B-cell_type
and	O
may	O
play	O
a	O
role	O
in	O
inflammatory	O
gene	O
expression	O
in	O
arthritis	O
.	O

###MEDLINE:20570933

peroxisome	B-protein
proliferator	I-protein
activator	I-protein
receptor-gamma	I-protein
agonists	O
and	O
00-deoxy-delta	B-protein
(	O
00	O
,	O
00	O
)	O
(	O
00	O
,	O
00	O
)	O
-pgj	O
(	O
0	O
)	O
induce	O
apoptosis	O
in	O
normal	B-cell_type
and	I-cell_type
malignant	I-cell_type
b-lineage	I-cell_type
cells	I-cell_type
.	O

the	O
research	O
described	O
herein	O
evaluates	O
the	O
expression	O
and	O
functional	O
significance	O
of	O
peroxisome	B-protein
proliferator	I-protein
activator	I-protein
receptor-gamma	I-protein
(	O
ppar-gamma	B-protein
)	O
on	O
b-lineage	B-cell_type
cells	I-cell_type
.	O

normal	B-cell_type
mouse	I-cell_type
b	I-cell_type
cells	I-cell_type
and	O
a	O
variety	O
of	O
b	B-cell_line
lymphoma	I-cell_line
cells	I-cell_line
reflective	O
of	O
stages	O
of	O
b	B-cell_type
cell	I-cell_type
differentiation	O
(	O
e.g.	O
,	O
00z/0	B-protein
,	O
ch00	B-protein
,	O
wehi-000	O
,	O
ch00	B-protein
,	O
and	O
j000	B-protein
)	O
express	O
ppar-gamma	B-protein
mrna	O
and	O
,	O
by	O
western	O
blot	O
analysis	O
,	O
the	O
00-kda	O
ppar-gamma	B-protein
protein	O
.	O

00-deoxy-delta	O
(	O
00	O
,	O
00	O
)	O
-pgj	O
(	O
0	O
)	O
(	O
00d-pgj	O
(	O
0	O
)	O
)	O
,	O
a	O
ppar-gamma	B-protein
agonist	O
,	O
has	O
a	O
dose-dependent	O
antiproliferative	O
and	O
cytotoxic	O
effect	O
on	O
normal	B-cell_type
and	I-cell_type
malignant	I-cell_type
b	I-cell_type
cells	I-cell_type
as	O
shown	O
by	O
[	O
(	O
0	O
)	O
h	O
]	O
thymidine	O
and	O
0-	O
[	O
0	O
,	O
0-dimethylthiazol-0-yl	B-protein
]	I-protein
-0	I-protein
,	O
0-diphenyltetrazolium	O
bromide	O
assays	O
.	O

only	O
ppar-gamma	B-protein
agonists	O
(	O
thiazolidinediones	O
)	O
,	O
and	O
not	O
ppar-alpha	B-protein
agonists	O
,	O
mimicked	O
the	O
effect	O
of	O
00d-pgj	O
(	O
0	O
)	O
on	O
b-lineage	B-cell_type
cells	I-cell_type
,	O
indicating	O
that	O
the	O
mechanism	O
by	O
which	O
00d-pgj	O
(	O
0	O
)	O
negatively	O
affects	O
b-lineage	B-cell_type
cells	I-cell_type
involves	O
in	O
part	O
ppar-gamma	O
.	O

the	O
mechanism	O
by	O
which	O
ppar-gamma	B-protein
agonists	O
induce	O
cytotoxicity	O
is	O
via	O
apoptosis	O
,	O
as	O
shown	O
by	O
annexin	O
v	O
staining	O
and	O
as	O
confirmed	O
by	O
dna	O
fragmentation	O
detected	O
using	O
the	O
tunel	O
assay	O
.	O

interestingly	O
,	O
addition	O
of	O
pgf	O
(	O
0alpha	O
)	O
,	O
which	O
was	O
not	O
known	O
to	O
affect	O
lymphocytes	B-cell_type
,	O
dramatically	O
attenuated	O
the	O
deleterious	O
effects	O
of	O
ppar-gamma	B-protein
agonists	O
on	O
b	B-cell_type
lymphomas	I-cell_type
.	O

surprisingly	O
,	O
00d-pgj	O
(	O
0	O
)	O
induced	O
a	O
massive	O
increase	O
in	O
nuclear	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
activation	O
,	O
and	O
pretreatment	O
with	O
pgf	O
(	O
0alpha	O
)	O
blunted	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
activation	O
.	O

this	O
is	O
the	O
first	O
study	O
evaluating	O
ppar-gamma	B-protein
expression	O
and	O
its	O
significance	O
on	O
b	B-cell_type
lymphocytes	I-cell_type
.	O

ppar-gamma	B-protein
agonists	O
may	O
serve	O
as	O
a	O
counterbalance	O
to	O
the	O
stimulating	O
effects	O
of	O
other	O
pgs	O
,	O
namely	O
pge	O
(	O
0	O
)	O
,	O
which	O
promotes	O
b	O
cell	O
differentiation	O
.	O

finally	O
,	O
the	O
use	O
of	O
pgs	B-protein
,	O
such	O
as	O
00d-pgj	O
(	O
0	O
)	O
,	O
and	O
synthetic	O
ppar-gamma	O
agonists	O
to	O
induce	O
apoptosis	O
in	O
b-lineage	B-cell_type
cells	I-cell_type
may	O
lead	O
to	O
the	O
development	O
of	O
novel	O
therapies	O
for	O
fatal	O
b	B-cell_type
lymphomas	I-cell_type

###MEDLINE:21102393

inhibition	O
of	O
stat0	B-protein
signaling	O
leads	O
to	O
apoptosis	O
of	O
leukemic	O
large	B-cell_type
granular	I-cell_type
lymphocytes	I-cell_type
and	O
decreased	O
mcl-0	O
expression	O
.	O

large	B-cell_type
granular	I-cell_type
lymphocyte	I-cell_type
(	O
lgl	B-cell_type
)	O
leukemia	O
is	O
characterized	O
by	O
the	O
expansion	O
of	O
antigen-activated	B-cell_type
cytotoxic	I-cell_type
t	I-cell_type
lymphocytes	I-cell_type
.	O

these	O
leukemic	B-cell_type
cells	I-cell_type
are	O
resistant	O
to	O
fas-mediated	O
apoptosis	O
despite	O
expressing	O
high	O
levels	O
of	O
fas	B-protein
.	O

we	O
found	O
that	O
leukemic	O
lgl	B-cell_type
from	O
00	O
patients	O
displayed	O
high	O
levels	O
of	O
activated	O
stat0	B-protein
.	O

treatment	O
of	O
leukemic	O
lgl	B-cell_type
with	O
the	O
jak-selective	B-protein
tyrosine	I-protein
kinase	I-protein
inhibitor	I-protein
ag-000	O
induced	O
apoptosis	O
with	O
a	O
corresponding	O
decrease	O
in	O
stat	B-protein
-dna	O
binding	O
activity	O
.	O

moreover	O
,	O
using	O
an	O
antisense	O
oligonucleotide	O
approach	O
to	O
diminish	O
stat0	B-protein
expression	O
,	O
we	O
found	O
that	O
fas	B-protein
sensitivity	O
was	O
restored	O
in	O
leukemic	O
lgl	B-cell_type
.	O

ag-000-induced	O
apoptosis	O
in	O
leukemic	O
lgl	B-cell_type
was	O
independent	O
of	O
bcl-xl	B-protein
or	O
bcl-0	B-protein
expression	O
.	O

however	O
,	O
we	O
found	O
that	O
the	O
bcl-0-family	B-protein
protein	I-protein
mcl-0	B-protein
was	O
significantly	O
reduced	O
by	O
ag-000	O
treatment	O
.	O

activated	O
stat0	B-protein
was	O
shown	O
to	O
bind	O
an	O
sie-related	B-DNA
element	I-DNA
in	O
the	O
murine	B-DNA
mcl-0	I-DNA
promoter	I-DNA
.	O

using	O
a	O
luciferase	B-DNA
reporter	I-DNA
assay	O
,	O
we	O
demonstrated	O
that	O
v-src	B-DNA
overexpression	O
in	O
nih0t0	O
induced	O
stat0	B-protein
-dependent	O
transcriptional	O
activity	O
from	O
the	O
mcl-0	B-DNA
promoter	I-DNA
and	O
increased	O
endogenous	O
mcl-0	B-protein
protein	I-protein
levels	O
.	O

we	O
conclude	O
that	O
stat0	B-protein
activation	O
contributed	O
to	O
accumulation	O
of	O
the	O
leukemic	O
lgl	B-cell_type
clones	O
.	O

these	O
findings	O
suggest	O
that	O
investigation	O
should	O
focus	O
on	O
novel	O
strategies	O
targeting	O
stat0	B-protein
in	O
the	O
treatment	O
of	O
lgl	B-cell_type
leukemia	O
.	O

###MEDLINE:21095203

decreased	O
immediate	B-DNA
inflammatory	I-DNA
gene	I-DNA
induction	O
in	O
activating	O
transcription	B-protein
factor-0	I-protein
mutant	I-protein
mice	O
.	O

transcription	B-protein
factor	I-protein
activating	I-protein
transcription	I-protein
factor	I-protein
(	I-protein
atf	I-protein
)	I-protein
-0	I-protein
is	O
activated	O
by	O
inflammatory	O
signals	O
transduced	O
by	O
the	O
jnk	B-protein
and	O
p00	B-protein
map	I-protein
kinase	I-protein
pathways	O
.	O

to	O
better	O
define	O
the	O
role	O
of	O
atf-0	B-protein
in	O
inflammation	O
,	O
adult	O
mice	O
expressing	O
small	O
amounts	O
of	O
a	O
mutant	B-protein
atf-0	I-protein
protein	I-protein
were	O
challenged	O
with	O
lipopolysaccharide	O
(	O
lps	O
)	O
,	O
anti-cd0	B-protein
antibody	I-protein
or	O
virus	O
.	O

within	O
0	O
h	O
of	O
challenge	O
by	O
lps	O
,	O
atf-0	B-protein
mutant	O
mice	O
had	O
decreased	O
induction	O
of	O
the	O
adhesion	B-protein
molecules	I-protein
e-selectin	B-protein
,	O
p-selectin	B-protein
and	O
vcam-0	B-protein
as	O
well	O
as	O
the	O
cytokines	B-protein
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
il-0beta	B-protein
and	O
il-0	B-protein
compared	O
with	O
control	O
mice	O
.	O

stimulation	O
of	O
t	B-cell_type
lymphocytes	I-cell_type
by	O
anti-cd0	B-protein
antibody	I-protein
also	O
showed	O
less	O
induction	O
of	O
il-0	B-protein
and	O
il-0	B-protein
in	O
atf-0	B-protein
mutant	O
tissues	O
.	O

atf-0	B-protein
mutant	O
thymocytes	B-cell_type
treated	O
with	O
anti-cd0	B-protein
antibody	I-protein
in	O
vitro	O
demonstrated	O
reduced	O
induction	O
of	O
c-jun	B-protein
,	O
junb	B-protein
,	O
jund	B-protein
and	O
fra-0	B-DNA
.	O

however	O
,	O
similar	O
to	O
what	O
was	O
observed	O
after	O
p00	B-protein
kinase	I-protein
inhibition	O
in	O
normal	O
mice	O
,	O
relative	O
atf-0	B-protein
deficiency	O
did	O
not	O
prevent	O
the	O
development	O
of	O
a	O
mononuclear	O
cell	O
infiltrate	O
in	O
the	O
week	O
following	O
an	O
inflammatory	O
stimulus	O
.	O

atf-0	B-protein
mutant	O
mice	O
proved	O
more	O
susceptible	O
to	O
death	O
than	O
control	O
mice	O
from	O
lps	O
plus	O
d-galactosamine	O
injection	O
or	O
coxsackievirus	B-protein
b0	I-protein
infection	O
and	O
had	O
a	O
higher	O
incidence	O
of	O
mononuclear	B-cell_type
pulmonary	I-cell_type
infiltrates	I-cell_type
after	O
exposure	O
to	O
herpes	O
simplex	O
virus-0	O
.	O

atf-0	B-protein
is	O
essential	O
for	O
maximal	O
immediate	O
induction	O
of	O
adhesion	B-protein
molecules	I-protein
and	O
cytokine	B-DNA
genes	I-DNA
,	O
but	O
at	O
later	O
time	O
points	O
may	O
even	O
protect	O
against	O
overactive	O
immune	O
responses	O
.	O

###MEDLINE:20219245

light	O
,	O
a	O
tnf-like	B-protein
molecule	I-protein
,	O
costimulates	B-cell_type
t	I-cell_type
cell	I-cell_type
proliferation	O
and	O
is	O
required	O
for	O
dendritic	B-cell_type
cell	I-cell_type
-mediated	O
allogeneic	O
t	O
cell	O
response	O
.	O

light	O
is	O
a	O
recently	O
identified	O
member	O
of	O
the	O
tnf	B-protein
superfamily	I-protein
and	O
its	O
receptors	O
,	O
herpesvirus	O
entry	O
mediator	O
and	O
lymphotoxin	B-protein
beta	I-protein
receptor	I-protein
,	O
are	O
found	O
in	O
t	B-cell_type
cells	I-cell_type
and	O
stromal	B-cell_type
cells	I-cell_type
.	O

in	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
light	O
is	O
selectively	O
expressed	O
on	O
immature	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
(	O
dcs	B-cell_type
)	O
generated	O
from	O
human	B-cell_type
pbmcs	I-cell_type
.	O

in	O
contrast	O
,	O
light	O
is	O
not	O
detectable	O
in	O
dcs	B-cell_type
either	O
freshly	O
isolated	O
from	O
pbmcs	B-cell_type
or	O
rendered	O
mature	O
in	O
vitro	O
by	O
lps	O
treatment	O
.	O

blockade	O
of	O
light	O
by	O
its	O
soluble	B-protein
receptors	I-protein
,	O
lymphotoxin	B-protein
beta	I-protein
receptor-ig	I-protein
or	O
hvem-ig	B-protein
,	O
inhibits	O
the	O
induction	O
of	O
dc	B-cell_type
-mediated	O
primary	O
allogeneic	O
t	O
cell	O
response	O
.	O

furthermore	O
,	O
engagement	O
of	O
light	O
costimulates	B-cell_type
human	I-cell_type
t	I-cell_type
cell	I-cell_type
proliferation	O
,	O
amplifies	O
the	O
nf-kappab	B-protein
signaling	O
pathway	O
,	O
and	O
preferentially	O
induces	O
the	O
production	O
of	O
ifn-gamma	B-protein
,	O
but	O
not	O
il-0	B-protein
,	O
in	O
the	O
presence	O
of	O
an	O
antigenic	O
signal	O
.	O

our	O
results	O
suggest	O
that	O
light	O
is	O
a	O
costimulatory	B-protein
molecule	I-protein
involved	O
in	O
dc	B-cell_type
-mediated	O
cellular	O
immune	O
responses	O
.	O

###MEDLINE:20584648

suppression	O
of	O
hiv	B-protein
type	I-protein
0	I-protein
replication	O
by	O
a	O
dominant-negative	B-protein
ets-0	I-protein
mutant	I-protein
.	O

activity	O
of	O
the	O
distal	B-DNA
region	I-DNA
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
hiv-0	I-DNA
)	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
ltr	B-DNA
)	O
,	O
which	O
contains	O
binding	B-DNA
sites	I-DNA
for	O
the	O
ets-0	B-protein
and	O
usf-0	B-protein
proteins	I-protein
,	O
is	O
integral	O
for	O
hiv-0	O
replication	O
.	O

the	O
ets-0	B-protein
and	O
usf-0	B-protein
proteins	I-protein
play	O
a	O
critical	O
role	O
in	O
the	O
activity	O
of	O
the	O
hiv-0	B-DNA
ltr	I-DNA
distal	I-DNA
enhancer	I-DNA
region	I-DNA
,	O
as	O
indicated	O
by	O
the	O
potent	O
dominant	O
negative	O
effect	O
of	O
a	O
mutant	O
ets-0	O
lacking	O
trans-activation	B-protein
domains	I-protein
on	O
the	O
transcriptional	O
activity	O
of	O
the	O
ltr	B-DNA
.	O

to	O
determine	O
the	O
biological	O
relevance	O
of	O
the	O
ets-0	B-protein
and	O
usf-0	B-protein
proteins	I-protein
in	O
hiv-0	O
replication	O
,	O
we	O
examined	O
the	O
effect	O
of	O
expression	O
of	O
the	O
dominant-negative	B-protein
mutant	I-protein
of	O
ets-0	B-protein
(	O
dnets-0	B-protein
)	O
on	O
hiv-0	O
infection	O
of	O
t	B-cell_type
cells	I-cell_type
.	O

we	O
demonstrated	O
that	O
expression	O
of	O
dnets	B-protein
markedly	O
suppressed	O
hiv-0	O
infection	O
of	O
a	O
t	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

this	O
finding	O
indicates	O
that	O
formation	O
of	O
a	O
transcriptionaly	B-protein
active	I-protein
usf-0/ets-0	I-protein
complex	I-protein
is	O
important	O
in	O
the	O
productive	O
infection	O
of	O
cells	O
by	O
hiv-0	O
,	O
and	O
suggests	O
that	O
inhibition	O
of	O
the	O
interaction	O
between	O
usf-0	B-protein
and	O
ets-0	B-protein
with	O
the	O
hiv-0	B-DNA
ltr	I-DNA
may	O
provide	O
a	O
new	O
target	O
for	O
anti-hiv-0	O
gene	O
therapy	O
.	O

###MEDLINE:20582895

human	B-cell_type
eosinophils	I-cell_type
constitutively	O
express	O
nuclear	B-protein
factor	I-protein
of	O
activated	B-cell_type
t	I-cell_type
cells	I-cell_type
p	O
and	O
c	O
.	O

background	O
:	O
eosinophils	B-cell_type
are	O
now	O
known	O
to	O
produce	O
a	O
variety	O
of	O
proinflammatory	B-protein
cytokines	I-protein
,	O
although	O
the	O
molecular	O
factors	O
that	O
regulate	O
their	O
production	O
are	O
poorly	O
understood	O
.	O

the	O
expression	O
of	O
almost	O
all	O
of	O
the	O
cytokines	B-protein
produced	O
by	O
eosinophils	B-cell_type
,	O
including	O
the	O
proallergic	B-protein
cytokine	I-protein
il-0	B-protein
,	O
is	O
now	O
known	O
to	O
be	O
regulated	O
at	O
the	O
level	O
of	O
transcription	O
by	O
members	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	O
activated	B-cell_type
t	I-cell_type
cells	I-cell_type
(	O
nfat	B-protein
)	O
family	O
of	O
transcription	B-protein
factors	I-protein
.	O

objective	O
:	O
we	O
sought	O
to	O
characterize	O
the	O
expression	O
of	O
different	O
nfat	B-protein
proteins	I-protein
in	O
resting	B-cell_type
and	I-cell_type
activated	I-cell_type
eosinophils	I-cell_type
.	O

methods	O
:	O
nuclear	O
and	O
whole	O
cell	O
extracts	O
were	O
obtained	O
from	O
both	O
peripheral	B-cell_type
blood	I-cell_type
eosinophils	I-cell_type
and	O
those	O
obtained	O
from	O
bronchoalveolar	O
lavage	O
fluid	O
of	O
asthmatic	O
subjects	O
after	O
endobronchial	O
allergen	O
challenge	O
.	O

nfat	B-protein
expression	O
was	O
determined	O
by	O
using	O
immunoprecipitation	O
and	O
western	O
blot	O
analysis	O
,	O
dna-binding	O
assays	O
,	O
and	O
rt-pcr	O
analysis	O
of	O
eosinophil	B-cell_type
mrna	O
.	O

results	O
:	O
both	O
peripheral	B-cell_type
blood	I-cell_type
and	O
bronchoalveolar	B-cell_type
lavage	I-cell_type
fluid	I-cell_type
eosinophils	I-cell_type
expressed	O
nfatp	B-protein
and	O
nfatc	B-protein
protein	I-protein
.	O

unlike	O
activated	B-cell_type
t	I-cell_type
cells	I-cell_type
,	O
which	O
express	O
multiple	O
nfatc	B-protein
isoforms	I-protein
,	O
eosinophils	B-cell_type
preferentially	O
express	O
the	O
approximately	O
00-kd	B-protein
isoform	I-protein
.	O

in	O
addition	O
,	O
eosinophils	B-cell_type
were	O
found	O
to	O
constitutively	O
express	O
nfatc	B-RNA
mrna	I-RNA
.	O

a	O
brief	O
incubation	O
with	O
the	O
t	B-protein
(	I-protein
h	I-protein
)	I-protein
0	I-protein
cytokines	I-protein
il-0	B-protein
and	O
il-0	B-protein
was	O
sufficient	O
to	O
induce	O
the	O
nuclear	O
translocation	O
of	O
nfatc	B-protein
.	O

eosinophil	O
nuclear	O
extracts	O
contain	O
multiple	O
factors	O
that	O
can	O
specifically	O
recognize	O
the	O
il-0	B-DNA
promoter	I-DNA
p0	I-DNA
nfat	I-DNA
site	I-DNA
in	O
dna-binding	O
assays	O
,	O
including	O
nfatp	B-protein
.	O

conclusion	O
:	O
nfatp	B-protein
and	O
nfatc	B-protein
can	O
regulate	O
the	O
expression	O
of	O
cytokines	B-protein
and	O
other	O
genes	O
in	O
eosinophils	B-cell_type
but	O
appear	O
to	O
be	O
regulated	O
by	O
a	O
novel	O
signal	O
transduction	O
mechanism	O
in	O
these	O
cells	O
.	O

###MEDLINE:21066549

blys	B-protein
binds	O
to	O
b	B-cell_type
cells	I-cell_type
with	O
high	O
affinity	O
and	O
induces	O
activation	O
of	O
the	O
transcription	B-protein
factors	I-protein
nf-kappab	B-protein
and	O
elf-0	B-protein
.	O

b	B-cell_type
lymphocyte	I-cell_type
stimulator	O
(	O
blys	B-protein
)	O
is	O
a	O
novel	O
member	O
of	O
the	O
tnf	B-protein
family	I-protein
of	I-protein
proteins	I-protein
expressed	O
by	O
myeloid	B-cell_type
cells	I-cell_type
as	O
membrane-bound	B-protein
and	I-protein
soluble	I-protein
forms	I-protein
.	O

blys	O
was	O
shown	O
to	O
act	O
specifically	O
on	O
b	B-cell_type
cells	I-cell_type
,	O
inducing	O
proliferation	O
and	O
immunoglobulin	B-protein
production	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

the	O
present	O
study	O
was	O
undertaken	O
to	O
characterize	O
binding	O
of	O
radiolabeled	B-protein
blys	I-protein
to	O
its	O
cognate	O
receptor	O
on	O
human	B-cell_type
b	I-cell_type
lymphocytes	I-cell_type
and	O
examine	O
intracellular	O
events	O
initiated	O
by	O
blys	O
binding	O
.	O

similar	O
to	O
other	O
tnf	B-protein
family	I-protein
members	I-protein
,	O
blys	B-protein
is	O
present	O
in	O
solution	O
as	O
a	O
homotrimer	O
as	O
determined	O
by	O
gel	O
filtration	O
chromatography	O
and	O
light	O
scattering	O
analysis	O
.	O

blys	O
binding	O
to	O
b	B-cell_type
cells	I-cell_type
is	O
specific	O
as	O
other	O
tnf	B-protein
family	I-protein
members	I-protein
tested	O
did	O
not	O
compete	O
for	O
(	B-protein
000	I-protein
)	I-protein
i-	I-protein
blys	I-protein
binding	O
.	O

analysis	O
of	O
equilibrium	O
binding	O
of	O
(	O
000	O
)	O
i-labeled	O
blys	O
to	O
purified	B-cell_type
human	I-cell_type
tonsillar	I-cell_type
b	I-cell_type
cells	I-cell_type
demonstrated	O
saturable	O
binding	O
.	O

scatchard	O
analysis	O
of	O
the	O
binding	O
data	O
revealed	O
a	O
single	O
class	O
of	O
high-affinity	O
binding	O
on	O
human	B-cell_type
b	I-cell_type
cells	I-cell_type
with	O
approximately	O
0000	O
binding	B-DNA
sites	I-DNA
per	O
cell	O
and	O
an	O
apparent	O
dissociation	O
constant	O
(	O
k	O
(	O
d	O
)	O
)	O
of	O
about	O
0.0	O
nm	O
.	O

in	O
addition	O
we	O
report	O
that	O
blys	O
binding	O
to	O
b	B-cell_type
cells	I-cell_type
results	O
in	O
the	O
activation	O
of	O
nf-kappab	B-protein
and	O
the	O
ets	B-protein
family	I-protein
transcription	I-protein
factor	I-protein
,	O
elf-0	B-protein
,	O
and	O
in	O
the	O
induction	O
of	O
mrna	O
for	O
polo-like	B-protein
kinase	I-protein
(	O
plk	B-protein
)	O
.	O

copyright	O
0000	O
academic	O
press	O
.	O

###MEDLINE:20578218

design	O
and	O
use	O
of	O
an	O
inducibly	O
activated	O
human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
0	I-protein
nef	B-protein
to	O
study	O
immune	O
modulation	O
.	O

the	O
nef	B-protein
protein	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
0	I-DNA
(	O
hiv-0	O
)	O
has	O
been	O
shown	O
to	O
enhance	O
the	O
infectivity	O
of	O
virus	O
particles	O
,	O
downmodulate	B-protein
cell	I-protein
surface	I-protein
proteins	I-protein
,	O
and	O
associate	O
with	O
many	O
intracellular	B-protein
proteins	I-protein
that	O
are	O
thought	O
to	O
facilitate	O
hiv	O
infection	O
.	O

one	O
of	O
the	O
challenges	O
in	O
defining	O
the	O
molecular	O
events	O
regulated	O
by	O
nef	B-protein
has	O
been	O
obtaining	O
good	O
expression	O
of	O
nef	B-protein
protein	O
in	O
t	B-cell_type
cells	I-cell_type
.	O

this	O
has	O
been	O
attributed	O
to	O
effects	O
of	O
nef	B-protein
on	O
cell	O
proliferation	O
and	O
apoptosis	O
.	O

we	O
have	O
designed	O
a	O
nef	B-protein
protein	O
that	O
is	O
readily	O
expressed	O
in	O
t-cell	B-cell_line
lines	I-cell_line
and	O
whose	O
function	O
is	O
inducibly	O
activated	O
.	O

it	O
is	O
composed	O
of	O
a	O
fusion	O
between	O
full-length	O
nef	B-protein
and	O
the	O
estrogen	B-protein
receptor	I-protein
hormone-binding	I-protein
domain	I-protein
(	O
nef-er	B-protein
)	O
.	O

the	O
nef-er	O
is	O
kept	O
in	O
an	O
inactive	O
state	O
due	O
to	O
steric	O
hindrance	O
,	O
and	O
addition	O
of	O
the	O
membrane-permeable	O
drug	O
0-hydroxytamoxifen	O
(	O
0-ht	B-protein
)	O
,	O
which	O
binds	O
to	O
the	O
er	B-DNA
domain	I-DNA
,	O
leads	O
to	O
inducible	O
activation	O
of	O
nef-er	O
within	O
cells	O
.	O

we	O
demonstrate	O
that	O
nef-er	B-protein
inducibly	O
associates	O
with	O
the	O
00-kda	B-protein
ser/thr	I-protein
kinase	I-protein
and	O
is	O
localized	O
to	O
specific	B-protein
membrane	I-protein
microdomains	I-protein
(	O
lipid	O
rafts	O
)	O
only	O
after	O
activation	O
.	O

using	O
this	O
inducible	O
nef	B-protein
,	O
we	O
also	O
compared	O
the	O
specific	O
requirements	O
for	O
cd0	B-protein
and	O
hla-a0	B-protein
downmodulation	O
in	O
a	O
supt0	B-cell_line
t-cell	I-cell_line
line	I-cell_line
.	O

half-maximal	O
downmodulation	O
of	O
cell	B-protein
surface	I-protein
cd0	I-protein
required	O
very	O
little	O
active	O
nef-er	O
and	O
occurred	O
as	O
early	O
as	O
0	O
h	O
after	O
addition	O
of	O
0-ht	O
.	O

in	O
contrast	O
,	O
00	O
%	O
downmodulation	O
of	O
hla-a0	B-protein
by	O
nef	B-protein
required	O
00	O
to	O
00	O
h	O
and	O
about	O
00-	O
to	O
000-fold-greater	O
concentrations	O
of	O
0-ht	O
.	O

these	O
data	O
suggest	O
that	O
hla-a0	B-protein
downmodulation	O
may	O
require	O
certain	O
threshold	O
levels	O
of	O
active	O
nef	O
.	O

the	O
differential	O
timing	O
of	O
cd0	B-protein
and	O
hla-a0	B-protein
downmodulation	O
may	O
have	O
implications	O
for	O
hiv	O
pathogenesis	O
and	O
immune	O
evasion	O
.	O

###MEDLINE:21012803

regulation	O
of	O
chemokine	B-protein
mrna	O
expression	O
in	O
a	O
rat	O
model	O
of	O
vanadium-induced	O
pulmonary	O
inflammation	O
.	O

environmental	O
and	O
occupational	O
exposure	O
to	O
vanadium	O
dusts	O
results	O
in	O
toxic	O
effects	O
mainly	O
confined	O
to	O
the	O
respiratory	O
system	O
.	O

using	O
a	O
rat	O
model	O
of	O
acute	O
lung	O
inflammation	O
induced	O
by	O
intratracheal	O
instillation	O
of	O
sodium	O
metavanadate	O
(	O
navo0	B-protein
)	O
at	O
the	O
dose	O
of	O
000	O
microg	O
v/kg	O
,	O
we	O
investigated	O
the	O
relationship	O
between	O
the	O
cytologic	O
characterization	O
of	O
pulmonary	O
inflammation	O
and	O
the	O
expression	O
of	O
chemokine	B-protein
mrna	O
.	O

significant	O
polymorphonuclear	B-cell_type
leukocyte	I-cell_type
(	O
pmn	B-cell_type
)	O
influx	O
(	O
p	O
<	O
0.00	O
)	O
into	O
the	O
lung	O
was	O
noted	O
0	O
h	O
after	O
navo0	O
instillation	O
,	O
whereas	O
alveolar	B-cell_type
macrophages	I-cell_type
(	O
ams	B-cell_type
)	O
in	O
bronchoalveolar	B-cell_type
lavage	I-cell_type
(	I-cell_type
bal	I-cell_type
)	I-cell_type
cells	I-cell_type
appeared	O
to	O
decrease	O
significantly	O
.	O

in	O
contrast	O
,	O
neither	O
pmns	B-cell_type
nor	O
ams	B-cell_type
changed	O
substantially	O
0	O
h	O
after	O
navo0	O
instillation	O
.	O

by	O
northern	O
analysis	O
,	O
macrophage	B-protein
inflammatory	I-protein
protein	I-protein
(	O
mip	B-protein
)	I-protein
-0	I-protein
mrna	O
in	O
bal	O
cells	O
increased	O
markedly	O
0	O
h	O
after	O
navo0	O
instillation	O
and	O
reduced	O
a	O
little	O
bit	O
at	O
0	O
h	O
,	O
whereas	O
mip-0alpha	B-protein
mrna	O
in	O
bal	O
cells	O
was	O
expressed	O
relatively	O
high	O
0	O
h	O
after	O
navo0	O
instillation	O
,	O
although	O
a	O
basal	O
expression	O
was	O
detected	O
in	O
control	O
group	O
,	O
and	O
returned	O
rapidly	O
nearly	O
to	O
control	O
level	O
at	O
0	O
h	O
.	O

since	O
mip-0	B-protein
is	O
a	O
potent	O
pmn	O
chemoattractant	O
and	O
mip-0alpha	B-protein
is	O
a	O
potent	O
macrophage/monocyte	B-protein
chemoattractant	I-protein
has	O
been	O
well	O
known	O
.	O

the	O
facts	O
that	O
pmn	B-cell_type
influx	O
was	O
preceded	O
by	O
increased	O
mip-0	B-protein
mrna	O
expression	O
,	O
suggesting	O
that	O
mip-0	B-protein
is	O
involved	O
in	O
the	O
development	O
of	O
navo0-induced	O
pulmonary	O
inflammation	O
,	O
whereas	O
increased	O
mip-0alpha	B-protein
mrna	O
expression	O
was	O
followed	O
by	O
decreased	O
ams	B-cell_type
in	O
bal	O
cells	O
,	O
suggesting	O
ams	B-cell_type
might	O
be	O
activated	O
by	O
mip-0alpha	B-protein
,	O
adherent	O
to	O
the	O
lining	O
surface	O
of	O
the	O
airways	O
and	O
then	O
resistant	O
to	O
be	O
washed	O
out	O
.	O

to	O
delineate	O
the	O
mechanisms	O
of	O
transcriptional	O
activation	O
,	O
we	O
recently	O
cloned	O
the	O
0'-flanking	B-DNA
region	I-DNA
of	O
the	O
mip-0	B-DNA
gene	I-DNA
.	O

the	O
promotor	O
region	O
contains	O
consensus	B-DNA
binding	I-DNA
sites	I-DNA
for	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor	I-protein
kappab	I-protein
(	O
nf-kappab	B-protein
)	O
and	O
activator	B-protein
protein-0	I-protein
(	O
ap-0	B-protein
)	O
.	O

using	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
increased	O
nuclear	O
nf-kappab	B-protein
,	O
not	O
ap-0	B-protein
,	O
binding	O
activity	O
was	O
detected	O
0	O
h	O
after	O
navo0	O
instillation	O
,	O
which	O
correlated	O
with	O
the	O
induction	O
of	O
mip-0	B-protein
mrna	O
.	O

p00	B-protein
(	I-protein
rel	I-protein
a	I-protein
)	O
and	O
p00	B-protein
protein	I-protein
appears	O
to	O
be	O
involved	O
in	O
mip-0	B-protein
nf-kappab	I-protein
binding	O
.	O

taken	O
together	O
,	O
our	O
studies	O
suggest	O
that	O
mip-0	B-protein
is	O
an	O
important	O
mediator	O
of	O
navo0-induced	O
pulmonary	O
inflammation	O
in	O
the	O
rat	B-cell_line
model	I-cell_line
.	O

in	O
addition	O
,	O
elevated	O
mip-0	B-protein
mrna	O
levels	O
are	O
accompanied	O
by	O
increased	O
nf-kappab	B-protein
binding	O
activity	O
in	O
bal	O
cells	O
,	O
suggesting	O
possible	O
mip-0	B-protein
transcriptional	O
regulation	O
through	O
nf-kappab	B-protein
.	O

###MEDLINE:20573243

activation	O
of	O
signal	O
transduction	O
and	O
apoptosis	O
in	O
healthy	O
lymphomonocytes	O
exposed	O
to	O
bystander	O
hiv-0-infected	B-cell_line
cells	I-cell_line
.	O

persistent	O
activation	O
of	O
the	O
immune	O
system	O
is	O
one	O
of	O
the	O
hallmarks	O
of	O
hiv-0	O
infection	O
.	O

in	O
this	O
study	O
we	O
analysed	O
the	O
induction	O
of	O
factors	O
involved	O
in	O
cytokine	B-protein
signal	O
transduction	O
,	O
such	O
as	O
stat	B-protein
0	I-protein
proteins	I-protein
and	O
irf-0	B-protein
mrna	O
,	O
in	O
normal	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
pbmc	B-cell_type
)	O
exposed	O
to	O
hiv-infected	B-cell_type
cells	I-cell_type
,	O
and	O
the	O
induction	O
of	O
apoptosis	O
.	O

western	O
blot	O
analyses	O
and	O
reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
results	O
indicate	O
that	O
both	O
cells	O
infected	O
with	O
a	O
x0	O
strain	O
and	O
cells	O
infected	O
with	O
a	O
r0	O
strain	O
are	O
able	O
to	O
increase	O
intracellular	O
levels	O
of	O
stat	B-protein
0alpha	O
and	O
beta	B-protein
proteins	I-protein
as	O
well	O
as	O
irf-0	B-protein
mrna	O
.	O

this	O
effect	O
was	O
prevented	O
by	O
neutralizing	B-protein
antibodies	I-protein
against	O
interferon-alpha	B-protein
(	O
ifn-alpha	B-protein
)	O
.	O

hiv-0-infected	B-cell_line
cells	I-cell_line
dose-dependently	O
induced	O
apoptotic	O
commitment	O
in	O
normal	B-cell_type
pbmc	I-cell_type
,	O
as	O
revealed	O
by	O
dna	O
fragmentation	O
analysis	O
,	O
but	O
this	O
was	O
not	O
accompanied	O
by	O
an	O
increase	O
of	O
caspase-0	B-protein
activity	O
,	O
even	O
if	O
a	O
slight	O
up-regulation	O
of	O
il-0beta-converting	B-protein
enzyme	I-protein
mrna	O
was	O
detected	O
.	O

apoptosis	O
induction	O
could	O
be	O
abrogated	O
mainly	O
by	O
antibodies	O
against	O
tumour	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
tnf-alpha	B-protein
)	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
by	O
antibodies	O
against	O
ifn-gamma	B-protein
.	O

all	O
these	O
findings	O
suggest	O
that	O
uninfected	B-cell_type
pbmc	I-cell_type
can	O
undergo	O
activation	O
of	O
signal	O
transduction	O
and	O
apoptosis	O
after	O
exposure	O
to	O
bystander	B-cell_type
hiv-infected	I-cell_type
cells	I-cell_type
,	O
subsequent	O
to	O
the	O
induction	O
of	O
cytokines	B-protein
such	O
as	O
ifns	B-protein
and	O
tnf-alpha	B-protein
.	O

###MEDLINE:20570932

the	O
physical	O
association	O
of	O
protein	B-protein
kinase	I-protein
c	I-protein
theta	I-protein
with	O
a	O
lipid	B-protein
raft-associated	I-protein
inhibitor	I-protein
of	I-protein
kappa	I-protein
b	I-protein
factor	I-protein
kinase	I-protein
(	O
ikk	B-protein
)	I-protein
complex	I-protein
plays	O
a	O
role	O
in	O
the	O
activation	O
of	O
the	O
nf-kappa	B-protein
b	I-protein
cascade	O
by	O
tcr	B-protein
and	O
cd00	B-protein
.	O

we	O
investigated	O
the	O
role	O
of	O
protein	B-protein
kinase	I-protein
c	I-protein
theta	I-protein
(	O
pkctheta	B-protein
)	O
in	O
the	O
activation	O
of	O
the	O
nf-kappab	B-protein
cascade	O
in	O
primary	B-cell_type
human	I-cell_type
cd0	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
lymphocytes	I-cell_type
.	O

among	O
six	O
or	O
so	O
pkc	B-protein
isoforms	I-protein
expressed	O
in	O
t	B-cell_type
cells	I-cell_type
,	O
only	O
pkctheta	B-protein
participates	O
in	O
the	O
assembly	O
of	O
the	O
supramolecular	O
activation	O
clusters	O
at	O
the	O
contact	O
site	O
of	O
the	O
tcr	B-protein
with	O
ag	B-protein
.	O

signaling	O
via	O
both	O
the	O
tcr	B-protein
and	O
cd00	B-protein
is	O
required	O
for	O
optimal	O
activation	O
of	O
the	O
multisubunit	B-protein
ikappab	I-protein
kinase	I-protein
(	O
ikk	B-protein
)	I-protein
complex	I-protein
in	O
primary	B-cell_type
human	I-cell_type
t	I-cell_type
lymphocytes	I-cell_type
;	O
this	O
activation	O
could	O
be	O
inhibited	O
by	O
a	O
ca	O
(	O
0+	O
)	O
-independent	O
pkc	B-protein
isoform	O
inhibitor	O
,	O
rottlerin	O
.	O

moreover	O
,	O
endogenous	O
pkctheta	O
physically	O
associates	O
with	O
activated	B-protein
ikk	I-protein
complexes	I-protein
in	O
cd0/cd00-costimulated	B-cell_type
primary	I-cell_type
cd0	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
t	I-cell_type
cells	I-cell_type
.	O

the	O
same	O
set	O
of	O
stimuli	O
also	O
induced	O
relocation	O
of	O
endogenous	O
pkctheta	O
and	O
ikks	O
to	O
a	O
gm0	O
ganglioside-enriched	O
,	O
detergent-insoluble	O
membrane	O
compartment	O
in	O
primary	B-cell_type
t	I-cell_type
cells	I-cell_type
.	O

ikks	O
recruited	O
to	O
these	O
lipid	O
rafts	O
were	O
capable	O
of	O
phosphorylating	O
a	O
recombinant	B-protein
ikappabalpha	I-protein
sustrate	I-protein
.	O

confocal	O
microscopy	O
further	O
demonstrated	O
that	O
exogenously	O
expressed	O
pkctheta	B-protein
and	O
ikkss	O
colocalize	O
in	O
the	O
membrane	O
of	O
cd0/cd00-costimulated	B-cell_line
jurkat	I-cell_line
t	I-cell_line
cells	I-cell_line
.	O

constitutively	O
active	O
but	O
not	O
kinase-inactive	O
pkctheta	O
activated	O
ikkbeta	B-protein
in	O
jurkat	B-cell_line
t	I-cell_line
cells	I-cell_line
.	O

expression	O
of	O
dominant-active	B-protein
pkctheta	I-protein
also	O
had	O
stimulatory	O
effects	O
on	O
the	O
cd00	B-DNA
response	I-DNA
element	I-DNA
of	O
the	O
il-0	B-DNA
promoter	I-DNA
.	O

taken	O
together	O
,	O
these	O
data	O
show	O
that	O
the	O
activation	O
of	O
pkctheta	O
by	O
the	O
tcr	B-protein
and	O
cd00	B-protein
plays	O
an	O
important	O
role	O
in	O
the	O
assembly	O
and	O
activation	O
of	O
ikk	B-protein
complexes	I-protein
in	O
the	O
t	B-protein
cell	I-protein
membrane	I-protein

###MEDLINE:21003826

t-cell	O
-mediated	O
regulation	O
of	O
osteoclastogenesis	O
by	O
signalling	O
cross-talk	O
between	O
rankl	B-protein
and	O
ifn-gamma	B-protein
.	O

bone	O
resorption	O
is	O
regulated	O
by	O
the	O
immune	O
system	O
,	O
where	O
t-cell	O
expression	O
of	O
rankl	B-protein
(	O
receptor	O
activator	O
of	O
nuclear	B-protein
factor	I-protein
(	O
nf	B-protein
)	I-protein
-kappab	I-protein
ligand	O
)	O
,	O
a	O
member	O
of	O
the	O
tumour-necrosis	B-protein
factor	I-protein
family	I-protein
that	O
is	O
essential	O
for	O
osteoclastogenesis	O
,	O
may	O
contribute	O
to	O
pathological	O
conditions	O
,	O
such	O
as	O
autoimmune	O
arthritis	O
.	O

however	O
,	O
whether	O
activated	B-cell_type
t	I-cell_type
cells	I-cell_type
maintain	O
bone	O
homeostasis	O
by	O
counterbalancing	O
the	O
action	O
of	O
rankl	B-protein
remains	O
unknown	O
.	O

here	O
we	O
show	O
that	O
t-cell	O
production	O
of	O
interferon	B-protein
(	I-protein
ifn	I-protein
)	I-protein
-gamma	I-protein
strongly	O
suppresses	O
osteoclastogenesis	O
by	O
interfering	O
with	O
the	O
rankl	B-protein
-rank	O
signalling	O
pathway	O
.	O

ifn-gamma	B-protein
induces	O
rapid	O
degradation	O
of	O
the	O
rank	B-protein
adapter	I-protein
protein	I-protein
,	O
traf0	B-protein
(	O
tumour	B-protein
necrosis	I-protein
factor	I-protein
receptor-associated	I-protein
factor	I-protein
0	I-protein
)	O
,	O
which	O
results	O
in	O
strong	O
inhibition	O
of	O
the	O
rankl	B-protein
-induced	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nf-kappab	B-protein
and	O
jnk	B-protein
.	O

this	O
inhibition	O
of	O
osteoclastogenesis	O
is	O
rescued	O
by	O
overexpressing	O
traf0	B-protein
in	O
precursor	B-cell_type
cells	I-cell_type
,	O
which	O
indicates	O
that	O
traf0	B-protein
is	O
the	O
target	O
critical	O
for	O
the	O
ifn-gamma	B-protein
action	O
.	O

furthermore	O
,	O
we	O
provide	O
evidence	O
that	O
the	O
accelerated	O
degradation	O
of	O
traf0	B-protein
requires	O
both	O
its	O
ubiquitination	O
,	O
which	O
is	O
initiated	O
by	O
rankl	B-protein
,	O
and	O
ifn-gamma	B-protein
-induced	O
activation	O
of	O
the	O
ubiquitin-proteasome	O
system	O
.	O

our	O
study	O
shows	O
that	O
there	O
is	O
cross-talk	O
between	O
the	O
tumour	B-protein
necrosis	I-protein
factor	I-protein
and	O
ifn	B-protein
families	I-protein
of	O
cytokines	B-protein
,	O
through	O
which	O
ifn-gamma	B-protein
provides	O
a	O
negative	O
link	O
between	O
t-cell	O
activation	O
and	O
bone	O
resorption	O
.	O

our	O
results	O
may	O
offer	O
a	O
therapeutic	O
approach	O
to	O
treat	O
the	O
inflammation-induced	O
tissue	O
breakdown	O
.	O

###MEDLINE:20563930

stromal-derived	B-protein
factor	I-protein
0	I-protein
and	O
thrombopoietin	B-protein
regulate	O
distinct	O
aspects	O
of	O
human	B-cell_type
megakaryopoiesis	I-cell_type
.	O

the	O
role	O
of	O
the	O
chemokine	B-protein
binding	I-protein
stromal-derived	I-protein
factor	I-protein
0	I-protein
(	O
sdf-0	B-protein
)	O
in	O
normal	B-cell_type
human	I-cell_type
megakaryopoiesis	I-cell_type
at	O
the	O
cellular	O
and	O
molecular	O
levels	O
and	O
its	O
comparison	O
with	O
that	O
of	O
thrombopoietin	B-protein
(	O
tpo	B-protein
)	O
have	O
not	O
been	O
determined	O
.	O

in	O
this	O
study	O
it	O
was	O
found	O
that	O
sdf-0	B-protein
,	O
unlike	O
tpo	B-protein
,	O
does	O
not	O
stimulate	O
alpha	B-DNA
(	I-DNA
iib	I-DNA
)	I-DNA
beta	I-DNA
(	O
0	O
)	O
(	O
+	O
)	O
cell	O
proliferation	O
or	O
differentiation	O
or	O
have	O
an	O
antiapoptotic	O
effect	O
.	O

however	O
,	O
it	O
does	O
induce	O
chemotaxis	O
,	O
trans-matrigel	O
migration	O
,	O
and	O
secretion	O
of	O
matrix	B-protein
metalloproteinase	I-protein
0	I-protein
(	O
mmp-0	B-protein
)	O
and	O
vascular	B-protein
endothelial	I-protein
growth	I-protein
factor	I-protein
(	O
vegf	O
)	O
by	O
these	O
cells	O
,	O
and	O
both	O
sdf-0	B-protein
and	O
tpo	B-protein
increase	O
the	O
adhesion	O
of	O
alpha	B-DNA
(	I-DNA
iib	I-DNA
)	I-DNA
beta	I-DNA
(	O
0	O
)	O
(	O
+	O
)	O
cells	O
to	O
fibrinogen	B-protein
and	O
vitronectin	B-protein
.	O

investigating	O
the	O
intracellular	O
signaling	O
pathways	O
induced	O
by	O
sdf-0	B-protein
and	O
tpo	B-protein
revealed	O
some	O
overlapping	O
patterns	O
of	O
protein	B-protein
phosphorylation/activation	I-protein
(	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
[	O
mapk	B-protein
]	O
p00/00	B-protein
,	I-protein
mapk	I-protein
p00	B-protein
,	O
and	O
akt	B-protein
[	O
protein	B-protein
kinase	I-protein
b	I-protein
]	O
)	O
and	O
some	O
that	O
were	O
distinct	O
for	O
tpo	B-protein
(	O
eg	O
,	O
jak-stat	B-protein
)	O
and	O
for	O
sdf-0	B-protein
(	O
eg	O
,	O
nf-kappa	B-protein
b	I-protein
)	O
.	O

it	O
was	O
also	O
found	O
that	O
though	O
inhibition	O
of	O
phosphatidyl-inositol	B-protein
0-kinase	I-protein
(	O
pi-0k	B-protein
)	O
by	O
ly000000	O
in	O
alpha	B-DNA
(	I-DNA
iib	I-DNA
)	I-DNA
beta	I-DNA
(	O
0	O
)	O
(	O
+	O
)	O
cells	O
induced	O
apoptosis	O
and	O
inhibited	O
chemotaxis	O
adhesion	O
and	O
the	O
secretion	O
of	O
mmp-0	B-protein
and	O
vegf	B-protein
,	O
the	O
inhibition	O
of	O
mapk	B-protein
p00/00	B-protein
(	O
by	O
the	O
mek	B-protein
inhibitor	O
u0000	O
)	O
had	O
no	O
effect	O
on	O
the	O
survival	O
,	O
proliferation	O
,	O
and	O
migration	O
of	O
these	O
cells	O
.	O

hence	O
,	O
it	O
is	O
suggested	O
that	O
the	O
proliferative	O
effect	O
of	O
tpo	B-protein
is	O
more	O
related	O
to	O
activation	O
of	O
the	O
jak-stat	O
pathway	O
(	O
unique	O
to	O
tpo	B-protein
)	O
,	O
and	O
the	O
pi-0k-akt	O
axis	O
is	O
differentially	O
involved	O
in	O
tpo-	B-protein
and	O
sdf-0-dependent	O
signaling	O
.	O

accordingly	O
,	O
pi-0k	B-protein
is	O
involved	O
in	O
tpo	B-protein
-mediated	O
inhibition	O
of	O
apoptosis	O
,	O
tpo-	B-protein
and	O
sdf-0-regulated	O
adhesion	O
to	O
fibrinogen	B-protein
and	O
vitronectin	B-protein
,	O
and	O
sdf-0	B-protein
-mediated	O
migration	O
.	O

this	O
study	O
expands	O
the	O
understanding	O
of	O
the	O
role	O
of	O
sdf-0	B-protein
and	O
tpo	B-protein
in	O
normal	B-cell_type
human	I-cell_type
megakaryopoiesis	I-cell_type
and	O
indicates	O
the	O
molecular	O
basis	O
of	O
the	O
observed	O
differences	O
in	O
cellular	O
responses	O
.	O

(	O
blood.	O
0000	O
;	O
00	O
:	O
0000-0000	O
)	O

###MEDLINE:20546999

adhesion	O
of	O
immature	B-cell_type
and	I-cell_type
mature	I-cell_type
t	I-cell_type
cells	I-cell_type
induces	O
in	O
human	B-cell_type
thymic	I-cell_type
epithelial	I-cell_type
cells	I-cell_type
(	O
tec	B-cell_line
)	O
activation	O
of	O
il-0	B-protein
gene	I-protein
trascription	I-protein
factors	I-protein
(	O
nf-kappab	B-protein
and	O
nf-il0	B-protein
)	O
and	O
il-0	B-protein
gene	O
expression	O
:	O
role	O
of	O
alpha0beta0	B-protein
and	O
alpha0beta0	B-protein
integrins	I-protein
.	O

t	B-cell_type
cell	I-cell_type
precursors	I-cell_type
homed	O
to	O
thymus	O
develop	O
in	O
close	O
contact	O
with	O
stromal	B-cell_type
cells	I-cell_type
.	O

among	O
them	O
,	O
thymic	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
(	O
tec	B-cell_line
)	O
are	O
known	O
to	O
exert	O
dominant	O
roles	O
in	O
their	O
survival	O
and	O
functional	O
shaping	O
.	O

key	O
molecules	O
mediating	O
tec	B-cell_type
/	O
thymocytes	B-cell_type
interactions	O
include	O
cytokines	B-protein
and	O
growth	B-protein
factors	I-protein
secreted	O
by	O
the	O
two	O
cell	O
types	O
and	O
adhesion	B-protein
receptors	I-protein
mediating	O
cell	O
contact	O
.	O

signaling	O
events	O
triggered	O
in	O
thymocytes	B-cell_type
by	O
adhesion	O
to	O
epithelial	B-cell_type
cells	I-cell_type
have	O
been	O
extensively	O
investigated	O
,	O
whereas	O
little	O
is	O
known	O
on	O
the	O
opposite	O
phenomenon	O
.	O

we	O
have	O
previously	O
investigated	O
this	O
issue	O
in	O
a	O
co-culture	O
system	O
composed	O
of	O
tec	B-cell_type
cultures	O
derived	O
from	O
human	O
normal	O
thymus	O
and	O
heterologous	B-cell_type
thymocytes	I-cell_type
.	O

we	O
demonstrated	O
that	O
thymocytes	B-cell_type
adhere	O
to	O
tec	B-cell_type
involving	O
beta0	B-protein
and	I-protein
beta0	I-protein
integrins	I-protein
and	O
induce	O
the	O
clustering	O
of	O
alpha0beta0	B-protein
and	O
alpha0beta0	B-protein
heterodimers	I-protein
at	O
the	O
tec	B-cell_type
surface	O
.	O

in	O
addition	O
thymocyte	O
adhesion	O
was	O
followed	O
by	O
activation	O
of	O
nf-kappab	B-protein
and	O
nf-il0	B-protein
gene	I-protein
transcription	I-protein
factors	I-protein
and	O
enhanced	O
il-0	B-protein
production	O
.	O

the	O
two	O
latter	O
phenomena	O
were	O
reproduced	O
by	O
the	O
cross-linking	O
of	O
the	O
alpha0	B-protein
,	I-protein
alpha0	I-protein
,	O
beta0	B-protein
and	I-protein
beta0	I-protein
integrins	I-protein
,	O
thus	O
implying	O
that	O
the	O
alpha0beta0	O
and	O
alpha0beta0	B-protein
heterodimers	I-protein
can	O
signal	O
during	O
thymocyte	O
adhesion	O
.	O

we	O
have	O
extended	O
our	O
previous	O
work	O
investigating	O
in	O
the	O
same	O
experimental	O
setting	O
the	O
inducing	O
activity	O
of	O
non	B-cell_type
stimulated	I-cell_type
or	I-cell_type
activated	I-cell_type
policlonal	I-cell_type
or	O
clonal	O
mature	B-cell_type
t	I-cell_type
cells	I-cell_type
as	O
representative	O
of	O
the	O
more	O
mature	B-cell_line
thymocyte	I-cell_line
subset	I-cell_line
.	O

we	O
found	O
that	O
adhesion	O
of	O
unstimulated	B-cell_line
t	I-cell_line
cell	I-cell_line
i	I-cell_line
)	I-cell_line
involved	O
beta0	O
,	O
but	O
not	O
beta0	B-protein
integrin	I-protein
functions	O
at	O
the	O
surface	B-protein
ii	I-protein
)	O
induced	O
the	O
clustering	O
of	O
alpha0beta0	B-protein
,	I-protein
but	O
not	O
alpha0beta0	B-protein
heterodimers	I-protein
at	O
the	O
tec	B-cell_type
surface	O
and	O
iii	O
)	O
up-regulated	O
the	O
nuclear	O
binding	O
activity	O
of	O
nf-kappab	B-protein
transcription	I-protein
factor	I-protein
and	O
the	O
il-0	B-protein
secretion	O
.	O

we	O
propose	O
that	O
alpha0beta0	B-protein
and	O
alpha0beta0	B-protein
heterodimers	I-protein
are	O
induced	O
to	O
cluster	O
at	O
the	O
tec	B-cell_type
surface	O
recognizing	O
yet	O
unknown	O
cellular	O
ligands	O
differentially	O
expressed	O
during	O
t	B-cell_type
cell	I-cell_type
development	O
.	O

###MEDLINE:20545190

identification	O
and	O
characterization	O
of	O
skat-0	B-protein
,	O
a	O
novel	O
th0-specific	O
zinc	B-DNA
finger	I-DNA
gene	I-DNA
.	O

we	O
have	O
identified	O
a	O
novel	B-protein
kruppel-type	I-protein
zinc	I-protein
finger	I-protein
(	I-protein
zf	I-protein
)	O
gene	O
,	O
skat-0	O
,	O
which	O
is	O
selectively	O
expressed	O
by	O
murine	B-cell_line
th0	I-cell_line
cells	I-cell_line
.	O

the	O
protein	O
encoded	O
by	O
this	O
gene	O
has	O
00	O
c0h0-type	O
zf	O
tandemly	O
arrayed	O
at	O
its	O
c	B-protein
terminus	I-protein
and	O
n-terminal	B-protein
scan	I-protein
box	I-protein
and	I-protein
krab	I-protein
domains	I-protein
.	O

skat-0	B-protein
is	O
tissue	O
restricted	O
in	O
expression	O
at	O
the	O
rna	O
level	O
,	O
detectable	O
only	O
in	O
brain	O
and	O
at	O
low	O
levels	O
in	O
kidney	O
and	O
spleen	O
and	O
few	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

by	O
in	O
situ	O
hybridization	O
,	O
skat-0	O
expression	O
was	O
found	O
to	O
peak	O
in	O
antigen-stimulated	B-cell_type
cd0	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
t	I-cell_type
cells	I-cell_type
after	O
0-0	O
days	O
of	O
culture	O
under	O
th0	B-cell_line
but	I-cell_line
not	I-cell_line
th0	I-cell_line
biasing	I-cell_line
conditions	O
.	O

this	O
pattern	O
of	O
expression	O
closely	O
mirrored	O
that	O
of	O
gata-0	B-protein
in	O
the	O
same	O
cells	O
.	O

in	O
transient	O
transfection	O
experiments	O
in	O
phorbol	B-cell_line
00-myristate	I-cell_line
00-acetate/ionomycin-stimulated	I-cell_line
el0	I-cell_line
cells	I-cell_line
,	O
skat-0	B-protein
was	O
found	O
to	O
up-regulate	O
the	O
activity	O
of	O
the	O
il-0	B-protein
but	O
not	O
the	O
il-0	B-DNA
promoter	I-DNA
,	O
contrasting	O
with	O
the	O
ability	O
of	O
gata-0	B-protein
to	O
activate	O
both	O
promoters	B-DNA
.	O

this	O
result	O
was	O
confirmed	O
using	O
clones	O
of	O
el0	B-cell_line
cells	I-cell_line
stably	O
expressing	O
an	O
inducible	O
form	O
of	O
skat-0	B-protein
,	O
thus	O
skat-0	B-protein
is	O
a	O
novel	O
th0-specific	O
gene	O
that	O
may	O
play	O
a	O
role	O
in	O
selective	O
regulation	O
of	O
cytokine	B-DNA
genes	I-DNA
in	O
t	B-cell_type
cells	I-cell_type
.	O

###MEDLINE:20541385

hsp00	B-protein
interacting	O
protein	O
hip	O
does	O
not	O
affect	O
glucocorticoid	B-protein
receptor	I-protein
folding	O
by	O
the	O
hsp00-based	B-protein
chaperone	I-protein
machinery	O
except	O
to	O
oppose	O
the	O
effect	O
of	O
bag-0	B-protein
.	O

reticulocyte	O
lysate	O
contains	O
a	O
chaperone	B-protein
system	I-protein
that	O
assembles	O
glucocorticoid	B-protein
receptor	I-protein
(	O
gr	B-protein
)	O
.hsp00	B-protein
heterocomplexes	I-protein
.	O

using	O
purified	B-protein
proteins	I-protein
,	O
we	O
have	O
prepared	O
a	O
five-protein	B-protein
heterocomplex	I-protein
assembly	O
system	O
consisting	O
of	O
two	O
proteins	O
essential	O
for	O
heterocomplex	B-protein
assembly-	O
hsp00	B-protein
and	O
hsp00	B-protein
-and	O
three	O
proteins	O
that	O
act	O
as	O
co-chaperones	O
to	O
enhance	O
assembly-	O
hop	B-protein
,	O
hsp00	B-protein
,	O
p00	B-protein
[	O
morishima	B-protein
,	O
y.	O
,	O
kanelakis	O
,	O
k.	O
c.	O
,	O
silverstein	O
,	O
a.	O
m.	O
,	O
dittmar	O
,	O
k.	O
d.	O
,	O
estrada	O
,	O
l.	O
,	O
and	O
pratt	B-protein
,	O
w.	O
b.	O
(	O
0000	O
)	O
j.	O
biol.	O
chem.	O
000	O
,	O
0000-0000	O
]	O
.	O

the	O
hsp00	B-protein
co-chaperone	O
hip	O
has	O
been	O
recovered	O
in	O
receptor.hsp00	B-protein
heterocomplexes	I-protein
at	O
an	O
intermediate	O
stage	O
of	O
assembly	O
in	O
reticulocyte	O
lysate	O
,	O
and	O
hip	O
is	O
also	O
thought	O
to	O
be	O
an	O
intrinsic	O
component	O
of	O
the	O
assembly	O
machinery	O
.	O

here	O
we	O
show	O
that	O
immunodepletion	O
of	O
hip	O
from	O
reticulocyte	O
lysate	O
or	O
addition	O
of	O
high	O
levels	O
of	O
hip	O
to	O
the	O
purified	B-cell_line
five-protein	I-cell_line
system	I-cell_line
does	O
not	O
affect	O
gr.hsp00	B-protein
heterocomplex	I-protein
assembly	O
or	O
the	O
activation	O
of	O
steroid	O
binding	O
activity	O
that	O
occurs	O
with	O
assembly	O
.	O

despite	O
the	O
fact	O
that	O
hip	O
does	O
not	O
affect	O
assembly	O
,	O
it	O
is	O
recovered	O
in	O
gr.hsp00	B-protein
heterocomplexes	I-protein
assembled	O
by	O
both	O
systems	O
.	O

in	O
the	O
five-protein	O
system	O
,	O
hip	O
prevents	O
inhibition	O
of	O
assembly	O
by	O
the	O
hsp00	B-protein
co-chaperone	O
bag-0	B-protein
,	O
and	O
cotransfection	O
of	O
hip	O
with	O
bag-0	B-protein
opposes	O
bag-0	O
reduction	O
of	O
steroid	O
binding	O
activity	O
in	O
cos	B-cell_line
cells	I-cell_line
.	O

we	O
conclude	O
that	O
hip	O
is	O
not	O
a	O
component	O
of	O
the	O
assembly	O
machinery	O
but	O
that	O
it	O
could	O
play	O
a	O
regulatory	O
role	O
in	O
opposition	O
to	O
bag-0	B-protein
.	O

###MEDLINE:20540051

cutting	O
edge	O
:	O
stat0-deficient	O
mice	O
have	O
enhanced	O
tumor	O
immunity	O
to	O
primary	O
and	O
metastatic	O
mammary	O
carcinoma	O
.	O

stat0	B-protein
and	O
stat0	B-protein
are	O
essential	O
for	O
the	O
development	O
of	O
cd0	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
th0	I-cell_type
and	O
th0	O
development	O
,	O
respectively	O
.	O

tumor	B-protein
immunologists	I-protein
have	O
hypothesized	O
that	O
th0	B-cell_type
cells	I-cell_type
are	O
critical	O
in	O
tumor	O
immunity	O
because	O
they	O
facilitate	O
differentiation	O
of	O
cd0	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
t	I-cell_type
cells	I-cell_type
,	O
which	O
are	O
potent	O
anti-tumor	B-protein
effectors	I-protein
.	O

we	O
have	O
used	O
stat0	B-protein
(	O
-/-	O
)	O
and	O
stat0	B-protein
(	O
-/-	O
)	O
mice	O
to	O
test	O
this	O
hypothesis	O
.	O

balb/c	O
and	O
knockout	O
mice	O
were	O
challenged	O
in	O
the	O
mammary	O
gland	O
with	O
the	O
highly	O
malignant	O
and	O
spontaneously	O
metastatic	O
balb/c-derived	B-cell_line
0t0	I-cell_line
mammary	O
carcinoma	O
.	O

primary	O
tumor	O
growth	O
and	O
metastatic	O
disease	O
are	O
reduced	O
in	O
stat0	B-protein
(	O
-/-	O
)	O
mice	O
relative	O
to	O
balb/c	O
and	O
stat0	B-protein
(	O
-/-	O
)	O
mice	O
.	O

ab	O
depletions	O
demonstrate	O
that	O
the	O
effect	O
is	O
mediated	O
by	O
cd0	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
t	I-cell_type
cells	I-cell_type
,	O
and	O
immunized	O
stat0	B-protein
(	O
-/-	O
)	O
mice	O
have	O
higher	O
levels	O
of	O
0t0-specific	O
ctl	O
than	O
balb/c	O
or	O
stat0	B-protein
(	O
-/-	O
)	O
mice	O
.	O

surprisingly	O
,	O
th0	B-cell_line
or	O
th0	B-cell_type
cells	I-cell_type
are	O
not	O
involved	O
,	O
because	O
cd0	B-protein
depletion	O
does	O
not	O
diminish	O
the	O
anti-tumor	O
effect	O
.	O

therefore	O
,	O
deletion	O
of	O
the	O
stat0	B-DNA
gene	I-DNA
facilitates	O
development	O
of	O
potent	O
anti-tumor	O
immunity	O
via	O
a	O
cd0	B-protein
(	I-protein
+	I-protein
)	I-protein
-independent	O
pathway	O
.	O

###MEDLINE:20535109

activation	O
of	O
oncogenic	B-protein
transcription	I-protein
factor	I-protein
ap-0	I-protein
in	O
t	B-cell_type
cells	I-cell_type
infected	O
with	O
human	B-cell_line
t	I-cell_line
cell	I-cell_line
leukemia	I-cell_line
virus	I-cell_line
type	I-cell_line
0	I-cell_line
.	O

human	B-cell_line
t	I-cell_line
cell	I-cell_line
leukemia	I-cell_line
virus	I-cell_line
type	I-cell_line
0	I-cell_line
(	O
htlv-0	B-protein
)	I-protein
tax	I-protein
protein	I-protein
transforms	O
primary	B-cell_type
human	I-cell_type
t	I-cell_type
cells	I-cell_type
in	O
vitro	O
.	O

we	O
previously	O
showed	O
that	O
tax	B-protein
induces	O
the	O
expression	O
of	O
various	O
family	O
members	O
of	O
the	O
transcription	B-protein
factor	I-protein
ap-0	B-protein
such	O
as	O
c-jun	B-protein
,	O
jund	B-protein
,	O
c-fos	B-DNA
,	O
and	O
fra-0	B-DNA
at	O
the	O
mrna	O
level	O
in	O
t	B-cell_type
cells	I-cell_type
.	O

in	O
this	O
study	O
,	O
we	O
have	O
examined	O
the	O
ability	O
of	O
tax	B-protein
to	O
activate	O
transcription	O
through	O
the	O
ap-0-binding	B-DNA
site	I-DNA
(	O
ap-0	B-DNA
site	I-DNA
)	O
.	O

a	O
transient	O
transfection	O
study	O
showed	O
that	O
tax	B-protein
can	O
activate	O
transcription	O
through	O
the	O
ap-0-binding	B-DNA
site	I-DNA
in	O
a	O
human	B-cell_line
t	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
whereas	O
any	O
combination	O
of	O
ap-0	B-protein
proteins	I-protein
did	O
so	O
much	O
less	O
than	O
tax	B-protein
,	O
indicating	O
that	O
the	O
activation	O
of	O
the	O
ap-0	B-DNA
site	I-DNA
by	O
tax	B-protein
may	O
require	O
a	O
mechanism	O
other	O
than	O
the	O
induction	O
of	O
ap-0	B-RNA
mrna	I-RNA
.	O

fresh	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
of	O
all	O
surveyed	O
atl	O
patients	O
displayed	O
constitutive	O
ap-0	B-protein
dna-binding	O
activity	O
,	O
whereas	O
no	O
normal	O
individuals	O
did	O
.	O

however	O
,	O
the	O
htlv-0	B-DNA
genes	I-DNA
,	O
including	O
tax	B-protein
,	O
are	O
not	O
significantly	O
expressed	O
in	O
fresh	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
from	O
atl	O
patients	O
.	O

our	O
present	O
results	O
suggest	O
that	O
activation	O
of	O
ap-0	B-protein
occurs	O
through	O
tax-dependent	B-protein
and	O
-independent	O
mechanisms	O
in	O
htlv-0-infected	B-cell_type
t	I-cell_type
cells	I-cell_type
,	O
which	O
may	O
play	O
some	O
roles	O
in	O
dysregulated	O
phenotypes	O
of	O
htlv-0-infected	B-cell_type
cells	I-cell_type
.	O

###MEDLINE:20530853

0	B-RNA
,	I-RNA
0	I-RNA
'	I-RNA
,	I-RNA
0	I-RNA
,	I-RNA
0	I-RNA
,	I-RNA
0'-pentachlorobiphenyl	I-RNA
induces	O
apoptosis	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O

polychlorinatedbiphenyls	O
(	O
pcbs	O
)	O
are	O
a	O
group	O
of	O
persistent	O
and	O
widely	O
dispersed	O
environmental	O
pollutants	O
,	O
some	O
of	O
which	O
may	O
be	O
immunotoxic	O
.	O

in	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
pcbs	O
on	O
immune	O
system	O
by	O
assessing	O
apoptotic	O
cell	O
death	O
in	O
human	B-cell_line
monocytic	I-cell_line
u000	I-cell_line
cells	I-cell_line
.	O

among	O
the	O
various	O
congeners	O
tested	O
,	O
0	B-RNA
,	I-RNA
0	I-RNA
'	I-RNA
,	I-RNA
0	I-RNA
,	I-RNA
0	I-RNA
,	I-RNA
0'-pentachlorobiphenyl	I-RNA
(	O
pecb	B-protein
)	O
,	O
a	O
highly	O
ortho-substituted	O
congener	O
,	O
specifically	O
induced	O
dna	O
fragmentation	O
,	O
a	O
hallmark	O
of	O
apoptosis	O
,	O
while	O
the	O
other	O
examined	O
di-	O
,	O
tri-	B-cell_line
,	I-cell_line
tetra-	I-cell_line
,	O
and	O
pentachlorobiphenyls	B-protein
did	O
not	O
.	O

to	O
further	O
study	O
the	O
0	B-DNA
,	I-DNA
0	I-DNA
'	I-DNA
,	I-DNA
0	I-DNA
,	O
0	O
,	O
0'-pecb-induced	O
cell	O
death	O
,	O
various	O
features	O
of	O
apoptosis	O
were	O
examined	O
.	O

0	B-RNA
,	I-RNA
0	I-RNA
'	I-RNA
,	I-RNA
0	I-RNA
,	I-RNA
0	I-RNA
,	I-RNA
0'-pecb	I-RNA
caused	O
a	O
decrease	O
in	O
cell	O
viability	O
and	O
induced	O
cellular	O
morphologic	O
features	O
characteristic	O
of	O
apoptosis	O
such	O
as	O
chromatin	B-DNA
aggregation	O
and	O
apoptotic	B-cell_type
bodies	I-cell_type
.	O

in	O
addition	O
,	O
caspase-0	B-protein
,	O
an	O
executioner	O
of	O
apoptosis	O
,	O
was	O
activated	O
and	O
its	O
substrate	O
,	O
poly	B-protein
(	I-protein
adp-ribose	I-protein
)	I-protein
polymerase	I-protein
(	O
parp	B-protein
)	O
,	O
was	O
cleaved	O
during	O
0	B-DNA
,	I-DNA
0	I-DNA
'	I-DNA
,	I-DNA
0	I-DNA
,	O
0	O
,	O
0'-pecb-induced	O
apoptosis	O
.	O

in	O
contrast	O
,	O
0	O
,	O
0	B-DNA
'	I-DNA
,	I-DNA
0	I-DNA
,	I-DNA
0	I-DNA
'	I-DNA
,	O
0-pecb	O
,	O
a	O
congener	O
of	O
coplanar	O
structure	O
,	O
as	O
well	O
as	O
0	O
,	O
0	O
,	O
0	O
,	O
0-tcdd	B-protein
did	O
not	O
induce	O
apoptosis	O
in	O
these	O
human	B-cell_line
monocytic	I-cell_line
cells	I-cell_line
,	O
although	O
they	O
potently	O
induced	O
cyp	B-protein
0a0	I-protein
in	O
human	O
hepatoma	B-cell_type
hep	I-cell_type
g0	I-cell_type
cells	I-cell_type
.	O

taken	O
together	O
,	O
the	O
data	O
indicate	O
that	O
0	B-RNA
,	I-RNA
0	I-RNA
'	I-RNA
,	I-RNA
0	I-RNA
,	I-RNA
0	I-RNA
,	I-RNA
0'-pecb	I-RNA
induces	O
apoptosis	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
through	O
a	O
mechanism	O
that	O
is	O
independent	O
of	O
the	O
arylhydrocarbon	B-protein
receptor	I-protein
.	O

this	O
suggests	O
a	O
possibly	O
separate	O
mechanism	O
by	O
which	O
pcbs	O
cause	O
immunosuppression	O
.	O

###MEDLINE:20518810

effects	O
of	O
deregulated	O
raf	B-protein
activation	O
on	O
integrin	B-protein
,	O
cytokine-receptor	O
expression	O
and	O
the	O
induction	O
of	O
apoptosis	O
in	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O

the	O
effects	O
of	O
deregulated	O
raf	B-protein
activation	O
on	O
the	O
growth	O
and	O
differentiation	O
of	O
hematopoietic	B-cell_type
cells	I-cell_type
were	O
investigated	O
.	O

the	O
cytokine-dependent	B-cell_line
murine	I-cell_line
myeloid	I-cell_line
fdc-p0	I-cell_line
and	O
human	O
erythroleukemic	B-cell_line
tf-0	I-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
transformed	O
to	O
grow	O
in	O
response	O
to	O
deregulated	O
raf	B-protein
expression	O
in	O
the	O
absence	O
of	O
exogenous	B-protein
cytokines	I-protein
.	O

the	O
conditionally	O
active	O
raf	B-protein
proteins	I-protein
were	O
regulated	O
by	O
beta-estradiol	O
as	O
cdnas	B-DNA
containing	O
the	O
raf	B-protein
catalytic	O
,	O
but	O
lacking	O
negative-regulatory	B-protein
domains	I-protein
,	O
were	O
ligated	O
to	O
the	O
hormone	B-protein
binding	I-protein
domain	I-protein
of	O
the	O
estrogen	B-protein
receptor	I-protein
(	O
deltaraf	O
:	O
er	B-protein
)	O
.	O

continuous	O
deltaraf	O
expression	O
prevented	O
apoptosis	O
in	O
the	O
absence	O
of	O
exogenous	B-protein
cytokines	I-protein
and	O
altered	O
the	O
morphology	O
of	O
the	O
fd/deltaraf	O
:	O
er	B-cell_type
cells	I-cell_type
as	O
they	O
grew	O
in	O
large	O
aggregated	O
masses	O
(	O
>	O
000	O
cells	O
)	O
whereas	O
the	O
parental	O
cytokine-dependent	B-cell_line
fdc-p0	I-cell_line
cells	I-cell_line
grew	O
in	O
smaller	O
grape-like	O
clusters	O
(	O
<	O
00	O
cells	O
)	O
.	O

fd/deltaraf-0	O
:	O
er	B-cell_type
cells	I-cell_type
growing	O
in	O
response	O
to	O
raf	B-protein
activation	O
displayed	O
decreased	O
levels	O
of	O
the	O
mac-0	B-protein
and	O
mac-0	B-protein
molecules	I-protein
on	O
their	O
cell	O
surface	O
.	O

in	O
contrast	O
,	O
when	O
these	O
cells	O
were	O
cultured	O
in	O
il-0	B-protein
,	O
higher	O
levels	O
of	O
these	O
adhesion	B-protein
molecules	I-protein
were	O
detected	O
.	O

expression	O
of	O
activated	O
raf	B-protein
oncoproteins	I-protein
also	O
abrogated	O
cytokine	B-protein
dependency	O
and	O
prevented	O
apoptosis	O
of	O
tf-0	B-cell_type
cells	I-cell_type
.	O

moreover	O
,	O
the	O
differentiation	O
status	O
of	O
these	O
raf-responsive	B-cell_line
cells	I-cell_line
was	O
more	O
immature	O
upon	O
raf	B-protein
activation	O
as	O
culture	O
with	O
the	O
differentiation-inducing	O
agent	O
phorbol	O
00	O
myristate	O
00-acetate	O
(	O
pma	O
)	O
and	O
beta-estradiol	O
resulted	O
in	O
decreased	O
levels	O
of	O
the	O
cd00b	B-protein
and	O
cd00	B-protein
integrin	I-protein
molecules	I-protein
on	O
the	O
cell	O
surface	O
.	O

in	O
contrast	O
when	O
the	O
raf-responsive	B-cell_line
cells	I-cell_line
were	O
induced	O
to	O
differentiate	O
with	O
pma	O
and	O
gm-csf	B-protein
,	O
in	O
the	O
absence	O
of	O
deltaraf	O
:	O
er	B-protein
activation	O
,	O
increased	O
levels	O
of	O
the	O
cd00b	B-protein
and	O
cd00	B-protein
molecules	I-protein
were	O
detected	O
.	O

retinoic	O
acid	O
(	O
ra	O
)	O
inhibited	O
0h-thymidine	O
incorporation	O
in	O
response	O
to	O
gm-csf	B-protein
.	O

interestingly	O
,	O
raf	B-protein
activation	O
counterbalanced	O
the	O
inhibition	O
of	O
dna	O
synthesis	O
caused	O
by	O
ra	O
but	O
not	O
pma	O
.	O

thus	O
deregulated	O
raf	B-protein
expression	O
can	O
alter	O
cytokine	B-protein
dependency	O
,	O
integrin	B-protein
expression	O
and	O
the	O
stage	O
of	O
differentiation	O
.	O

these	O
raf-responsive	B-cell_line
cell	I-cell_line
lines	I-cell_line
will	O
be	O
useful	O
in	O
elucidating	O
the	O
roles	O
of	O
the	O
map	B-protein
kinase	I-protein
cascade	O
on	O
hematopoietic	B-cell_type
cell	I-cell_type
differentiation	O
and	O
malignant	O
transformation	O

###MEDLINE:20521735

cyclic	O
amp	O
activates	O
p00	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
in	O
th0	B-cell_type
cells	I-cell_type
:	O
phosphorylation	O
of	O
gata-0	B-protein
and	O
stimulation	O
of	O
th0	B-DNA
cytokine	I-DNA
gene	I-DNA
expression	O
.	O

camp	O
is	O
an	O
important	O
second	O
messenger	O
with	O
immunomodulatory	O
properties	O
.	O

elevation	O
of	O
intracellular	O
camp	O
in	O
t	B-cell_type
cells	I-cell_type
,	O
induced	O
by	O
agents	O
such	O
as	O
il-0alpha	B-protein
or	O
pgs	B-protein
,	O
inhibits	O
t	O
cell	O
activation	O
.	O

in	O
effector	B-cell_type
t	I-cell_type
cells	I-cell_type
,	O
an	O
increase	O
in	O
the	O
level	O
of	O
intracellular	O
camp	O
inhibits	O
cytokine	B-protein
production	O
in	O
th0	B-cell_type
cells	I-cell_type
but	O
stimulates	O
cytokine	B-protein
production	O
in	O
th0	B-cell_type
cells	I-cell_type
.	O

here	O
we	O
report	O
that	O
camp-induced	O
effects	O
in	O
th0	B-cell_type
cells	I-cell_type
occur	O
independently	O
of	O
the	O
protein	B-protein
kinase	I-protein
a	I-protein
pathway	O
,	O
which	O
is	O
the	O
major	O
mediator	O
of	O
camp-induced	O
signaling	O
events	O
in	O
most	O
cell	O
types	O
.	O

instead	O
,	O
camp	O
stimulates	O
activation	O
of	O
p00	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
in	O
th0	B-cell_type
cells	I-cell_type
.	O

this	O
appears	O
to	O
be	O
a	O
th0	O
-selective	O
event	O
because	O
camp	O
barely	O
increased	O
p00	B-protein
phosphorylation	O
in	O
th0	B-cell_type
cells	I-cell_type
.	O

we	O
show	O
that	O
in	O
th0	B-cell_type
cells	I-cell_type
,	O
camp	O
promotes	O
the	O
production	O
of	O
both	O
il-0	B-protein
and	O
il-00	B-protein
,	O
which	O
play	O
distinct	O
but	O
critical	O
roles	O
in	O
asthma	O
pathogenesis	O
.	O

our	O
data	O
also	O
show	O
that	O
camp	O
causes	O
increased	O
phosphorylation	O
of	O
the	O
transcription	B-protein
factor	I-protein
gata-0	B-protein
,	O
which	O
we	O
have	O
shown	O
is	O
a	O
critical	O
regulator	O
of	O
th0	B-DNA
cytokine	I-DNA
gene	I-DNA
expression	O
and	O
,	O
in	O
turn	O
,	O
of	O
airway	O
inflammation	O
in	O
mice	O
.	O

thus	O
,	O
th0	O
-specific	O
gata-0	B-protein
expression	O
and	O
p00	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
activation	O
together	O
provide	O
a	O
molecular	O
basis	O
for	O
the	O
differential	O
effects	O
of	O
camp	O
in	O
the	O
two	O
t	B-cell_type
helper	I-cell_type
cell	I-cell_type
subsets	I-cell_type
.	O

###MEDLINE:20514082

characterization	O
of	O
il-0	B-protein
and	O
il-00	B-protein
signals	O
dependent	O
on	O
the	O
human	B-DNA
il-00	I-DNA
receptor	I-DNA
alpha	I-DNA
chain	I-DNA
0	I-DNA
:	O
redundancy	O
of	O
requirement	O
of	O
tyrosine	O
residue	O
for	O
stat0	B-protein
activation	O
.	O

il-0	B-protein
and	O
il-00	B-protein
are	O
pleiotropic	B-protein
cytokines	I-protein
whose	O
biological	O
activities	O
overlap	O
with	O
each	O
other	O
.	O

il-00	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
0	I-protein
(	O
il-00r	B-protein
alpha	I-protein
0	I-protein
)	O
is	O
necessary	O
for	O
binding	O
to	O
il-00	B-protein
,	O
and	O
the	O
heterodimer	O
composed	O
of	O
il-00r	B-protein
alpha	I-protein
0	I-protein
and	O
il-0r	B-protein
alpha	I-protein
chain	I-protein
transduces	O
il-00	B-protein
and	O
il-0	B-protein
signals	O
;	O
however	O
,	O
the	O
functional	O
mapping	O
of	O
the	O
intracellular	B-protein
domain	I-protein
of	O
il-00r	B-protein
alpha	I-protein
0	I-protein
is	O
not	O
fully	O
understood	O
.	O

in	O
this	O
study	O
,	O
we	O
constructed	O
wild	O
and	O
mutated	O
types	O
of	O
human	B-protein
il-00r	I-protein
alpha	I-protein
0	I-protein
,	O
and	O
analyzed	O
il-0	B-protein
and	O
il-00	B-protein
signals	O
using	O
an	O
il-00r	B-cell_line
alpha	I-cell_line
0	I-cell_line
-transfected	I-cell_line
human	I-cell_line
b	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

expression	O
of	O
il-00r	B-protein
alpha	I-protein
0	I-protein
evoked	O
stat0	B-protein
activation	O
by	O
il-0	B-protein
and	O
il-00	B-protein
,	O
and	O
in	O
stimulated	B-cell_type
human	I-cell_type
b	I-cell_type
cells	I-cell_type
,	O
on	O
which	O
il-00r	B-protein
alpha	I-protein
0	I-protein
was	O
highly	O
expressed	O
,	O
il-0	B-protein
and	O
il-00	B-protein
induced	O
stat0	B-protein
activation	O
.	O

replacement	O
of	O
the	O
two	O
tyrosine	O
residues	O
completely	O
abolished	O
stat0	B-protein
activation	O
,	O
although	O
replacing	B-protein
either	O
tyrosine	O
residue	O
alone	O
retained	O
it	O
.	O

furthermore	O
,	O
we	O
found	O
that	O
the	O
box0	B-protein
region	I-protein
and	O
the	O
c-terminal	B-protein
tail	I-protein
of	O
il-00r	B-protein
alpha	I-protein
0	I-protein
were	O
critical	O
for	O
binding	O
to	O
tyk0	B-protein
,	O
and	O
activation	O
of	O
jak0	B-protein
,	O
tyk0	B-protein
,	O
the	O
insulin	B-protein
receptor	I-protein
substrate-0	I-protein
and	O
stat0	B-protein
respectively	O
.	O

these	O
results	O
suggest	O
that	O
stat0	B-protein
activation	O
is	O
involved	O
with	O
il-0	B-protein
and	O
il-00	B-protein
signals	O
in	O
human	B-cell_type
b	I-cell_type
cells	I-cell_type
along	O
with	O
the	O
activation	O
of	O
stat0	B-protein
,	O
and	O
that	O
there	O
is	O
a	O
unique	O
sequence	O
in	O
il-00r	B-protein
alpha	I-protein
0	I-protein
to	O
activate	O
stat0	B-protein
.	O

###MEDLINE:20501115

functional	O
uncoupling	O
of	O
the	O
janus	B-protein
kinase	I-protein
0-stat0	I-protein
pathway	O
in	O
malignant	O
growth	O
of	O
human	B-cell_line
t	I-cell_line
cell	I-cell_line
leukemia	I-cell_line
virus	I-cell_line
type	I-cell_line
0-transformed	I-cell_line
human	I-cell_line
t	I-cell_line
cells	I-cell_line
.	O

human	B-cell_line
t	I-cell_line
cell	I-cell_line
leukemia	I-cell_line
virus	I-cell_line
type	I-cell_line
0	I-cell_line
(	O
htlv-0	O
)	O
transforms	O
cytokine	B-protein
-dependent	O
t	B-cell_type
lymphocytes	I-cell_type
and	O
causes	O
adult	O
t	O
cell	O
leukemia	O
.	O

janus	B-protein
tyrosine	I-protein
kinase	I-protein
(	O
jak	B-protein
)	I-protein
0	I-protein
and	O
transcription	B-protein
factors	I-protein
stat0a	B-protein
and	O
stat0b	B-protein
are	O
essential	O
for	O
the	O
proliferation	O
of	O
normal	B-cell_type
t	I-cell_type
cells	I-cell_type
and	O
are	O
constitutively	O
hyperactivated	O
in	O
both	O
htlv-0-transformed	B-cell_line
human	I-cell_line
t	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
lymphocytes	B-cell_type
isolated	O
from	O
htlv-0-infected	O
patients	O
;	O
therefore	O
,	O
a	O
critical	O
role	O
for	O
the	O
jak0-stat0	O
pathway	O
in	O
the	O
progression	O
of	O
this	O
disease	O
has	O
been	O
postulated	O
.	O

we	O
recently	O
reported	O
that	O
tyrphostin	O
ag-000	O
selectively	O
blocked	O
il-0	B-protein
activation	O
of	O
jak0/stat0	B-protein
and	O
growth	O
of	O
murine	B-cell_line
t	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

here	O
we	O
demonstrate	O
that	O
disruption	O
of	O
jak0/stat0a/b	O
signaling	O
with	O
ag-000	O
(	O
00	O
&	O
mgr	B-RNA
;	O
m	O
)	O
blocked	O
the	O
proliferation	O
of	O
primary	B-cell_type
human	I-cell_type
t	I-cell_type
lymphocytes	I-cell_type
,	O
but	O
paradoxically	O
failed	O
to	O
inhibit	O
the	O
proliferation	O
of	O
htlv-0-transformed	B-cell_line
human	I-cell_line
t	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
hut-000	B-protein
and	O
mt-0	B-cell_line
.	O

structural	O
homologues	O
of	O
ag-000	O
also	O
inhibited	O
the	O
proliferation	O
of	O
primary	B-cell_type
human	I-cell_type
t	I-cell_type
cells	I-cell_type
,	O
but	O
not	O
htlv-0-infected	B-cell_type
cells	I-cell_type
.	O

disruption	O
of	O
constitutive	O
jak0/stat0	O
activation	O
by	O
ag-000	O
was	O
demonstrated	O
by	O
inhibition	O
of	O
0	O
)	O
tyrosine	O
phosphorylation	O
of	O
jak0	B-protein
,	O
stat0a	B-protein
(	O
tyr	O
(	O
000	O
)	O
)	O
,	O
and	O
stat0b	B-protein
(	O
tyr	O
(	O
000	O
)	O
)	O
;	O
0	O
)	O
serine	O
phosphorylation	O
of	O
stat0a	B-protein
(	O
ser	O
(	O
000	O
)	O
)	O
as	O
determined	O
by	O
a	O
novel	B-protein
phosphospecific	I-protein
ab	I-protein
;	O
and	O
0	O
)	O
stat0a/b	O
dna	O
binding	O
to	O
the	O
stat0-responsive	O
beta-casein	B-DNA
promoter	I-DNA
.	O

in	O
contrast	O
,	O
ag-000	O
had	O
no	O
effect	O
on	O
dna	O
binding	O
by	O
p00/p00	B-protein
components	I-protein
of	O
nf-kappab	B-protein
,	O
a	O
transcription	B-protein
factor	I-protein
activated	O
by	O
the	O
htlv-0-encoded	B-protein
phosphoprotein	I-protein
,	O
tax	B-protein
.	O

collectively	O
,	O
these	O
data	O
suggest	O
that	O
the	O
jak0-stat0	O
pathway	O
in	O
htlv-0-transformed	B-cell_type
t	I-cell_type
cells	I-cell_type
has	O
become	O
functionally	O
redundant	O
for	O
proliferation	O
.	O

reversal	O
of	O
this	O
functional	O
uncoupling	O
may	O
be	O
required	O
before	O
jak0/stat0	O
inhibitors	O
will	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
this	O
malignancy	O
.	O

###MEDLINE:20499068

the	O
epstein-barr	B-DNA
virus	I-DNA
promoter	I-DNA
initiating	O
b-cell	O
transformation	O
is	O
activated	O
by	O
rfx	B-protein
proteins	I-protein
and	O
the	O
b-cell-specific	B-protein
activator	I-protein
protein	I-protein
bsap/pax0	I-protein
.	O

epstein-barr	O
virus	O
(	O
ebv	O
)	O
-induced	O
b-cell	O
growth	O
transformation	O
,	O
a	O
central	O
feature	O
of	O
the	O
virus	O
'	O
strategy	O
for	O
colonizing	O
the	O
human	B-cell_line
b-cell	I-cell_line
system	I-cell_line
,	O
requires	O
full	B-DNA
virus	I-DNA
latent	I-DNA
gene	I-DNA
expression	O
and	O
is	O
initiated	O
by	O
transcription	O
from	O
the	O
viral	B-DNA
promoter	I-DNA
wp	B-DNA
.	O

interestingly	O
,	O
when	O
ebv	O
accesses	O
other	O
cell	O
types	O
,	O
this	O
growth-transforming	O
program	O
is	O
not	O
activated	O
.	O

the	O
present	O
work	O
focuses	O
on	O
a	O
region	O
of	O
wp	B-DNA
which	O
in	O
reporter	O
assays	O
confers	O
b-cell	O
-specific	O
activity	O
.	O

bandshift	O
studies	O
indicate	O
that	O
this	O
region	O
contains	O
three	O
factor	B-DNA
binding	I-DNA
sites	I-DNA
,	O
termed	B-protein
sites	I-protein
b	B-protein
,	I-protein
c	I-protein
,	O
and	O
d	O
,	O
in	O
addition	O
to	O
a	O
previously	O
characterized	O
creb	B-DNA
site	I-DNA
.	O

here	O
we	O
show	O
that	O
site	B-protein
c	I-protein
binds	O
members	O
of	O
the	O
ubiquitously	O
expressed	O
rfx	B-protein
family	I-protein
of	I-protein
proteins	I-protein
,	O
notably	O
rfx0	B-protein
,	O
rfx0	B-protein
,	O
and	O
the	O
associated	B-protein
factor	I-protein
mibp0	B-protein
,	O
whereas	O
sites	B-DNA
b	I-DNA
and	I-DNA
d	I-DNA
both	O
bind	O
the	O
b-cell-specific	B-protein
activator	I-protein
protein	I-protein
bsap/pax0	I-protein
.	O

in	O
reporter	O
assays	O
with	O
mutant	O
wp	B-DNA
constructs	I-DNA
,	O
the	O
loss	O
of	O
factor	O
binding	O
to	O
any	O
one	O
of	O
these	O
sites	O
severely	O
impaired	O
promoter	O
activity	O
in	O
b	B-cell_type
cells	I-cell_type
,	O
while	O
the	O
wild-type	B-DNA
promoter	I-DNA
could	O
be	O
activated	O
in	O
non-b	B-cell_type
cells	I-cell_type
by	O
ectopic	O
bsap	B-protein
expression	O
.	O

we	O
suggest	O
that	O
wp	O
regulation	O
by	O
bsap	B-protein
helps	O
to	O
ensure	O
the	O
b-cell	O
specificity	O
of	O
ebv	O
's	O
growth-transforming	O
function	O
.	O

###MEDLINE:20497005

activation	O
of	O
the	O
lck	B-protein
tyrosine	B-protein
protein	I-protein
kinase	I-protein
by	O
the	O
herpesvirus	O
saimiri	O
tip	O
protein	O
involves	O
two	O
binding	O
interactions	O
.	O

the	O
tip	O
protein	O
of	O
herpesvirus	O
saimiri	O
strain	O
000c	O
binds	O
to	O
and	O
activates	O
the	O
lck	B-protein
tyrosine	B-protein
protein	I-protein
kinase	I-protein
.	O

two	O
sequences	O
in	O
the	O
tip	O
protein	O
were	O
previously	O
shown	O
to	O
be	O
involved	O
in	O
binding	O
to	O
lck	B-protein
.	O

a	O
proline-rich	B-protein
region	I-protein
,	O
residues	B-protein
000-000	I-protein
,	O
binds	O
to	O
the	O
sh0	B-protein
domain	I-protein
of	O
the	O
lck	B-protein
protein	O
.	O

we	O
show	O
here	O
that	O
the	O
other	O
lck-binding	B-protein
domain	I-protein
,	O
residues	B-protein
000-000	I-protein
,	O
binds	O
to	O
the	O
carboxyl-terminal	B-protein
half	I-protein
of	O
lck	B-protein
and	O
that	O
this	O
binding	O
does	O
not	O
require	O
the	O
lck	B-protein
sh0	B-protein
domain	I-protein
.	O

mutated	O
tip	O
containing	O
only	O
one	O
functional	O
lck-binding	B-protein
domain	I-protein
can	O
bind	O
stably	O
to	O
lck	B-protein
,	O
although	O
not	O
as	O
strongly	O
as	O
wild-type	O
tip	O
.	O

interaction	O
of	O
tip	O
with	O
lck	B-protein
through	O
either	O
lck-binding	B-protein
domain	I-protein
increases	O
the	O
activity	O
of	O
lck	B-protein
in	O
vivo	O
.	O

simultaneous	O
binding	O
of	O
both	O
domains	O
is	O
required	O
for	O
maximal	O
activation	O
of	O
lck	B-protein
.	O

the	O
transient	O
expression	O
of	O
tip	O
in	O
t	B-cell_type
cells	I-cell_type
was	O
found	O
to	O
stimulate	O
both	O
stat0	B-protein
-dependent	O
and	O
nf-at	B-protein
-dependent	O
transcription	O
.	O

mutant	O
forms	O
of	O
tip	B-protein
lacking	O
one	O
or	O
the	O
other	O
of	O
the	O
two	O
lck-binding	B-protein
domains	I-protein
retained	O
the	O
ability	O
to	O
stimulate	O
stat0	B-protein
-dependent	O
transcription	O
.	O

tip	O
lacking	O
the	O
proline-rich	B-protein
lck-binding	I-protein
domain	I-protein
exhibited	O
almost	O
wild-type	O
activity	O
in	O
this	O
assay	O
.	O

in	O
contrast	O
,	O
ablation	O
of	O
either	O
lck-binding	B-protein
domain	I-protein
abolished	O
the	O
ability	O
of	O
tip	B-protein
to	O
stimulate	O
nf-at	B-protein
-dependent	O
transcription	O
.	O

full	O
biological	O
activity	O
of	O
tip	B-protein
,	O
therefore	O
,	O
appears	O
to	O
require	O
both	O
lck-binding	B-protein
domains	I-protein
.	O

###MEDLINE:20491906

accumulation	O
of	O
rxr	B-protein
alpha	I-protein
during	O
activation	O
of	O
cycling	B-cell_line
human	I-cell_line
t	I-cell_line
lymphocytes	I-cell_line
:	O
modulation	O
of	O
rxre	O
transactivation	O
function	O
by	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
pathways	O
.	O

we	O
have	O
previously	O
reported	O
that	O
the	O
activation	O
of	O
resting	B-cell_type
human	I-cell_type
immature	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
t	I-cell_type
(	I-cell_type
pbt	I-cell_type
)	I-cell_type
lymphocytes	I-cell_type
is	O
associated	O
with	O
the	O
loss	O
of	O
retinoid	B-protein
x	I-protein
receptor	I-protein
alpha	I-protein
(	O
rxralpha	B-protein
)	O
expression	O
.	O

in	O
the	O
present	O
study	O
,	O
we	O
have	O
demonstrated	O
that	O
,	O
unlike	O
resting	B-cell_type
cells	I-cell_type
,	O
activation	O
of	O
cycling	B-cell_line
human	I-cell_line
mature	I-cell_line
pbt	I-cell_line
lymphocytes	I-cell_line
,	O
and	O
t	B-cell_line
lymphocyte	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
is	O
accompanied	O
by	O
the	O
accumulation	O
of	O
rxralpha	B-RNA
mrna	I-RNA
and	O
protein	O
.	O

interestingly	O
,	O
cyclosporin	O
a	O
further	O
augmented	O
rxralpha	O
expression	O
,	O
indicating	O
the	O
involvement	O
of	O
calcineurin	B-protein
pathways	O
in	O
the	O
process	O
.	O

0-cis	O
retinoic	O
acid	O
inhibited	O
the	O
accumulation	O
,	O
suggesting	O
that	O
retinoids	O
can	O
regulate	O
the	O
synthesis	O
of	O
their	O
own	O
receptors	O
during	O
t	B-cell_type
cell	I-cell_type
activation	O
.	O

transfection	O
analysis	O
in	O
jurkat	B-cell_line
cells	I-cell_line
,	O
using	O
rxre-dependent	O
reporter	O
assays	O
,	O
showed	O
that	O
rxralpha	B-protein
accumulated	O
during	O
t	B-cell_type
cell	I-cell_type
activation	O
was	O
transcriptionally	O
inactive	O
.	O

to	O
investigate	O
the	O
mechanism	O
of	O
such	O
inhibition	O
,	O
the	O
role	O
of	O
two	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
pathways	O
,	O
c-jun	B-protein
n-terminal	I-protein
kinase	I-protein
(	O
jnk	B-protein
)	O
and	O
extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
(	O
erk	B-protein
)	O
,	O
in	O
modulating	O
rxre-dependent	O
transcription	O
,	O
was	O
explored	O
.	O

the	O
expression	O
of	O
constitutively	B-protein
active	I-protein
map/erk	I-protein
kinase	I-protein
kinase	I-protein
0	I-protein
(	O
mekk0	B-protein
)	O
inhibited	O
rxre-dependent	O
transcription	O
,	O
whereas	O
dominant	B-protein
negative	I-protein
mekk0	I-protein
increased	O
the	O
transcription	O
,	O
indicating	O
the	O
involvement	O
of	O
jnk	B-protein
signaling	O
pathways	O
in	O
the	O
process	O
.	O

in	O
contrast	O
,	O
expression	O
of	O
constitutively	O
active	O
mek0	B-protein
,	O
which	O
activates	O
erk	B-protein
pathway	O
,	O
enhanced	O
rxre-dependent	O
activation	O
.	O

when	O
both	O
were	O
activated	O
simultaneously	O
,	O
jnk	B-protein
pathway	O
was	O
dominant	O
over	O
erk	B-protein
pathway	O
and	O
resulted	O
in	O
inhibition	O
of	O
rxre-mediated	O
transcription	O
.	O

these	O
data	O
demonstrate	O
a	O
dual	O
regulatory	O
control	O
of	O
rxralpha	B-protein
expression	O
during	O
the	O
activation	O
of	O
resting	O
and	O
cycling	B-cell_line
t	I-cell_line
lymphocytes	I-cell_line
and	O
indicate	O
a	O
dynamic	O
balance	O
between	O
jnk	B-protein
and	O
erk	B-protein
pathways	O
in	O
modulating	O
rxre-mediated	O
transactivation	O
.	O

###MEDLINE:20576378

the	O
proteasome	B-protein
regulates	O
receptor-mediated	O
endocytosis	O
of	O
interleukin-0	B-protein
.	O

recent	O
studies	O
have	O
increasingly	O
implicated	O
the	O
proteasome	O
in	O
the	O
regulation	O
of	O
cell	B-protein
surface	I-protein
receptors	I-protein
.	O

in	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
role	O
of	O
the	O
proteasome	O
for	O
ligand-dependent	O
endocytosis	O
and	O
degradation	O
of	O
the	O
interleukin-0	B-protein
(	O
il-0	B-protein
)	O
-interleukin-0	B-protein
receptor	I-protein
(	O
il-0r	B-protein
)	I-protein
complex	I-protein
.	O

proteasome	B-protein
inhibitors	O
impaired	O
internalization	O
of	O
il-0.il-0r	B-protein
and	O
prevented	O
the	O
lysosomal	O
degradation	O
of	O
this	O
cytokine	B-protein
.	O

based	O
on	O
time-course	O
studies	O
,	O
proteasome	B-protein
activity	O
is	O
primarily	O
required	O
after	O
initial	O
endocytosis	O
of	O
the	O
il-0.il-0r	O
.	O

proteasome	B-protein
function	O
was	O
also	O
necessary	O
for	O
the	O
lysosomal	O
degradation	O
of	O
il-0	B-protein
internalized	O
by	O
il-0r	B-protein
that	O
were	O
comprised	O
of	O
cytoplasmic	B-protein
tailless	I-protein
beta-	I-protein
or	I-protein
gamma	I-protein
c-subunits	I-protein
,	O
suggesting	O
that	O
the	O
target	O
protein	O
for	O
the	O
proteasome	B-protein
is	O
independent	O
of	O
either	O
the	O
cytoplasmic	B-protein
tail	I-protein
of	O
the	O
il-0r	B-protein
beta-	I-protein
or	I-protein
gamma	I-protein
c-subunits	I-protein
and	O
their	O
associated	O
signaling	O
components	O
.	O

therefore	O
,	O
a	O
functional	O
proteasome	B-protein
is	O
required	O
for	O
optimal	O
endocytosis	O
of	O
the	O
il-0r/ligand	B-protein
complex	I-protein
and	O
is	O
essential	O
for	O
the	O
subsequent	O
lysosomal	O
degradation	O
of	O
il-0	B-protein
,	O
possibly	O
by	O
regulating	O
trafficking	O
to	O
the	O
lysosome	O
.	O

###MEDLINE:20483847

functional	O
characterization	O
of	O
the	O
two	O
alternative	B-DNA
promoters	I-DNA
of	O
human	B-protein
p00	I-protein
nf-e0	I-protein
gene	O
.	O

objective	O
:	O
the	O
transcription	B-protein
factor	I-protein
nf-e0	I-protein
,	O
a	O
heterodimeric	B-protein
protein	I-protein
complex	I-protein
composed	O
of	O
p00	B-protein
and	O
small	B-protein
maf	I-protein
family	I-protein
proteins	I-protein
,	O
is	O
considered	O
crucial	O
for	O
the	O
proper	O
differentiation	O
of	O
erythrocytes	B-cell_type
and	O
megakaryocytes	B-cell_type
in	O
vivo	O
.	O

we	O
report	O
the	O
results	O
of	O
studies	O
aimed	O
at	O
understanding	O
the	O
regulatory	O
mechanisms	O
controlling	O
p00	B-protein
gene	O
expression	O
in	O
erythroid	B-cell_type
cells	I-cell_type
.	O

materials	O
and	O
methods	O
:	O
human	O
p00	B-RNA
mrnas	I-RNA
have	O
two	O
alternative	O
isoforms	O
,	O
anf-e0	B-DNA
and	I-DNA
fnf-e0	I-DNA
,	O
and	O
these	O
isoforms	O
are	O
transcribed	O
from	O
the	O
alternative	B-DNA
promoters	I-DNA
.	O

we	O
investigated	O
lineage-specific	O
expression	O
of	O
both	O
isomers	O
in	O
human	B-cell_type
erythroid	I-cell_type
and	I-cell_type
megakaryocytic	I-cell_type
cells	I-cell_type
by	O
reverse	B-protein
transcriptase	I-protein
polymerase	I-protein
chain	I-protein
reaction	O
or	O
northern	O
blot	O
analysis	O
.	O

for	O
functional	O
characterization	O
of	O
both	O
promoters	B-DNA
,	O
plasmids	B-DNA
in	O
which	O
reporter	B-DNA
genes	I-DNA
were	O
placed	O
under	O
the	O
control	O
of	O
a	O
series	O
of	O
truncated	O
or	O
mutated	B-DNA
promoter	I-DNA
fragments	I-DNA
were	O
transfected	O
to	O
human	B-cell_line
hematopoietic	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

results	O
:	O
when	O
cd00	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
isolated	O
from	O
human	B-cell_type
cord	I-cell_type
blood	I-cell_type
were	O
induced	O
to	O
unilineage	O
erythroid	O
or	O
megakaryocytic	O
differentiation	O
in	O
liquid	B-cell_line
suspension	I-cell_line
culture	I-cell_line
,	O
both	O
transcripts	O
,	O
although	O
barely	O
detected	O
at	O
day	O
0	O
,	O
were	O
induced	O
in	O
both	O
erythroid	O
and	O
megakaryocytic	B-cell_line
cultures	I-cell_line
.	O

fnf-e0	B-RNA
mrna	I-RNA
was	O
found	O
to	O
be	O
more	O
abundant	O
in	O
erythroid	B-cell_type
cells	I-cell_type
than	O
megakaryocytic	B-cell_type
cells	I-cell_type
at	O
day	O
0	O
of	O
culture	O
.	O

although	O
both	O
isomers	O
were	O
expressed	O
in	O
human	B-cell_line
erythroid-megakaryocytic	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
megakaryocytic	O
maturation	O
with	O
loss	O
of	O
erythroid	B-cell_type
phenotype	I-cell_type
induced	O
by	O
phorbol	O
00-myristate	O
00-acetate	O
(	O
pma	O
)	O
resulted	O
in	O
exclusive	O
downregulation	O
of	O
fnf-e0	B-protein
,	O
suggesting	O
that	O
fnf-e0	B-DNA
promoter	I-DNA
is	O
more	O
erythroid	O
specific	O
.	O

functional	O
analysis	O
of	O
fnf-e0	B-DNA
promoter	I-DNA
showed	O
that	O
the	O
promoter	O
is	O
active	O
only	O
in	O
erythroid-megakaryocytic	B-cell_type
cells	I-cell_type
and	O
that	O
the	O
double	O
gata	B-protein
sit	B-protein
e	O
in	O
the	O
proximal	B-DNA
region	I-DNA
is	O
necessary	O
for	O
its	O
efficient	O
activity	O
.	O

conclusion	O
:	O
these	O
results	O
suggest	O
that	O
gata	B-protein
proteins	I-protein
,	O
which	O
govern	O
the	O
differentiation	O
of	O
erythroid	B-cell_type
lineage	I-cell_type
cells	I-cell_type
,	O
are	O
required	O
for	O
full	O
promoter	O
activity	O
of	O
the	O
p00	B-DNA
gene	I-DNA
.	O

###MEDLINE:20470674

transcriptional	O
activation	O
of	O
heme	B-protein
oxygenase-0	O
and	O
its	O
functional	O
significance	O
in	O
acetaminophen-induced	O
hepatitis	O
and	O
hepatocellular	O
injury	O
in	O
the	O
rat	O
.	O

background/aim	O
:	O
glutathione	O
depletion	O
contributes	O
to	O
acetaminophen	O
hepatotoxicity	O
and	O
is	O
known	O
to	O
induce	O
the	O
oxidative	O
stress	O
reactant	O
heme	O
oxygenase-0	O
.	O

the	O
metabolites	O
of	O
the	O
heme	O
oxygenase	O
pathway	O
,	O
biliverdin	O
,	O
carbon	O
monoxide	O
,	O
and	O
iron	O
may	O
modulate	O
acetaminophen	O
toxicity	O
.	O

the	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
cell-type	O
specific	O
expression	O
of	O
heme	B-protein
oxygenase-0	O
and	O
its	O
impact	O
on	O
liver	O
injury	O
and	O
microcirculatory	O
disturbances	O
in	O
a	O
model	O
of	O
acetaminophen-induced	O
hepatitis	O
.	O

methods	O
:	O
gene	O
expression	O
of	O
heme	B-protein
oxygenase-0	O
was	O
studied	O
by	O
northern-	B-protein
and	O
western	O
analysis	O
as	O
well	O
as	O
immunohistochemistry	O
.	O

the	O
time	O
course	O
of	O
heme	B-protein
oxygenase-0	O
and	O
-0	O
,	O
cytokine-induced	O
neutrophil	O
chemoattractant-0	O
,	O
and	O
intercellular	B-protein
adhesion	I-protein
molecule-0	I-protein
was	O
studied	O
by	O
northern	O
analysis	O
.	O

dna-binding	O
activity	O
of	O
nuclear	B-protein
factor-kappab	I-protein
was	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

sinusoidal	O
perfusion	O
and	O
leukocyte-endothelial	O
interactions	O
were	O
assessed	O
by	O
intravital	O
microscopy	O
.	O

results	O
:	O
acetaminophen	O
caused	O
a	O
moderate	O
sinusoidal	O
perfusion	O
failure	O
(	O
-00	O
%	O
)	O
and	O
infiltration	O
of	O
neutrophils	B-cell_type
along	O
with	O
activation	O
of	O
nuclear	B-protein
factor-kappab	I-protein
and	O
intercellular	B-protein
adhesion	I-protein
molecule-0	I-protein
and	O
cytokine-induced	O
neutrophil	O
chemoattractant-0	B-RNA
mrnas	I-RNA
.	O

induction	O
of	O
heme	B-protein
oxygenase-0	B-RNA
mrna	I-RNA
and	O
protein	O
(	O
approximately	O
00-fold	O
)	O
in	O
hepatocytes	B-cell_type
and	O
non-parenchymal	B-cell_type
cells	I-cell_type
paralleled	O
the	O
inflammatory	O
response	O
.	O

blockade	O
of	O
heme	B-protein
oxygenase	O
activity	O
with	O
tin-protoporphyrin-ix	B-protein
abrogated	O
acetaminophen-induced	O
hepatic	O
neutrophil	O
accumulation	O
and	O
nuclear	B-protein
factor-kappab	I-protein
activation	O
,	O
but	O
failed	O
to	O
affect	O
sinusoidal	O
perfusion	O
and	O
liver	O
injury	O
.	O

conclusions	O
:	O
the	O
inflammatory	O
response	O
associated	O
with	O
acetaminophen	O
hepatotoxicity	O
is	O
modulated	O
by	O
the	O
parallel	O
induction	O
of	O
the	O
heme	O
oxygenase-0	B-DNA
gene	I-DNA
.	O

however	O
,	O
heme	B-protein
oxygenase-0	O
has	O
no	O
permissive	O
effect	O
on	O
sinusoidal	O
perfusion	O
and	O
does	O
not	O
affect	O
liver	O
injury	O
in	O
this	O
model	O
.	O

these	O
data	O
argue	O
against	O
a	O
central	O
role	O
of	O
nuclear	B-protein
factor-kappab	I-protein
activation	O
and	O
neutrophil	O
infiltration	O
as	O
perpetuating	O
factors	O
of	O
liver	O
injury	O
in	O
acetaminophen	O
toxicity	O
.	O

###MEDLINE:20465088

tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
-induced	O
proliferation	O
requires	O
synthesis	O
of	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
.	O

objective	O
:	O
tumor	B-protein
necrosis	I-protein
factor-	I-protein
alpha	I-protein
(	O
tnf-alpha	B-protein
)	O
induces	O
a	O
variety	O
of	O
cellular	O
responses	O
,	O
some	O
of	O
them	O
being	O
at	O
least	O
seemingly	O
contradictory	O
.	O

thus	O
,	O
we	O
set	O
out	O
to	O
find	O
differences	O
in	O
the	O
modes	O
of	O
proliferative	O
and	O
apoptotic	O
responses	O
to	O
tnf-	B-protein
alpha	I-protein
.	O

materials	O
and	O
methods	O
:	O
we	O
screened	O
a	O
panel	O
of	O
acute	B-cell_line
myeloid	I-cell_line
leukemia-derived	I-cell_line
cell	I-cell_line
lines	I-cell_line
for	O
tnf-	B-protein
alpha	I-protein
-responsiveness	I-protein
.	O

in	O
two	O
lines	O
(	O
oci-aml-0	B-protein
,	O
oci-aml-00	B-protein
)	O
,	O
tnf-	B-protein
alpha	I-protein
acted	O
as	O
an	O
apoptotic	O
agent	O
;	O
in	O
others	O
(	O
hu-0	B-protein
,	O
m-00e	O
,	O
tf-0	B-protein
)	O
,	O
it	O
had	O
the	O
opposite	O
effect	O
,	O
preventing	O
apoptosis	O
and	O
inducing	O
proliferation	O
.	O

direct	O
and	O
indirect	O
signaling	O
mechanisms	O
,	O
including	O
nf-kappab	B-protein
activation	O
and	O
cytokine	B-protein
synthesis	O
,	O
were	O
analyzed	O
.	O

results	O
:	O
all	O
cell	B-cell_line
lines	I-cell_line
tested	O
expressed	O
tnf-	B-protein
alpha	I-protein
receptors	I-protein
i	B-protein
and	I-protein
ii	I-protein
and	O
responded	O
to	O
tnf-	B-protein
alpha	I-protein
by	O
upregulation	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-0	I-protein
.	O

in	O
contrast	O
to	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
gm-csf	B-protein
)	O
,	O
tnf-	B-protein
alpha	I-protein
did	O
not	O
activate	O
the	O
map	B-protein
kinase	I-protein
and	O
p00s0	B-protein
kinase	I-protein
pathways	O
.	O

nevertheless	O
,	O
inhibitors	O
of	O
these	O
pathways	O
clearly	O
reduced	O
the	O
tnf-alpha	B-protein
-induced	O
cell	O
growth	O
,	O
indicating	O
that	O
tnf-	B-protein
alpha-proliferative	I-protein
cells	I-protein
produced	O
a	O
growth	B-protein
factor	I-protein
that	O
induced	O
proliferation	O
upon	O
stimulation	O
of	O
the	O
above	O
pathways	O
.	O

anti-gm-csf	B-protein
antibodies	I-protein
inhibited	O
the	O
tnf-alpha	B-protein
-induced	O
growth	O
,	O
suggesting	O
the	O
presence	O
of	O
an	O
autocrine	O
loop	O
for	O
cell	O
proliferation	O
mediated	O
by	O
gm-csf	B-protein
.	O

supporting	O
this	O
notion	O
,	O
tnf-alpha	B-protein
-induced	O
upregulation	O
of	O
gm-csf	B-RNA
mrna	I-RNA
levels	O
and	O
protein	O
secretion	O
in	O
the	O
tnf-alpha	B-DNA
-proliferative	I-DNA
,	O
but	O
not	O
in	O
the	O
tnf-alpha-apoptotic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

conclusion	O
:	O
these	O
data	O
identify	O
gm-csf	B-protein
synthesis	O
as	O
an	O
early	O
and	O
essential	O
step	O
in	O
tnf-	O
alpha-induced	O
proliferation	O
.	O

we	O
show	O
for	O
the	O
first	O
time	O
that	O
tnf-alpha-treated	B-cell_line
cell	I-cell_line
lines	I-cell_line
producing	O
no	O
or	O
only	O
minimal	O
amounts	O
of	O
gm-csf	B-protein
demonstrate	O
an	O
apoptotic	O
phenotype	O
,	O
while	O
cell	B-cell_line
lines	I-cell_line
with	O
high	O
gm-csf	B-protein
expression	O
rates	O
can	O
escape	O
from	O
growth	O
arrest	O
or	O
even	O
apoptosis	O
.	O

in	O
this	O
context	O
,	O
we	O
discuss	O
arguments	O
pointing	O
at	O
nf-kappab	B-protein
as	O
regulator	O
of	O
gm-csf	B-protein
synthesis	O
and	O
thus	O
indirectly	O
as	O
regulator	O
for	O
the	O
escape	O
of	O
tnf-alpha	B-protein
-induced	O
apoptosis	O

###MEDLINE:81143525

glucocorticoid	B-protein
receptor	I-protein
content	O
of	O
t	B-cell_type
lymphocytes	I-cell_type
:	O
evidence	O
for	O
heterogeneity	O
.	O

glucocorticoid	B-protein
receptors	I-protein
were	O
measured	O
in	O
t	B-cell_type
lymphocytes	I-cell_type
that	O
were	O
isolated	O
from	O
peripheral	B-cell_type
blood	I-cell_type
by	O
either	O
nylon	O
wool	O
filtration	O
or	O
e-rosette	O
sedimentation	O
.	O

t	B-cell_type
cells	I-cell_type
isolated	O
by	O
nylon	O
wool	O
filtration	O
specifically	O
bind	O
0.0	O
+/-	O
0.0	O
fmol	O
of	O
dexamethasone	O
per	O
million	O
cells	O
(	O
equivalent	O
to	O
0000	O
+/-	O
000	O
receptors	O
per	O
cell	O
)	O
,	O
whereas	O
t	B-cell_type
cells	I-cell_type
isolated	O
by	O
e-rosette	O
sedimentation	O
bind	O
00.0	O
+/-	O
0.0	O
fmol	O
of	O
dexamethasone	O
per	O
million	O
cells	O
(	O
equivalent	O
to	O
0000	O
+/-	O
000	O
receptors	O
per	O
cell	O
)	O
.	O

this	O
difference	O
in	O
the	O
amount	O
of	O
dexamethasone	O
bound	O
by	O
the	O
two	O
t	O
cell	O
preparations	O
was	O
significant	O
(	O
p	O
less	O
than	O
.000	O
)	O
and	O
was	O
present	O
immediately	O
after	O
cell	O
isolation	O
.	O

the	O
binding	O
affinities	O
of	O
the	O
different	O
t	O
cell	O
preparations	O
for	O
dexamethasone	O
were	O
similar	O
.	O

t	B-cell_type
cells	I-cell_type
that	O
are	O
isolated	O
by	O
a	O
combination	O
of	O
nylon	O
wool	O
filtration	O
followed	O
by	O
e-rosette	O
sedimentation	O
bind	O
the	O
same	O
amount	O
of	O
dexamethasone	O
as	O
t	B-cell_type
cells	I-cell_type
isolated	O
by	O
nylon	O
wool	O
filtration	O
alone	O
.	O

t	B-cell_type
cells	I-cell_type
isolated	O
by	O
a	O
combination	O
of	O
e-rosette	O
sedimentation	O
following	O
by	O
nylon	O
wool	O
filtration	O
bind	O
less	O
dexamethasone	O
than	O
do	O
t	B-cell_type
cells	I-cell_type
isolated	O
by	O
e-rosette	O
sedimentation	O
alone	O
.	O

these	O
findings	O
suggest	O
that	O
t	B-cell_type
cells	I-cell_type
are	O
heterogeneous	O
with	O
respect	O
to	O
their	O
quantity	O
of	O
glucocorticoid	B-protein
receptors	I-protein
.	O

isolation	O
of	O
t	B-cell_type
cells	I-cell_type
by	O
e-rosette	O
sedimentation	O
enriches	O
for	O
t	B-cell_type
cells	I-cell_type
that	O
have	O
a	O
greater	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
,	O
and	O
isolation	O
of	O
t	B-cell_type
cells	I-cell_type
by	O
nylon	O
wool	O
filtration	O
enriches	O
for	O
t	B-cell_type
cells	I-cell_type
that	O
have	O
a	O
lesser	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
.	O

###MEDLINE:81141012

glucocorticoid	B-protein
receptors	I-protein
and	O
glucocorticoid	O
sensitivity	O
of	O
human	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
.	O

we	O
have	O
established	O
optimal	O
conditions	O
for	O
the	O
measurement	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
gr	B-protein
)	O
in	O
human	B-cell_type
white	I-cell_type
cells	I-cell_type
using	O
a	O
whole-cell	O
binding	O
assay	O
with	O
[	O
0h	O
]	O
dexamethasone	O
as	O
the	O
ligand	O
,	O
and	O
the	O
subsequent	O
determination	O
of	O
the	O
gr	B-protein
content	O
in	O
normal	B-cell_type
human	I-cell_type
lymphocytes	I-cell_type
and	O
in	O
leukemic	B-cell_type
cells	I-cell_type
of	O
patients	O
with	O
various	O
forms	O
of	O
acute	O
and	O
chronic	O
leukemia	O
.	O

a	O
number	O
of	O
leukemia	B-cell_line
cell	I-cell_line
lines	I-cell_line
in	O
continuous	B-cell_line
culture	I-cell_line
were	O
also	O
subjected	O
to	O
the	O
gr	B-protein
assay	O
,	O
and	O
the	O
results	O
were	O
correlated	O
with	O
the	O
sensitivity	O
of	O
these	O
cell	B-cell_line
lines	I-cell_line
to	O
glucocorticoid	O
steroids	O
in	O
vitro	O
.	O

the	O
gr	B-protein
content	O
of	O
normal	B-cell_type
human	I-cell_type
lymphocytes	I-cell_type
amounted	O
to	O
0	O
,	O
000	O
+/-	O
0	O
,	O
000	O
(	O
mean	O
+/-	O
sd	O
)	O
receptors/cell	O
.	O

the	O
mean	O
equilibrium	O
dissociation	O
constant	O
(	O
kd	O
)	O
of	O
the	O
interaction	O
of	O
[	O
0h	O
]	O
dexamethasone	O
with	O
the	O
gr	B-protein
was	O
0.0	O
x	O
00	O
(	O
-0	O
)	O
m	O
.	O

steroidal	O
compounds	O
with	O
a	O
known	O
glucocorticoid	O
potency	O
effectively	O
competed	O
for	O
the	O
binding	O
,	O
whereas	O
steroids	O
devoid	O
of	O
glucocorticoid	O
activity	O
(	O
e.g.	O
estradiol-00	B-protein
beta	I-protein
and	O
testosterone	O
)	O
were	O
ineffective	O
.	O

the	O
gr	B-protein
content	O
of	O
the	O
blast	B-cell_type
cells	I-cell_type
obtained	O
from	O
eight	O
patients	O
suffering	O
from	O
acute	O
leukemia	O
and	O
four	O
patients	O
with	O
a	O
blast	O
crisis	O
of	O
chronic	O
myelocytic	O
leukemia	O
was	O
found	O
to	O
be	O
highly	O
variable	O
(	O
0	O
,	O
000-00	O
,	O
000	O
receptors/cell	O
)	O
,	O
while	O
the	O
lymphocytes	O
of	O
six	O
patients	O
with	O
chronic	O
lymphatic	O
leukemia	O
contained	O
a	O
rather	O
stable	O
gr	B-protein
content	O
(	O
0	O
,	O
000-0	O
,	O
000	O
receptors/cell	O
)	O
,	O
which	O
was	O
comparable	O
with	O
that	O
of	O
normal	B-cell_type
lymphocytes	I-cell_type
.	O

gr	B-protein
was	O
identified	O
in	O
all	O
the	O
00	O
malignant	O
continuous	O
white	O
cell	B-cell_line
lines	I-cell_line
studied	O
.	O

large	B-cell_type
cells	I-cell_type
contained	O
more	O
gr	O
than	O
the	O
smaller	O
ones	O
.	O

there	O
was	O
no	O
apparent	O
correlation	O
between	O
the	O
gr	B-protein
concentration	O
and	O
the	O
sensitivity	O
of	O
the	O
cells	O
in	O
vitro	O
to	O
glucocorticoids	O
as	O
judged	O
by	O
[	O
0h	O
]	O
thymidine	O
incorporation	O
studies	O
.	O

distribution	O
of	O
the	O
surface	B-protein
markers	I-protein
in	O
the	O
leukemic	B-cell_line
cell	I-cell_line
lines	I-cell_line
did	O
not	O
relate	O
to	O
the	O
gr	B-protein
concentration	O
.	O

we	O
conclude	O
that	O
the	O
presence	O
of	O
gr	B-protein
is	O
probably	O
a	O
universal	O
feature	O
of	O
the	O
leukemic	B-cell_line
cells	I-cell_line
,	O
and	O
,	O
from	O
a	O
clinical	O
standpoint	O
,	O
probably	O
does	O
not	O
alone	O
imply	O
steroid	O
responsiveness	O
.	O

###MEDLINE:81229128

evidence	O
for	O
a	O
steroid	B-protein
receptor	I-protein
in	O
rheumatoid	B-cell_type
synovial	I-cell_type
tissue	I-cell_type
cells	I-cell_type
.	O

one	O
mechanism	O
by	O
which	O
glucocorticoids	O
could	O
exert	O
their	O
anti-inflammatory	O
action	O
is	O
via	O
rapidly	O
saturable	O
,	O
stereo-specific	B-protein
cytoplasmic	I-protein
protein	I-protein
receptors	I-protein
.	O

this	O
report	O
is	O
of	O
an	O
investigation	O
into	O
such	O
a	O
possibility	O
in	O
synovial	B-cell_type
cells	I-cell_type
.	O

synovium	O
,	O
obtained	O
from	O
knee	O
joints	O
of	O
rheumatoid	O
patients	O
undergoing	O
surgery	O
,	O
was	O
incubated	O
with	O
clostridiopeptidase	B-protein
a	I-protein
and	O
trypsin-edta	O
to	O
obtain	O
cell	O
suspensions	O
.	O

these	O
,	O
together	O
with	O
cells	O
obtained	O
from	O
synovial	B-cell_type
fluid	I-cell_type
aspirated	I-cell_type
from	O
patients	O
with	O
rheumatoid	O
arthritis	O
,	O
were	O
identified	O
by	O
electron	O
microscopy	O
.	O

duplicate	O
samples	O
of	O
these	O
cell	O
suspensions	O
were	O
incubated	O
with	O
increasing	O
concentrations	O
of	O
h0dexamethasone	B-protein
(	I-protein
0	I-protein
x	I-protein
00	I-protein
(	O
-00	O
)	O
m-0	O
x	O
00	O
(	O
-0	O
)	O
m	O
)	O
for	O
00	O
minutes	O
at	O
00	O
degrees	O
c	O
.	O

analysis	O
of	O
the	O
proportion	O
of	O
steroid	O
bound	O
to	O
whole	B-cell_type
cells	I-cell_type
showed	O
evidence	O
for	O
specific	O
,	O
rapidly	O
saturable	O
,	O
receptors	O
in	O
the	O
cells	O
obtained	O
from	O
synovial	B-cell_type
tissue	I-cell_type
,	O
but	O
this	O
was	O
not	O
found	O
in	O
synovial	B-cell_type
fluid	I-cell_type
cells	I-cell_type
.	O

electron	O
micrographs	O
showed	O
that	O
cells	O
obtained	O
from	O
synovial	O
tissue	O
consisted	O
of	O
synovial	B-cell_type
fibroblast	I-cell_type
-	I-cell_type
and	I-cell_type
macrophage-types	I-cell_type
,	I-cell_type
lymphocytes	I-cell_type
,	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
.	O

polymorphonuclear	B-cell_type
leucocytes	I-cell_type
appeared	O
to	O
be	O
absent	O
.	O

however	O
,	O
in	O
synovial	B-cell_type
fluid	I-cell_type
cell	I-cell_type
type	I-cell_type
polymorphonuclear	I-cell_type
leucocytes	I-cell_type
were	O
the	O
predominant	O
cell	O
type	O
.	O

we	O
concluded	O
from	O
this	O
,	O
that	O
one	O
or	O
more	O
of	O
the	O
cell	O
types	O
present	O
in	O
synovial	B-cell_type
tissue	I-cell_type
contain	O
a	O
specific	O
steroid	B-protein
receptor	I-protein
,	O
but	O
that	O
this	O
is	O
lacking	O
in	O
synovial	B-cell_type
fluid	I-cell_type
polymorphonuclear	I-cell_type
leucocytes	I-cell_type
.	O

###MEDLINE:79022914

clinical	O
implications	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
human	O
leukemia	O
.	O

glucorticoid	B-protein
receptors	I-protein
were	O
studied	O
in	O
various	O
populations	O
of	O
normal	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
and	O
leukemic	B-cell_type
lymphoblasts	I-cell_type
.	O

normal	B-cell_type
lymphocytes	I-cell_type
contain	O
low	O
levels	O
of	O
glucocorticoid	B-protein
receptor	I-protein
(	O
approximately	O
0	O
,	O
000	O
sites/cell	O
)	O
which	O
are	O
identical	O
in	O
t-	B-cell_type
and	I-cell_type
non-t-fractions	I-cell_type
.	O

phytohemagglutinin	B-protein
treatment	O
increases	O
levels	O
about	O
0-fold	O
.	O

leukemic	B-cell_type
lymphoblasts	I-cell_type
contain	O
larger	O
numbers	O
of	O
receptor	O
sites	O
.	O

presence	O
of	O
receptor	O
is	O
correlated	O
with	O
in	O
vitro	O
sensitivitiy	O
to	O
glucocorticoids	O
and	O
in	O
vivo	O
response	O
to	O
therapy	O
.	O

quantity	O
of	O
receptor	O
is	O
also	O
correlated	O
with	O
complete	O
remission	O
duration	O
independently	O
of	O
leukemic	B-cell_line
cell	I-cell_line
type	I-cell_line
(	I-cell_line
t	I-cell_line
or	O
null	O
)	O
,	O
initial	O
wbc	O
,	O
or	O
age	O
of	O
patient	O
.	O

quantitative	O
determination	O
of	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
in	O
acute	O
lymphoblastic	O
leukemia	O
may	O
be	O
of	O
value	O
both	O
as	O
an	O
independent	O
prognostic	O
variable	O
and	O
in	O
suggesting	O
which	O
patients	O
should	O
receive	O
glucocorticoid	O
therapy	O
.	O

###MEDLINE:94086562

functional	O
and	O
physical	O
interaction	O
of	O
protein-tyrosine	B-protein
kinases	I-protein
fyn	B-protein
and	O
csk	B-protein
in	O
the	O
t-cell	O
signaling	O
system	O
.	O

the	O
src-like	B-protein
protein-tyrosine	I-protein
kinase	I-protein
fyn	B-protein
is	O
associated	O
with	O
t-cell	B-protein
antigen	I-protein
receptor	I-protein
.	O

transient	O
expression	O
of	O
actively	O
mutated	O
fyn	B-protein
,	O
having	O
phe-000	O
instead	O
of	O
tyr-000	O
or	O
thr-000	O
instead	O
of	O
ile-000	O
,	O
in	O
jurkat	B-cell_line
t-cells	I-cell_line
stimulated	O
the	O
serum	B-DNA
response	I-DNA
element	I-DNA
(	O
sre	B-DNA
)	O
,	O
00-o-tetradecanoyl-phorbol-00-acetate	O
response	O
element	O
,	O
cyclic	B-DNA
amp	I-DNA
response	I-DNA
element	I-DNA
,	O
and	O
c-fos	B-DNA
promoter	I-DNA
.	O

the	O
stimulation	O
of	O
sre	B-DNA
was	O
particularly	O
prominent	O
not	O
only	O
with	O
active	O
fyn	B-protein
but	O
also	O
with	O
normal	O
(	O
wild-type	B-cell_line
)	O
fyn	B-protein
.	O

sre	B-DNA
was	O
also	O
stimulated	O
by	O
both	O
normal	O
and	O
active	O
lck	B-protein
.	O

furthermore	O
,	O
normal	O
and	O
active	O
fyn	B-protein
stimulated	O
transcription	O
from	O
the	O
il-0	B-DNA
gene	I-DNA
promoter	I-DNA
when	O
transfected	B-cell_line
cells	I-cell_line
were	O
stimulated	O
by	O
concanavalin	O
a	O
plus	O
00-o-tetradecanoylphorbol-00-acetate	O
.	O

under	O
the	O
same	O
conditions	O
,	O
lck	B-protein
did	O
not	O
stimulate	O
il-0	B-DNA
promoter	I-DNA
unless	O
it	O
was	O
activated	O
by	O
mutation	O
.	O

interestingly	O
,	O
a	O
mutant	O
fyn	B-protein
,	O
which	O
has	O
deletions	O
within	O
the	O
sh0	B-protein
region	I-protein
and	O
so	O
is	O
able	O
to	O
transform	O
chicken	O
embryo	B-cell_line
fibroblasts	I-cell_line
,	O
did	O
not	O
stimulate	O
either	O
the	O
c-fos	B-DNA
or	I-DNA
il-0	I-DNA
promoter	I-DNA
,	O
suggesting	O
the	O
importance	O
of	O
this	O
region	O
in	O
t-cell	O
signaling	O
.	O

csk	B-protein
,	O
which	O
phosphorylates	O
tyrosine	O
residues	O
in	O
the	O
negative	B-DNA
regulatory	I-DNA
sites	I-DNA
of	O
src	B-protein
family	I-protein
kinases	I-protein
,	O
down-regulated	O
fyn-	B-protein
and	O
lck-mediated	O
stimulation	O
of	O
the	O
serum	B-DNA
response	I-DNA
element	I-DNA
and	O
fyn-mediated	O
enhancement	O
of	O
il-0	B-DNA
promoter	I-DNA
activity	O
.	O

these	O
data	O
suggest	O
that	O
fyn	B-protein
and	O
lck	B-protein
,	O
whose	O
activities	O
are	O
regulated	O
by	O
csk	B-protein
,	O
are	O
involved	O
in	O
different	O
phases	O
of	O
t-cell	O
activation	O
.	O

###MEDLINE:94067143

a	O
novel	O
nf-kappa	B-protein
b	I-protein
complex	I-protein
containing	O
p00	B-protein
homodimers	I-protein
:	O
implications	O
for	O
transcriptional	O
control	O
at	O
the	O
level	O
of	O
subunit	O
dimerization	O
.	O

the	O
predominant	O
inducible	O
form	O
of	O
the	O
nf-kappa	B-protein
b	I-protein
transcription	I-protein
factor	I-protein
is	O
a	O
heteromeric	B-protein
complex	I-protein
containing	O
two	O
rel-related	B-protein
dna-binding	I-protein
subunits	I-protein
,	O
termed	O
p00	B-protein
and	O
p00	B-protein
.	O

prior	O
transfection	O
studies	O
have	O
shown	O
that	O
when	O
these	O
p00	B-protein
and	I-protein
p00	I-protein
subunits	I-protein
are	O
expressed	O
independently	O
as	O
stable	O
homodimers	O
,	O
p00	B-protein
stimulates	O
kappa	O
b-directed	O
transcription	O
,	O
whereas	O
p00	B-protein
functions	O
as	O
a	O
kappa	B-protein
b-specific	I-protein
repressor	I-protein
.	O

while	O
authentic	O
p00	B-protein
homodimers	I-protein
(	O
previously	O
termed	O
kbf0	B-protein
)	O
have	O
been	O
detected	O
in	O
nuclear	O
extracts	O
from	O
nontransfected	B-cell_line
cells	I-cell_line
,	O
experimental	O
evidence	O
supporting	O
the	O
existence	O
of	O
p00	B-protein
homodimers	I-protein
in	O
vivo	O
was	O
lacking	O
.	O

we	O
now	O
provide	O
direct	O
biochemical	O
evidence	O
for	O
the	O
presence	O
of	O
an	O
endogenous	O
pool	O
of	O
inducible	O
p00	B-protein
homodimers	I-protein
in	O
intact	B-cell_type
human	I-cell_type
t	I-cell_type
cells	I-cell_type
.	O

as	O
with	O
the	O
prototypical	O
nf-kappa	B-protein
b	I-protein
p00-p00	I-protein
heterodimer	I-protein
,	O
this	O
novel	O
p00	B-protein
homodimeric	I-protein
form	I-protein
of	O
nf-kappa	B-protein
b	I-protein
is	O
functionally	O
sequestered	O
in	O
the	O
cytoplasm	O
but	O
rapidly	O
appears	O
in	O
the	O
nuclear	O
compartment	O
following	O
cellular	O
stimulation	O
.	O

site-directed	O
mutagenesis	O
studies	O
indicate	O
that	O
the	O
homodimerization	O
function	O
of	O
p00	B-protein
is	O
dependent	O
upon	O
the	O
presence	O
of	O
cysteine	O
000	O
and	O
a	O
conserved	B-DNA
recognition	I-DNA
motif	I-DNA
for	O
protein	B-protein
kinase	I-protein
a	I-protein
(	O
rrps	O
;	O
amino	B-protein
acids	I-protein
000	I-protein
to	O
000	O
)	O
,	O
both	O
of	O
which	O
reside	O
within	O
a	O
00-amino-acid	B-protein
segment	I-protein
of	O
the	O
rel	B-protein
homology	I-protein
domain	I-protein
that	O
mediates	O
self-association	O
.	O

in	O
contrast	O
,	O
mutations	O
at	O
these	O
two	O
sites	O
do	O
not	O
affect	O
heterodimerization	O
of	O
p00	B-protein
with	O
p00	B-protein
or	O
its	O
functional	O
interaction	O
with	O
i	B-protein
kappa	I-protein
b	I-protein
alpha	I-protein
.	O

these	O
later	O
findings	O
indicate	O
that	O
neither	O
homo-	O
nor	O
heterodimer	B-protein
formation	O
is	O
an	O
absolute	O
prerequisite	O
for	O
i	B-protein
kappa	I-protein
b	I-protein
alpha	I-protein
recognition	O
of	O
p00	B-protein
.	O

taken	O
together	O
with	O
prior	O
in	O
vivo	O
transcription	O
studies	O
,	O
these	O
results	O
suggest	O
that	O
the	O
biological	O
activities	O
of	O
p00	B-protein
and	O
p00	B-protein
homodimers	I-protein
are	O
independently	O
regulated	O
,	O
thereby	O
providing	O
an	O
integrated	O
and	O
flexible	O
control	O
mechanism	O
for	O
the	O
rapid	O
activation	O
and	O
repression	O
of	O
nf-kappa	B-protein
b	I-protein
/	O
rel	B-protein
-directed	O
gene	O
expression	O
.	O

###MEDLINE:94044828

carrier	O
determination	O
for	O
x-linked	O
agammaglobulinemia	O
using	O
x	O
inactivation	O
analysis	O
of	O
purified	B-cell_type
b	I-cell_type
cells	I-cell_type
.	O

we	O
report	O
the	O
development	O
of	O
a	O
relatively	O
quick	O
and	O
simple	O
method	O
for	O
the	O
assessment	O
of	O
x	O
inactivation	O
status	O
for	O
carrier	O
determination	O
in	O
families	O
affected	O
by	O
x-linked	O
agammaglobulinemia	O
(	O
xla	B-DNA
)	O
.	O

this	O
method	O
utilises	O
an	O
immunomagnetic	O
separation	O
technique	O
for	O
b	B-cell_type
cell	I-cell_type
purification	O
and	O
a	O
polymerase	O
chain	O
reaction	O
(	O
pcr	O
)	O
based	O
assay	O
for	O
the	O
determination	O
of	O
methylation	O
status	O
at	O
the	O
androgen	B-DNA
receptor	I-DNA
(	I-DNA
ar	I-DNA
)	I-DNA
gene	I-DNA
locus	I-DNA
to	O
assess	O
whether	O
x	O
inactivation	O
is	O
random	O
or	O
non-random	O
at	O
this	O
locus	O
.	O

we	O
report	O
the	O
results	O
we	O
have	O
obtained	O
using	O
this	O
assay	O
to	O
investigate	O
females	O
known	O
to	O
be	O
carriers	O
of	O
various	O
x-linked	O
immunodeficiency	O
disorders	O
.	O

in	O
addition	O
,	O
we	O
investigated	O
four	O
females	O
from	O
different	O
families	O
affected	O
by	O
xla	B-DNA
,	O
two	O
of	O
whom	O
were	O
of	O
unknown	O
carrier	O
status	O
,	O
and	O
we	O
discuss	O
the	O
results	O
obtained	O
with	O
this	O
and	O
other	O
x-inactivation	O
assays	O
.	O

a	O
similar	O
assay	O
has	O
recently	O
been	O
described	O
by	O
allen	O
et	O
al.	O
(	O
0000	O
)	O
and	O
applied	O
to	O
members	O
of	O
one	O
family	O
affected	O
by	O
xla	B-DNA
.	O

###MEDLINE:94049846

effects	O
of	O
il-0	B-protein
and	O
fc	B-protein
gamma	I-protein
receptor	I-protein
ii	I-protein
engagement	O
on	O
egr-0	B-protein
expression	O
during	O
stimulation	O
of	O
b	B-cell_type
lymphocytes	I-cell_type
by	O
membrane	B-protein
immunoglobulin	I-protein
crosslinking	O
.	O

egr-0	B-protein
is	O
an	O
immediate	B-DNA
early	I-DNA
gene	I-DNA
that	O
is	O
rapidly	O
upregulated	O
in	O
response	O
to	O
mitogenic	O
signals	O
induced	O
by	O
antigen	B-protein
receptor	I-protein
crosslinking	O
on	O
murine	B-cell_type
b	I-cell_type
lymphocytes	I-cell_type
.	O

it	O
has	O
been	O
shown	O
that	O
levels	O
of	O
egr-0	B-protein
expression	O
are	O
closely	O
correlated	O
with	O
b	B-cell_type
cell	I-cell_type
proliferation	O
in	O
several	O
models	O
of	O
b	B-cell_type
cell	I-cell_type
activation	O
and	O
tolerance	O
.	O

we	O
compared	O
the	O
expression	O
of	O
egr-0	B-protein
during	O
b	B-cell_type
cell	I-cell_type
stimulation	O
with	O
fab'0	B-protein
and	O
igg	B-protein
anti-immunoglobulin	O
(	O
anti-ig	B-protein
)	O
,	O
since	O
it	O
is	O
known	O
that	O
fab'0	O
anti-ig	B-protein
is	O
mitogenic	O
while	O
igg	B-protein
anti-ig	B-protein
is	O
not	O
,	O
owing	O
to	O
a	O
dominant	O
inhibitory	O
effect	O
of	O
crosslinking	O
the	O
b	B-protein
cell	I-protein
fc	I-protein
gamma	I-protein
rii	I-protein
to	O
membrane	O
ig	O
.	O

while	O
mitogenic	O
doses	O
of	O
fab'0	O
anti-ig	B-protein
induce	O
large	O
and	O
rapid	O
increases	O
in	O
egr-0	B-protein
expression	O
,	O
igg	B-protein
anti-ig	O
results	O
in	O
smaller	O
increases	O
in	O
egr-0	B-RNA
mrna	I-RNA
,	O
comparable	O
to	O
that	O
seen	O
with	O
submitogenic	O
concentrations	O
of	O
fab'0	O
anti-ig	B-protein
.	O

however	O
,	O
the	O
correlation	O
between	O
egr-0	B-protein
expression	O
and	O
b	O
cell	O
proliferation	O
breaks	O
down	O
when	O
il-0	B-protein
is	O
added	O
as	O
a	O
co-mitogen	O
to	O
induce	O
b	O
cell	O
proliferation	O
with	O
igg	B-protein
anti-ig	B-protein
or	O
submitogenic	O
concentrations	O
of	O
fab'0	O
anti-ig	B-protein
.	O

no	O
corresponding	O
increases	O
in	O
egr-0	B-RNA
mrna	I-RNA
levels	O
are	O
observed	O
when	O
il-0	B-protein
is	O
added	O
.	O

therefore	O
,	O
il-0	B-protein
overcomes	O
fc	B-protein
receptor-mediated	O
inhibition	O
of	O
b	B-cell_type
cell	I-cell_type
proliferation	O
without	O
affecting	O
inhibition	O
of	O
egr-0	B-RNA
mrna	I-RNA
induction	O
,	O
as	O
demonstrated	O
earlier	O
for	O
c-myc	B-RNA
mrna	I-RNA
in	O
this	O
system	O
.	O

###MEDLINE:93389400

identification	O
of	O
a	O
novel	O
cyclosporin-sensitive	B-DNA
element	I-DNA
in	O
the	O
human	B-DNA
tumor	I-DNA
necrosis	I-DNA
factor	I-DNA
alpha	I-DNA
gene	I-DNA
promoter	I-DNA
.	O

tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
tnf-alpha	B-protein
)	O
,	O
a	O
cytokine	O
with	O
pleiotropic	O
biological	O
effects	O
,	O
is	O
produced	O
by	O
a	O
variety	O
of	O
cell	O
types	O
in	O
response	O
to	O
induction	O
by	O
diverse	O
stimuli	O
.	O

in	O
this	O
paper	O
,	O
tnf-alpha	B-RNA
mrna	I-RNA
is	O
shown	O
to	O
be	O
highly	O
induced	O
in	O
a	O
murine	B-cell_line
t	I-cell_line
cell	I-cell_line
clone	I-cell_line
by	O
stimulation	O
with	O
t	B-protein
cell	I-protein
receptor	I-protein
(	O
tcr	B-protein
)	O
ligands	O
or	O
by	O
calcium	O
ionophores	O
alone	O
.	O

induction	O
is	O
rapid	O
,	O
does	O
not	O
require	O
de	O
novo	O
protein	O
synthesis	O
,	O
and	O
is	O
completely	O
blocked	O
by	O
the	O
immunosuppressant	O
cyclosporin	O
a	O
(	O
csa	O
)	O
.	O

we	O
have	O
identified	O
a	O
human	B-DNA
tnf-alpha	I-DNA
promoter	I-DNA
element	I-DNA
,	O
kappa	B-protein
0	I-protein
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
the	O
calcium-mediated	O
inducibility	O
and	O
csa	O
sensitivity	O
of	O
the	O
gene	O
.	O

in	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
an	O
oligonucleotide	O
containing	O
kappa	B-DNA
0	I-DNA
forms	O
two	O
dna	B-protein
protein	I-protein
complexes	I-protein
with	O
proteins	O
that	O
are	O
present	O
in	O
extracts	O
from	O
unstimulated	B-cell_type
t	I-cell_type
cells	I-cell_type
.	O

these	O
complexes	O
appear	O
in	O
nuclear	O
extracts	O
only	O
after	O
t	B-cell_type
cell	I-cell_type
stimulation	O
.	O

induction	O
of	O
the	O
inducible	O
nuclear	B-protein
complexes	I-protein
is	O
rapid	O
,	O
independent	O
of	O
protein	O
synthesis	O
,	O
and	O
blocked	O
by	O
csa	O
,	O
and	O
thus	O
,	O
exactly	O
parallels	O
the	O
induction	O
of	O
tnf-alpha	B-RNA
mrna	I-RNA
by	O
tcr	B-protein
ligands	I-protein
or	O
by	O
calcium	O
ionophore	O
.	O

our	O
studies	O
indicate	O
that	O
the	O
kappa	B-protein
0	I-protein
binding	I-protein
factor	I-protein
resembles	O
the	O
preexisting	O
component	O
of	O
nuclear	B-protein
factor	I-protein
of	O
activated	B-cell_type
t	I-cell_type
cells	I-cell_type
.	O

thus	O
,	O
the	O
tnf-alpha	B-DNA
gene	I-DNA
is	O
an	O
immediate	B-DNA
early	I-DNA
gene	I-DNA
in	O
activated	B-cell_type
t	I-cell_type
cells	I-cell_type
and	O
provides	O
a	O
new	O
model	O
system	O
in	O
which	O
to	O
study	O
csa-sensitive	O
gene	O
induction	O
in	O
activated	B-cell_type
t	I-cell_type
cells	I-cell_type
.	O

###MEDLINE:93371352

differences	O
in	O
expression	O
of	O
transcription	B-protein
factor	I-protein
ap-0	B-protein
in	O
human	B-cell_line
promyelocytic	I-cell_line
hl-00	I-cell_line
cells	I-cell_line
during	O
differentiation	O
towards	O
macrophages	B-cell_type
versus	O
granulocytes	B-cell_type
.	O

commitment	O
of	O
hl-00	B-cell_line
cells	I-cell_line
to	O
macrophage	O
or	O
granulocytic	O
differentiation	O
was	O
achieved	O
by	O
incubation	O
with	O
0	O
beta-phorbol	O
00-myristate	O
00-acetate	O
(	O
pma	O
)	O
for	O
00-00	O
min	O
or	O
with	O
dimethyl	O
sulphoxide	O
(	O
dmso	O
)	O
for	O
00	O
h	O
respectively	O
.	O

the	O
commitment	O
stage	O
towards	O
pma-induced	O
macrophage	O
differentiation	O
was	O
associated	O
with	O
increases	O
in	O
jun	B-protein
b	I-protein
and	O
c-fos	B-RNA
mrna	I-RNA
levels	O
,	O
as	O
well	O
as	O
with	O
an	O
increase	O
in	O
the	O
binding	O
activity	O
of	O
transcription	B-protein
factor	I-protein
ap-0	B-protein
.	O

nevertheless	O
,	O
gel	O
retardation	O
analysis	O
indicated	O
that	O
the	O
ap-0	B-protein
activity	O
detected	O
in	O
untreated	B-cell_type
cells	I-cell_type
was	O
drastically	O
reduced	O
during	O
the	O
commitment	O
stage	O
of	O
dmso-induced	O
hl-00	O
differentiation	O
towards	O
granulocytes	B-cell_type
.	O

when	O
hl-00	B-cell_line
cells	I-cell_line
were	O
treated	O
with	O
sodium	O
butyrate	O
,	O
which	O
induced	O
monocytic	O
differentiation	O
,	O
a	O
remarkable	O
increase	O
in	O
ap-0	B-protein
binding	O
activity	O
was	O
detected	O
.	O

treatment	O
of	O
hl-00	B-cell_line
cells	I-cell_line
with	O
0	B-protein
alpha	I-protein
,	O
00-dihydroxyvitamin	O
d0	O
,	O
another	O
monocytic	O
differentiation	O
agent	O
,	O
induced	O
a	O
weak	O
,	O
but	O
appreciable	O
,	O
increase	O
in	O
ap-0	B-protein
activity	O
.	O

furthermore	O
,	O
addition	O
of	O
sodium	O
butyrate	O
or	O
0	B-protein
alpha	I-protein
,	O
00-dihydroxyvitamin	O
d0	O
to	O
hl-00	B-cell_line
cells	I-cell_line
induced	O
the	O
expression	O
of	O
c-fos	B-protein
,	O
c-jun	B-protein
,	O
jun	B-protein
b	I-protein
and	O
jun	B-DNA
d	I-DNA
proto-oncogenes	I-DNA
.	O

in	O
contrast	O
,	O
when	O
hl-00	B-cell_line
cells	I-cell_line
were	O
treated	O
with	O
retinoic	O
acid	O
,	O
a	O
granulocytic	O
differentiation	O
inducer	O
,	O
no	O
enhanced	O
ap-0	B-protein
binding	O
activity	O
was	O
observed	O
,	O
and	O
only	O
a	O
weak	O
increase	O
in	O
jun	B-protein
d	O
mrna	O
level	O
was	O
detected	O
.	O

these	O
data	O
indicate	O
that	O
formation	O
of	O
ap-0	B-protein
is	O
not	O
required	O
for	O
the	O
induction	O
of	O
hl-00	O
differentiation	O
towards	O
granulocytes	B-cell_type
,	O
whereas	O
induction	O
of	O
monocytic	O
differentiation	O
is	O
correlated	O
with	O
an	O
increase	O
in	O
ap-0	B-protein
activity	O
.	O

the	O
differential	O
expression	O
of	O
ap-0	B-protein
activity	O
may	O
be	O
critical	O
in	O
the	O
differentiation	O
of	O
hl-00	B-cell_line
cells	I-cell_line
towards	O
monocytic	O
or	O
granulocytic	B-cell_type
lineages	I-cell_type

###MEDLINE:81161585

glucocorticoid	B-protein
receptors	I-protein
and	O
sensitivity	O
in	O
leukemias	O
.	O

in	O
an	O
attempt	O
to	O
investigate	O
the	O
utility	O
of	O
glucocorticoid	B-protein
receptor	I-protein
determination	O
to	O
predict	O
clinical	O
responsiveness	O
in	O
human	O
leukemias	O
we	O
have	O
studied	O
glucocorticoid	B-protein
receptors	I-protein
in	O
the	O
leukemic	B-cell_type
cells	I-cell_type
from	O
00	O
patients	O
and	O
in	O
the	O
lymphocytes	O
from	O
00	O
normal	O
donors	O
.	O

in	O
the	O
normal	O
lymphocytes	O
there	O
were	O
0	O
,	O
000	O
(	O
median	O
)	O
specific	O
binding	O
sites	O
per	O
cell	O
.	O

the	O
blasts	O
from	O
00	O
patients	O
with	O
anll	O
had	O
on	O
average	O
higher	O
levels	O
of	O
binding	B-DNA
sites	I-DNA
per	O
cell	O
(	O
median	O
=	O
0	O
,	O
000	O
,	O
range	O
:	O
0	O
to	O
00	O
,	O
000	O
)	O
than	O
the	O
other	O
leukemias	O
.	O

of	O
the	O
00	O
patients	O
with	O
cll	O
,	O
six	O
had	O
received	O
glucocorticoid	O
treatment	O
for	O
0	O
to	O
0	O
years	O
.	O

their	O
lymphocytes	O
had	O
lower	O
number	O
of	O
receptors	O
(	O
median	O
=	O
0	O
,	O
000	O
)	O
than	O
the	O
other	O
cases	O
which	O
were	O
newly	O
diagnosed	O
(	O
median	O
=	O
0	O
,	O
000	O
)	O
.	O

four	O
patients	O
had	O
all/aul	O
,	O
three	O
patients	O
had	O
blast	O
crisis	O
as	O
terminal	O
phase	O
of	O
cml	O
,	O
and	O
seven	O
had	O
leukemic	O
non-hodgkin	O
lymphomas	O
(	O
median	O
=	O
0	O
,	O
000	O
sites/cell	O
)	O
.	O

in	O
00	O
patients	O
we	O
have	O
also	O
studied	O
the	O
in	O
vitro	O
sensitivity	O
of	O
the	O
leukemic	B-cell_type
cells	I-cell_type
to	O
dexamethasone	O
.	O

there	O
was	O
no	O
marked	O
correlation	O
between	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
and	O
in	O
vitro	O
sensitivity	O
.	O

an	O
attempt	O
to	O
correlate	O
receptor	O
levels	O
with	O
clinical	O
responsiveness	O
demonstrated	O
that	O
glucocorticoid	B-protein
receptor	I-protein
determination	O
might	O
be	O
of	O
value	O
in	O
patients	O
with	O
lymphoid	B-cell_type
malignancies	I-cell_type
but	O
probably	O
not	O
in	O
patients	O
with	O
other	O
leukemias	O
.	O

###MEDLINE:80254646

'activation-labile	B-protein
'	I-protein
glucocorticoid-receptor	I-protein
complexes	I-protein
of	O
a	O
steroid-resistant	O
variant	O
of	O
cem-c0	B-cell_line
human	I-cell_line
lymphoid	I-cell_line
cells	I-cell_line
.	O

for	O
cytoplasmic	B-protein
glucocorticoid-receptor	I-protein
complexes	I-protein
to	O
enter	O
and	O
accumulate	O
in	O
the	O
nucleus	O
a	O
temperature-dependent	O
event	O
,	O
'activation	O
'	O
is	O
required	O
.	O

activation	O
can	O
be	O
achieved	O
in	O
vitro	O
by	O
increased	O
ionic	O
strength	O
,	O
dilution	O
or	O
gel	O
filtration	O
and	O
is	O
manifested	O
by	O
an	O
increased	O
affinity	O
of	O
steroid-receptor	B-protein
complex	I-protein
for	O
dna	O
and	O
an	O
altered	O
elution	O
profile	O
from	O
ion-exchange	O
resins	O
.	O

munck	O
and	O
foley	O
have	O
shown	O
that	O
activated	B-protein
complexes	I-protein
isolated	O
from	O
thymocytes	B-cell_type
elute	O
from	O
deae-cellulose	O
in	O
a	O
manner	O
identical	O
to	O
complexes	O
activated	O
in	O
vitro	O
.	O

we	O
report	O
here	O
that	O
deae-cellulose	O
chromatography	O
of	O
steroid-receptor	B-protein
complexes	I-protein
from	O
cem-c0	B-cell_line
,	O
a	O
cloned	B-cell_line
human	I-cell_line
leukaemic	I-cell_line
t-cell	I-cell_line
line	I-cell_line
sensitive	O
to	O
the	O
cytolytic	O
action	O
of	O
glucocorticoids	O
,	O
and	O
its	O
steroid-resistant	O
subclone	O
0r0	O
demonstrated	O
that	O
steroid	B-protein
receptors	I-protein
of	O
clone	B-cell_line
0r0	I-cell_line
can	O
not	O
form	O
stable	O
activated	B-protein
complexes	I-protein
.	O

this	O
defines	O
a	O
new	O
defect	O
in	O
receptor	O
action	O
,	O
activation	O
lability	O
(	O
r+act0	B-protein
)	O
,	O
which	O
is	O
unlike	O
either	O
the	O
r-	O
,	O
r+nt-	O
,	O
or	O
r+nti	O
phenotypes	O
previously	O
described	O
for	O
mouse	B-cell_line
lymphoid	I-cell_line
variants	I-cell_line
.	O

###MEDLINE:80074787

granulocytes	B-cell_type
in	O
the	O
endometrium	O
of	O
post-partum	O
women	O
.	O

endometrial	O
samples	O
of	O
women	O
at	O
various	O
stages	O
of	O
gonadal	O
activity	O
after	O
parturition	O
were	O
examined	O
for	O
the	O
presence	O
and	O
numbers	O
of	O
endometrial	B-cell_type
granulocytes	I-cell_type
.	O

although	O
samples	O
at	O
all	O
the	O
stages	O
contained	O
significant	O
numbers	O
of	O
the	O
granulocytes	O
(	O
i.e.	O
greater	O
than	O
0/high-power	O
field	O
)	O
,	O
the	O
000	O
%	O
values	O
for	O
late-proliferative	B-protein
and	O
adaptation	O
hyperplasia	O
were	O
significantly	O
higher	O
than	O
the	O
values	O
for	O
the	O
resting	O
(	O
00.0	O
%	O
)	O
,	O
early	O
(	O
00.0	O
%	O
)	O
and	O
mid-	B-protein
(	O
00.0	O
%	O
)	O
proliferative	O
and	O
secretory	O
(	O
00.0	O
%	O
)	O
phases	O
.	O

we	O
suggest	O
that	O
this	O
correlates	O
with	O
the	O
suggestion	O
that	O
the	O
granulocytes	O
constitute	O
a	O
receptor	O
system	O
for	O
oestrogens	O
.	O

###MEDLINE:78243961

interaction	O
of	O
glucocorticoids	O
with	O
macrophages	B-cell_type
.	O

identification	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
.	O

glucocorticoid	O
binding	O
was	O
measured	O
in	O
resident	B-cell_type
and	I-cell_type
thioglycollate-elicited	I-cell_type
mouse	I-cell_type
peritoneal	I-cell_type
macrophages	I-cell_type
,	O
rabbit	O
alveolar	B-cell_type
macrophages	I-cell_type
,	O
and	O
human	B-cell_type
monocytes	I-cell_type
.	O

two	O
assays	O
of	O
binding	O
were	O
used	O
--	O
an	O
assay	O
with	O
intact	B-cell_type
cells	I-cell_type
in	O
suspension	B-cell_line
or	I-cell_line
monolayers	I-cell_line
,	O
and	O
an	O
assay	O
of	O
cytosol	O
and	O
nuclear	O
forms	O
of	O
glucocorticoid	B-protein
receptors	I-protein
.	O

the	O
mononuclear	B-cell_type
phagocytes	I-cell_type
contained	O
approximately	O
equal	O
to	O
0	O
--	O
00	O
x	O
00	O
(	O
0	O
)	O
high	O
affinity	O
receptor	O
sites	O
per	O
cell	O
,	O
with	O
dissociation	O
constants	O
of	O
approximately	O
equal	O
to	O
0	O
--	O
0	O
nm	O
dexamethasone	O
.	O

the	O
binding	O
to	O
the	O
saturable	O
sites	O
was	O
specific	O
for	O
steroids	O
with	O
glucocorticoid	O
or	O
antiglucocorticoid	O
activity	O
.	O

cortisol	O
,	O
corticosterone	O
,	O
and	O
progesterone	O
competed	O
with	O
dexamethasone	O
for	O
binding	O
,	O
whereas	O
estradiol	O
,	O
dihydrotestosterone	O
,	O
and	O
00-epicortisol	B-protein
competed	O
very	O
little	O
.	O

binding	O
of	O
dexamethasone	O
to	O
cytosol	O
and	O
nuclear	O
forms	O
of	O
the	O
receptor	B-protein
complex	I-protein
and	O
temperature-sensitive	O
translocation	O
of	O
cytosol	O
forms	O
to	O
nuclear	O
forms	O
were	O
shown	O
.	O

at	O
00	O
degrees	O
c	O
the	O
predominant	O
form	O
of	O
the	O
hormone-receptor	O
complex	O
was	O
nuclear	O
.	O

these	O
results	O
demonstrate	O
that	O
corticosteroids	O
interact	O
with	O
macrophages	B-cell_type
at	O
physiological	O
concentrations	O
.	O

###MEDLINE:94081368

nitric	O
oxide	O
signaling	O
:	O
a	O
possible	O
role	O
for	O
g	B-protein
proteins	I-protein
.	O

we	O
have	O
previously	O
reported	O
various	O
inductive	O
effects	O
of	O
nitric	O
oxide	O
on	O
human	B-cell_type
pbmc	I-cell_type
.	O

we	O
describe	O
a	O
novel	O
and	O
potentially	O
important	O
mechanism	O
of	O
nitric	B-protein
oxide	I-protein
signaling-through	I-protein
direct	O
activation	O
of	O
guanine	B-protein
nucleotide-binding	I-protein
proteins	I-protein
(	O
g	B-protein
proteins	I-protein
)	O
.	O

we	O
have	O
found	O
that	O
nitric	O
oxide	O
treatment	O
of	O
membranes	O
isolated	O
from	O
fresh	B-cell_type
human	I-cell_type
pbmc	I-cell_type
enhances	O
the	O
ability	O
of	O
these	O
membranes	O
to	O
hydrolyze	O
[	O
gamma-00p	O
]	O
gtp	O
and	O
bind	O
[	O
gamma-00s	O
]	O
gtp	O
.	O

in	O
addition	O
,	O
treatment	O
of	O
whole	B-cell_type
cells	I-cell_type
with	O
nitric	O
oxide	O
yielded	O
membranes	O
with	O
enhanced	O
gtpase	B-protein
activity	O
.	O

furthermore	O
,	O
the	O
gtpase	B-protein
activity	O
of	O
pure	B-protein
,	I-protein
recombinant	I-protein
gs	I-protein
alpha	I-protein
,	O
gi	B-protein
alpha	I-protein
0	I-protein
,	O
and	O
p00ras	B-protein
was	O
greatly	O
enhanced	O
by	O
nitric	O
oxide	O
.	O

in	O
support	O
of	O
the	O
existence	O
of	O
this	O
pathway	O
in	O
whole	B-cell_type
cells	I-cell_type
,	O
we	O
found	O
that	O
the	O
g	B-protein
protein	I-protein
inhibitor	I-protein
,	O
gdp-beta-s	O
,	O
blocked	O
nf-kappa	B-protein
b	I-protein
translocation	O
induced	O
by	O
nitric	O
oxide	O
or	O
lps	O
in	O
permeabilized	B-cell_type
cells	I-cell_type
.	O

in	O
addition	O
,	O
nitric	O
oxide	O
greatly	O
reduced	O
the	O
pertussis	B-protein
toxin-mediated	I-protein
adp-ribosylation	I-protein
of	O
00-	O
and	O
00-kda	B-protein
proteins	I-protein
in	O
membranes	O
of	O
these	O
cells	O
.	O

because	O
g	B-protein
proteins	I-protein
play	O
a	O
central	O
role	O
in	O
many	O
diverse	O
signaling	O
systems	O
,	O
activation	O
by	O
an	O
endogenous	O
and	O
inducible	O
oxidant	O
may	O
represent	O
a	O
novel	O
signaling	O
pathway	O
.	O

###MEDLINE:94067100

the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
promoter	I-DNA
cis-acting	I-DNA
element	I-DNA
cle0	B-DNA
mediates	O
induction	O
signals	O
in	O
t	B-cell_type
cells	I-cell_type
and	O
is	O
recognized	O
by	O
factors	O
related	O
to	O
ap0	B-protein
and	O
nfat	B-protein
.	O

expression	O
of	O
the	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
gm-csf	B-DNA
)	I-DNA
gene	I-DNA
in	O
t	B-cell_type
cells	I-cell_type
is	O
activated	O
by	O
the	O
combination	O
of	O
phorbol	O
ester	O
(	O
phorbol	O
myristate	O
acetate	O
)	O
and	O
calcium	O
ionophore	O
(	O
a00000	O
)	O
,	O
which	O
mimic	O
antigen	O
stimulation	O
through	O
the	O
t-cell	B-protein
receptor	I-protein
.	O

we	O
have	O
previously	O
shown	O
that	O
a	O
fragment	O
containing	O
bp	B-DNA
-00	I-DNA
to	I-DNA
+00	I-DNA
of	O
the	O
mouse	B-DNA
gm-csf	I-DNA
promoter	I-DNA
can	O
confer	O
inducibility	O
to	O
reporter	B-DNA
genes	I-DNA
in	O
the	O
human	B-cell_line
jurkat	I-cell_line
t-cell	I-cell_line
line	I-cell_line
.	O

here	O
we	O
use	O
an	O
in	O
vitro	O
transcription	O
system	O
to	O
demonstrate	O
that	O
a	O
cis-acting	B-DNA
element	I-DNA
(	O
positions	B-DNA
-00	I-DNA
to	O
-00	O
)	O
,	O
referred	O
to	O
as	O
cle0	B-DNA
,	O
is	O
a	O
target	O
for	O
the	O
induction	O
signals	O
.	O

we	O
observed	O
induction	O
with	O
templates	O
containing	O
intact	O
cle0	B-DNA
but	O
not	O
with	O
templates	O
with	O
deleted	O
or	O
mutated	O
cle0	B-DNA
.	O

we	O
also	O
observed	O
that	O
two	O
distinct	O
signals	O
were	O
required	O
for	O
the	O
stimulation	O
through	O
cle0	B-DNA
,	O
since	O
only	O
extracts	O
from	O
cells	O
treated	O
with	O
both	O
phorbol	O
myristate	O
acetate	O
and	O
a00000	O
supported	O
optimal	O
induction	O
.	O

stimulation	O
probably	O
was	O
mediated	O
by	O
cle0-binding	B-protein
proteins	I-protein
because	O
depletion	O
of	O
these	O
proteins	O
specifically	O
reduced	O
gm-csf	B-protein
transcription	O
.	O

one	O
of	O
the	O
binding	B-protein
factors	I-protein
possessed	O
biochemical	O
and	O
immunological	O
features	O
identical	O
to	O
those	O
of	O
the	O
transcription	B-protein
factor	I-protein
ap0	B-protein
.	O

another	O
factor	O
resembled	O
the	O
t-cell-specific	B-protein
factor	I-protein
nfat	B-protein
.	O

the	O
characteristics	O
of	O
these	O
two	O
factors	O
are	O
consistent	O
with	O
their	O
involvement	O
in	O
gm-csf	B-protein
induction	O
.	O

the	O
presence	O
of	O
cle0-like	B-DNA
elements	I-DNA
in	O
the	O
promoters	O
of	O
interleukin-0	B-protein
(	O
il-0	B-protein
)	O
,	O
il-0	B-protein
,	O
il-0	B-protein
,	O
gm-csf	B-protein
,	O
and	O
nfat	B-DNA
sites	I-DNA
in	O
the	O
il-0	B-DNA
promoter	I-DNA
suggests	O
that	O
the	O
factors	O
we	O
detected	O
,	O
or	O
related	O
factors	O
that	O
recognize	O
these	O
sites	O
,	O
may	O
account	O
for	O
the	O
coordinate	O
induction	O
of	O
these	O
genes	O
during	O
t-cell	O
activation	O
.	O

###MEDLINE:94019377

identification	O
and	O
characterization	O
of	O
an	O
alu-containing	B-DNA
,	I-DNA
t-cell-specific	I-DNA
enhancer	I-DNA
located	O
in	O
the	O
last	O
intron	O
of	O
the	O
human	B-DNA
cd0	I-DNA
alpha	I-DNA
gene	I-DNA
.	O

expression	O
of	O
the	O
human	B-DNA
cd0	I-DNA
alpha	I-DNA
gene	I-DNA
is	O
restricted	O
to	O
cells	O
of	O
the	O
lymphoid	B-cell_type
lineage	I-cell_type
and	O
developmentally	O
regulated	O
during	O
thymopoiesis	O
.	O

as	O
an	O
initial	O
step	O
towards	O
understanding	O
the	O
molecular	O
basis	O
for	O
tissue-specific	O
expression	O
of	O
this	O
gene	O
,	O
we	O
surveyed	O
the	O
surrounding	O
chromatin	O
structure	O
for	O
potential	O
cis-acting	B-DNA
regulatory	I-DNA
regions	I-DNA
by	O
dnase	B-protein
i	I-protein
hypersensitivity	O
mapping	O
and	O
found	O
four	O
hypersensitive	B-DNA
sites	I-DNA
,	O
three	O
of	O
which	O
were	O
t	B-cell_type
cell	I-cell_type
restricted	O
.	O

by	O
using	O
a	O
reporter-based	O
expression	O
approach	O
,	O
a	O
t-cell-specific	B-DNA
enhancer	I-DNA
was	O
identified	O
by	O
its	O
close	O
association	O
with	O
a	O
prominent	O
t-cell-restricted	B-DNA
hypersensitive	I-DNA
sites	I-DNA
in	O
the	O
last	O
intron	O
of	O
the	O
cd0	B-DNA
alpha	I-DNA
gene	I-DNA
.	O

deletion	O
studies	O
demonstrated	O
that	O
the	O
minimal	B-DNA
enhancer	I-DNA
is	O
adjacent	O
to	O
a	O
negative	B-DNA
regulatory	I-DNA
element	I-DNA
.	O

dna	O
sequence	O
analysis	O
of	O
the	O
minimal	B-DNA
enhancer	I-DNA
revealed	O
a	O
striking	O
cluster	O
of	O
consensus	B-DNA
binding	I-DNA
sites	I-DNA
for	O
ets-0	B-protein
,	O
tcf-0	B-protein
,	O
cre	B-DNA
,	O
gata-0	B-protein
,	O
lyf-0	O
,	O
and	O
bhlh	B-protein
proteins	I-protein
which	O
were	O
verified	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

in	O
addition	O
,	O
the	O
0	B-DNA
'	I-DNA
end	I-DNA
of	O
the	O
enhancer	O
was	O
composed	O
of	O
an	O
alu	B-DNA
repeat	I-DNA
which	O
contained	O
the	O
gata-0	B-protein
,	O
bhlh	B-protein
,	O
and	O
lyf-0	B-DNA
binding	I-DNA
sites	I-DNA
.	O

site-directed	O
mutation	O
of	O
the	O
ets-0	B-DNA
and	I-DNA
gata-0	I-DNA
sites	I-DNA
dramatically	O
reduced	O
enhancer	O
activity	O
.	O

the	O
functional	O
importance	O
of	O
the	O
other	O
binding	O
sites	O
only	O
became	O
apparent	O
when	O
combinations	O
of	O
mutations	O
were	O
analyzed	O
.	O

taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
human	B-DNA
cd0	I-DNA
alpha	I-DNA
gene	I-DNA
is	O
regulated	O
by	O
the	O
interaction	O
of	O
multiple	B-protein
t-cell	I-protein
nuclear	I-protein
proteins	I-protein
with	O
a	O
transcriptional	B-DNA
enhancer	I-DNA
located	O
in	O
the	O
last	O
intron	O
of	O
the	O
gene	O
.	O

comparison	O
of	O
the	O
cd0	B-DNA
alpha	I-DNA
enhancer	I-DNA
with	O
other	O
recently	O
identified	O
t-cell-specific	B-DNA
regulatory	I-DNA
elements	I-DNA
suggests	O
that	O
a	O
common	O
set	O
of	O
transcription	B-protein
factors	I-protein
regulates	O
several	O
t-cell	B-DNA
genes	I-DNA
.	O

###MEDLINE:94045455

molecular	O
regulation	O
of	O
the	O
human	B-DNA
il-0	I-DNA
gene	I-DNA
:	O
inducible	O
t	O
cell-restricted	O
expression	O
requires	O
intact	O
ap-0	B-protein
and	O
elf-0	B-protein
nuclear	B-protein
protein	I-protein
binding	I-protein
sites	I-protein
.	O

interleukin	B-protein
0	I-protein
(	O
il-0	B-protein
)	O
is	O
a	O
hematopoietic	B-protein
stem-cell	I-protein
growth	I-protein
and	I-protein
differentiation	I-protein
factor	I-protein
that	O
is	O
expressed	O
solely	O
in	O
activated	B-cell_type
t	I-cell_type
and	I-cell_type
nk	I-cell_type
cells	I-cell_type
.	O

studies	O
to	O
date	O
have	O
identified	O
elements	O
0	O
'	O
to	O
the	O
il-0	B-DNA
coding	I-DNA
sequences	I-DNA
that	O
regulate	O
its	O
transcription	O
,	O
but	O
the	O
sequences	O
that	O
confer	O
t	O
cell-specific	O
expression	O
remain	O
to	O
be	O
clearly	O
defined	O
.	O

we	O
have	O
now	O
identified	O
dna	B-DNA
sequences	I-DNA
that	O
are	O
required	O
for	O
t	O
cell-restricted	O
il-0	B-DNA
gene	I-DNA
transcription	O
.	O

a	O
series	O
of	O
transient	O
transfections	O
performed	O
with	O
human	B-DNA
il-0-chloramphenicol	I-DNA
acetyltransferase	I-DNA
(	I-DNA
cat	I-DNA
)	I-DNA
reporter	I-DNA
plasmids	I-DNA
in	O
t	O
and	O
non-t	B-cell_type
cells	I-cell_type
revealed	O
that	O
a	O
plasmid	B-DNA
containing	O
000	B-DNA
bp	I-DNA
of	I-DNA
0	I-DNA
'	I-DNA
flanking	I-DNA
sequences	I-DNA
was	O
active	O
exclusively	O
in	O
t	B-cell_type
cells	I-cell_type
.	O

deletion	O
analysis	O
revealed	O
that	O
t	B-cell_type
cell	I-cell_type
specificity	O
was	O
conferred	O
by	O
a	O
00-bp	B-DNA
fragment	I-DNA
(	I-DNA
bp	I-DNA
-000	I-DNA
to	I-DNA
-000	I-DNA
)	O
that	O
included	O
a	O
potential	B-DNA
binding	I-DNA
site	I-DNA
for	O
ap-0	B-protein
transcription	I-protein
factors	I-protein
0	B-DNA
bp	I-DNA
upstream	I-DNA
of	O
a	O
binding	B-DNA
site	I-DNA
for	O
elf-0	B-protein
,	O
a	O
member	O
of	O
the	O
ets	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O

dnasei	B-protein
footprint	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
analyses	O
performed	O
with	O
mla-000	B-cell_type
t	I-cell_type
cell	I-cell_type
nuclear	O
extracts	O
demonstrated	O
that	O
this	O
00-bp	B-DNA
region	I-DNA
contains	O
a	O
nuclear	B-protein
protein	I-protein
binding	I-protein
region	I-protein
that	O
includes	O
consensus	B-DNA
ap-0	I-DNA
and	I-DNA
elf-0	I-DNA
binding	I-DNA
sites	I-DNA
.	O

in	O
addition	O
,	O
extracts	O
prepared	O
from	O
purified	B-cell_type
human	I-cell_type
t	I-cell_type
cells	I-cell_type
contained	O
proteins	O
that	O
bound	O
to	O
synthetic	O
oligonucleotides	O
corresponding	O
to	O
the	O
ap-0	B-DNA
and	I-DNA
elf-0	I-DNA
binding	I-DNA
sites	I-DNA
.	O

in	O
vitro-transcribed	B-protein
and	I-protein
-translated	I-protein
elf-0	I-protein
protein	I-protein
bound	O
specifically	O
to	O
the	O
elf-0	B-DNA
site	I-DNA
,	O
and	O
elf-0	B-protein
antisera	O
competed	O
and	O
super	B-protein
shifted	I-protein
nuclear	I-protein
protein	I-protein
complexes	I-protein
present	O
in	O
mla-000	O
nuclear	O
extracts	O
.	O

moreover	O
,	O
addition	O
of	O
anti-jun	B-protein
family	I-protein
antiserum	O
in	O
electrophoretic	O
mobility	O
shift	O
assay	O
reactions	O
completely	O
blocked	O
formation	O
of	O
the	O
ap-0-related	B-protein
complexes	I-protein
.	O

transient	O
transfection	O
studies	O
in	O
mla-000	B-cell_type
t	I-cell_type
cells	I-cell_type
revealed	O
that	O
constructs	O
containing	O
mutations	O
in	O
the	O
ap-0	B-DNA
site	I-DNA
almost	O
completely	O
abolished	O
cat	B-protein
activity	O
while	O
mutation	O
of	O
the	O
elf-0	B-DNA
site	I-DNA
or	O
the	O
nf-il-0	B-DNA
site	I-DNA
,	O
a	O
previously	O
described	O
nuclear	B-protein
protein	I-protein
binding	I-protein
site	I-protein
(	O
bp.	O
-000	O
to	O
-000	O
)	O
in	O
the	O
il-0	B-DNA
promoter	I-DNA
,	O
reduced	O
cat	B-protein
activity	O
to	O
<	O
00	O
%	O
of	O
the	O
activity	O
given	O
by	O
wild-type	B-DNA
constructs	I-DNA
.	O

we	O
conclude	O
that	O
expression	O
of	O
the	O
human	B-DNA
il-0	I-DNA
gene	I-DNA
requires	O
the	O
ap-0	B-DNA
and	I-DNA
elf-0	I-DNA
binding	I-DNA
sites	I-DNA
;	O
however	O
,	O
unlike	O
other	O
previously	O
characterized	O
cytokine	B-DNA
genes	I-DNA
such	O
as	O
il-0	B-protein
,	O
the	O
ap-0	B-protein
and	I-protein
elf-0	I-protein
factors	I-protein
can	O
bind	O
independently	O
in	O
the	O
il-0	B-DNA
gene	I-DNA
.	O

(	O
abstract	O
truncated	O
at	O
000	O
words	O
)	O

###MEDLINE:93389174

combination	O
il-0	B-protein
and	O
il-0	B-protein
reduces	O
glucocorticoid	B-protein
receptor-binding	I-protein
affinity	O
and	O
t	B-cell_type
cell	I-cell_type
response	O
to	O
glucocorticoids	O
.	O

the	O
mechanisms	O
contributing	O
to	O
persistent	O
t	O
cell	O
activation	O
and	O
poor	O
response	O
to	O
glucocorticoids	O
in	O
chronic	O
inflammatory	O
illnesses	O
such	O
as	O
steroid	O
resistant	O
(	O
sr	B-protein
)	O
asthma	O
are	O
poorly	O
defined	O
.	O

we	O
examined	O
the	O
possibility	O
that	O
certain	O
cytokines	B-protein
,	O
specifically	O
il-0	B-protein
and	O
il-0	B-protein
,	O
could	O
affect	O
t	O
cell	O
response	O
to	O
glucocorticoids	O
.	O

a	O
[	O
0h	O
]	O
dexamethasone	O
radioligand-binding	O
assay	O
was	O
used	O
to	O
measure	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
gr	B-protein
)	O
and	O
dissociation	O
constant	O
(	O
kd	O
)	O
in	O
pbmc	B-cell_type
from	O
normal	O
donors	O
and	O
patients	O
with	O
sr	O
asthma	O
,	O
cultured	O
in	O
the	O
absence	O
and	O
presence	O
of	O
these	O
cytokines	B-protein
.	O

pbmc	B-cell_type
from	O
normal	O
donors	O
incubated	O
for	O
00	O
h	O
in	O
the	O
presence	O
of	O
combination	O
il-0	B-protein
+	O
il-0	B-protein
had	O
nuclear	O
gr	O
with	O
significantly	O
reduced	O
binding	O
affinity	O
(	O
gr	B-protein
kd	O
=	O
00.0	O
+/-	O
0.00	O
nm	O
,	O
mean	O
+/-	O
sem	O
;	O
p	O
=	O
0.0000	O
)	O
as	O
compared	O
with	O
pbmc	B-cell_type
incubated	O
with	O
medium	O
alone	O
(	O
gr	B-protein
kd	O
=	O
0.00	O
+/-	O
0.00	O
nm	O
)	O
.	O

the	O
cytosolic	B-protein
gr	I-protein
kd	O
remained	O
unchanged	O
.	O

however	O
,	O
when	O
pbmc	B-cell_type
were	O
incubated	O
with	O
il-0	B-protein
alone	O
or	O
il-0	B-protein
alone	O
,	O
no	O
change	O
in	O
gr-binding	O
affinity	O
was	O
observed	O
.	O

furthermore	O
,	O
when	O
t	B-cell_type
cells	I-cell_type
and	O
non-t	B-cell_type
cells	I-cell_type
were	O
individually	O
stimulated	O
with	O
combination	O
il-0	B-protein
+	O
il-0	B-protein
,	O
a	O
significant	O
reduction	O
in	O
gr-binding	O
affinity	O
was	O
observed	O
only	O
in	O
the	O
t	B-cell_line
cell	I-cell_line
population	I-cell_line
(	O
p	O
=	O
0.0000	O
)	O
.	O

the	O
il-0	B-protein
+	O
il-0-induced	O
alteration	O
in	O
pbmc	B-cell_type
gr	B-protein
kd	O
was	O
associated	O
with	O
an	O
increase	O
in	O
gr	B-protein
number	O
(	O
0000	O
+/-	O
000	O
vs	O
0000	O
+/-	O
000	O
sites/cell	O
;	O
p	O
=	O
0.0000	O
)	O
.	O

more	O
importantly	O
,	O
the	O
alteration	O
in	O
pbmc	B-cell_type
gr-binding	O
affinity	O
with	O
il-0	B-protein
+	O
il-0	B-protein
was	O
associated	O
with	O
a	O
functional	O
change	O
in	O
t	B-cell_type
cell	I-cell_type
response	O
to	O
methylprednisolone	O
mpn	O
,	O
i.e.	O
,	O
a	O
reduced	O
inhibitory	O
effect	O
of	O
mpn	O
on	O
pma/ionomycin-induced	O
t	O
cell	O
proliferation	O
.	O

these	O
effects	O
of	O
il-0	B-protein
+	O
il-0	B-protein
on	O
pbmc	B-cell_type
gr	B-protein
affinity	O
and	O
response	O
to	O
mpn	O
were	O
blocked	O
by	O
co-incubation	O
with	O
ifn-gamma	B-protein
.	O

freshly	O
isolated	O
pbmc	B-cell_type
from	O
four	O
patients	O
with	O
sr	O
asthma	O
had	O
a	O
significantly	O
reduced	O
gr-binding	O
affinity	O
(	O
kd	O
=	O
00.0	O
+/-	O
0.00	O
nm	O
;	O
p	O
=	O
0.0000	O
)	O
when	O
compared	O
with	O
seven	O
normal	O
subjects	O
(	O
0.00	O
+/-	O
0.00	O
nm	O
)	O
.	O

the	O
altered	O
pbmc	B-cell_type
gr	B-protein
binding	O
from	O
patients	O
with	O
sr	O
asthma	O
reversed	O
to	O
normal	O
when	O
incubated	O
with	O
medium	O
alone	O
,	O
but	O
was	O
sustained	O
with	O
il-0	B-protein
+	O
il-0	B-protein
.	O

these	O
observations	O
suggest	O
that	O
with	O
persistent	O
inflammation	O
certain	O
cytokines	B-protein
may	O
contribute	O
to	O
an	O
impaired	O
response	O
to	O
glucocorticoids	O
.	O

furthermore	O
,	O
the	O
effects	O
of	O
il-0	B-protein
and	O
il-0	B-protein
were	O
blocked	O
by	O
ifn-gamma	B-protein
.	O

###MEDLINE:93361522

characterization	O
of	O
the	O
human	B-DNA
cd0	I-DNA
gene	I-DNA
promoter	I-DNA
:	O
transcription	O
from	O
the	O
cd0	B-DNA
gene	I-DNA
core	I-DNA
promoter	I-DNA
is	O
tissue-specific	O
and	O
is	O
activated	O
by	O
ets	B-protein
proteins	I-protein
.	O

we	O
analyzed	O
the	O
0	B-DNA
'	I-DNA
transcription	I-DNA
control	I-DNA
sequences	I-DNA
of	O
the	O
human	B-DNA
cd0	I-DNA
gene	I-DNA
.	O

we	O
located	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
and	O
showed	O
that	O
the	O
cd0	B-DNA
core	I-DNA
promoter	I-DNA
(	O
positions	B-DNA
-00	I-DNA
to	I-DNA
+00	I-DNA
)	O
lacks	O
a	O
classical	O
``	O
tata	B-DNA
''	I-DNA
or	O
initiator	O
positioning	O
consensus	B-DNA
sequence	I-DNA
but	O
directs	O
precise	O
and	O
efficient	O
transcription	O
when	O
coupled	O
to	O
the	O
ubiquitously	B-DNA
active	I-DNA
simian	I-DNA
virus	I-DNA
00	I-DNA
enhancer	I-DNA
.	O

the	O
transcriptional	O
activity	O
of	O
the	O
cd0	B-DNA
gene	I-DNA
promoter	I-DNA
correlated	O
with	O
cd0	B-protein
expression	O
in	O
various	O
cell	O
types	O
.	O

interestingly	O
,	O
the	O
cd0	B-DNA
core	I-DNA
promoter	I-DNA
also	O
displayed	O
a	O
tissue-specific	O
transcriptional	O
activity	O
.	O

within	O
this	O
fragment	O
,	O
three	O
nucleic	O
acid	O
sequences	O
are	O
completely	O
conserved	O
in	O
the	O
murine	B-DNA
cd0	I-DNA
gene	I-DNA
.	O

one	O
of	O
these	O
sequences	O
contains	O
a	O
perfect	B-DNA
ets	I-DNA
consensus	I-DNA
sequence	I-DNA
.	O

another	O
ets	B-DNA
consensus	I-DNA
sequence	I-DNA
is	O
located	O
0000	O
nt	B-DNA
upstream	I-DNA
.	O

electrophoretic-mobility-shift	O
assays	O
showed	O
that	O
the	O
core	B-DNA
promoter	I-DNA
ets	I-DNA
motif	I-DNA
binds	O
an	O
ets-related	B-protein
protein	I-protein
specifically	O
expressed	O
at	O
high	O
levels	O
in	O
cd0+	B-cell_type
cells	I-cell_type
.	O

moreover	O
,	O
in	O
cd0-	B-cell_type
cells	I-cell_type
,	O
overexpression	O
of	O
ets-0	B-protein
or	O
ets-0	B-protein
efficiently	O
and	O
specifically	O
activated	O
transcription	O
from	O
the	O
cd0	B-DNA
promoter	I-DNA
and	I-DNA
core	I-DNA
promoter	I-DNA
.	O

these	O
data	O
indicate	O
that	O
ets	B-protein
transcription	I-protein
factors	I-protein
play	O
a	O
central	O
role	O
in	O
controlling	O
cd0	B-DNA
gene	I-DNA
expression	O
,	O
by	O
binding	O
to	O
both	O
a	O
classical	O
remote	B-DNA
site	I-DNA
and	O
an	O
unusual	O
proximal	B-DNA
activator	I-DNA
sequence	I-DNA

###MEDLINE:81093967

glucocorticoid	B-protein
receptor	I-protein
activation	O
and	O
inactivation	O
in	O
c	O
ultured	O
human	B-cell_type
lymphocytes	I-cell_type
.	O

although	O
glucocorticoids	O
are	O
not	O
cytolytic	O
for	O
and	O
do	O
not	O
inhibit	O
the	O
growth	O
of	O
the	O
im-0	B-cell_line
line	I-cell_line
of	O
cultured	B-cell_line
human	I-cell_line
lymphoblasts	I-cell_line
,	O
these	O
cells	O
have	O
a	O
high	O
steroid-binding	O
capacity	O
.	O

we	O
have	O
used	O
im-0	B-cell_line
cells	I-cell_line
in	O
order	O
to	O
examine	O
whether	O
unoccupied	B-protein
glucocorticoid	I-protein
receptors	I-protein
are	O
inactivated	O
and	O
activated	O
in	O
intact	B-cell_type
cells	I-cell_type
.	O

when	O
im-0	B-cell_line
cells	I-cell_line
are	O
incubated	O
in	O
glucose-free	O
medium	O
in	O
a	O
nitrogen	O
atmosphere	O
,	O
both	O
their	O
ability	O
to	O
bind	O
triamcinolone	O
acetonide	O
and	O
their	O
atp	O
levels	O
decline	O
and	O
,	O
when	O
glucose	O
and	O
oxygen	O
are	O
reintroduced	O
,	O
atp	O
levels	O
and	O
receptor	O
activity	O
return	O
.	O

the	O
specific	O
glucocorticoid-binding	O
activity	O
of	O
cytosol	O
prepared	O
from	O
cells	O
exposed	O
to	O
various	O
degrees	O
of	O
energy	O
limitation	O
is	O
directly	O
correlated	O
with	O
the	O
atp	O
content	O
.	O

receptor	O
activation	O
in	O
intact	B-cell_type
cells	I-cell_type
is	O
rapid	O
and	O
independent	O
of	O
protein	O
synthesis	O
.	O

cytosol	O
prepared	O
from	O
inactivated	O
cells	O
can	O
not	O
be	O
activated	O
by	O
addition	O
of	O
atp	O
.	O

the	O
inactivation	O
of	O
glucocorticoid	B-protein
receptors	I-protein
that	O
occurs	O
when	O
cytosol	O
from	O
normal	B-cell_line
im-0	I-cell_line
cells	I-cell_line
is	O
incubated	O
at	O
00	O
degrees	O
c	O
is	O
inhibited	O
by	O
molybdate	O
,	O
vanadate	O
,	O
fluoride	O
,	O
atp	O
,	O
and	O
several	O
other	O
nucleotides	O
.	O

the	O
experiments	O
with	O
intact	B-cell_type
human	I-cell_type
lymphoblasts	I-cell_type
suggest	O
that	O
assays	O
of	O
specific	O
glucocorticoid-binding	O
capacity	O
do	O
not	O
necessarily	O
reflect	O
the	O
cellular	O
content	O
of	O
receptor	B-protein
protein	I-protein
.	O

###MEDLINE:80205384

glucocorticoids	O
and	O
lymphocytes	B-cell_type
.	O

ii	O
.	O

cell	O
cycle-dependent	O
changes	O
in	O
glucocorticoid	B-protein
receptor	I-protein
content	O
.	O

to	O
study	O
variations	O
in	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
during	O
the	O
cell	O
cycle	O
,	O
we	O
have	O
separated	O
mitogen-stimulated	B-cell_type
human	I-cell_type
peripheral	I-cell_type
lymphocytes	I-cell_type
and	O
rat	B-cell_type
lymph	I-cell_type
node	I-cell_type
cells	I-cell_type
by	O
unit	O
gravity	O
sedimentation	O
and	O
measured	O
glucocorticoid	O
binding	O
in	O
the	O
resultant	O
fractions	O
.	O

by	O
morphologic	O
criteria	O
and	O
thymidine	O
incorporation	O
,	O
the	O
fractions	O
were	O
separated	O
into	O
populations	O
of	O
g0	O
and	O
g0	O
phase	O
and	O
s	O
and	O
post-s	O
phase	O
cells	O
.	O

a	O
0-	O
to	O
0-fold	O
increase	O
in	O
glucocorticoid	B-protein
receptor	I-protein
sites	I-protein
per	O
cell	O
,	O
for	O
cells	O
in	O
the	O
s	O
and	O
post-s	O
phase	O
over	O
those	O
in	O
g0	O
and	O
g0	O
,	O
was	O
observed	O
with	O
both	O
nonstimulated	B-cell_type
rat	I-cell_type
lymph	I-cell_type
node	I-cell_type
cell	I-cell_type
suspensions	I-cell_type
and	O
concanavalin	O
a-stimulated	O
human	B-cell_type
peripheral	I-cell_type
lymphocytes	I-cell_type
.	O

these	O
observations	O
together	O
with	O
those	O
from	O
other	O
studies	O
indicate	O
that	O
formation	O
of	O
new	O
glucocorticoid	B-protein
receptors	I-protein
near	O
the	O
s	O
phase	O
may	O
be	O
a	O
general	O
phenomenon	O
in	O
proliferating	B-cell_type
cells	I-cell_type
.	O

we	O
propose	O
that	O
this	O
increase	O
in	O
glucocorticoid	B-protein
receptors	I-protein
during	O
the	O
cell	O
cycle	O
may	O
explain	O
the	O
increase	O
in	O
glucocorticoid	B-protein
receptors	I-protein
in	O
mitogen-stimulated	B-cell_type
lymphocytes	I-cell_type
.	O

###MEDLINE:79225924

the	O
leukocyte	O
migration	O
inhibition	O
response	O
to	O
certain	O
breast	O
cancer-related	B-protein
antigens	I-protein
(	O
mcf-0	B-protein
and	O
mumtv	B-protein
)	O
:	O
their	O
potential	O
as	O
discriminants	O
.	O

certain	O
oncogenic	O
viruses	O
have	O
been	O
implicated	O
in	O
human	O
breast	O
cancer	O
,	O
including	O
the	O
murine	B-DNA
mammary	I-DNA
tumor	I-DNA
virus	I-DNA
(	I-DNA
mumtv	I-DNA
)	O
and	O
the	O
mason-pfizer	B-protein
monkey	I-protein
virus	I-protein
(	I-protein
mpmv	I-protein
)	O
.	O

we	O
have	O
used	O
the	O
leukocyte	O
migration	O
inhibition	O
(	O
lmi	B-protein
)	O
response	O
to	O
assay	O
the	O
response	O
to	O
several	O
potential	O
breast	O
cancer-related	B-protein
antigens	I-protein
,	O
including	O
mumtv	B-protein
,	O
mpmv	O
,	O
and	O
a	O
breast	O
cancer	O
cultured	B-cell_line
cell	I-cell_line
line	I-cell_line
,	I-cell_line
mcf-0	I-cell_line
,	O
in	O
00	O
breast	O
cancer	O
patients	O
,	O
in	O
00	O
women	O
with	O
benign	O
breast	O
disease	O
,	O
and	O
in	O
00	O
normal	O
women	O
.	O

the	O
lowest	O
tenth	O
percentile	O
of	O
control	O
(	O
lmi	B-protein
)	O
responses	O
was	O
used	O
as	O
the	O
cutoff	O
point	O
to	O
designate	O
responders	O
.	O

breast	O
cancer	O
patients	O
showed	O
significant	O
responses	O
to	O
mumtv	O
(	O
00	O
%	O
and	O
to	O
mcf-0	O
(	O
00	O
%	O
)	O
,	O
but	O
not	O
to	O
mpmv	O
(	O
00	O
%	O
)	O
.	O

in	O
a	O
paired-antigen	O
study	O
using	O
mumtv	B-cell_line
and	I-cell_line
mcf-0	I-cell_line
,	O
00	O
%	O
of	O
the	O
breast	O
cancer	O
patients	O
responded	O
,	O
versus	O
00	O
%	O
of	O
the	O
normal	O
women	O
(	O
p	O
less	O
than	O
0.0000	O
)	O
.	O

the	O
potential	O
for	O
this	O
assay	O
to	O
distinguish	O
``	O
normal	O
''	O
from	O
``	O
breast	O
cancer	O
''	O
was	O
analyzed	O
using	O
a	O
migration	O
index	O
derived	O
from	O
discriminant	O
analysis	O
.	O

the	O
ability	O
of	O
the	O
assay	O
to	O
discriminate	O
``	O
normal	O
''	O
from	O
``	O
cancer	O
''	O
was	O
significant	O
(	O
p	O
less	O
than	O
0.000	O
)	O
and	O
showed	O
a	O
sensitivity	O
of	O
detecting	O
``	O
cancer	O
''	O
of	O
00	O
%	O
.	O

the	O
overall	O
responses	O
to	O
mumtv	B-cell_line
and	I-cell_line
mcf-0	I-cell_line
were	O
analyzed	O
with	O
reference	O
to	O
certain	O
prognostic	O
factors	O
,	O
but	O
showed	O
no	O
relation	O
to	O
age	O
,	O
menstrual	O
status	O
,	O
estrogen	B-protein
receptor	I-protein
status	O
,	O
or	O
stage	O
of	O
disease	O
.	O

the	O
above	O
reactions	O
suggest	O
that	O
a	O
large	O
proportion	O
of	O
breast	O
cancer	O
patients	O
exhibit	O
presensitization	O
to	O
antigenfs	O
found	O
in	O
mumtv	B-cell_line
and	I-cell_line
mcf-0	I-cell_line
,	O
which	O
may	O
be	O
cross-reactive	O
with	O
antigens	O
in	O
the	O
primary	O
cancer	O
.	O

these	O
responses	O
appear	O
to	O
be	O
independent	O
of	O
major	O
prognostic	O
variables	O
.	O

further	O
refinement	O
of	O
this	O
assay	O
may	O
yield	O
one	O
which	O
is	O
more	O
highly	O
discriminating	O
for	O
breast	O
cancer	O
.	O

###MEDLINE:78165928

chronic	O
lymphatic	O
leukaemia	O
:	O
cellular	O
effects	O
of	O
glucocorticoids	O
in	O
vitro	O
.	O

glucocorticoid	B-protein
receptor	I-protein
levels	O
and	O
steroid	O
induced	O
inhibition	O
of	O
nucleic	O
acid	O
precursors	O
have	O
been	O
examined	O
in	O
lymphocytes	B-cell_type
from	O
00	O
patients	O
at	O
different	O
stages	O
of	O
chronic	O
lymphatic	O
leukaemia	O
.	O

no	O
correlation	O
can	O
be	O
found	O
between	O
the	O
level	O
of	O
glucocorticoid	B-protein
receptors	I-protein
and	O
the	O
stage	O
of	O
the	O
disease	O
.	O

on	O
the	O
other	O
hand	O
,	O
a	O
significant	O
difference	O
(	O
p	O
less	O
than	O
0.00	O
)	O
was	O
found	O
between	O
stage	O
o	O
and	O
stage	O
iii/iv	O
patients	O
,	O
in	O
terms	O
of	O
the	O
in	O
vitro	O
effect	O
of	O
dexamethasone	O
on	O
[	O
0h	O
]	O
uridine	O
incorporation	O
.	O

###MEDLINE:94081349

pyrrolidine	O
dithiocarbamate	O
inhibits	O
nf-kappa	B-protein
b	I-protein
mobilization	O
and	O
tnf	B-protein
production	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

the	O
human	B-DNA
tnf	I-DNA
promoter	I-DNA
contains	O
four	O
potential	O
nuclear	B-protein
factor-kappa	I-protein
b	I-protein
(	O
nf-kappa	B-protein
b	I-protein
)	I-protein
-binding	I-protein
sites	I-protein
,	O
with	O
the	O
strongest	O
binding	O
seen	O
for	O
the	O
-000	B-DNA
motif	I-DNA
.	O

nuclear	O
extracts	O
from	O
unstimulated	B-cell_type
cells	I-cell_type
of	O
the	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
mono	B-cell_line
mac	I-cell_line
0	I-cell_line
,	O
contain	O
one	O
specific	B-protein
binding	I-protein
protein	I-protein
(	I-protein
complex	I-protein
ii	O
)	O
,	O
consistent	O
with	O
a	O
constitutive	O
p00	B-protein
homodimer	I-protein
.	O

stimulation	O
of	O
mono	B-cell_line
mac	I-cell_line
0	I-cell_line
cells	I-cell_line
with	O
lps	O
will	O
increase	O
complex	B-protein
ii	I-protein
and	O
will	O
strongly	O
induce	O
a	O
second	O
specific	B-protein
complex	I-protein
(	O
complex	B-protein
i	I-protein
)	O
,	O
which	O
represents	O
the	O
p00/00	B-protein
heterodimer	I-protein
.	O

treatment	O
of	O
mono	B-cell_line
mac	I-cell_line
0	I-cell_line
cells	I-cell_line
with	O
pyrrolidine-dithiocarbamate	B-protein
(	O
pdtc	O
)	O
at	O
000	O
microm	O
will	O
block	O
the	O
lps-induced	B-protein
complex	I-protein
i	I-protein
almost	O
completely	O
and	O
will	O
reduce	O
complex	B-protein
ii	I-protein
to	O
the	O
constitutive	O
level	O
.	O

binding	O
activity	O
of	O
other	O
nuclear	B-protein
factors	I-protein
that	O
recognize	O
the	O
sp-0	B-DNA
and	I-DNA
c/ebp	I-DNA
motifs	I-DNA
of	O
the	O
human	B-DNA
tnf	I-DNA
promoter	I-DNA
is	O
not	O
affected	O
by	O
such	O
treatment	O
.	O

northern	O
blot	O
analysis	O
demonstrates	O
that	O
pdtc	O
treatment	O
will	O
strongly	O
reduce	O
lps-induced	O
tnf	B-RNA
transcripts	I-RNA
.	O

secreted	O
tnf	B-protein
protein	I-protein
as	O
detected	O
in	O
the	O
wehi	O
000s/actd	O
bioassay	O
and	O
in	O
a	O
sandwich	O
immunoassay	O
was	O
similarly	O
reduced	O
by	O
pdtc	O
.	O

kinetic	O
analyses	O
show	O
that	O
after	O
lps	O
stimulation	O
,	O
nf-kappa	B-protein
b	I-protein
will	O
peak	O
at	O
0	O
h	O
,	O
tnf	B-RNA
transcript	I-RNA
prevalence	O
at	O
0	O
h	O
,	O
and	O
tnf	B-protein
protein	I-protein
at	O
0	O
h	O
.	O

pdtc	O
did	O
not	O
shift	O
this	O
response	O
to	O
lps	O
to	O
a	O
later	O
time	O
,	O
but	O
suppressed	O
nf-kappa	B-protein
b	I-protein
mobilization	O
,	O
tnf	B-RNA
transcripts	I-RNA
,	O
and	O
tnf	B-protein
protein	I-protein
over	O
the	O
entire	O
0-h	O
observation	O
period	O
.	O

analysis	O
of	O
freshly	B-cell_type
isolated	I-cell_type
,	I-cell_type
lps-stimulated	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
showed	O
a	O
similar	O
blockade	O
of	O
nf-kappa	B-protein
b	I-protein
.	O

furthermore	O
,	O
in	O
these	O
primary	B-cell_type
cells	I-cell_type
,	O
induction	O
of	O
tnf	B-RNA
transcripts	I-RNA
,	O
as	O
determined	O
by	O
northern	O
blot	O
analysis	O
and	O
by	O
quantitative	O
polymerase	O
chain	O
reaction	O
,	O
was	O
prevented	O
by	O
pdtc	O
as	O
was	O
tnf	B-protein
protein	I-protein
production	O
.	O

these	O
data	O
show	O
that	O
dithiocarbamates	O
can	O
profoundly	O
affect	O
cytokine	B-protein
expression	O
and	O
suggest	O
that	O
nf-kappa	B-protein
b	I-protein
is	O
involved	O
in	O
lps-induced	O
tnf	B-DNA
gene	I-DNA
expression	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

###MEDLINE:94047364

comparing	O
regions	O
of	O
the	O
epstein-barr	B-protein
virus	I-protein
zebra	I-protein
protein	I-protein
which	O
function	O
as	O
transcriptional	O
activating	B-DNA
sequences	I-DNA
in	O
saccharomyces	O
cerevisiae	O
and	O
in	O
b	B-cell_type
cells	I-cell_type
.	O

the	O
zebra	B-protein
protein	I-protein
activates	O
expression	O
of	O
epstein-barr	B-DNA
virus	I-DNA
early-lytic-cycle	I-DNA
genes	I-DNA
in	O
human	B-cell_type
b	I-cell_type
lymphocytes	I-cell_type
.	O

here	O
it	O
is	O
shown	O
that	O
zebra	B-protein
also	O
behaves	O
as	O
a	O
sequence-specific	B-protein
transcriptional	I-protein
activator	I-protein
in	O
saccharomyces	O
cerevisiae	O
.	O

deletional	O
mutagenesis	O
defined	O
three	O
regions	O
of	O
zebra	B-protein
that	O
participate	O
in	O
activation	O
in	O
s.	O
cerevisiae	O
.	O

these	O
regions	O
are	O
designated	O
yi	B-protein
(	I-protein
amino	I-protein
acids	I-protein
[	I-protein
aa	I-protein
]	I-protein
0	I-protein
to	O
00	O
)	O
,	O
yii	O
(	O
aa	O
00	O
to	O
000	O
)	O
,	O
and	O
yiii	B-protein
(	I-protein
aa	I-protein
000	I-protein
to	O
000	O
)	O
.	O

two	O
of	O
the	O
three	O
regions	O
of	O
the	O
native	B-protein
zebra	I-protein
protein	I-protein
act	O
together	O
to	O
mediate	O
activation	O
when	O
assayed	O
on	O
zebra	B-DNA
binding	I-DNA
sites	I-DNA
.	O

however	O
,	O
when	O
fused	O
to	O
the	O
dna	B-DNA
binding	I-DNA
domain	I-DNA
of	O
gal	B-protein
0	I-protein
and	O
assayed	O
on	O
gal0	B-DNA
binding	I-DNA
sites	I-DNA
,	O
regions	O
yii	O
and	O
yiii	B-protein
were	O
each	O
sufficient	O
to	O
confer	O
activation	O
in	O
s.	O
cerevisiae	O
.	O

regions	O
of	O
zebra	B-protein
which	O
affected	O
activation	O
in	O
s.	O
cerevisiae	O
were	O
also	O
required	O
in	O
human	B-cell_type
b	I-cell_type
lymphocytes	I-cell_type
.	O

the	O
amino-terminal	B-protein
region	I-protein
of	O
zebra	B-protein
(	I-protein
aa	I-protein
0	I-protein
to	O
00	O
)	O
was	O
required	O
for	O
activation	O
both	O
in	O
s.	O
cerevisiae	O
and	O
in	O
human	B-cell_type
b	I-cell_type
cells	I-cell_type
;	O
deletion	O
of	O
the	O
carboxy-terminal	B-protein
00	I-protein
aa	O
also	O
significantly	O
reduced	O
activation	O
in	O
both	O
cell	O
types	O
.	O

thus	O
,	O
the	O
behavior	O
of	O
zebra	B-protein
in	O
human	B-cell_type
b	I-cell_type
cells	I-cell_type
and	O
s.	O
cerevisiae	O
suggests	O
that	O
the	O
protein	O
contains	O
universal	O
activation	O
motifs	O
that	O
interact	O
with	O
conserved	O
components	O
of	O
the	O
transcription	O
machinery	O
.	O

however	O
,	O
certain	O
deletion	O
mutants	O
of	O
zebra	B-protein
containing	O
mutations	O
in	O
the	O
n-terminal	B-protein
region	I-protein
exhibited	O
discordant	O
behaviors	O
in	O
s.	O
cerevisiae	O
and	O
in	O
b	B-cell_type
cells	I-cell_type
.	O

for	O
example	O
,	O
deletion	O
of	O
zebra	B-protein
aa	O
00	O
to	O
00	O
impaired	O
activation	O
to	O
a	O
great	O
extent	O
in	O
b	B-cell_type
cells	I-cell_type
but	O
had	O
little	O
or	O
no	O
effect	O
in	O
s.	O
cerevisiae	O
.	O

the	O
discordant	O
mutants	O
may	O
reflect	O
interactions	O
with	O
a	O
variable	B-protein
domain	I-protein
of	O
a	O
conserved	B-protein
component	I-protein
or	O
unique	O
interactions	O
with	O
specialized	O
components	O
of	O
the	O
basal	O
transcription	O
apparatus	O
in	O
different	O
cells	O
.	O

###MEDLINE:94019346

functional	O
interaction	O
of	O
the	O
v-rel	B-protein
and	I-protein
c-rel	I-protein
oncoproteins	I-protein
with	O
the	O
tata-binding	B-protein
protein	I-protein
and	O
association	O
with	O
transcription	B-protein
factor	I-protein
iib	I-protein
.	O

rel	B-protein
family	I-protein
proteins	I-protein
regulate	O
the	O
expression	O
of	O
genes	O
linked	O
to	O
kappa	B-DNA
b-binding	I-DNA
motifs	I-DNA
.	O

little	O
is	O
known	O
,	O
however	O
,	O
of	O
the	O
mechanism	O
by	O
which	O
they	O
enhance	O
transcription	O
.	O

we	O
have	O
investigated	O
the	O
ability	O
of	O
the	O
v-rel	B-protein
and	I-protein
c-rel	I-protein
oncoproteins	I-protein
to	O
interact	O
with	O
components	O
of	O
the	O
basal	O
transcription	O
machinery	O
.	O

here	O
we	O
report	O
that	O
both	O
the	O
acidic	B-protein
transcription	I-protein
activation	I-protein
domain	I-protein
mapping	O
to	O
the	O
unique	B-protein
c	I-protein
terminus	I-protein
of	O
chicken	B-protein
c-rel	I-protein
and	O
the	O
f0	B-DNA
cell-specific	I-DNA
activation	I-DNA
region	I-DNA
common	O
to	O
both	O
v-rel	B-protein
and	I-protein
c-rel	I-protein
interact	O
with	O
the	O
tata-binding	B-protein
protein	I-protein
(	O
tbp	B-protein
)	O
and	O
transcription	B-protein
factor	I-protein
iib	I-protein
(	O
tfiib	O
)	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

we	O
also	O
demonstrate	O
that	O
tpb	O
interaction	O
with	O
rel	B-protein
activation	I-protein
regions	I-protein
leads	O
to	O
synergistic	O
activation	O
of	O
transcription	O
of	O
a	O
kappa	B-DNA
b-linked	I-DNA
reporter	I-DNA
gene	I-DNA
.	O

combined	O
with	O
the	O
observation	O
that	O
the	O
mouse	B-DNA
c-rel	I-DNA
and	O
human	B-protein
rela	I-protein
proteins	I-protein
also	O
interact	O
with	O
tbp	B-protein
and	O
tfiib	O
in	O
vitro	O
,	O
these	O
results	O
suggest	O
that	O
association	O
with	O
basal	O
transcription	B-protein
factors	I-protein
is	O
important	O
for	O
the	O
transcriptional	O
activities	O
of	O
rel	B-protein
family	I-protein
proteins	I-protein
.	O

###MEDLINE:94045438

p00ras	B-protein
and	O
calcineurin	B-protein
synergize	O
to	O
regulate	O
the	O
nuclear	B-protein
factor	I-protein
of	O
activated	B-cell_type
t	I-cell_type
cells	I-cell_type
.	O

in	O
t	B-cell_type
lymphocytes	I-cell_type
,	O
triggering	O
of	O
the	O
t	B-protein
cell	I-protein
receptor	I-protein
(	O
tcr	B-protein
)	O
induces	O
several	O
signaling	O
cascades	O
which	O
ultimately	O
synergize	O
to	O
induce	O
the	O
activity	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	O
activated	B-cell_type
t	I-cell_type
cells	I-cell_type
(	O
nfat	B-protein
)	O
,	O
a	O
dna	B-protein
binding	I-protein
complex	I-protein
critical	O
to	O
the	O
inducibility	O
and	O
t	B-cell_type
cell	I-cell_type
specificity	O
of	O
the	O
t	B-protein
cell	I-protein
growth	I-protein
factor	I-protein
interleukin	I-protein
0	I-protein
.	O

one	O
immediate	O
consequence	O
of	O
t	B-cell_type
cell	I-cell_type
activation	O
via	O
the	O
tcr	B-protein
is	O
an	O
increase	O
in	O
cytosolic	O
calcium	O
.	O

calcium	O
signals	O
are	O
important	O
for	O
nfat	B-protein
induction	O
,	O
and	O
recent	O
studies	O
have	O
identified	O
calcineurin	B-protein
,	O
a	O
calcium-calmodulin	B-protein
dependent	I-protein
serine-threonine	I-protein
phosphatase	I-protein
,	O
as	O
a	O
prominent	O
component	O
of	O
the	O
calcium	O
signaling	O
pathway	O
in	O
t	B-cell_type
cells	I-cell_type
.	O

a	O
second	O
important	O
molecule	O
in	O
tcr	B-protein
signal	O
transduction	O
is	O
the	O
guanine	B-protein
nucleotide	I-protein
binding	I-protein
protein	I-protein
,	O
p00ras	B-protein
,	O
which	O
is	O
coupled	O
to	O
the	O
tcr	B-protein
by	O
a	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
dependent	O
mechanism	O
.	O

the	O
experiments	O
presented	O
here	O
show	O
that	O
expression	O
by	O
transfection	O
of	O
mutationally	O
activated	O
calcineurin	B-protein
or	O
activated	O
p00ras	B-protein
alone	O
is	O
insufficient	O
for	O
nfat	B-protein
transactivation	O
.	O

however	O
,	O
coexpression	O
of	O
the	O
activated	O
calcineurin	B-protein
with	O
activated	B-protein
p00ras	I-protein
could	O
mimic	O
tcr	B-protein
signals	O
in	O
nfat	B-protein
induction	O
.	O

these	O
data	O
identify	O
calcineurin	B-protein
and	O
p00ras	B-protein
as	O
cooperative	O
partners	O
in	O
t	B-cell_type
cell	I-cell_type
activation	O
.	O

###MEDLINE:94116450

expression	O
of	O
the	O
chicken	B-DNA
gata	I-DNA
factor	I-DNA
family	I-DNA
during	O
early	O
erythroid	O
development	O
and	O
differentiation	O
.	O

the	O
dna	B-DNA
motif	I-DNA
wgatar	B-DNA
has	O
been	O
identified	O
within	O
transcriptional	B-protein
regulatory	I-protein
domains	I-protein
of	O
globin	B-protein
and	O
other	O
erythroid-specific	B-DNA
genes	I-DNA
and	O
the	O
activator	B-protein
proteins	I-protein
that	O
bind	O
to	O
this	O
regulatory	B-DNA
element	I-DNA
,	O
the	O
gata	B-protein
factors	I-protein
,	O
belong	O
to	O
a	O
multi-gene	B-protein
family	I-protein
that	O
is	O
expressed	O
in	O
chicken	B-cell_type
erythroid	I-cell_type
cells	I-cell_type
.	O

here	O
we	O
show	O
that	O
,	O
as	O
in	O
chickens	O
,	O
multiple	O
members	O
of	O
the	O
gata	B-protein
factor	I-protein
family	I-protein
are	O
expressed	O
in	O
human	B-cell_type
and	I-cell_type
murine	I-cell_type
erythroid	I-cell_type
cells	I-cell_type
.	O

during	O
the	O
early	O
stages	O
of	O
chicken	O
embryogenesis	O
(	O
well	O
before	O
blood	O
island	O
formation	O
)	O
,	O
each	O
of	O
the	O
gata	B-protein
family	I-protein
members	I-protein
is	O
transcribed	O
with	O
a	O
unique	O
temporal	O
and	O
spatial	O
pattern	O
.	O

in	O
the	O
primitive	B-cell_type
erythroid	I-cell_type
lineage	I-cell_type
,	O
transcription	O
of	O
the	O
embryonic	B-DNA
epsilon-globin	I-DNA
gene	I-DNA
parallels	O
gata-0	B-protein
expression	O
while	O
the	O
switch	O
to	O
beta-globin	B-protein
transcription	O
in	O
definitive	O
erythroid	B-cell_type
cells	I-cell_type
is	O
directly	O
preceded	O
by	O
a	O
pronounced	O
increase	O
in	O
gata-0	B-protein
accumulation	O
.	O

the	O
timing	O
and	O
pattern	O
of	O
expression	O
of	O
these	O
different	O
mrnas	B-RNA
during	O
avian	O
erythroid	O
development	O
and	O
differentiation	O
suggests	O
that	O
temporally	O
regulated	O
changes	O
in	O
gata	B-protein
factor	I-protein
expression	O
are	O
required	O
for	O
vertebrate	O
hematopoiesis	O
.	O

###MEDLINE:93361521

molecular	O
regulation	O
of	O
human	O
interleukin	B-protein
0	I-protein
and	O
t-cell	O
function	O
by	O
interleukin	B-protein
0	I-protein
.	O

distinct	O
functional	O
t-cell	B-cell_type
subsets	I-cell_type
,	O
differing	O
in	O
the	O
patterns	O
of	O
lymphokines	B-protein
produced	O
,	O
regulate	O
cell-mediated	O
and	O
humoral	O
immune	O
responses	O
.	O

the	O
two	O
major	O
types	O
and	O
their	O
principal	O
products	O
,	O
interleukin	B-protein
0	I-protein
and	O
interferon	B-protein
gamma	I-protein
(	O
il-0	B-protein
and	O
ifn-gamma	B-protein
)	O
,	O
are	O
reciprocally	O
negatively	O
interactive	O
.	O

to	O
analyze	O
the	O
molecular	O
mechanism	O
of	O
il-0-mediated	O
suppression	O
of	O
cell-mediated	O
immunity	O
we	O
studied	O
its	O
effects	O
on	O
expression	O
of	O
interleukin	B-protein
0	I-protein
(	O
il-0	B-protein
)	O
and	O
ifn-gamma	B-protein
.	O

il-0	B-protein
pretreatment	O
of	O
jurkat	B-cell_line
cells	I-cell_line
prior	O
to	O
stimulation	O
resulted	O
in	O
a	O
decrease	O
in	O
transcription	O
of	O
the	O
il0	B-DNA
gene	I-DNA
.	O

il-0	B-protein
suppressed	O
il-0	B-protein
and	O
ifn-gamma	B-RNA
mrna	I-RNA
levels	O
in	O
primary	B-cell_type
human	I-cell_type
t	I-cell_type
cells	I-cell_type
,	O
and	O
addition	O
of	O
anti-cd00	B-protein
antibodies	I-protein
relieved	O
this	O
suppression	O
.	O

using	O
enhancer-reporter	B-DNA
constructs	I-DNA
,	O
il-0	B-protein
specifically	O
down-regulated	O
the	O
nfil-0b	B-DNA
element	O
.	O

electrophoretic	O
mobility	O
shift	O
assays	O
using	O
a	O
dna	B-DNA
oligomer	I-DNA
containing	O
the	O
nfil-0b	B-DNA
binding	O
site	O
indicated	O
that	O
il-0	B-protein
inhibited	O
the	O
nfil-0b	B-DNA
complex	O
and	O
that	O
the	O
nfil-0b	B-DNA
dna	O
binding	O
factor	O
is	O
distinct	O
from	O
ap-	B-protein
0	I-protein
.	O

these	O
results	O
suggest	O
that	O
il-0	B-protein
may	O
regulate	O
development	O
and	O
function	O
of	O
t-cell	B-cell_type
subsets	I-cell_type
involved	O
in	O
cell-mediated	O
immunity	O
in	O
part	O
by	O
inhibiting	O
factors	O
required	O
for	O
transcription	O
of	O
the	O
il0	B-DNA
gene	I-DNA

###MEDLINE:81088140

immunochemical	O
differences	O
between	O
glucocorticoid	B-protein
receptors	I-protein
from	O
corticoid-sensitive	B-protein
and	O
-resistant	O
malignant	B-cell_type
lymphocytes	I-cell_type
.	O

we	O
have	O
explored	O
the	O
possibility	O
of	O
using	O
antibodies	O
against	O
purified	B-cell_type
rat	I-cell_type
liver	I-cell_type
glucocorticoid	B-protein
receptors	I-protein
to	O
study	O
the	O
immunochemical	O
properties	O
of	O
glucocorticoid	B-protein
receptors	I-protein
from	O
murine	B-cell_type
and	I-cell_type
human	I-cell_type
malignant	I-cell_type
lymphocytes	I-cell_type
.	O

for	O
this	O
purpose	O
,	O
purified	O
immune	O
immunoglobulin	B-DNA
g	I-DNA
was	O
covalently	O
linked	O
to	O
sepharose	O
cl-0b	O
.	O

we	O
then	O
examined	O
the	O
ability	O
of	O
the	O
affinity	O
gel	O
to	O
recognize	O
cytosolic	O
[	O
0h	O
]	O
triamcinolone	B-protein
acetonide-receptor	I-protein
complexes	I-protein
from	O
the	O
corticoid-sensitive	O
(	O
cs	O
)	O
and	O
-resistant	O
strains	O
of	O
mouse	B-cell_line
lymphoma	I-cell_line
p0000	I-cell_line
,	O
from	O
cs	O
lymphocytes	O
of	O
patients	O
with	O
chronic	O
lymphatic	O
leukemia	O
,	O
and	O
from	O
a	O
cs	O
clone	O
of	O
human	B-cell_type
leukemic	I-cell_type
lymphoblasts	I-cell_type
in	O
tissue	O
culture	O
(	O
ch0	O
)	O
.	O

mouse	O
thymus	O
was	O
used	O
as	O
a	O
source	O
of	O
glucocorticoid	B-protein
receptor	I-protein
from	O
normal	O
cs	O
lymphocytes	O
.	O

whereas	O
the	O
immunoaffinity	O
column	O
retained	O
00	O
to	O
00	O
%	O
of	O
the	O
00-	O
to	O
00-a	O
(	O
stokes	O
radius	O
)	O
[	O
0h	O
]	O
triamcinolone	O
acetonide-receptor	B-protein
complexes	I-protein
characteristic	O
of	O
the	O
cs	O
mouse	O
and	O
human	B-cell_type
lymphocytes	I-cell_type
,	O
it	O
failed	O
to	O
recognize	O
the	O
00-	O
to	O
00-a	B-protein
(	I-protein
stokes	I-protein
radius	I-protein
)	I-protein
glucocorticoid	I-protein
receptor	I-protein
present	O
in	O
corticoid-resistant	B-cell_line
mouse	I-cell_line
lymphoma	I-cell_line
p0000	I-cell_line
cells	I-cell_line
.	O

therefore	O
,	O
under	O
appropriate	O
experimental	O
conditions	O
,	O
it	O
was	O
possible	O
to	O
demonstrate	O
cross-reactivity	O
between	O
the	O
antiserum	O
against	O
rat	B-cell_type
liver	I-cell_type
glucocorticoid	B-protein
receptor	I-protein
and	O
the	O
00-	O
to	O
00-a	B-protein
(	O
stokes	B-protein
radius	I-protein
)	I-protein
glucocorticoid	I-protein
receptor	I-protein
from	O
species	O
as	O
diverse	O
as	O
mouse	O
and	O
humans	O
.	O

###MEDLINE:80222614

heterogeneity	O
of	O
the	O
in	O
vitro	O
responses	O
to	O
glucocorticoids	O
in	O
acute	O
leukemia	O
.	O

in	O
leukocyte	B-cell_type
population	I-cell_type
freshly	O
isolated	O
from	O
the	O
blood	O
of	O
00	O
patients	O
with	O
acute	O
leukemia	O
,	O
we	O
have	O
measured	O
several	O
parameters	O
including	O
glucocorticoid	B-protein
receptors	I-protein
,	O
nucleoside	O
incorporation	O
,	O
percentage	O
of	O
cells	O
in	O
s	O
phase	O
,	O
and	O
steroid-induced	O
cell	O
lysis	O
.	O

in	O
addition	O
,	O
in	O
some	O
cases	O
,	O
the	O
short-term	O
response	O
to	O
steroid	O
therapy	O
was	O
determined	O
.	O

although	O
,	O
in	O
all	O
the	O
patients	O
studied	O
,	O
leukocytes	B-cell_type
were	O
found	O
to	O
contain	O
glucocorticoid	B-protein
receptors	I-protein
,	O
we	O
failed	O
to	O
demonstrate	O
any	O
correlation	O
between	O
the	O
level	O
of	O
binding	B-DNA
sites	I-DNA
and	O
the	O
in	O
vitro	O
or	O
in	O
vivo	O
response	O
to	O
glucocorticoids	O
.	O

this	O
absence	O
of	O
correlation	O
could	O
be	O
in	O
part	O
explained	O
by	O
the	O
marked	O
heterogeneity	O
of	O
the	O
steroid	O
response	O
demonstrated	O
in	O
leukocyte	B-cell_type
subpopulations	I-cell_type
.	O

it	O
appears	O
,	O
however	O
,	O
that	O
the	O
degree	O
of	O
steroid	O
action	O
in	O
vitro	O
as	O
well	O
as	O
the	O
extent	O
of	O
spontaneous	O
and	O
dexamethasone-induced	O
cell	O
death	O
may	O
be	O
related	O
to	O
the	O
number	O
of	O
cells	O
in	O
the	O
s	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

###MEDLINE:80068767

glucocorticoid	B-protein
receptors	I-protein
in	O
cytosol	O
and	O
nuclear	O
extract	O
of	O
human	B-cell_type
leukocytes	I-cell_type
.	O

cortisol	O
binding	O
by	O
cytosol	O
and	O
0.0	O
m	O
kcl	O
extract	O
of	O
the	O
nuclear	O
fraction	O
of	O
human	B-cell_type
leukocytes	I-cell_type
were	O
studied	O
by	O
gel	O
chromatography	O
and	O
ion	O
exchange	O
filtration	O
on	O
deae	O
cellulose	O
.	O

the	O
cytoplasmic	O
cortisol	O
binding	O
protein	O
has	O
a	O
molecular	O
weight	O
00	O
000	O
and	O
the	O
soluble	B-protein
nuclear	I-protein
binding	I-protein
protein	I-protein
00	I-protein
000	I-protein
.	O

the	O
absence	O
of	O
the	O
uptake	O
of	O
radioactive	O
cortisol	O
by	O
isolated	O
nuclei	O
and	O
the	O
apparent	O
requirement	O
of	O
the	O
cytosol	O
for	O
glucocorticoid	O
specific	O
binding	O
in	O
nuclear	B-protein
receptor	I-protein
sites	I-protein
was	O
observed	O
.	O

the	O
association	O
constant	O
characterising	O
the	O
binding	O
of	O
cortisol	O
to	O
cytosol	O
was	O
ka	O
=	O
0.0	O
.	O
00	O
(	O
0	O
)	O
l/mol	O
.	O

###MEDLINE:78142957

corticosteroid-induced	O
lymphopenia	O
,	O
immunosuppression	O
,	O
and	O
body	O
defense	O
.	O

the	O
apparent	O
paradox	O
of	O
heightened	O
adrenal	O
corticosteroid	O
levels	O
associated	O
with	O
reduction	O
in	O
the	O
competence	O
of	O
the	O
body	O
's	O
defensive	O
apparatus	O
to	O
cope	O
with	O
exposure	O
to	O
new	O
microbial	B-protein
antigens	I-protein
is	O
considered	O
.	O

the	O
question	O
is	O
asked	O
how	O
this	O
lowered	O
defensive	O
capability	O
,	O
which	O
occurs	O
in	O
the	O
face	O
of	O
a	O
threat	O
to	O
body	O
integrity	O
,	O
is	O
consistent	O
with	O
cannon	O
's	O
principals	O
of	O
the	O
``	O
wisdom	O
of	O
the	O
body.	B-DNA
''	I-DNA

the	O
suggestion	O
is	O
offered	O
that	O
the	O
immunologic	O
response	O
to	O
self-antigens	B-protein
exposed	O
by	O
disease	O
or	O
trauma	O
may	O
be	O
suppressed	O
by	O
corticosteroid	O
to	O
offset	O
the	O
likelihood	O
of	O
autoimmune	O
attack	O
.	O

###MEDLINE:94081319

protein	B-protein
tyrosine	I-protein
kinase	I-protein
activation	O
is	O
required	O
for	O
lipopolysaccharide	O
induction	O
of	O
cytokines	B-protein
in	O
human	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
.	O

bacterial	O
lps	O
induce	O
production	O
of	O
cytokines	B-protein
such	O
as	O
il-0	B-protein
,	O
il-0	B-protein
,	O
and	O
tnf	B-protein
in	O
mononuclear	B-cell_type
phagocytes	I-cell_type
,	O
and	O
this	O
represents	O
a	O
central	O
component	O
in	O
the	O
pathogenesis	O
of	O
septic	O
shock	O
syndrome	O
.	O

however	O
,	O
the	O
mechanisms	O
by	O
which	O
lps	O
activates	O
these	O
cells	O
to	O
express	O
cytokines	B-protein
are	O
not	O
completely	O
characterized	O
.	O

the	O
present	O
study	O
addressed	O
the	O
role	O
of	O
different	O
protein	B-protein
kinases	I-protein
in	O
the	O
lps	O
induction	O
of	O
cytokines	B-protein
.	O

it	O
is	O
shown	O
that	O
lps	O
induced	O
a	O
00-	O
to	O
00-fold	O
increase	O
in	O
il-0	B-RNA
beta	I-RNA
,	I-RNA
il-0	I-RNA
,	I-RNA
and	I-RNA
tnf-alpha	I-RNA
mrna	I-RNA
levels	O
,	O
and	O
this	O
was	O
completely	O
or	O
more	O
than	O
00	O
%	O
blocked	O
by	O
the	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
specific	I-protein
inhibitors	I-protein
herbimycin	I-protein
a	I-protein
and	O
genistein	O
at	O
the	O
concentrations	O
of	O
0.0	O
and	O
00	O
microm	O
,	O
respectively	O
.	O

protein	B-protein
kinase	I-protein
c	I-protein
inhibition	O
by	O
staurosporine	O
reduced	O
lps	O
induction	O
of	O
tnf-alpha	B-protein
,	O
whereas	O
it	O
had	O
no	O
effects	O
on	O
il-0	B-protein
and	O
il-0	B-protein
beta	I-protein
.	O

inhibition	O
of	O
protein	B-protein
kinase	I-protein
a	I-protein
by	O
h00	O
reduced	O
il-0	B-RNA
mrna	I-RNA
levels	O
but	O
did	O
not	O
detectably	O
change	O
il-0	B-RNA
beta	I-RNA
or	I-RNA
tnf-alpha	I-RNA
mrna	I-RNA
levels	O
.	O

in	O
contrast	O
,	O
lps	O
did	O
not	O
increase	O
leukemia	B-protein
inhibitory	I-protein
factor	I-protein
mrna	O
,	O
which	O
was	O
constitutively	O
expressed	O
and	O
not	O
significantly	O
reduced	O
by	O
these	O
inhibitors	O
.	O

in	O
addition	O
to	O
cytokine	B-RNA
mrna	I-RNA
levels	O
,	O
lps-induced	O
il-0	B-protein
protein	I-protein
synthesis	O
and	O
il-0	B-protein
bioactivity	O
were	O
also	O
reduced	O
to	O
baseline	O
levels	O
by	O
the	O
ptk	B-protein
inhibitors	I-protein
herbimycin	I-protein
a	I-protein
and	O
genistein	O
.	O

both	O
ptk	B-protein
inhibitors	I-protein
also	O
reduced	O
the	O
lps	O
activation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
b	I-protein
(	O
nf-kappa	B-protein
b	I-protein
)	O
,	O
which	O
is	O
a	O
transcription	B-protein
factor	I-protein
involved	O
in	O
the	O
expression	O
of	O
cytokine	B-DNA
genes	I-DNA
such	O
as	O
il-0	B-protein
and	O
tnf-alpha	B-protein
.	O

the	O
activation	O
of	O
nf-kappa	B-protein
b	I-protein
was	O
also	O
reduced	O
by	O
h00	O
,	O
whereas	O
staurosporine	O
had	O
no	O
effect	O
on	O
this	O
response	O
.	O

in	O
summary	O
,	O
these	O
findings	O
suggest	O
that	O
protein	B-protein
kinase	I-protein
c	I-protein
and	I-protein
protein	I-protein
kinase	I-protein
a	I-protein
appear	O
to	O
have	O
selective	O
effects	O
in	O
the	O
lps	O
induction	O
of	O
cytokines	B-protein
,	O
whereas	O
ptk	B-protein
is	O
required	O
for	O
lps	O
induction	O
of	O
a	O
broad	O
spectrum	O
of	O
cytokines	B-protein
and	O
nf-kappa	B-protein
b	I-protein
activation	O
in	O
monocytes	B-cell_type
.	O

###MEDLINE:94038952

in	O
vivo	O
control	O
of	O
nf-kappa	B-protein
b	I-protein
activation	O
by	O
i	B-protein
kappa	I-protein
b	I-protein
alpha	I-protein
.	O

the	O
transcription	B-protein
factor	I-protein
nf-kappa	I-protein
b	I-protein
is	O
stored	O
in	O
the	O
cytoplasm	O
in	O
complexes	O
with	O
the	O
inhibitor	B-protein
protein	I-protein
i	I-protein
kappa	I-protein
b	I-protein
alpha	I-protein
.	O

it	O
has	O
been	O
shown	O
in	O
vitro	O
that	O
dissociation	O
of	O
i	B-protein
kappa	I-protein
b	I-protein
alpha	I-protein
from	O
these	O
complexes	O
results	O
in	O
active	O
nf-kappa	B-protein
b	I-protein
.	O

in	O
this	O
report	O
we	O
show	O
that	O
lipopolysaccharide	O
(	O
lps	O
)	O
-induced	O
activation	O
of	O
b	B-cell_type
or	I-cell_type
pre-b	I-cell_type
cells	I-cell_type
results	O
in	O
loss	O
of	O
i	B-protein
kappa	I-protein
b	I-protein
alpha	I-protein
from	O
nf-kappa	B-protein
b	I-protein
complexes	I-protein
in	O
vivo	O
.	O

many	O
liberated	O
nf-kappa	B-protein
b	I-protein
dimers	I-protein
reached	O
the	O
nucleus	O
,	O
where	O
increased	O
c-rel	B-protein
,	O
p00	B-protein
and	O
p00	B-protein
were	O
detected	O
by	O
immunoblotting	O
and	O
by	O
dna	O
binding	O
assays	O
.	O

some	O
liberated	O
dimers	O
were	O
retained	O
in	O
the	O
cytoplasm	O
,	O
however	O
,	O
through	O
binding	O
to	O
newly	O
synthesized	O
i	B-protein
kappa	I-protein
b	I-protein
alpha	I-protein
,	O
a	O
finding	O
which	O
strongly	O
suggests	O
(	O
i	O
)	O
that	O
the	O
lps-induced	O
signal	O
causes	O
dissociation	O
of	O
complexes	O
rather	O
than	O
preventing	O
their	O
association	O
and	O
(	O
ii	O
)	O
that	O
dissociation	O
results	O
from	O
modification	O
of	O
i	B-protein
kappa	I-protein
b	I-protein
alpha	I-protein
and	O
not	O
of	O
c-rel	B-protein
or	O
p00	B-protein
.	O

no	O
effect	O
of	O
lps	O
treatment	O
was	O
detected	O
on	O
p000	B-protein
or	O
p000	B-protein
,	O
which	O
also	O
retain	O
rel	B-protein
family	I-protein
members	I-protein
in	O
the	O
cytoplasm	O
.	O

quite	O
unexpectedly	O
,	O
we	O
also	O
found	O
that	O
in	O
unstimulated	B-cell_line
cells	I-cell_line
there	O
is	O
a	O
constant	O
ongoing	O
process	O
of	O
degradation	O
and	O
replacement	O
of	O
complexed	O
i	B-protein
kappa	I-protein
b	I-protein
alpha	I-protein
.	O

we	O
propose	O
that	O
this	O
turnover	O
results	O
in	O
the	O
low	O
level	O
of	O
active	O
nf-kappa	B-protein
b	I-protein
presumably	O
necessary	O
even	O
in	O
the	O
unstimulated	O
cell	O
,	O
and	O
that	O
the	O
high	O
rate	O
of	O
synthesis	O
of	O
i	B-protein
kappa	I-protein
b	I-protein
alpha	I-protein
provides	O
the	O
ability	O
to	O
turn	O
off	O
nf-kappa	B-protein
b	I-protein
activity	O
rapidly	O
as	O
soon	O
as	O
the	O
activating	O
signal	O
ceases	O
.	O

###MEDLINE:94019342

identification	O
of	O
a	O
killer	O
cell-specific	O
regulatory	B-DNA
element	I-DNA
of	O
the	O
mouse	B-DNA
perforin	I-DNA
gene	I-DNA
:	O
an	O
ets-binding	B-DNA
site-homologous	I-DNA
motif	I-DNA
that	O
interacts	O
with	O
ets-related	B-protein
proteins	I-protein
.	O

the	O
gene	O
encoding	O
the	O
cytolytic	B-protein
protein	I-protein
perforin	B-protein
is	O
selectively	O
expressed	O
by	O
activated	B-cell_type
killer	I-cell_type
lymphocytes	I-cell_type
.	O

to	O
understand	O
the	O
mechanisms	O
underlying	O
the	O
cell-type-specific	O
expression	O
of	O
this	O
gene	O
,	O
we	O
have	O
characterized	O
the	O
regulatory	O
functions	O
and	O
the	O
dna-protein	O
interactions	O
of	O
the	O
0'-flanking	B-DNA
region	I-DNA
of	O
the	O
mouse	B-DNA
perforin	I-DNA
gene	I-DNA
(	O
pfp	B-protein
)	O
.	O

a	O
region	O
extending	O
from	O
residues	O
+00	O
through	O
-000	O
,	O
which	O
possesses	O
the	O
essential	O
promoter	O
activity	O
,	O
and	O
regions	O
further	O
upstream	O
,	O
which	O
are	O
able	O
to	O
either	O
enhance	O
or	O
suppress	O
gene	O
expression	O
,	O
were	O
identified	O
.	O

the	O
region	O
between	O
residues	O
-000	B-DNA
and	I-DNA
-000	I-DNA
was	O
chosen	O
for	O
further	O
characterization	O
,	O
since	O
it	O
contains	O
an	O
enhancer-like	O
activity	O
.	O

we	O
have	O
identified	O
a	O
00-mer	B-DNA
sequence	I-DNA
(	O
residues	O
-000	O
to	O
-000	O
)	O
which	O
appeared	O
to	O
be	O
capable	O
of	O
enhancing	O
gene	O
expression	O
in	O
a	O
killer	O
cell-specific	O
manner	O
.	O

within	O
this	O
segment	O
,	O
a	O
0-mer	B-DNA
motif	I-DNA
(	O
0'-acaggaagt-0	B-DNA
'	I-DNA
,	I-DNA
residues	I-DNA
-000	B-DNA
to	I-DNA
-000	I-DNA
;	I-DNA
designated	I-DNA
nf-p	I-DNA
motif	I-DNA
)	O
,	O
which	O
is	O
highly	O
homologous	O
to	O
the	O
ets	B-DNA
proto-oncoprotein-binding	I-DNA
site	I-DNA
,	O
was	O
found	O
to	O
interact	O
with	O
two	O
proteins	O
,	O
nf-p0	B-protein
and	O
nf-p0	O
.	O

nf-p0	B-protein
appears	O
to	O
be	O
induced	O
by	O
reagents	O
known	O
to	O
up-regulate	O
the	O
perforin	B-protein
message	O
level	O
and	O
is	O
present	O
exclusively	O
in	O
killer	B-cell_type
cells	I-cell_type
.	O

electrophoretic	O
mobility	O
shift	O
assay	O
and	O
uv	O
cross-linking	O
experiments	O
revealed	O
that	O
nf-p0	B-protein
and	O
nf-p0	B-protein
may	O
possess	O
common	O
dna-binding	B-protein
subunits	I-protein
.	O

however	O
,	O
the	O
larger	O
native	O
molecular	O
mass	O
of	O
nf-p0	B-protein
suggests	O
that	O
nf-p0	B-protein
contains	O
an	O
additional	O
non-dna-binding	B-protein
subunit	I-protein
(	O
s	O
)	O
.	O

in	O
view	O
of	O
the	O
homology	O
between	O
the	O
nf-p	B-DNA
motif	I-DNA
and	O
other	O
ets	B-DNA
proto-oncoprotein-binding	I-DNA
sites	I-DNA
,	O
it	O
is	O
postulated	O
that	O
nf-p0	B-protein
and	O
nf-p0	O
belong	O
to	O
the	O
ets	B-protein
protein	I-protein
family	I-protein
.	O

results	O
obtained	O
from	O
the	O
binding	O
competition	O
assay	O
,	O
nevertheless	O
,	O
suggest	O
that	O
nf-p0	B-protein
and	O
nf-p0	B-protein
are	O
related	O
to	O
but	O
distinct	O
from	O
ets	B-protein
proteins	I-protein
,	O
e.g.	O
,	O
ets-0	B-protein
,	O
ets-0	B-protein
,	O
and	O
nf-at/elf-0	B-protein
,	O
known	O
to	O
be	O
expressed	O
in	O
t	B-cell_type
cells	I-cell_type
.	O

###MEDLINE:94128612

the	O
role	O
of	O
nf-kappa	B-protein
b0	I-protein
(	O
p00/p000	B-DNA
)	I-DNA
gene	I-DNA
expression	O
in	O
activation	O
of	O
human	B-cell_type
blood	I-cell_type
t-lymphocytes	I-cell_type
via	O
cd0	B-protein
and	O
cd00	B-protein
adhesion	I-protein
molecules	I-protein
.	O

stimulation	O
of	O
primary	B-cell_type
human	I-cell_type
t-lymphocytes	I-cell_type
via	O
cd0	B-protein
and	O
cd00	B-protein
adhesion	I-protein
molecules	I-protein
induces	O
a	O
long-lasting	O
proliferation	O
(	O
>	O
0	O
weeks	O
)	O
.	O

this	O
potent	O
activation	O
does	O
not	O
require	O
accessory	B-cell_type
cells	I-cell_type
,	O
such	O
as	O
monocytes	B-cell_type
,	O
but	O
depends	O
on	O
persistent	O
interleukin	B-protein
0	I-protein
(	O
il-0	B-protein
)	O
secretion	O
and	O
receptivity	O
,	O
which	O
is	O
associated	O
with	O
high	O
and	O
prolonged	O
expression	O
of	O
the	O
inducible	B-DNA
cd00/il-0	I-DNA
receptor	I-DNA
alpha	I-DNA
(	I-DNA
il-0r	I-DNA
alpha	I-DNA
)	I-DNA
chain	I-DNA
gene	I-DNA
.	O

the	O
transcription	B-protein
factor	I-protein
nf-kappa	I-protein
b	I-protein
participates	O
in	O
the	O
regulation	O
of	O
both	O
il-0	B-DNA
and	I-DNA
il-0r	I-DNA
alpha	I-DNA
genes	I-DNA
,	O
as	O
well	O
as	O
multiple	O
cellular	O
genes	O
involved	O
in	O
t-cell	O
proliferation	O
.	O

to	O
evaluate	O
the	O
role	O
of	O
nf-kappa	B-protein
b	I-protein
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
t-lymphocytes	I-cell_type
,	O
we	O
previously	O
analyzed	O
the	O
activation	O
of	O
nf-kappa	B-protein
b-related	I-protein
complexes	I-protein
in	O
response	O
to	O
cd0+cd00	O
costimulation	O
.	O

we	O
demonstrated	O
a	O
long-term	O
induction	O
of	O
p00/p00	B-protein
heterodimer	I-protein
,	O
a	O
putative	B-protein
p00/c-rel	I-protein
heterodimer	I-protein
,	O
and	O
a	O
constitutive	O
nuclear	O
expression	O
of	O
kbf0/p00	B-protein
homodimers	I-protein
.	O

as	O
the	O
role	O
of	O
p00	B-protein
remains	O
unclear	O
,	O
we	O
focused	O
our	O
present	O
study	O
on	O
nf-kappa	B-protein
b0	I-protein
(	O
p00/p000	B-DNA
)	I-DNA
gene	I-DNA
regulation	O
.	O

using	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
western	O
and	O
northern	O
blot	O
analyses	O
,	O
we	O
studied	O
nf-kappa	B-DNA
b0	I-DNA
gene	I-DNA
expression	O
during	O
t-cell	O
stimulation	O
via	O
cd0+cd00	O
.	O

we	O
observed	O
a	O
transient	O
0-	O
to	O
0-fold	O
increase	O
of	O
nf-kappa	B-protein
b0	I-protein
gene	O
expression	O
at	O
both	O
the	O
mrna	O
and	O
protein	O
levels	O
,	O
lasting	O
for	O
at	O
least	O
00	O
h	O
.	O

p00	B-protein
dna-binding	O
activity	O
apparently	O
stays	O
highly	O
controlled	O
when	O
p000	B-protein
expression	O
is	O
enhanced	O
by	O
a	O
physiological	O
stimulus	O
of	O
peripheral	B-cell_type
blood	I-cell_type
t-cells	I-cell_type
.	O

partial	O
inhibition	O
of	O
p00	B-protein
and	O
p000	B-protein
expression	O
by	O
nf-kappa	B-protein
b0	I-protein
antisense	O
oligonucleotides	O
significantly	O
reduced	O
t-cell	O
proliferation	O
and	O
cd00/il-0r	B-protein
alpha	I-protein
cell	O
surface	O
expression	O
.	O

(	O
abstract	O
truncated	O
at	O
000	O
words	O
)	O

###MEDLINE:94102419

vitamin	B-protein
d	I-protein
receptor	I-protein
quantitation	O
in	O
human	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
in	O
health	O
and	O
disease	O
.	O

vitamin	B-protein
d	I-protein
receptor	I-protein
(	O
vdr	B-protein
)	O
concentration	O
was	O
quantitated	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
pbmc	B-cell_type
)	O
from	O
patients	O
with	O
absorptive	O
hypercalciuria	O
(	O
ah	B-protein
)	I-protein
and	O
patients	O
with	O
high	O
0	O
,	O
00	O
(	O
oh	O
)	O
0d0	O
due	O
to	O
acquired	O
or	O
transient	O
disease	O
states	O
and	O
the	O
results	O
compared	O
to	O
those	O
in	O
normal	O
subjects	O
.	O

vdr	B-protein
concentration	O
in	O
resting	B-cell_type
cells	I-cell_type
was	O
not	O
different	O
between	O
the	O
three	O
groups	O
and	O
represented	O
constitutive	O
receptor	O
expression	O
of	O
monocytes	B-cell_type
.	O

following	O
activation	O
with	O
phytohemagglutinin	B-protein
,	O
patients	O
with	O
hypercalcitriolemia	B-protein
demonstrated	O
significantly	O
greater	O
vdr	B-protein
concentrations	O
.	O

patients	O
with	O
ah	O
demonstrated	O
a	O
normal	O
value	O
for	O
the	O
group	O
,	O
but	O
0	O
patients	O
had	O
significantly	O
greater	O
concentrations	O
of	O
vdr	B-protein
despite	O
normal	O
plasma	B-protein
0	I-protein
,	O
00	O
(	O
oh	O
)	O
0d0	O
in	O
four	O
of	O
the	O
patients	O
.	O

proliferation	O
,	O
as	O
assessed	O
from	O
[	O
0h	O
]	O
thymidine	O
incorporation	O
was	O
inversely	O
correlated	O
with	O
serum	B-protein
0	I-protein
,	O
00	O
(	O
oh	O
)	O
0d0	O
and	O
was	O
significant	O
(	O
r	B-protein
=	O
-0.000	O
,	O
p	O
=	O
0.000	O
)	O
.	O

taken	O
together	O
,	O
the	O
results	O
suggest	O
that	O
pbmc	B-cell_type
provide	O
a	O
useful	O
system	O
for	O
studying	O
vdr	B-protein
status	O
in	O
transient	O
or	O
acquired	O
states	O
of	O
hypercalcitriolemia	O
.	O

furthermore	O
,	O
the	O
studies	O
in	O
patients	O
with	O
absorptive	O
hypercalciuria	O
disclosed	O
it	O
to	O
be	O
a	O
heterogeneous	O
disorder	O
,	O
characterized	O
by	O
both	O
vitamin	O
d-dependent	O
and	O
d-independent	O
forms	O
of	O
receptor	O
up-regulation	O
.	O

###MEDLINE:93357477

reactive	O
oxygen	O
intermediates	O
activate	O
nf-kappa	B-protein
b	I-protein
in	O
a	O
tyrosine	O
kinase-dependent	O
mechanism	O
and	O
in	O
combination	O
with	O
vanadate	O
activate	O
the	O
p00lck	B-protein
and	O
p00fyn	B-protein
tyrosine	B-protein
kinases	I-protein
in	O
human	B-cell_type
lymphocytes	I-cell_type
.	O

we	O
have	O
previously	O
observed	O
that	O
ionizing	O
radiation	O
induces	O
tyrosine	O
phosphorylation	O
in	O
human	B-cell_type
b-lymphocyte	I-cell_type
precursors	I-cell_type
by	O
stimulation	O
of	O
unidentified	B-protein
tyrosine	I-protein
kinases	I-protein
and	O
this	O
phosphorylation	O
is	O
substantially	O
augmented	O
by	O
vanadate	O
.	O

ionizing	O
radiation	O
generates	O
reactive	O
oxygen	O
intermediates	O
(	O
roi	O
)	O
.	O

because	O
h0o0	O
is	O
a	O
potent	O
roi	O
generator	O
that	O
readily	O
crosses	O
the	O
plasma	O
membrane	O
,	O
we	O
used	O
h0o0	O
to	O
examine	O
the	O
effects	O
of	O
roi	O
on	O
signal	O
transduction	O
.	O

we	O
now	O
provide	O
evidence	O
that	O
the	O
tyrosine	B-protein
kinase	I-protein
inhibitor	I-protein
herbimycin	I-protein
a	I-protein
and	O
the	O
free	O
radical	O
scavenger	O
n-acetyl-cysteine	O
inhibit	O
both	O
radiation-induced	O
and	O
h0o0-induced	O
activation	O
of	O
nf-kappa	B-protein
b	I-protein
,	O
indicating	O
that	O
activation	O
triggered	O
by	O
roi	O
is	O
dependent	O
on	O
tyrosine	B-protein
kinase	I-protein
activity	O
.	O

h0o0	O
was	O
found	O
to	O
stimulate	O
ins-0	B-protein
,	I-protein
0	I-protein
,	O
0-p0	O
production	O
in	O
a	O
tyrosine	O
kinase-dependent	O
manner	O
and	O
to	O
induce	O
calcium	O
signals	O
that	O
were	O
greatly	O
augmented	O
by	O
vanadate	O
.	O

the	O
synergistic	O
induction	O
of	O
tyrosine	O
phosphorylation	O
by	O
h0o0	O
plus	O
vanadate	O
included	O
physiologically	O
relevant	O
proteins	O
such	O
as	O
plc	B-protein
gamma	I-protein
0	I-protein
.	O

although	O
treatment	O
of	O
cells	O
with	O
h0o0	O
alone	O
did	O
not	O
affect	O
the	O
activity	O
of	O
src	B-protein
family	I-protein
kinases	I-protein
,	O
treatment	O
with	O
h0o0	O
plus	O
vanadate	O
led	O
to	O
activation	O
of	O
the	O
p00lck	B-protein
and	O
p00fyn	B-protein
tyrosine	B-protein
kinases	I-protein
.	O

the	O
combined	O
inhibition	O
of	O
phosphatases	B-protein
and	O
activation	O
of	O
kinases	B-protein
provides	O
a	O
potent	O
mechanism	O
for	O
the	O
synergistic	O
effects	O
of	O
h0o0	O
plus	O
vanadate	O
.	O

induction	O
of	O
tyrosine	O
phosphorylation	O
by	O
roi	O
may	O
thus	O
lead	O
to	O
many	O
of	O
the	O
pleiotropic	O
effects	O
of	O
roi	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
,	O
including	O
downstream	O
activation	O
of	O
plc	B-protein
gamma	I-protein
0	I-protein
and	O
nf-kappa	B-protein
b	I-protein

###MEDLINE:81105535

influence	O
of	O
sex	O
hormone	O
binding	O
globulin	O
and	O
serum	B-protein
albumin	I-protein
on	O
the	O
conversion	O
of	O
androstenedione	O
to	O
testosterone	O
by	O
human	B-cell_type
erythrocytes	I-cell_type
.	O

the	O
influence	O
of	O
human	B-protein
serum	I-protein
albumin	I-protein
and	O
sex	O
hormone	O
binding	O
globulin	O
(	O
shbg	O
)	O
on	O
the	O
enzymic	O
conversion	O
of	O
androstenedione	O
to	O
testosterone	O
in	O
human	B-cell_type
erythrocytes	I-cell_type
was	O
investigated	O
in	O
vitro	O
.	O

total	O
plasma	O
and	O
albumin	B-protein
delayed	O
the	O
conversion	O
rate	O
of	O
androstenedione	O
,	O
while	O
shbg	O
increased	O
it	O
markedly	O
.	O

the	O
effect	O
of	O
shbg	O
was	O
largely	O
abolished	O
by	O
heating	O
to	O
00	O
degrees	O
c	O
for	O
0	O
h	O
and	O
by	O
saturating	O
its	O
binding	O
sites	O
by	O
dht	O
.	O

the	O
effect	O
of	O
both	O
proteins	O
was	O
found	O
to	O
be	O
related	O
to	O
their	O
concentration	O
.	O

it	O
appears	O
that	O
the	O
binding	B-DNA
sites	I-DNA
of	O
albumin	B-protein
provide	O
a	O
mechanism	O
for	O
retarding	O
androstenedione	O
uptake	O
by	O
the	O
erythrocytes	B-cell_type
and	O
that	O
the	O
high	O
binding	O
affinity	O
of	O
shbg	O
for	O
testosterone	O
facilitates	O
the	O
diffusion	O
of	O
this	O
steroid	O
out	O
of	O
the	O
cell	O
and	O
thus	O
,	O
displaces	O
the	O
chemical	O
equilibrium	O
within	O
the	O
cell	O
.	O

###MEDLINE:80161233

glucocorticoids	O
and	O
lymphocytes	B-cell_type
.	O

i	O
.	O

increased	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
in	O
antigen-stimulated	B-cell_type
lymphocytes	I-cell_type
.	O

recently	O
a	O
0-	O
to	O
0-fold	O
increase	O
in	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
human	B-cell_type
peripheral	I-cell_type
lymphocytes	I-cell_type
has	O
been	O
noted	O
after	O
in	O
vitro	O
mitogen	O
stimulation	O
.	O

here	O
,	O
we	O
extend	O
these	O
observations	O
to	O
in	O
vivo	O
immunization	O
.	O

after	O
unilateral	O
immunization	O
of	O
adrenalectomized	O
male	O
rats	O
,	O
a	O
00	O
%	O
increase	O
in	O
glucocorticoid	B-protein
receptor	I-protein
sites	I-protein
per	O
cell	O
,	O
determined	O
by	O
binding	O
of	O
dexamethasone	O
,	O
was	O
observed	O
in	O
cell	O
suspensions	O
of	O
homolateral	O
lymph	O
nodes	O
over	O
those	O
from	O
the	O
contralateral	O
nonimmunized	O
side	O
of	O
the	O
same	O
animal	O
.	O

the	O
association	O
constant	O
for	O
dexamethasone	O
was	O
similar	O
in	O
both	O
groups	O
,	O
as	O
was	O
the	O
stereospecificity	O
for	O
various	O
steroids	O
,	O
the	O
time	O
course	O
of	O
cytoplasmic	O
and	O
nuclear	O
association	O
,	O
and	O
cytoplasmic-to-nuclear	O
translocation	O
.	O

despite	O
a	O
00	O
%	O
increase	O
in	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptor	I-protein
sites	I-protein
per	O
cell	O
,	O
the	O
cells	O
from	O
the	O
homolateral	O
and	O
controlateral	O
lymph	O
nodes	O
were	O
equally	O
sensitive	O
to	O
the	O
inhibitory	O
effects	O
of	O
dexamethasone	O
,	O
as	O
determined	O
by	O
measurements	O
of	O
the	O
incorporation	O
of	O
radiolabeled	O
precursors	O
of	O
protein	O
,	O
rna	O
,	O
and	O
dna	O
,	O
or	O
measurements	O
of	O
in	O
vitro	O
cell	O
survival	O
.	O

###MEDLINE:80032538

glucocorticoid	B-protein
receptors	I-protein
and	O
actions	O
in	O
rat	B-cell_type
thymocytes	I-cell_type
and	O
immunologically	O
stimulated	O
human	B-cell_type
peripheral	I-cell_type
lymphocytes	I-cell_type
.	O

after	O
reviewing	O
briefly	O
our	O
earlier	O
studies	O
on	O
glucocorticoid	B-protein
receptors	I-protein
and	O
mechanisms	O
in	O
thymus	B-cell_line
cells	I-cell_line
,	O
we	O
have	O
outlined	O
results	O
from	O
the	O
following	O
two	O
areas	O
of	O
current	O
interest	O
in	O
our	O
laboratories	O
:	O
the	O
``	O
life-cycle	O
''	O
of	O
glucocorticoid	B-protein
receptors	I-protein
and	O
complexes	O
in	O
thymus	B-cell_line
cells	I-cell_line
,	O
and	O
the	O
levels	O
of	O
glucocorticoid	B-protein
receptors	I-protein
and	O
sensitivity	O
in	O
immunologically	O
stimulated	O
human	B-cell_type
peripheral	I-cell_type
lymphocytes	I-cell_type
.	O

several	O
of	O
our	O
results	O
on	O
energetics	O
and	O
kinetics	O
of	O
hormone	O
binding	O
to	O
glucocorticoid	B-protein
receptors	I-protein
in	O
rat	O
thymus	O
cells	O
seem	O
to	O
require	O
extension	O
of	O
the	O
simplest	O
model	O
of	O
hormone-receptor	O
transformations	O
in	O
intact	B-cell_type
cells	I-cell_type
.	O

atp-depletion	O
experiments	O
suggest	O
the	O
existence	O
of	O
a	O
nonbinding	O
form	O
of	O
the	O
receptor	O
;	O
``	O
chase	O
''	O
experiments	O
suggest	O
reaction	O
of	O
hormone	O
directly	O
with	O
nuclear-bound	B-protein
receptor	I-protein
;	O
experiments	O
on	O
depletion	O
and	O
replenishment	O
of	O
cytoplasmic	B-protein
receptor	I-protein
using	O
cortisol	O
and	O
dexamethasone	O
suggest	O
the	O
existence	O
of	O
at	O
least	O
two	O
subpopulations	O
of	O
nuclear-bound	O
hormone-receptor	O
complex	O
.	O

we	O
have	O
found	O
that	O
mitogen	B-protein
or	O
immunologic	O
stimulation	O
of	O
human	B-cell_type
peripheral	I-cell_type
lymphocytes	I-cell_type
in	O
culture	O
leads	O
within	O
00	O
h	O
or	O
so	O
to	O
a	O
striking	O
increase	O
in	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptor	I-protein
sites	I-protein
per	O
cell	O
.	O

we	O
believe	O
this	O
increase	O
may	O
be	O
due	O
to	O
partial	O
synchronization	O
of	O
the	O
cell	O
population	O
in	O
a	O
phase	O
of	O
the	O
cell	O
cycle	O
in	O
which	O
receptor	O
content	O
is	O
high	O
.	O

contrary	O
to	O
the	O
widely	O
held	O
view	O
that	O
mitogen-stimulated	B-cell_type
cells	I-cell_type
become	O
insensitive	O
to	O
glucocorticoids	O
,	O
our	O
experiments	O
show	O
that	O
with	O
respect	O
to	O
inhibition	O
of	O
thymidine	O
and	O
uridine	O
incorporation	O
and	O
glucose	O
uptake	O
,	O
the	O
cells	O
are	O
highly	O
sensitive	O
to	O
dexamethasone	O
at	O
00	O
,	O
00	O
,	O
and	O
00	O
h	O
after	O
stimulation	O
with	O
concanavalin	O
a	O
.	O

###MEDLINE:79064946

nuclear	O
glucocorticoid	O
binding	O
in	O
chronic	O
lymphatic	O
leukemia	B-cell_type
lymphocytes	I-cell_type
.	O

a	O
reliable	O
procedure	O
is	O
described	O
for	O
isolating	O
0h-triamcinolone	O
acetonide	O
(	O
0h-ta	B-protein
)	I-protein
receptor	I-protein
complexes	I-protein
from	O
purified	O
chronic	O
lymphatic	O
leukemia	O
(	O
cll	B-cell_line
)	O
lymphocyte	O
nuclei	O
,	O
based	O
on	O
the	O
use	O
of	O
carbobenzoxy-l-phenylalanine	B-protein
(	O
cbz-l-phe	B-protein
)	O
to	O
prevent	O
breakdown	O
of	O
hormone-receptor	O
complexes	O
during	O
extraction	O
of	O
nuclei	O
with	O
0.0m	O
kcl	O
.	O

using	O
this	O
method	O
,	O
specific	O
nuclear	O
glucocorticoid	O
binding	O
was	O
demonstrated	O
in	O
00/00	O
patients	O
with	O
untreated	O
cll	O
.	O

no	O
correlation	O
was	O
found	O
between	O
levels	O
of	O
nuclear-associated	B-cell_type
0h-ta	I-cell_type
and	I-cell_type
peripheral	I-cell_type
white	I-cell_type
blood	I-cell_type
cell	I-cell_type
count	O
or	O
rosetting	O
ability	O
of	O
circulating	B-cell_type
lymphocytes	I-cell_type
.	O

###MEDLINE:94111992

multiple	O
closely-linked	B-DNA
nfat/octamer	I-DNA
and	I-DNA
hmg	I-DNA
i	I-DNA
(	I-DNA
y	I-DNA
)	I-DNA
binding	I-DNA
sites	I-DNA
are	O
part	O
of	O
the	O
interleukin-0	B-DNA
promoter	I-DNA
.	O

we	O
show	O
here	O
that	O
the	O
immediate	B-DNA
upstream	I-DNA
region	I-DNA
(	O
from	O
position	O
-00	O
to	O
-000	O
)	O
of	O
the	O
murine	B-DNA
interleukin	I-DNA
0	I-DNA
(	I-DNA
il-0	I-DNA
)	I-DNA
gene	I-DNA
harbors	O
a	O
strong	O
cell-type	O
specific	O
transcriptional	B-DNA
enhancer	I-DNA
.	O

in	O
t	B-cell_line
lymphoma	I-cell_line
cells	I-cell_line
,	O
the	O
activity	O
of	O
the	O
il-0	B-DNA
promoter/enhancer	I-DNA
is	O
stimulated	O
by	O
phorbol	O
esters	O
,	O
ca++	O
ionophores	O
and	O
agonists	O
of	O
protein	B-protein
kinase	I-protein
a	I-protein
and	O
inhibited	O
by	O
low	O
doses	O
of	O
the	O
immunosuppressant	O
cyclosporin	O
a	O
.	O

the	O
il-0	B-DNA
promoter/enhancer	I-DNA
is	O
transcriptionally	O
inactive	O
in	O
b	B-cell_line
lymphoma	I-cell_line
cells	I-cell_line
and	O
hela	B-cell_line
cells	I-cell_line
.	O

dnase	B-protein
i	I-protein
footprint	O
protection	O
experiments	O
revealed	O
six	O
sites	O
of	O
the	O
il-0	B-DNA
promoter/enhancer	I-DNA
to	O
be	O
bound	O
by	O
nuclear	B-protein
proteins	I-protein
from	O
lymphoid	B-cell_type
and	I-cell_type
myeloid	I-cell_type
cells	I-cell_type
.	O

among	O
them	O
are	O
four	O
purine	B-DNA
boxes	I-DNA
which	O
have	O
been	O
described	O
to	O
be	O
important	O
sequence	O
motifs	O
of	O
the	O
il-0	B-DNA
promoter	I-DNA
.	O

they	O
contain	O
the	O
motif	O
ggaaa	O
and	O
are	O
recognized	O
by	O
the	O
inducible	O
and	O
cyclosporin	O
a-sensitive	O
transcription	B-protein
factor	I-protein
nfat-0	B-protein
.	O

three	O
of	O
the	O
il-0	B-DNA
nfat-0	I-DNA
sites	I-DNA
are	O
closely	O
linked	O
to	O
weak	O
binding	O
sites	O
of	O
octamer	B-protein
factors	I-protein
.	O

several	O
purine	B-DNA
boxes	I-DNA
and	O
an	O
at-rich	B-DNA
protein-binding	I-DNA
site	I-DNA
of	O
the	O
il-0	B-DNA
promoter	I-DNA
are	O
also	O
recognized	O
by	O
the	O
high	B-protein
mobility	I-protein
group	I-protein
protein	I-protein
hmg	I-protein
i	I-protein
(	I-protein
y	I-protein
)	I-protein
.	O

whereas	O
the	O
binding	O
of	O
nfat-0	B-protein
and	O
octamer	B-protein
factors	I-protein
enhance	O
the	O
activity	O
of	O
the	O
il-0	B-DNA
promoter	I-DNA
,	O
the	O
binding	O
of	O
hmg	B-protein
i	I-protein
(	I-protein
y	I-protein
)	I-protein
suppresses	O
its	O
activity	O
and	O
,	O
therefore	O
,	O
appears	O
to	O
be	O
involved	O
in	O
the	O
suppression	O
of	O
il-0	B-protein
transcription	O
in	O
resting	B-cell_type
t	I-cell_type
lymphocytes	I-cell_type
.	O

###MEDLINE:94176179

reversibility	O
of	O
the	O
differentiated	O
state	O
in	O
somatic	B-cell_line
cells	I-cell_line
.	O

analysis	O
of	O
de	O
novo	O
gene	O
activation	O
in	B-cell_type
multinucleated	I-cell_type
heterokaryons	I-cell_type
has	O
shown	O
that	O
the	O
differentiated	O
state	O
,	O
although	O
stable	O
,	O
is	O
not	O
irreversible	O
,	O
and	O
can	O
be	O
reprogrammed	O
in	O
the	O
presence	O
of	O
appropriate	O
combinations	O
of	O
trans-acting	B-protein
regulatory	I-protein
molecules	I-protein
.	O

these	O
properties	O
have	O
been	O
exploited	O
to	O
design	O
strategies	O
for	O
identifying	O
novel	O
regulators	O
of	O
cellular	O
differentiation	O
.	O

###MEDLINE:94016843

phosphatidylcholine	O
hydrolysis	O
activates	O
nf-kappa	B-protein
b	I-protein
and	O
increases	O
human	O
immunodeficiency	O
virus	O
replication	O
in	O
human	B-cell_type
monocytes	I-cell_type
and	O
t	B-cell_type
lymphocytes	I-cell_type
.	O

we	O
have	O
tested	O
whether	O
breakdown	O
of	O
phosphatidylcholine	O
(	O
pc	B-cell_type
)	O
initiated	O
by	O
exogenous	O
addition	O
of	O
a	O
pc-specific	B-protein
phospholipase	I-protein
c	I-protein
(	O
pc-plc	B-protein
)	O
from	O
bacillus	O
cereus	O
or	O
by	O
endogenous	O
overexpression	O
of	O
pc-plc	B-protein
induces	O
functional	O
activation	O
of	O
nf-kappa	B-protein
b	I-protein
and	O
increases	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
hiv	I-DNA
)	I-DNA
enhancer	I-DNA
activity	O
.	O

pc-plc-activated	O
hydrolysis	O
of	O
pc	B-cell_type
was	O
found	O
to	O
induce	O
bona	O
fide	O
p00/p00	B-protein
nf-kappa	I-protein
b	I-protein
binding	O
activity	O
in	O
three	O
different	O
cell	B-cell_line
lines	I-cell_line
of	O
human	B-cell_type
or	I-cell_type
murine	I-cell_type
origin	I-cell_type
.	O

no	O
significant	O
changes	O
in	O
the	O
turnover	O
of	O
other	O
cellular	O
phospholipids	O
were	O
detected	O
in	O
pc-plc-treated	B-cell_type
cells	I-cell_type
.	O

induction	O
of	O
nf-kappa	B-protein
b	I-protein
by	O
pc-plc	B-protein
did	O
not	O
depend	O
on	O
de	O
novo	O
synthesis	O
of	O
proteins	O
or	O
autocrine	O
secretion	O
of	O
either	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
or	O
interleukin	B-protein
0	I-protein
.	O

in	O
human	B-cell_line
monocytic	I-cell_line
and	I-cell_line
lymphoblastoid	I-cell_line
t-cell	I-cell_line
lines	I-cell_line
,	O
induction	O
of	O
nf-kappa	B-protein
b	I-protein
by	O
pc-plc	B-protein
resulted	O
in	O
clear	O
induction	O
of	O
luciferase	B-DNA
expression	I-DNA
vectors	I-DNA
placed	O
under	O
the	O
control	O
of	O
synthetic	O
kappa	B-DNA
b	I-DNA
enhancers	I-DNA
or	O
wild	O
type	O
,	O
but	O
not	O
kappa	B-DNA
b-mutated	I-DNA
,	I-DNA
hiv	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
constructs	I-DNA
.	O

hiv	O
replication	O
was	O
increased	O
by	O
pc-plc	B-protein
in	O
chronically	B-cell_type
infected	I-cell_type
monocytes	I-cell_type
and	O
t	B-cell_type
lymphocytes	I-cell_type
.	O

nf-kappa	B-protein
b	I-protein
activation	O
promoted	O
by	O
addition	O
of	O
exogenous	O
pc-plc	B-protein
correlated	O
with	O
an	O
intense	O
production	O
of	O
diacylglycerol	O
.	O

however	O
,	O
addition	O
of	O
a	O
phosphatidylinositol-specific	O
plc	O
from	O
b.cereus	B-protein
also	O
induced	O
diacylglycerol	O
but	O
did	O
not	O
activate	O
kappa	B-DNA
b	I-DNA
enhancer-directed	I-DNA
vectors	I-DNA
.	O

pc-plc-induced	O
nf-kappa	B-protein
b	I-protein
activation	O
could	O
not	O
be	O
blocked	O
by	O
a	O
specific	O
inhibitor	O
of	O
phorbol	B-protein
ester-inducible	I-protein
protein	I-protein
kinases	I-protein
c	O
.	O

these	O
results	O
indicate	O
that	O
a	O
cellular	O
transduction	O
pathway	O
,	O
dependent	O
on	O
specific	O
pc	O
breakdown	O
,	O
is	O
functional	O
in	O
t	B-cell_type
lymphocytes	I-cell_type
and	O
monocytes	B-cell_type
and	O
may	O
be	O
used	O
by	O
various	O
transmembrane	B-protein
receptors	I-protein
to	O
activate	O
hiv	O
transcription	O
through	O
nf-kappa	O
b-dependent	O
induction	O
of	O
the	O
hiv	B-DNA
enhancer	I-DNA
.	O

###MEDLINE:94014350

novel	O
mechanism	O
for	O
inhibition	O
of	O
human	B-cell_type
t	I-cell_type
cells	I-cell_type
by	O
glucocorticoids	O
.	O

glucocorticoids	O
inhibit	O
signal	O
transduction	O
through	O
il-0	B-protein
receptor	I-protein
.	O

interaction	O
of	O
il-0	B-protein
with	O
its	O
high	B-protein
affinity	I-protein
membrane	I-protein
receptor	I-protein
complex	I-protein
(	O
il-0r	B-protein
)	O
present	O
on	O
activated	B-cell_type
t	I-cell_type
lymphocytes	I-cell_type
induces	O
cell	O
proliferation	O
and	O
mediates	O
effector	O
functions	O
.	O

glucocorticoids	O
inhibit	O
il-0	B-protein
production	O
by	O
inhibiting	O
tcr-mediated	O
signal	O
transduction	O
.	O

we	O
asked	O
whether	O
they	O
also	O
inhibit	O
the	O
action	O
of	O
il-0	B-protein
by	O
inhibiting	O
signal	O
transduction	O
through	O
il-0r	B-protein
.	O

human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
t	I-cell_type
cells	I-cell_type
,	O
stimulated	O
with	O
pma	O
for	O
00	O
h	O
(	O
pma	O
blasts	O
)	O
,	O
were	O
incubated	O
with	O
il-0	B-protein
in	O
the	O
presence	O
of	O
incremental	O
dosages	O
of	O
dexamethasone	O
(	O
dex	O
;	O
00	O
(	O
-0	O
)	O
-00	O
(	O
-0	O
)	O
m	O
)	O
.	O

dex	O
inhibited	O
the	O
il-0-dependent	B-cell_line
proliferation	I-cell_line
of	I-cell_line
pma	I-cell_line
blasts	I-cell_line
in	O
a	O
dose-dependent	O
fashion	O
(	O
ic00	O
,	O
0	O
x	O
00	O
(	O
-0	O
)	O
m	O
)	O
.	O

cell	O
surface	O
expression	O
of	O
il-0r	B-protein
alpha-	I-protein
and	I-protein
beta-chains	I-protein
as	O
determined	O
by	O
immunofluorescence	O
analysis	O
was	O
not	O
affected	O
by	O
dex	O
.	O

in	O
addition	O
,	O
scatchard	O
plot	O
analysis	O
of	O
000i-labeled	O
il-0	B-protein
showed	O
that	O
dex	O
did	O
not	O
affect	O
the	O
binding	O
of	O
il-0	B-protein
,	O
thus	O
suggesting	O
that	O
inhibition	O
is	O
due	O
to	O
a	O
postreceptor	O
effect	O
.	O

inhibition	O
of	O
t	B-cell_type
cell	I-cell_type
proliferation	O
by	O
dex	O
was	O
associated	O
with	O
decreased	O
il-0-dependent	O
tyrosine	O
phosphorylation	O
of	O
several	O
intracellular	B-protein
proteins	I-protein
and	O
decreased	O
phosphorylation	O
of	O
the	O
retinoblastoma	B-protein
gene	I-protein
product	I-protein
rb	B-protein
,	O
a	O
protein	O
essential	O
for	O
controlling	O
the	O
progression	O
of	O
cells	O
through	O
the	O
cell	O
cycle	O
.	O

il-0-dependent	O
il-0r	B-protein
alpha	I-protein
expression	O
in	O
pma	O
blasts	O
and	O
nf-kb	B-protein
induction	O
in	O
resting	B-cell_type
human	I-cell_type
t	I-cell_type
cells	I-cell_type
were	O
also	O
inhibited	O
by	O
dex	O
.	O

these	O
results	O
demonstrate	O
that	O
glucocorticoids	O
inhibit	O
preactivated	B-cell_type
t	I-cell_type
cells	I-cell_type
by	O
down-regulating	O
signal	O
transduction	O
through	O
il-0r	B-protein
.	O

###MEDLINE:93353597

chronic	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
0	I-DNA
infection	O
stimulates	O
distinct	O
nf-kappa	B-protein
b/rel	I-protein
dna	O
binding	O
activities	O
in	O
myelomonoblastic	B-cell_type
cells	I-cell_type
.	O

the	O
relationship	O
between	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
0	I-DNA
(	O
hiv-0	O
)	O
infection	O
and	O
the	O
induction	O
of	O
nf-kappa	B-protein
b	I-protein
binding	O
activity	O
was	O
examined	O
in	O
a	O
myeloid	O
cell	O
model	O
of	O
hiv-0	O
infection	O
derived	O
from	O
the	O
plb-000	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

chronic	O
infection	O
of	O
plb-000	B-cell_line
cells	I-cell_line
led	O
to	O
increased	O
monocyte-specific	O
surface	O
marker	O
expression	O
,	O
increased	O
c-fms	B-DNA
gene	I-DNA
transcription	O
,	O
and	O
morphological	O
alterations	O
consistent	O
with	O
differentiation	O
along	O
the	O
monocytic	O
pathway	O
.	O

plb-iiib	B-cell_line
cells	I-cell_line
displayed	O
a	O
constitutive	O
nf-kappa	B-protein
b-like	I-protein
binding	I-protein
activity	I-protein
that	O
was	O
distinct	O
from	O
that	O
induced	O
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
or	O
phorbol	O
00-myristate	O
00-acetate	O
treatment	O
of	O
the	O
parental	B-cell_line
plb-000	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

this	O
unique	O
dna	O
binding	O
activity	O
consisted	O
of	O
proteins	O
of	O
00	O
,	O
00	O
,	O
and	O
000	O
kda	O
with	O
a	O
high	O
degree	O
of	O
binding	O
specificity	O
for	O
the	O
nf-kappa	B-DNA
b	I-DNA
site	I-DNA
within	O
the	O
prdii	B-DNA
domain	I-DNA
of	O
beta	B-protein
interferon	I-protein
.	O

in	O
this	O
report	O
,	O
we	O
characterize	O
the	O
nature	O
of	O
these	O
proteins	O
and	O
demonstrate	O
that	O
binding	O
of	O
these	O
proteins	O
is	O
also	O
induced	O
following	O
sendai	O
paramyxovirus	O
infection	O
.	O

the	O
00-kda	B-protein
protein	I-protein
corresponds	O
to	O
the	O
nf-kappa	B-protein
b	I-protein
rela	I-protein
(	O
p00	B-protein
)	I-protein
subunit	I-protein
,	O
which	O
is	O
activated	O
in	O
response	O
to	O
an	O
acute	O
paramyxovirus	O
infection	O
or	O
a	O
chronic	O
hiv-0	O
infection	O
.	O

virus	O
infection	O
does	O
not	O
appear	O
to	O
alter	O
the	O
amount	O
of	O
rela	B-protein
(	O
p00	B-protein
)	O
or	O
nfkb0	B-protein
(	O
p00	B-protein
)	O
but	O
rather	O
affects	O
the	O
capacity	O
of	O
i	B-protein
kappa	I-protein
b	I-protein
alpha	I-protein
to	O
sequester	O
rela	B-protein
(	O
p00	B-protein
)	O
,	O
therefore	O
leading	O
to	O
constitutive	O
levels	O
of	O
rela	B-protein
dna	O
binding	O
activity	O
and	O
to	O
increased	O
levels	O
of	O
nf-kappa	B-DNA
b-dependent	I-DNA
gene	I-DNA
activity	O
.	O

the	O
virally	O
induced	O
00-	O
to	O
000-kda	B-protein
proteins	I-protein
have	O
a	O
distinct	O
binding	O
specificity	O
for	O
the	O
prdii	B-DNA
domain	I-DNA
and	O
an	O
at-rich	B-DNA
sequence	I-DNA
but	O
do	O
not	O
cross-react	O
with	O
nf-kappa	B-protein
b	I-protein
subunit-specific	O
antisera	O
directed	O
against	O
nfkb0	B-protein
(	O
p000	B-protein
or	O
p00	B-protein
)	O
,	O
nfkb0	B-protein
(	O
p000	B-protein
or	O
p00	B-protein
)	O
,	O
rela	B-protein
(	O
p00	B-protein
)	O
,	O
or	O
c-rel	B-protein
.	O

dna	O
binding	O
of	O
the	O
00-	O
to	O
000-kda	B-protein
proteins	I-protein
was	O
not	O
inhibited	O
by	O
recombinant	B-protein
i	I-protein
kappa	I-protein
b	I-protein
alpha/mad-0	I-protein
and	O
was	O
resistant	O
to	O
tryptic	O
digestion	O
,	O
suggesting	O
that	O
these	O
proteins	O
may	O
not	O
be	O
nf-kappa	B-protein
b	I-protein
related	O
.	O

transient	O
cotransfection	O
experiments	O
demonstrated	O
that	O
rela	B-protein
and	O
nfkb0	B-protein
expression	O
maximally	O
stimulated	O
hiv-0	B-DNA
ltr-	I-DNA
and	I-DNA
nf-kappa	I-DNA
b-dependent	I-DNA
reporter	I-DNA
genes	I-DNA
;	O
differences	O
in	O
nf-kappa	B-protein
b-like	I-protein
binding	I-protein
activity	I-protein
were	O
also	O
reflected	O
in	O
higher	O
constitutive	O
levels	O
of	O
nf-kappa	B-DNA
b-regulated	I-DNA
gene	I-DNA
expression	O
in	O
hiv-0-infected	B-cell_line
myeloid	I-cell_line
cells	I-cell_line
.	O

###MEDLINE:93343972

presence	O
of	O
estrogen-binding	B-DNA
sites	I-DNA
on	O
macrophage-like	B-cell_type
synoviocytes	I-cell_type
and	I-cell_type
cd0+	I-cell_type
,	I-cell_type
cd00+	I-cell_type
,	I-cell_type
cd00ro+	I-cell_type
t	I-cell_type
lymphocytes	I-cell_type
in	O
normal	O
and	O
rheumatoid	O
synovium	O
.	O

objective	O
.	O

to	O
study	O
the	O
presence	O
of	O
estrogen-binding	B-protein
sites	I-protein
(	O
ebs	B-DNA
)	O
in	O
the	O
synovial	O
tissues	O
of	O
male	O
and	O
female	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
ra	O
)	O
and	O
in	O
age-	O
and	O
sex-matched	O
healthy	O
controls	O
.	O

methods	O
.	O

both	O
type	B-protein
0	I-protein
(	O
high	O
affinity	O
,	O
low	O
binding	O
capacity	O
)	O
and	O
type	B-protein
0	I-protein
(	O
reduced	O
affinity	O
,	O
higher	O
binding	O
capacity	O
)	O
ebs	B-DNA
were	O
investigated	O
in	O
both	O
soluble	O
and	O
nuclear	O
fractions	O
of	O
homogenized	B-cell_type
synovial	I-cell_type
tissue	I-cell_type
samples	I-cell_type
by	O
a	O
dextran-coated	O
charcoal	O
method	O
.	O

to	O
determine	O
what	O
type	O
of	O
synovial	B-cell_type
cell	I-cell_type
was	O
positive	O
for	O
ebs	B-DNA
,	O
cryosections	O
of	O
synovial	O
tissues	O
were	O
immunostained	O
with	O
a	O
specific	O
monoclonal	O
anti-estrogen	O
receptor	B-protein
antibody	I-protein
(	O
anti-er	B-protein
mab	I-protein
)	O
using	O
both	O
immunofluorescence	O
and	O
immunoperoxidase	O
techniques	O
.	O

double	O
immunostaining	O
with	O
the	O
anti-er	B-protein
mab	I-protein
and	O
with	O
specific	B-protein
mab	I-protein
to	O
detect	O
different	O
macrophage	B-protein
antigens	I-protein
(	O
ber-mac0	B-protein
,	O
mac000	O
,	O
cd00	B-protein
)	O
and	O
cd0+	B-cell_type
t	I-cell_type
cell	I-cell_type
subsets	I-cell_type
(	O
cd00+	B-cell_line
,	O
cd00ro+	B-cell_type
and	I-cell_type
cd00-	I-cell_type
,	I-cell_type
cd00ro-	I-cell_type
)	O
was	O
performed	O
.	O

results	O
.	O

higher	B-protein
affinity	I-protein
ebs	I-protein
were	O
found	O
mostly	O
in	O
nuclear	O
cell	O
fractions	O
of	O
either	O
ra	O
or	O
control	O
synovial	O
tissues	O
(	O
00	O
of	O
the	O
00	O
)	O
.	O

these	O
ebs	B-DNA
were	O
present	O
to	O
a	O
lesser	O
extent	O
in	O
soluble	O
cell	O
fractions	O
(	O
00	O
of	O
the	O
00	O
)	O
.	O

immunostaining	O
showed	O
the	O
estrogen	O
receptor-positive	B-cell_type
cells	I-cell_type
to	O
be	O
the	O
macrophage-like	B-cell_type
synoviocytes	I-cell_type
and	O
the	O
cd0+	B-cell_type
,	I-cell_type
cd00+	I-cell_type
t	I-cell_type
cells	I-cell_type
both	O
in	O
ra	O
and	O
in	O
control	B-cell_type
synovial	I-cell_type
tissues	I-cell_type
.	O

higher	O
nuclear	O
content	O
of	O
ebs	B-DNA
was	O
consistent	O
with	O
more	O
intense	O
nuclear	O
staining	O
of	O
synoviocytes	B-cell_type
and	O
t	B-cell_type
cells	I-cell_type
.	O

conclusion	O
.	O

it	O
is	O
conceivable	O
that	O
the	O
immunomodulatory	O
activity	O
exerted	O
by	O
estrogens	O
is	O
at	O
least	O
partly	O
mediated	O
through	O
their	O
interaction	O
with	O
ebs	B-DNA
that	O
are	O
present	O
on	O
macrophage-like	B-cell_type
synoviocytes	I-cell_type
,	O
functioning	O
as	O
antigen-processing	B-protein
and	O
antigen-presenting	B-cell_type
cells	I-cell_type
,	O
and	O
on	O
antigen-experienced	B-cell_type
(	I-cell_type
memory	I-cell_type
)	I-cell_type
cd0+	I-cell_type
t	I-cell_type
lymphocytes	I-cell_type
(	O
cd00+	B-cell_line
,	O
cd00ro+	B-cell_type

